<SEC-DOCUMENT>0001077183-23-000042.txt : 20230509
<SEC-HEADER>0001077183-23-000042.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509163846
ACCESSION NUMBER:		0001077183-23-000042
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOGENOMICS INC
		CENTRAL INDEX KEY:			0001077183
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		IRS NUMBER:				742897368
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35756
		FILM NUMBER:		23902811

	BUSINESS ADDRESS:	
		STREET 1:		9490 NEOGENOMICS WAY
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33912
		BUSINESS PHONE:		2397680600

	MAIL ADDRESS:	
		STREET 1:		9490 NEOGENOMICS WAY
		CITY:			FORT MYERS
		STATE:			FL
		ZIP:			33912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN COMMUNICATIONS ENTERPRISES INC
		DATE OF NAME CHANGE:	19990120
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>neo-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:9dc41751-b83b-431c-b18e-08aa28ccd964,g:b69a919b-a967-4814-b0e5-6634100d0d89,d:e8083b97acb547a982e84d715e3cf283--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:neo="http://neogenomics.com/20230331" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>neo-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF8zLTEtMS0xLTE2NzU0NQ_0f96bc16-fb2a-4bb2-b02b-340f85d32afe">0001077183</ix:nonNumeric><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF80LTEtMS0xLTE2NzU0NQ_2d98b125-48bc-4db6-85be-24687ab0d124">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF81LTEtMS0xLTE2NzU0NQ_1c98e454-fe09-492d-b977-fea2e33becea">2023</ix:nonNumeric><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF82LTEtMS0xLTE2NzU0NQ_828937ea-ef98-4db5-9fb7-ae7c3b2f12c4">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF83LTEtMS0xLTE2NzU0NQ_e3bab8ba-a346-426f-9e5b-ec0b39d64cc4">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="neo-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide298903e2814b3691a9fe4a01ba981e_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i07ed7276d306438c829d302392f7b033_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f22d3306074426850c066c83f4fad2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe390f745ed4eca957b49e083feac70_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1863049f937940c499e969956396ab07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2707608d9f224b6ea1ad5d5d7f84d1b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876d38822e24498d879a3ab240be09a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035f530335b749e188af838868c59214_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1caf8ef350438b9c76c704b6ea7ba7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2722299e2e54f68a4514ccee1e3eb82_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfee91888ba4bbe8c107385485e0364_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba385e087f94defb90c20be01b30692_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3537e2b2319b47afafdc2563a4fe34c9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b5e4798787448caf33060025f52e51_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f9e943825942a7b01c83b2eaacb3d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79595b9a231b4236a3065c84f3b094e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312ff0fa5d2e4b28aa9a59ff81523b57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf5dc7a570d4b40afef1ad9a2c2afa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie714ae56c66b4a099f1db8dc8c6474fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245e7c47a46c401abe4388c05022edc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd1f4fdbef9465d8834bed27b491755_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d22b4cf5a3440539edd117dd9c35a86_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d2ec838c7d43b1814352266b3a6fe5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ec944b9e4b458fa0a2f3458676f6d7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bba56276d3c4175888b91c4ac33bc23_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8925c88775946e58ab40caee41543ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5ac7b5971d4ab4bfc8063f863485f2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3231ed75cf147cd8562dc1eb6475ade_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3df88625d7d4b79abc18906edfac694_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a32a8c1adf04752a2088e1fe8031686_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea924912a062451a84ce6ae2de1bc5cf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f7b461087345aaa9abd14ef4c75f71_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b89e92263f34f90963302abcacb623e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c598cbef0946909ac15453b1e078f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1dc66208c4d42149ee22af031b70b4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc02f25dbebc48aca77b271035670aa4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d34acf37be43769a927e85ccbd4413_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004aaabb0349419fb34c1f104c808679_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20fd8019e30e4ef59757dfbd552fefeb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f72321e8d346c1b9be055441f0522d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61de5d25d8d448a888213f0ef7c3c93_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d77419ee434f6d947c0e5684e90599_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75d7c777de1492c9afb624404e70f75_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb2da309f705473cb33d6513d2d19040_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86086c5acace448bb8b6dabbe453c7be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cef6dfefe3f46798762dc09c193dcd0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e671e8e2cf407bb994e16200e27c76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed5d50e23774aa184b8e4f93485b926_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifda741ccd246402297be5d1bebec2777_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ed3e307ef849bfba217e3b1fcfa083_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c3929fc1b70423592f232d6a018be6a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65fc87ebe854a83bcf13322733d9557_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98f3e45c8ce247d9b943649f14ba658f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8cf7e134e204d52adbadf5546e01d3a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3247270c4bc14b0aa820a377e20562d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedde0d2d8fe34264951d0503e5c197b9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a9a7f37116407f959fe7f724da7dad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc3fd0f9e99e4320b6637e1380b3bce5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029abd7f614f43d5a623df347ff6580e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if10ce274df2c4249b4324db839548e83_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc449c252d24578be1789efa8d675cc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dfd45837ded4c3d8128215042b47480_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e227c6d3ee48169e743fbe4f36fe59_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ccb7220b1d436480b06a47fc83f4ee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17f174d18f64b4991198db92b4c8ae0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ca769c06f34caab7a01fa701dd33ae_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i850e29d393ab4d448d3e09260828b223_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7838cdae8934aa7bf7358f76022d88d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39ff6c2d66a41949d09b075c81e15de_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93fb5da9266349929735ffd80af05646_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29826c914306440c8b40afad7d4e56ec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d59563f70954f8497c1438ea92e442a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8144c05b43464394a4a6145a9a634b35_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54945d1251c4441a2ac49774ce617f9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d2cf2340a864d6998bf33d1d77a4392_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82eca2166b614d8eb21a538228c7f1e7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i262590bf4922435bbe6f1bac3c1def5e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9562a1c78e4bddbc52f9bef81cbed5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dba6ced43c849c9b749eb64351e67f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc7421b8125439e8a22041f284e8ebc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d558e5bb5fa4d8cbbe97eca0573db11_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516b4da2b0b24ab4a71025b9383c4617_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f6f6af9b184accb1eaff0152baad1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bcfd50343e7421882cf69bfe1e791f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04a302973b364b1588a1306eed18fe90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief43d0a3f2004fddb2988edc9ffc1db7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7dbd954120a4a10b873c3b2d48c8d49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0a5c00a8a5486f9c09d4373fd16f53_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3aa409a34fd4aeeb322282e6be87924_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d9ad9c26cc4a97894893e214f893f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59835bdf1de54dc3a48328b7959328f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dee9db4a6134911883daae2b127b1bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib768cc7d37f345a5b55d7bb1727a8e78_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied859b3bfe82436e90e318d8e56a78e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215f68b232644561b266ba62b04dfd65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3fb5fa062e447e8d199b4b11655520_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463acfa7a3c04bef8a12ae1f93cb16d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2fd1c3e7e64fb7b43f4cbbe181cd25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a646025d4924bfdb1a9695ebcdf84bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3bfade97a184c86b6180bc197f2e725_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1749cb686d884db7a9db215233a80ff9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2d2220b415e487cb212f61ed9379605_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64302d40674f4f668abac29df75dbd08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10b30abc40c456a88f7a33b38bddab3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9283a1102d45bbb21af57e2510969a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b4c1be3902041dea01bb81350a399fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9a7584dfdd402fbb79771f6d4e5a9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8c26fd3116483f97d7f3c916a5aadd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e51fb83d6764e358db23f5748f2e935_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d782115f910461ebaa72bdf726eb86b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i404c6343a4ff4c68abad1297de44d068_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c3cbd76eb2472ea8dc34f7fb98f41d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33036807c49d4896a9d79aecfb8f9205_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14bfd72886cc4c9aaf201e65540075bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2868dd906c41e081be0d5635abba54_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee14aadf28745e58a865d5fcc44e840_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id753f0b755d344a0b0bdf1feb8643feb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9561a855e94d8eaf7a7d262bd98518_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373380b438ca40aea3be8180eff81a98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4d19a07e4d4c6b8fa3f9a7a166e31c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieff90c10aa6e47e395b6fced1a0dabfc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1ab8ebd44e43e58d7c8ba3e808b947_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e1858214854850becd063395aada4d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd160d8807e0436c83ea5c0c12b91fc8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c657c0e98341bbbc4ddc31647ac2b6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ff16f279754224a25c4ced6f282de9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e9d62bddb1f4f688e043921e3f5282a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc32c676c0194721a3de605c721c7774_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5e9af89b9f4994b751ddbc6c96ae25_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib997aee08c8e473bb492e4695716145d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af4eb0b49b046e8b55345cc060257f8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d2008a400814d3fb508d405fef19e64_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie573780cd0664b138a05a0e5835aced1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1bb85243b8446f88ff933b1b86f31f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00db418b1f6455fb09b2677268bc6e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic69d55a1ed4a4e4e9dadc2f09c415671_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9932df4812244904b018651543ab7697_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic50858980989426ebbf9e3e896cff83b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib23b6c43131945bf975f36256bb931eb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i489270e3fa944888970ab2fee62822f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d3f64016074292b7c1e2da1f2c9ed2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdf7019ad564417a87f14091ba7ee081_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83abff9eb9764eda9517f9f96b3a9e85_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c1f4bb1df84121b986b7e6c99816e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7df8ca34dc349b6a74c42cd48d424c1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f505f6d5c4d49cdac4ad18e9a62c42a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i821b3f256d5440b6bea9447ea968ec92_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d88d8c28f9b449184647686d36c0f4a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4fa73897df4f2f8b41c9cf59104254_I20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i61fa222768e04a5282a731261a6c92db_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="day"><xbrli:measure>neo:day</xbrli:measure></xbrli:unit><xbrli:context id="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc5630007bf4025ab16a7d4dbffd844_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8528ca596729487298c1867438155cae_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ba8428c60f458195216b9cdad76629_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dae2c2009134637be004106df1ea18f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic91661eeb2ac4b54baf73ff541a0d067_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b9d072356745b8a8360da4654cefcb_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b7b175d56e84a4eb34fc4843d19177f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6906beeb9ed54b49b24795b298297e33_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2aa31d2ad384df88f27d19c894362af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ef92042d6eb4a88aa6d7e9f6a975c9a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e92033c77f541ad96bf59d87f798f51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da554b61949435884736cf902fdd198_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8dfcc988724045b9e80d0e895dc241_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55a517d33ae4df6997fc44f609d4dfa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26129e32e0847b28250bb921ab579d5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c010ac793694faaa7a1d1b387f6224b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed6ecf9b84046808c7c599bf940501d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>neo:segment</xbrli:measure></xbrli:unit><xbrli:context id="i37155bb755b5477e8fbeac7342fd0122_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5be18713caa049f98bd25ee684a48d54_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d2caa28bcd47f08e1eeac2e9fde476_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a0583c3c0842779bca3dd6c45d8eae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029263e85dca4857a798b85580af5632_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic451e6718033441284f8fab001983ece_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0934976619bb435f972eb14ee73bc235_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f79cb85f8e47b78073f6f575ba7ce5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c752dcd1ca45ff827097c99008c859_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:SeveranceAndOtherEmployeeCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99667b42ce8d4309bbdc2e318c38ed7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:FacilityFootprintOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id986d81110f2465fa821ef6a63bd6657_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:ConsultingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:SeveranceAndOtherEmployeeCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:FacilityFootprintOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:ConsultingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ea221a5e49464f94ac854559238414_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:SeveranceAndOtherEmployeeCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9cb7bbbb4784cb198eec618ef26686a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:FacilityFootprintOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbec686c7a42479b9a9e4877006b5814_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:ConsultingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef7183b65cb4f2f9f4adf9f0a5bb5b6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb4dbfbf647436ebf637a1b3d7cc7d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief61d5bc03a04fc793734af9dc810aab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe85cf00c6914ff48f891eb304bfa59f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca7d72eb0dc4c1794a0c06f7f6fa78d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61b3ab81b6f5476ea3f286adedb2c683_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207470ae354943faa9001607fe4529a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad53f6ac95fd426b9947f85a93074c2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if650c426e70e4f4a8a39d610bfaab9b5_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa8cf70c5a204e4ba1dd0ff819094a7a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic233566287de4d36bb1a6bb64acf5924_D20210120-20210120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-20</xbrli:startDate><xbrli:endDate>2021-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>neo:patent</xbrli:measure></xbrli:unit><xbrli:context id="i52bebd24ded945888e4e9c5d03543ea8_D20221220-20221220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-20</xbrli:startDate><xbrli:endDate>2022-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d357522f0b4460a9c80ae8413a0dce2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d234e06879f4d25b290bf7fa83aa615_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i954166d7487547128bc5b533688dd6d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001077183</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie8083b97acb547a982e84d715e3cf283_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y184NQ_800b66c1-8a0c-420c-9a42-8d8e7e80791d">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6OTk3Y2E5M2I3ZGM4NDMyZDhhZTdlYWY5N2ZjYmI3M2MvdGFibGVyYW5nZTo5OTdjYTkzYjdkYzg0MzJkOGFlN2VhZjk3ZmNiYjczY18wLTAtMS0xLTE2NzU0NQ_b47703b9-06d5-41d7-93ec-055880182705">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xMjE_c2aaee65-a75a-4a8b-a0d8-a96e8aacb85c">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center;text-indent:42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6MDEzM2EzNGVhMzQwNGQ4MzhhZmFkN2NiNjVhYTgxZmQvdGFibGVyYW5nZTowMTMzYTM0ZWEzNDA0ZDgzOGFmYWQ3Y2I2NWFhODFmZF8wLTAtMS0xLTE2NzU0NQ_00f3fd63-765c-4c06-8241-6af4178ba948">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yMTU_72c05c78-fe23-488a-a97e-62c9e90c1055">001-35756</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yMTg_02f7543a-02b2-4c63-93e4-f6c3b9a0b109">NEOGENOMICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:28.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18wLTAtMS0xLTE2NzU0NQ_5ec8eef5-d7ad-4804-a642-a831bddfea73">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18wLTMtMS0xLTE2NzU0NQ_6871d7e0-7088-4f13-8268-abb4997302e6">74-2897368</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18zLTAtMS0xLTE2NzU0NQ_ccfd564b-987c-4a95-b115-3ccc4d25a4d9">9490 NeoGenomics Way,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18zLTEtMS0xLTE2NzU0NQ_43f1ae2b-0088-4f4e-bb2f-de08cb989fb9">Fort Myers,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y180LTAtMS0xLTE2NzU0NQ_34b1e42a-b42d-485f-bfe1-08d507d03235">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y180LTMtMS0xLTE2NzU0NQ_c9a00190-1a29-49bd-8faa-38fa683cc94a">33912</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yODE_48a82dfa-0b87-4593-8b65-10746833ea30">(239)</ix:nonNumeric> <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yODQ_e61f0460-baa3-4ca9-80b4-231aaad1a6e9">768-0600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:29.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6NmUzNmU0MWY1MTE4NDdhNjhmYTBjYzAzZTA2MTAyY2UvdGFibGVyYW5nZTo2ZTM2ZTQxZjUxMTg0N2E2OGZhMGNjMDNlMDYxMDJjZV8xLTAtMS0xLTE2NzU0NQ_1f0cdf23-382b-4bf3-aced-690525be14d1">Common stock ($0.001 par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6NmUzNmU0MWY1MTE4NDdhNjhmYTBjYzAzZTA2MTAyY2UvdGFibGVyYW5nZTo2ZTM2ZTQxZjUxMTg0N2E2OGZhMGNjMDNlMDYxMDJjZV8xLTItMS0xLTE2NzU0NQ_be536784-4f39-4627-8e76-21e2d09e5044">NEO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6NmUzNmU0MWY1MTE4NDdhNjhmYTBjYzAzZTA2MTAyY2UvdGFibGVyYW5nZTo2ZTM2ZTQxZjUxMTg0N2E2OGZhMGNjMDNlMDYxMDJjZV8xLTQtMS0xLTE2NzU0NQ_e86b449c-9c3f-436c-b16f-8e7f4a5992b6">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y183NTE_1cd39586-2e08-4fdb-bb72-2a8f3a122dab">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">No&#160;&#160;&#9744;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;<ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xMDc1_8d275d90-fb58-4381-b525-a46daa40f7ac">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6ODdiMjRiZmIyYmMwNDNjYWE4NDBmOTY2ZjMyOTFhNWUvdGFibGVyYW5nZTo4N2IyNGJmYjJiYzA0M2NhYTg0MGY5NjZmMzI5MWE1ZV8wLTAtMS0xLTE2NzU0NQ_0b95d3c2-cc32-45a0-917f-48b5c2902065">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">S</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6ODdiMjRiZmIyYmMwNDNjYWE4NDBmOTY2ZjMyOTFhNWUvdGFibGVyYW5nZTo4N2IyNGJmYjJiYzA0M2NhYTg0MGY5NjZmMzI5MWE1ZV8xLTQtMS0xLTE2NzU0NQ_26ebc3b3-7745-4b29-a258-6755a42add28">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6ODdiMjRiZmIyYmMwNDNjYWE4NDBmOTY2ZjMyOTFhNWUvdGFibGVyYW5nZTo4N2IyNGJmYjJiYzA0M2NhYTg0MGY5NjZmMzI5MWE1ZV8yLTQtMS0xLTE2NzU0NQ_344359a8-a4d8-46c1-b760-58f197b97699">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xOTE4_5a3524d5-9d1e-4c5e-8c91-e3f88c0629f2">S</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of May&#160;5, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="ide298903e2814b3691a9fe4a01ba981e_I20230505" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xODUw_8f6fb5ff-bf5d-4303-92e1-20fca5894b83">127,578,138</ix:nonFraction> shares of Common Stock, par value $0.001 per share outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:90.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_13">PART I FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_16">Item 1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_94">Item 2. Management&#8217;s Discussion and Analysis of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_94">&#160;Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_94">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_130">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_130">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_133">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_133">33</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_136">PART II OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_139">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_139">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_142">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_142">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_145">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_145">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_148">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_148">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_151">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_151">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_154">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_154">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_157">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_157">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie8083b97acb547a982e84d715e3cf283_160">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8083b97acb547a982e84d715e3cf283_160">37</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements generally can be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements address various matters, including the Company&#8217;s strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, projected costs, prospects and plans and objectives of management. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 24, 2023, and in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to respond to rapid scientific change;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The risk of liability in conducting clinical trials and providing research services and the sufficiency of our insurance to cover such claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to implement our business strategy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The expected reimbursement levels from governmental payers and private insurers and proposed changes to those levels;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The application, to our business and the services we provide, of existing laws, rules and regulations, including without limitation, Medicare laws, anti-kickback laws, Health Insurance Portability and Accountability Act of 1996 regulations, state medical privacy laws, international privacy laws, federal and state false claims laws and corporate practice of medicine laws;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Regulatory developments in the United States including downward pressure on health care reimbursement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to maintain our license under the Clinical Laboratory Improvement Amendments of 1988 (&#8220;CLIA&#8221;);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Food and Drug Administration, or FDA regulation of Laboratory Developed Tests (&#8220;LDTs&#8221;);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Failure to timely or accurately bill for our services;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to expand our operations and increase our market share;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to expand our service offerings by adding new testing capabilities and overcome capacity constraints;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to develop or acquire licenses for new or improved testing technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to meet our future capital requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to manage our indebtedness;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to manage the quality of our investment portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our expectations regarding the conversion of our outstanding 1.25% Convertible Senior Notes due May 2025 (the &#8220;2025 Convertible Notes&#8221;) or our outstanding 0.25% Convertible Senior Notes due January 2028 (the &#8220;2028 Convertible Notes&#8221;) in the aggregate principal amount of $201.3 million and $345.0 million, respectively, and our ability to make debt service payments under the 2025 Convertible Notes or 2028 Convertible Notes if such notes are not converted;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to have sufficient cash to pay our obligations under the 2025 Convertible Notes or the 2028 Convertible Notes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The dilutive impact of the conversion of the 2025 Convertible Notes or the 2028 Convertible Notes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to protect our intellectual property from infringement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to integrate acquisitions and costs related to such acquisitions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to realize estimated benefits from our cost reduction and restructuring efforts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The effects of seasonality on our business;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to maintain service levels and compete with other diagnostic laboratories;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to hire and retain sufficient managerial, sales, clinical and other personnel to meet our needs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to successfully scale our business, including expanding our facilities, our backup systems and infrastructure;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our handling, storage and disposal of biological and hazardous materials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The accuracy of our estimates regarding reimbursement, expenses, future revenues and capital requirements; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to manage expenses and risks associated with international operations, including anti-corruption and trade sanction laws and other regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this report, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can it assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_13"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8212; FINANCIAL INFORMATION</span></div><div id="ie8083b97acb547a982e84d715e3cf283_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="ie8083b97acb547a982e84d715e3cf283_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.181%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)<br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMy0yLTEtMS0xNjc1NDU_5bc931c9-9d9b-45da-966d-69362b226e9f">275,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMy00LTEtMS0xNjc1NDU_552d5561-dba8-4af6-ba46-5f557471e735">263,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNS0yLTEtMS0xNjc1NDU_3d0aee65-f295-4c78-8860-14800a838a93">142,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNS00LTEtMS0xNjc1NDU_4a7647b6-5a6e-487e-9079-087010f55ce8">174,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNi0yLTEtMS0xNjc1NDU_3f94ce4b-9e4e-48a6-b3d3-43c8a3e58874">118,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNi00LTEtMS0xNjc1NDU_4ccf5fa5-05a3-45b1-b988-0b9c4a8c6b93">119,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNy0yLTEtMS0xNjc1NDU_a226c791-ad8f-4d29-8a58-0ec14be6fd2a">24,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNy00LTEtMS0xNjc1NDU_1c9079da-e991-42a4-9220-a0daf30db3cb">24,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfOC0yLTEtMS0xNjc1NDU_7a6ecc71-2095-40c7-a1b7-8475e81fcacd">16,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfOC00LTEtMS0xNjc1NDU_eddf52ae-7944-4fc2-a3a4-06fc9399a707">15,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTAtMi0xLTEtMTY3NTQ1_bd5f8551-3e37-4dc6-adf0-ffb70dad92b7">7,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTAtNC0xLTEtMTY3NTQ1_ed73fb8e-bfd7-41f4-a32e-65fe7cdeeaaf">8,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTEtMi0xLTEtMTY3NTQ1_a7876481-2fd1-4b24-b5e4-dd34badc3f25">584,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTEtNC0xLTEtMTY3NTQ1_e45d3880-4d40-4a04-aef1-4d3f00bedc9a">605,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment (net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246M2E5NTUyNDM3YTY1NGNkNmI1NTdmNDcwZWYyNTVhOGJfNjM_ba48864c-e3bd-4961-a4f7-62d4f892340d">138,863</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246M2E5NTUyNDM3YTY1NGNkNmI1NTdmNDcwZWYyNTVhOGJfNzA_e9fb6b8d-4847-4f2e-a799-3dbcdb8407ca">131,930</ix:nonFraction>, respectively)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItMi0xLTEtMTY3NTQ1_d13f20e2-3e5f-44d0-8fdd-70412260b0a4">102,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItNC0xLTEtMTY3NTQ1_ce125c68-061e-46ca-8741-9d4991708031">102,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTMtMi0xLTEtMTY3NTQ1_cfc70912-91a7-451b-9737-8c1743ec35af">93,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTMtNC0xLTEtMTY3NTQ1_9c08d1d7-8714-4b98-9259-4ce70e9ab8aa">96,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTUtMi0xLTEtMTY3NTQ1_57163e0b-d355-47df-aa23-c8f19b5aec34">399,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTUtNC0xLTEtMTY3NTQ1_296eb2b8-48e4-4f46-92cd-b222b2c7b5e8">408,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTYtMi0xLTEtMTY3NTQ1_1218b664-a13e-481c-b475-41182df96841">522,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTYtNC0xLTEtMTY3NTQ1_5afa49a0-4ef9-4b6e-b424-edd042a722d8">522,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjEtMi0xLTEtMTY3NTQ1_ce4ae0a9-f264-4342-978c-9479194064f3">5,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjEtNC0xLTEtMTY3NTQ1_7603ff3a-18f9-4b9b-bd30-15c541c613ff">5,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjItMi0xLTEtMTY3NTQ1_908a2bd2-9ffc-4413-8a97-4f75883c978c">1,124,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjItNC0xLTEtMTY3NTQ1_c66febe2-1e51-4227-963b-1ee2406fef5e">1,134,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjMtMi0xLTEtMTY3NTQ1_5189001b-2615-4293-96b3-0ff490531810">1,709,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjMtNC0xLTEtMTY3NTQ1_0ce1c7ab-6a5f-44d5-88db-74ccc6471381">1,740,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjYtMi0xLTEtMTY3NTQ1_6a0a4221-204e-43b9-9b31-834860d9058e">22,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjYtNC0xLTEtMTY3NTQ1_5bcdcc23-3ce0-469b-ae21-d8b84c85f17a">20,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjctMi0xLTEtMTY3NTQ1_5b6dcc81-e61c-4455-8c0a-fc9506bd364c">32,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjctNC0xLTEtMTY3NTQ1_0a287ec2-b338-407d-8c84-4eaea5227343">40,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjgtMi0xLTEtMTY3NTQ1_32ecb73f-8aaa-4053-b704-279c6944ace4">17,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjgtNC0xLTEtMTY3NTQ1_f3d52c19-dbbe-4646-9303-594d6eb17d6f">15,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of equipment financing obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjktMi0xLTEtMTY3NTQ1_fdd88853-d96c-45d7-95c7-87c3b2f0a604">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjktNC0xLTEtMTY3NTQ1_b2755a40-21b2-41f9-b764-113a3cebed1a">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzAtMi0xLTEtMTY3NTQ1_87cee8e2-5156-40c5-8ef1-4ccdcec0b238">6,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzAtNC0xLTEtMTY3NTQ1_a5fd3cb3-e097-4f21-b68a-b85bf516d858">6,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharma contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzMtMi0xLTEtMTY3NTQ1_f211e5fd-9ce5-421c-9afa-452d4958085d">6,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzMtNC0xLTEtMTY3NTQ1_9dcd315f-76a8-4b09-80e3-ae7fee9c4498">7,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzQtMi0xLTEtMTY3NTQ1_7d69c2bc-e56a-4c8f-8ba5-83dce5a32be0">86,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzQtNC0xLTEtMTY3NTQ1_d453f42d-e9c6-4776-be3f-5e15239305a9">89,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzYtMi0xLTEtMTY3NTQ1_a8b5931e-bee9-499c-aca6-c606076ab2e8">536,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzYtNC0xLTEtMTY3NTQ1_ee5ec29b-7459-44fc-813d-859bca58d7eb">535,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzgtMi0xLTEtMTY3NTQ1_88df0e93-da9f-49a9-a8dc-fd7609a678d2">67,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzgtNC0xLTEtMTY3NTQ1_788227a7-8f7c-40cb-a889-9431b5274b69">68,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDEtMi0xLTEtMTY3NTQ1_9272280f-ac81-4d28-a358-853e48eef4e1">31,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDEtNC0xLTEtMTY3NTQ1_25eb5c7a-9da5-40cf-aae5-062eafc92748">34,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDItMi0xLTEtMTY3NTQ1_1e08ccd1-ed05-41db-8645-66de5cf56eb2">13,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDItNC0xLTEtMTY3NTQ1_0c1ce738-8471-4d94-9924-c0c32cec8343">13,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDMtMi0xLTEtMTY3NTQ1_0511b5d9-2aee-4f9a-b769-bfa877441cf3">648,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDMtNC0xLTEtMTY3NTQ1_c6fb88f4-1b6e-4c07-9596-dbefcdcc4e7a">652,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDQtMi0xLTEtMTY3NTQ1_cf646798-ffb0-4dd4-8963-6c0bba2e1aab">734,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDQtNC0xLTEtMTY3NTQ1_c3f95156-3ff1-459f-9ef5-59dff7d9680b">742,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDUtMi0xLTEtMTY3NTQ1_d935d85e-ebc4-43b6-b9c1-826bebe27cd4"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDUtNC0xLTEtMTY3NTQ1_819b8937-611a-452d-9f7d-0ebf58ae6899"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMTg_762f93f3-fcec-4899-9b9a-8a84e2a5255f"><ix:nonFraction unitRef="usdPerShare" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMTg_83392568-96e8-4bb4-9f9b-82259f7cda0a">0.001</ix:nonFraction></ix:nonFraction> par value, (<ix:nonFraction unitRef="shares" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMzM_0ce7df19-7eec-4d04-8acd-aaa6e246431e"><ix:nonFraction unitRef="shares" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMzM_97fdc5eb-d62f-4c69-888e-bbac9e4ba230">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNTU_7bf1fcc5-6100-438b-8798-4d68891e6283"><ix:nonFraction unitRef="shares" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNTU_982c9308-cf2a-4eb1-ab83-22bbcc3f686d">127,200,491</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNjI_b8670134-d43c-4179-b4a9-7850b6b9b6da"><ix:nonFraction unitRef="shares" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNjI_ca1cf557-67ce-4894-9920-02867bd86f97">126,913,992</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMi0xLTEtMTY3NTQ1_57cf3f8a-59e8-4c16-bf3a-7fdacc9d0e36">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctNC0xLTEtMTY3NTQ1_c4b9528f-f779-47f5-bcb7-5f517210eb1a">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDgtMi0xLTEtMTY3NTQ1_89af1e16-39d6-4cde-9a90-2bae8e38ae61">1,167,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDgtNC0xLTEtMTY3NTQ1_9d87bd29-9b9b-4306-9436-779503dfb41c">1,160,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDktMi0xLTEtMTY3NTQ1_4352c6ab-e807-43ed-b306-9a26cc638423">2,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDktNC0xLTEtMTY3NTQ1_d26951f7-a9f9-40a5-8473-2e719498097c">3,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTAtMi0xLTEtMTY3NTQ1_6b1aae06-65ad-4c11-8c20-a09075eb9fc4">189,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTAtNC0xLTEtMTY3NTQ1_28c579a9-0c4f-4656-ae28-6f18e4d3f7c1">159,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTEtMi0xLTEtMTY3NTQ1_f965dc36-7fd5-4ca9-aa69-df98a546df03">974,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTEtNC0xLTEtMTY3NTQ1_cb015538-835c-4df6-9ea9-2cebf7f3099b">998,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTItMi0xLTEtMTY3NTQ1_3de77bc8-411f-4c97-a0f2-ee8bba0b260c">1,709,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTItNC0xLTEtMTY3NTQ1_e4c1c68a-6fa5-4ef8-887c-b3ba8d2239ee">1,740,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements. </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:63.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET REVENUE</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMy0xLTEtMS0xNjc1NDU_135f1747-f423-40c1-ab85-4cf9508a2d42">114,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMy0zLTEtMS0xNjc1NDU_af3fce82-4739-4c23-84e9-22328d849f99">98,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNC0xLTEtMS0xNjc1NDU_2f4b617d-e21c-46ee-83ab-e3569dbaa6e6">22,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNC0zLTEtMS0xNjc1NDU_7141825e-5ebd-4492-b1a0-72cada340efc">18,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNS0xLTEtMS0xNjc1NDU_db8829d9-e110-40e2-9fa9-c2375eb180c0">137,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNS0zLTEtMS0xNjc1NDU_86a0ea6c-1157-46cc-9828-a7e4e54cc3f0">117,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COST OF REVENUE</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNy0xLTEtMS0xNjc1NDU_e47cb1d5-5afe-410c-89ef-fbc637e23d5a">82,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNy0zLTEtMS0xNjc1NDU_84bca0e3-ee2e-4eeb-b37b-deea0e49f099">78,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GROSS PROFIT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfOS0xLTEtMS0xNjc1NDU_4439f81d-aca7-4245-9ffd-2bd1ee88c306">54,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfOS0zLTEtMS0xNjc1NDU_dbbcd18e-71d5-4150-b61a-eed129e341a7">38,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTEtMS0xLTEtMTY3NTQ1_5b965920-1972-481b-89e1-073441002557">61,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTEtMy0xLTEtMTY3NTQ1_85a867b9-fdb7-4626-b63e-7f98f1cf7e28">66,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTItMS0xLTEtMTY3NTQ1_ce2da932-0316-470a-a70e-7c3cc5933b76">7,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTItMy0xLTEtMTY3NTQ1_9cdf1354-5f28-4fb7-b56d-f2fa35874edb">7,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTMtMS0xLTEtMTY3NTQ1_9cc24f35-40f5-4049-9e37-fd997526534a">16,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTMtMy0xLTEtMTY3NTQ1_71d3ecd1-5a5a-4470-8c04-20b170b6e229">16,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMS0xLTEtMTcyMDg0_4880c224-39d5-4229-83be-747ddada2099">4,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMy0xLTEtMTcyMDg3_2f2553d8-1c3a-4ec2-b219-e71d712a83db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTQtMS0xLTEtMTY3NTQ1_a57ce70e-3bf9-4201-b8ac-c7782be3c22b">89,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTQtMy0xLTEtMTY3NTQ1_96e367db-37fc-4cd7-8e1a-533cc99c3183">90,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LOSS FROM OPERATIONS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMS0xLTEtMTY3NTQ1_d3618c6f-d616-4cfb-9076-5625143d7740">35,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMy0xLTEtMTY3NTQ1_d624831c-bb07-414c-9908-7a19cc6b6749">52,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTYtMS0xLTEtMTY3NTQ1_f77e0466-9253-403e-b195-c0f201e05a98">1,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTYtMy0xLTEtMTY3NTQ1_04319ed1-42be-4470-aaa6-eb86a1f46af7">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTctMS0xLTEtMTY3NTQ1_f1638474-9a50-4b05-889c-7f93ebe0ed77">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTctMy0xLTEtMTY3NTQ1_7b3d2464-2ff1-4ddc-aa92-92a17af69938">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjEtMS0xLTEtMTY3NTQ1_77c8fd0d-43d6-4e6f-bdb3-334eb8a93678">33,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjEtMy0xLTEtMTY3NTQ1_6fa525ea-0115-4b80-88c2-c8458ea8df83">53,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjItMS0xLTEtMTY3NTQ1_826a3157-f431-4b40-9715-bc9e47d42f8a">2,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjItMy0xLTEtMTY3NTQ1_c4d45d99-137f-464c-b9d6-274321e54425">3,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET LOSS</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjMtMS0xLTEtMTY3NTQ1_154c5601-d62b-4c07-b500-85185541b341">30,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjMtMy0xLTEtMTY3NTQ1_78d0dbbd-8582-4ab2-96a8-0285f3ea817d">49,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET LOSS PER SHARE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzEtMS0xLTEtMTY3NTQ1_dc7a037c-ab76-4ded-ada8-146fa08a780c">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzEtMy0xLTEtMTY3NTQ1_ebf0a8bc-886c-4c1a-a811-bd2ab651be0e">0.40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzItMS0xLTEtMTY3NTQ1_924c053b-1e72-4728-99f0-2ad73eb26948">0.25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzItMy0xLTEtMTY3NTQ1_89fad222-631d-4412-9b44-9dd2f3fcee3a">0.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzUtMS0xLTEtMTY3NTQ1_083248af-b360-4859-ad47-92edc6cd6db0">125,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzUtMy0xLTEtMTY3NTQ1_967ba903-1f72-4a98-bf43-da0b08eb3201">123,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzYtMS0xLTEtMTY3NTQ1_5102ff0d-f773-46af-8dea-a5f039133ea9">125,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzYtMy0xLTEtMTY3NTQ1_43e9940c-26a7-4124-aa7a-9116f6a201fb">123,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:61.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMi0yLTEtMS0xNjc1NDU_20f41089-30aa-4324-ae8f-bd06fd95fe4a">30,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMi00LTEtMS0xNjc1NDU_6e8eb65f-e55f-4bb9-aeb0-dccc5afc992d">49,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER COMPREHENSIVE GAIN (LOSS):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on marketable securities, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfNi0yLTEtMS0xNjc1NDU_4d37a016-307b-4937-aacd-9be4745d1fd7">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfNi00LTEtMS0xNjc1NDU_b1cc1c42-7067-4d76-b0d8-1b754a534a93">2,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total other comprehensive gain (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfOS0yLTEtMS0xNjc1NDU_17cbfaf8-8a2b-4c6a-b6fa-8417563f6823">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfOS00LTEtMS0xNjc1NDU_db6154c2-28f9-4248-bf06-2816fd11ce77">2,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMPREHENSIVE LOSS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMTAtMi0xLTEtMTY3NTQ1_5612af4f-900c-4d93-907c-f9473c894cc0">29,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMTAtNC0xLTEtMTY3NTQ1_52dc042a-a1cb-4df9-9370-1fcc915ed21d">51,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2707608d9f224b6ea1ad5d5d7f84d1b1_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi02LTEtMS0xNjc1NDU_77d168ee-4579-4a19-a40b-dfad1ac05224">126,913,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2707608d9f224b6ea1ad5d5d7f84d1b1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi04LTEtMS0xNjc1NDU_a5308337-6b0b-4945-92eb-0d394b50ab1e">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876d38822e24498d879a3ab240be09a8_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xMC0xLTEtMTY3NTQ1_209d9084-ad54-4e70-988a-d739f17a56f9">1,160,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i035f530335b749e188af838868c59214_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xMi0xLTEtMTY3NTQ1_d764d640-0b68-4388-b969-42a243b2bdde">3,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b1caf8ef350438b9c76c704b6ea7ba7_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xNC0xLTEtMTY3NTQ1_0cab2750-d58b-4fc1-9127-f890313e52e5">159,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xNi0xLTEtMTY3NTQ1_39619022-5127-4216-87af-9f84aae543aa">998,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for ESPP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMy02LTEtMS0xNjc1NDU_a14e4043-6375-4405-8fb9-a50a81f65304">96,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMy0xMC0xLTEtMTY3NTQ1_e19e947f-63ef-468b-ac9e-09c8bf15e99a">811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMy0xNi0xLTEtMTY3NTQ1_1a292cd5-3982-43ad-b5c8-e9ab0c2cc4ae">811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNC02LTEtMS0xNjc1NDU_3ece2fca-5643-4e53-a7d0-96b1b023bd0e">114,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNC0xMC0xLTEtMTY3NTQ1_419fb858-19df-4d6b-a977-dffb684b315e">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNC0xNi0xLTEtMTY3NTQ1_3ad5acb4-626c-4372-be84-f414188f5265">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNS02LTEtMS0xNjc1NDU_1b88c0ae-5221-4c03-af3a-97aaf3b6adaf">75,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNS0xMC0xLTEtMTY3NTQ1_48f815be-a1c9-4677-b349-4fb9c97da64e">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNS0xNi0xLTEtMTY3NTQ1_5b8fd7d5-e9ea-4ecd-bfe5-e09b59a771eb">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock issuance fees and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNi0xMC0xLTEtMTY3NTQ1_575b577c-d610-4158-ae7d-d5155c62f0b0">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNi0xNi0xLTEtMTY3NTQ1_f5cf3dda-7fb9-4afc-bae2-a83959c53526">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - ESPP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNy0xMC0xLTEtMTY3NTQ1_1bc064ba-e357-4d11-a03a-20b5e3b796d4">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNy0xNi0xLTEtMTY3NTQ1_513c8dad-2304-433f-a5cb-700c59762ae8">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOC0xMC0xLTEtMTY3NTQ1_3ed9d52e-d3e1-4e7c-999a-15d4a15c4300">4,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOC0xNi0xLTEtMTY3NTQ1_e6843bcd-f367-484c-b977-bc795e610285">4,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2722299e2e54f68a4514ccee1e3eb82_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOS0xMi0xLTEtMTY3NTQ1_b222691c-7140-4932-bfdd-d83a4a346752">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOS0xNi0xLTEtMTY3NTQ1_81bee72d-8233-429c-8962-1872515358ac">1,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bfee91888ba4bbe8c107385485e0364_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTAtMTQtMS0xLTE2NzU0NQ_35699244-40e7-494f-95e8-369a859d0c6e">30,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTAtMTYtMS0xLTE2NzU0NQ_d31180e6-0222-4f09-b2de-3deeafb8fac6">30,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba385e087f94defb90c20be01b30692_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtNi0xLTEtMTY3NTQ1_c3d1a3bb-5278-4043-8bee-b46aa35cca7c">127,200,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba385e087f94defb90c20be01b30692_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtOC0xLTEtMTY3NTQ1_e3a78a2c-1ae0-4a6a-a410-8379dd9445ae">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3537e2b2319b47afafdc2563a4fe34c9_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTAtMS0xLTE2NzU0NQ_7934c582-7925-403e-a21c-3fa51b77a953">1,167,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0b5e4798787448caf33060025f52e51_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTItMS0xLTE2NzU0NQ_48654c14-c9d9-463c-b7fa-c69b63f96a46">2,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2f9e943825942a7b01c83b2eaacb3d9_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTQtMS0xLTE2NzU0NQ_efb5402a-1bef-4143-9495-65c9421e553a">189,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTYtMS0xLTE2NzU0NQ_09fb7597-b520-4eca-8490-db1267fec650">974,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79595b9a231b4236a3065c84f3b094e4_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi02LTEtMS0xNjc3MjI_ac7f7d5b-f79d-405c-a0aa-e63b31fc9a20">124,107,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79595b9a231b4236a3065c84f3b094e4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi04LTEtMS0xNjc3MjI_1ea76774-089b-46fb-9172-3467cf0bc66d">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312ff0fa5d2e4b28aa9a59ff81523b57_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xMC0xLTEtMTY3NzIy_5fbaf557-3623-4b31-9bcc-56a93ad40625">1,123,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cf5dc7a570d4b40afef1ad9a2c2afa0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xMi0xLTEtMTY3NzIy_bb156ea8-9a90-4f1a-8054-8e874b83ef0e">638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie714ae56c66b4a099f1db8dc8c6474fc_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xNC0xLTEtMTY3NzIy_a05f5dc7-b997-4c12-bf65-f89bfc35a791">14,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245e7c47a46c401abe4388c05022edc4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xNi0xLTEtMTY3NzIy_5dc58ce0-9e90-479a-8f52-5f41d121cc3b">1,108,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for ESPP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMy02LTEtMS0xNjc3MjI_a0d2e076-9db0-4691-b264-435dad9f1dd2">47,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMy0xMC0xLTEtMTY3NzIy_0dd4aca1-f474-4a9b-ba10-f910ba402f70">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMy0xNi0xLTEtMTY3NzIy_8cd1c851-2549-43a4-9454-4afd97c754ae">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNC02LTEtMS0xNjc3MjI_adc685a7-adac-4e39-8c62-8ee343156277">100,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNC0xMC0xLTEtMTY3NzIy_0afdefb8-005d-45fb-8624-3698e9376342">1,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNC0xNi0xLTEtMTY3NzIy_0c3db3ee-fb35-4a82-8f98-642f8931d064">1,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS02LTEtMS0xNjc3MjI_7036d4fe-bbd1-487f-bd6b-c54f0e2f293b">466,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS04LTEtMS0xNjc3MjI_fd1492f0-abff-451e-8ef1-9c4f68387fa9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS0xMC0xLTEtMTY3NzIy_d1c91250-28c3-4abb-b9ea-14cd6c95d5b1">6,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS0xNi0xLTEtMTY3NzIy_4c99fa3a-d46e-4ac6-90de-3f6db695af0d">6,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - ESPP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNy0xMC0xLTEtMTY3NzIy_76c65ab3-ee25-4d0f-bae6-db742b83ed21">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNy0xNi0xLTEtMTY3NzIy_62da73cf-4b98-45f2-963d-d4fa94870bac">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation expense - options and restricted stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOC0xMC0xLTEtMTY3NzIy_e09573f5-3654-48e1-a025-117f8d33a13b">11,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOC0xNi0xLTEtMTY3NzIy_09f402f8-e061-44de-a7a4-d784ec0ba962">11,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdd1f4fdbef9465d8834bed27b491755_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOS0xMi0xLTEtMTY3NzIy_6ab93b2a-952c-449c-8d12-db4da32487a2">2,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOS0xNi0xLTEtMTY3NzIy_03903097-37c7-41fa-b0c3-a817f447a699">2,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d22b4cf5a3440539edd117dd9c35a86_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTAtMTQtMS0xLTE2NzcyMg_e58a7507-0c4d-4fd1-a6cc-f948cafaef7e">49,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTAtMTYtMS0xLTE2NzcyMg_f3b7d644-4f19-4b60-a52e-1b6026579ef3">49,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67d2ec838c7d43b1814352266b3a6fe5_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtNi0xLTEtMTY3NzIy_33521879-5415-4164-8927-2df248eb94b7">124,722,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d2ec838c7d43b1814352266b3a6fe5_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtOC0xLTEtMTY3NzIy_6ed1c1ef-ec92-41e7-a9ac-191de87b7dcf">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec944b9e4b458fa0a2f3458676f6d7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTAtMS0xLTE2NzcyMg_c4a2873e-d90c-4041-855e-076881c7f283">1,142,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bba56276d3c4175888b91c4ac33bc23_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTItMS0xLTE2NzcyMg_fe633e71-5eb9-43b0-932a-4199bcb36f7a">3,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8925c88775946e58ab40caee41543ef_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTQtMS0xLTE2NzcyMg_519ae376-a754-4502-8294-366f28086051">64,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5ac7b5971d4ab4bfc8063f863485f2_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTYtMS0xLTE2NzcyMg_1ca25585-1cf2-42c3-b1c6-0f49eabd5485">1,075,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_31"></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.629%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMy0yLTEtMS0xNjc1NDU_ca19906c-8572-4b35-98b4-7fbe9a974f84">30,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMy00LTEtMS0xNjc1NDU_8b399075-ad8a-41e7-b0db-f4266703280e">49,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net&#160;cash&#160;used in operating&#160;activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNS0yLTEtMS0xNjc1NDU_df22972d-c66e-45ae-9691-81cfc618841e">9,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNS00LTEtMS0xNjc1NDU_e3645c43-2f47-4475-bbf4-cf217a23a92b">8,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNi0yLTEtMS0xNjc1NDU_ea837c63-9f46-420d-b4fb-1c3cdd828659">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNi00LTEtMS0xNjc1NDU_f656615c-c317-4283-a867-ce1a4572ea00">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNy0yLTEtMS0xNjc1NDU_b4efb194-13ab-4d57-99d7-d0dc166b50e6">4,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNy00LTEtMS0xNjc1NDU_6cb93d14-1bb1-4978-ad9b-d601fef3a5a5">12,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOC0yLTEtMS0xNjc1NDU_5422f6af-0aa2-446d-b41d-c4938e91ecbe">2,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOC00LTEtMS0xNjc1NDU_912c7868-dcca-4e76-bbb7-5ae42ecfdbc9">2,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of convertible debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOS0yLTEtMS0xNjc1NDU_9d83c037-a18c-455c-9d51-8076797503c0">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOS00LTEtMS0xNjc1NDU_1c43bf34-6760-44d7-a9c6-f30041d0d6fc">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issue costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTAtMi0xLTEtMTY3NTQ1_e8c9a959-6fbd-4464-bdbe-083c25babeb1">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTAtNC0xLTEtMTY3NTQ1_e1e72fa9-f58b-4b97-9a1b-e50d8cb9cc63">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTUtMi0xLTEtMTY3NTQ1_fa910f31-bc70-42c4-a6ed-c649c80e30b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTUtNC0xLTEtMTY3NTQ1_fc3e9bf9-49bb-483b-9ebb-d706b6c62564">2,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTMtMi0xLTEtMTc0ODE4_5d8b5a8c-e44d-4e98-a99e-d3749c060d5b">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTMtNC0xLTEtMTc1OTM3_3fa646af-f125-4af1-9309-c60015602f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTctMi0xLTEtMTY3NTQ1_9c5224f7-09e8-42fd-b195-cc08aebbc385">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTctNC0xLTEtMTY3NTQ1_2359d14c-7000-475b-b124-8dbf31f8698d">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTktMi0xLTEtMTY3NTQ1_762b8e22-b07c-409e-b88f-307c272bfdd7">870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTktNC0xLTEtMTY3NTQ1_84b64c52-0a76-46f3-b1b8-ca194848382f">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjAtMi0xLTEtMTY3NTQ1_9a92a8f3-2f00-46db-b56b-d226d21aedb0">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjAtNC0xLTEtMTY3NTQ1_2fd4609f-9a56-4570-b18a-490d613f86bd">445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItMi0xLTEtMTY3NTQ1_2f2ebead-572f-4784-8048-7bc64705452a">1,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItNC0xLTEtMTY3NTQ1_877c9deb-d58a-4b0b-b9d2-1f7be4a034f4">2,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItMi0xLTEtMTc3NDY4_a0a78806-ff2b-467b-a329-12a7a42b8c57">1,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItNC0xLTEtMTc3NDY4_697834fa-fb88-454e-a41e-88cdd4b9dcba">2,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjMtMi0xLTEtMTc3NDY4_2b9b0c09-adcf-4e89-8f16-4f52cd3c4a10">3,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjMtNC0xLTEtMTc3NDY4_4a91f81e-fe5f-48b0-ac5a-d08c3b905c09">3,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtMi0xLTEtMTc3NDY4_d9c62145-f69b-493a-9b0e-ed0ba3dfb157">7,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtNC0xLTEtMTc3NDY4_fc8d84b0-eab8-4d65-9e2a-08a779e5ec6a">5,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtMi0xLTEtMTY3NTQ1_2bacde25-6d88-4c57-9b1b-7d490af53e0c">4,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtNC0xLTEtMTY3NTQ1_cf0741bb-13ff-47f6-b1eb-3391e15f41ce">2,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjUtMi0xLTEtMTY3NTQ1_39ba5361-7215-45e9-9727-4fbd05156266">12,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjUtNC0xLTEtMTY3NTQ1_1242f56c-4a63-4d57-87a6-1d56072f0c00">29,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjctMi0xLTEtMTY3NTQ1_de30eb93-d2ac-488a-bd6b-684153372506">6,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjctNC0xLTEtMTY3NTQ1_ca4eaa3e-1f94-41b6-a02a-e9f9ca95e8b7">16,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjgtMi0xLTEtMTY3NTQ1_a3539fe6-6283-40b9-a9f3-9d185e9c3ecf">40,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjgtNC0xLTEtMTY3NTQ1_7fac4859-3921-4f0c-a488-f10ea51f6bc9">36,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjktMi0xLTEtMTY3NTQ1_4020a56b-61ba-4b4a-b886-20bc9fbd5639">9,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjktNC0xLTEtMTY3NTQ1_b5d27dfc-8fa4-4eef-a9dc-a64efd0ac8bf">8,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzMtMi0xLTEtMTY3NTQ1_5ca1138b-ceb7-4697-abc4-214425694d1b">23,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzMtNC0xLTEtMTY3NTQ1_7317abe7-d0ad-447b-a7b0-20f1c870ff3e">12,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of equipment financing obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="neo:RepaymentsOfEquipmentAndOtherFinanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzUtMi0xLTEtMTY3NTQ1_a3617a34-6afe-439e-8542-c4eb803aa172">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="neo:RepaymentsOfEquipmentAndOtherFinanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzUtNC0xLTEtMTY3NTQ1_b7c02e39-135c-4a70-ace1-618f5fa4303b">346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzYtMi0xLTEtMTY3NTQ1_060f93be-c614-400c-b3eb-132a3b3e35ca">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzYtNC0xLTEtMTY3NTQ1_57b25107-c8df-4e39-8777-df29498d9f42">6,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDEtMi0xLTEtMTY3NTQ1_25caed04-614c-4e55-8a41-c5792a9f04ab">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDEtNC0xLTEtMTY3NTQ1_874a956d-aff4-408a-b2cd-cb02d691a90a">6,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDMtMi0xLTEtMTY3NTQ1_8e30ed8b-26b9-40b5-8425-2efbb5b14396">12,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDMtNC0xLTEtMTY3NTQ1_e57a7b3c-6fae-4906-a74f-a2948a57e4b5">10,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDQtMi0xLTEtMTY3NTQ1_347256a5-74ea-42fc-8829-1919221faf2a">263,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245e7c47a46c401abe4388c05022edc4_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDQtNC0xLTEtMTY3NTQ1_f8be3f91-74a6-4d62-9a70-8bb1f2006a35">316,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDUtMi0xLTEtMTY3NTQ1_7ce4548c-5e51-4d9d-b2b5-95fed2ad8178">275,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5ac7b5971d4ab4bfc8063f863485f2_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDUtNC0xLTEtMTY3NTQ1_0a13901c-c98d-4218-a19e-b0104e39c027">305,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:68.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfOS0yLTEtMS0xNjc1NDU_8c83a232-58a5-43da-b1ac-25dd7c4e51a3">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfOS00LTEtMS0xNjc1NDU_1f3d1776-e695-4fe7-85d0-62e90dc1373a">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in other current assets for the sale of assets held for sale</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="neo:NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTUtMi0xLTEtMTY3NTQ1_caf764bb-f4dd-4946-862d-d26cb18609c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="neo:NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTUtNC0xLTEtMTY3NTQ1_6077a853-2f66-4def-a9fb-036fd339e23b">12,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTYtMi0xLTEtMTY3NTQ1_2cb2e64f-f0c9-43de-b03e-60147de8f6dd">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTYtNC0xLTEtMTY3NTQ1_6f90963c-c0f6-449d-bab0-3593eca37529">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zNy9mcmFnOmRhODM1YTMxZWIxMzRiYTQ4MGY5ZDRkNDc3MTIzN2E3L3RleHRyZWdpb246ZGE4MzVhMzFlYjEzNGJhNDgwZjlkNGQ0NzcxMjM3YTdfMzE2NA_05de81bb-4208-4556-b0de-bdbe42f8f2a5" continuedAt="idccbd5ba221143a79b92fcbb0e60840a" escape="true">Nature of the Business</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idccbd5ba221143a79b92fcbb0e60840a">NeoGenomics, Inc., a Nevada corporation (the &#8220;Parent,&#8221; &#8220;Company,&#8221; or &#8220;NeoGenomics&#8221;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#8217;s Clinical Laboratory Improvement Act, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.</ix:continuation></span></div><div id="ie8083b97acb547a982e84d715e3cf283_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MTE_68a8c172-2e11-43a1-bbc1-4fa5a50ab054" continuedAt="i86432f8c83d7451fa4b53403cc940bfb" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i86432f8c83d7451fa4b53403cc940bfb" continuedAt="ia4473bd347184514b84fe655ad8cd205"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MTI_ef47b560-8124-437e-8000-bd2dfce14397" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, except for new accounting standards discussed under Recent Accounting Pronouncements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in the Company&#8217;s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim unaudited Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations presented in this Quarterly Report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.</span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MDY_dd084d47-3d7b-4866-a6d9-f029a6fa2117" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, impairment analysis of goodwill, and restructuring reserves. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MDk_f322f5fe-0982-4692-a331-bca895ee2802" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three months ended March 31, 2023 and 2022.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMzg0ODI5MDczODE5MA_9a707dca-89b8-47e7-957f-4029775d480e" continuedAt="i11915fa5d51f4b03a4cfb77fab233d25" escape="true">Restructuring charges</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i11915fa5d51f4b03a4cfb77fab233d25">Restructuring charges relate to a restructuring program to improve execution and drive efficiency across the organization. Restructuring charges consist of severance and other employee costs, costs for optimizing the Company&#8217;s geographic presence, and consulting and other costs.</ix:continuation> For further details on the Company&#8217;s restructuring activities, please refer to Note 8. Restructuring.</span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MTA_86b473ee-3aae-4952-b34f-82bbfe3f8d45" continuedAt="i9e557a543ce64d5aa2f33a09c85e3cbf" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#8220;ASU 2021-08&#8221;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia4473bd347184514b84fe655ad8cd205"><ix:continuation id="i9e557a543ce64d5aa2f33a09c85e3cbf">beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted this standard as of January 1, 2023 and there was no impact on its Consolidated Financial Statements.</ix:continuation></ix:continuation></span></div><div id="ie8083b97acb547a982e84d715e3cf283_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzMg_d1f00605-25c6-4b6e-a1b5-e1b49ac60366" continuedAt="i6774fb490dc24b9b9ab0071a2ccec7bf" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i6774fb490dc24b9b9ab0071a2ccec7bf" continuedAt="if36625c5d9314c4a8661a2e44b7ff5f7"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#8217;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets and are included in cash and cash equivalents on the Consolidated Balance Sheets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.</span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzNA_6efe5277-d67a-4400-b3dd-70c0a5753d9c" continuedAt="i79b39a0967bd4ee68a9ef67afaae95cf" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of March 31, 2023 and December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC0yLTEtMS0xNjc1NDU_d7ba26fb-0d07-44be-8c9f-79811358e092">37,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC00LTEtMS0xNjc1NDU_ab9faaca-00d0-4205-867b-aafb2df1d218">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC02LTEtMS0xNjc1NDU_f8951c62-5af6-41c3-b44f-fc3939137fdd">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC04LTEtMS0xNjc1NDU_68579518-d583-4896-96ae-1467f985bec0">36,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi0yLTEtMS0xNjc1NDU_ea2d3a2e-ca0d-424f-8349-4246e79cce27">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi00LTEtMS0xNjc1NDU_c7fcc4b7-b122-446e-aca7-6ba45d7607fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi02LTEtMS0xNjc1NDU_04338877-c1eb-43cc-83ce-3a6d38a4aa58">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi04LTEtMS0xNjc1NDU_00aa60a1-31d8-489c-a13f-ea3df728efa8">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy0yLTEtMS0xNjc1NDU_9d8445a7-e260-415d-b5b6-28bb540d8dbf">6,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy00LTEtMS0xNjc1NDU_359acff9-a2be-4cc8-b347-0cbd8dd218f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy02LTEtMS0xNjc1NDU_fb310984-641c-434a-ad6f-3a4c9fb964dd">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy04LTEtMS0xNjc1NDU_2576de50-4985-4a1e-b455-99d7fed4648e">5,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC0yLTEtMS0xNjc1NDU_a102f27d-30b0-4819-a96c-ec3875cc3af1">12,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC00LTEtMS0xNjc1NDU_7ae6297c-c90d-4a7f-af20-d00ec33bcb86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC02LTEtMS0xNjc1NDU_18e69962-59e6-47aa-8dac-2c18bbc986d0">902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC04LTEtMS0xNjc1NDU_f58e9230-cf38-4e73-add4-08bd59314e8c">11,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS0yLTEtMS0xNjc1NDU_00bc019e-5649-4f81-b4aa-6dbb8508f603">2,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS00LTEtMS0xNjc1NDU_c68733d1-4761-4856-9979-4114e51f2aac">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS02LTEtMS0xNjc1NDU_8365b6d4-a4f6-45a6-9235-5797f109706c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS04LTEtMS0xNjc1NDU_7cbd4dd8-1ae4-4ba2-aa1a-a28903f8e0d3">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtMi0xLTEtMTY3NTQ1_df1046ee-6dec-4f9b-b8f0-49b1d827883f">21,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtNC0xLTEtMTY3NTQ1_e5a014e2-6606-43bf-aaee-7b371be58f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtNi0xLTEtMTY3NTQ1_cdbdb9bf-e80a-416c-b9c5-329d4624122d">291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtOC0xLTEtMTY3NTQ1_63ece9e9-e184-47c2-a2a4-9ca2805331ed">21,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtMi0xLTEtMTY3NTQ1_baf5ef01-a98b-46cf-b576-4f17ee1b7abf">62,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtNC0xLTEtMTY3NTQ1_62c927f4-fc94-4500-b32c-b79d29b688db">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtNi0xLTEtMTY3NTQ1_6d554a56-310c-489b-b9c5-cf96c1582000">1,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtOC0xLTEtMTY3NTQ1_b58f970a-b3eb-433d-be5e-f6a61ff26d54">60,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItMi0xLTEtMTY3NTQ1_4c323b44-7552-475c-bf06-4ea040d8dbcf">145,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItNC0xLTEtMTY3NTQ1_6419e34e-10cc-4ba1-a4e3-bfd02c05df2f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItNi0xLTEtMTY3NTQ1_e813a0a7-c05f-407b-8e31-5acb7a4c911c">3,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItOC0xLTEtMTY3NTQ1_ec70ff91-a107-4dfb-9852-c3e5df3c550f">142,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="if36625c5d9314c4a8661a2e44b7ff5f7" continuedAt="i8d8c998119774643be997cafc37f2c4d"><div style="text-align:justify"><ix:continuation id="i79b39a0967bd4ee68a9ef67afaae95cf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC0yLTEtMS0xNjc1NDU_c042803c-7e92-4d23-bb2d-d3454f0690f1">56,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC00LTEtMS0xNjc1NDU_e4f15301-d35a-4b04-b1a4-6966ecf3ff59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC02LTEtMS0xNjc1NDU_1ad54598-1fe0-4a91-a550-5ba9c1e9008f">651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC04LTEtMS0xNjc1NDU_fd4c198f-07ca-4075-a83e-3b58e4b490b7">55,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS0yLTEtMS0xNjc1NDU_48983f28-2d85-49f0-8576-1b9d48decfa8">5,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS00LTEtMS0xNjc1NDU_4c5dfb5e-a29f-4462-b77e-ced819d118a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS02LTEtMS0xNjc1NDU_417b5c8b-f9b3-43f8-9ae4-6f2e734e3fea">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS04LTEtMS0xNjc1NDU_81e54165-dbb1-4162-a2d3-dfd2f73bdb82">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi0yLTEtMS0xNjc1NDU_7c8af31d-f454-491c-b046-820c29822b04">12,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi00LTEtMS0xNjc1NDU_f024a090-5929-4242-8812-7895526d7e1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi02LTEtMS0xNjc1NDU_dfce57b8-140a-415d-9231-4588c8be8a0a">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi04LTEtMS0xNjc1NDU_44307aad-c146-4e7c-9c38-2256caa583e3">12,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy0yLTEtMS0xNjc1NDU_f5d325c8-73fd-4f7b-a069-01d06037c6b5">12,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy00LTEtMS0xNjc1NDU_54fa24e4-8bb6-42d8-a128-5ace81d1dd9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy02LTEtMS0xNjc1NDU_fdef5de0-364f-4909-bff6-676f9ce9d325">1,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy04LTEtMS0xNjc1NDU_656c9a6d-36ed-4a8c-8657-acfc3c97c0cb">11,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC0yLTEtMS0xNjc1NDU_e4f150f0-ec7c-478c-babd-ee6a2f195f97">2,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC00LTEtMS0xNjc1NDU_c4b2f4fa-883d-40a9-bd1d-782bf7f00e6c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC02LTEtMS0xNjc1NDU_f98230f3-5568-407c-a513-2d59d3647fdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC04LTEtMS0xNjc1NDU_03d8cb7f-6dcd-497f-9693-a72f9f05675d">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS0yLTEtMS0xNjc1NDU_5a01fabe-1f61-4978-b26d-c0feba2b185a">25,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS00LTEtMS0xNjc1NDU_797cc571-b95d-4b3e-960c-c0622b50a82a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS02LTEtMS0xNjc1NDU_b5b85bd5-0f6a-458d-8acf-959caa2af734">427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS04LTEtMS0xNjc1NDU_a45beb1f-7cf2-42e0-9ede-277b464c1ddb">25,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtMi0xLTEtMTY3NTQ1_ec195096-f805-42e5-9c21-fae543037229">63,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtNC0xLTEtMTY3NTQ1_0ce79a2c-7d6b-41e1-b643-1eab24451783">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtNi0xLTEtMTY3NTQ1_6d38e0ac-ac1c-420c-b7c7-f93f4fa74ac2">2,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtOC0xLTEtMTY3NTQ1_4a71d057-66c9-4b83-bf8f-d005f462adf7">61,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtMi0xLTEtMTY3NTQ1_508c6fee-c9c2-4832-b856-011dc7876ab0">179,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtNC0xLTEtMTY3NTQ1_48e3b48c-71cf-4411-9a8a-58298ba6ae71">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtNi0xLTEtMTY3NTQ1_1d483200-a308-4fa6-b95b-1df5177d3284">4,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtOC0xLTEtMTY3NTQ1_06a98c38-177e-421f-b56b-33cbdfff4221">174,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNTQ5NzU1ODE4MTA2_bd1dfa2a-6b6b-47a4-87ec-2af20c1101f8">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNTQ5NzU1ODE4MTE0_3308f20c-01c7-46a9-b34a-943f1fb65580">0.9</ix:nonFraction>&#160;million of accrued interest receivable at March 31, 2023 and December 31, 2022, respectively, included in other current assets on its Consolidated Balance Sheets related to its marketable securities. There were no realized gains or losses on marketable securities for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzMA_a276286d-8071-4e42-876a-11d9a08e2af5" continuedAt="ifa3ad4af27b648afab00438279d6b031" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at March 31, 2023 and December 31, 2022. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC0yLTEtMS0xNjc1NDU_7f8937f7-5874-4a1b-8179-55c0ff27cc0d">29,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC00LTEtMS0xNjc1NDU_cb411fb2-a4bd-41d4-9638-0ac9e9e8124a">7,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC02LTEtMS0xNjc1NDU_04295acd-b14d-4872-a72c-9066ad214136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC04LTEtMS0xNjc1NDU_fa4ba8a4-2baa-4a90-90b1-6e43df4dde88">36,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi0yLTEtMS0xNjc1NDU_fb48105d-99aa-4fd6-a6cb-fbebb0f5b84b">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi00LTEtMS0xNjc1NDU_6d16fba7-5739-4bda-81eb-5fd99cb70f4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi02LTEtMS0xNjc1NDU_82a850a6-c6a6-433d-a184-fbc04ba808ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi04LTEtMS0xNjc1NDU_c3fa673c-c742-442b-9304-c849778f4a68">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy0yLTEtMS0xNjc1NDU_8b10f1ea-1878-485e-8c13-26fccaf7836c">3,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy00LTEtMS0xNjc1NDU_f9424ec0-634e-41e2-aa92-10d4bae21275">2,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy02LTEtMS0xNjc1NDU_288696a7-0d0b-4e31-9d2c-8365ab5da257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3df88625d7d4b79abc18906edfac694_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy04LTEtMS0xNjc1NDU_2e07fe29-30e3-4b52-929b-e6ef54b370ec">5,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC0yLTEtMS0xNjc1NDU_5db006b8-0e75-43c1-9f7a-6448a4ed5fad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC00LTEtMS0xNjc1NDU_ffecc07a-6a55-435d-b04c-3a8a4b4e1cc3">11,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC02LTEtMS0xNjc1NDU_f60d8a67-5699-4ced-88b7-ed12f1f7be31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC04LTEtMS0xNjc1NDU_c259755e-e2ff-4f6d-9ed8-6066d4b79e73">11,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS0yLTEtMS0xNjc1NDU_1ac7eafd-c33e-49f3-9143-429e16997466">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS00LTEtMS0xNjc1NDU_7e8a4b34-5575-4455-85f5-5da30754b244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS02LTEtMS0xNjc1NDU_2989a010-b193-4934-b06d-1918d5ac1ee6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS04LTEtMS0xNjc1NDU_abea24fa-3bb6-4157-96c6-cc1e6cd46aa0">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtMi0xLTEtMTY3NTQ1_1e4f82e0-0316-4772-af94-126a90160e1d">21,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtNC0xLTEtMTY3NTQ1_b43d1ae9-65ee-4218-a52d-404eeb213ef0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtNi0xLTEtMTY3NTQ1_a1018442-53f6-497f-b026-756ec6b21f2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtOC0xLTEtMTY3NTQ1_adaa0d6f-9c09-4b06-9433-53e4dfae40d8">21,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtMi0xLTEtMTY3NTQ1_942a4f2f-7702-45e9-939e-91dd282939e1">33,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtNC0xLTEtMTY3NTQ1_d962a4d0-10ad-404b-9012-59386dd63ca3">27,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtNi0xLTEtMTY3NTQ1_d9b3b2fb-8609-4002-a6d1-92bb70102306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b89e92263f34f90963302abcacb623e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtOC0xLTEtMTY3NTQ1_67a76c23-ea47-4df1-9a3a-002d37865d07">60,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItMi0xLTEtMTY3NTQ1_78945ca6-4f28-407a-abbe-1d094de97403">93,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItNC0xLTEtMTY3NTQ1_25b16239-3dc7-483f-bda1-948e8051a5a7">48,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItNi0xLTEtMTY3NTQ1_cbc246ea-caad-4a48-a34b-2514ffa513b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItOC0xLTEtMTY3NTQ1_d5035a56-ce74-4dd9-be19-1ebf9641dd0a">142,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i8d8c998119774643be997cafc37f2c4d" continuedAt="i9857df41cfcf455983186ebc41e74dde"><div style="text-align:justify"><ix:continuation id="ifa3ad4af27b648afab00438279d6b031"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC0yLTEtMS0xNjc1NDU_17567811-6dd3-4f91-8d46-7635f0b743a0">40,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC00LTEtMS0xNjc1NDU_89032835-ae00-4f29-af2d-07e347b4078e">14,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC02LTEtMS0xNjc1NDU_c1ffa56b-703b-4c1b-bd17-8eeae2113089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC04LTEtMS0xNjc1NDU_e9440e97-28bc-4002-8c38-07788c69326f">55,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS0yLTEtMS0xNjc1NDU_38bd1d58-f211-4f82-b219-4b5a7695f7ed">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS00LTEtMS0xNjc1NDU_505bcc56-b02c-4002-b549-bf1fc931c74b">2,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS02LTEtMS0xNjc1NDU_133fe962-aada-4f15-9a4a-a53c9be213da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS04LTEtMS0xNjc1NDU_7e1019b5-41a3-4ce7-af05-9591c2eb8747">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi0yLTEtMS0xNjc1NDU_14e312c6-cb0f-47f0-b906-fc7492cb851d">6,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi00LTEtMS0xNjc1NDU_fd33b7d1-6a04-449c-8c95-3eb74c1be2ef">5,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi02LTEtMS0xNjc1NDU_832ee970-bcb3-48e5-be98-0560c75a4254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi04LTEtMS0xNjc1NDU_8a87e218-7d9e-48a2-b09d-6ad51baaf35c">12,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy0yLTEtMS0xNjc1NDU_40819585-e428-4f30-8c18-d1c9e3620fa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy00LTEtMS0xNjc1NDU_7464d490-10e4-4669-828b-c7819eb4b00f">11,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy02LTEtMS0xNjc1NDU_5ecf180a-ffc0-44bc-96a6-f380756ffa8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy04LTEtMS0xNjc1NDU_1ab6a8d5-ecd8-4eab-b098-11bb6181b383">11,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC0yLTEtMS0xNjc1NDU_e3737886-7552-43ec-be68-b500b26d081f">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC00LTEtMS0xNjc1NDU_bb29c6b9-7e55-4c28-8a26-e83cc12c9582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC02LTEtMS0xNjc1NDU_295c469d-4e10-49e4-b8c0-4bff88673ac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC04LTEtMS0xNjc1NDU_d72edce5-c9ea-4b87-a575-5832a966352e">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS0yLTEtMS0xNjc1NDU_41ef8d79-a262-449b-952b-e8e33b631a48">23,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS00LTEtMS0xNjc1NDU_f45d7afb-f24a-4f11-bba3-d2d73468ff2c">1,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS02LTEtMS0xNjc1NDU_764619d3-3a1c-4d9d-90e0-2d8514df295d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS04LTEtMS0xNjc1NDU_b57fb4ec-0476-4826-96f8-83e5330634ed">25,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtMi0xLTEtMTY3NTQ1_ffbf06d6-f05d-4074-a022-168ef38abb3a">35,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtNC0xLTEtMTY3NTQ1_a87b11fe-0cdb-4f02-86e5-d1ae48d44759">26,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtNi0xLTEtMTY3NTQ1_f12b13d4-34f1-45f9-a09e-2d25fff4d190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtOC0xLTEtMTY3NTQ1_28ded449-bd0b-435a-8605-d760cb956bd6">61,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtMi0xLTEtMTY3NTQ1_4fa1f7f8-4b9b-4e2e-ae77-224901c46aa0">111,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtNC0xLTEtMTY3NTQ1_1cbe2000-46b4-49e9-bfc5-a31405b2cf0f">63,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtNi0xLTEtMTY3NTQ1_c85a4485-0452-4c5f-973f-3e18d1cfc9a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtOC0xLTEtMTY3NTQ1_4861be5e-0ec7-459b-b105-977dc361b0ef">174,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzMQ_ee0bed04-dfea-42da-b38d-7006b7660162" continuedAt="i181082bfeb92477baf4b9655d7ac4587" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of March 31, 2023 and December 31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i004aaabb0349419fb34c1f104c808679_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC0yLTEtMS0xNjc1NDU_2c205d5c-42a6-435a-ba2d-7c73de3bfe57">263,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20fd8019e30e4ef59757dfbd552fefeb_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC00LTEtMS0xNjc1NDU_68fc5a2c-2927-4b0a-bacd-07de08b41b97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f72321e8d346c1b9be055441f0522d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC02LTEtMS0xNjc1NDU_ee7879d7-a2b3-4071-aa5e-99c1652ab3a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61de5d25d8d448a888213f0ef7c3c93_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC04LTEtMS0xNjc1NDU_fe80ce37-8733-4511-87e8-d0da17b59380">263,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d77419ee434f6d947c0e5684e90599_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi0yLTEtMS0xNjc1NDU_dcdea882-fa09-4b21-9211-224310b4d576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75d7c777de1492c9afb624404e70f75_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi00LTEtMS0xNjc1NDU_44c16367-eb8c-47fa-b847-3c0967194623">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2da309f705473cb33d6513d2d19040_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi02LTEtMS0xNjc1NDU_8924cccb-0e7f-44ab-9f6b-e1c74ec36ac3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86086c5acace448bb8b6dabbe453c7be_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi04LTEtMS0xNjc1NDU_0097f86e-2a5f-4d4a-aa79-0037805c1b12">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cef6dfefe3f46798762dc09c193dcd0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC0yLTEtMS0xNjc1NDU_3317f57a-ae27-4ab2-88f1-b5430809f3bc">36,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e671e8e2cf407bb994e16200e27c76_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC00LTEtMS0xNjc1NDU_b1c7428e-1984-49bd-a811-148135214310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ed5d50e23774aa184b8e4f93485b926_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC02LTEtMS0xNjc1NDU_aff5bce9-7bcc-474b-ab8c-270785a7985c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda741ccd246402297be5d1bebec2777_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC04LTEtMS0xNjc1NDU_009b584b-3303-4925-ba02-91b9d9ea382f">36,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ed3e307ef849bfba217e3b1fcfa083_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtMi0xLTEtMTY3NTQ1_2699ac29-0281-43a4-ab86-662b2fa40de1">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3929fc1b70423592f232d6a018be6a_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtNC0xLTEtMTY3NTQ1_3bf0e05e-87c7-43b0-9ae4-99e864351001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id65fc87ebe854a83bcf13322733d9557_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtNi0xLTEtMTY3NTQ1_29fd498f-0983-409c-9e80-be120ea85180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f3e45c8ce247d9b943649f14ba658f_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtOC0xLTEtMTY3NTQ1_4e5923ce-26c8-4119-9df4-77c063916a2f">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cf7e134e204d52adbadf5546e01d3a_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtMi0xLTEtMTY3NTQ1_f067b368-09f3-4865-96e2-c6161af1873d">5,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3247270c4bc14b0aa820a377e20562d6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtNC0xLTEtMTY3NTQ1_ebad6272-21f0-445d-9def-7987983f98d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedde0d2d8fe34264951d0503e5c197b9_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtNi0xLTEtMTY3NTQ1_87fc5f7d-d444-4a9b-a65a-28cfa0bc14f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a9a7f37116407f959fe7f724da7dad_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtOC0xLTEtMTY3NTQ1_0d1b288d-515e-4dd1-95c0-13784ad9bf05">5,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3fd0f9e99e4320b6637e1380b3bce5_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItMi0xLTEtMTY3NTQ1_6ed1f451-f934-40db-b2af-c6529f1a90b2">11,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029abd7f614f43d5a623df347ff6580e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItNC0xLTEtMTY3NTQ1_948f17b8-ba7f-4824-9015-b1083b8dea08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if10ce274df2c4249b4324db839548e83_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItNi0xLTEtMTY3NTQ1_02776113-56b8-4866-9ede-7b5adde199c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc449c252d24578be1789efa8d675cc_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItOC0xLTEtMTY3NTQ1_f19d4646-c5bc-4bdd-9959-d4d7c368822f">11,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dfd45837ded4c3d8128215042b47480_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtMi0xLTEtMTY3NTQ1_4e8c885a-6b89-4b1d-a060-37861a891b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e227c6d3ee48169e743fbe4f36fe59_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtNC0xLTEtMTY3NTQ1_a18bda19-363c-4508-88ad-595bd3f916e7">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ccb7220b1d436480b06a47fc83f4ee_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtNi0xLTEtMTY3NTQ1_1b2d6d9b-89b1-4e27-8783-eb890216862d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17f174d18f64b4991198db92b4c8ae0_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtOC0xLTEtMTY3NTQ1_17be809b-d825-49be-8c57-e32d1cf8a844">2,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ca769c06f34caab7a01fa701dd33ae_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtMi0xLTEtMTY3NTQ1_ba3ba1a5-62f2-4a33-bb12-4be6fa3b604b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i850e29d393ab4d448d3e09260828b223_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtNC0xLTEtMTY3NTQ1_7b63de4d-f39d-4b79-a0e2-d706686d31f8">21,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7838cdae8934aa7bf7358f76022d88d_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtNi0xLTEtMTY3NTQ1_8d33183d-2154-4769-90d8-a858eec3cb58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39ff6c2d66a41949d09b075c81e15de_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtOC0xLTEtMTY3NTQ1_0314397c-d1b9-41c2-a53a-721250fb4fd8">21,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fb5da9266349929735ffd80af05646_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtMi0xLTEtMTY3NTQ1_2ffc6003-6957-4fc0-91e9-b5944e07bcb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29826c914306440c8b40afad7d4e56ec_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtNC0xLTEtMTY3NTQ1_2b81287b-3273-474c-9e74-c8bcc876701b">60,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d59563f70954f8497c1438ea92e442a_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtNi0xLTEtMTY3NTQ1_cf2c8df2-1987-4c6c-b298-f766ed42e014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8144c05b43464394a4a6145a9a634b35_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtOC0xLTEtMTY3NTQ1_b3dfe93d-8049-488e-b6da-a2d117c1815a">60,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54945d1251c4441a2ac49774ce617f9_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtMi0xLTEtMTY3NTQ1_96ee056e-7939-475f-850c-7fb0e95cf2e7">321,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2cf2340a864d6998bf33d1d77a4392_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtNC0xLTEtMTY3NTQ1_2089ce61-76e3-4dbb-ba5b-0c389e4e29ab">85,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82eca2166b614d8eb21a538228c7f1e7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtNi0xLTEtMTY3NTQ1_0293ed07-610f-47e0-aa65-7c56c81355ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262590bf4922435bbe6f1bac3c1def5e_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtOC0xLTEtMTY3NTQ1_1e08d461-00bc-4aca-9f9d-69f64f36fd4c">406,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i9857df41cfcf455983186ebc41e74dde"><div style="text-align:justify"><ix:continuation id="i181082bfeb92477baf4b9655d7ac4587"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9562a1c78e4bddbc52f9bef81cbed5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC0yLTEtMS0xNjc1NDU_7c156af3-ed47-4ff2-924d-49b20c77e0dc">196,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dba6ced43c849c9b749eb64351e67f3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC00LTEtMS0xNjc1NDU_60b69692-2549-4c47-8e50-20e8095af767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc7421b8125439e8a22041f284e8ebc_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC02LTEtMS0xNjc1NDU_7b901eae-eb25-4e6e-a57d-2afa8cf61c1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d558e5bb5fa4d8cbbe97eca0573db11_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC04LTEtMS0xNjc1NDU_74d7a7b7-23e3-47a5-8902-a28dc2173fb1">196,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516b4da2b0b24ab4a71025b9383c4617_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi0yLTEtMS0xNjc1NDU_43741d67-412c-49f8-87cd-4a5febeee76b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f6f6af9b184accb1eaff0152baad1b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi00LTEtMS0xNjc1NDU_aaf9a075-3604-495e-adf0-47a78077596f">36,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcfd50343e7421882cf69bfe1e791f4_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi02LTEtMS0xNjc1NDU_957c3511-b0cc-4b47-b16e-5168f7cc3065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a302973b364b1588a1306eed18fe90_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi04LTEtMS0xNjc1NDU_552f75fd-afd3-43d4-91ae-63643ef9ad00">36,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief43d0a3f2004fddb2988edc9ffc1db7_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC0yLTEtMS0xNjc1NDU_c149d086-735f-4a71-a151-3c41a20192b2">55,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7dbd954120a4a10b873c3b2d48c8d49_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC00LTEtMS0xNjc1NDU_38d5ee8a-83f9-48e4-812c-010d3dfad5a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0a5c00a8a5486f9c09d4373fd16f53_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC02LTEtMS0xNjc1NDU_5764710e-943e-4520-ac4a-9d9e174b982c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3aa409a34fd4aeeb322282e6be87924_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC04LTEtMS0xNjc1NDU_b5cf637e-8346-48c2-bd2a-9dafb4937007">55,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d9ad9c26cc4a97894893e214f893f0_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS0yLTEtMS0xNjc1NDU_bbd4f7b8-0304-45eb-befb-686c72f874e6">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59835bdf1de54dc3a48328b7959328f7_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS00LTEtMS0xNjc1NDU_0d9cd879-4d87-4319-9181-70719d263cf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dee9db4a6134911883daae2b127b1bb_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS02LTEtMS0xNjc1NDU_ccc40910-b497-4ec3-a143-f5f6ec9a5490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib768cc7d37f345a5b55d7bb1727a8e78_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS04LTEtMS0xNjc1NDU_e30705d2-7c2b-4db3-9c9e-acfe32d2ffef">5,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied859b3bfe82436e90e318d8e56a78e0_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtMi0xLTEtMTY3NTQ1_ef356e15-d407-4c1f-9c2c-4bc5fe3fc362">12,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i215f68b232644561b266ba62b04dfd65_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtNC0xLTEtMTY3NTQ1_414101dd-a863-415a-a0ad-47c90c3de5ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3fb5fa062e447e8d199b4b11655520_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtNi0xLTEtMTY3NTQ1_f269496e-d6b2-4809-8aad-9eb9eb0da140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463acfa7a3c04bef8a12ae1f93cb16d8_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtOC0xLTEtMTY3NTQ1_75749e0e-fef8-4e55-8ebf-138d62bfca0e">12,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2fd1c3e7e64fb7b43f4cbbe181cd25_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtMi0xLTEtMTY3NTQ1_b29e0f27-07bc-4d65-9712-bf776b6203ad">11,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a646025d4924bfdb1a9695ebcdf84bf_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtNC0xLTEtMTY3NTQ1_1d9f34d5-cfa1-4fd2-9702-40e99793e6da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3bfade97a184c86b6180bc197f2e725_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtNi0xLTEtMTY3NTQ1_37d55dca-88be-45f5-a13c-ed39301992c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1749cb686d884db7a9db215233a80ff9_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtOC0xLTEtMTY3NTQ1_fb910002-3cee-4989-859e-eb03f3140522">11,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d2220b415e487cb212f61ed9379605_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItMi0xLTEtMTY3NTQ1_811af86f-a76e-4ce9-8732-276c62d247b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64302d40674f4f668abac29df75dbd08_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItNC0xLTEtMTY3NTQ1_4c37bdb4-1c2c-4821-bcfd-5e52bd41f203">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10b30abc40c456a88f7a33b38bddab3_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItNi0xLTEtMTY3NTQ1_feeb4305-6e62-4076-9351-bfee3fd00a22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9283a1102d45bbb21af57e2510969a_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItOC0xLTEtMTY3NTQ1_58dd8115-f96d-4ae3-b83f-28a87c19a9d4">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b4c1be3902041dea01bb81350a399fb_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtMi0xLTEtMTY3NTQ1_52be9883-7f85-440c-bafb-0047f8a5b2f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a7584dfdd402fbb79771f6d4e5a9b_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtNC0xLTEtMTY3NTQ1_7cf0c278-bab1-48af-8957-63405bd1f71c">25,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8c26fd3116483f97d7f3c916a5aadd_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtNi0xLTEtMTY3NTQ1_3a9d00a3-08c3-4aa5-ab6e-bf64be86dd1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e51fb83d6764e358db23f5748f2e935_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtOC0xLTEtMTY3NTQ1_937a6249-8679-4c83-8628-a707429cc228">25,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d782115f910461ebaa72bdf726eb86b_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtMi0xLTEtMTY3NTQ1_41eb5956-da1a-4941-b930-3fd279c92bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404c6343a4ff4c68abad1297de44d068_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtNC0xLTEtMTY3NTQ1_a9d3a7dc-096f-40c3-86bc-5073b3d0a5ae">61,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c3cbd76eb2472ea8dc34f7fb98f41d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtNi0xLTEtMTY3NTQ1_8c5855b0-04dd-4f66-800a-99c0621b6230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33036807c49d4896a9d79aecfb8f9205_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtOC0xLTEtMTY3NTQ1_51a0eb3b-a29a-43e5-b5a4-8cf430f2cbfa">61,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14bfd72886cc4c9aaf201e65540075bf_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtMi0xLTEtMTY3NTQ1_b19f3ab6-09ed-4d3f-9318-6d993b804944">281,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a2868dd906c41e081be0d5635abba54_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtNC0xLTEtMTY3NTQ1_6efae6e9-40a5-4a88-a88f-5be09fa3de6f">126,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee14aadf28745e58a865d5fcc44e840_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtNi0xLTEtMTY3NTQ1_f0583e19-1116-42bb-a452-e8dc44550194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id753f0b755d344a0b0bdf1feb8643feb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtOC0xLTEtMTY3NTQ1_0e80035b-edcc-4931-be66-919d384992b3">408,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the three months ended March 31, 2023 and 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other liabilities, and other current assets and liabilities, are considered reasonable estimates of their respective fair values at March 31, 2023 and December 31, 2022 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, and long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and, as such, these are considered Level 3 fair value measurements.</span></div></ix:continuation><div id="ie8083b97acb547a982e84d715e3cf283_52"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTcw_604e240c-9903-4a4b-88f3-6fd3db5b3d57" continuedAt="i2d22e0595aa74aaa877bab83fc185510" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i2d22e0595aa74aaa877bab83fc185510" continuedAt="i3b16f3661435449c8a58c92ee3bf45eb"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfMzI5ODUzNDg5MDUzMA_38c500f3-cd06-49be-8a83-85fc82c590df" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of goodwill by segment at March 31, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:56.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9561a855e94d8eaf7a7d262bd98518_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMS0yLTEtMS0xNzY0MDI_ce6ea594-a0f0-4bad-9dba-265f0f8ccf29">458,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373380b438ca40aea3be8180eff81a98_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMS00LTEtMS0xNzY0MDI_e52c6ac7-22ba-4df2-904d-59c0e726241b">458,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4d19a07e4d4c6b8fa3f9a7a166e31c_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMi0yLTEtMS0xNzY0MDI_54b49748-bac8-43b8-808a-4f35dd6015ab">63,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff90c10aa6e47e395b6fced1a0dabfc_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMi00LTEtMS0xNzY0MDI_32a3e5cf-9e06-41c3-b93a-2811880f53b5">63,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMy0yLTEtMS0xNzY0MDI_96ef8931-19bd-40d7-8723-a938611f728d">522,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMy00LTEtMS0xNzY0MDI_5e0e2c08-fb19-42b4-9a44-accaf35991c5">522,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTcz_bc2cf519-5298-491f-a66b-db1a75f45d32" continuedAt="i6b58ac28165e45d1b90741c942568456" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c1ab8ebd44e43e58d7c8ba3e808b947_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozNjQ1ODYyYWIyMzA0YjQ5ODg0MmU0ZTJiMGYzNzk5OV80_cf628014-7a82-42cc-8ba1-3a570230db0f">7</ix:nonNumeric> - <ix:nonNumeric contextRef="if1e1858214854850becd063395aada4d_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozNjQ1ODYyYWIyMzA0YjQ5ODg0MmU0ZTJiMGYzNzk5OV85_d424cc33-3d3a-404d-83ec-b7a0208cca62">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd160d8807e0436c83ea5c0c12b91fc8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC00LTEtMS0xNjc1NDU_5f1718e7-b94a-4830-99dd-67abb6b740fe">143,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd160d8807e0436c83ea5c0c12b91fc8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC02LTEtMS0xNjc1NDU_979b6d5f-1ada-4c3f-a319-9bbb2e88a83a">58,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd160d8807e0436c83ea5c0c12b91fc8_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC04LTEtMS0xNjc1NDU_a832a6b8-7e31-431f-a405-69ff71381e7e">84,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71c657c0e98341bbbc4ddc31647ac2b6_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozZjg4YzJjMjA5ZDU0ZmI5OWU5ZGYxZmU2OTdkNzUzZl80_27c2e94a-a296-49ba-908b-50acb638322d">10</ix:nonNumeric> - <ix:nonNumeric contextRef="ib0ff16f279754224a25c4ced6f282de9_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozZjg4YzJjMjA5ZDU0ZmI5OWU5ZGYxZmU2OTdkNzUzZl85_7f3c3add-b64c-48a7-8a0c-f3f9201d191d">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS00LTEtMS0xNjc1NDU_a633c5bf-f9a2-46e3-bb5a-e0cb545705a7">310,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS02LTEtMS0xNjc1NDU_a2227e20-fb91-4aee-8554-70e83f49c396">38,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS04LTEtMS0xNjc1NDU_b1212035-42f8-4234-8100-85273f4c407a">271,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e9d62bddb1f4f688e043921e3f5282a_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo3ZTdjMjI2N2ExZDM0OTEyODkzOWRjNWQ3YTc3MDhhOV80_30800bf5-e231-408a-af60-13076d1c42fa">4</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc32c676c0194721a3de605c721c7774_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi00LTEtMS0xNjc1NDU_5b8f9423-123d-4d69-902b-97a0d0446998">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc32c676c0194721a3de605c721c7774_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi02LTEtMS0xNjc1NDU_49713346-9ead-4cd4-8090-559440039bb7">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc32c676c0194721a3de605c721c7774_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi04LTEtMS0xNjc1NDU_7ed6fc37-5cf6-4a45-a691-a122fb49215f">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b5e9af89b9f4994b751ddbc6c96ae25_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo2M2M3ZGFjOWM2Njg0ZmJmOWRlODg3NmRlNDRlZTRiOF80_b2a46d40-47fd-43c5-9d99-f3dee0dc4298">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib997aee08c8e473bb492e4695716145d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy00LTEtMS0xNjc1NDU_56fe4694-be32-4d8f-8491-9d425eb9e004">31,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib997aee08c8e473bb492e4695716145d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy02LTEtMS0xNjc1NDU_8d8295c7-55bf-4034-a6e2-481466871c43">3,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib997aee08c8e473bb492e4695716145d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy04LTEtMS0xNjc1NDU_9f321d40-5055-4382-9477-4add2ba875ca">27,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5af4eb0b49b046e8b55345cc060257f8_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjphYmJmYTc1YTc5MDQ0MzgyYTdmOTZjNmMxNTFiY2EwZF80_f3c39b9a-a0c2-49d5-a446-655dc82e5702">2.5</ix:nonNumeric> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC00LTEtMS0xNjc1NDU_649af00d-6a73-419f-b8e5-55f6ed5df4ad">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC02LTEtMS0xNjc1NDU_086b7318-7561-4861-8de0-4f8366e2a182">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC04LTEtMS0xNjc1NDU_cf5f18c3-6b28-4486-aefb-8e2bdfdd16cf">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2008a400814d3fb508d405fef19e64_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOS00LTEtMS0xNjc1NDU_1aca561f-4ae4-440a-b3ee-f8ba5171bea1">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2008a400814d3fb508d405fef19e64_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOS04LTEtMS0xNjc1NDU_fdcff29d-82a1-4d09-a899-c87fa7c32b86">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfMTAtNC0xLTEtMTY3NTQ1_74c7da16-ec18-4122-8b5d-e8a33cff6164">501,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfMTAtNi0xLTEtMTY3NTQ1_5ca78655-3142-49d2-924f-ce7b6d13c57a">101,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfMTAtOC0xLTEtMTY3NTQ1_7edab79f-8085-4082-be7c-68a79050a469">399,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i3b16f3661435449c8a58c92ee3bf45eb"><div><ix:continuation id="i6b58ac28165e45d1b90741c942568456"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie573780cd0664b138a05a0e5835aced1_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpmNTIwNzRiMjg1ZDY0YzRjOWNiZWIwM2M3YTY4ZTFlZl80_a1a37609-4a23-4af0-a6d9-3bbbb9e087a3">7</ix:nonNumeric> - <ix:nonNumeric contextRef="i1a1bb85243b8446f88ff933b1b86f31f_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpmNTIwNzRiMjg1ZDY0YzRjOWNiZWIwM2M3YTY4ZTFlZl85_45b1515a-8105-4503-b282-c889d5889f3e">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00db418b1f6455fb09b2677268bc6e7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi00LTEtMS0xNjc1NDU_1f3eda1f-06ff-45b3-a9f3-ad67a5227f87">143,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00db418b1f6455fb09b2677268bc6e7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi02LTEtMS0xNjc1NDU_94d6cae9-3dca-448e-9b98-0e65c70e3be7">55,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00db418b1f6455fb09b2677268bc6e7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi04LTEtMS0xNjc1NDU_eb7abe8b-c83e-49fc-9de7-2b61ce9d3806">87,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic69d55a1ed4a4e4e9dadc2f09c415671_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjoxNWVmOTYwNGQyZDY0NGYzYmViZjQwOGU2NGZlZTg1NV80_2c33b8eb-5b62-4248-b498-a179134376ea">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i9932df4812244904b018651543ab7697_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjoxNWVmOTYwNGQyZDY0NGYzYmViZjQwOGU2NGZlZTg1NV85_0958f4af-437a-4393-897b-c8b407717e4a">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50858980989426ebbf9e3e896cff83b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy00LTEtMS0xNjc1NDU_194c5c80-627b-46a1-9d65-9dcce6654d2e">310,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50858980989426ebbf9e3e896cff83b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy02LTEtMS0xNjc1NDU_ed43cebc-4029-4871-843a-6db1471bbc61">33,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50858980989426ebbf9e3e896cff83b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy04LTEtMS0xNjc1NDU_c6effee6-27a7-4426-8491-c824b03d92f2">277,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib23b6c43131945bf975f36256bb931eb_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC0yLTEtMS0xNjc1NDU_5803d2e7-92c5-40bc-ba92-445c8dc436b8">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489270e3fa944888970ab2fee62822f7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC00LTEtMS0xNjc1NDU_0009e7ba-9830-4671-91f3-04f3acc1042c">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489270e3fa944888970ab2fee62822f7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC02LTEtMS0xNjc1NDU_d0b99082-fed5-41da-b8a5-8d38b2f73f45">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i489270e3fa944888970ab2fee62822f7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC04LTEtMS0xNjc1NDU_b0636414-41ec-4e37-afdb-a1c5e0b16b0f">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8d3f64016074292b7c1e2da1f2c9ed2_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS0yLTEtMS0xNjc1NDU_ab646d1d-2359-4d8d-8701-b0334ee9afbf">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf7019ad564417a87f14091ba7ee081_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS00LTEtMS0xNjc1NDU_d9439cd0-f927-4221-9196-a02fd566b4a9">31,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf7019ad564417a87f14091ba7ee081_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS02LTEtMS0xNjc1NDU_0405c6b6-edf9-4009-a6cc-99cbaac58924">3,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf7019ad564417a87f14091ba7ee081_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS04LTEtMS0xNjc1NDU_d56aae11-e287-40b0-8813-fe77e0fef592">28,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83abff9eb9764eda9517f9f96b3a9e85_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi0yLTEtMS0xNjc1NDU_d630045d-b789-458f-871b-4255f7770d36">2.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi00LTEtMS0xNjc1NDU_6644a273-6bfa-421c-a90e-41783bc16e1e">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi02LTEtMS0xNjc1NDU_27903812-d27f-44c6-8694-6c8795f33ed6">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi04LTEtMS0xNjc1NDU_b0b11fc4-55eb-411e-8481-0d2ee0a4ad79">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c1f4bb1df84121b986b7e6c99816e1_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNy00LTEtMS0xNjc1NDU_1ac17b54-186a-49e1-b547-1c41442fdf3f">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c1f4bb1df84121b986b7e6c99816e1_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNy04LTEtMS0xNjc1NDU_f242de3f-640d-430c-bb4e-93c3d26d81c4">13,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfOC00LTEtMS0xNjc1NDU_e4bcb7d9-5404-493f-bcab-1617a4d78857">501,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfOC02LTEtMS0xNjc1NDU_c22e161f-b202-445e-b326-409d44b02fa3">93,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfOC04LTEtMS0xNjc1NDU_e4fdf060-7416-4dcd-b14a-07d90e54252b">408,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="neo:ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTc0_9078af27-fd29-4c67-b657-0de3a41f37d2" continuedAt="i52dd39c0efee4f96a1bf685810c11520" escape="true">The following table summarizes the amortization expense for the three months ended March 31, 2023 and 2022 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:justify"><ix:continuation id="i52dd39c0efee4f96a1bf685810c11520"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7df8ca34dc349b6a74c42cd48d424c1_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMi0yLTEtMS0xNjc1NDU_a150959c-aabf-4c96-aa5b-bc765b73ad84">4,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f505f6d5c4d49cdac4ad18e9a62c42a_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMi00LTEtMS0xNjc1NDU_3c8dda46-8a8d-478b-b0ae-07d8e740fad6">4,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821b3f256d5440b6bea9447ea968ec92_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMy0yLTEtMS0xNjc1NDU_acdd0966-2472-4894-8114-b79418eacf13">3,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d88d8c28f9b449184647686d36c0f4a_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMy00LTEtMS0xNjc1NDU_a4c09d56-d32e-40ba-b42e-c1a88319e3be">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfNC0yLTEtMS0xNjc1NDU_8f3bbd76-81a9-451b-9dbf-47250be3f5ea">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfNC00LTEtMS0xNjc1NDU_c283eb50-121f-4512-9d8a-39dd90e44085">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTY5_3160ae36-de01-4de5-9e30-c697cf788b9c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense related to amortizable intangible assets for each of the following periods as of March 31, 2023 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMC0xLTEtMS0xNjc1NDU_d4a0d1ad-15ad-4b5e-9670-5ce0e48d5c79">26,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMS0xLTEtMS0xNjc1NDU_5cc96473-0536-464e-b54f-57f28975adc8">33,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMi0xLTEtMS0xNjc1NDU_18aae685-4b2a-4c3d-8c31-bec1ee58b8a4">33,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMy0xLTEtMS0xNjc1NDU_5d27e0cf-a692-4269-9d5f-c87bd74791d4">33,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfNC0xLTEtMS0xNjc1NDU_b8023219-6c74-4580-acf8-874a056de0e3">32,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="neo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfNi0xLTEtMS0xNjc1NDU_ec7a191e-5760-4479-8223-8fe59b6574c7">226,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfNy0xLTEtMS0xNjc1NDU_2ae2f2ff-76ef-4dc6-8249-132e9bff559e">386,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ie8083b97acb547a982e84d715e3cf283_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTUzMA_00014295-2f4e-44f4-b8c1-464533c42016" continuedAt="i0789c3c940894935b4934a53dd94235b" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i0789c3c940894935b4934a53dd94235b" continuedAt="ifc1efdc7b65e4817890263228b3b9015"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, the Company completed the sale of $<ix:nonFraction unitRef="usd" contextRef="iba4fa73897df4f2f8b41c9cf59104254_I20210111" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTA0_e8855579-9d5d-46f1-94f1-e3220c36ed67">345.0</ix:nonFraction>&#160;million of Convertible Senior Notes with a stated interest rate of <ix:nonFraction unitRef="rate" contextRef="iba4fa73897df4f2f8b41c9cf59104254_I20210111" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTY2_db725fe8-3dbf-4ee5-8e3a-ad03eb8ca6dd">0.25</ix:nonFraction>% and a maturity date of January 15, 2028 (the &#8220;2028 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzg2_66d53fc8-f27e-4eb2-aef8-3b2c41647cb7">130.0</ix:nonFraction>% of the conversion price of the 2028 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDU1_b00baba0-4efb-4c31-a877-bcdc1ae4ab33">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDcw_9bd7222b-de22-4604-b7de-a5672cc07608">30</ix:nonFraction> consecutive trading days of the quarter ended December 31, 2022. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the first quarter of 2023. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNzkz_d87e0e3c-2aab-4715-89f1-f3321dd30fe0">130.0</ix:nonFraction>% of the conversion price of the 2028 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfODYy_a9a6c41b-876a-4d40-a39b-ff764288ef1b">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfODc3_453a7b23-ac7a-4f7d-b474-0fd4acfd9a48">30</ix:nonFraction> consecutive trading days of the quarter ended March 31, 2023. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the second quarter of 2023. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTIxMw_b670899e-b6ba-4f81-99c6-32651eb29698">17.41</ix:nonFraction> on March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2028 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i8528ca596729487298c1867438155cae_D20230101-20230331" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTI5NA_deadddda-4e6d-4a3b-940c-8812e83b9a97">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i8528ca596729487298c1867438155cae_D20230101-20230331" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTI5OA_63862fa7-d243-4d52-850e-74317c9bf9ff">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8528ca596729487298c1867438155cae_D20230101-20230331" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTMwNQ_136f31e8-ed74-472c-8e4d-57428255074d">8,500</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2023. The interest expense recognized on the 2028 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTU0OA_0bc156aa-8315-4941-83ad-92d92b0df8cb">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTU1Mg_53526671-c2a9-40e9-b6ef-50bfc1a83b8a">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTU1OQ_bcdecea7-d597-421c-b775-dae661dca3ce">8,400</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2022. The effective interest rate on the 2028 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjI5NA_b1f24756-b4af-4b99-839d-54fcc47c57bc">0.70</ix:nonFraction>%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="rate" contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjQ3Mw_c6a7976e-9243-413e-9151-ed8bdb4f84c4">0.25</ix:nonFraction>% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="ifc1efdc7b65e4817890263228b3b9015" continuedAt="i8d063e887fc54995af8013a7192fe9e3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, the estimated fair values (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjYzOA_6904ba22-4d65-432a-8a57-9ad0365b288d">0.25</ix:nonFraction>% Convertible Senior Notes due 2028 was $<ix:nonFraction unitRef="usd" contextRef="i40ba8428c60f458195216b9cdad76629_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjY3OQ_36be30ff-929f-435d-95d0-feeeeecc3e7f">258.8</ix:nonFraction>&#160;million. At December 31, 2022, the estimated fair value (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="i5dae2c2009134637be004106df1ea18f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjczMg_da8831d1-2f4a-4988-9690-4921afcb94cc">0.25</ix:nonFraction>% Convertible Senior Notes due 2028 was $<ix:nonFraction unitRef="usd" contextRef="ic91661eeb2ac4b54baf73ff541a0d067_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjc3Mw_01ef6e80-0cb2-4b50-a212-716f2e6ad082">218.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2025 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, the Company completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i82b9d072356745b8a8360da4654cefcb_I20200504" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjg1Nw_7aba2dd5-f940-4950-a52a-abf28e557903">201.3</ix:nonFraction>&#160;million of Convertible Senior Notes with a stated interest rate of <ix:nonFraction unitRef="rate" contextRef="i82b9d072356745b8a8360da4654cefcb_I20200504" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjkxOQ_30cc93f2-3c8f-4a79-a69a-6602e0ed5d4e">1.25</ix:nonFraction>% and a maturity date of May 1, 2025 (the &#8220;2025 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzEzNQ_f297bafd-043b-4e17-843c-ba4409744a41">130.0</ix:nonFraction>% of the conversion price of the 2025 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzIwNA_83d86da8-f5fc-46e2-a74e-e2c9d1c5b07d">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzIxOQ_c31e50db-70dc-44b6-93e7-47d152bff657">30</ix:nonFraction> consecutive trading days of the quarter ended December 31, 2022. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the first quarter of 2023. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to <ix:nonFraction unitRef="number" contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzU0Mg_49cf3e4c-f7d5-4c9f-8cf7-e9dfe184f0ea">130.0</ix:nonFraction>% of the conversion price of the 2025 Convertible Notes on at least <ix:nonFraction unitRef="day" contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzYxMQ_cad98951-dbe7-420d-94b6-3e29e1d23a82">20</ix:nonFraction> of the last <ix:nonFraction unitRef="day" contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzYyNg_b6e1d639-7c3b-4ddb-93b6-94944112da32">30</ix:nonFraction> consecutive trading days of the quarter ended March 31, 2023. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the second quarter of 2023. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTA5OTUxMTYzNDEyOA_b670899e-b6ba-4f81-99c6-32651eb29698">17.41</ix:nonFraction> on March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDA0Mw_9b796511-be7e-4a44-866c-d229900e398f">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDA0Nw_86fac9e3-85ed-4536-8afd-d4481c98f64e">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDA1NA_46cdcfeb-c2b8-4772-b9ba-c965e769f121">37,600</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2023. The interest expense recognized on the 2025 Convertible Notes includes $<ix:nonFraction unitRef="usd" contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331" decimals="-5" name="neo:InterestExpenseDebtContractualCouponInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDI5Nw_a36d37a2-c449-452a-831d-bd99bc2497ac">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331" decimals="-5" name="neo:InterestExpenseDebtAccretionOfDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDMwMQ_58409099-88a1-4ae0-8c28-5b656a90beb2">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331" decimals="-2" name="neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDMwOA_6e8f8433-a4bc-4002-bd1b-a7d15f858dd6">36,800</ix:nonFraction> for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2022. The effective interest rate on the 2025 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTA0NA_2c1cba43-aa57-446f-a611-b89c36780954">1.96</ix:nonFraction>%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i3b7b175d56e84a4eb34fc4843d19177f_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTIyMw_b1e28858-bc5d-4a99-a01f-6a8c94960cdd">1.25</ix:nonFraction>% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8d063e887fc54995af8013a7192fe9e3">At March 31, 2023, the estimated fair values (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="i3b7b175d56e84a4eb34fc4843d19177f_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTM5MQ_2cd957ab-163a-42e0-901d-5b1c9b07f14f">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 was $<ix:nonFraction unitRef="usd" contextRef="i6906beeb9ed54b49b24795b298297e33_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTQzMg_dabf66a5-a1eb-4ef5-9f19-32139ecf30ae">186.8</ix:nonFraction>&#160;million. At December 31, 2022, the estimated fair value (Level 2) of the <ix:nonFraction unitRef="rate" contextRef="ic2aa31d2ad384df88f27d19c894362af_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTQ4NQ_ca48584a-2c65-477b-975c-9b134c87011a">1.25</ix:nonFraction>% Convertible Senior Notes due 2025 was $<ix:nonFraction unitRef="usd" contextRef="i1ef92042d6eb4a88aa6d7e9f6a975c9a_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTUyNg_e2c29a86-0234-4f50-875c-fe839a30d0f5">169.6</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_67"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc2Ng_e19b30b0-03f4-469d-8fad-874e0071fb9f" continuedAt="ie785d201d8094d8fb35f2a1bfc58cfb7" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ie785d201d8094d8fb35f2a1bfc58cfb7" continuedAt="i70a87888de4a410d8b565b789c87daae"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfNzM_00821d02-de0b-469a-a4cd-3f04926fe3ec">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfODA_d5726440-1036-43c2-9deb-759009c753f6">12.1</ix:nonFraction> million for stock-based compensation in general and administrative expenses </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc2OQ_d03e2ee3-e597-4303-b1e7-b230bbfb3a19" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s plans for the three months ended March 31, 2023 is as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMS0yLTEtMS0xNjc1NDU_50f8beb0-d705-4128-ab86-7b87d8d75eeb">4,214,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMS00LTEtMS0xNjc1NDU_81b60d67-790b-4e35-ad12-776b8606bafe">16.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMi0yLTEtMS0xNjc1NDU_d162a761-d043-4d30-a499-5b8a597bc27a">338,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMi00LTEtMS0xNjc1NDU_5603bae3-6688-4b4d-b2b5-9d84cde4c320">10.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNC0yLTEtMS0xNjc1NDU_1c283ff0-6784-4ed9-9860-4acc1edcb66c">75,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNC00LTEtMS0xNjc1NDU_aa76aa56-11c5-4986-b2b9-bafd69cc1c2f">10.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNS0yLTEtMS0xNjc1NDU_5fee0394-a3e0-42c9-b752-947e5690911e">347,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNS00LTEtMS0xNjc1NDU_8861882e-8574-4dbc-8157-f2288c6f79d5">20.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNi0yLTEtMS0xNjc1NDU_8e3bf385-a06d-4482-aae0-e23a69c95a2e">4,130,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNi00LTEtMS0xNjc1NDU_3fe026d4-ba15-4a6a-b94d-6e84ed17cc73">15.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNy0yLTEtMS0xNjc1NDU_fde426f5-712f-4306-a22a-4644997e8ff1">754,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNy00LTEtMS0xNjc1NDU_869c7bd8-7fae-4eb5-bbef-8ceb6b1a1726">29.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc3MA_8a48ed79-bd24-4168-bba4-889353e7fb08" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award granted during the three months ended March 31, 2023 was estimated as of the grant date using a Black-Scholes model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMS0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjplN2U0NmQ1NTQ0NzI0MjAzYmZkNmIwYjZmZmI0MjIxMV80_c6b7c4fc-4a4e-47fe-854d-034ab3809fa3">4.0</ix:nonNumeric> - <ix:nonNumeric contextRef="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMS0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjplN2U0NmQ1NTQ0NzI0MjAzYmZkNmIwYjZmZmI0MjIxMV85_2bb031e1-afe2-4e8f-b1c7-076bcbbde45c">5.5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMi0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpkMmJlMzhkYzI3NWE0OWJlOGUwNjI2ZDBiOTg0MmE0MV80_ac846ca6-780b-4748-8b02-84117484f5e3">3.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMi0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpkMmJlMzhkYzI3NWE0OWJlOGUwNjI2ZDBiOTg0MmE0MV85_36ba975d-8877-47b9-ba52-6d6af90c0c97">4.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMy0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo0OTk3Y2VhMDQxMTA0ZjE2YmUyYjc5NjZhMWZjZjVjNF80_f10c7cb1-5475-4a02-921c-b09d51209dc1">54.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMy0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo0OTk3Y2VhMDQxMTA0ZjE2YmUyYjc5NjZhMWZjZjVjNF85_84f4cefe-93dd-453f-80f6-cc1abf605012">65.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfNC0xLTEtMS0xNjc1NDU_fc14b1ef-2f34-4050-96ec-96f60682e0e7">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfNS0xLTEtMS0xNjc1NDU_f44709c5-4889-4c89-99aa-37943aa34466">5.66</ix:nonFraction></span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i70a87888de4a410d8b565b789c87daae" continuedAt="i6eb51244f7a3456cb09a2a76dffc01e6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfNjYx_adf67db4-cb7d-4a01-94fe-d4e2f926da29">12.2</ix:nonFraction> million of unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfODEw_5fb309c4-d099-4023-8ab6-0e2fe80409b9">2.1</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Awards</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc2NA_45013e64-733e-40a0-944a-c07d891a214e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock activity under the Company&#8217;s plans for the three months ended March 31, 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e92033c77f541ad96bf59d87f798f51_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMS0yLTEtMS0xNjc1NDU_83488a52-66ba-449e-b223-ec0974c6aede">1,994,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e92033c77f541ad96bf59d87f798f51_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMS00LTEtMS0xNjc1NDU_5ec93c87-00b8-434e-aa67-30fe3b74428f">12.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMi0yLTEtMS0xNjc1NDU_d80fe961-a7fc-44e3-a5f2-9d201ccfa4fd">213,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMi00LTEtMS0xNjc1NDU_bdba5991-7519-4cdc-b6a4-0e010d09d7e3">10.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMy0yLTEtMS0xNjc1NDU_5a4509da-e31f-4e5f-bf7b-0ef5f0019661">33,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMy00LTEtMS0xNjc1NDU_2a6f0efb-0780-4bed-8e70-0e8debe18916">23.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNC0yLTEtMS0xNjc1NDU_f247bbfa-f5aa-44d8-8459-c918d2d42fab">89,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNC00LTEtMS0xNjc1NDU_ac10863c-eda9-4d34-83de-01e80578f4dc">12.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNS0yLTEtMS0xNjc1NDU_b97b789e-53cf-44d1-a027-5511f17ca478">2,085,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNS00LTEtMS0xNjc1NDU_bc6d6021-3824-4eb8-b848-ee8373bedb99">12.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfOTkw_3dde4b37-d9ee-413a-ac89-b69750729ac1">15.5</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to restricted stock that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMTE0Mg_e5c5f4a8-ca7d-435a-b9ec-e8e6acbbf2ec">2.3</ix:nonNumeric> years.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Modification of Stock Option and Restricted Stock Awards</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6eb51244f7a3456cb09a2a76dffc01e6">In the first quarter of 2022, upon the Chief Executive Officer&#8217;s departure from the Company and in accordance with the terms of the Chief Executive Officer&#8217;s separation agreement, <ix:nonFraction unitRef="shares" contextRef="i9e8dfcc988724045b9e80d0e895dc241_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjE2NA_263cf25f-c6ad-47a9-9792-3d0c67c1c1d9">237,960</ix:nonFraction> previously granted time-based vesting stock option awards and <ix:nonFraction unitRef="shares" contextRef="ic55a517d33ae4df6997fc44f609d4dfa_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjIyOQ_a24d11c3-aeb1-44c4-8b6b-87104825feb3">142,302</ix:nonFraction> previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $<ix:nonFraction unitRef="usd" contextRef="ie26129e32e0847b28250bb921ab579d5_D20230101-20230331" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjQzMA_8cca2e50-ab22-4012-92c6-ca7d7b04f7d3">5.9</ix:nonFraction> million of incremental stock-based compensation which consisted of $<ix:nonFraction unitRef="usd" contextRef="i9e8dfcc988724045b9e80d0e895dc241_D20220101-20220331" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjQ5Mg_d86599c7-c155-4f8b-b6ec-2d3b25bcedd0">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic55a517d33ae4df6997fc44f609d4dfa_D20220101-20220331" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjQ5OQ_08742551-0bca-46e1-b05a-466caf062f54">3.6</ix:nonFraction> million for the acceleration of stock option awards and restricted stock awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the three months ended March 31, 2022. There were <ix:nonFraction unitRef="usd" contextRef="i9c010ac793694faaa7a1d1b387f6224b_D20230101-20230331" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjcxOA_2d0e77ee-9553-49a9-b562-fe681699e1ce"><ix:nonFraction unitRef="usd" contextRef="i2ed6ecf9b84046808c7c599bf940501d_D20230101-20230331" decimals="-5" name="us-gaap:AcceleratedShareRepurchaseProgramAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjcxOA_f51c335f-e9c4-45cb-bbdb-505dbb3eb7bc">no</ix:nonFraction></ix:nonFraction> such amounts for the three months ended March 31, 2023.</ix:continuation> </span></div><div id="ie8083b97acb547a982e84d715e3cf283_70"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNzIxOA_3862503c-c7cd-4a37-ad65-3b6ea81090b3" continuedAt="icfb315fd958c4405b6c3f9293cbfb525" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="icfb315fd958c4405b6c3f9293cbfb525" continuedAt="i2b15743573c24f1b8b3492df656deedd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s <ix:nonFraction unitRef="segment" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODI2NDUy_7e9cfdcc-76bf-459b-95ba-9f64df8df276">two</ix:nonFraction> reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or an electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other contract research organizations (&#8220;CROs&#8221;) to provide research and clinical trial services. Such services also include validation studies and assay development. The Company records revenue on a unit-of-service basis based on the number of units completed towards the satisfaction of a performance obligation. In addition, certain contracts include upfront fees and the revenue for those contracts is recognized over time as services are performed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional offerings within the Pharma Services portfolio includes Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data. Informatics revenue is recognized at a point in time upon delivery of retrospective data or over time for prospective data feeds. The Company negotiates billing schedules and payment terms on a contract-by-contract basis, and contract terms generally provide for payments based on a unit-of-service arrangement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i2b15743573c24f1b8b3492df656deedd" continuedAt="i6c2f0eff4fab466b9181185212d2dce9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, Pharma Services incurs sales commissions in the process of obtaining contracts with customers. Sales commissions that are payable upon contract award are recognized as assets and amortized over the expected contract term. The amortization of commission expense is based on the weighted average contract duration for all commissionable awards in the respective business in which the commission expense is paid, which approximates the period over which goods and services are transferred to the customer. For offerings with primarily short-term contracts, such as Informatics, the Company applies the practical expedient which allows costs to obtain a contract to be expensed when incurred, if the amortization period of the assets that would otherwise have been recognized is one year or less. Contract assets and capitalized commissions are included in other current assets and other assets on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNzIyMQ_30a992c2-65e2-4c8c-8c5b-89a8623bc882" continuedAt="ib268fd8d4dd0482f9a84b996778fb533" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMS0xLTEtMS0xNjc1NDU_8d34feaa-4375-4814-8e0a-6c55cb01b635">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMS0zLTEtMS0xNjc1NDU_b47a8635-8778-4c8b-b3a7-c266965cf38b">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMi0xLTEtMS0xNjc1NDU_1fb4f5d5-f8c5-4840-a940-2544c52c0f1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMi0zLTEtMS0xNjc1NDU_5b4aa348-2a57-42e2-8c97-a09fb0a732b1">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMy0xLTEtMS0xNjc1NDU_ad46efec-2c4a-4336-b1b4-d2d8c318fcd5">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMy0zLTEtMS0xNjc1NDU_ecf0b137-e13e-4caf-b45c-88be9e1eda11">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNi0xLTEtMS0xNjc1NDU_e4ff9976-fe7e-4f47-88e4-70db624ca7ed">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNi0zLTEtMS0xNjc1NDU_ffe78b55-e70f-4bd3-aa4b-cb73ec268d7f">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNy0xLTEtMS0xNjc1NDU_f2cbfcfa-b26c-46dd-b04a-521a2165a12b">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNy0zLTEtMS0xNjc1NDU_35a86b7d-2837-4d5f-8e33-7a9c2305207d">715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfOC0xLTEtMS0xNjc1NDU_bdf3fb3e-1429-4878-9aa0-e7550be61676">1,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfOC0zLTEtMS0xNjc1NDU_6dbfec09-1221-4ba4-b11b-951bea21fc72">1,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTEtMS0xLTEtMTY3NTQ1_1919a6b1-a325-421c-bf37-725beb01eaf5">6,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTEtMy0xLTEtMTY3NTQ1_65879f34-5b4f-4bb7-abc4-979a9daee00b">7,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTItMS0xLTEtMTY3NTQ1_62017bb8-0744-4396-9f80-675edf68a915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTItMy0xLTEtMTY3NTQ1_fcfcc197-2dd8-44ce-96ec-eabe2db1c2c8">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTMtMS0xLTEtMTY3NTQ1_e79e49fd-ce43-41af-ac9e-64508e04f51f">6,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTMtMy0xLTEtMTY3NTQ1_5a6d120f-adbb-4517-bf5d-749b88ca1c30">7,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded within other current assets on the Consolidated Balance Sheets.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other assets on the Consolidated Balance Sheets. </span></div></ix:nonNumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ib268fd8d4dd0482f9a84b996778fb533" continuedAt="i82b7b0ec7b68423b821d57f653572a3e">(3)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i82b7b0ec7b68423b821d57f653572a3e"> Recorded within other long-term liabilities on the Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized related to Pharma contract liability balances outstanding at the beginning of the period was $<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODM4MDMw_0f36942d-884c-4a95-abda-7b8d03491af7">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODI0Njgx_58e7b5f0-5aab-49b9-8f41-27fb95ab0353">3.1</ix:nonFraction>&#160;million for the three months ended March 31, 2023 and 2022, respectively. Amortization of capitalized commissions was $<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODM4MDM3_67013cc3-a575-4e37-81a7-2c2be53e1f9d">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODI0Njkw_52185709-9b87-4bb1-bbc5-509258d8ba60">0.1</ix:nonFraction>&#160;million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i6c2f0eff4fab466b9181185212d2dce9"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNzIxNg_4838d4f1-64fd-4a08-bcc1-67594dcd494f" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services segments (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37155bb755b5477e8fbeac7342fd0122_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfMy0yLTEtMS0xNjc1NDU_2725892c-18c6-4b6c-a4aa-8a41c163a334">76,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be18713caa049f98bd25ee684a48d54_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfMy00LTEtMS0xNjc1NDU_a87e076f-9ef5-4a73-9819-c41826d42d44">65,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial Insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d2caa28bcd47f08e1eeac2e9fde476_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNC0yLTEtMS0xNjc1NDU_41674f17-36cf-43a6-af39-44ab9a0d8e25">21,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a0583c3c0842779bca3dd6c45d8eae_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNC00LTEtMS0xNjc1NDU_c09d3660-1b82-4b73-af23-7c2622a4a616">18,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029263e85dca4857a798b85580af5632_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNS0yLTEtMS0xNjc1NDU_0b72e44f-e8ac-494a-acb7-f1f5559dfaeb">16,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic451e6718033441284f8fab001983ece_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNS00LTEtMS0xNjc1NDU_d2484db9-bf43-449c-8ae5-84af0b68f05a">15,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-Pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0934976619bb435f972eb14ee73bc235_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNi0yLTEtMS0xNjc1NDU_959295e4-2f41-44e8-afd6-11deb99d79ce">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f79cb85f8e47b78073f6f575ba7ce5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNi00LTEtMS0xNjc1NDU_ff27c15b-a7e2-48cf-a8d1-ba83abe08c84">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNy0yLTEtMS0xNjc1NDU_48069bcc-5f25-4f9a-9f4b-af1c5ee74f9c">114,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNy00LTEtMS0xNjc1NDU_317c08c8-7fd2-4616-a707-5eaf6951035e">98,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOC0yLTEtMS0xNjc1NDU_e9e7d35a-87fe-4210-b890-1cbce81719d7">22,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOC00LTEtMS0xNjc1NDU_50f754cb-52cf-45a5-910a-48720b1a311a">18,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOS0yLTEtMS0xNjc1NDU_2eff7533-1223-4e5b-add3-05533ade4000">137,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOS00LTEtMS0xNjc1NDU_13d64218-679b-4dc6-9ef5-c948c7fa0fa5">117,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_1111"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF8zODQ4MjkwNjk4NTk1_ca0f4c40-1d13-4a1d-8944-eb683e2abd87" continuedAt="ib421f6162ebe4c63ad3a657e43485e1f" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="ib421f6162ebe4c63ad3a657e43485e1f" continuedAt="i440bebbcfd7c4a2195e6f565f65f8e3c"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company embarked on a restructuring program to improve execution and drive efficiency across the organization. This program is a framework for identifying, prioritizing and executing operational improvements. Restructuring charges incurred consist of severance and other employee costs, costs for optimizing the Company&#8217;s geographic presence (&#8220;Facility Footprint Optimization&#8221;), and consulting and other costs. There were no such charges for the three months ended March 31, 2022.</span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF8zODQ4MjkwNjk4NTk2_003b8b27-3f5b-4a43-8b27-e63c3e21ecbb" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:40.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Other Employee Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility Footprint Optimization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consulting and Other Costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c752dcd1ca45ff827097c99008c859_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTQtMS0xLTE3MTg5Mg_bdb62da6-510c-4236-b454-33387d1fa0f0">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99667b42ce8d4309bbdc2e318c38ed7a_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTYtMS0xLTE3MTg5Mg_e08af3a4-36df-4dc0-8bb4-693ad4fa8f06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id986d81110f2465fa821ef6a63bd6657_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8xLTgtMS0xLTE3NTQ4Mg_7d589b78-a2ea-4cbf-960e-8e503afdc024">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ed7276d306438c829d302392f7b033_I20221231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTE0LTEtMS0xNzE4OTI_0f68b98f-a5ed-439e-bf82-de8579145d46">1,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="neo:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTAtMS0xLTE3MTk5Mg_b8cf4641-7eb6-4077-988b-0a6764f9ed19">Restructuring charges incurred</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTQtMS0xLTE3MTg5Mg_8cd60543-6666-40cf-b28c-261e01aeb5f8">3,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTYtMS0xLTE3MTg5Mg_cd78a629-6e7e-4398-b61c-28b0303b66fd">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTgtMS0xLTE3NTQ4Mg_f8eac49b-6285-4582-8f4b-304ec4337b11">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTE0LTEtMS0xNzE4OTI_6077f7b8-0647-42fb-bed8-daa774214d4d">4,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of facility related assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV80LTQtMS0xLTE3MTg5Mg_a4354446-ef28-40ef-ad0d-62f9d6e2465f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV80LTYtMS0xLTE3MTg5Mg_afbdc660-4fc0-47b5-8f32-97ad22532952">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTgtMS0xLTE3NTQ4Mg_86e35f10-141d-48eb-98d8-bd070c8342ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV80LTE0LTEtMS0xNzE4OTI_36b107fa-ee4f-48f4-9777-ad6b32b14024">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments and other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTQtMS0xLTE3MTg5Mg_71ffed7a-6590-4320-b54e-bb2873be967e">1,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTYtMS0xLTE3MTg5Mg_97c8a78b-23f5-4481-a5df-da5b650f6f2b">564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV81LTgtMS0xLTE3NTQ4Mg_03449d8a-cf17-422f-8660-b16ecb6a914e">346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTE0LTEtMS0xNzE4OTI_3426811c-4d32-4b2f-b6e3-4d2ed263e8e4">2,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ea221a5e49464f94ac854559238414_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV83LTQtMS0xLTE3MTg5Mg_4a0bb92f-b15c-4518-8025-69538f407b98">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9cb7bbbb4784cb198eec618ef26686a_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV83LTYtMS0xLTE3MTg5Mg_b21cd7dc-4e3e-43ab-b138-77ff527c6fce">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbec686c7a42479b9a9e4877006b5814_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTgtMS0xLTE3NTQ4Mg_40f18b5d-6fba-417e-87a3-10615d767e8e">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV83LTE0LTEtMS0xNzE4OTI_c7d68873-0464-4c1f-81a5-f306921207b6">4,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV84LTE0LTEtMS0xNzE4OTI_cc77a38b-4f22-495a-9ade-fd1d5ca3679c">4,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:RestructuringReserveNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV85LTE0LTEtMS0xNzE4OTI_7f654af7-b598-40ef-83a8-d81e5a5b08bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8xMC0xNC0xLTEtMTcxODky_57dfb45f-52ad-44e1-8b07-53535609576d">4,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments include non-cash asset charges related to Facility Footprint Optimization costs.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i440bebbcfd7c4a2195e6f565f65f8e3c">The Company will continue this restructuring program in 2023 and expects to incur additional restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxMTg_41c0e9f2-0930-42ca-a784-b478c38f98e3">3.0</ix:nonFraction>&#160;million. The Company estimates these additional restructuring charges to be comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="ia5ea221a5e49464f94ac854559238414_I20230331" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxMzI_3552c953-999b-4a62-9d98-ed875247f949">1.0</ix:nonFraction>&#160;million in severance and other employee costs, $<ix:nonFraction unitRef="usd" contextRef="ic9cb7bbbb4784cb198eec618ef26686a_I20230331" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxNDY_46942fda-941c-4506-b739-2ca32f34f188">1.0</ix:nonFraction>&#160;million of Facility Footprint Optimization costs, and $<ix:nonFraction unitRef="usd" contextRef="ifbec686c7a42479b9a9e4877006b5814_I20230331" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxNjA_5020d934-2081-4446-8225-ae34362ea6d8">1.0</ix:nonFraction>&#160;million of consulting and other costs. The Company&#8217;s restructuring activities are expected to be complete by December 31, 2023.</ix:continuation> </span></div><div><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_73"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183My9mcmFnOjljZDgyYWRhNTY2MzRmMmI4NDI1ZDcxMWNiN2I3YTY0L3RleHRyZWdpb246OWNkODJhZGE1NjYzNGYyYjg0MjVkNzExY2I3YjdhNjRfMjAzMA_072244c2-fe2c-425c-85b9-27a323491b07" continuedAt="ia6a936de443b4950858db56d546f4447" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ia6a936de443b4950858db56d546f4447" continuedAt="i9df88ff3d142418d87a623dbad76d21a"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each interim period, management estimates the annual effective tax rate based on forecasted pre-tax results of the Company&#8217;s global operations and applies such rate to its ordinary quarterly earnings to calculate income tax expense related to ordinary income. The tax effects of items significant, unusual and infrequent in nature are discretely calculated and recognized in the period during which they occur. These discrete items often relate to changes in tax laws, excess tax benefits/deficiencies related to share-based compensation or adjustments to previously reported tax expense/benefits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing available positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred income tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9df88ff3d142418d87a623dbad76d21a">A cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome. Cumulative loss in recent years is commonly defined as a three-year cumulative loss position. As of March 31, 2023, the Company&#8217;s U.S. ongoing operations were in a three-year cumulative loss position. Management determined that sufficient objectively verifiable positive evidence did not exist to overcome the negative evidence of the Company&#8217;s U.S. cumulative loss position. Accordingly, the Company&#8217;s estimated annual effective tax rate applied to the Company&#8217;s pre-tax loss for the three months ended March 31, 2023, includes the unfavorable impact of a valuation allowance against the Company&#8217;s deferred income tax assets expected to be created in 2023 for additional U.S. net operating loss and tax credit carryforwards as well as Switzerland, China and Singapore deferred tax assets. Management has however determined that sufficient objectively verifiable positive evidence does exist to overcome the negative evidence of the Company&#8217;s U.K. cumulative loss position. The reversal of U.K. deferred tax liabilities will provide a sufficient source of realization to support the full recognition of the U.K. deferred tax assets and therefore no valuation allowance has been established for those deferred tax assets. Accordingly, the Company&#8217;s estimated annual effective tax rate applied to the Company&#8217;s pre-tax loss for the three months ended March 31, 2023, includes the favorable impact of recognizing the U.K. benefit.</ix:continuation> </span></div><div id="ie8083b97acb547a982e84d715e3cf283_76"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMjAyNA_0d9a6986-be81-421c-b036-be680b33a30c" continuedAt="i4eeb0e75afc14f66bd99ace8f17ff413" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i4eeb0e75afc14f66bd99ace8f17ff413"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents both basic earnings per share (&#8220;EPS&#8221;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock options were exercised, stock awards vested and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury stock method based on the average market value of the Company&#8217;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#8217;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).</span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMjAyNw_02892cf9-18c7-403b-bd82-d44096f43468" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations (in thousands, except net loss per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:59.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMy0yLTEtMS0xNjc1NDU_aaa6f58a-49dd-4ddd-97b1-48a957dbbf69">30,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMy00LTEtMS0xNjc1NDU_ce41fc0e-f14b-47e9-a85e-66c190bb1275">49,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfOC0yLTEtMS0xNjc1NDU_707c3b20-1da6-41c9-86d3-f251f6102f97">125,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfOC00LTEtMS0xNjc1NDU_b7bc6760-c9ab-467b-b511-149aa12574fc">123,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTMtMi0xLTEtMTY3NTQ1_f7640f00-eda9-4d24-9b8e-4a569acc6580">125,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTMtNC0xLTEtMTY3NTQ1_d28b0513-8d03-4b57-9b84-d218948a2c76">123,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTUtMi0xLTEtMTY3NTQ1_e2794ca1-3a1d-4997-a3d8-119612193fc0">0.25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTUtNC0xLTEtMTY3NTQ1_fdf25283-9c2e-4d9b-9221-91981412a03c">0.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTYtMi0xLTEtMTY3NTQ1_09be69c3-9618-4b69-ae56-41f10c3aa9ab">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTYtNC0xLTEtMTY3NTQ1_4f3d95c1-053a-4685-ae69-48ef6c24c1d4">0.40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMjAyOA_34e50eba-12e0-4903-a4e4-6fef5cbef545" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:59.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef7183b65cb4f2f9f4adf9f0a5bb5b6_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMi0yLTEtMS0xNjc1NDU_233ab3f9-60f1-4ccd-b11e-7392a49731c7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdb4dbfbf647436ebf637a1b3d7cc7d8_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMi00LTEtMS0xNjc1NDU_2efd1d49-b9ab-4b71-9c26-5c1b37453a2c">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief61d5bc03a04fc793734af9dc810aab_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMy0yLTEtMS0xNjc1NDU_b64db7b9-a6ff-4df7-8700-5981562a0215">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe85cf00c6914ff48f891eb304bfa59f_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMy00LTEtMS0xNjc1NDU_c703b71c-4a07-4116-8d3c-645387459dfe">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ca7d72eb0dc4c1794a0c06f7f6fa78d_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNC0yLTEtMS0xNjc1NDU_aecc3815-b8b3-4aa8-a51f-d06731207646">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61b3ab81b6f5476ea3f286adedb2c683_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNC00LTEtMS0xNjc1NDU_151a774d-9912-4f8b-9927-967f6989291e">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i207470ae354943faa9001607fe4529a7_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNS0yLTEtMS0xNjc1NDU_6e685c07-d73b-494d-b8ec-66715b49a522">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad53f6ac95fd426b9947f85a93074c2e_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNS00LTEtMS0xNjc1NDU_385243fc-0775-4e18-bdd0-8012fe11b4cf">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#8220;Capped Call Transactions&#8221;) with option counterparties pursuant to capped call confirmations at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="if650c426e70e4f4a8a39d610bfaab9b5_D20210111-20210111" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMTY4Mw_ad7060f9-f4b4-41c6-a926-1eb3358d3620">29.3</ix:nonFraction>&#160;million. The potential effect of the Capped Call Transactions were excluded from the calculation of diluted net loss per share in the three months ended March 31, 2023 as the Company&#8217;s closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMTA5OTUxMTYyOTgyNw_b670899e-b6ba-4f81-99c6-32651eb29698">17.41</ix:nonFraction> on March 31, 2023 did not exceed the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa8cf70c5a204e4ba1dd0ff819094a7a_I20230331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMTkwNw_86c1a15b-fed5-4fe3-8464-3e07c3ad5628">85.75</ix:nonFraction> per share. The Capped Call Transactions are not reflected in diluted net loss per share as they are anti-dilutive.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfMjc4MA_a46a834f-804e-49da-9d12-4c8256edbce2" continuedAt="ifd0d756d35264a748036a7b4df716892" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ifd0d756d35264a748036a7b4df716892"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#8217;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in U.S. District Court for the district of Delaware, alleging Inivata&#8217;s InVisionFirst&#174;-Lung cancer diagnostic test of infringing <ix:nonFraction unitRef="patent" contextRef="ic233566287de4d36bb1a6bb64acf5924_D20210120-20210120" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfNTQ5NzU1ODE5NDI2_58a7892a-ce49-4b01-ac1c-7c116aaaed8c">two</ix:nonFraction> patents. Natera then filed a second patent infringement complaint on December 20, 2022 against Inivata Limited and Inivata Inc. alleging that RaDaR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> minimal residual disease test infringes <ix:nonFraction unitRef="patent" contextRef="i52bebd24ded945888e4e9c5d03543ea8_D20221220-20221220" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfNTQ5NzU1ODE5NDMx_9d4000eb-a24f-4275-8c74-b847f416e238">one</ix:nonFraction> patent. The litigation is approaching the discovery stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2022, a purported shareholder class action captioned Daniel Goldenberg v. NeoGenomics, Inc., Douglas VanOort, Mark Mallon, Kathryn McKenzie, and William Bonello was filed in the United States District Court for the Southern District of New York, naming the Company and certain of the Company&#8217;s current and former officers as defendants. This lawsuit was filed by a stockholder who claims to be suing on behalf of anyone who purchased or otherwise acquired the Company&#8217;s securities between February 27, 2020 and April 26, 2022. The lawsuit alleges that material misrepresentations and/or omissions of material fact were made in the Company&#8217;s public disclosures in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The alleged improper disclosures relate to statements regarding the Company&#8217;s menu of tests, business operations and compliance with health care laws and regulations. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney&#8217;s fees and expert fees. The Company believes that it has valid defenses to the claims alleged in this lawsuit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company made an offer to remedy a dispute and the dispute is now in pre-litigation non-binding mediation.&#160;As a result, the Company has recorded a liability in accrued expenses and other liabilities as of March 31, 2023 on the Consolidated Balance Sheets based on the offer to settle this dispute, which reflects management&#8217;s best estimate of the minimum probable loss associated with this matter.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) of the Company&#8217;s internal investigation in November 2021. The Company&#8217;s interactions with regulatory authorities and the Company&#8217;s related review of this matter are ongoing. The Company has a reserve of $<ix:nonFraction unitRef="usd" contextRef="i7d357522f0b4460a9c80ae8413a0dce2_I20230331" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfMTI2MQ_ab8e92a3-f1cf-4e09-8c28-3ebbe5dd5a8f"><ix:nonFraction unitRef="usd" contextRef="i7d234e06879f4d25b290bf7fa83aa615_I20221231" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfMTI2MQ_efd5a65b-e56c-43d2-a7b4-40524b9ce0be">11.2</ix:nonFraction></ix:nonFraction> million in other long-term liabilities as of March 31, 2023 and December 31, 2022 on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#8217;s best estimate of the minimum probable loss associated with this matter. As a result of the internal investigation and ongoing interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. The Company was notified on June 30, 2022 that the Department of Justice (&#8220;DOJ&#8221;) will be participating in the investigation of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, DOJ, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#8217;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, exclusion from participation in federal healthcare programs or other losses or conduct restrictions, which could be material to the Company&#8217;s financial results or business operations.</span></div></ix:continuation><div><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_85"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184NS9mcmFnOjBhMGFkNTY5MDU5ZTRkMDBiZWNkMTA0ZDRiZGEwZWI4L3RleHRyZWdpb246MGEwYWQ1NjkwNTllNGQwMGJlY2QxMDRkNGJkYTBlYjhfMjA0Nw_4fcd00a7-0cd1-4b6d-b815-48b9de3a50ef" continuedAt="i3234f04e95cb4ba3a1ae4ea9789b7e7d" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3234f04e95cb4ba3a1ae4ea9789b7e7d">The Company has Pharma Services contracts with HOOKIPA Pharma, Inc., an entity with whom a director of the Company, Michael A. Kelly, was a director of until April 2023. In connection with these contracts, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i954166d7487547128bc5b533688dd6d9_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184NS9mcmFnOjBhMGFkNTY5MDU5ZTRkMDBiZWNkMTA0ZDRiZGEwZWI4L3RleHRyZWdpb246MGEwYWQ1NjkwNTllNGQwMGJlY2QxMDRkNGJkYTBlYjhfMTgyMw_37b03f58-b588-4f31-97a2-50d1a1ef5133">0.2</ix:nonFraction>&#160;million of revenue in the Consolidated Statements of Operations for the three months ended March 31, 2023. Revenue recognized in connection with these contracts for the three months ended March 31, 2022 was immaterial.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTkwOQ_9bc06a6b-37b8-4df2-9702-5107487a1539" continuedAt="i9a4031c5009f48a2b81c32893834aeca" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="i9a4031c5009f48a2b81c32893834aeca"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under <ix:nonFraction unitRef="segment" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfNTQ5NzU1ODIxOTU5_7e9cfdcc-76bf-459b-95ba-9f64df8df276">two</ix:nonFraction> reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#8217; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes segment information for the three months ended March 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTkxMA_70a3caa3-09af-48cd-bde3-3c996875335f" continuedAt="i71c55deaf8e24d738b7fb802526f10fe" escape="true">(in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><ix:continuation id="i71c55deaf8e24d738b7fb802526f10fe"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:63.833%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMy0yLTEtMS0xNjc1NDU_32389eac-6cba-483d-a048-fd38ad37b451">114,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMy00LTEtMS0xNjc1NDU_cacc4296-29e7-4665-be5d-66d928bfcdda">98,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNC0yLTEtMS0xNjc1NDU_b5937a9c-7bb7-4430-b902-7d73f65e0380">22,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNC00LTEtMS0xNjc1NDU_942ff5b0-4411-4114-a865-563c700743c4">18,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNS0yLTEtMS0xNjc1NDU_77f0f390-89ba-4aaf-859a-7541ba0c4b78">137,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNS00LTEtMS0xNjc1NDU_aef235e2-1ee0-4693-a955-4c0812bc290c">117,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOC0yLTEtMS0xNjc1NDU_8ea9a0ad-69ac-49f3-a11d-38005e39500b">67,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOC00LTEtMS0xNjc1NDU_799ade7d-e277-4822-b9e6-c87c944b1c4b">65,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOS0yLTEtMS0xNjc1NDU_251814f6-8cb5-4fc5-b900-5b8c6f71503e">15,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOS00LTEtMS0xNjc1NDU_1e87aa20-0846-48ef-9c8b-8f394c0126f1">13,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTAtMi0xLTEtMTY3NTQ1_dadbda83-03df-4c61-8ff7-048f8087c5e9">82,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTAtNC0xLTEtMTY3NTQ1_7a996486-e019-4394-9dbe-e0cc212edd24">78,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTMtMi0xLTEtMTY3NTQ1_b57edaf8-d1ee-4d7e-b55f-d18ea8b814f6">47,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTMtNC0xLTEtMTY3NTQ1_b6e2f8be-e2bc-48db-a6a5-a4c5d5e80b58">33,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTQtMi0xLTEtMTY3NTQ1_f480a1c2-7f7a-42e3-b21a-95397b61cf8e">7,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTQtNC0xLTEtMTY3NTQ1_03b80edf-cb0c-4b8a-9eae-57962065ea9c">4,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTUtMi0xLTEtMTY3NTQ1_d4743ee0-79d5-454b-af88-e76b06eac177">54,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTUtNC0xLTEtMTY3NTQ1_d0416ae2-2269-4297-ba20-f87e773ccf30">38,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTgtMi0xLTEtMTY3NTQ1_02005dd8-d5b7-48ea-bf16-2695c2d009aa">61,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTgtNC0xLTEtMTY3NTQ1_12e2627f-6ea5-4b1d-a9dd-8916155068dd">66,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTktMi0xLTEtMTY3NTQ1_b80d3ae7-9473-478a-af18-cf4225c7d994">7,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTktNC0xLTEtMTY3NTQ1_4db74006-9496-4e87-9956-f48aa16f05e3">7,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjAtMi0xLTEtMTY3NTQ1_8a771858-91fc-40d4-9ac1-5db55375ca21">16,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjAtNC0xLTEtMTY3NTQ1_c3ae94b7-cf1b-4002-a0db-ea566df01db4">16,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtMi0xLTEtMTcyMzg4_e32e2ef7-9cde-45cf-af88-8aa62e57b617">4,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtNC0xLTEtMTcyMzg4_ea223d3c-eb57-4aba-812f-9089a590a9fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtMi0xLTEtMTY3NTQ1_3a53f132-01ab-43d8-b6e0-d903c120f479">89,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtNC0xLTEtMTY3NTQ1_500d459e-e309-4d85-abc2-f7c164a2eb0a">90,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjItMi0xLTEtMTY3NTQ1_dec30675-95f3-45a5-960f-db78ba31017c">35,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjItNC0xLTEtMTY3NTQ1_d267a51e-12bf-42a5-93cd-38903964c86b">52,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjMtMi0xLTEtMTY3NTQ1_d2877a2c-83f5-4dd4-925d-bf140170c368">1,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjMtNC0xLTEtMTY3NTQ1_aabdef88-88b4-4072-9ff1-a198f46f8222">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjQtMi0xLTEtMTY3NTQ1_a7762951-6626-4df2-8a09-233f40e4a720">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjQtNC0xLTEtMTY3NTQ1_0b03503b-8e1e-4fce-bc8d-d75714c21a9c">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjgtMi0xLTEtMTY3NTQ1_487aeeb3-0815-47e3-8da7-50bcc56e1b1e">33,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjgtNC0xLTEtMTY3NTQ1_6a0dbd29-2db4-4fad-bff0-e701ce8252b8">53,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjktMi0xLTEtMTY3NTQ1_86bec0c6-16c2-444f-af37-73fad1060c5d">2,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjktNC0xLTEtMTY3NTQ1_b5cbc842-170e-46e1-8484-ef94d635a6d0">3,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMzAtMi0xLTEtMTY3NTQ1_c0bdc8a9-6d9a-4411-9c60-82cfd28e356a">30,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMzAtNC0xLTEtMTY3NTQ1_1dfb214a-efdc-4e91-9c80-ebe0aeb6a1dd">49,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTEzNg_0b88e68a-f4dc-420a-b6b0-b339099f7332"><ix:nonFraction unitRef="usd" contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTEzNg_b8a94e41-6540-4211-8beb-ae7d1cb39115">4.3</ix:nonFraction></ix:nonFraction>&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 include $<ix:nonFraction unitRef="usd" contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTY1NQ_139100be-569a-4c89-a2ff-ce92393dc9b2"><ix:nonFraction unitRef="usd" contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331" decimals="-5" name="neo:IntangibleAssetsAcquiredAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTY1NQ_a6890b21-094b-416d-9b70-3af6aca5df04">0.6</ix:nonFraction></ix:nonFraction>&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_94"></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_97"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NeoGenomics, Inc., a Nevada corporation (referred to individually as the &#8220;Parent Company&#8221; or collectively with its subsidiaries as &#8220;NeoGenomics,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221; in this Quarterly Report) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;NEO&#8221;.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included herein. The information contained below includes statements of the Company&#8217;s or management&#8217;s beliefs, expectations, hopes, goals and plans that, if not historical, are forward-looking statements subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion on forward-looking statements, see the information set forth in the introductory note to this Quarterly Report on Form 10-Q under the caption &#8220;Forward-Looking Statements,&#8221; which information is incorporated herein by reference.</span></div><div id="ie8083b97acb547a982e84d715e3cf283_100"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a network of cancer-focused testing laboratories in the United States, Europe and Asia. Our mission is to improve patient care through exceptional cancer-focused testing services. Our vision is to be the world&#8217;s leading cancer testing and information company by delivering uncompromising quality, exceptional service and innovative solutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we operated College of American Pathologists (&#8220;CAP&#8221;) accredited and Clinical Laboratory Improvement Amendments of 1988 (&#8220;CLIA&#8221;) certified laboratories in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and CAP accredited full-service, sample-processing laboratories in Rolle, Switzerland; Singapore and China. CAP accreditation is pending in Cambridge, United Kingdom. We also have several, small, non-processing laboratory locations across the United States for providing analysis services. We currently offer the following types of testing services:</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cytogenetics (&#8220;karyotype analysis&#8221;) &#8211; the study of normal and abnormal chromosomes and their relationship to disease. Cytogenetics involves analyzing the chromosome structure to identify changes from patterns seen in normal chromosomes. Cytogenetic studies are often performed to provide diagnostic, prognostic and occasionally predictive information for patients with hematological malignancies.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fluorescence In-Situ Hybridization (&#8220;FISH&#8221;) &#8211; a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes. The technique uses fluorescent probes that bind to only those parts of the chromosome with which they show a high degree of sequence similarity. Fluorescence microscopy is used to visualize the fluorescent probes bound to the chromosomes. FISH can be used to help identify numerous types of gene alterations, including amplifications, deletions, and translocations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Flow cytometry &#8211; a technique utilized to measure the characteristics of cell populations. Typically performed on liquid samples such as peripheral blood and bone marrow aspirate, it may also be performed on solid tissue samples such as lymph nodes following additional processing steps. Cells are labeled with selective fluorescent antibodies and analyzed as they flow in a fluid stream through a beam of light. The properties measured in these antibodies include the relative size, relative granularity or internal complexity, and relative fluorescence intensity. These fluorescent antibodies bind to specific cellular antigens and are used to identify abnormal and/or malignant cell populations. Flow cytometry is typically utilized in diagnosing a wide variety of hematopoietic and lymphoid neoplasms. Flow cytometry is also used to monitor patients during the course of therapy to identify extremely low levels of residual malignant cells, known as minimal residual disease (&#8220;MRD&#8221;) monitoring.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Immunohistochemistry (&#8220;IHC&#8221;) and Digital Imaging &#8211; the process of localizing cellular proteins in tissue sections and relies on the principle of antigen-antibody binding. IHC is widely used in the diagnosis of abnormal cells such as those found in cancer. Specific surface membrane, cytoplasmic, or nuclear markers may be identified. IHC is also widely used to understand the distribution and localization of differentially expressed proteins. Digital imaging allows clients to visualize scanned slides and also perform quantitative analysis for certain stains. Scanned slides are received online in real time and can be previewed often a full day before the glass slides can be shipped back to clients.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Molecular testing &#8211; a rapidly growing field which includes a broad range of laboratory techniques utilized in cancer testing. Most molecular techniques rely on the analysis of DNA and/or RNA, as well as the structure and function of genes at the molecular level. Molecular testing technologies include: liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases; DNA fragment length analysis; polymerase chain reaction (&#8220;PCR&#8221;) analysis; reverse transcriptase polymerase chain reaction (&#8220;RT-PCR&#8221;) analysis, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">real-time (or quantitative) polymerase chain reaction (&#8220;qPCR&#8221;) analysis; bi-directional Sanger sequencing analysis; and next-generation sequencing (&#8220;NGS&#8221;) analysis.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morphologic analysis &#8211; the process of analyzing cells under the microscope by a pathologist, usually for the purpose of diagnosis. Morphologic analysis may be performed on a wide variety of samples, such as peripheral blood, bone marrow, lymph node, and from other sites such as lung, breast, etc. The services provided at NeoGenomics may include primary diagnosis, in which a sample is received for processing and our pathologists provide the initial diagnosis; or may include secondary consultations, in which slides and/or tissue blocks are received from an outside institution for second opinion. In the latter setting, the expert pathologists at NeoGenomics assist our client pathologists on their most difficult and complex cases.</span></div><div style="margin-bottom:5pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Segment </span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical cancer testing services we offer to community-based pathologists and oncologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. We believe our relationship as a non-competitive partner to community-based pathology practices, hospital pathology labs, reference labs, and academic centers can empower them to expand their breadth of testing to provide a menu of services that could match or exceed the level of service found in any center of excellence around the world. Community-based pathology practices and hospital pathology labs may order certain testing services on a technical component only (&#8220;TC&#8221; or &#8220;tech-only&#8221;) basis, which allows them to participate in the diagnostic process by performing the professional component (&#8220;PC&#8221;) interpretation services without having to hire laboratory technologists or purchase the sophisticated equipment needed to perform the technical component of the tests. We also support our pathology clients with interpretation and consultative services using our own specialized team of pathologists for difficult or complex cases and we provide overflow interpretation services when requested by clients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of Heme Molecular and NGS testing and one of the key providers of solid tumor NGS testing solutions. These tests are interpreted by NeoGenomics&#8217; team of Molecular experts and are often ordered in conjunction with other testing modalities. NGS panels are one of our fastest growing testing areas and clients can often receive a significant amount of biomarker information from very limited samples. These comprehensive panels can allow for faster treatment decisions for patients as compared to a series of single-gene molecular tests being ordered sequentially. We have a broad Molecular testing menu and our targeted NeoTYPE panels include genes relevant to a particular cancer type, as well as other complementary tests such as IHC and FISH. In addition, we offer molecular-only NGS targeted and comprehensive panels which combine DNA and RNA into a single work stream in order to report a full spectrum of genomic alterations, including mutations, fusions, copy number variations, and gene expression. This comprehensive menu means that our clients can get most of their oncology testing needs satisfied by our laboratory. This is attractive to our clients as patient samples do not need to be split and then managed across several laboratories. The acquisition of Inivata provided us with oncology Liquid Biopsy technology capabilities. InVisionFirst&#174;-Lung is a highly sensitive, targeted plasma-based assay for patients with non-small cell lung cancer, and RaDaR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an industry-leading liquid biopsy assay designed to detect residual disease and recurrence in plasma samples from patients with solid tumor malignancies. We expect our Molecular laboratory and NGS capabilities to be a key growth driver in the coming years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we directly serve oncology, dermatology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic testing services. We typically serve these types of clients with a comprehensive service offering where we perform both the technical and professional components of the tests ordered. In certain instances, larger clinician practices have begun to internalize pathology interpretation services, and our tech-only service offering allows these larger clinician practices to also participate in the diagnostic process by performing the PC interpretation services on TC testing performed by us.&#160;In these instances we will typically provide all of the more complex, molecular testing services.</span></div><div style="margin-bottom:5pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Segment</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services revenue consists of three revenue streams:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Clinical trials and research;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Validation laboratory services; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Informatics.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research.&#160;This portion of our business often involves working with the pharmaceutical firms (&#8220;sponsors&#8221;) on study design as well as performing the required testing.&#160;Our medical team often advises the sponsor and works closely with them as specimens are received from the enrolled sites.&#160;We also work on developing tests that will be used as part of a companion diagnostic to determine patients&#8217; response to a particular drug.&#160;As studies unfold, our clinical trials team reports the data and often provides key analysis and insights back to the sponsors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharma Services segment provides comprehensive testing services in support of our pharmaceutical clients&#8217; oncology programs from discovery to commercialization.&#160;In biomarker discovery, our aim is to help our customers discover the right content.&#160;We help our customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing our discovery tools with the informatics to capture meaningful data.&#160;In other pre-clinical and non-clinical work, we can use our platforms to characterize markers of interest.&#160;Moving from discovery to development, we seek to help our customers refine their biomarker strategy and, if applicable, develop a companion diagnostic pathway using the optimal technology for large-scale clinical trial testing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether serving as the single contract research organization or partnering with one, our Pharma Services team provides significant technical expertise, working closely with our customers to support each stage of clinical trial development.&#160;Each trial we support comes with rapid turnaround time, dedicated project management and quality assurance oversight. We have experience in supporting submissions to the Federal Drug Administration (&#8220;FDA&#8221;) for companion diagnostics. Our Pharma Services strategy is focused on helping to bring more effective oncology treatments to market through providing world-class laboratory services in oncology to key pharmaceutical companies in the industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we are well positioned to service Pharma sponsors across the full continuum of the drug development process. Our Pharma Services team can work with these sponsors during the basic research and development phase as compounds come out of translational research departments, as well as work with clients from Phase I, Phase II and Phase III clinical trials as the sponsors work to demonstrate the efficacy of their drugs. The laboratory biomarker tests that are developed during this process may become companion diagnostic (&#8220;CDx&#8221;) tests, that will be used on patients to determine if they could respond to a certain therapy. We are able to offer these CDx tests to the market immediately after FDA approval as part of our Day 1 readiness program. This ability helps to speed the commercialization of a drug and can enable Pharma sponsors to reach patients through our broad distribution channel in the Clinical Services segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to connecting patients with life-altering therapies and trials. In carrying out these commitments, we aim to provide transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and have invested in leading technologies to ensure the data we maintain is secure at all times. We are continuing to develop and broaden our informatics and data-related tools to leverage our unique market position and oncology expertise to help our stakeholders solve real-world problems such as identifying patients for clinical trials or providing clinical decision support tools for physicians and providers. We also offer testing and informatics tools, such as Trapelo&#8482;, to help health care professionals navigate the rapidly evolving field of precision medicine. Trapelo&#8482; is an end-to-end, clinical decision-support platform designed to resolve the complexities of precision oncology &#8211; from test ordering to therapy selection to navigating prior authorization.</span></div><div id="ie8083b97acb547a982e84d715e3cf283_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Focus Areas: </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to sustainable growth while transforming cancer care for patients and providers. Our focus for 2023 is to sustain a purpose driven culture that maintains excellence in service and performance while growing through innovation. We expect the following initiatives to allow us to continue on our path to become one of the world&#8217;s leading cancer testing and information companies:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Profitably Grow Core Business</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grow volume and NGS mix;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improve turnaround time;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Win on service;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expand and optimize commercial optimization; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improve product offering.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accelerate Pharma Services</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Execute clinical RaDaR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MRD) launch;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launch Neo Comprehensive, new NGS offering;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue to improve Pharma growth and profitability; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Focus on enterprise data strategy. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Improve Profitability</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increase productivity and efficiency;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manage general and administrative spend;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Focused investments; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prioritize revenue cycle management.</span></div><div id="ie8083b97acb547a982e84d715e3cf283_106"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Strengths</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe the following areas are competitive differentiators:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Turnaround Times</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consistently focus on improving turnaround times for test results to our clients nationwide in the Clinical Services segment. By providing information to our clients in a timely manner, physicians can begin treating their patients as soon as possible. Timeliness of results by our Clinical Services segment is a driver of additional testing requests by referring physicians. Turnaround times allow for the performance of other adjunctive tests within an acceptable diagnosis window in order to augment or confirm results and more fully inform treatment options. Additionally, we believe that our rapid turnaround time on testing and our project milestones are a key factor in our Pharma Services segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Innovative Service Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we currently have the most extensive menu of tech-only FISH services in the country as well as extensive and advanced tech-only flow cytometry and IHC testing services. These types of testing services allow the professional interpretation component of a test to be performed and billed separately by our physician clients. Our tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order only the technical component of testing so they can perform the professional interpretation, or order &#8220;global&#8221; services and receive a comprehensive test report which includes a NeoGenomics pathologist&#8217;s interpretation of the test results. Our clients appreciate the flexibility to access NeoGenomics&#8217; medical staff for difficult or complex cases or when they are otherwise unavailable to perform professional interpretations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a comprehensive suite of technical and professional interpretation services to meet the needs of clients who are not credentialed and/or trained in interpreting various testing modalities and who require Neo pathology specialists to interpret their testing results. In our global service offerings, our lab performs the technical component of testing and our MDs and PhDs provide the professional component of testing by interpreting the results of those tests. Our professional staff is also available for post-test consultative services. Clients using our global service offering rely on the expertise of our medical team to give them the answers they need in a timely manner to help inform their diagnoses and treatment decisions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Molecular and NGS test menus provide clients with the ability to order single gene molecular tests, targeted NeoTYPE panels that include the relevant actionable genes for a particular cancer type as well as large NGS panels. Our Pharma Services segment offers a full range of sequencing testing including whole exome and whole genome sequencing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Direct Sales Force</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct sales force has been trained extensively in cancer genetic testing and consultative selling skills to service the needs of clients. Our sales team for the clinical cancer testing services is organized into nine regions &#8211; Northeast, Northwest, Mid-Atlantic, South, Southeast, Southwest, West, Great Lakes, and South Central. Our sales team will be focused on end-to-end client experience as a growth driver. Our Pharma Services segment has a dedicated team of business development specialists who are experienced in working with Pharma sponsors and helping them with the testing needs of their research and development projects as well as Phase I, II and III studies. These sales representatives utilize our custom Customer Relationship Management System (&#8220;CRM&#8221;) to manage their territories, and we have integrated the key customer care functionality within our Laboratory Information Services (&#8220;LIS&#8221;) into the CRM so that our sales representatives can stay informed of emerging issues and opportunities within their regions. Our in-house customer care team is aligned with our field sales team to serve the needs of our clients by utilizing the same LIS and CRM. Our field teams can see in real-time when a client calls the laboratory, the reason for the call, the resolution, and if face-to-face interaction is needed for follow-up. Our sales force educates clients on new test offerings and their proper utilization and our representatives are often seen as trusted advisors by our clients.</span></div><div id="ie8083b97acb547a982e84d715e3cf283_109"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our clinical testing volume is dependent on patients being treated by hematology/oncology professionals and other healthcare providers. The volume of our testing services generally declines modestly during the summer vacation season, year-end holiday periods and other major holidays, particularly when those holidays fall during the middle of the week. In addition, the volume of our testing tends to decline due to extreme adverse weather conditions, such as excessively hot or cold spells, heavy snow, hurricanes or tornadoes in certain regions, consequently reducing revenues and cash flows in any affected period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Pharma Services segment, we enter into both short-term and long-term contracts, ranging from one month to several years. While the volume of this testing is not as directly affected by seasonality as described above, the testing volume does vary based on the terms of the contract. Our volumes are often based on how quickly sponsors can get patient enrollees for their trials and seasonality can impact how quickly patients are enrolled. Many of our long-term contracts contain specific </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations where the testing is performed on a specific schedule. In addition, this results in backlog that can be significant and highly dependent on Pharma clinical trial enrollment, which continues to recover from the slowdown experienced due to the COVID-19 pandemic.</span></div><div id="ie8083b97acb547a982e84d715e3cf283_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended March 31, 2023 as Compared to the Three Months Ended March 31, 2022</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations as a percentage of net revenue for the periods presented are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue for the both the three months ended March 31, 2023 and 2022 includes $4.9 million of amortization of acquired Inivata developed technology intangible assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Services and Pharma Services net revenues for the periods presented are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated revenues increased $20.1&#160;million, or 17.1%, year-over-year. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Services revenue for the three months ended March 31, 2023 increased $16.1 million when compared to the same period in 2022. The increase in Clinical Services revenue reflects an increase in clinical testing volume, a more favorable test mix and an increase in average unit price due to strategic reimbursement initiatives.</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma Services revenue for the three months ended March 31, 2023 increased $4.0 million compared to the same period in 2022 due to the timing of project activity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Revenue and Gross Profit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payroll and payroll-related costs for performing tests, maintenance and/or depreciation of laboratory equipment, rent for laboratory facilities, laboratory reagents, probes and supplies, delivery and courier costs relating to the transportation of specimens to be tested, and amortization for acquired Inivata developed technology intangible assets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated cost of revenue and gross profit metrics for the periods presented are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,937&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $4.3 million of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $0.6 million of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated cost of revenue increased for the three months ended March 31, 2023 when compared to the same period in 2022 primarily due to higher payroll and payroll-related costs and an increase in supplies expense. These increases were partially offset by a decrease in professional fees.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit margin for the three months ended March 31, 2023 was 39.9% compared to 32.6% in the same period in 2022. The increase of 7.3% for the three months ended March 31, 2023 was primarily related to the increase in revenue offset by higher payroll and payroll-related costs and an increase in supplies expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of payroll and payroll-related costs for our executive, billing, finance, human resources, information technology, and other administrative personnel, as well as stock-based compensation. We also allocate professional services, facilities expense, IT infrastructure costs, depreciation, amortization and other administrative-related costs to general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated general and administrative expenses for the periods presented are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,699)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a % of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased $4.7 million for the three months ended March 31, 2023, when compared to the same period in 2022. This decrease was partially due to a $7.3&#160;million decrease in incremental non-cash stock-based compensation expense, of which $5.9&#160;million related to the acceleration of stock option and restricted stock awards upon the Chief Executive Officer&#8217;s departure in the first quarter of 2022. In addition, there was a $1.4&#160;million decrease in professional fees incurred in the first quarter of 2023 when compared to the same period in 2022. These decreases were partially offset by net increases in cash-based payroll and payroll-related expenses of $1.4&#160;million, an increase in depreciation expense of $0.5&#160;million, and an increase in amortization expense of $0.3&#160;million. In addition, the three months ended March 31, 2022 included a gain on sale of assets held for sale of $2.0&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses relate to costs of developing new proprietary and non-proprietary genetic tests, including payroll and payroll-related costs, maintenance of laboratory equipment, laboratory supplies (reagents), and outside consultants and experts assisting our research and development team.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated research and development expenses for the periods presented are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a % of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $0.3 million for the three months ended March 31, 2023 when compared to the same period in 2022 primarily due to a decrease in payroll and payroll-related costs partially offset by an increase in materials expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate research and development expenditures will increase in the future as we continue to invest in development costs for strategic innovation projects and bringing new tests to market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales and marketing expenses for the periods presented are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:44.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a % of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales and marketing expenses were flat for the three months ended March 31, 2023, when compared to the same period in 2022 resulting from increases in sales commissions, conference and tradeshow expenses, and advertising expenses offset by decreases in professional fees, bonus expense and travel expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect higher commissions expense in the coming quarters as our sales representatives generate new business in our business segments. We expect our sales and marketing expenses over the long term to align with changes in revenue and we continue to evaluate the effectiveness of our incentive compensation plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restructuring charges</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated restructuring charges for the periods presented are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:45.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a % of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges relate to a restructuring program to improve execution and drive efficiency across the organization. Restructuring charges consist of severance and other employee costs, costs for optimizing our geographic presence, and consulting and other costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, we recorded $4.7 million of restructuring charges. The charges were comprised of $3.1 million in severance and other employee costs, $1.5 million in Facility Footprint Optimization costs, and $0.1 million of consulting and other costs. There were no such amounts recorded for the three months ended March 31, 2022. We will continue this restructuring program in 2023 and expects to incur additional restructuring charges of approximately $3.0&#160;million. Our restructuring activities are expected to be complete by December 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest (income) expense, net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (income) expense, net, for the three months ended March 31, 2023 and 2022 is as follows (dollars in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:45.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,467)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (income) expense, net, was income of $1.5&#160;million for the three months ended March 31, 2023 compared to expense of $1.3&#160;million for the same period in 2022. Interest income includes interest earned on funds held in our cash equivalent and marketable securities accounts. Interest expense reflects the effective interest rate on the 2028 Convertible Notes and the 2025 Convertible Notes which is 0.70% and 1.96%, respectively. Interest on the 2028 Convertible Notes and 2025 Convertible Notes began accruing upon issuance and is payable semi-annually. Interest expense also includes amortization related to our fixed income investments. The increase in interest income for the three months ended March 31, 2023 was due to the higher interest rate environment experienced when compared to the same period in 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further details regarding our investments in marketable securities and the convertible notes, please refer to Note 3. Fair Value Measurements and Note 5. Debt, respectively, in the accompanying notes to the unaudited Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides consolidated net loss for each period along with the computation of basic and diluted net loss per share for the three months ended March 31, 2023 and 2022 (in thousands, except net loss per share data):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_115"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide greater transparency regarding our operating performance, the financial results and financial guidance include the use of certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to our core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of our core test-level operating results across reporting periods and when comparing those same results to those published by our peers. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures used by other companies.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definitions of Non-GAAP Measures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-GAAP Adjusted EBITDA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Adjusted EBITDA&#8221; is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest (income) expense, net, (ii) tax (benefit) or expense, (iii) depreciation and amortization expense, (iv) non-cash stock-based compensation expense, and, if applicable in a reporting period, (v) acquisition and integration related expenses, (vi) restructuring charges, and (vii) other significant or non-operating (income) or expenses, net.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of GAAP net loss to Non-GAAP EBITDA and Adjusted EBITDA for the three months ended March 31, 2023:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:60.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss (GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to net loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA (non-GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,356)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Further adjustments to EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other significant (income) expenses, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA (non-GAAP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,011)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> For the three months ended March 31, 2023, other significant (income) expenses, net, includes CEO transition costs, fees related to a regulatory matter, and other non-recurring items. For the three months ended March 31, 2022, other significant (income) expenses, net, includes a gain on the sale of a building, fees related to the regulatory matter, CEO transition costs, and other non-recurring items.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_118"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through cash generated from operations, public and private sales of debt and equity securities, and bank debt borrowings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of our consolidated cash flows for operating, investing and financing activities for the three months ended March 31, 2023 and 2022 as well balances of cash and cash equivalents and working capital:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,931)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working Capital </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, end of period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,390&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,030&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Defined as current assets less current liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities during the three months ended March 31, 2023, was $12.7 million compared to $29.0 million in the same period in 2022. This $16.3 million decrease was primarily driven by our operating results (net loss adjusted for depreciation, amortization of intangibles, and other non-cash charges) which resulted in $13.7 million of lower cash used by operating activities year-over-year, as well as a $2.6 million decrease in cash used resulting from net changes in operating assets and liabilities. The decrease in cash used related to our operating activities was primarily driven by an improvement in gross profit of $16.6&#160;million. In addition, timing of cash receipts and cash payments in the ordinary course of business caused operating cash flow to fluctuate from period to period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, cash provided by investing activities was $23.7 million compared to $12.1 million of cash provided by investing activities in the same period in 2022. This change was primarily due to a $9.4 million </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in purchases of marketable securities, as well as an increase in proceeds from sales and maturities of marketable securities of $4.0 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Financing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, cash provided by financing activities was $1.4 million compared to $6.1 million in the same period in 2022. The cash provided by financing activities during the three months ended March 31, 2023 primarily consisted of $1.4 million for the net issuance of common stock. The primary reason for the decrease in cash provided by financing activities year-over-year was the timing of cash payments for stock option exercises which can fluctuate from period to period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Outlook</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $275.6 million in unrestricted cash and cash equivalents as of March 31, 2023 in addition to $142.3&#160;million of marketable securities available to support current operational liquidity needs. We anticipate that the cash on hand, marketable securities and cash collections are sufficient to fund our near-term capital and operating needs for at least the next 12 months. Operating needs include, but are not limited to, the planned costs to operate our business, including amounts required to fund working capital and capital expenditures, continued research and development efforts, and potential strategic acquisitions and investments.</span></div><div id="ie8083b97acb547a982e84d715e3cf283_121"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We forecast capital expenditures in order to execute on our business plan and maintain growth; however, the actual amount and timing of such capital expenditures will ultimately be determined by the volume of business. We currently anticipate that our capital expenditures for the year ending December 31, 2023 will be in the range of $30.0 million to $40.0 million. During the three months ended March 31, 2023, we purchased, with cash, approximately $9.9 million of capital equipment, software and leasehold improvements. We have funded and plan to continue funding these capital expenditures with cash and financing.</span></div><div id="ie8083b97acb547a982e84d715e3cf283_124"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with United States generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our management routinely makes judgments and estimates about the effects of matters that are inherently uncertain. Please refer to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022 and Note 2. Summary of Significant Accounting Policies, in the accompanying notes to the unaudited Consolidated Financial Statements for a complete description of our significant accounting policies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks, including changes in interest rates and foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued $201.3 million aggregate principal amount of the 2025 Convertible Notes. The 2025 Convertible Notes have a fixed annual interest rate of 1.25%; therefore, we do not have economic interest rate exposure with respect to the 2025 Convertible Notes. In January 2021, we issued $345.0 million aggregate principal amount of the 2028 Convertible Notes. The 2028 Convertible Notes have a fixed annual interest rate of 0.25%; therefore, we do not have economic interest rate exposure with respect to the 2028 Convertible Notes. However, the fair value of the 2025 Convertible Notes and 2028 Convertible Notes is exposed to interest rate risk. Generally, the fair market value will increase as interest rates fall and decrease as interest rates rise. In addition, the fair value is affected by our common stock price. The fair value will generally increase as our common stock price increases and will generally decrease as our common stock price declines. We carry the 2025 Convertible Notes and 2028 Convertible Notes at face value less unamortized debt discount and debt issuance costs on our balance sheet, and we present the fair value for required disclosure purposes only.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality U.S. government and other highly credit rated debt securities. Our investments are exposed to market risk due to fluctuations in interest rates, which may affect our interest income and the fair market value of our investments. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities with short maturities. If a 1% change in interest rates were to have occurred on March 31, 2023, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we do not believe that we have a material financial market risk exposure and do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates. While we believe our marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in Cambridge, United Kingdom; Rolle, Switzerland; Suzhou, China; and Singapore. Our international revenues and expenses denominated in foreign currencies (primarily British Pounds, Swiss Francs, Chinese Renminbi and Singapore Dollars) expose us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. We do not </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hedge foreign currency exchange risks and do not currently believe that these risks are significant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ie8083b97acb547a982e84d715e3cf283_133"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure Controls and Procedures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 15d-15, our management carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this report.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8212; OTHER INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie8083b97acb547a982e84d715e3cf283_139"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time the Company is engaged in legal proceedings in the ordinary course of business. For further information on legal proceedings, please refer to Note 11. Commitments and Contingencies, in the notes to the unaudited Consolidated Financial Statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ie8083b97acb547a982e84d715e3cf283_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider each of the risk factors described in Part I, Item 1A, &#8220;Risk Factors&#8221; contained in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 24, 2023, as well as the other information set forth in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None for the quarterly period ended March 31, 2023 that have not previously been included in a Current Report on Form 8-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning our purchases of common stock for the periods indicated:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Period of Repurchase</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023 - January 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2023 - February 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2023 - March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36.82pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s Equity Incentive Plan, as amended on May 27, 2021, allows participants to surrender already-owned shares having a fair market value equal to the required withholding tax related to the vesting of restricted stock. Pursuant to a share withholding election made by participants in connection with the vesting of such awards, all of which were outside of a publicly-announced repurchase plan, we acquired from such participants the shares noted in the table above to satisfy tax withholding obligations related to the vesting of their restricted stock. The average prices listed in the above table are averages of the fair market prices at which we valued shares withheld for purposes of calculating the number of shares to be withheld.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ie8083b97acb547a982e84d715e3cf283_148"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ie8083b97acb547a982e84d715e3cf283_151"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ie8083b97acb547a982e84d715e3cf283_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.02</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Appointment of New Chief Accounting Officer</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, the Board of Directors appointed Greg D. Aunan, age 54, as the Chief Accounting Officer of the Company effective May 15, 2023. Mr. Aunan joined NeoGenomics in April 2023 and has recently served as a Senior Vice President, Accounting &amp; Treasury. Prior to joining the Company, Mr. Aunan served as Senior Vice President and Chief Accounting Officer of HMS Holdings Corp. from June 2015 to July 2021. Prior to his time with HMS, Mr. Aunan served as Chief Financial Officer of the international law firm Locke Lord LLP from March 2013 to December 2014. Prior to that time, Mr. Aunan was at KPMG LLP from 1996, where he served as an audit partner from 2008 to February 2013. Mr. Aunan has over 20 years of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressive accounting and auditing experience with focus in consumer markets and retail sectors. He is a licensed Certified Public Accountant and holds an M.B.A. from Drake University and a B.B.A. from the University of Iowa.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Mr. Aunan entered into an Offer Letter that provides that Mr. Aunan&#8217;s base salary will be $360,000 per year and that he will be eligible to receive a performance-based bonus, which will be targeted at 40% of his base salary. This bonus is contingent on completion of certain metrics approved by the Chief Financial Officer and/or Chief Executive Officer of the Company for each fiscal year. Mr. Aunan is entitled to participate in all medical and other benefits that the Company has established for its employees including 15 days of paid time off per year. The Offer Letter provides that Mr. Aunan will receive an equity grant valued at $450,000, half in restricted stock and half in stock options, both of which will vest ratably over four years from date of grant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Mr. Aunan is terminated without cause or if he is terminated in connection with a change in control, the Company agrees to provide to Mr. Aunan as severance an amount equal to four months of his monthly base salary and reimbursement of premiums to continue health care benefits coverage under COBRA for the four months following the date of his termination.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company and Mr. Aunan entered into a Confidentiality, Non-Solicitation and Non-Compete Agreement (the &#8220;Non-Compete Agreement&#8221;). In part, the Non-Compete Agreement contains a non-solicitation and non-compete provision which will be in effect for a twelve month period following the termination of Mr. Aunan&#8217;s employment relationship with the Company for any reason.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Aunan does not have any related party transactions or family relationships with the Company or any of the Company&#8217;s other officers or directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Executive Changes </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cynthia Dieter, will be stepping down as the Chief Accounting Officer of the Company effective May 15, 2023. Although Ms. Dieter will no longer be an officer of the Company, Ms. Dieter will remain an employee of the Company to provide transition and onboarding support to the Company&#8217;s new Chief Accounting Officer through June 30, 2023. Additionally, on May 4, 2023, the Board of Directors of the Company determined that Dr. Shashikant Kulkarni no longer qualifies as a named executive officer of the Company as a result of certain responsibilities being assigned to other executives. </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOGENOMICS, INC.</span></div><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:7.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NO.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-offerletterda.htm">Offer Letter dated March 27, 2023 between NeoGenomics Laboratories and Mr. Greg Aunan.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a03312023neo-ex311.htm">Certification by Principal Executive Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a03312023neo-ex312.htm">Certification by Principal Financial Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a03312023neo-ex321.htm">Certification by Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive File (formatted as inline XBRL and contained within Exhibit 101)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denotes a management contract or compensatory plan or arrangement.</span></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ie8083b97acb547a982e84d715e3cf283_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date: May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEOGENOMICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Christopher M. Smith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Smith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Jeffrey S. Sherman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey S. Sherman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-offerletterda.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit101-offerletterda</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit101-offerletterda001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-offerletterda001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-offerletterda002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-offerletterda002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-offerletterda003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-offerletterda003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-offerletterda004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-offerletterda004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-offerletterda005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-offerletterda005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-offerletterda006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-offerletterda006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a03312023neo-ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1563224c3b2348139813ff5b92c3b4b3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher M. Smith, certify that&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of NeoGenomics, Inc.&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Christopher M. Smith</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Smith</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a03312023neo-ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id3d80b01e26f4dbd8904eb809387eb1e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey S. Sherman, certify that&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of NeoGenomics, Inc.&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey S. Sherman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey S. Sherman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a03312023neo-ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2f0b3e921adb4333a719d9fdc7ccc0ed_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Quarterly Report of NeoGenomics, Inc. (the &#8220;Company&#8221;) on Form 10-Q as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the dates indicated below, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his or her knowledge&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:14pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Christopher M. Smith</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Smith</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey S. Sherman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey S. Sherman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>neo-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9dc41751-b83b-431c-b18e-08aa28ccd964,g:b69a919b-a967-4814-b0e5-6634100d0d89-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:neo="http://neogenomics.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://neogenomics.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="neo-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://neogenomics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusiness" roleURI="http://neogenomics.com/role/NatureoftheBusiness">
        <link:definition>0000008 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://neogenomics.com/role/FairValueMeasurements">
        <link:definition>0000010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000011 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://neogenomics.com/role/Debt">
        <link:definition>0000012 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://neogenomics.com/role/StockBasedCompensation">
        <link:definition>0000013 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://neogenomics.com/role/RevenueRecognition">
        <link:definition>0000014 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://neogenomics.com/role/Restructuring">
        <link:definition>0000015 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://neogenomics.com/role/IncomeTaxes">
        <link:definition>0000016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://neogenomics.com/role/NetLossPerShare">
        <link:definition>0000017 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://neogenomics.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://neogenomics.com/role/RelatedPartyTransactions">
        <link:definition>0000019 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://neogenomics.com/role/SegmentInformation">
        <link:definition>0000020 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://neogenomics.com/role/FairValueMeasurementsTables">
        <link:definition>0000022 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000023 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://neogenomics.com/role/StockBasedCompensationTables">
        <link:definition>0000024 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://neogenomics.com/role/RevenueRecognitionTables">
        <link:definition>0000025 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://neogenomics.com/role/RestructuringTables">
        <link:definition>0000026 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://neogenomics.com/role/NetLossPerShareTables">
        <link:definition>0000027 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://neogenomics.com/role/SegmentInformationTables">
        <link:definition>0000028 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAmortizedCostDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails">
        <link:definition>0000029 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValuebyContractualMaturityDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails">
        <link:definition>0000030 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails">
        <link:definition>0000031 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofGoodwillDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails">
        <link:definition>0000032 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetail" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail">
        <link:definition>0000033 - Disclosure - Goodwill and Intangible Assets - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails">
        <link:definition>0000034 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1">
        <link:definition>0000034 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails">
        <link:definition>0000035 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails">
        <link:definition>0000036 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://neogenomics.com/role/DebtDetails">
        <link:definition>0000037 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000038 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>0000039 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails">
        <link:definition>0000040 - Disclosure - Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockActivityDetails" roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails">
        <link:definition>0000041 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>0000042 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractAssetsandLiabilitiesDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails">
        <link:definition>0000043 - Disclosure - Revenue Recognition - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>0000044 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringActivitiesDetails" roleURI="http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails">
        <link:definition>0000045 - Disclosure - Restructuring - Schedule of Restructuring Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativesDetails" roleURI="http://neogenomics.com/role/RestructuringNarrativesDetails">
        <link:definition>0000046 - Disclosure - Restructuring - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" roleURI="http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails">
        <link:definition>0000047 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSharesDetails" roleURI="http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails">
        <link:definition>0000048 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000049 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000050 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://neogenomics.com/role/SegmentInformationDetails">
        <link:definition>0000051 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="neo_PharmaServicesMember" abstract="true" name="PharmaServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" abstract="false" name="NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_IntangibleAssetsAcquiredAmortizationExpense" abstract="false" name="IntangibleAssetsAcquiredAmortizationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_ConsultingCostsMember" abstract="true" name="ConsultingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_FacilityFootprintOptimizationMember" abstract="true" name="FacilityFootprintOptimizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_CommercialInsuranceMember" abstract="true" name="CommercialInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ClientDirectBillingMember" abstract="true" name="ClientDirectBillingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_SelfPayServicesMember" abstract="true" name="SelfPayServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_MedicareAndOtherGovernmentalMember" abstract="true" name="MedicareAndOtherGovernmentalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="neo_InterestExpenseDebtAccretionOfDebtDiscount" abstract="false" name="InterestExpenseDebtAccretionOfDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_YankeeBondsMember" abstract="true" name="YankeeBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" abstract="false" name="RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="neo_ContractualObligationLineItems" abstract="true" name="ContractualObligationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="neo_InterestExpenseDebtContractualCouponInterest" abstract="false" name="InterestExpenseDebtContractualCouponInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_SeveranceAndOtherEmployeeCostsMember" abstract="true" name="SeveranceAndOtherEmployeeCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_CappedCallTransactionsMember" abstract="true" name="CappedCallTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" abstract="false" name="InterestExpenseDebtAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" abstract="true" name="OnePointTwoFivePercentConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_PatentInfringementComplaintMember" abstract="true" name="PatentInfringementComplaintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ContractualObligationTable" abstract="true" name="ContractualObligationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="neo_RepaymentsOfEquipmentAndOtherFinanceObligation" abstract="false" name="RepaymentsOfEquipmentAndOtherFinanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" abstract="true" name="PharmaServicesContractsWithHOOKIPAPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_FederalHealthcareProgramRevenueMember" abstract="true" name="FederalHealthcareProgramRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" abstract="true" name="ZeroPointTwoFivePercentConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>neo-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9dc41751-b83b-431c-b18e-08aa28ccd964,g:b69a919b-a967-4814-b0e5-6634100d0d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b9fcbf8a-9110-4621-9818-b441410d9b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_49fa6e3f-e9b2-447b-9ffe-89f314c359d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b9fcbf8a-9110-4621-9818-b441410d9b02" xlink:to="loc_us-gaap_AssetsCurrent_49fa6e3f-e9b2-447b-9ffe-89f314c359d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_64dfad38-9087-4319-afb3-f36626d09872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b9fcbf8a-9110-4621-9818-b441410d9b02" xlink:to="loc_us-gaap_AssetsNoncurrent_64dfad38-9087-4319-afb3-f36626d09872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_49424e2d-64b6-404c-b9a3-6b255b33b454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a2e1a626-af07-4819-835b-76adeb3c4043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49424e2d-64b6-404c-b9a3-6b255b33b454" xlink:to="loc_us-gaap_AccountsPayableCurrent_a2e1a626-af07-4819-835b-76adeb3c4043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1323a91f-1f6c-441d-8481-40dcad71ab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49424e2d-64b6-404c-b9a3-6b255b33b454" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1323a91f-1f6c-441d-8481-40dcad71ab1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_03c3c1a2-8d25-411f-9db6-07f3bfb70d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49424e2d-64b6-404c-b9a3-6b255b33b454" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_03c3c1a2-8d25-411f-9db6-07f3bfb70d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0c3da31e-7472-484d-9b26-733c9f06204f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49424e2d-64b6-404c-b9a3-6b255b33b454" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0c3da31e-7472-484d-9b26-733c9f06204f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5192f8a3-7f21-4ade-97a6-b3e252db0f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49424e2d-64b6-404c-b9a3-6b255b33b454" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5192f8a3-7f21-4ade-97a6-b3e252db0f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb315e1a-3036-4dff-a9b9-93def922b20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_49424e2d-64b6-404c-b9a3-6b255b33b454" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fb315e1a-3036-4dff-a9b9-93def922b20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_0101cf50-a784-418a-b8d0-eee0b503c5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9d4586b1-1284-448b-bcbb-efdfe61da4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_0101cf50-a784-418a-b8d0-eee0b503c5cc" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9d4586b1-1284-448b-bcbb-efdfe61da4ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_181ce6ed-1a53-45c5-be2f-7d603b86e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_0101cf50-a784-418a-b8d0-eee0b503c5cc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_181ce6ed-1a53-45c5-be2f-7d603b86e8cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a0a1c2a-dad2-42d0-b11d-aa815b26f834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_0101cf50-a784-418a-b8d0-eee0b503c5cc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8a0a1c2a-dad2-42d0-b11d-aa815b26f834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8819ed93-0b8a-4a10-8746-4c5a78524c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_0101cf50-a784-418a-b8d0-eee0b503c5cc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8819ed93-0b8a-4a10-8746-4c5a78524c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_300e3861-6eb6-43bb-a60c-634b438d405d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b982402f-c2ef-4faa-9ccc-88a0643534be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_300e3861-6eb6-43bb-a60c-634b438d405d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b982402f-c2ef-4faa-9ccc-88a0643534be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_51bac72c-0a49-44a9-bcca-d8ecce30adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_300e3861-6eb6-43bb-a60c-634b438d405d" xlink:to="loc_us-gaap_Goodwill_51bac72c-0a49-44a9-bcca-d8ecce30adc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a358fe93-862b-4f58-91e4-de6006521733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_300e3861-6eb6-43bb-a60c-634b438d405d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a358fe93-862b-4f58-91e4-de6006521733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c719e02f-1b15-4b60-91e9-b7fd51914f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_300e3861-6eb6-43bb-a60c-634b438d405d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c719e02f-1b15-4b60-91e9-b7fd51914f5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_169f33e6-2dd1-4755-8a0a-2f80da44420a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_300e3861-6eb6-43bb-a60c-634b438d405d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_169f33e6-2dd1-4755-8a0a-2f80da44420a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0a1cb5e4-3568-4916-987d-d1520cc42e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_22b5842b-d8ec-4caa-b5f1-bc1f57a35a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a1cb5e4-3568-4916-987d-d1520cc42e25" xlink:to="loc_us-gaap_InventoryNet_22b5842b-d8ec-4caa-b5f1-bc1f57a35a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_603d1c35-cebc-43ac-ac78-8c815e1ff3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a1cb5e4-3568-4916-987d-d1520cc42e25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_603d1c35-cebc-43ac-ac78-8c815e1ff3bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a542494b-c900-4beb-b19d-51854ca625be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a1cb5e4-3568-4916-987d-d1520cc42e25" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a542494b-c900-4beb-b19d-51854ca625be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_022d41fe-33dd-4e42-9af6-56eda44799a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a1cb5e4-3568-4916-987d-d1520cc42e25" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_022d41fe-33dd-4e42-9af6-56eda44799a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ac7fa6bd-b116-4ce8-ba6d-f9d902c9a979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a1cb5e4-3568-4916-987d-d1520cc42e25" xlink:to="loc_us-gaap_OtherAssetsCurrent_ac7fa6bd-b116-4ce8-ba6d-f9d902c9a979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7b917409-aa0a-40d4-ad2b-d7efe44a0518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0a1cb5e4-3568-4916-987d-d1520cc42e25" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7b917409-aa0a-40d4-ad2b-d7efe44a0518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b65a52f2-56e3-46a7-875e-a331ead5f338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_f20fd092-44bc-48ef-b984-7676a621c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b65a52f2-56e3-46a7-875e-a331ead5f338" xlink:to="loc_us-gaap_CommonStockValueOutstanding_f20fd092-44bc-48ef-b984-7676a621c1b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a20de061-ffbe-401f-a08a-4c1ad09ffae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b65a52f2-56e3-46a7-875e-a331ead5f338" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a20de061-ffbe-401f-a08a-4c1ad09ffae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6ae4f5b9-ff62-4db8-87a3-5723d2a077d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b65a52f2-56e3-46a7-875e-a331ead5f338" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6ae4f5b9-ff62-4db8-87a3-5723d2a077d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c12c6d53-3367-4867-b226-da71716a86ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b65a52f2-56e3-46a7-875e-a331ead5f338" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c12c6d53-3367-4867-b226-da71716a86ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_383ae447-c49f-4df6-b359-fd61334ad916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8c0ae862-8962-498f-bb46-704d0493c131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_383ae447-c49f-4df6-b359-fd61334ad916" xlink:to="loc_us-gaap_Liabilities_8c0ae862-8962-498f-bb46-704d0493c131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_665173bf-75ac-4a60-9532-8cba7358e8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_383ae447-c49f-4df6-b359-fd61334ad916" xlink:to="loc_us-gaap_StockholdersEquity_665173bf-75ac-4a60-9532-8cba7358e8c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ea7e4898-6c67-46e1-8304-e48e97fa08a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_383ae447-c49f-4df6-b359-fd61334ad916" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ea7e4898-6c67-46e1-8304-e48e97fa08a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5cdc095b-39a2-41b7-a3b7-9fcbacf12db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4535a602-fbd1-4a7a-97d1-8a6fb22bf1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5cdc095b-39a2-41b7-a3b7-9fcbacf12db7" xlink:to="loc_us-gaap_LiabilitiesCurrent_4535a602-fbd1-4a7a-97d1-8a6fb22bf1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_50660994-6f64-45ef-a052-a14c1368fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5cdc095b-39a2-41b7-a3b7-9fcbacf12db7" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_50660994-6f64-45ef-a052-a14c1368fc74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2047dc2d-cf82-412c-9c11-4c67d627d4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cbdd9b77-de13-45ee-b911-5f75f170f719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2047dc2d-cf82-412c-9c11-4c67d627d4e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cbdd9b77-de13-45ee-b911-5f75f170f719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_91167e80-15ba-4568-b8f9-733a69927533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2047dc2d-cf82-412c-9c11-4c67d627d4e2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_91167e80-15ba-4568-b8f9-733a69927533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_90798493-fe12-4c30-b0b4-58852667a24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4570cd5c-d516-4480-a825-9a969ee07b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_90798493-fe12-4c30-b0b4-58852667a24d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4570cd5c-d516-4480-a825-9a969ee07b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b517d1c5-0511-4f8b-8d39-1cabf6677e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_90798493-fe12-4c30-b0b4-58852667a24d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b517d1c5-0511-4f8b-8d39-1cabf6677e0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f4d5444-fe82-45d7-b892-324ac87dbb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d67e3928-7419-461a-ae5b-6cd25f34c29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f4d5444-fe82-45d7-b892-324ac87dbb0d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d67e3928-7419-461a-ae5b-6cd25f34c29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_60673881-cbf1-4ed0-abbd-c22cd9032b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f4d5444-fe82-45d7-b892-324ac87dbb0d" xlink:to="loc_us-gaap_OperatingIncomeLoss_60673881-cbf1-4ed0-abbd-c22cd9032b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_929c2314-ab42-4727-baa2-ec755d9c45c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9f4d5444-fe82-45d7-b892-324ac87dbb0d" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_929c2314-ab42-4727-baa2-ec755d9c45c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2b3c4efe-3e86-4d4b-9df8-954c91a214f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_19f381bc-0742-4c05-b864-1a94e0063a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2b3c4efe-3e86-4d4b-9df8-954c91a214f2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_19f381bc-0742-4c05-b864-1a94e0063a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_971be09f-4a92-4990-a3fd-088cfb77595f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2b3c4efe-3e86-4d4b-9df8-954c91a214f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_971be09f-4a92-4990-a3fd-088cfb77595f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_b0915fd1-39d7-4c2b-a9ae-d710fc1e17f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2b3c4efe-3e86-4d4b-9df8-954c91a214f2" xlink:to="loc_us-gaap_SellingAndMarketingExpense_b0915fd1-39d7-4c2b-a9ae-d710fc1e17f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5708d757-52b8-48b9-8589-f9f571c2c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2b3c4efe-3e86-4d4b-9df8-954c91a214f2" xlink:to="loc_us-gaap_RestructuringCharges_5708d757-52b8-48b9-8589-f9f571c2c7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e2be1ba6-fc17-429e-ba71-508c6565032f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_adafb5a8-9c42-47a3-9a21-e8a379c0fdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e2be1ba6-fc17-429e-ba71-508c6565032f" xlink:to="loc_us-gaap_GrossProfit_adafb5a8-9c42-47a3-9a21-e8a379c0fdd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d70d3cc1-92a3-4b62-91b5-ae0b0c700135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e2be1ba6-fc17-429e-ba71-508c6565032f" xlink:to="loc_us-gaap_OperatingExpenses_d70d3cc1-92a3-4b62-91b5-ae0b0c700135" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fd651c6a-a8fa-4111-b2a6-3dba4306cb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ae500163-4526-488c-9701-2836302241f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fd651c6a-a8fa-4111-b2a6-3dba4306cb7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ae500163-4526-488c-9701-2836302241f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b47ff78e-7f43-4029-bada-1bf6ae02f641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_832d12ec-e706-47a1-83df-1a7eebbcfc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b47ff78e-7f43-4029-bada-1bf6ae02f641" xlink:to="loc_us-gaap_NetIncomeLoss_832d12ec-e706-47a1-83df-1a7eebbcfc9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0e8a9e24-6761-4c3b-a46f-bf336183eea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b47ff78e-7f43-4029-bada-1bf6ae02f641" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0e8a9e24-6761-4c3b-a46f-bf336183eea7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3652aeb1-2173-4316-ac5f-038911b8c7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b8ee2222-7c37-494c-b91e-87e879f4e00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3652aeb1-2173-4316-ac5f-038911b8c7fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b8ee2222-7c37-494c-b91e-87e879f4e00d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfc7a47d-b8ac-457c-af09-9dc751efa25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3652aeb1-2173-4316-ac5f-038911b8c7fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfc7a47d-b8ac-457c-af09-9dc751efa25c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fdfb99d-8644-4096-ad91-0d619ca0b6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3652aeb1-2173-4316-ac5f-038911b8c7fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fdfb99d-8644-4096-ad91-0d619ca0b6ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75f92c5e-4058-4e4f-9437-835905c03da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_09023678-1750-4eea-9a4b-67a117ca9e7e" xlink:href="neo-20230331.xsd#neo_RepaymentsOfEquipmentAndOtherFinanceObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75f92c5e-4058-4e4f-9437-835905c03da6" xlink:to="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_09023678-1750-4eea-9a4b-67a117ca9e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_100d2676-15a9-4de0-9b30-a3a5494918de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75f92c5e-4058-4e4f-9437-835905c03da6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_100d2676-15a9-4de0-9b30-a3a5494918de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3983b2d8-81e4-4994-bfb0-fcb42007926a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_NetIncomeLoss_3983b2d8-81e4-4994-bfb0-fcb42007926a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_81bcc57b-7ec4-4b8e-b8d7-dcbc178637ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_81bcc57b-7ec4-4b8e-b8d7-dcbc178637ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1d9cd3b3-bb5f-4834-a83c-b1b73a4415bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1d9cd3b3-bb5f-4834-a83c-b1b73a4415bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4a123c14-0ed4-4e4b-963c-256bbfa3be45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4a123c14-0ed4-4e4b-963c-256bbfa3be45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a9b4d3d-1248-4059-8063-fe7d0556c527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a9b4d3d-1248-4059-8063-fe7d0556c527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a98b33a3-edf5-4081-90e9-c19e5b21e456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_ShareBasedCompensation_a98b33a3-edf5-4081-90e9-c19e5b21e456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_024daf5d-0e8a-4d80-a143-d20e2bcf16db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_Depreciation_024daf5d-0e8a-4d80-a143-d20e2bcf16db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_31c64fc0-7898-429b-8685-3007c2baca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_31c64fc0-7898-429b-8685-3007c2baca2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f852cbf8-5c0e-4156-bb7e-9b8a1be9edc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f852cbf8-5c0e-4156-bb7e-9b8a1be9edc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_2e914c09-17dd-4b18-bf0a-d48cd9409e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_OperatingLeaseExpense_2e914c09-17dd-4b18-bf0a-d48cd9409e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a75e0581-9bb5-4e4f-913b-f4ecca33da6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a75e0581-9bb5-4e4f-913b-f4ecca33da6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_d7a72390-5833-442c-920f-b273db698d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_d7a72390-5833-442c-920f-b273db698d4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_39c20726-715b-421b-9eb7-7f7bfc36106e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_39c20726-715b-421b-9eb7-7f7bfc36106e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_348ec3a0-d3f6-43bc-b959-f033e6d15a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_348ec3a0-d3f6-43bc-b959-f033e6d15a87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fe59fd0e-3dd9-4b44-b2d5-2e07d046b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fe59fd0e-3dd9-4b44-b2d5-2e07d046b44a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d1fa0c0d-ae36-4605-a749-3e305d2fac03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d1fa0c0d-ae36-4605-a749-3e305d2fac03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ae6ae406-c8ed-479d-b97d-9fb1823c58bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a070ac3-f0e0-4095-bd31-698a3804fd9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ae6ae406-c8ed-479d-b97d-9fb1823c58bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eb663e4-3d52-425e-a78c-bf84bbe3c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_44220abb-c037-48fd-b76c-9dd09ac50297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eb663e4-3d52-425e-a78c-bf84bbe3c07a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_44220abb-c037-48fd-b76c-9dd09ac50297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24ed8548-9967-40a6-adaf-1c0a2410ec9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eb663e4-3d52-425e-a78c-bf84bbe3c07a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_24ed8548-9967-40a6-adaf-1c0a2410ec9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_beaf983d-5f28-478e-9598-243face3045f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eb663e4-3d52-425e-a78c-bf84bbe3c07a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_beaf983d-5f28-478e-9598-243face3045f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_a9066079-eb07-457a-a3c8-06df9ba9a676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d8ee881a-44c2-4088-b72e-545231ed5d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_a9066079-eb07-457a-a3c8-06df9ba9a676" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d8ee881a-44c2-4088-b72e-545231ed5d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_f1ac2d47-46ae-44f7-8008-a7e09c1e9a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_a9066079-eb07-457a-a3c8-06df9ba9a676" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_f1ac2d47-46ae-44f7-8008-a7e09c1e9a40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6089d984-a022-40c9-b816-56075ca605e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_a9066079-eb07-457a-a3c8-06df9ba9a676" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6089d984-a022-40c9-b816-56075ca605e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_d31bdb65-f861-4378-9a8d-79f402b0402a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_adbb3034-75b4-4bd6-b792-2113d47d147e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_d31bdb65-f861-4378-9a8d-79f402b0402a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_adbb3034-75b4-4bd6-b792-2113d47d147e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_812fa1a5-5fd4-4bb9-bd91-1ce0fbbd1faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_d31bdb65-f861-4378-9a8d-79f402b0402a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_812fa1a5-5fd4-4bb9-bd91-1ce0fbbd1faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a8e91a6b-d1f3-49de-ae11-e509b8ecd2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_d31bdb65-f861-4378-9a8d-79f402b0402a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a8e91a6b-d1f3-49de-ae11-e509b8ecd2dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6e28234a-a136-4039-93fb-092ed6d0f48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_453ad08d-021b-4a25-a147-af466535de5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6e28234a-a136-4039-93fb-092ed6d0f48e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_453ad08d-021b-4a25-a147-af466535de5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_77fcfdaa-0781-42a4-92bd-8e7c10cc2403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6e28234a-a136-4039-93fb-092ed6d0f48e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_77fcfdaa-0781-42a4-92bd-8e7c10cc2403" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8df7a5eb-946e-4731-b537-95632b88d8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_91fd77a1-09af-40b0-a451-99241c19ca49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8df7a5eb-946e-4731-b537-95632b88d8b4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_91fd77a1-09af-40b0-a451-99241c19ca49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ee8f255b-e4fe-4cc9-bc5b-6ea347b9192e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8df7a5eb-946e-4731-b537-95632b88d8b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ee8f255b-e4fe-4cc9-bc5b-6ea347b9192e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7f257f91-ce0c-4467-8a85-053efaf478d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef4faced-6712-4d8f-9973-ee95882e0362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7f257f91-ce0c-4467-8a85-053efaf478d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef4faced-6712-4d8f-9973-ee95882e0362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ae499686-bb31-4b7d-8962-359ff98fb6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7f257f91-ce0c-4467-8a85-053efaf478d6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ae499686-bb31-4b7d-8962-359ff98fb6ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_108cdc0a-171f-4fa7-85d3-3434966750b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fb16646d-ae6a-4378-9d69-c164b2e4411f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_108cdc0a-171f-4fa7-85d3-3434966750b5" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fb16646d-ae6a-4378-9d69-c164b2e4411f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f5f303d5-6614-47c9-b97e-3359ba30aded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_108cdc0a-171f-4fa7-85d3-3434966750b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f5f303d5-6614-47c9-b97e-3359ba30aded" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_269072de-2b99-4793-8615-b35feba6c68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b23adb7e-cb15-43cf-96c6-989619f7cdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_269072de-2b99-4793-8615-b35feba6c68e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b23adb7e-cb15-43cf-96c6-989619f7cdeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7cc5b61a-5f91-46a5-a739-5599d78b5891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_269072de-2b99-4793-8615-b35feba6c68e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7cc5b61a-5f91-46a5-a739-5599d78b5891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_97e8751b-6174-4eae-96ba-e95024609f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_269072de-2b99-4793-8615-b35feba6c68e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_97e8751b-6174-4eae-96ba-e95024609f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d1eb42c5-20b2-40c9-a4bc-8c382a9ce618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_269072de-2b99-4793-8615-b35feba6c68e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d1eb42c5-20b2-40c9-a4bc-8c382a9ce618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7ce987eb-9b0c-47b5-86b1-f300cab22599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_269072de-2b99-4793-8615-b35feba6c68e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7ce987eb-9b0c-47b5-86b1-f300cab22599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_fd5123bc-5c7a-42e0-9d32-29cc78c1cf2a" xlink:href="neo-20230331.xsd#neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_269072de-2b99-4793-8615-b35feba6c68e" xlink:to="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_fd5123bc-5c7a-42e0-9d32-29cc78c1cf2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RevenueRecognitionContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_bb2edcf0-20ec-4656-803d-2b7c29cb8cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_786173c8-7ed4-4b50-b01c-df362e098be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_bb2edcf0-20ec-4656-803d-2b7c29cb8cda" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_786173c8-7ed4-4b50-b01c-df362e098be4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_43164ffe-047d-4836-9579-6c561ed91a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_bb2edcf0-20ec-4656-803d-2b7c29cb8cda" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_43164ffe-047d-4836-9579-6c561ed91a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_5dd2c43d-e854-4a5e-9c0e-f1d9b39a2f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_059ddbc2-5441-4551-b21e-9d4e83acf274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedContractCostGross_5dd2c43d-e854-4a5e-9c0e-f1d9b39a2f0b" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_059ddbc2-5441-4551-b21e-9d4e83acf274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_90186206-4f01-4238-8b5b-02b2d6e2c80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedContractCostGross_5dd2c43d-e854-4a5e-9c0e-f1d9b39a2f0b" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_90186206-4f01-4238-8b5b-02b2d6e2c80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0f7b1569-b248-4338-b5af-fb41090a8c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_855be4a9-e563-43ab-8bcb-980af75c70c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_0f7b1569-b248-4338-b5af-fb41090a8c4d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_855be4a9-e563-43ab-8bcb-980af75c70c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_93cfedcb-ea6b-4cdb-83fa-aa7aefaf101f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_0f7b1569-b248-4338-b5af-fb41090a8c4d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_93cfedcb-ea6b-4cdb-83fa-aa7aefaf101f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>neo-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9dc41751-b83b-431c-b18e-08aa28ccd964,g:b69a919b-a967-4814-b0e5-6634100d0d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="icf2d4538ad554e7083ee236151c56728_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97814465-19c7-4401-b2d3-cfcbfe511221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97814465-19c7-4401-b2d3-cfcbfe511221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0fd362ae-c287-4ce7-94ca-4bc70e3355c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0fd362ae-c287-4ce7-94ca-4bc70e3355c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_84f13b04-0e87-4834-ac9a-3db6c8817e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_GrossProfit_84f13b04-0e87-4834-ac9a-3db6c8817e70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e09fff45-b4c6-4b78-84df-6410560f1d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e09fff45-b4c6-4b78-84df-6410560f1d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8cff7430-20ed-43c9-a73e-3b3d3c9d9f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8cff7430-20ed-43c9-a73e-3b3d3c9d9f11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_745676a5-b96b-4c1f-8b41-23c903a0aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_SellingAndMarketingExpense_745676a5-b96b-4c1f-8b41-23c903a0aec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0387a9e3-f80c-406e-bbdf-692c34c551a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_RestructuringCharges_0387a9e3-f80c-406e-bbdf-692c34c551a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dbcbc456-b157-4a6a-8ff0-af42de01def7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_OperatingExpenses_dbcbc456-b157-4a6a-8ff0-af42de01def7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2b0a238b-101b-403c-ae0a-a2a78951bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_OperatingIncomeLoss_2b0a238b-101b-403c-ae0a-a2a78951bb9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_26497b8e-73b8-4e18-85a4-ba97afdb67d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_26497b8e-73b8-4e18-85a4-ba97afdb67d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_beca7966-04b7-4c47-9200-eb6be206b477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_beca7966-04b7-4c47-9200-eb6be206b477" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eb97b92a-ec51-4dba-a907-fcdbada2ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eb97b92a-ec51-4dba-a907-fcdbada2ae50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d37cf647-c479-4688-81fb-bb20f8d8bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d37cf647-c479-4688-81fb-bb20f8d8bcfe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e86ae5f1-c3bd-4dee-af27-2387eeee06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_NetIncomeLoss_e86ae5f1-c3bd-4dee-af27-2387eeee06e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_77927bc7-a5c3-4750-bec5-e85cc57c2d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_77927bc7-a5c3-4750-bec5-e85cc57c2d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4e8acdcd-5296-49cb-b646-036e40e635ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4e8acdcd-5296-49cb-b646-036e40e635ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_faa2f2c8-4053-45f6-8391-6d340fca1b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_faa2f2c8-4053-45f6-8391-6d340fca1b3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7863513-5d5f-451c-9c2b-d4687c8a8047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7863513-5d5f-451c-9c2b-d4687c8a8047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_859d9b14-e9af-435b-a69a-82d2398b5da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_StatementTable_859d9b14-e9af-435b-a69a-82d2398b5da7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_859d9b14-e9af-435b-a69a-82d2398b5da7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb" xlink:to="loc_us-gaap_SegmentDomain_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb" xlink:to="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_5a5ec1ea-659b-471b-80b4-5594225d9fda" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:to="loc_neo_ClinicalServicesMember_5a5ec1ea-659b-471b-80b4-5594225d9fda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_5c67364e-92ea-4ab9-b029-52d1a65c2750" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:to="loc_neo_PharmaServicesMember_5c67364e-92ea-4ab9-b029-52d1a65c2750" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i2e89a0255dfc41709a069a0ff90ad768_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fa30cb59-7ad5-447c-8bdb-c6360c70fe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fa30cb59-7ad5-447c-8bdb-c6360c70fe0b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3e61d655-4639-4b8a-868a-22888065d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_SharesOutstanding_3e61d655-4639-4b8a-868a-22888065d74d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff2a7bb8-f85b-4eb2-94bb-dfb3932287c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockholdersEquity_ff2a7bb8-f85b-4eb2-94bb-dfb3932287c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5e07bd-64d8-46c1-bcb1-6aee048b24b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5e07bd-64d8-46c1-bcb1-6aee048b24b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3f49f9f2-00a5-4e0a-ab5b-a44409be478c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3f49f9f2-00a5-4e0a-ab5b-a44409be478c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db1bea7e-33c9-43bc-8611-89a3b0ac3066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db1bea7e-33c9-43bc-8611-89a3b0ac3066" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11dbbf3b-3533-4822-9b6c-298ff2e985a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11dbbf3b-3533-4822-9b6c-298ff2e985a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_706e50cb-291e-44e7-bcb7-aff692a28386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_706e50cb-291e-44e7-bcb7-aff692a28386" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7fcb4156-7e3f-4d42-94e7-00bd1e69125c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7fcb4156-7e3f-4d42-94e7-00bd1e69125c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d87eb346-8767-4763-aa8c-9c7e6eb31e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d87eb346-8767-4763-aa8c-9c7e6eb31e60" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_4640431d-7350-4f00-9c2b-419920e73a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_4640431d-7350-4f00-9c2b-419920e73a41" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d540db1-691b-422c-9eee-e778c7fe1fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d540db1-691b-422c-9eee-e778c7fe1fad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f47797cd-c77e-49e8-80e4-42303bf33c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f47797cd-c77e-49e8-80e4-42303bf33c5b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdced2bb-d643-49ab-bddc-dc59daad8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_NetIncomeLoss_fdced2bb-d643-49ab-bddc-dc59daad8e7d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_24ce5ca2-05d8-4e68-9e24-83729599b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61f7bf67-0891-48be-9df9-ebdc44ba8b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2a5f231-9bd8-457a-b840-d564ff5b2a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fa30cb59-7ad5-447c-8bdb-c6360c70fe0b" xlink:to="loc_us-gaap_StatementTable_f2a5f231-9bd8-457a-b840-d564ff5b2a61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f2a5f231-9bd8-457a-b840-d564ff5b2a61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5" xlink:to="loc_us-gaap_EquityComponentDomain_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5" xlink:to="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_827c82b9-a43b-4a30-84ba-4e93d2c397ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_CommonStockMember_827c82b9-a43b-4a30-84ba-4e93d2c397ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bbf7c8d3-f7a2-4965-8d48-9074bdbb662d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bbf7c8d3-f7a2-4965-8d48-9074bdbb662d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7cb10fa2-17aa-422d-8556-db504eec825f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7cb10fa2-17aa-422d-8556-db504eec825f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3855c85b-af83-487e-93fc-d50fdeb7e302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_RetainedEarningsMember_3855c85b-af83-487e-93fc-d50fdeb7e302" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended" id="ibeadbb9705de4e09be2e123b3d493c10_FairValueMeasurementsScheduleofAmortizedCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_5e65d550-8d0b-4af0-b450-21d3bf3978a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_5e65d550-8d0b-4af0-b450-21d3bf3978a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e9a694c0-d0c0-4fbc-8ddb-3ab011ba9af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e9a694c0-d0c0-4fbc-8ddb-3ab011ba9af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_171d8f62-ef07-4933-93dd-1899845f5afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_171d8f62-ef07-4933-93dd-1899845f5afb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_74e038d1-82af-4b1d-ab8d-0258fad9db50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_74e038d1-82af-4b1d-ab8d-0258fad9db50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_51da0fff-0354-4831-a643-ee98a2846c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_51da0fff-0354-4831-a643-ee98a2846c38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72d1c7aa-c817-47fa-b2cc-3b9442377815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72d1c7aa-c817-47fa-b2cc-3b9442377815" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b361bf62-a757-4640-9226-adb40e3e2633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72d1c7aa-c817-47fa-b2cc-3b9442377815" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b361bf62-a757-4640-9226-adb40e3e2633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b361bf62-a757-4640-9226-adb40e3e2633_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b361bf62-a757-4640-9226-adb40e3e2633" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b361bf62-a757-4640-9226-adb40e3e2633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b361bf62-a757-4640-9226-adb40e3e2633" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bf429e51-9c87-48ee-a2ab-cc7dd243f78f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bf429e51-9c87-48ee-a2ab-cc7dd243f78f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_e68a6a07-d824-4c5b-94e5-2119d9f9652b" xlink:href="neo-20230331.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_neo_YankeeBondsMember_e68a6a07-d824-4c5b-94e5-2119d9f9652b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_e0a02b3c-e99a-45bb-b655-7ce93fde738c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_AgencySecuritiesMember_e0a02b3c-e99a-45bb-b655-7ce93fde738c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_4dc6c6be-4d2c-48bb-8062-3001f84d2e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_MunicipalBondsMember_4dc6c6be-4d2c-48bb-8062-3001f84d2e94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_52b30648-8e96-4069-b300-9da24eb47569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_CommercialPaperMember_52b30648-8e96-4069-b300-9da24eb47569" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_597d7e75-6814-4d30-936e-0eecc0f0f213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_597d7e75-6814-4d30-936e-0eecc0f0f213" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c146eacf-863b-4d42-8600-f053c91364a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c146eacf-863b-4d42-8600-f053c91364a5" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended" id="id167221ba4ae46bcace340af15e2371c_FairValueMeasurementsFairValuebyContractualMaturityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d774c622-d545-4257-a1ba-219b9eaa8e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d774c622-d545-4257-a1ba-219b9eaa8e26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0d673d2f-3d22-4050-b83c-64d012a277c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0d673d2f-3d22-4050-b83c-64d012a277c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_92c8369a-158d-40b3-97b8-b3d68b2582d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_92c8369a-158d-40b3-97b8-b3d68b2582d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_2734435a-cd39-49aa-a07d-4a1144424889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_2734435a-cd39-49aa-a07d-4a1144424889" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f6a3c27-9a3b-4dbb-8d50-8a5a258486e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f6a3c27-9a3b-4dbb-8d50-8a5a258486e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_df4c619a-d120-482b-9587-af2bd5e5fd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f6a3c27-9a3b-4dbb-8d50-8a5a258486e1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_df4c619a-d120-482b-9587-af2bd5e5fd8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df4c619a-d120-482b-9587-af2bd5e5fd8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_df4c619a-d120-482b-9587-af2bd5e5fd8d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df4c619a-d120-482b-9587-af2bd5e5fd8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_df4c619a-d120-482b-9587-af2bd5e5fd8d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_16f43f7b-ff10-4f66-8676-a544b8c41a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_16f43f7b-ff10-4f66-8676-a544b8c41a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_ad73bc59-43bb-4919-b573-e52c0f367335" xlink:href="neo-20230331.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_neo_YankeeBondsMember_ad73bc59-43bb-4919-b573-e52c0f367335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_af2ef80a-f8aa-478c-8364-9af66353e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_AgencySecuritiesMember_af2ef80a-f8aa-478c-8364-9af66353e260" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2f9874fd-6d73-46ed-95f6-5b7e4c9fa730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_MunicipalBondsMember_2f9874fd-6d73-46ed-95f6-5b7e4c9fa730" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_359476c3-8d73-44ec-9f29-ba0d9572050f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_CommercialPaperMember_359476c3-8d73-44ec-9f29-ba0d9572050f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d0388b11-518f-4003-b4fb-38c87ce87f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d0388b11-518f-4003-b4fb-38c87ce87f7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_604a6b71-9811-4648-86f1-8fa593dd476b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_604a6b71-9811-4648-86f1-8fa593dd476b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended" id="ic2becae54cac482cad067654d6ba4889_FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_533d3320-6700-4b7b-a017-e8bf8e73fed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_533d3320-6700-4b7b-a017-e8bf8e73fed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_cc694cc5-6814-42cc-a830-0beb2de5351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_cc694cc5-6814-42cc-a830-0beb2de5351a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_312ea018-68f5-4c71-9ece-afb6efd44df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_312ea018-68f5-4c71-9ece-afb6efd44df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28a987ca-e40f-45bc-990a-34ae86b226b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28a987ca-e40f-45bc-990a-34ae86b226b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28a987ca-e40f-45bc-990a-34ae86b226b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28a987ca-e40f-45bc-990a-34ae86b226b9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_28a987ca-e40f-45bc-990a-34ae86b226b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_381aaf8a-455c-406e-bc72-a2b305feb43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28a987ca-e40f-45bc-990a-34ae86b226b9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_381aaf8a-455c-406e-bc72-a2b305feb43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cbb39672-e9cc-4b64-a244-3104f860ce06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_381aaf8a-455c-406e-bc72-a2b305feb43e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cbb39672-e9cc-4b64-a244-3104f860ce06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d76877eb-5c2d-4b75-8180-dbd6ff85bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d76877eb-5c2d-4b75-8180-dbd6ff85bac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76877eb-5c2d-4b75-8180-dbd6ff85bac9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d76877eb-5c2d-4b75-8180-dbd6ff85bac9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d76877eb-5c2d-4b75-8180-dbd6ff85bac9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d76877eb-5c2d-4b75-8180-dbd6ff85bac9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3ef76bca-97e5-4672-8681-b84fc3407658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3ef76bca-97e5-4672-8681-b84fc3407658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_08d5fcd0-9e26-41e2-8d6a-d0c0c7fc5398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_08d5fcd0-9e26-41e2-8d6a-d0c0c7fc5398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_feadb906-89a4-4db5-8932-2c132b8e116b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_feadb906-89a4-4db5-8932-2c132b8e116b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b00e95a1-da1e-46dc-8297-e64e4e389440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b00e95a1-da1e-46dc-8297-e64e4e389440" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b00e95a1-da1e-46dc-8297-e64e4e389440_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b00e95a1-da1e-46dc-8297-e64e4e389440" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b00e95a1-da1e-46dc-8297-e64e4e389440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b00e95a1-da1e-46dc-8297-e64e4e389440" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cf0b28af-e7f6-418f-a962-aeeefcd62e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cf0b28af-e7f6-418f-a962-aeeefcd62e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_476ddb56-bc6f-4dbc-b1cf-d8db794c6b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:to="loc_us-gaap_CommercialPaperMember_476ddb56-bc6f-4dbc-b1cf-d8db794c6b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7b169213-3f43-46f5-908e-8fdfdbdfe914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7b169213-3f43-46f5-908e-8fdfdbdfe914" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b169213-3f43-46f5-908e-8fdfdbdfe914_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b169213-3f43-46f5-908e-8fdfdbdfe914" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b169213-3f43-46f5-908e-8fdfdbdfe914_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b169213-3f43-46f5-908e-8fdfdbdfe914" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_dc63af15-dfa9-4787-9909-4b44be392daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_dc63af15-dfa9-4787-9909-4b44be392daa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_ba78f028-559a-4441-bdc2-ba263bf07009" xlink:href="neo-20230331.xsd#neo_YankeeBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_neo_YankeeBondsMember_ba78f028-559a-4441-bdc2-ba263bf07009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_e4f9b1b2-8de6-4adc-a0ff-62b83aaa78bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_AgencySecuritiesMember_e4f9b1b2-8de6-4adc-a0ff-62b83aaa78bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2884aa8f-646e-4a69-8374-1294b30a6da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_MunicipalBondsMember_2884aa8f-646e-4a69-8374-1294b30a6da7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3537f433-19f1-4ea0-ae33-a60630167774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_CommercialPaperMember_3537f433-19f1-4ea0-ae33-a60630167774" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_bfc5bc3a-f418-483f-8a85-d483c149bdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_bfc5bc3a-f418-483f-8a85-d483c149bdea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d9b4f931-6ea5-4a9c-8395-2976d82af26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d9b4f931-6ea5-4a9c-8395-2976d82af26f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="extended" id="i194f8104b64c490a9f3f726acfc68824_GoodwillandIntangibleAssetsScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_651a9f9a-ebf4-40bb-a485-a5c3cec95e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f44cdb1-e9cb-4b7e-be33-b9372305615e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_651a9f9a-ebf4-40bb-a485-a5c3cec95e0a" xlink:to="loc_us-gaap_Goodwill_3f44cdb1-e9cb-4b7e-be33-b9372305615e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9502ae68-b027-4b36-b5a6-574707cbfba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_651a9f9a-ebf4-40bb-a485-a5c3cec95e0a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9502ae68-b027-4b36-b5a6-574707cbfba2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1de2757c-7cc3-4573-8c6b-ca1e85c82d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9502ae68-b027-4b36-b5a6-574707cbfba2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1de2757c-7cc3-4573-8c6b-ca1e85c82d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1de2757c-7cc3-4573-8c6b-ca1e85c82d74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1de2757c-7cc3-4573-8c6b-ca1e85c82d74" xlink:to="loc_us-gaap_SegmentDomain_1de2757c-7cc3-4573-8c6b-ca1e85c82d74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1de2757c-7cc3-4573-8c6b-ca1e85c82d74" xlink:to="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_5f2a3478-cee9-4502-a7d5-c64325e335f4" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:to="loc_neo_ClinicalServicesMember_5f2a3478-cee9-4502-a7d5-c64325e335f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_80e69fac-bd9f-4374-9fe0-ced1e09b86f2" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:to="loc_neo_PharmaServicesMember_80e69fac-bd9f-4374-9fe0-ced1e09b86f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsNarrativeDetail"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail" xlink:type="extended" id="iedbd2bea7ef04e1a9adabbb3d8a1b252_GoodwillandIntangibleAssetsNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5abef6f4-ea79-4ff3-abd7-4b9209d2127c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_25750669-f059-40c9-92ea-7b39d9c33a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5abef6f4-ea79-4ff3-abd7-4b9209d2127c" xlink:to="loc_us-gaap_Goodwill_25750669-f059-40c9-92ea-7b39d9c33a9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4ecf99d-a752-4c59-b4be-bedad4c5d8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5abef6f4-ea79-4ff3-abd7-4b9209d2127c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4ecf99d-a752-4c59-b4be-bedad4c5d8aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ee9e1b78-5731-443d-b354-5fa83191b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4ecf99d-a752-4c59-b4be-bedad4c5d8aa" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ee9e1b78-5731-443d-b354-5fa83191b58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ee9e1b78-5731-443d-b354-5fa83191b58a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee9e1b78-5731-443d-b354-5fa83191b58a" xlink:to="loc_us-gaap_SegmentDomain_ee9e1b78-5731-443d-b354-5fa83191b58a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee9e1b78-5731-443d-b354-5fa83191b58a" xlink:to="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_42cd29b8-8d7a-4c22-aa88-b503a360b8a0" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:to="loc_neo_ClinicalServicesMember_42cd29b8-8d7a-4c22-aa88-b503a360b8a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_b394e100-745f-49ea-96bd-71a2f7641dc3" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:to="loc_neo_PharmaServicesMember_b394e100-745f-49ea-96bd-71a2f7641dc3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended" id="i4ddb2dfd07334cfcb14fbd33528baa73_GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3cd96b77-eda8-4fa3-bc2c-8d3b38f3f722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3cd96b77-eda8-4fa3-bc2c-8d3b38f3f722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0e1a4a54-a4e9-420c-933c-a5d2e6f47ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0e1a4a54-a4e9-420c-933c-a5d2e6f47ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5530d3c1-ba14-451f-af31-1766345c9423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5530d3c1-ba14-451f-af31-1766345c9423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ca1d66f0-931c-41cb-b15e-740c7cb2599d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ca1d66f0-931c-41cb-b15e-740c7cb2599d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4aa88340-886b-4266-ac64-f32be7517404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4aa88340-886b-4266-ac64-f32be7517404" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ed6b14-4de3-4c27-885d-e030d3752882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ed6b14-4de3-4c27-885d-e030d3752882" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3736b5e0-dc10-4af8-9826-18e7c322452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3736b5e0-dc10-4af8-9826-18e7c322452f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13412051-a5ca-49fc-ac69-aafd9f99b065" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:to="loc_srt_RangeAxis_13412051-a5ca-49fc-ac69-aafd9f99b065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13412051-a5ca-49fc-ac69-aafd9f99b065_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13412051-a5ca-49fc-ac69-aafd9f99b065" xlink:to="loc_srt_RangeMember_13412051-a5ca-49fc-ac69-aafd9f99b065_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13412051-a5ca-49fc-ac69-aafd9f99b065" xlink:to="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08a59bb4-6c02-435a-b6eb-1fbd235b132a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:to="loc_srt_MinimumMember_08a59bb4-6c02-435a-b6eb-1fbd235b132a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2601579-0efb-43cd-bc97-52a3308154d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:to="loc_srt_MaximumMember_b2601579-0efb-43cd-bc97-52a3308154d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2321d80-3090-48b0-999a-2874ace37eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2321d80-3090-48b0-999a-2874ace37eb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2321d80-3090-48b0-999a-2874ace37eb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2321d80-3090-48b0-999a-2874ace37eb9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2321d80-3090-48b0-999a-2874ace37eb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2321d80-3090-48b0-999a-2874ace37eb9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_20b9070c-a11a-4e07-b4ce-009fed059264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_CustomerRelationshipsMember_20b9070c-a11a-4e07-b4ce-009fed059264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ba2a0e88-0120-4009-bb50-47baf3590d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ba2a0e88-0120-4009-bb50-47baf3590d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_dc8a7014-ce37-44ba-8128-6e018cd32b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_dc8a7014-ce37-44ba-8128-6e018cd32b70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_3bacea27-ed3d-47f2-b706-86058fb2b282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_TrademarksMember_3bacea27-ed3d-47f2-b706-86058fb2b282" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2430b664-cf4e-4fc2-9712-fdfcc41caa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_TradeNamesMember_2430b664-cf4e-4fc2-9712-fdfcc41caa9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_43513f65-fd6e-4977-a7db-953e59ae48f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_43513f65-fd6e-4977-a7db-953e59ae48f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_43513f65-fd6e-4977-a7db-953e59ae48f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_43513f65-fd6e-4977-a7db-953e59ae48f3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_43513f65-fd6e-4977-a7db-953e59ae48f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4aaf0caa-ba99-40ea-8d65-210f5ff73277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_43513f65-fd6e-4977-a7db-953e59ae48f3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4aaf0caa-ba99-40ea-8d65-210f5ff73277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_e7694be9-715f-43f3-be5f-26f50ab05ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4aaf0caa-ba99-40ea-8d65-210f5ff73277" xlink:to="loc_us-gaap_TrademarksMember_e7694be9-715f-43f3-be5f-26f50ab05ae1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended" id="ic1ea05ce9ff542caa1ed8ad0ab6d49f2_GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52199471-f732-4383-a0ec-606f0fdb1595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d26810fc-805f-4bdd-ad05-616b90107ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52199471-f732-4383-a0ec-606f0fdb1595" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d26810fc-805f-4bdd-ad05-616b90107ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b5a55783-8588-4ac7-bd76-693f78c06564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52199471-f732-4383-a0ec-606f0fdb1595" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b5a55783-8588-4ac7-bd76-693f78c06564" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8bb8f26b-a5a4-454f-a93f-693100660cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b5a55783-8588-4ac7-bd76-693f78c06564" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8bb8f26b-a5a4-454f-a93f-693100660cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8bb8f26b-a5a4-454f-a93f-693100660cc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8bb8f26b-a5a4-454f-a93f-693100660cc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8bb8f26b-a5a4-454f-a93f-693100660cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8bb8f26b-a5a4-454f-a93f-693100660cc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e82ba6cf-2b4a-40e1-ab3d-0e8a538a3916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:to="loc_us-gaap_CostOfSalesMember_e82ba6cf-2b4a-40e1-ab3d-0e8a538a3916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1602efdf-b356-47b6-b56d-2dc49d0966d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1602efdf-b356-47b6-b56d-2dc49d0966d1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/DebtDetails" xlink:type="extended" id="iad86e90115e749abbbc501eb921d987a_DebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6f8f0b4d-697e-402b-828b-b4f847d0640b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6f8f0b4d-697e-402b-828b-b4f847d0640b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b405d40a-38bd-4ec6-aaf9-0ebb0452c041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b405d40a-38bd-4ec6-aaf9-0ebb0452c041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_59692cba-9db1-481c-95ec-a59d4603a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_59692cba-9db1-481c-95ec-a59d4603a709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2309bff8-bdec-4ed1-b0c6-0bcb42eef07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2309bff8-bdec-4ed1-b0c6-0bcb42eef07a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_23671371-4b22-49ac-82b5-a4f4a52f439f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_23671371-4b22-49ac-82b5-a4f4a52f439f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_132d3598-fe9c-44d2-a211-0abe73713912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_132d3598-fe9c-44d2-a211-0abe73713912" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest_8bf444ec-8ced-481b-be95-65719f8a4bb7" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_neo_InterestExpenseDebtContractualCouponInterest_8bf444ec-8ced-481b-be95-65719f8a4bb7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_c93077b4-a5a7-4d88-b0d3-5dd53671f150" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_c93077b4-a5a7-4d88-b0d3-5dd53671f150" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_34f1d2cb-ec71-4f6f-8bfd-99e2e0cf42e5" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_34f1d2cb-ec71-4f6f-8bfd-99e2e0cf42e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_59974425-78d2-463b-999e-ec3cd6ad6424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_59974425-78d2-463b-999e-ec3cd6ad6424" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_2b4a6a2d-f82d-47ff-8af1-470996e8eb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentFairValue_2b4a6a2d-f82d-47ff-8af1-470996e8eb33" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8e66fb35-8a94-4174-a08e-e91976f78f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_DebtInstrumentAxis_8e66fb35-8a94-4174-a08e-e91976f78f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8e66fb35-8a94-4174-a08e-e91976f78f6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8e66fb35-8a94-4174-a08e-e91976f78f6a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8e66fb35-8a94-4174-a08e-e91976f78f6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8e66fb35-8a94-4174-a08e-e91976f78f6a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_50380f5e-a4b6-45c4-a1cd-2e03dca83190" xlink:href="neo-20230331.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_50380f5e-a4b6-45c4-a1cd-2e03dca83190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_b41ee6eb-72b9-42c2-915a-5cf5c0750530" xlink:href="neo-20230331.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_b41ee6eb-72b9-42c2-915a-5cf5c0750530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_217aae75-95e4-4f93-8665-b68eb404fb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_217aae75-95e4-4f93-8665-b68eb404fb4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_217aae75-95e4-4f93-8665-b68eb404fb4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_217aae75-95e4-4f93-8665-b68eb404fb4c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_217aae75-95e4-4f93-8665-b68eb404fb4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_acc0fafb-45d5-412f-9713-2d3896687824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_217aae75-95e4-4f93-8665-b68eb404fb4c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_acc0fafb-45d5-412f-9713-2d3896687824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_08ad41b8-430f-4b34-96b7-bc8d79980289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_acc0fafb-45d5-412f-9713-2d3896687824" xlink:to="loc_us-gaap_ConvertibleDebtMember_08ad41b8-430f-4b34-96b7-bc8d79980289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_06b5750d-5113-48ca-b6cb-10eaa788d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_06b5750d-5113-48ca-b6cb-10eaa788d77d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_06b5750d-5113-48ca-b6cb-10eaa788d77d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_06b5750d-5113-48ca-b6cb-10eaa788d77d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_06b5750d-5113-48ca-b6cb-10eaa788d77d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_969cdc1c-36e0-413c-a251-b800de525482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_06b5750d-5113-48ca-b6cb-10eaa788d77d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_969cdc1c-36e0-413c-a251-b800de525482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d01eae4b-ae8f-46f4-a136-b34f19ff2fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_969cdc1c-36e0-413c-a251-b800de525482" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d01eae4b-ae8f-46f4-a136-b34f19ff2fff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57c40e9f-5af8-4543-8ca8-2a1d34966201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57c40e9f-5af8-4543-8ca8-2a1d34966201" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57c40e9f-5af8-4543-8ca8-2a1d34966201_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57c40e9f-5af8-4543-8ca8-2a1d34966201" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57c40e9f-5af8-4543-8ca8-2a1d34966201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86601542-750f-457b-be49-e3f7faded8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57c40e9f-5af8-4543-8ca8-2a1d34966201" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86601542-750f-457b-be49-e3f7faded8f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cd754337-eff0-4ed0-96a0-f32bbf2993b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86601542-750f-457b-be49-e3f7faded8f3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cd754337-eff0-4ed0-96a0-f32bbf2993b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ib72ea7555de84dfda6edab1550cca850_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc07e317-d70e-4d96-aac0-2c41f069b6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc07e317-d70e-4d96-aac0-2c41f069b6d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_443bf5f0-2282-4840-b349-797101e0efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_443bf5f0-2282-4840-b349-797101e0efc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_014b0e5c-0fa5-4124-bfbb-8d81a6a743e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_014b0e5c-0fa5-4124-bfbb-8d81a6a743e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a10fff09-c7b9-4585-b661-1a45e1910351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a10fff09-c7b9-4585-b661-1a45e1910351" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_ad9fddc9-78bd-4cfd-a58d-bfec3822c840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_ad9fddc9-78bd-4cfd-a58d-bfec3822c840" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2312164f-0bce-4518-88ac-13d44e11fe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:to="loc_us-gaap_AwardTypeAxis_2312164f-0bce-4518-88ac-13d44e11fe1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2312164f-0bce-4518-88ac-13d44e11fe1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2312164f-0bce-4518-88ac-13d44e11fe1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2312164f-0bce-4518-88ac-13d44e11fe1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2312164f-0bce-4518-88ac-13d44e11fe1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1eea8e14-cd93-48e6-a499-c79772ca1918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:to="loc_us-gaap_RestrictedStockMember_1eea8e14-cd93-48e6-a499-c79772ca1918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1864b834-d205-4034-be45-4abc1fb4851f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1864b834-d205-4034-be45-4abc1fb4851f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b7aa490e-87f5-4fc0-8c00-4124558d1f7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:to="loc_srt_TitleOfIndividualAxis_b7aa490e-87f5-4fc0-8c00-4124558d1f7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7aa490e-87f5-4fc0-8c00-4124558d1f7c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b7aa490e-87f5-4fc0-8c00-4124558d1f7c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7aa490e-87f5-4fc0-8c00-4124558d1f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79b153e9-66c8-4418-bfeb-b637f416f9ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b7aa490e-87f5-4fc0-8c00-4124558d1f7c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79b153e9-66c8-4418-bfeb-b637f416f9ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_8919effe-8d16-49e7-9ffa-f9e7b87dc8b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79b153e9-66c8-4418-bfeb-b637f416f9ae" xlink:to="loc_srt_ChiefExecutiveOfficerMember_8919effe-8d16-49e7-9ffa-f9e7b87dc8b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="extended" id="i73ae8c74d653469aa02e6076cf76e013_StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b81f2bb4-7056-4037-a915-458c20409e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b81f2bb4-7056-4037-a915-458c20409e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ddcb12e6-3a17-4e1e-a40b-19f15bef7f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ddcb12e6-3a17-4e1e-a40b-19f15bef7f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a670f9-9ca8-4e82-9959-d01c8ca21447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a670f9-9ca8-4e82-9959-d01c8ca21447" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7d98265d-ce97-44c1-ace6-a6e268e6ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7d98265d-ce97-44c1-ace6-a6e268e6ee2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_07e790df-3184-4d2f-a7b1-09b4d3358c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_07e790df-3184-4d2f-a7b1-09b4d3358c0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49257464-1a22-4953-97b6-0274f69c7282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49257464-1a22-4953-97b6-0274f69c7282" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49257464-1a22-4953-97b6-0274f69c7282" xlink:to="loc_srt_RangeAxis_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23" xlink:to="loc_srt_RangeMember_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23" xlink:to="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3c5b078-52b3-4c1e-9f5e-21af2e5ea75b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:to="loc_srt_MinimumMember_d3c5b078-52b3-4c1e-9f5e-21af2e5ea75b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fc730721-a9a2-4cb7-9712-5897dcca6f73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:to="loc_srt_MaximumMember_fc730721-a9a2-4cb7-9712-5897dcca6f73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="ia75f7c00297040df84c90d50f90e7549_StockBasedCompensationSummaryofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d47e08f-76ff-415d-9e88-e580855c9773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d47e08f-76ff-415d-9e88-e580855c9773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a72aa40e-3d85-4881-a6ae-3269417aeded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a72aa40e-3d85-4881-a6ae-3269417aeded" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7b2c37a3-84db-4dce-a3db-32f533333584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7b2c37a3-84db-4dce-a3db-32f533333584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4f364b2-2517-444d-abe1-b25944eb8e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4f364b2-2517-444d-abe1-b25944eb8e14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef1bfc97-b4b9-4c93-a217-86f0e65adbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e96eb482-2e3b-4442-8a9e-9f26b4f3ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e96eb482-2e3b-4442-8a9e-9f26b4f3ec1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2fb4aadf-589d-40ed-9d8e-ec69c0742c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2fb4aadf-589d-40ed-9d8e-ec69c0742c1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_234a00d5-cc1d-4abc-b3a0-7e3ce4555624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_234a00d5-cc1d-4abc-b3a0-7e3ce4555624" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_86f894ba-9449-4636-ac14-544bf51da861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_86f894ba-9449-4636-ac14-544bf51da861" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d12b50e1-64a8-4ed9-bfe8-9901442c4fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_650b3e96-0063-42a5-9726-f8625da35adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_650b3e96-0063-42a5-9726-f8625da35adf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_650b3e96-0063-42a5-9726-f8625da35adf" xlink:to="loc_us-gaap_AwardTypeAxis_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6346b7c-bd45-4317-8cb6-fa03b8966b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6346b7c-bd45-4317-8cb6-fa03b8966b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0b30a5f7-adc2-43f7-9e27-c9835e759041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6346b7c-bd45-4317-8cb6-fa03b8966b89" xlink:to="loc_us-gaap_RestrictedStockMember_0b30a5f7-adc2-43f7-9e27-c9835e759041" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i6c1350266fb049dba0c2a21a5470aebb_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_730bd857-82d1-4c7c-be2f-e94929542ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_904b4a4f-5777-4662-990e-eb0298ae4622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_730bd857-82d1-4c7c-be2f-e94929542ca5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_904b4a4f-5777-4662-990e-eb0298ae4622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_730bd857-82d1-4c7c-be2f-e94929542ca5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_eb5fc884-c2d4-41df-8225-ffae26441e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_eb5fc884-c2d4-41df-8225-ffae26441e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb5fc884-c2d4-41df-8225-ffae26441e45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eb5fc884-c2d4-41df-8225-ffae26441e45" xlink:to="loc_us-gaap_SegmentDomain_eb5fc884-c2d4-41df-8225-ffae26441e45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eb5fc884-c2d4-41df-8225-ffae26441e45" xlink:to="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_c8cd89f1-351b-44a4-8777-a3f0fb7b440a" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:to="loc_neo_ClinicalServicesMember_c8cd89f1-351b-44a4-8777-a3f0fb7b440a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_871f3d99-2051-4134-859b-5a6246464d75" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:to="loc_neo_PharmaServicesMember_871f3d99-2051-4134-859b-5a6246464d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_503b940b-77bd-4d18-b2ce-f2542a153ea9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:to="loc_srt_ProductOrServiceAxis_503b940b-77bd-4d18-b2ce-f2542a153ea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_503b940b-77bd-4d18-b2ce-f2542a153ea9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_503b940b-77bd-4d18-b2ce-f2542a153ea9" xlink:to="loc_srt_ProductsAndServicesDomain_503b940b-77bd-4d18-b2ce-f2542a153ea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_503b940b-77bd-4d18-b2ce-f2542a153ea9" xlink:to="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember_e71e8134-3ed3-465a-8a28-a6ca6f40da00" xlink:href="neo-20230331.xsd#neo_ClientDirectBillingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_ClientDirectBillingMember_e71e8134-3ed3-465a-8a28-a6ca6f40da00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember_fc1c0aa4-248f-442d-8159-0ea79e63bf7d" xlink:href="neo-20230331.xsd#neo_CommercialInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_CommercialInsuranceMember_fc1c0aa4-248f-442d-8159-0ea79e63bf7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndOtherGovernmentalMember_cc45e66c-0ddc-46f8-a8b4-c93b052f25ce" xlink:href="neo-20230331.xsd#neo_MedicareAndOtherGovernmentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_MedicareAndOtherGovernmentalMember_cc45e66c-0ddc-46f8-a8b4-c93b052f25ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember_da4227f6-cfce-4162-9e9c-52577b536293" xlink:href="neo-20230331.xsd#neo_SelfPayServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_SelfPayServicesMember_da4227f6-cfce-4162-9e9c-52577b536293" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RestructuringScheduleofRestructuringActivitiesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails" xlink:type="extended" id="i24110d7b3e224079941582f19b15b918_RestructuringScheduleofRestructuringActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2c950093-b9e4-43f4-997a-03bbd87289d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_RestructuringReserve_2c950093-b9e4-43f4-997a-03bbd87289d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fef4fe7-6a1f-4034-8b2f-e8e5a829b5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fef4fe7-6a1f-4034-8b2f-e8e5a829b5af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_93e7f856-ec42-4017-b058-5aa73f3006c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_AssetImpairmentCharges_93e7f856-ec42-4017-b058-5aa73f3006c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_c0d48d48-f6a5-43c5-899a-81cd97697329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_PaymentsForRestructuring_c0d48d48-f6a5-43c5-899a-81cd97697329" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2a9dba91-eddc-4afc-80d2-392abfd466c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_25a85b61-ec6f-4e29-b187-5c5ffca8e720" xlink:href="neo-20230331.xsd#neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_25a85b61-ec6f-4e29-b187-5c5ffca8e720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_39552027-7b43-4098-845e-063455326a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_RestructuringReserveCurrent_39552027-7b43-4098-845e-063455326a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_018b4459-7a60-4bb5-8f89-e741328f810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_RestructuringReserveNoncurrent_018b4459-7a60-4bb5-8f89-e741328f810f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_351ad3d8-d921-461b-8318-543b2dbd390a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73d6e83f-14ad-4842-b73a-974800c5dc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73d6e83f-14ad-4842-b73a-974800c5dc0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6695e35e-4a17-438e-ae6a-401a01ec199a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73d6e83f-14ad-4842-b73a-974800c5dc0d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6695e35e-4a17-438e-ae6a-401a01ec199a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6695e35e-4a17-438e-ae6a-401a01ec199a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6695e35e-4a17-438e-ae6a-401a01ec199a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6695e35e-4a17-438e-ae6a-401a01ec199a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6695e35e-4a17-438e-ae6a-401a01ec199a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SeveranceAndOtherEmployeeCostsMember_a4b9a20a-6d39-4109-981c-802eb069362b" xlink:href="neo-20230331.xsd#neo_SeveranceAndOtherEmployeeCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:to="loc_neo_SeveranceAndOtherEmployeeCostsMember_a4b9a20a-6d39-4109-981c-802eb069362b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FacilityFootprintOptimizationMember_d14749ed-8b0a-4c98-9865-94ce8147eb1b" xlink:href="neo-20230331.xsd#neo_FacilityFootprintOptimizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:to="loc_neo_FacilityFootprintOptimizationMember_d14749ed-8b0a-4c98-9865-94ce8147eb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ConsultingCostsMember_a9761303-e6af-4f2b-a83c-534078996c9d" xlink:href="neo-20230331.xsd#neo_ConsultingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:to="loc_neo_ConsultingCostsMember_a9761303-e6af-4f2b-a83c-534078996c9d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RestructuringNarrativesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RestructuringNarrativesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RestructuringNarrativesDetails" xlink:type="extended" id="i8f6160a17d42432b8aa9150389d5471c_RestructuringNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9d9c6303-de0b-4c97-ab56-094ceb4f3e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f4accac0-0d5b-4d0e-b020-e6108581d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d9c6303-de0b-4c97-ab56-094ceb4f3e2d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f4accac0-0d5b-4d0e-b020-e6108581d1d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_283fbf39-c615-4bed-b7d4-94cb1db57ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d9c6303-de0b-4c97-ab56-094ceb4f3e2d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_283fbf39-c615-4bed-b7d4-94cb1db57ed5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e114f546-2979-41d1-ae9f-412d8b3ad65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_283fbf39-c615-4bed-b7d4-94cb1db57ed5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e114f546-2979-41d1-ae9f-412d8b3ad65f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e114f546-2979-41d1-ae9f-412d8b3ad65f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e114f546-2979-41d1-ae9f-412d8b3ad65f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e114f546-2979-41d1-ae9f-412d8b3ad65f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e114f546-2979-41d1-ae9f-412d8b3ad65f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SeveranceAndOtherEmployeeCostsMember_ad23ab26-ad41-4017-a765-c4e34c2e93fe" xlink:href="neo-20230331.xsd#neo_SeveranceAndOtherEmployeeCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:to="loc_neo_SeveranceAndOtherEmployeeCostsMember_ad23ab26-ad41-4017-a765-c4e34c2e93fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FacilityFootprintOptimizationMember_d8d8cae4-a0e1-4191-854d-d82ad391199b" xlink:href="neo-20230331.xsd#neo_FacilityFootprintOptimizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:to="loc_neo_FacilityFootprintOptimizationMember_d8d8cae4-a0e1-4191-854d-d82ad391199b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ConsultingCostsMember_8c3dc817-98a7-4c2e-84eb-70a4389a80ec" xlink:href="neo-20230331.xsd#neo_ConsultingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:to="loc_neo_ConsultingCostsMember_8c3dc817-98a7-4c2e-84eb-70a4389a80ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#NetLossPerShareScheduleofAntidilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="extended" id="ida537a22c61240248f616150b2d3a8f7_NetLossPerShareScheduleofAntidilutiveSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed474fc2-03b4-4fa9-8c04-31929cf1d50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed474fc2-03b4-4fa9-8c04-31929cf1d50a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_fda946c1-bf06-4c5b-b4a2-dc411e52dcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_fda946c1-bf06-4c5b-b4a2-dc411e52dcd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fe3c1b47-7994-4860-b2b1-f361f354a168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fe3c1b47-7994-4860-b2b1-f361f354a168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6b70f58b-0f3a-4ee9-a5bb-39274b0262fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6b70f58b-0f3a-4ee9-a5bb-39274b0262fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9ce4fb-0086-4b5d-8d74-ee01061ad387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9ce4fb-0086-4b5d-8d74-ee01061ad387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a9ce4fb-0086-4b5d-8d74-ee01061ad387_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9ce4fb-0086-4b5d-8d74-ee01061ad387" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a9ce4fb-0086-4b5d-8d74-ee01061ad387_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9ce4fb-0086-4b5d-8d74-ee01061ad387" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94ab8ee1-b31f-48a0-aeee-d3fafa18b209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94ab8ee1-b31f-48a0-aeee-d3fafa18b209" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_672f8cc6-0198-46e2-933d-d67182ceb1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:to="loc_us-gaap_RestrictedStockMember_672f8cc6-0198-46e2-933d-d67182ceb1bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ec76566-b28d-44e9-a5de-9c489ea28d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ec76566-b28d-44e9-a5de-9c489ea28d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_e27155b0-2fa7-4d81-b130-c43ae369f1ef" xlink:href="neo-20230331.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_e27155b0-2fa7-4d81-b130-c43ae369f1ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_5dd236cf-49d3-47d6-abce-283c5f1eeb61" xlink:href="neo-20230331.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_5dd236cf-49d3-47d6-abce-283c5f1eeb61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf988537-3a0e-4fcf-bbe6-d9536ec3d406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf988537-3a0e-4fcf-bbe6-d9536ec3d406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_50bdfe1d-d575-4a35-b08e-938965827f80" xlink:href="neo-20230331.xsd#neo_CappedCallTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf988537-3a0e-4fcf-bbe6-d9536ec3d406" xlink:to="loc_neo_CappedCallTransactionsMember_50bdfe1d-d575-4a35-b08e-938965827f80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b2e2326f-44c4-4633-a15f-b2370e28166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b2e2326f-44c4-4633-a15f-b2370e28166f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b2e2326f-44c4-4633-a15f-b2370e28166f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b2e2326f-44c4-4633-a15f-b2370e28166f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b2e2326f-44c4-4633-a15f-b2370e28166f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c5ba52de-c33c-4ba2-b414-e12dc4d90ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b2e2326f-44c4-4633-a15f-b2370e28166f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c5ba52de-c33c-4ba2-b414-e12dc4d90ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_cc621277-9a50-44b9-b5e4-c60e2644502a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c5ba52de-c33c-4ba2-b414-e12dc4d90ac6" xlink:to="loc_us-gaap_ConvertibleDebtMember_cc621277-9a50-44b9-b5e4-c60e2644502a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i0435ab73f8b74687a1216f5cf49b89d8_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:href="neo-20230331.xsd#neo_ContractualObligationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_f9f2efc7-696e-4974-8171-6d1fe037bf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_f9f2efc7-696e-4974-8171-6d1fe037bf8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_389bacdd-8ae1-4570-a99a-39c1aa0d63eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_389bacdd-8ae1-4570-a99a-39c1aa0d63eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationTable_9fdb602b-66cd-4a88-9531-7f24d3732f6b" xlink:href="neo-20230331.xsd#neo_ContractualObligationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:to="loc_neo_ContractualObligationTable_9fdb602b-66cd-4a88-9531-7f24d3732f6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_neo_ContractualObligationTable_9fdb602b-66cd-4a88-9531-7f24d3732f6b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a" xlink:to="loc_us-gaap_LossContingencyNatureDomain_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember_fa66dadf-9504-4d69-b038-9ef8fb505083" xlink:href="neo-20230331.xsd#neo_PatentInfringementComplaintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:to="loc_neo_PatentInfringementComplaintMember_fa66dadf-9504-4d69-b038-9ef8fb505083" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember_1cf540d2-5795-4dc6-ba90-fa040cc402d5" xlink:href="neo-20230331.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:to="loc_neo_FederalHealthcareProgramRevenueMember_1cf540d2-5795-4dc6-ba90-fa040cc402d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i1ad4528a35d1494bbbc9bc6c4299b2d3_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_792c198c-b08b-4f1a-9e9f-f17bb82936d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_de500f9d-5ae4-4587-9a06-6a40f558ef55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_792c198c-b08b-4f1a-9e9f-f17bb82936d8" xlink:to="loc_us-gaap_RevenueFromRelatedParties_de500f9d-5ae4-4587-9a06-6a40f558ef55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_792c198c-b08b-4f1a-9e9f-f17bb82936d8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8e9257ab-4702-4437-b294-82ed0b5144a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8e9257ab-4702-4437-b294-82ed0b5144a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8e9257ab-4702-4437-b294-82ed0b5144a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8e9257ab-4702-4437-b294-82ed0b5144a6" xlink:to="loc_us-gaap_RelatedPartyDomain_8e9257ab-4702-4437-b294-82ed0b5144a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e9a3fd12-b937-40d3-9932-5c5b20966b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8e9257ab-4702-4437-b294-82ed0b5144a6" xlink:to="loc_us-gaap_RelatedPartyDomain_e9a3fd12-b937-40d3-9932-5c5b20966b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_348ac845-1acc-47c4-ab4b-6c21cba3030e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e9a3fd12-b937-40d3-9932-5c5b20966b15" xlink:to="loc_srt_AffiliatedEntityMember_348ac845-1acc-47c4-ab4b-6c21cba3030e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d2ccb883-2cab-43a0-874b-390d3bd7241f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d2ccb883-2cab-43a0-874b-390d3bd7241f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d2ccb883-2cab-43a0-874b-390d3bd7241f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d2ccb883-2cab-43a0-874b-390d3bd7241f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d2ccb883-2cab-43a0-874b-390d3bd7241f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_73b72e9e-9f01-4027-a8b4-90b9eec02783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d2ccb883-2cab-43a0-874b-390d3bd7241f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_73b72e9e-9f01-4027-a8b4-90b9eec02783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_b33dbb93-f16d-410c-b154-d59c7bf0121f" xlink:href="neo-20230331.xsd#neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_73b72e9e-9f01-4027-a8b4-90b9eec02783" xlink:to="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_b33dbb93-f16d-410c-b154-d59c7bf0121f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="extended" id="icc05e9cd72a84ef89962f56d4598a637_SegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cf14f058-dffa-452e-ad13-f0efb21ca9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cf14f058-dffa-452e-ad13-f0efb21ca9a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5d061d2e-a20b-4d6a-9c7e-dd11b5470f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5d061d2e-a20b-4d6a-9c7e-dd11b5470f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_bfe8b027-5668-4330-ab34-6cb3e6a0178e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_GrossProfit_bfe8b027-5668-4330-ab34-6cb3e6a0178e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b37edd3e-ff41-4f66-bb79-69ec04f4fc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b37edd3e-ff41-4f66-bb79-69ec04f4fc4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5de9eee6-081b-406d-ba19-86d88fb74e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5de9eee6-081b-406d-ba19-86d88fb74e19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_c6c3dbe8-ec04-4011-8fc1-e24faab01156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_SellingAndMarketingExpense_c6c3dbe8-ec04-4011-8fc1-e24faab01156" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_442590a1-5943-4205-a0a0-6a539462a5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_RestructuringCharges_442590a1-5943-4205-a0a0-6a539462a5e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1d2524e3-ccac-4a89-86d8-3e888f05fcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_OperatingExpenses_1d2524e3-ccac-4a89-86d8-3e888f05fcc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_76ce96ef-c1e7-4f5c-8edf-dad8bf80b802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_OperatingIncomeLoss_76ce96ef-c1e7-4f5c-8edf-dad8bf80b802" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6a8d3ee4-41e4-4d44-96fe-d6df3a80d2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_6a8d3ee4-41e4-4d44-96fe-d6df3a80d2a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0fda9bd4-a257-4909-9428-e4f45913dd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0fda9bd4-a257-4909-9428-e4f45913dd0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b77847f7-badf-479a-a14e-13d974c565d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b77847f7-badf-479a-a14e-13d974c565d3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4293b251-c0f1-4cfe-bfff-b9ba7c184be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4293b251-c0f1-4cfe-bfff-b9ba7c184be8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c1686eff-75a4-4cf0-8ecf-cf9ec83dbfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_NetIncomeLoss_c1686eff-75a4-4cf0-8ecf-cf9ec83dbfa5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_7a3cf139-6718-4eb5-9a23-6ccc44ff1706" xlink:href="neo-20230331.xsd#neo_IntangibleAssetsAcquiredAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_7a3cf139-6718-4eb5-9a23-6ccc44ff1706" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c9efde0-c788-4b4f-811c-08430a75a5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c9efde0-c788-4b4f-811c-08430a75a5e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c9efde0-c788-4b4f-811c-08430a75a5e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129" xlink:to="loc_us-gaap_SegmentDomain_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129" xlink:to="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_1ebebb55-ce6e-4ae9-8110-4474dee3128c" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:to="loc_neo_ClinicalServicesMember_1ebebb55-ce6e-4ae9-8110-4474dee3128c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_2b68d389-3a22-4f89-a73c-16dfeffe69ea" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:to="loc_neo_PharmaServicesMember_2b68d389-3a22-4f89-a73c-16dfeffe69ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>neo-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9dc41751-b83b-431c-b18e-08aa28ccd964,g:b69a919b-a967-4814-b0e5-6634100d0d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ea901ec6-20b5-4569-83a3-dc97a5a29d43_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Year or Less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0dae0087-933d-4d27-8ebb-a9ca6d8b30cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ed4f74e8-b01b-48ba-b87b-013bfdc3de1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PatentInfringementComplaintMember_273c8255-b8f1-4db6-ba78-8e7d63fd0734_terseLabel_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint</link:label>
    <link:label id="lab_neo_PatentInfringementComplaintMember_label_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint [Member]</link:label>
    <link:label id="lab_neo_PatentInfringementComplaintMember_documentation_en-US" xlink:label="lab_neo_PatentInfringementComplaintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember" xlink:href="neo-20230331.xsd#neo_PatentInfringementComplaintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PatentInfringementComplaintMember" xlink:to="lab_neo_PatentInfringementComplaintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2fbae037-bcda-4680-8a27-5eba48ccba27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days (in days)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_72047a46-e996-4555-87f3-3562b69ad7c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a755a7bd-a089-4578-a229-482d8e6bbc7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_915b4efc-445e-45fb-9954-a8f68c4625bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_b7402aa3-dcf8-40de-8519-82a9fde1a9a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_254cf5c7-ff92-4a47-bb64-9ed1b349fbc4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_14526906-c3fc-40bf-ae16-8dd5e6331a76_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over Five Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_7349378b-796b-4728-ae01-8e7f269c0f75_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb838729-eebe-4829-a849-e0632234caed_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6d6cf4b6-f5f7-4ce5-92a5-c94592219df9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c123e25f-f889-4525-b544-a93443d6e6c0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7e4e2c75-2846-4dd4-931f-5bfcff20afa3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c4295bdb-a0f2-4e6a-bd3f-89da347d4e90_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_58b941ce-0361-4149-befe-e48227137bc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9cb0a9da-e877-4951-b1fa-0e19c7416cce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_14bd44d1-31fd-424b-b8c5-5de48e74dc5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_7b61c1fd-8d64-4c88-8945-e151923ed4b2_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_379e2a54-a475-463e-aa31-b4a2108ce7df_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5a20fc25-9ccf-4c80-b50b-26027c24f78a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value/share at grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5b924d62-32e2-4223-bd7e-90566fcbd479_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c6ab9955-5675-4b0a-819e-89de06c14a68_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_de0512bd-f3ac-49a3-b990-0ce79168c618_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9cc5938c-9090-416c-95db-97ba8fa9f906_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_62860f4d-e052-4493-8bf2-c62997fec3a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Each Stock Option Award Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_04482778-9f11-4e67-96b4-7a4cb579cebf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_36ca2851-a235-462f-84f2-6045778cea7b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over One Year Through Five Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_IntangibleAssetsAcquiredAmortizationExpense_0ef14434-0d89-40c2-a4ae-31e49c9d562c_terseLabel_en-US" xlink:label="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_neo_IntangibleAssetsAcquiredAmortizationExpense_label_en-US" xlink:label="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Acquired, Amortization Expense</link:label>
    <link:label id="lab_neo_IntangibleAssetsAcquiredAmortizationExpense_documentation_en-US" xlink:label="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Acquired, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:href="neo-20230331.xsd#neo_IntangibleAssetsAcquiredAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:to="lab_neo_IntangibleAssetsAcquiredAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bf1453a2-f145-4f63-9b12-cc311bc1a4cd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2bbabb7b-00fc-4a63-85c5-7976eb0cc03d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_58143ff7-f82e-43be-89fc-e908c329e70e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_fb1212b8-dea6-4e04-bc45-f6fb399670c2_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_08a0edfa-7848-4baa-be43-87b5f735e71d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8fcaf811-831b-4d4b-a418-ff7a58d87321_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_935aad6e-4343-4dd9-80d6-e6c752c296ac_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3364522f-c309-45f3-99e4-c5dd97dd71ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c12b5f4b-5f18-4972-b4a4-6a44de446ec7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_57442201-b899-4ba9-86e0-9aa3e35c22c4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_a3a7766e-b229-4869-b1aa-021454cb66fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_e853ad6e-3b1d-44fd-afdc-629915edff05_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, (250,000,000 shares authorized; 127,200,491 and 126,913,992 shares issued and outstanding, respectively)</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7e56fb86-e38b-4b45-8a9b-e66bd270c9c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ec073a9f-dbe5-4aea-b74c-4223a7e04edc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6ffa9061-e4e4-493d-a50b-6a9688de389f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE GAIN (LOSS):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_237bcbf1-8958-4f7f-b755-86bb9caca98c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_566d1a16-c0ae-43b3-9e71-30fd2bbce930_verboseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_127f96ba-0ad9-4409-a510-90870cde4c45_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_96f26859-c266-47db-ac34-917a8c882d2a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_74fe16d2-6e39-475e-9e9e-f78f661113ce_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b8a1d7c5-a6b1-4a58-b7a4-009774a0e55f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_077a1a63-5e10-44ad-9c31-e5b0441aed16_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3a0c5f72-dcfa-457c-b1a6-195a740d733d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1b85d1a6-c549-45ce-93a1-1e28febb8636_terseLabel_en-US" xlink:label="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="neo-20230331.xsd#neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1f532276-e268-46f4-86f5-4d8fc50040c3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0239348-64ae-4ea1-968c-b0797df0af30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_46acb2ef-1b7a-455f-a9be-7d7cd6f365af_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_ecb6b1a2-6082-4148-9c6b-2709a68b2aa4_negatedLabel_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of equipment financing obligations</link:label>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_label_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Equipment and Other Finance Obligation</link:label>
    <link:label id="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_documentation_en-US" xlink:label="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Equipment and Other Finance Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:href="neo-20230331.xsd#neo_RepaymentsOfEquipmentAndOtherFinanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:to="lab_neo_RepaymentsOfEquipmentAndOtherFinanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_da068fec-108e-4fc3-89dd-582b9f5581a9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01166fe7-6352-4535-9ad5-3a1cdeb74d4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_814209b1-7810-45a8-8d18-2ccbaa466790_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a56ff250-02d3-454c-a67b-203c29fbe62c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e14f4056-248b-4616-971f-d7341b4a9926_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Restricted Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_8f676dc4-02cb-448d-a282-100db23750b8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c47991b-b156-4c00-9a3c-799f4010428e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e4d3d15d-23f7-47da-9948-b06f52e61dd5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a88afa43-aaba-4ed3-a660-35b27746cf66_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ae3df11e-b477-4cf1-8776-c1d15c0c3217_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f2f0d5a8-4294-4cbd-a1d6-f89953178070_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet_248e0cb7-91ac-47a4-b46e-ac652e329f19_terseLabel_en-US" xlink:label="lab_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other current assets for the sale of assets held for sale</link:label>
    <link:label id="lab_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet_label_en-US" xlink:label="lab_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Gain On Sale Of Property Included In Accounts Receivable, Net</link:label>
    <link:label id="lab_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet_documentation_en-US" xlink:label="lab_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Gain On Sale Of Property Included In Accounts Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" xlink:href="neo-20230331.xsd#neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" xlink:to="lab_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cece83bc-fc7f-4201-9046-c491fe31287e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_02b1bf96-66e9-4ff0-ad50-eb727b6c7887_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_49647d04-732b-483d-aa0e-b61280be3d46_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_f0d07a5c-5312-4ee0-a355-f4af8e6b8722_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_44efdd75-9c9a-4cc0-9e7e-35a3c75f8e63_terseLabel_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing Assets</link:label>
    <link:label id="lab_us-gaap_MarketingRelatedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="lab_us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_a9c5384c-d912-41ca-a833-0e80b7a73620_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense - ESPP</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ee5f5c52-0e52-4496-9bd6-df57ef782c31_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9bb2e812-7b0c-4147-864c-bbd58e023166_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_287dfe7a-07c4-4b69-8949-801abfdad503_verboseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ddc36f93-393e-40d8-847e-61d6c122e52f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contract Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7ad76bb8-28fb-4c23-91f8-fa3e6d627101_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_93787f0d-4b95-4eeb-96e4-4821b3c5d7e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance fees and expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_4a9f4809-8bbc-48bc-83d2-ae49b6a8608c_terseLabel_en-US" xlink:label="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services contracts with HOOKIPA Pharma, Inc</link:label>
    <link:label id="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_label_en-US" xlink:label="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services contracts with HOOKIPA Pharma, Inc [Member]</link:label>
    <link:label id="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_documentation_en-US" xlink:label="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services contracts with HOOKIPA Pharma, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:href="neo-20230331.xsd#neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:to="lab_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_23f4d15e-1eec-49ef-9dfa-74691324640a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fa32e2b9-745f-470c-8c5a-01656e5f155d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8da664e2-a14d-4305-b548-774919f22f24_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba4c5aa4-84df-49a0-a5a6-2b2129f166c1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_1446ea0b-ebe6-4aa3-a4f7-f3e1a45eebd0_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental stock-based compensation for accelerated vesting</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Program, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:to="lab_us-gaap_AcceleratedShareRepurchaseProgramAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0a1822bf-36d2-4183-9a5f-72a9762f9ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveNoncurrent_1b4e0dc1-b678-4b39-bb81-354e5af949ee_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveNoncurrent" xlink:to="lab_us-gaap_RestructuringReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_3750129a-23eb-49ba-a423-f866326e473f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8c14393d-71d3-4682-8705-4585b1199418_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a8d177b3-a37a-43b4-88bf-fc04df474eab_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_98f5265f-310f-4439-a4f7-c3021e6da05d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_bc508de8-6977-48ef-9406-610d7914a01e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7424360b-2a10-4efb-ad16-76e87697198f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a3f822c5-5e8a-4b37-91f2-adbeb1aaaba0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_351d5754-4b1f-4c57-a5be-dc6ba6e2f95c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_c6139278-f55b-46e1-a5f6-a82e3cfcc27d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bc5f9d75-2286-4fde-9c43-cfd36b1a378b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_7dc65067-358f-4255-bad7-cfde994a8aff_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_50c533b2-26af-4156-97b5-642c8079196f_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_0a5fe1c7-a60c-4a3b-af90-4cb0e9df20f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_caa7a08c-1403-40cc-ae14-70327e7b5721_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d760fbf3-03cc-456d-86e4-48ef4d4721a9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fdc5451-ef6b-4fa2-97a3-e5ffa9a8b693_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e16f66b-fa09-44ed-a8c2-a6346433538b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80374a5a-c030-4c3f-9ae4-0b514654220b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense, weighted-average recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_5ca4666a-16ab-425b-84ba-2ce7ae8fbf97_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GROSS PROFIT</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31e7d37b-f97b-418c-a48f-2920eee8a83c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4e36d12b-3719-49d4-8336-07535aea4d59_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0139c85f-0850-4046-bae0-51ca2ea24f7f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_70614d38-f213-44f5-adda-075fdb743631_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aae2d98a-b213-4f1d-8247-6035fc042edc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (%)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_c9630e99-889f-43b1-9d4b-d1369cbbbe0c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_90eb9dea-6b0c-48d0-b32f-25890330e43d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7e691c65-3795-4d1f-978f-44c4a4519399_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_d2283344-0736-479d-a35c-5ccabddb7525_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, accretion of debt discount</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_label_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Accretion Of Debt Discount</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Accretion Of Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:to="lab_neo_InterestExpenseDebtAccretionOfDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6b866ecd-6c8d-4770-8524-615606835894_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b08b435c-3862-40c2-805b-75ae58f237ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_80afa985-18e8-442b-a0e8-e1d772c07601_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d944519c-f891-4c78-8cf0-9386d7744789_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b885c631-e083-4b77-9729-1a90c9886b7b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_83a95220-f164-4ab5-ba73-c256e9ae01d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_122ac9e7-eca3-46fc-a8f1-581595e9340b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7c891c0e-9f1b-42f5-8ce7-2a1c35d467f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8ce1c69e-070d-4395-8d74-c5d24ed5ba98_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6f2f0c94-e6db-4d8e-9e9f-beaa32af3703_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_be196316-9719-4d97-a89d-1ae44fbf9088_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_36668adc-4af9-4507-b248-6a7c6e653969_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, amortization of debt issuance costs</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Amortization Of Debt Issuance Costs</link:label>
    <link:label id="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:to="lab_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_50a0ea84-8877-4a5a-b2c8-15232ab75698_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5445340f-0371-4b59-8003-ea287aee8ffe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_661457c7-276f-4315-aa89-a31012612bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_97080aaa-51d9-4a63-bc6e-d8cc387a85ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_80728a32-e3b1-40ba-9ec9-3026dc0215a2_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51cd18ed-c97f-4c93-8e91-8f4328f941f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d7750430-cf10-4b6f-8444-7d08f8dbae6a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_55a9eaf4-2fd0-4aca-9f85-d656db0b85ca_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6934fc94-4ab7-4087-a6cc-c859565a0237_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_a626f820-459f-4bb1-86f0-5f08010c9398_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3bcaff6b-c57d-4412-a008-06dbea890b23_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_bc6aad1d-ab70-46ae-abc5-f74c6c94ae94_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0658f644-80c8-40bd-af0f-6e51437dc7c7_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_18d450e4-59d2-422d-a21d-bbb9a3368ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_aa76ea33-e3c9-46f0-a4ae-4910f824df0b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_d54632d0-f3dd-4522-99e3-c15fd02fce63_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ContractualObligationTable_072132a8-0915-48b2-b5e0-3e3084c38426_terseLabel_en-US" xlink:label="lab_neo_ContractualObligationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Table]</link:label>
    <link:label id="lab_neo_ContractualObligationTable_label_en-US" xlink:label="lab_neo_ContractualObligationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Table]</link:label>
    <link:label id="lab_neo_ContractualObligationTable_documentation_en-US" xlink:label="lab_neo_ContractualObligationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationTable" xlink:href="neo-20230331.xsd#neo_ContractualObligationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ContractualObligationTable" xlink:to="lab_neo_ContractualObligationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_6c2b5576-0e60-4561-bebf-33e1f4b526c6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_83a6b94f-452d-48d9-9498-e3b4dc1e07cb_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c28845e5-a2f2-4c89-a080-ac8ae73cebe4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3c948dff-6d1c-430f-a261-487ae5326330_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5873c385-98e8-4f35-9d14-b8b9ae0e8bea_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_63dad548-6376-4786-89a4-57dee7f9b899_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_d739bd6c-9fef-4c1f-9aa0-3b25e8d0861b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_723aaa29-df5a-47b4-95d5-6540b646cdd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_70de468f-5d59-4caa-9032-cf11f0802d56_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b723b45d-9521-4a51-9e70-ca7d3390b8bd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_1a578f52-deb0-4526-8b5a-6e065db2373c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c0a1f6f4-545f-4771-89af-f2db67645ab9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_3b92dc95-df87-4bb2-a359-269504ee3b38_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e8c1064-7e0c-4e58-91c5-ab5fa0115a45_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b5387f1b-0f83-4feb-bc93-bb511115f510_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_602c012e-fd71-4a1c-8035-852bed9793c0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_47092ce1-fba5-444e-a0be-b5c9c4abab99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_58579dd4-f56b-4547-88b4-f4f98797cf42_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_3a7f2b84-c8b5-4976-a915-440d6023e0b4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0fda0549-e911-4f99-a1de-5dae1e30b9aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e05ab172-bd28-47c4-a37d-7e9e14435e97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_47370c69-f273-41d5-ab83-8744f967dd9a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6c644d7b-fc9c-4803-8a93-2163e07f202b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_149c64e6-0943-4f14-be8a-a4ce976a9ea5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_75658e99-9014-498d-84ed-ecd3d5f16d40_terseLabel_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual coupon interest</link:label>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_label_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Contractual Coupon Interest</link:label>
    <link:label id="lab_neo_InterestExpenseDebtContractualCouponInterest_documentation_en-US" xlink:label="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Contractual Coupon Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_InterestExpenseDebtContractualCouponInterest" xlink:to="lab_neo_InterestExpenseDebtContractualCouponInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a6590625-7b09-4920-98fb-5c26e2d7eb59_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7dfe39c1-7b9f-450b-a4bc-6ef9c7f04134_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a1bde5af-7aa9-4a6c-875f-67982cc48544_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f16afe94-587e-4030-b62e-0c5ffef20cf6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fffc8811-64eb-4ead-9533-16d63a62d881_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademark - Indefinite lived</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_97627110-3841-434f-a0b2-a2cab00f9304_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_26aca914-abef-4772-81a7-447b88062fa3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dee59ee7-73f0-47e4-bf12-ab952b3a50ae_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_3743705e-332c-4804-a328-75583462ad9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_c2f293b2-7c73-4b3f-bbc9-061aa701f32f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c9068449-eb3d-474e-bf71-299cc3eea7d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c55c6356-d223-4ead-b2f5-b69e08b584dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ad00bdba-c13c-4ab3-a250-cfc9bf06b95b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_c4cca8b6-4ee4-44b5-a1ed-4b847f0091e6_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_fa54348a-7fea-4c2a-bd58-5b52b90da1d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_172098fd-49ea-48cf-b88a-970e526a2b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_YankeeBondsMember_cac7fa02-4ecc-4b31-865d-02200be821dd_terseLabel_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee bonds</link:label>
    <link:label id="lab_neo_YankeeBondsMember_label_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bonds [Member]</link:label>
    <link:label id="lab_neo_YankeeBondsMember_documentation_en-US" xlink:label="lab_neo_YankeeBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yankee Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember" xlink:href="neo-20230331.xsd#neo_YankeeBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_YankeeBondsMember" xlink:to="lab_neo_YankeeBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e433c0a8-2d7b-420a-bf1b-aba527cfc0b3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ff7ef5ff-75b0-413d-a56e-7bc385d2b148_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_3c978323-a995-471b-be55-947e949c552e_terseLabel_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes</link:label>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_c3aa6be7-fa2e-424a-87cf-d6ec339a768c_verboseLabel_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 Convertible Notes</link:label>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Two Five Percent Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zero Point Two Five Percent Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:href="neo-20230331.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:to="lab_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a5fdc711-3fbc-4646-a4f6-265baeac72c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_130546b7-97a8-4033-94b6-2d0cd90efac4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5459519f-66da-437f-8781-a5b96ee1c50c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FacilityFootprintOptimizationMember_6f70b408-4c08-4e22-ba41-a603876116b4_terseLabel_en-US" xlink:label="lab_neo_FacilityFootprintOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Footprint Optimization</link:label>
    <link:label id="lab_neo_FacilityFootprintOptimizationMember_label_en-US" xlink:label="lab_neo_FacilityFootprintOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Footprint Optimization [Member]</link:label>
    <link:label id="lab_neo_FacilityFootprintOptimizationMember_documentation_en-US" xlink:label="lab_neo_FacilityFootprintOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Footprint Optimization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FacilityFootprintOptimizationMember" xlink:href="neo-20230331.xsd#neo_FacilityFootprintOptimizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FacilityFootprintOptimizationMember" xlink:to="lab_neo_FacilityFootprintOptimizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7c074b17-8216-4e0b-94c7-ba5d03ba1562_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f936960-8628-4276-887c-564708a7f6fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_f6c4eec7-c47f-4edd-a884-949cfdeda2f3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a9189073-2584-4f44-a222-5369da927338_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_472722d8-6faa-44b1-84b1-9a17692f90da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_74b3908a-2e59-4eff-9dc0-2b730253f3fe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_6652a170-230e-4db0-847e-2d0a921892d7_terseLabel_en-US" xlink:label="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Asset Amortization Expense [Table Text Block]</link:label>
    <link:label id="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Asset Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:href="neo-20230331.xsd#neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:to="lab_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_0c6b5731-6c4f-4777-a2f2-979c49203485_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_ee879dda-ee7e-4ff5-9183-623d9f54aff8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_557df51d-616c-480e-974c-4314b7a3c1ff_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_28f9b55b-0c59-4d28-857e-91af8cf281d7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3b4ddde1-b416-4340-9eb3-524802ad5b30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3a6928bb-45aa-4b9f-987f-8f6432dfd85f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_b0bcf0cb-74b7-40ec-97dc-01d846265eac_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_57cb7746-abc9-49c4-86ac-4093f383b547_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b9f2822-ffac-46c1-8aa3-07f066237c3d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_16840003-c678-45c2-8d1d-c1d743558594_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2cfb0400-5e45-4966-ad58-6b84a9a89284_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_64f4dc8a-0e88-43a5-a124-82929013559b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c029389c-1504-4dc0-9204-a7c882d9d298_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ab6d306a-75a6-4088-8bfa-39fb2f9b414c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net&#160;cash&#160;used in operating&#160;activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0ad93c98-12a3-46a3-81f1-f71545d749dd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_269d95f4-68ee-4b0e-a346-d2957db1421e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_55cb3c79-77ce-4996-9a23-26d22f1c3d15_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_cd610b44-1c86-4b82-bf0d-11b219b30bfc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60b20624-0a13-4064-8431-ce41fb7adde6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_331fa8bb-9314-4bd5-b9b8-17aad01affe3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c075e10f-bcb6-4c82-9be7-3de7e38799f5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_bc7d8fab-bdfb-4550-be09-a473bb2998b8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CommercialInsuranceMember_80abf88b-14ca-490e-8eaf-9902492bd386_terseLabel_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance</link:label>
    <link:label id="lab_neo_CommercialInsuranceMember_label_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance [Member]</link:label>
    <link:label id="lab_neo_CommercialInsuranceMember_documentation_en-US" xlink:label="lab_neo_CommercialInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember" xlink:href="neo-20230331.xsd#neo_CommercialInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CommercialInsuranceMember" xlink:to="lab_neo_CommercialInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_caf5db7b-922a-4abf-90db-a885a7c39095_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COST OF REVENUE</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9321e580-bb78-4cad-bd85-12bed1523017_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0b51789b-d974-439c-99ae-f87e7dcdaf3b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_500b30a9-870f-43cf-9d80-0056466276b5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0af2c21d-2bef-45d0-a7a5-1cedd6edd59d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_3942fd09-fc8e-4274-b2fd-337dd4bda06f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_81e3b9ae-ceba-47eb-9262-8dbada88820a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_4e6a9864-436c-4d1e-bb64-96e7dfabd0d7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_315d22ea-a1b1-4448-9587-83c5436c0771_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6a6977fc-5ac5-456a-9ecf-122cc98466ca_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fcfdf5fd-0b67-4c61-9ea6-82c77e1a819a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3f71e879-cec4-49fc-a592-723329a48b5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_49061a04-1764-48f8-8208-9ced2162f680_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_3c2889fb-ea0f-49ba-b84b-b2ad3c9cb32f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eec4781e-ba55-45f1-b01a-b1f6318fd0e3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee7f6647-9cc5-4757-926f-84638bd82fa5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9593832b-e963-4ba7-8038-df805a7e647f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments an Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2f2fa2c4-c4b9-4459-a369-18c38d8822ca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6601ca01-11c2-4577-95b9-4be2248b3611_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_fb53f8df-7a45-4b33-a2eb-3717ed931c3c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, at fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_b1469557-bf06-4872-a0a4-07943e750bb7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e7d4d195-d63b-40a0-a8a1-f46b92d4dcb5_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_918a1903-18e2-4761-847e-bc271732c074_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ClinicalServicesMember_ccaed679-34be-4df4-b4fd-dfc832df5eb7_terseLabel_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_neo_ClinicalServicesMember_label_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_neo_ClinicalServicesMember_documentation_en-US" xlink:label="lab_neo_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ClinicalServicesMember" xlink:to="lab_neo_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0b4b0f7b-0243-4c8e-a84f-87df7307e39d_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6a36521e-f86d-4229-8d95-5846f88c6de2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d02221ec-37f5-445e-8459-a7c0676f907c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_caaee769-7e3c-4639-a6cd-36ce68fbaff5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_f3300b4d-088a-4691-802f-cfa5b12b131d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of equipment financing obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db7bb2e9-f0b8-48f4-b6a3-4a73a63d9ac7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a7129950-08a9-4002-9cf5-8778e0adf1c7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3b45d428-2d4f-4755-ac11-214012dfe2ef_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2ffe96c6-72c1-4ded-8522-9dbb91d6181c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6da808f5-cdb3-400d-875d-cb071c5cc14f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SelfPayServicesMember_09df2abb-9bf3-4ab4-b28e-6dce4e12edb8_terseLabel_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay</link:label>
    <link:label id="lab_neo_SelfPayServicesMember_label_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Pay Services [Member]</link:label>
    <link:label id="lab_neo_SelfPayServicesMember_documentation_en-US" xlink:label="lab_neo_SelfPayServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Pay Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember" xlink:href="neo-20230331.xsd#neo_SelfPayServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SelfPayServicesMember" xlink:to="lab_neo_SelfPayServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_97b8c3db-b375-4c82-aefb-dca1baac55ab_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_85311e28-85aa-4a97-a43a-8025a9dba8d8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_f4f07a79-fe7e-4a2e-882d-6ed0b3ebf5a3_terseLabel_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue</link:label>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_label_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue [Member]</link:label>
    <link:label id="lab_neo_FederalHealthcareProgramRevenueMember_documentation_en-US" xlink:label="lab_neo_FederalHealthcareProgramRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Healthcare Program Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember" xlink:href="neo-20230331.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_FederalHealthcareProgramRevenueMember" xlink:to="lab_neo_FederalHealthcareProgramRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_74f86400-6cb7-494e-b763-2936b12b16cd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2fbf9a3a-ee9f-411e-a2cb-b9ab3086866b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0024244f-7e09-4ba5-8bfa-e4023f55ce25_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0da1f2d7-10da-4e24-ba1b-39babe71f3c0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ContractualObligationLineItems_8f507faf-63c3-421d-856b-5eaf4572b802_terseLabel_en-US" xlink:label="lab_neo_ContractualObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Line Items]</link:label>
    <link:label id="lab_neo_ContractualObligationLineItems_label_en-US" xlink:label="lab_neo_ContractualObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation [Line Items]</link:label>
    <link:label id="lab_neo_ContractualObligationLineItems_documentation_en-US" xlink:label="lab_neo_ContractualObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationLineItems" xlink:href="neo-20230331.xsd#neo_ContractualObligationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ContractualObligationLineItems" xlink:to="lab_neo_ContractualObligationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_92a7df37-f49c-4991-9e10-28d065480aa7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6c9569e9-9844-4815-8598-2beb35366dfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23bcaa14-6342-407f-b07a-ca845304ba78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_a1deb8a6-68c2-41b4-b1e6-331b96f6c2bd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_251837aa-1911-42e4-b382-a2e37f330780_terseLabel_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes</link:label>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_c439f679-7e1f-4add-ac55-58d58a60ad96_verboseLabel_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Convertible Notes</link:label>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Two Five Percent Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:href="neo-20230331.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:to="lab_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_0c0416e1-952e-4d75-a148-5e66fd46119b_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_29e10eb3-01a9-4eec-a80b-ad6c2d2c738e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term pharma capitalized commissions</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8aaf5215-5736-4d07-bfa9-d4e7c9d9fe10_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3f307fd5-91b5-4f3d-8a74-10af7e79dd42_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f340a1ba-7584-4b99-a21c-027caab0d007_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_ef12f39d-1484-4917-a9da-b237a06808f4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9680b049-1558-4f95-88bb-31fb9a63098c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_956e0ba9-fa79-48f9-ad6d-d233a594440d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2ee31839-88c4-488e-8efe-6e4b321cccbc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (net of accumulated depreciation of $138,863 and $131,930, respectively)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_24c3fdf1-03dd-452d-8f81-d96480645976_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2c901cc7-d5be-4f11-ae9b-fef1acde97d8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_1fd7fcdd-2474-4822-830d-ec3ad5103d42_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e23eb97-fb66-4206-97ed-bf628ee1fd62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (%)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_d6e7a577-cac7-4b9b-8225-162c1f2cb092_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_e34cc0f5-11c0-4e5c-8cdb-899095e64c5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_77a20b26-e529-40bf-beb1-ce32ac7d4885_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_68510bf5-05b6-451c-82a3-c4f1d36e5888_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_738d88ea-d59d-41e7-b665-fea3165b0598_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d8193c13-ce90-4860-9858-58523b7c3e69_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_55243814-6e5b-4f6a-893a-53a63aab6605_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_7d520402-c6e2-40ca-bbca-e76d66fabcd5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d8a48e85-d202-4d81-bb3e-51ea7c2b741d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2fef8d38-677c-489b-8400-66cbc15890ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e208940e-7132-42b1-b9bb-a8b5d3f35bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_85553da9-dabe-4488-ac41-1861e69c72c1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_29fc51ce-d124-4d4e-bd95-6840fd153941_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00e47ba9-e13b-4fa2-ba9b-bd41d15f16b1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_CappedCallTransactionsMember_bc117065-fc10-4c80-ad6a-ef12880b71c3_terseLabel_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions</link:label>
    <link:label id="lab_neo_CappedCallTransactionsMember_label_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions [Member]</link:label>
    <link:label id="lab_neo_CappedCallTransactionsMember_documentation_en-US" xlink:label="lab_neo_CappedCallTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember" xlink:href="neo-20230331.xsd#neo_CappedCallTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_CappedCallTransactionsMember" xlink:to="lab_neo_CappedCallTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_SeveranceAndOtherEmployeeCostsMember_6dbc3397-ff10-499f-8ea3-712e3fed2b83_terseLabel_en-US" xlink:label="lab_neo_SeveranceAndOtherEmployeeCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and Other Employee Costs</link:label>
    <link:label id="lab_neo_SeveranceAndOtherEmployeeCostsMember_label_en-US" xlink:label="lab_neo_SeveranceAndOtherEmployeeCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance And Other Employee Costs [Member]</link:label>
    <link:label id="lab_neo_SeveranceAndOtherEmployeeCostsMember_documentation_en-US" xlink:label="lab_neo_SeveranceAndOtherEmployeeCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance And Other Employee Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SeveranceAndOtherEmployeeCostsMember" xlink:href="neo-20230331.xsd#neo_SeveranceAndOtherEmployeeCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_SeveranceAndOtherEmployeeCostsMember" xlink:to="lab_neo_SeveranceAndOtherEmployeeCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_MedicareAndOtherGovernmentalMember_27af3563-c3b7-4967-b368-be5eb3b59b96_terseLabel_en-US" xlink:label="lab_neo_MedicareAndOtherGovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicaid</link:label>
    <link:label id="lab_neo_MedicareAndOtherGovernmentalMember_label_en-US" xlink:label="lab_neo_MedicareAndOtherGovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare And Other Governmental [Member]</link:label>
    <link:label id="lab_neo_MedicareAndOtherGovernmentalMember_documentation_en-US" xlink:label="lab_neo_MedicareAndOtherGovernmentalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare And Other Governmental [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndOtherGovernmentalMember" xlink:href="neo-20230331.xsd#neo_MedicareAndOtherGovernmentalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_MedicareAndOtherGovernmentalMember" xlink:to="lab_neo_MedicareAndOtherGovernmentalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_21fa678a-0b36-46ec-8089-aa315e851087_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1886abf1-74d8-4586-9f49-89d434e33aed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d1be67de-3c3a-47bd-bd7d-f837fc6e704c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4e100951-19d2-4021-a891-a01783c16580_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma contract liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_352a85e3-f4d9-43a6-82a7-9b6387a0ebae_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_725a8fe5-f443-4702-963e-8d4f44de73c6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_de493ec9-a986-44fe-b6ba-2a814dfc6931_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_af1ceb03-6047-4353-b19c-c9f104a2f55d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f0f2e583-55d0-42ea-a46c-09d25855f592_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_42efe3cc-6523-4368-9e49-038f2eab2cef_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_070d9c64-6227-467d-92b3-8130a3d51b73_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6d419392-644d-421e-baa6-d997121c6df5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9c5a086f-7622-4678-90b2-51860a22749e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ad6fb60d-ea2b-4e20-9eee-5e6110fb0492_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days (in days)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_bbec5f95-138b-4057-b553-3d57288d7de1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of convertible debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_970f1b20-01ac-4fd2-a318-fff8282eb4dc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_50c91c35-4f10-460a-8a13-c182cc785334_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f7208ebb-d97b-418a-a05e-bf976ba955f3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_37a40f90-3a93-435d-a232-6be2a92c58de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_43229022-13ac-40c0-b05f-1aac9312bfd4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_1765cf4c-e1ad-4b9d-a863-066b527cd944_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Classes of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9f9e45b3-f17e-47f2-99ea-196153482d49_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92eb0da9-ca65-43e6-8ba1-10f24981a6a4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0d98c58a-1309-48f7-84ff-9467f9579fa8_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_da0c0b42-cb57-42b8-b8c7-1096b101bfdf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d60d8769-0e92-4df3-907f-26583980e563_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e5024831-3c5f-475b-8035-241dd16e3ba4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_PharmaServicesMember_0c748fe9-68e8-4be6-a2ff-2b46e6881c2f_terseLabel_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services</link:label>
    <link:label id="lab_neo_PharmaServicesMember_label_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services [Member]</link:label>
    <link:label id="lab_neo_PharmaServicesMember_documentation_en-US" xlink:label="lab_neo_PharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_PharmaServicesMember" xlink:to="lab_neo_PharmaServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_ef9e5eda-9dae-4483-b09f-c715e9385309_terseLabel_en-US" xlink:label="lab_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring incurred cost statement of income or comprehensive income extensible enumeration not disclosed flag</link:label>
    <link:label id="lab_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:href="neo-20230331.xsd#neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9154bb22-96f5-439b-a079-a79581aad92b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a8b41d68-ae85-4e65-8005-447f96882f4b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_887ff212-f1e7-4440-9d24-42e3e4a1c8f8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f62ab80a-8043-4960-b3de-258d46883ccc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price on applicable trading day (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_82d81fea-ac80-4ca6-84f7-2ad7e11d04ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0152abb6-13df-49e0-964f-2d1bc7a71469_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6c783f0a-2971-4827-981c-b2a3ad60db22_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a56eca81-4dde-46a3-8b6e-521633488b48_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_23f68ac4-3618-43e9-aa61-e45a490e13c3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_727e0b6a-35dc-45de-a812-884765d4c6bd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_664c66c0-cbc3-4a2d-acdd-f3eba19403e3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ClientDirectBillingMember_8d86f082-4d0d-4bb6-965c-fee2ac5aec43_terseLabel_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client direct billing</link:label>
    <link:label id="lab_neo_ClientDirectBillingMember_label_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Direct Billing [Member]</link:label>
    <link:label id="lab_neo_ClientDirectBillingMember_documentation_en-US" xlink:label="lab_neo_ClientDirectBillingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Direct Billing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember" xlink:href="neo-20230331.xsd#neo_ClientDirectBillingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ClientDirectBillingMember" xlink:to="lab_neo_ClientDirectBillingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f39a2fe0-37f4-472f-80ea-9504b0a8935e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense (gain)</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_cfed1d82-a13d-4f9f-8fdb-57dbcab34c80_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6b95ba46-2363-4df4-8e76-44fd5e0e4169_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_997c2b35-d827-48d7-bf61-8aea34b26bda_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2b5ad398-1db4-44a3-9d10-eafb7bf901fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_43859baa-eef7-42c3-8029-2b8fe8acc8eb_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Period (years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_048b0e7b-fb33-46bb-89e9-3b83250b51e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3142fb8c-dfc2-4413-afe7-305757928cf0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles included in general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_42188b40-ae27-45ce-8922-ad2ea7715f89_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_79e693f2-e1cb-4da9-8da6-51e64effb5c5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fc416ca5-cbdb-458d-83a8-9d70e4be72b4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f82d7877-0686-46a6-b019-4b0e6dd32ef4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_5ab7cd46-a912-46db-8848-d511c7597495_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_778604d4-e99a-41cd-b95b-7a6f67a00ce9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d0fa76a2-fa8c-4407-8462-25f92c38094e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e71339d6-b697-4c19-934c-d9aed23ea723_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_9e0daaab-ceb9-4cb4-a8ed-84b8e52e26dc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f74bda0-1271-4076-859b-238fd5d3b269_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (%)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_a2b45035-c2d4-41ec-8912-dc52c1bd6d83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income) expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_97b86cfe-6240-4794-831e-e104a80f3e25_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income) expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_476f7c69-ed36-4f7f-a096-66ff91349715_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_76239fce-43f2-4c59-aad6-7526ce5c7aa0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issue costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0aaf0b4b-64a7-4b70-b3be-b0082f73ade4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_672336c8-cf3e-42a6-a391-58cbd79beae9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_55e7b7f5-7d11-4847-b4cf-7c6f08537611_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5e864911-eef1-4b0e-babd-7893112582d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_95088566-886c-4f88-9291-97519bbc9876_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_94482569-b037-49dd-8828-3e85091f12e8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c085eee1-6a54-4be0-8b7a-635e42d84a8f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3bf1cb1e-1807-4da2-8dde-cba45f64db15_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_514def08-5ab4-4afa-8693-682966eb6a06_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5816f14a-e2b7-4f42-a57a-f633831d2611_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense - options and restricted stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAbstract_cf3500e8-b38c-4d05-86f4-8e480f760f39_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract" xlink:to="lab_us-gaap_CapitalizedContractCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_675b7120-457a-45dd-be5d-6b3151863456_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ca0f3101-b17e-4f5c-b838-438e0ccbb782_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_50e862df-0de1-43a9-af07-8f2a5db263a6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dc29dbef-6835-4e98-9707-4643424c4619_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_dda36262-3555-4767-adea-57e57c7838d6_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pharma contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_cdefb9f8-3911-4ed0-b136-ce289d50a329_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_31d4be5d-2e45-47ef-a73e-7f8f4dbb6f38_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cf02e9cc-33e6-4a68-b780-10e9a2c8135a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_38fb1728-4f7f-4ccd-8e1a-9625617448c3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_65335439-9d5e-49f4-abd9-788e400607cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c7a17376-2f0a-4bb3-bb21-cd833ebb24e9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9a433be-7766-493b-9db7-bf916338b780_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ba9a0120-23e3-43ca-b7ab-266cfe1fc671_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a93b8b84-5f71-4b70-998a-98976e005e09_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_645a07d0-0e39-4dbf-a4e6-abe3eda24df8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current pharma contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f91754f4-63cd-4c16-8d13-d7d9551681a0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_f4541466-8466-4c8d-9fcc-ef0f9a5438c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on Convertible Notes (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8821a903-589b-4bc4-9800-62e9eaa2b8db_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_7fb5d841-8a2c-44e9-9016-814c30fa7ed1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_2a5a49ac-21ca-4735-a7e9-f5698d23fb23_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_36ea8681-fd6a-4606-87f4-c274e210f218_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f546e10a-57d1-4c95-805e-44761130d694_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3708881a-d267-4eb5-ace0-b57294460a25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9c9e8b2c-6496-41e2-967e-14c41fc18982_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_90ef4c0c-31bb-42c0-9475-f687b5c323dd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34c27bbb-8f4f-42dd-b672-89df5960ac38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a20ccc44-54ff-44a6-b1e6-1ffcfa2207a6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9c07c7f0-e8e4-41cb-8236-ebbe7046fe7f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f6426e2d-d1ee-4c5e-bcc5-7a070872738b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4068b641-e09c-4833-bbc6-7c7849a91feb_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7eb0df47-c946-4351-ac7d-81157502d6c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b6c1d257-1a7b-4023-a587-841d4dbbf85a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_f49dbf6a-1025-4ee2-809d-035dec9db69c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Marketing Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6763a42e-9e75-44b2-a4ff-a2ad706a63d3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_f4aa3f69-7c32-43ee-b384-0d942921f63f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d763d05c-b3df-4696-ac60-42074a3e36e3_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ab6d32c6-363a-45a3-b1cf-56781a56337e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_neo_ConsultingCostsMember_e4c3d321-f31f-4f60-beed-580da26b3e6d_terseLabel_en-US" xlink:label="lab_neo_ConsultingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and Other Costs</link:label>
    <link:label id="lab_neo_ConsultingCostsMember_label_en-US" xlink:label="lab_neo_ConsultingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Costs [Member]</link:label>
    <link:label id="lab_neo_ConsultingCostsMember_documentation_en-US" xlink:label="lab_neo_ConsultingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ConsultingCostsMember" xlink:href="neo-20230331.xsd#neo_ConsultingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_neo_ConsultingCostsMember" xlink:to="lab_neo_ConsultingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2cf52007-2f6c-458c-a950-39535ab7c2fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_ac7251f0-e514-41e4-9cfe-3dea6f465b00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of facility related assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a3c2b132-d614-4270-9aaa-8e1b88056070_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_eef478e1-eab7-4b82-806c-2fe4a20e4f12_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8d7a7336-e531-48f7-93e3-88557069686a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_22775c3a-e2b8-419f-a741-c39047dccead_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_c508035d-504c-4e1e-bdff-c5ab11c0377f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles included in cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>neo-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9dc41751-b83b-431c-b18e-08aa28ccd964,g:b69a919b-a967-4814-b0e5-6634100d0d89-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neogenomics.com/role/Cover" xlink:type="simple" xlink:href="neo-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0a8e4f0f-6090-44ec-97a3-2c90d4a8cb46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_DocumentType_0a8e4f0f-6090-44ec-97a3-2c90d4a8cb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_61243051-387b-455f-8408-0cb20615e756" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_DocumentQuarterlyReport_61243051-387b-455f-8408-0cb20615e756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_428b4abf-36ae-48d7-b4bb-a25f0ba561cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_DocumentPeriodEndDate_428b4abf-36ae-48d7-b4bb-a25f0ba561cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_cde31449-3df6-46f5-bb7f-b22e860edccf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_DocumentTransitionReport_cde31449-3df6-46f5-bb7f-b22e860edccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4442c37a-cd69-46b8-8ec1-00ce3fafa75e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityFileNumber_4442c37a-cd69-46b8-8ec1-00ce3fafa75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3696833b-70c1-485b-9833-dacb2adc55ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityRegistrantName_3696833b-70c1-485b-9833-dacb2adc55ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7b1b167a-9726-4a32-a258-9444bdb78299" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7b1b167a-9726-4a32-a258-9444bdb78299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_29581d4c-4702-4c8f-8755-a6b9b5d0890a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityTaxIdentificationNumber_29581d4c-4702-4c8f-8755-a6b9b5d0890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_eec5b87d-3b0b-4231-a0cb-a3b12082739e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityAddressAddressLine1_eec5b87d-3b0b-4231-a0cb-a3b12082739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0ef7b0ab-5180-4bb7-946e-1c26e55f93d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityAddressCityOrTown_0ef7b0ab-5180-4bb7-946e-1c26e55f93d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bf1c8a4b-89d6-4b68-abea-d91aa383297e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityAddressStateOrProvince_bf1c8a4b-89d6-4b68-abea-d91aa383297e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_efc2f371-2d08-4122-8b58-30af596b9772" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityAddressPostalZipCode_efc2f371-2d08-4122-8b58-30af596b9772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1ad1aaca-1448-447d-9517-d82fd7730fb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_CityAreaCode_1ad1aaca-1448-447d-9517-d82fd7730fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_abf0af80-f954-4377-a3d1-3c28193953ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_LocalPhoneNumber_abf0af80-f954-4377-a3d1-3c28193953ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d14205bd-21c9-4701-866f-b843c2d49a6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_Security12bTitle_d14205bd-21c9-4701-866f-b843c2d49a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5b805a13-662f-4a5e-a863-b983ef5a6cf9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_TradingSymbol_5b805a13-662f-4a5e-a863-b983ef5a6cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5fab05f5-834d-4084-861c-bd07bcc61117" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_SecurityExchangeName_5fab05f5-834d-4084-861c-bd07bcc61117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_397253e7-bf6f-4685-ba33-90254f9edbbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityCurrentReportingStatus_397253e7-bf6f-4685-ba33-90254f9edbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9694cdc7-5aed-4ba0-95e7-e66383c125eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityInteractiveDataCurrent_9694cdc7-5aed-4ba0-95e7-e66383c125eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_008fbd2c-fac2-4640-b20b-e45274df0580" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityFilerCategory_008fbd2c-fac2-4640-b20b-e45274df0580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ccb9d159-01a8-4f81-8c61-a490413db0b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntitySmallBusiness_ccb9d159-01a8-4f81-8c61-a490413db0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_feae6501-6d83-4dc2-820f-7921184ccbd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityEmergingGrowthCompany_feae6501-6d83-4dc2-820f-7921184ccbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f639f0f3-0911-4941-84b0-41e37d533043" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityShellCompany_f639f0f3-0911-4941-84b0-41e37d533043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_be85849a-8719-4446-819b-6bf896abc32b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_be85849a-8719-4446-819b-6bf896abc32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_277729cb-6209-46d2-844e-c49f83c1c242" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_EntityCentralIndexKey_277729cb-6209-46d2-844e-c49f83c1c242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ed8cb407-6580-4d38-a47a-ebe3fa71a6a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_CurrentFiscalYearEndDate_ed8cb407-6580-4d38-a47a-ebe3fa71a6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b7b27cfc-ed97-4b9d-a1e4-19ee0321e93d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_DocumentFiscalYearFocus_b7b27cfc-ed97-4b9d-a1e4-19ee0321e93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_33d12ff8-7609-4bed-979b-b000b561defc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_DocumentFiscalPeriodFocus_33d12ff8-7609-4bed-979b-b000b561defc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ce101b7b-fc26-4443-a3db-668577617c0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b479c1c7-f069-49ab-9ba1-819479536847" xlink:to="loc_dei_AmendmentFlag_ce101b7b-fc26-4443-a3db-668577617c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ecc6249d-fc3b-4448-b28e-8037407cf898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ecc6249d-fc3b-4448-b28e-8037407cf898" xlink:to="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f909a0a-26e0-4c72-adea-067d412f9b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f909a0a-26e0-4c72-adea-067d412f9b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_01314e58-cb79-447f-8c60-47fe4b83bc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_01314e58-cb79-447f-8c60-47fe4b83bc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_25e00a66-d9bf-48b9-825d-8dbf6a2e1c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_25e00a66-d9bf-48b9-825d-8dbf6a2e1c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4365a69b-acf3-481c-80f7-9e56f23f4c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:to="loc_us-gaap_InventoryNet_4365a69b-acf3-481c-80f7-9e56f23f4c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5c6e18c0-7e3d-4cfd-bf64-742d0b277381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5c6e18c0-7e3d-4cfd-bf64-742d0b277381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a116afe6-9597-4912-b443-036360d7412b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:to="loc_us-gaap_OtherAssetsCurrent_a116afe6-9597-4912-b443-036360d7412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_358ab4cc-43db-4e2a-9087-8a47a16fcb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69482919-2863-4c70-a721-878dc05663f0" xlink:to="loc_us-gaap_AssetsCurrent_358ab4cc-43db-4e2a-9087-8a47a16fcb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fe4696bc-d7af-46c7-81b4-12a1d9b4b46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fe4696bc-d7af-46c7-81b4-12a1d9b4b46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_769d8a04-2ceb-45bb-9af1-df6d5635c5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_769d8a04-2ceb-45bb-9af1-df6d5635c5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_49b3c2d5-830a-42bc-8c11-983930140a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_49b3c2d5-830a-42bc-8c11-983930140a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b2743eb8-d990-43f4-b659-0f0f1dedb483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_Goodwill_b2743eb8-d990-43f4-b659-0f0f1dedb483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a169a619-989a-4e69-80ae-0907398ffb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a169a619-989a-4e69-80ae-0907398ffb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_229a3f24-3732-470d-bc1c-445c3a0afdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_AssetsNoncurrent_229a3f24-3732-470d-bc1c-445c3a0afdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_83342855-46ab-42c4-a582-dd82f1d44325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf48ef17-b347-4d51-8232-8155b2788b89" xlink:to="loc_us-gaap_Assets_83342855-46ab-42c4-a582-dd82f1d44325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ecc6249d-fc3b-4448-b28e-8037407cf898" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_978133f6-eba2-4365-a787-188c553eaec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:to="loc_us-gaap_AccountsPayableCurrent_978133f6-eba2-4365-a787-188c553eaec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3c55fe4b-5f94-4d03-9877-b687367eba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3c55fe4b-5f94-4d03-9877-b687367eba1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f3fb5250-0241-4f0e-a34e-f917cd45d933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f3fb5250-0241-4f0e-a34e-f917cd45d933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2e623670-4fbb-4898-89d8-b6dcc76eda30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2e623670-4fbb-4898-89d8-b6dcc76eda30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fc9e5868-73c2-44e5-89d2-57d0fa3d1439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fc9e5868-73c2-44e5-89d2-57d0fa3d1439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c61414ef-ecf7-4973-a9a2-5fe71af427f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c61414ef-ecf7-4973-a9a2-5fe71af427f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aeb52714-b1b3-4921-835e-553392b19b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a021baf3-689f-4bef-88e2-cd186bde739f" xlink:to="loc_us-gaap_LiabilitiesCurrent_aeb52714-b1b3-4921-835e-553392b19b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_cd6d9d7e-46e1-4037-b78b-69490da722f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_cd6d9d7e-46e1-4037-b78b-69490da722f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_c8852451-92e9-40c1-ab1e-15dc9530ae82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cd6d9d7e-46e1-4037-b78b-69490da722f8" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_c8852451-92e9-40c1-ab1e-15dc9530ae82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fc35e92e-0b1c-4d60-95d7-27cd45b4448a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cd6d9d7e-46e1-4037-b78b-69490da722f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fc35e92e-0b1c-4d60-95d7-27cd45b4448a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7301514b-975e-4b33-bb63-09cf903ea5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cd6d9d7e-46e1-4037-b78b-69490da722f8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7301514b-975e-4b33-bb63-09cf903ea5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5bd0999d-d9b1-4669-b877-d8c5b299c35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cd6d9d7e-46e1-4037-b78b-69490da722f8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5bd0999d-d9b1-4669-b877-d8c5b299c35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_404820a8-8442-4455-85c0-a66a084abb42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cd6d9d7e-46e1-4037-b78b-69490da722f8" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_404820a8-8442-4455-85c0-a66a084abb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c39219ca-d1eb-4948-8857-387c50d8e9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:to="loc_us-gaap_Liabilities_c39219ca-d1eb-4948-8857-387c50d8e9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_147b5c40-93db-444a-b19a-a14e6e8726a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_147b5c40-93db-444a-b19a-a14e6e8726a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_44e99ae2-d549-4a70-bdbd-86f5d062b27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_44e99ae2-d549-4a70-bdbd-86f5d062b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_d2995502-d864-457f-8e95-83e314dcc849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e99ae2-d549-4a70-bdbd-86f5d062b27b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_d2995502-d864-457f-8e95-83e314dcc849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4ee548a-7b7f-4199-9b82-755862da4b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e99ae2-d549-4a70-bdbd-86f5d062b27b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4ee548a-7b7f-4199-9b82-755862da4b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3e21cd1e-bc62-4963-99b2-f051e9312a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e99ae2-d549-4a70-bdbd-86f5d062b27b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3e21cd1e-bc62-4963-99b2-f051e9312a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27f234b1-83ae-476a-a6eb-0f71b8ff25f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e99ae2-d549-4a70-bdbd-86f5d062b27b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27f234b1-83ae-476a-a6eb-0f71b8ff25f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_717bfd06-9af8-4253-ad33-e859a061fc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44e99ae2-d549-4a70-bdbd-86f5d062b27b" xlink:to="loc_us-gaap_StockholdersEquity_717bfd06-9af8-4253-ad33-e859a061fc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f31e1f89-0f9f-4092-9a5e-50edc002f3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2053851a-9a70-493e-96b5-b01cc9ae6be2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f31e1f89-0f9f-4092-9a5e-50edc002f3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_526940ba-e895-478a-b66a-1f17c045b3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c4b40cb-18fc-4165-a9f4-9940c4338746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_526940ba-e895-478a-b66a-1f17c045b3e8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c4b40cb-18fc-4165-a9f4-9940c4338746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_306e7f9e-7356-42b9-b11f-104f21edc3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_526940ba-e895-478a-b66a-1f17c045b3e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_306e7f9e-7356-42b9-b11f-104f21edc3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c6920c31-9ed9-4229-98d7-f7cc8f618f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_526940ba-e895-478a-b66a-1f17c045b3e8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c6920c31-9ed9-4229-98d7-f7cc8f618f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_93f796cc-faf0-4b0a-980f-53c60f817171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_526940ba-e895-478a-b66a-1f17c045b3e8" xlink:to="loc_us-gaap_CommonStockSharesIssued_93f796cc-faf0-4b0a-980f-53c60f817171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2548c868-1b02-47dd-8168-5dec4153f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_526940ba-e895-478a-b66a-1f17c045b3e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2548c868-1b02-47dd-8168-5dec4153f14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_890fab3c-9161-40cf-a574-d7ace0276010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_859d9b14-e9af-435b-a69a-82d2398b5da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_890fab3c-9161-40cf-a574-d7ace0276010" xlink:to="loc_us-gaap_StatementTable_859d9b14-e9af-435b-a69a-82d2398b5da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_859d9b14-e9af-435b-a69a-82d2398b5da7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_361dcdcc-62c7-4fed-bb9d-b77c65de2ceb" xlink:to="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_5a5ec1ea-659b-471b-80b4-5594225d9fda" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:to="loc_neo_ClinicalServicesMember_5a5ec1ea-659b-471b-80b4-5594225d9fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_5c67364e-92ea-4ab9-b029-52d1a65c2750" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ff271f4b-86e9-4e57-839f-4415185ea96f" xlink:to="loc_neo_PharmaServicesMember_5c67364e-92ea-4ab9-b029-52d1a65c2750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_859d9b14-e9af-435b-a69a-82d2398b5da7" xlink:to="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97814465-19c7-4401-b2d3-cfcbfe511221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97814465-19c7-4401-b2d3-cfcbfe511221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0fd362ae-c287-4ce7-94ca-4bc70e3355c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0fd362ae-c287-4ce7-94ca-4bc70e3355c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_84f13b04-0e87-4834-ac9a-3db6c8817e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_GrossProfit_84f13b04-0e87-4834-ac9a-3db6c8817e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e09fff45-b4c6-4b78-84df-6410560f1d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e09fff45-b4c6-4b78-84df-6410560f1d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8cff7430-20ed-43c9-a73e-3b3d3c9d9f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8cff7430-20ed-43c9-a73e-3b3d3c9d9f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_745676a5-b96b-4c1f-8b41-23c903a0aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_SellingAndMarketingExpense_745676a5-b96b-4c1f-8b41-23c903a0aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0387a9e3-f80c-406e-bbdf-692c34c551a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_RestructuringCharges_0387a9e3-f80c-406e-bbdf-692c34c551a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dbcbc456-b157-4a6a-8ff0-af42de01def7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_05a765bf-ea5d-4fd2-97a5-f3cb3c6e2add" xlink:to="loc_us-gaap_OperatingExpenses_dbcbc456-b157-4a6a-8ff0-af42de01def7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2b0a238b-101b-403c-ae0a-a2a78951bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_OperatingIncomeLoss_2b0a238b-101b-403c-ae0a-a2a78951bb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_26497b8e-73b8-4e18-85a4-ba97afdb67d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_26497b8e-73b8-4e18-85a4-ba97afdb67d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_beca7966-04b7-4c47-9200-eb6be206b477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_beca7966-04b7-4c47-9200-eb6be206b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eb97b92a-ec51-4dba-a907-fcdbada2ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eb97b92a-ec51-4dba-a907-fcdbada2ae50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d37cf647-c479-4688-81fb-bb20f8d8bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d37cf647-c479-4688-81fb-bb20f8d8bcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e86ae5f1-c3bd-4dee-af27-2387eeee06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_NetIncomeLoss_e86ae5f1-c3bd-4dee-af27-2387eeee06e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_77927bc7-a5c3-4750-bec5-e85cc57c2d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_77927bc7-a5c3-4750-bec5-e85cc57c2d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4e8acdcd-5296-49cb-b646-036e40e635ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2d8e74df-b025-469f-af63-1225ea098e06" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4e8acdcd-5296-49cb-b646-036e40e635ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dc716259-3b3c-4543-9424-57b5d87372ff" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_faa2f2c8-4053-45f6-8391-6d340fca1b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_faa2f2c8-4053-45f6-8391-6d340fca1b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7863513-5d5f-451c-9c2b-d4687c8a8047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7585c784-406f-4297-a5ce-90c0a274608a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7863513-5d5f-451c-9c2b-d4687c8a8047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e24c887a-65cd-4101-b00f-45ac9e46f4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3234a7ba-a1ee-4822-b57c-48fa3e791d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e24c887a-65cd-4101-b00f-45ac9e46f4ad" xlink:to="loc_us-gaap_NetIncomeLoss_3234a7ba-a1ee-4822-b57c-48fa3e791d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_702ed3b1-1760-4af5-ae3c-c3f231885a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e24c887a-65cd-4101-b00f-45ac9e46f4ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_702ed3b1-1760-4af5-ae3c-c3f231885a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_516aa51b-9dba-4d33-86e5-3747a2e1edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_702ed3b1-1760-4af5-ae3c-c3f231885a7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_516aa51b-9dba-4d33-86e5-3747a2e1edd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e28da3ea-742d-42d3-b7c6-dae5ad9c0911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_702ed3b1-1760-4af5-ae3c-c3f231885a7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e28da3ea-742d-42d3-b7c6-dae5ad9c0911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_71feccd7-ceef-4e9e-b108-d7bd4bfbc119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e24c887a-65cd-4101-b00f-45ac9e46f4ad" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_71feccd7-ceef-4e9e-b108-d7bd4bfbc119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e104f52e-6001-4df1-854e-bca2b21e6128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f2a5f231-9bd8-457a-b840-d564ff5b2a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e104f52e-6001-4df1-854e-bca2b21e6128" xlink:to="loc_us-gaap_StatementTable_f2a5f231-9bd8-457a-b840-d564ff5b2a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2a5f231-9bd8-457a-b840-d564ff5b2a61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40cc55f1-cdaa-4e40-9043-a9d8c5ab1ac5" xlink:to="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_827c82b9-a43b-4a30-84ba-4e93d2c397ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_CommonStockMember_827c82b9-a43b-4a30-84ba-4e93d2c397ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_bbf7c8d3-f7a2-4965-8d48-9074bdbb662d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_bbf7c8d3-f7a2-4965-8d48-9074bdbb662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7cb10fa2-17aa-422d-8556-db504eec825f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7cb10fa2-17aa-422d-8556-db504eec825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3855c85b-af83-487e-93fc-d50fdeb7e302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85b2d77d-38a6-4d9c-a3dc-797cebe2af70" xlink:to="loc_us-gaap_RetainedEarningsMember_3855c85b-af83-487e-93fc-d50fdeb7e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fa30cb59-7ad5-447c-8bdb-c6360c70fe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f2a5f231-9bd8-457a-b840-d564ff5b2a61" xlink:to="loc_us-gaap_StatementLineItems_fa30cb59-7ad5-447c-8bdb-c6360c70fe0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fa30cb59-7ad5-447c-8bdb-c6360c70fe0b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3e61d655-4639-4b8a-868a-22888065d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_SharesOutstanding_3e61d655-4639-4b8a-868a-22888065d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff2a7bb8-f85b-4eb2-94bb-dfb3932287c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockholdersEquity_ff2a7bb8-f85b-4eb2-94bb-dfb3932287c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5e07bd-64d8-46c1-bcb1-6aee048b24b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5e07bd-64d8-46c1-bcb1-6aee048b24b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3f49f9f2-00a5-4e0a-ab5b-a44409be478c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3f49f9f2-00a5-4e0a-ab5b-a44409be478c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db1bea7e-33c9-43bc-8611-89a3b0ac3066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db1bea7e-33c9-43bc-8611-89a3b0ac3066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11dbbf3b-3533-4822-9b6c-298ff2e985a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11dbbf3b-3533-4822-9b6c-298ff2e985a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_706e50cb-291e-44e7-bcb7-aff692a28386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_706e50cb-291e-44e7-bcb7-aff692a28386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7fcb4156-7e3f-4d42-94e7-00bd1e69125c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7fcb4156-7e3f-4d42-94e7-00bd1e69125c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d87eb346-8767-4763-aa8c-9c7e6eb31e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d87eb346-8767-4763-aa8c-9c7e6eb31e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_4640431d-7350-4f00-9c2b-419920e73a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_4640431d-7350-4f00-9c2b-419920e73a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d540db1-691b-422c-9eee-e778c7fe1fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5d540db1-691b-422c-9eee-e778c7fe1fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f47797cd-c77e-49e8-80e4-42303bf33c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f47797cd-c77e-49e8-80e4-42303bf33c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdced2bb-d643-49ab-bddc-dc59daad8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_NetIncomeLoss_fdced2bb-d643-49ab-bddc-dc59daad8e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_24ce5ca2-05d8-4e68-9e24-83729599b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_SharesOutstanding_24ce5ca2-05d8-4e68-9e24-83729599b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61f7bf67-0891-48be-9df9-ebdc44ba8b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_028b1281-38e1-48e3-a5bd-9bf8b79f0d4e" xlink:to="loc_us-gaap_StockholdersEquity_61f7bf67-0891-48be-9df9-ebdc44ba8b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="neo-20230331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b9887c63-925b-4c5b-a8e9-80b48ce4cf93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b9887c63-925b-4c5b-a8e9-80b48ce4cf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_919e9097-434e-4fac-98e0-3376ba848fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b9887c63-925b-4c5b-a8e9-80b48ce4cf93" xlink:to="loc_us-gaap_NetIncomeLoss_919e9097-434e-4fac-98e0-3376ba848fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b9887c63-925b-4c5b-a8e9-80b48ce4cf93" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8c66a3da-c8f3-4b6d-9e72-e1f1afa1c912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_Depreciation_8c66a3da-c8f3-4b6d-9e72-e1f1afa1c912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b8604018-19c1-4759-8eed-9f00a32980a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b8604018-19c1-4759-8eed-9f00a32980a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_113ccf0b-eb98-4218-9f47-a7f3f92afc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_ShareBasedCompensation_113ccf0b-eb98-4218-9f47-a7f3f92afc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_dc9dd24c-3897-4d33-91dc-201650a21499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_OperatingLeaseExpense_dc9dd24c-3897-4d33-91dc-201650a21499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d52d67f4-f735-4b78-b5ca-76e680bf224a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d52d67f4-f735-4b78-b5ca-76e680bf224a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1b929091-8acd-46cc-a8d7-d27078b6c225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1b929091-8acd-46cc-a8d7-d27078b6c225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5cc4ca47-01d7-4e7d-9fd0-6098b4a17958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_5cc4ca47-01d7-4e7d-9fd0-6098b4a17958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4d029d5d-484f-406a-bc44-0c2619ca4ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4d029d5d-484f-406a-bc44-0c2619ca4ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_70323012-1b24-40bf-a06b-3da5e52d31b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_70323012-1b24-40bf-a06b-3da5e52d31b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_171d106b-55b3-4304-8189-3baf8d886a33" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc654ab1-1181-4b0e-ac57-0b031e0ddb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc654ab1-1181-4b0e-ac57-0b031e0ddb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a1266b86-66d6-4871-8e0b-08c94826ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a1266b86-66d6-4871-8e0b-08c94826ecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_45ae11c1-b87f-4ef4-bf35-47eb831279e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_45ae11c1-b87f-4ef4-bf35-47eb831279e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1379ab0b-719f-4b93-a9b8-25acca6bfb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1379ab0b-719f-4b93-a9b8-25acca6bfb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b7be595f-d6f6-45b9-8469-5640609c6ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b7be595f-d6f6-45b9-8469-5640609c6ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_dbea941a-44c5-411a-aeeb-4471efa3a8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_dbea941a-44c5-411a-aeeb-4471efa3a8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_dbf56b1a-b3e5-4536-8aa1-8664e273c139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89e158df-7b85-4128-929a-6a1b3b7a2475" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_dbf56b1a-b3e5-4536-8aa1-8664e273c139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9be65a2a-31f3-4cfd-bc47-d13891e9c41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b9887c63-925b-4c5b-a8e9-80b48ce4cf93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9be65a2a-31f3-4cfd-bc47-d13891e9c41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8eb76253-33aa-4649-be03-e242f275e089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8eb76253-33aa-4649-be03-e242f275e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_420b5f5d-a6cf-4fca-888d-1887450db083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8eb76253-33aa-4649-be03-e242f275e089" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_420b5f5d-a6cf-4fca-888d-1887450db083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4f4aee64-ea1d-4adf-847d-60f0a9ff8d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8eb76253-33aa-4649-be03-e242f275e089" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4f4aee64-ea1d-4adf-847d-60f0a9ff8d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8bcb3be-de14-4c78-b66a-06120ffda8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8eb76253-33aa-4649-be03-e242f275e089" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8bcb3be-de14-4c78-b66a-06120ffda8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95958164-6575-4683-b9d0-6e568cc43fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8eb76253-33aa-4649-be03-e242f275e089" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95958164-6575-4683-b9d0-6e568cc43fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8ace0dd9-2aa6-4382-a4bd-1cede1d4012e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8ace0dd9-2aa6-4382-a4bd-1cede1d4012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_30b843f5-4dcf-4d68-934e-10a29768a522" xlink:href="neo-20230331.xsd#neo_RepaymentsOfEquipmentAndOtherFinanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8ace0dd9-2aa6-4382-a4bd-1cede1d4012e" xlink:to="loc_neo_RepaymentsOfEquipmentAndOtherFinanceObligation_30b843f5-4dcf-4d68-934e-10a29768a522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78007c53-ebe8-4581-8a89-2856dce1a2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8ace0dd9-2aa6-4382-a4bd-1cede1d4012e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78007c53-ebe8-4581-8a89-2856dce1a2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02d7e78c-c1f8-4853-a382-d3ab1937bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8ace0dd9-2aa6-4382-a4bd-1cede1d4012e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_02d7e78c-c1f8-4853-a382-d3ab1937bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cc904719-0b7f-4238-9ce5-ae46a9f76f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cc904719-0b7f-4238-9ce5-ae46a9f76f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3157a0f4-82af-4b9a-8bf5-8c7a98704dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3157a0f4-82af-4b9a-8bf5-8c7a98704dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_431448de-4582-43b0-a767-7b1959b5fe89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_431448de-4582-43b0-a767-7b1959b5fe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f675ef1-1587-4a1d-9bb0-0c8d4b93cf20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f675ef1-1587-4a1d-9bb0-0c8d4b93cf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c3a2e4b0-e12e-4b46-af28-5065d69cfa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f675ef1-1587-4a1d-9bb0-0c8d4b93cf20" xlink:to="loc_us-gaap_InterestPaidNet_c3a2e4b0-e12e-4b46-af28-5065d69cfa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47866bd0-f253-40bb-ae29-732b8dbc1b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f7d16d9f-ae0e-44e2-b1b7-41b5c2d99ddf" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47866bd0-f253-40bb-ae29-732b8dbc1b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet_56b447a4-a5f6-407e-868f-9347c0462660" xlink:href="neo-20230331.xsd#neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47866bd0-f253-40bb-ae29-732b8dbc1b8b" xlink:to="loc_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet_56b447a4-a5f6-407e-868f-9347c0462660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2a747474-ec03-4b8d-9bef-aa3dc9a67411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47866bd0-f253-40bb-ae29-732b8dbc1b8b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2a747474-ec03-4b8d-9bef-aa3dc9a67411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NatureoftheBusiness" xlink:type="simple" xlink:href="neo-20230331.xsd#NatureoftheBusiness"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NatureoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae220e6c-ca0a-4df5-afd4-b69f18f6b068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dc1bb18e-3a2f-414f-8333-13a68f204de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae220e6c-ca0a-4df5-afd4-b69f18f6b068" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dc1bb18e-3a2f-414f-8333-13a68f204de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="neo-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ec2e9a2b-c5b4-4ecf-a046-d984ed5cd1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a74c62c4-13b6-413f-9713-a58f342d5f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ec2e9a2b-c5b4-4ecf-a046-d984ed5cd1a8" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_a74c62c4-13b6-413f-9713-a58f342d5f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f8710256-9806-467c-b358-b1d39d885db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2cdbb10c-3a70-4e39-968e-b44645551a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f8710256-9806-467c-b358-b1d39d885db6" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2cdbb10c-3a70-4e39-968e-b44645551a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66a62961-d765-44f5-b541-a500b0b43148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5133d900-247a-4388-b769-55973ff820bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_66a62961-d765-44f5-b541-a500b0b43148" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5133d900-247a-4388-b769-55973ff820bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/Debt" xlink:type="simple" xlink:href="neo-20230331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8040c2d6-e9dc-422e-a5b4-3dd1cc71aaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3e50c306-45d8-4cec-8b46-1bcffea09ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8040c2d6-e9dc-422e-a5b4-3dd1cc71aaea" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3e50c306-45d8-4cec-8b46-1bcffea09ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4d7a574f-6b87-4b98-8b25-31e066916afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_671693fa-9c00-4676-a4f7-6896cd70a939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4d7a574f-6b87-4b98-8b25-31e066916afc" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_671693fa-9c00-4676-a4f7-6896cd70a939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognition" xlink:type="simple" xlink:href="neo-20230331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71bd9d2b-f510-4af3-9ef2-f795d5fcaef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_14da06f0-97a9-4f5d-ac44-2c20572fb6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71bd9d2b-f510-4af3-9ef2-f795d5fcaef1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_14da06f0-97a9-4f5d-ac44-2c20572fb6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/Restructuring" xlink:type="simple" xlink:href="neo-20230331.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b4be1000-f57b-4908-8c8e-7b21ad7bfa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f05dcf39-21d7-4f90-809f-e166e891bff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b4be1000-f57b-4908-8c8e-7b21ad7bfa6a" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f05dcf39-21d7-4f90-809f-e166e891bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="neo-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b8fc9214-f723-4e39-b065-fc899be315d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9992963d-334c-4b38-8178-e5a294064ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b8fc9214-f723-4e39-b065-fc899be315d9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9992963d-334c-4b38-8178-e5a294064ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="neo-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b8b13ed-179f-4f93-bcfd-879e7e661d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e311f224-aa5a-4a43-8832-9e44b77e0755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8b13ed-179f-4f93-bcfd-879e7e661d48" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e311f224-aa5a-4a43-8832-9e44b77e0755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="neo-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0bcff1fe-555f-4e8d-bafb-a1e55c8dc4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_996ad052-e40f-4b99-9246-f3860f659399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0bcff1fe-555f-4e8d-bafb-a1e55c8dc4f8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_996ad052-e40f-4b99-9246-f3860f659399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="neo-20230331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0180e135-afb9-4934-95d3-42ed47eec202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_eee85cff-6deb-402f-9d85-3bbd4657b5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0180e135-afb9-4934-95d3-42ed47eec202" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_eee85cff-6deb-402f-9d85-3bbd4657b5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformation" xlink:type="simple" xlink:href="neo-20230331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a3b5bdf1-4ce7-4372-b6bc-f02a20bcdd06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_52c6b92b-769c-40fa-89a0-f66276956d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a3b5bdf1-4ce7-4372-b6bc-f02a20bcdd06" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_52c6b92b-769c-40fa-89a0-f66276956d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="neo-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ab20b851-be16-45f1-b5fa-985078a99fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_49eae902-b45b-4a97-a1ae-28666fd37414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ab20b851-be16-45f1-b5fa-985078a99fcf" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_49eae902-b45b-4a97-a1ae-28666fd37414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_484934ca-e9a8-49a2-b933-20b43a6feb53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ab20b851-be16-45f1-b5fa-985078a99fcf" xlink:to="loc_us-gaap_UseOfEstimates_484934ca-e9a8-49a2-b933-20b43a6feb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ace10fc9-d6c6-4754-9189-ac2f1c9eef80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ab20b851-be16-45f1-b5fa-985078a99fcf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_ace10fc9-d6c6-4754-9189-ac2f1c9eef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_610270ee-41d2-4c5a-acda-db138ad5edf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ab20b851-be16-45f1-b5fa-985078a99fcf" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_610270ee-41d2-4c5a-acda-db138ad5edf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a11d45e5-4ced-4a47-a6f9-bf55cad209ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ab20b851-be16-45f1-b5fa-985078a99fcf" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a11d45e5-4ced-4a47-a6f9-bf55cad209ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0439e13f-83d7-4514-9a40-eb59a6d31aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ebddbd47-1c44-412a-b048-2a5e2922856a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0439e13f-83d7-4514-9a40-eb59a6d31aaf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ebddbd47-1c44-412a-b048-2a5e2922856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7e6cb665-7a53-406d-94b1-c6a2ddbe149c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0439e13f-83d7-4514-9a40-eb59a6d31aaf" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7e6cb665-7a53-406d-94b1-c6a2ddbe149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b435e39e-4873-4349-b121-c1fd341b02fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0439e13f-83d7-4514-9a40-eb59a6d31aaf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b435e39e-4873-4349-b121-c1fd341b02fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf5f6cf0-1200-447b-9caf-69ace2cb8485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_3066e30d-139a-4618-8272-d35190a1b039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf5f6cf0-1200-447b-9caf-69ace2cb8485" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_3066e30d-139a-4618-8272-d35190a1b039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_73bdf85a-e1cd-4573-9beb-e783f16db42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf5f6cf0-1200-447b-9caf-69ace2cb8485" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_73bdf85a-e1cd-4573-9beb-e783f16db42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_37746d34-6b13-42e4-91f9-64472a9b6010" xlink:href="neo-20230331.xsd#neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf5f6cf0-1200-447b-9caf-69ace2cb8485" xlink:to="loc_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock_37746d34-6b13-42e4-91f9-64472a9b6010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_69590893-7ac0-4e45-822b-0bf486abbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf5f6cf0-1200-447b-9caf-69ace2cb8485" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_69590893-7ac0-4e45-822b-0bf486abbdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_514d8a98-a0fb-494d-a940-ed5750f8ba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ebe4d17f-d025-4c37-ba8f-b211f66df9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_514d8a98-a0fb-494d-a940-ed5750f8ba1f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ebe4d17f-d025-4c37-ba8f-b211f66df9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_e9a9823b-1a92-4386-a769-daca71be13e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_514d8a98-a0fb-494d-a940-ed5750f8ba1f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_e9a9823b-1a92-4386-a769-daca71be13e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ce39e011-2941-40f1-b432-6ca3e9894c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_514d8a98-a0fb-494d-a940-ed5750f8ba1f" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ce39e011-2941-40f1-b432-6ca3e9894c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="neo-20230331.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58dd2181-a508-4742-b72a-6f0c6091837d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cc93c2be-9d5c-4ce5-a812-dc3bf5770b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58dd2181-a508-4742-b72a-6f0c6091837d" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cc93c2be-9d5c-4ce5-a812-dc3bf5770b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6d96f93a-3098-4599-9e0d-cdfb8a2dc545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58dd2181-a508-4742-b72a-6f0c6091837d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6d96f93a-3098-4599-9e0d-cdfb8a2dc545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RestructuringTables" xlink:type="simple" xlink:href="neo-20230331.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d08e8156-3b0b-4b89-ba32-7386da1d5658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bfa91606-c22e-4afd-8ce1-6876e66bbf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d08e8156-3b0b-4b89-ba32-7386da1d5658" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bfa91606-c22e-4afd-8ce1-6876e66bbf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="neo-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a219d92e-cd54-47d1-88a0-2e1e8cd55a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e41eb000-8311-4391-8fc1-4a84206afd02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a219d92e-cd54-47d1-88a0-2e1e8cd55a64" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e41eb000-8311-4391-8fc1-4a84206afd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ceab3dba-57c7-4726-9d1f-e1e4f2d6f1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a219d92e-cd54-47d1-88a0-2e1e8cd55a64" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ceab3dba-57c7-4726-9d1f-e1e4f2d6f1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="neo-20230331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_547a1367-164e-4cda-80bb-5874b3f5d698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f2f9b03c-96ba-437b-82fc-79df65d238b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_547a1367-164e-4cda-80bb-5874b3f5d698" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f2f9b03c-96ba-437b-82fc-79df65d238b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsScheduleofAmortizedCostDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5fe9b37c-5379-4330-9b5b-beb2a782cb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72d1c7aa-c817-47fa-b2cc-3b9442377815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5fe9b37c-5379-4330-9b5b-beb2a782cb67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72d1c7aa-c817-47fa-b2cc-3b9442377815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b361bf62-a757-4640-9226-adb40e3e2633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72d1c7aa-c817-47fa-b2cc-3b9442377815" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b361bf62-a757-4640-9226-adb40e3e2633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b361bf62-a757-4640-9226-adb40e3e2633" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_bf429e51-9c87-48ee-a2ab-cc7dd243f78f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_bf429e51-9c87-48ee-a2ab-cc7dd243f78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_e68a6a07-d824-4c5b-94e5-2119d9f9652b" xlink:href="neo-20230331.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_neo_YankeeBondsMember_e68a6a07-d824-4c5b-94e5-2119d9f9652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_e0a02b3c-e99a-45bb-b655-7ce93fde738c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_AgencySecuritiesMember_e0a02b3c-e99a-45bb-b655-7ce93fde738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_4dc6c6be-4d2c-48bb-8062-3001f84d2e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_MunicipalBondsMember_4dc6c6be-4d2c-48bb-8062-3001f84d2e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_52b30648-8e96-4069-b300-9da24eb47569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_CommercialPaperMember_52b30648-8e96-4069-b300-9da24eb47569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_597d7e75-6814-4d30-936e-0eecc0f0f213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_597d7e75-6814-4d30-936e-0eecc0f0f213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c146eacf-863b-4d42-8600-f053c91364a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_39a5a138-26db-4c59-892a-468bb83d2948" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c146eacf-863b-4d42-8600-f053c91364a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_72d1c7aa-c817-47fa-b2cc-3b9442377815" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_5e65d550-8d0b-4af0-b450-21d3bf3978a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent_5e65d550-8d0b-4af0-b450-21d3bf3978a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e9a694c0-d0c0-4fbc-8ddb-3ab011ba9af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e9a694c0-d0c0-4fbc-8ddb-3ab011ba9af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_171d8f62-ef07-4933-93dd-1899845f5afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_171d8f62-ef07-4933-93dd-1899845f5afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_74e038d1-82af-4b1d-ab8d-0258fad9db50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_74e038d1-82af-4b1d-ab8d-0258fad9db50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_51da0fff-0354-4831-a643-ee98a2846c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62761baa-1323-4bc7-9e75-0e8259e41e30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_51da0fff-0354-4831-a643-ee98a2846c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsFairValuebyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c26bbb0f-741e-4eb8-9d0c-5664212b54c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f6a3c27-9a3b-4dbb-8d50-8a5a258486e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c26bbb0f-741e-4eb8-9d0c-5664212b54c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f6a3c27-9a3b-4dbb-8d50-8a5a258486e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_df4c619a-d120-482b-9587-af2bd5e5fd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f6a3c27-9a3b-4dbb-8d50-8a5a258486e1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_df4c619a-d120-482b-9587-af2bd5e5fd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_df4c619a-d120-482b-9587-af2bd5e5fd8d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_16f43f7b-ff10-4f66-8676-a544b8c41a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_16f43f7b-ff10-4f66-8676-a544b8c41a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_ad73bc59-43bb-4919-b573-e52c0f367335" xlink:href="neo-20230331.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_neo_YankeeBondsMember_ad73bc59-43bb-4919-b573-e52c0f367335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_af2ef80a-f8aa-478c-8364-9af66353e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_AgencySecuritiesMember_af2ef80a-f8aa-478c-8364-9af66353e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2f9874fd-6d73-46ed-95f6-5b7e4c9fa730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_MunicipalBondsMember_2f9874fd-6d73-46ed-95f6-5b7e4c9fa730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_359476c3-8d73-44ec-9f29-ba0d9572050f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_CommercialPaperMember_359476c3-8d73-44ec-9f29-ba0d9572050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d0388b11-518f-4003-b4fb-38c87ce87f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d0388b11-518f-4003-b4fb-38c87ce87f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_604a6b71-9811-4648-86f1-8fa593dd476b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1ea07ca-4b0d-46ad-a5dc-557956a07f1d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_604a6b71-9811-4648-86f1-8fa593dd476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f6a3c27-9a3b-4dbb-8d50-8a5a258486e1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d774c622-d545-4257-a1ba-219b9eaa8e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d774c622-d545-4257-a1ba-219b9eaa8e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0d673d2f-3d22-4050-b83c-64d012a277c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0d673d2f-3d22-4050-b83c-64d012a277c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_92c8369a-158d-40b3-97b8-b3d68b2582d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_92c8369a-158d-40b3-97b8-b3d68b2582d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_2734435a-cd39-49aa-a07d-4a1144424889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d72ba6c0-6e50-4311-a43e-5e42a9fd5265" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_2734435a-cd39-49aa-a07d-4a1144424889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bb662037-7420-447f-9748-0679c727dfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bb662037-7420-447f-9748-0679c727dfbd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28a987ca-e40f-45bc-990a-34ae86b226b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28a987ca-e40f-45bc-990a-34ae86b226b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_381aaf8a-455c-406e-bc72-a2b305feb43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_28a987ca-e40f-45bc-990a-34ae86b226b9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_381aaf8a-455c-406e-bc72-a2b305feb43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cbb39672-e9cc-4b64-a244-3104f860ce06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_381aaf8a-455c-406e-bc72-a2b305feb43e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cbb39672-e9cc-4b64-a244-3104f860ce06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d76877eb-5c2d-4b75-8180-dbd6ff85bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d76877eb-5c2d-4b75-8180-dbd6ff85bac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d76877eb-5c2d-4b75-8180-dbd6ff85bac9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3ef76bca-97e5-4672-8681-b84fc3407658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3ef76bca-97e5-4672-8681-b84fc3407658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_08d5fcd0-9e26-41e2-8d6a-d0c0c7fc5398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_08d5fcd0-9e26-41e2-8d6a-d0c0c7fc5398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_feadb906-89a4-4db5-8932-2c132b8e116b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2abd7815-a07b-4f5b-9c57-8455b686a067" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_feadb906-89a4-4db5-8932-2c132b8e116b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_b00e95a1-da1e-46dc-8297-e64e4e389440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_b00e95a1-da1e-46dc-8297-e64e4e389440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_b00e95a1-da1e-46dc-8297-e64e4e389440" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cf0b28af-e7f6-418f-a962-aeeefcd62e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cf0b28af-e7f6-418f-a962-aeeefcd62e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_476ddb56-bc6f-4dbc-b1cf-d8db794c6b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bd9dee6d-53a0-4899-ae9c-566fe4173ed1" xlink:to="loc_us-gaap_CommercialPaperMember_476ddb56-bc6f-4dbc-b1cf-d8db794c6b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7b169213-3f43-46f5-908e-8fdfdbdfe914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7b169213-3f43-46f5-908e-8fdfdbdfe914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b169213-3f43-46f5-908e-8fdfdbdfe914" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_dc63af15-dfa9-4787-9909-4b44be392daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_dc63af15-dfa9-4787-9909-4b44be392daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_YankeeBondsMember_ba78f028-559a-4441-bdc2-ba263bf07009" xlink:href="neo-20230331.xsd#neo_YankeeBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_neo_YankeeBondsMember_ba78f028-559a-4441-bdc2-ba263bf07009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_e4f9b1b2-8de6-4adc-a0ff-62b83aaa78bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_AgencySecuritiesMember_e4f9b1b2-8de6-4adc-a0ff-62b83aaa78bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2884aa8f-646e-4a69-8374-1294b30a6da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_MunicipalBondsMember_2884aa8f-646e-4a69-8374-1294b30a6da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3537f433-19f1-4ea0-ae33-a60630167774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_CommercialPaperMember_3537f433-19f1-4ea0-ae33-a60630167774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_bfc5bc3a-f418-483f-8a85-d483c149bdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_bfc5bc3a-f418-483f-8a85-d483c149bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d9b4f931-6ea5-4a9c-8395-2976d82af26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfc5d396-77fb-4db6-ae9d-0efbaa1a3e16" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d9b4f931-6ea5-4a9c-8395-2976d82af26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77dab24a-6d1a-4196-9618-f48916be7d5f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_533d3320-6700-4b7b-a017-e8bf8e73fed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_533d3320-6700-4b7b-a017-e8bf8e73fed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_cc694cc5-6814-42cc-a830-0beb2de5351a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_cc694cc5-6814-42cc-a830-0beb2de5351a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_312ea018-68f5-4c71-9ece-afb6efd44df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_df4236b1-d0d5-4c7b-84cf-4670fa4883a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_312ea018-68f5-4c71-9ece-afb6efd44df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ba312cb-b1f6-4445-acec-a77b8306d88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_9502ae68-b027-4b36-b5a6-574707cbfba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ba312cb-b1f6-4445-acec-a77b8306d88d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_9502ae68-b027-4b36-b5a6-574707cbfba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1de2757c-7cc3-4573-8c6b-ca1e85c82d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9502ae68-b027-4b36-b5a6-574707cbfba2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1de2757c-7cc3-4573-8c6b-ca1e85c82d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1de2757c-7cc3-4573-8c6b-ca1e85c82d74" xlink:to="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_5f2a3478-cee9-4502-a7d5-c64325e335f4" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:to="loc_neo_ClinicalServicesMember_5f2a3478-cee9-4502-a7d5-c64325e335f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_80e69fac-bd9f-4374-9fe0-ced1e09b86f2" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae4d8b19-9e7c-47ea-869a-ab7e1bee9c50" xlink:to="loc_neo_PharmaServicesMember_80e69fac-bd9f-4374-9fe0-ced1e09b86f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_651a9f9a-ebf4-40bb-a485-a5c3cec95e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_9502ae68-b027-4b36-b5a6-574707cbfba2" xlink:to="loc_us-gaap_GoodwillLineItems_651a9f9a-ebf4-40bb-a485-a5c3cec95e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f44cdb1-e9cb-4b7e-be33-b9372305615e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_651a9f9a-ebf4-40bb-a485-a5c3cec95e0a" xlink:to="loc_us-gaap_Goodwill_3f44cdb1-e9cb-4b7e-be33-b9372305615e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsNarrativeDetail"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_060929cb-a686-4c58-abe1-adbee8b830d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4ecf99d-a752-4c59-b4be-bedad4c5d8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_060929cb-a686-4c58-abe1-adbee8b830d0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4ecf99d-a752-4c59-b4be-bedad4c5d8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ee9e1b78-5731-443d-b354-5fa83191b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4ecf99d-a752-4c59-b4be-bedad4c5d8aa" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ee9e1b78-5731-443d-b354-5fa83191b58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee9e1b78-5731-443d-b354-5fa83191b58a" xlink:to="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_42cd29b8-8d7a-4c22-aa88-b503a360b8a0" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:to="loc_neo_ClinicalServicesMember_42cd29b8-8d7a-4c22-aa88-b503a360b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_b394e100-745f-49ea-96bd-71a2f7641dc3" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b7f54454-2552-4663-9075-ba4ba1b5c21e" xlink:to="loc_neo_PharmaServicesMember_b394e100-745f-49ea-96bd-71a2f7641dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5abef6f4-ea79-4ff3-abd7-4b9209d2127c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c4ecf99d-a752-4c59-b4be-bedad4c5d8aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5abef6f4-ea79-4ff3-abd7-4b9209d2127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_25750669-f059-40c9-92ea-7b39d9c33a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5abef6f4-ea79-4ff3-abd7-4b9209d2127c" xlink:to="loc_us-gaap_Goodwill_25750669-f059-40c9-92ea-7b39d9c33a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_934373ab-54f1-479b-98ac-fac64cbedba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_934373ab-54f1-479b-98ac-fac64cbedba0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13412051-a5ca-49fc-ac69-aafd9f99b065" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:to="loc_srt_RangeAxis_13412051-a5ca-49fc-ac69-aafd9f99b065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13412051-a5ca-49fc-ac69-aafd9f99b065" xlink:to="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08a59bb4-6c02-435a-b6eb-1fbd235b132a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:to="loc_srt_MinimumMember_08a59bb4-6c02-435a-b6eb-1fbd235b132a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2601579-0efb-43cd-bc97-52a3308154d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aaf54af7-3427-44f6-9e4c-53dc7dc01bf8" xlink:to="loc_srt_MaximumMember_b2601579-0efb-43cd-bc97-52a3308154d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2321d80-3090-48b0-999a-2874ace37eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2321d80-3090-48b0-999a-2874ace37eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d2321d80-3090-48b0-999a-2874ace37eb9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_20b9070c-a11a-4e07-b4ce-009fed059264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_CustomerRelationshipsMember_20b9070c-a11a-4e07-b4ce-009fed059264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ba2a0e88-0120-4009-bb50-47baf3590d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ba2a0e88-0120-4009-bb50-47baf3590d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_dc8a7014-ce37-44ba-8128-6e018cd32b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_MarketingRelatedIntangibleAssetsMember_dc8a7014-ce37-44ba-8128-6e018cd32b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_3bacea27-ed3d-47f2-b706-86058fb2b282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_TrademarksMember_3bacea27-ed3d-47f2-b706-86058fb2b282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2430b664-cf4e-4fc2-9712-fdfcc41caa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9dca5e6-e86f-4695-a2f9-b483f4197372" xlink:to="loc_us-gaap_TradeNamesMember_2430b664-cf4e-4fc2-9712-fdfcc41caa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_43513f65-fd6e-4977-a7db-953e59ae48f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_43513f65-fd6e-4977-a7db-953e59ae48f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4aaf0caa-ba99-40ea-8d65-210f5ff73277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_43513f65-fd6e-4977-a7db-953e59ae48f3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4aaf0caa-ba99-40ea-8d65-210f5ff73277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_e7694be9-715f-43f3-be5f-26f50ab05ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4aaf0caa-ba99-40ea-8d65-210f5ff73277" xlink:to="loc_us-gaap_TrademarksMember_e7694be9-715f-43f3-be5f-26f50ab05ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b6d9be7a-f3a4-44b0-b2ca-7183d9c3eeae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3cd96b77-eda8-4fa3-bc2c-8d3b38f3f722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3cd96b77-eda8-4fa3-bc2c-8d3b38f3f722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0e1a4a54-a4e9-420c-933c-a5d2e6f47ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0e1a4a54-a4e9-420c-933c-a5d2e6f47ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5530d3c1-ba14-451f-af31-1766345c9423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5530d3c1-ba14-451f-af31-1766345c9423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ca1d66f0-931c-41cb-b15e-740c7cb2599d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ca1d66f0-931c-41cb-b15e-740c7cb2599d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4aa88340-886b-4266-ac64-f32be7517404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4aa88340-886b-4266-ac64-f32be7517404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ed6b14-4de3-4c27-885d-e030d3752882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67ed6b14-4de3-4c27-885d-e030d3752882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3736b5e0-dc10-4af8-9826-18e7c322452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_57cfd062-a1c4-4e81-94a2-426b02c75540" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3736b5e0-dc10-4af8-9826-18e7c322452f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39a8ed2e-60d3-4b50-b1a2-8682d48a2943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b5a55783-8588-4ac7-bd76-693f78c06564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39a8ed2e-60d3-4b50-b1a2-8682d48a2943" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b5a55783-8588-4ac7-bd76-693f78c06564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8bb8f26b-a5a4-454f-a93f-693100660cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b5a55783-8588-4ac7-bd76-693f78c06564" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8bb8f26b-a5a4-454f-a93f-693100660cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8bb8f26b-a5a4-454f-a93f-693100660cc3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e82ba6cf-2b4a-40e1-ab3d-0e8a538a3916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:to="loc_us-gaap_CostOfSalesMember_e82ba6cf-2b4a-40e1-ab3d-0e8a538a3916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1602efdf-b356-47b6-b56d-2dc49d0966d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7ed38d5-d331-4b0e-a200-f1ddd7740fe6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1602efdf-b356-47b6-b56d-2dc49d0966d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52199471-f732-4383-a0ec-606f0fdb1595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b5a55783-8588-4ac7-bd76-693f78c06564" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52199471-f732-4383-a0ec-606f0fdb1595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d26810fc-805f-4bdd-ad05-616b90107ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52199471-f732-4383-a0ec-606f0fdb1595" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d26810fc-805f-4bdd-ad05-616b90107ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_40848bea-6820-4c91-81ec-a8794ddd3e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_40848bea-6820-4c91-81ec-a8794ddd3e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d038c29c-7264-4ecf-9131-4fb0dbe5fd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d038c29c-7264-4ecf-9131-4fb0dbe5fd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cf0233c0-b8b0-4ecb-9cfc-7aaa60835a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cf0233c0-b8b0-4ecb-9cfc-7aaa60835a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_94078d9c-7ac4-4927-9910-b5b3c6752636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_94078d9c-7ac4-4927-9910-b5b3c6752636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_048986cd-6c3b-4cd8-a2ea-f383a9a7e017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_048986cd-6c3b-4cd8-a2ea-f383a9a7e017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_2f7c239e-a143-407e-9124-50160230a5fc" xlink:href="neo-20230331.xsd#neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:to="loc_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_2f7c239e-a143-407e-9124-50160230a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e0cf06a1-6e0f-4569-9646-7c2e96f89e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3001447-631e-4c60-9ef9-677265e4ee6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e0cf06a1-6e0f-4569-9646-7c2e96f89e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/DebtDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e746a1ca-1bfa-4b12-a774-b671b2d54f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e746a1ca-1bfa-4b12-a774-b671b2d54f7d" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8e66fb35-8a94-4174-a08e-e91976f78f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_DebtInstrumentAxis_8e66fb35-8a94-4174-a08e-e91976f78f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8e66fb35-8a94-4174-a08e-e91976f78f6a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_50380f5e-a4b6-45c4-a1cd-2e03dca83190" xlink:href="neo-20230331.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_50380f5e-a4b6-45c4-a1cd-2e03dca83190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_b41ee6eb-72b9-42c2-915a-5cf5c0750530" xlink:href="neo-20230331.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df739c4f-a77a-46b2-a0b6-d13845335142" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_b41ee6eb-72b9-42c2-915a-5cf5c0750530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_217aae75-95e4-4f93-8665-b68eb404fb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_217aae75-95e4-4f93-8665-b68eb404fb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_acc0fafb-45d5-412f-9713-2d3896687824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_217aae75-95e4-4f93-8665-b68eb404fb4c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_acc0fafb-45d5-412f-9713-2d3896687824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_08ad41b8-430f-4b34-96b7-bc8d79980289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_acc0fafb-45d5-412f-9713-2d3896687824" xlink:to="loc_us-gaap_ConvertibleDebtMember_08ad41b8-430f-4b34-96b7-bc8d79980289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_06b5750d-5113-48ca-b6cb-10eaa788d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_06b5750d-5113-48ca-b6cb-10eaa788d77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_969cdc1c-36e0-413c-a251-b800de525482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_06b5750d-5113-48ca-b6cb-10eaa788d77d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_969cdc1c-36e0-413c-a251-b800de525482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d01eae4b-ae8f-46f4-a136-b34f19ff2fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_969cdc1c-36e0-413c-a251-b800de525482" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d01eae4b-ae8f-46f4-a136-b34f19ff2fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57c40e9f-5af8-4543-8ca8-2a1d34966201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57c40e9f-5af8-4543-8ca8-2a1d34966201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86601542-750f-457b-be49-e3f7faded8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57c40e9f-5af8-4543-8ca8-2a1d34966201" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86601542-750f-457b-be49-e3f7faded8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cd754337-eff0-4ed0-96a0-f32bbf2993b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86601542-750f-457b-be49-e3f7faded8f3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cd754337-eff0-4ed0-96a0-f32bbf2993b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dc14635a-7f4d-412b-963e-7b062d557574" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6f8f0b4d-697e-402b-828b-b4f847d0640b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6f8f0b4d-697e-402b-828b-b4f847d0640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b405d40a-38bd-4ec6-aaf9-0ebb0452c041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b405d40a-38bd-4ec6-aaf9-0ebb0452c041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_59692cba-9db1-481c-95ec-a59d4603a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_59692cba-9db1-481c-95ec-a59d4603a709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2309bff8-bdec-4ed1-b0c6-0bcb42eef07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2309bff8-bdec-4ed1-b0c6-0bcb42eef07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_23671371-4b22-49ac-82b5-a4f4a52f439f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_23671371-4b22-49ac-82b5-a4f4a52f439f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_132d3598-fe9c-44d2-a211-0abe73713912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_132d3598-fe9c-44d2-a211-0abe73713912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtContractualCouponInterest_8bf444ec-8ced-481b-be95-65719f8a4bb7" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtContractualCouponInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_neo_InterestExpenseDebtContractualCouponInterest_8bf444ec-8ced-481b-be95-65719f8a4bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_c93077b4-a5a7-4d88-b0d3-5dd53671f150" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtAccretionOfDebtDiscount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_neo_InterestExpenseDebtAccretionOfDebtDiscount_c93077b4-a5a7-4d88-b0d3-5dd53671f150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_34f1d2cb-ec71-4f6f-8bfd-99e2e0cf42e5" xlink:href="neo-20230331.xsd#neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts_34f1d2cb-ec71-4f6f-8bfd-99e2e0cf42e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_59974425-78d2-463b-999e-ec3cd6ad6424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_59974425-78d2-463b-999e-ec3cd6ad6424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_2b4a6a2d-f82d-47ff-8af1-470996e8eb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3eba3353-3001-4f78-910c-cb108054eeaa" xlink:to="loc_us-gaap_DebtInstrumentFairValue_2b4a6a2d-f82d-47ff-8af1-470996e8eb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7b43247b-d783-49e8-b3a1-2acf740791b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7b43247b-d783-49e8-b3a1-2acf740791b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2312164f-0bce-4518-88ac-13d44e11fe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:to="loc_us-gaap_AwardTypeAxis_2312164f-0bce-4518-88ac-13d44e11fe1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2312164f-0bce-4518-88ac-13d44e11fe1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1eea8e14-cd93-48e6-a499-c79772ca1918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:to="loc_us-gaap_RestrictedStockMember_1eea8e14-cd93-48e6-a499-c79772ca1918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1864b834-d205-4034-be45-4abc1fb4851f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57c3213e-29d7-450e-9def-543dc12b436c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1864b834-d205-4034-be45-4abc1fb4851f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b7aa490e-87f5-4fc0-8c00-4124558d1f7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:to="loc_srt_TitleOfIndividualAxis_b7aa490e-87f5-4fc0-8c00-4124558d1f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79b153e9-66c8-4418-bfeb-b637f416f9ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b7aa490e-87f5-4fc0-8c00-4124558d1f7c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79b153e9-66c8-4418-bfeb-b637f416f9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_8919effe-8d16-49e7-9ffa-f9e7b87dc8b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79b153e9-66c8-4418-bfeb-b637f416f9ae" xlink:to="loc_srt_ChiefExecutiveOfficerMember_8919effe-8d16-49e7-9ffa-f9e7b87dc8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64f1b801-5aa7-434b-a961-e909d308c647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc07e317-d70e-4d96-aac0-2c41f069b6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc07e317-d70e-4d96-aac0-2c41f069b6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_443bf5f0-2282-4840-b349-797101e0efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_443bf5f0-2282-4840-b349-797101e0efc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_014b0e5c-0fa5-4124-bfbb-8d81a6a743e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_014b0e5c-0fa5-4124-bfbb-8d81a6a743e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a10fff09-c7b9-4585-b661-1a45e1910351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_a10fff09-c7b9-4585-b661-1a45e1910351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_ad9fddc9-78bd-4cfd-a58d-bfec3822c840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchaseProgramAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a2db754-9e13-43c4-aea1-8c9377c6721e" xlink:to="loc_us-gaap_AcceleratedShareRepurchaseProgramAdjustment_ad9fddc9-78bd-4cfd-a58d-bfec3822c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8cc4344d-4181-4f1c-ad6c-2d4798859918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_03ffb4f6-e441-4468-856d-810b03f1cd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cc4344d-4181-4f1c-ad6c-2d4798859918" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_03ffb4f6-e441-4468-856d-810b03f1cd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bc0439c6-ba88-4823-b4c9-c6d40c35d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_03ffb4f6-e441-4468-856d-810b03f1cd94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bc0439c6-ba88-4823-b4c9-c6d40c35d8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6b7fb96-37cd-499a-a457-aba42c6795ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_03ffb4f6-e441-4468-856d-810b03f1cd94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6b7fb96-37cd-499a-a457-aba42c6795ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5d029d65-6e82-4816-835a-3de0339a214d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_03ffb4f6-e441-4468-856d-810b03f1cd94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5d029d65-6e82-4816-835a-3de0339a214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ab2a7a33-3ba0-4885-81d7-e8b5e6acdb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_03ffb4f6-e441-4468-856d-810b03f1cd94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ab2a7a33-3ba0-4885-81d7-e8b5e6acdb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b2344ad9-8ddd-404b-8d1b-97c8c4e7d149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_03ffb4f6-e441-4468-856d-810b03f1cd94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b2344ad9-8ddd-404b-8d1b-97c8c4e7d149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_15faea7d-f8b6-42ce-b533-60a34261232f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cc4344d-4181-4f1c-ad6c-2d4798859918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_15faea7d-f8b6-42ce-b533-60a34261232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_37ed57a0-d5cc-4cb4-8b66-c60b6c5d244d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cc4344d-4181-4f1c-ad6c-2d4798859918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_37ed57a0-d5cc-4cb4-8b66-c60b6c5d244d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_97b76b29-95cf-4142-a4ee-ea1b8fc8cef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_37ed57a0-d5cc-4cb4-8b66-c60b6c5d244d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_97b76b29-95cf-4142-a4ee-ea1b8fc8cef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_05ba414c-0a63-4b62-a977-53ca9ab5dcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_37ed57a0-d5cc-4cb4-8b66-c60b6c5d244d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_05ba414c-0a63-4b62-a977-53ca9ab5dcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b96a2fd5-111b-4c46-b74b-db07b0f2f1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_37ed57a0-d5cc-4cb4-8b66-c60b6c5d244d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b96a2fd5-111b-4c46-b74b-db07b0f2f1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2928be97-8f88-4a1c-8b1f-3875dca5e247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_37ed57a0-d5cc-4cb4-8b66-c60b6c5d244d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2928be97-8f88-4a1c-8b1f-3875dca5e247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_132dcc6f-f0c9-42ed-b00e-c0c8d9dc185a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_37ed57a0-d5cc-4cb4-8b66-c60b6c5d244d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_132dcc6f-f0c9-42ed-b00e-c0c8d9dc185a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_86e11d1c-10a6-4e9e-ad91-662cf37111dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cc4344d-4181-4f1c-ad6c-2d4798859918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_86e11d1c-10a6-4e9e-ad91-662cf37111dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2536b8ee-0abb-40fe-b0b9-550d2a16c54a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49257464-1a22-4953-97b6-0274f69c7282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2536b8ee-0abb-40fe-b0b9-550d2a16c54a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49257464-1a22-4953-97b6-0274f69c7282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49257464-1a22-4953-97b6-0274f69c7282" xlink:to="loc_srt_RangeAxis_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9d3c9803-cbc5-4e0b-8ea1-b8da51799a23" xlink:to="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3c5b078-52b3-4c1e-9f5e-21af2e5ea75b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:to="loc_srt_MinimumMember_d3c5b078-52b3-4c1e-9f5e-21af2e5ea75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fc730721-a9a2-4cb7-9712-5897dcca6f73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fbba2aba-f70f-4029-a2a9-abc128df3b84" xlink:to="loc_srt_MaximumMember_fc730721-a9a2-4cb7-9712-5897dcca6f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49257464-1a22-4953-97b6-0274f69c7282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b81f2bb4-7056-4037-a915-458c20409e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b81f2bb4-7056-4037-a915-458c20409e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ddcb12e6-3a17-4e1e-a40b-19f15bef7f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ddcb12e6-3a17-4e1e-a40b-19f15bef7f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a670f9-9ca8-4e82-9959-d01c8ca21447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66a670f9-9ca8-4e82-9959-d01c8ca21447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7d98265d-ce97-44c1-ace6-a6e268e6ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7d98265d-ce97-44c1-ace6-a6e268e6ee2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_07e790df-3184-4d2f-a7b1-09b4d3358c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fde7c663-a1c8-48b8-8ffa-6a20197271ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_07e790df-3184-4d2f-a7b1-09b4d3358c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_008726ff-da92-4236-8dab-faf750681582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_650b3e96-0063-42a5-9726-f8625da35adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_008726ff-da92-4236-8dab-faf750681582" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_650b3e96-0063-42a5-9726-f8625da35adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_650b3e96-0063-42a5-9726-f8625da35adf" xlink:to="loc_us-gaap_AwardTypeAxis_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6346b7c-bd45-4317-8cb6-fa03b8966b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9a3bcaa9-0c8b-4942-9ad7-4cf87238793c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6346b7c-bd45-4317-8cb6-fa03b8966b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0b30a5f7-adc2-43f7-9e27-c9835e759041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6346b7c-bd45-4317-8cb6-fa03b8966b89" xlink:to="loc_us-gaap_RestrictedStockMember_0b30a5f7-adc2-43f7-9e27-c9835e759041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_650b3e96-0063-42a5-9726-f8625da35adf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d47e08f-76ff-415d-9e88-e580855c9773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d47e08f-76ff-415d-9e88-e580855c9773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a72aa40e-3d85-4881-a6ae-3269417aeded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a72aa40e-3d85-4881-a6ae-3269417aeded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7b2c37a3-84db-4dce-a3db-32f533333584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7b2c37a3-84db-4dce-a3db-32f533333584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4f364b2-2517-444d-abe1-b25944eb8e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f4f364b2-2517-444d-abe1-b25944eb8e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef1bfc97-b4b9-4c93-a217-86f0e65adbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a2f7e265-a033-48e9-a1af-bce7af9c15eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef1bfc97-b4b9-4c93-a217-86f0e65adbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02e2b500-ce1c-475f-80bf-be84cbe31d40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e96eb482-2e3b-4442-8a9e-9f26b4f3ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e96eb482-2e3b-4442-8a9e-9f26b4f3ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2fb4aadf-589d-40ed-9d8e-ec69c0742c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2fb4aadf-589d-40ed-9d8e-ec69c0742c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_234a00d5-cc1d-4abc-b3a0-7e3ce4555624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_234a00d5-cc1d-4abc-b3a0-7e3ce4555624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_86f894ba-9449-4636-ac14-544bf51da861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_86f894ba-9449-4636-ac14-544bf51da861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d12b50e1-64a8-4ed9-bfe8-9901442c4fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6ff63da0-ffc6-445d-a02e-15d7d6a73c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d12b50e1-64a8-4ed9-bfe8-9901442c4fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71e4c577-aa07-4c51-9125-98a24cdf9b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_643c336a-4044-4130-878b-89eb0d9843f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71e4c577-aa07-4c51-9125-98a24cdf9b70" xlink:to="loc_us-gaap_NumberOfOperatingSegments_643c336a-4044-4130-878b-89eb0d9843f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_71aceffb-0bc2-473f-ab84-8eb21269336c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71e4c577-aa07-4c51-9125-98a24cdf9b70" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_71aceffb-0bc2-473f-ab84-8eb21269336c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_43532ce4-c5d6-46df-8352-201d1c548172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_71e4c577-aa07-4c51-9125-98a24cdf9b70" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_43532ce4-c5d6-46df-8352-201d1c548172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RevenueRecognitionContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_51742b0c-204a-4cc4-84d8-402740111fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_d763a1a1-52b5-4824-aea9-a06987d751e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_51742b0c-204a-4cc4-84d8-402740111fbd" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_d763a1a1-52b5-4824-aea9-a06987d751e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_80be1d85-c65b-4bb1-b75c-7761ed5817ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_d763a1a1-52b5-4824-aea9-a06987d751e0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_80be1d85-c65b-4bb1-b75c-7761ed5817ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_ea057232-ffaf-4829-8f25-0ad1a2ed8ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_d763a1a1-52b5-4824-aea9-a06987d751e0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_ea057232-ffaf-4829-8f25-0ad1a2ed8ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_8cd019cb-0360-4cd9-a771-4b924e049235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_d763a1a1-52b5-4824-aea9-a06987d751e0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_8cd019cb-0360-4cd9-a771-4b924e049235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAbstract_baf128f1-8d09-4a5a-95a1-eecf30926f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_51742b0c-204a-4cc4-84d8-402740111fbd" xlink:to="loc_us-gaap_CapitalizedContractCostAbstract_baf128f1-8d09-4a5a-95a1-eecf30926f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_2612998a-44be-471b-a740-7d09458ed74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_baf128f1-8d09-4a5a-95a1-eecf30926f6e" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_2612998a-44be-471b-a740-7d09458ed74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_653daefb-de26-442f-9462-9f3b714790c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_baf128f1-8d09-4a5a-95a1-eecf30926f6e" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_653daefb-de26-442f-9462-9f3b714790c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_dd85b743-a416-44f0-a4a3-3f7adab802cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAbstract_baf128f1-8d09-4a5a-95a1-eecf30926f6e" xlink:to="loc_us-gaap_CapitalizedContractCostGross_dd85b743-a416-44f0-a4a3-3f7adab802cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_6c3311e1-6e62-4331-94e3-4174e92509d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_51742b0c-204a-4cc4-84d8-402740111fbd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_6c3311e1-6e62-4331-94e3-4174e92509d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_891d3282-8c5d-46a2-afde-513953b4a7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_6c3311e1-6e62-4331-94e3-4174e92509d2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_891d3282-8c5d-46a2-afde-513953b4a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cc44924e-588a-4b09-9b68-b1bb0b639dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_6c3311e1-6e62-4331-94e3-4174e92509d2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cc44924e-588a-4b09-9b68-b1bb0b639dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d3a6e27e-5f65-4b1b-a6ed-f645f4286f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_6c3311e1-6e62-4331-94e3-4174e92509d2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d3a6e27e-5f65-4b1b-a6ed-f645f4286f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_024f674c-d9e7-4b81-ac47-d149630ac854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_024f674c-d9e7-4b81-ac47-d149630ac854" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_eb5fc884-c2d4-41df-8225-ffae26441e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_eb5fc884-c2d4-41df-8225-ffae26441e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eb5fc884-c2d4-41df-8225-ffae26441e45" xlink:to="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_c8cd89f1-351b-44a4-8777-a3f0fb7b440a" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:to="loc_neo_ClinicalServicesMember_c8cd89f1-351b-44a4-8777-a3f0fb7b440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_871f3d99-2051-4134-859b-5a6246464d75" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_62efd065-532c-43ed-b51f-165cb624e95c" xlink:to="loc_neo_PharmaServicesMember_871f3d99-2051-4134-859b-5a6246464d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_503b940b-77bd-4d18-b2ce-f2542a153ea9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:to="loc_srt_ProductOrServiceAxis_503b940b-77bd-4d18-b2ce-f2542a153ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_503b940b-77bd-4d18-b2ce-f2542a153ea9" xlink:to="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClientDirectBillingMember_e71e8134-3ed3-465a-8a28-a6ca6f40da00" xlink:href="neo-20230331.xsd#neo_ClientDirectBillingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_ClientDirectBillingMember_e71e8134-3ed3-465a-8a28-a6ca6f40da00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CommercialInsuranceMember_fc1c0aa4-248f-442d-8159-0ea79e63bf7d" xlink:href="neo-20230331.xsd#neo_CommercialInsuranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_CommercialInsuranceMember_fc1c0aa4-248f-442d-8159-0ea79e63bf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_MedicareAndOtherGovernmentalMember_cc45e66c-0ddc-46f8-a8b4-c93b052f25ce" xlink:href="neo-20230331.xsd#neo_MedicareAndOtherGovernmentalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_MedicareAndOtherGovernmentalMember_cc45e66c-0ddc-46f8-a8b4-c93b052f25ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SelfPayServicesMember_da4227f6-cfce-4162-9e9c-52577b536293" xlink:href="neo-20230331.xsd#neo_SelfPayServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_20c0bd76-2814-4919-a133-1d1c4282d78f" xlink:to="loc_neo_SelfPayServicesMember_da4227f6-cfce-4162-9e9c-52577b536293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_730bd857-82d1-4c7c-be2f-e94929542ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_33109647-d136-4cc0-a126-163b837a2725" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_730bd857-82d1-4c7c-be2f-e94929542ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_904b4a4f-5777-4662-990e-eb0298ae4622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_730bd857-82d1-4c7c-be2f-e94929542ca5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_904b4a4f-5777-4662-990e-eb0298ae4622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RestructuringScheduleofRestructuringActivitiesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b1b63f4c-e749-484c-b337-2731dbf950b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73d6e83f-14ad-4842-b73a-974800c5dc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b1b63f4c-e749-484c-b337-2731dbf950b5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73d6e83f-14ad-4842-b73a-974800c5dc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6695e35e-4a17-438e-ae6a-401a01ec199a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73d6e83f-14ad-4842-b73a-974800c5dc0d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6695e35e-4a17-438e-ae6a-401a01ec199a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6695e35e-4a17-438e-ae6a-401a01ec199a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SeveranceAndOtherEmployeeCostsMember_a4b9a20a-6d39-4109-981c-802eb069362b" xlink:href="neo-20230331.xsd#neo_SeveranceAndOtherEmployeeCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:to="loc_neo_SeveranceAndOtherEmployeeCostsMember_a4b9a20a-6d39-4109-981c-802eb069362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FacilityFootprintOptimizationMember_d14749ed-8b0a-4c98-9865-94ce8147eb1b" xlink:href="neo-20230331.xsd#neo_FacilityFootprintOptimizationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:to="loc_neo_FacilityFootprintOptimizationMember_d14749ed-8b0a-4c98-9865-94ce8147eb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ConsultingCostsMember_a9761303-e6af-4f2b-a83c-534078996c9d" xlink:href="neo-20230331.xsd#neo_ConsultingCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_05034b58-08f4-4230-ab0d-1434b6afae55" xlink:to="loc_neo_ConsultingCostsMember_a9761303-e6af-4f2b-a83c-534078996c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73d6e83f-14ad-4842-b73a-974800c5dc0d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2c950093-b9e4-43f4-997a-03bbd87289d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_RestructuringReserve_2c950093-b9e4-43f4-997a-03bbd87289d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fef4fe7-6a1f-4034-8b2f-e8e5a829b5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0fef4fe7-6a1f-4034-8b2f-e8e5a829b5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_93e7f856-ec42-4017-b058-5aa73f3006c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_AssetImpairmentCharges_93e7f856-ec42-4017-b058-5aa73f3006c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_c0d48d48-f6a5-43c5-899a-81cd97697329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_PaymentsForRestructuring_c0d48d48-f6a5-43c5-899a-81cd97697329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2a9dba91-eddc-4afc-80d2-392abfd466c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f11891f8-0299-47f6-9dd8-564f6092a761" xlink:to="loc_us-gaap_RestructuringReserve_2a9dba91-eddc-4afc-80d2-392abfd466c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_25a85b61-ec6f-4e29-b187-5c5ffca8e720" xlink:href="neo-20230331.xsd#neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_25a85b61-ec6f-4e29-b187-5c5ffca8e720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_39552027-7b43-4098-845e-063455326a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_RestructuringReserveCurrent_39552027-7b43-4098-845e-063455326a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_018b4459-7a60-4bb5-8f89-e741328f810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_RestructuringReserveNoncurrent_018b4459-7a60-4bb5-8f89-e741328f810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_351ad3d8-d921-461b-8318-543b2dbd390a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_309ea3e2-bed8-4280-a675-2de571cae1b8" xlink:to="loc_us-gaap_RestructuringReserve_351ad3d8-d921-461b-8318-543b2dbd390a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RestructuringNarrativesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RestructuringNarrativesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RestructuringNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d7d503dd-194b-4549-954f-864b233713bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_283fbf39-c615-4bed-b7d4-94cb1db57ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d7d503dd-194b-4549-954f-864b233713bb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_283fbf39-c615-4bed-b7d4-94cb1db57ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e114f546-2979-41d1-ae9f-412d8b3ad65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_283fbf39-c615-4bed-b7d4-94cb1db57ed5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e114f546-2979-41d1-ae9f-412d8b3ad65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e114f546-2979-41d1-ae9f-412d8b3ad65f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_SeveranceAndOtherEmployeeCostsMember_ad23ab26-ad41-4017-a765-c4e34c2e93fe" xlink:href="neo-20230331.xsd#neo_SeveranceAndOtherEmployeeCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:to="loc_neo_SeveranceAndOtherEmployeeCostsMember_ad23ab26-ad41-4017-a765-c4e34c2e93fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FacilityFootprintOptimizationMember_d8d8cae4-a0e1-4191-854d-d82ad391199b" xlink:href="neo-20230331.xsd#neo_FacilityFootprintOptimizationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:to="loc_neo_FacilityFootprintOptimizationMember_d8d8cae4-a0e1-4191-854d-d82ad391199b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ConsultingCostsMember_8c3dc817-98a7-4c2e-84eb-70a4389a80ec" xlink:href="neo-20230331.xsd#neo_ConsultingCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_510c9ed5-ff98-497b-9a5b-e19fadd23963" xlink:to="loc_neo_ConsultingCostsMember_8c3dc817-98a7-4c2e-84eb-70a4389a80ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9d9c6303-de0b-4c97-ab56-094ceb4f3e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_283fbf39-c615-4bed-b7d4-94cb1db57ed5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9d9c6303-de0b-4c97-ab56-094ceb4f3e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f4accac0-0d5b-4d0e-b020-e6108581d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9d9c6303-de0b-4c97-ab56-094ceb4f3e2d" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f4accac0-0d5b-4d0e-b020-e6108581d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e8ae6b2b-c645-4f54-8d93-698d42d0c4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c161b1d2-0a94-4710-9607-cc9678392f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e8ae6b2b-c645-4f54-8d93-698d42d0c4a9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c161b1d2-0a94-4710-9607-cc9678392f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_f133ba2c-862a-4d5d-86ab-44ec9d9d0259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e8ae6b2b-c645-4f54-8d93-698d42d0c4a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_f133ba2c-862a-4d5d-86ab-44ec9d9d0259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8375288c-3dec-4b93-967b-27811ab2ede1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e8ae6b2b-c645-4f54-8d93-698d42d0c4a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8375288c-3dec-4b93-967b-27811ab2ede1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_74429b93-a4ae-4f93-b18b-e35f024e29be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e8ae6b2b-c645-4f54-8d93-698d42d0c4a9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_74429b93-a4ae-4f93-b18b-e35f024e29be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_bec97baa-c85f-41a3-b7cb-31b153fbfc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e8ae6b2b-c645-4f54-8d93-698d42d0c4a9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_bec97baa-c85f-41a3-b7cb-31b153fbfc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#NetLossPerShareScheduleofAntidilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_63f41bde-0bc9-4858-9eef-203da3d26f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_63f41bde-0bc9-4858-9eef-203da3d26f93" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9ce4fb-0086-4b5d-8d74-ee01061ad387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9ce4fb-0086-4b5d-8d74-ee01061ad387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9ce4fb-0086-4b5d-8d74-ee01061ad387" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94ab8ee1-b31f-48a0-aeee-d3fafa18b209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94ab8ee1-b31f-48a0-aeee-d3fafa18b209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_672f8cc6-0198-46e2-933d-d67182ceb1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:to="loc_us-gaap_RestrictedStockMember_672f8cc6-0198-46e2-933d-d67182ceb1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ec76566-b28d-44e9-a5de-9c489ea28d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f120a823-cac7-4458-b8c4-50e6cb0ae06d" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ec76566-b28d-44e9-a5de-9c489ea28d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0235ab2-4aa0-4ba6-b61a-7c55683b6ca7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_e27155b0-2fa7-4d81-b130-c43ae369f1ef" xlink:href="neo-20230331.xsd#neo_OnePointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:to="loc_neo_OnePointTwoFivePercentConvertibleSeniorNotesMember_e27155b0-2fa7-4d81-b130-c43ae369f1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_5dd236cf-49d3-47d6-abce-283c5f1eeb61" xlink:href="neo-20230331.xsd#neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_38a26654-062e-47ec-a535-812f49e8b521" xlink:to="loc_neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember_5dd236cf-49d3-47d6-abce-283c5f1eeb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf988537-3a0e-4fcf-bbe6-d9536ec3d406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c0a26c66-bce7-42a0-ba85-22b65cf1ec5e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf988537-3a0e-4fcf-bbe6-d9536ec3d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_CappedCallTransactionsMember_50bdfe1d-d575-4a35-b08e-938965827f80" xlink:href="neo-20230331.xsd#neo_CappedCallTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf988537-3a0e-4fcf-bbe6-d9536ec3d406" xlink:to="loc_neo_CappedCallTransactionsMember_50bdfe1d-d575-4a35-b08e-938965827f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b2e2326f-44c4-4633-a15f-b2370e28166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b2e2326f-44c4-4633-a15f-b2370e28166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c5ba52de-c33c-4ba2-b414-e12dc4d90ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b2e2326f-44c4-4633-a15f-b2370e28166f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c5ba52de-c33c-4ba2-b414-e12dc4d90ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_cc621277-9a50-44b9-b5e4-c60e2644502a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c5ba52de-c33c-4ba2-b414-e12dc4d90ac6" xlink:to="loc_us-gaap_ConvertibleDebtMember_cc621277-9a50-44b9-b5e4-c60e2644502a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d811ba9c-595e-4424-8ee6-075dfc17ba55" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed474fc2-03b4-4fa9-8c04-31929cf1d50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ed474fc2-03b4-4fa9-8c04-31929cf1d50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_fda946c1-bf06-4c5b-b4a2-dc411e52dcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_fda946c1-bf06-4c5b-b4a2-dc411e52dcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fe3c1b47-7994-4860-b2b1-f361f354a168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fe3c1b47-7994-4860-b2b1-f361f354a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6b70f58b-0f3a-4ee9-a5bb-39274b0262fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2bcdc1f4-99f6-43fd-aba1-9acd546e4a1f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6b70f58b-0f3a-4ee9-a5bb-39274b0262fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_99943a41-fbda-41a4-9a01-d8e86099eb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationTable_9fdb602b-66cd-4a88-9531-7f24d3732f6b" xlink:href="neo-20230331.xsd#neo_ContractualObligationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_99943a41-fbda-41a4-9a01-d8e86099eb82" xlink:to="loc_neo_ContractualObligationTable_9fdb602b-66cd-4a88-9531-7f24d3732f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationTable_9fdb602b-66cd-4a88-9531-7f24d3732f6b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_5f9d2b0e-87a9-404c-8c2d-74cfd2231d3a" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PatentInfringementComplaintMember_fa66dadf-9504-4d69-b038-9ef8fb505083" xlink:href="neo-20230331.xsd#neo_PatentInfringementComplaintMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:to="loc_neo_PatentInfringementComplaintMember_fa66dadf-9504-4d69-b038-9ef8fb505083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_FederalHealthcareProgramRevenueMember_1cf540d2-5795-4dc6-ba90-fa040cc402d5" xlink:href="neo-20230331.xsd#neo_FederalHealthcareProgramRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_f9b9d9de-a0d2-48c8-9166-2fbf778f60ed" xlink:to="loc_neo_FederalHealthcareProgramRevenueMember_1cf540d2-5795-4dc6-ba90-fa040cc402d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:href="neo-20230331.xsd#neo_ContractualObligationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationTable_9fdb602b-66cd-4a88-9531-7f24d3732f6b" xlink:to="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_f9f2efc7-696e-4974-8171-6d1fe037bf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_f9f2efc7-696e-4974-8171-6d1fe037bf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_389bacdd-8ae1-4570-a99a-39c1aa0d63eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_neo_ContractualObligationLineItems_7a81f49a-7f89-4bea-b89d-612a4be81c0b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_389bacdd-8ae1-4570-a99a-39c1aa0d63eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c94a7fda-b79b-4e94-bb85-49ad24a4318c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c94a7fda-b79b-4e94-bb85-49ad24a4318c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8e9257ab-4702-4437-b294-82ed0b5144a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8e9257ab-4702-4437-b294-82ed0b5144a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e9a3fd12-b937-40d3-9932-5c5b20966b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8e9257ab-4702-4437-b294-82ed0b5144a6" xlink:to="loc_us-gaap_RelatedPartyDomain_e9a3fd12-b937-40d3-9932-5c5b20966b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_348ac845-1acc-47c4-ab4b-6c21cba3030e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e9a3fd12-b937-40d3-9932-5c5b20966b15" xlink:to="loc_srt_AffiliatedEntityMember_348ac845-1acc-47c4-ab4b-6c21cba3030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d2ccb883-2cab-43a0-874b-390d3bd7241f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d2ccb883-2cab-43a0-874b-390d3bd7241f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_73b72e9e-9f01-4027-a8b4-90b9eec02783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d2ccb883-2cab-43a0-874b-390d3bd7241f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_73b72e9e-9f01-4027-a8b4-90b9eec02783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_b33dbb93-f16d-410c-b154-d59c7bf0121f" xlink:href="neo-20230331.xsd#neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_73b72e9e-9f01-4027-a8b4-90b9eec02783" xlink:to="loc_neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember_b33dbb93-f16d-410c-b154-d59c7bf0121f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_792c198c-b08b-4f1a-9e9f-f17bb82936d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3f5d1535-11fa-47d8-b3b4-a6af7b7b192a" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_792c198c-b08b-4f1a-9e9f-f17bb82936d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_de500f9d-5ae4-4587-9a06-6a40f558ef55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_792c198c-b08b-4f1a-9e9f-f17bb82936d8" xlink:to="loc_us-gaap_RevenueFromRelatedParties_de500f9d-5ae4-4587-9a06-6a40f558ef55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="neo-20230331.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://neogenomics.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f0122c2c-b775-42d1-b1e2-f2f7377748d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f63d8020-a903-4c8b-8fd4-3df0c3e7e328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f0122c2c-b775-42d1-b1e2-f2f7377748d2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f63d8020-a903-4c8b-8fd4-3df0c3e7e328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c9efde0-c788-4b4f-811c-08430a75a5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f0122c2c-b775-42d1-b1e2-f2f7377748d2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c9efde0-c788-4b4f-811c-08430a75a5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c9efde0-c788-4b4f-811c-08430a75a5e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ace04a7f-f3f4-4cc2-9ca7-5d480c5ad129" xlink:to="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_ClinicalServicesMember_1ebebb55-ce6e-4ae9-8110-4474dee3128c" xlink:href="neo-20230331.xsd#neo_ClinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:to="loc_neo_ClinicalServicesMember_1ebebb55-ce6e-4ae9-8110-4474dee3128c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_PharmaServicesMember_2b68d389-3a22-4f89-a73c-16dfeffe69ea" xlink:href="neo-20230331.xsd#neo_PharmaServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_211b61d4-f975-405d-80cf-ffdcf568326c" xlink:to="loc_neo_PharmaServicesMember_2b68d389-3a22-4f89-a73c-16dfeffe69ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c9efde0-c788-4b4f-811c-08430a75a5e8" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cf14f058-dffa-452e-ad13-f0efb21ca9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_cf14f058-dffa-452e-ad13-f0efb21ca9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5d061d2e-a20b-4d6a-9c7e-dd11b5470f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5d061d2e-a20b-4d6a-9c7e-dd11b5470f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_bfe8b027-5668-4330-ab34-6cb3e6a0178e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_GrossProfit_bfe8b027-5668-4330-ab34-6cb3e6a0178e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b37edd3e-ff41-4f66-bb79-69ec04f4fc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b37edd3e-ff41-4f66-bb79-69ec04f4fc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5de9eee6-081b-406d-ba19-86d88fb74e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5de9eee6-081b-406d-ba19-86d88fb74e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_c6c3dbe8-ec04-4011-8fc1-e24faab01156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_SellingAndMarketingExpense_c6c3dbe8-ec04-4011-8fc1-e24faab01156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_442590a1-5943-4205-a0a0-6a539462a5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_RestructuringCharges_442590a1-5943-4205-a0a0-6a539462a5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1d2524e3-ccac-4a89-86d8-3e888f05fcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_OperatingExpenses_1d2524e3-ccac-4a89-86d8-3e888f05fcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_76ce96ef-c1e7-4f5c-8edf-dad8bf80b802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_OperatingIncomeLoss_76ce96ef-c1e7-4f5c-8edf-dad8bf80b802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6a8d3ee4-41e4-4d44-96fe-d6df3a80d2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_6a8d3ee4-41e4-4d44-96fe-d6df3a80d2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0fda9bd4-a257-4909-9428-e4f45913dd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0fda9bd4-a257-4909-9428-e4f45913dd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b77847f7-badf-479a-a14e-13d974c565d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b77847f7-badf-479a-a14e-13d974c565d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4293b251-c0f1-4cfe-bfff-b9ba7c184be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4293b251-c0f1-4cfe-bfff-b9ba7c184be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c1686eff-75a4-4cf0-8ecf-cf9ec83dbfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_us-gaap_NetIncomeLoss_c1686eff-75a4-4cf0-8ecf-cf9ec83dbfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_7a3cf139-6718-4eb5-9a23-6ccc44ff1706" xlink:href="neo-20230331.xsd#neo_IntangibleAssetsAcquiredAmortizationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bcc88eca-3bab-4299-8409-478d0a6182a0" xlink:to="loc_neo_IntangibleAssetsAcquiredAmortizationExpense_7a3cf139-6718-4eb5-9a23-6ccc44ff1706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>exhibit101-offerletterda001.jpg
<TEXT>
begin 644 exhibit101-offerletterda001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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MBB@ J"[_ -2O_76/_P!#%3U!=_ZI?^NL?_H8H GHHHH **** "BBB@ HHHH
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M9-/=OW-PI91VWC_ZV?RKMK15:E[6.YQT9.E4]G(]8HI*6O./0"BBB@ HHHH
M**** "BBB@ HHHH **** "H+O_5+_P!=8_\ T,5/4%U_JE_ZZQ_^AB@">BBB
M@ HHHH **** "BBB@ HHHH HZ/\ \@J'\?YFK2_Z]_\ =7^9JKH__(*@_'^9
MJTHQ._\ NC^9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH ***0]* $C_ -4G
MT%.ID)S"A]5%/H **** .-\3C/BC1_7S8_\ T8*[*N.\3?\ (SZ/_P!=8_\
MT8*[&FQ(*;_RT'T-.IO\8/L:0Q)!G;_O"GTU_P"'ZBG4 %%%% !1110 4444
M %%%% %6W_X^KO\ ZZ+_ .@+5JJMO_Q]7?\ UT7_ - 6K5 !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&BD/2@#@OB;>-'8VED
MI.)W+, >H7'7\3^E='X5TQ-,\/6L(0+(R"23CJQY/^?:N/\ & ^V^.].LV *
M?N@1[%LFO254*,#I6]32E&/?4YZ>M23(;N$3VSQ]R.#Z&LS1)2&F@/7.[\>
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M"O7]#U:+6M)@O(\ N,.H/W6[BO(?%X*^*]1YY,OY\"L\%&U1IFF,=Z::/2O
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M_AVKNK-4:7LUNSBI)UJG.]C7P:6BBO./0"BBB@ HHHH **** "BBB@ HHHH
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M!^H^M.IC]OJ*?0 4444 %%%% !1110 4444 5;?_ (^KO_KHO_H"U:JM;_\
M'U=_]=%_] 6K- !1110 4444 %%%% !0*#TH% !1110 4444 %%%% !1110
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M,'[?44ZFOV^M.H **** "BBB@ HHHH **** *UO_ ,?-W_UT7_T!:LU5M_\
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MCTKR5&6"C.!WSS45RCMI<*A"3\N5%2Z;BI=VOQ"PFHY=K:,DA#U].U:B *N
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M "#(?Q_F:M#_ %S?[H_K0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &Q
M_P"J3Z"G4V/_ %:_04Z@ HHHH X_Q+_R,NC_ /75/_0Q785Q_B7_ )&;2/\
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M_$O_ ",VD?\ 75/_ $,5V IB04W^,?C3J;_&/QI#!^WU%.IK]OJ*=0 4444
M%%%% !1110 4444 5K?_ (^KO_KHO_H"U9JM;_\ 'U=_]=%_] 6K- !1110
M4444 %%%%  >E H/2@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:AN?N+_ +Z?^A"I
MC4-S_JU_ZZ)_Z$* )Z*** "BBB@ HHHH **** "@]**#0!2TG_D&0_\  OYF
MK*_Z]O\ ='\S5;2/^09#^/\ ,U:'^N;_ '1_6@!]%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[\>]+XDT_5]3U6WA%F+C1X=LLD2SA#/(#D*^?X!C.._?I5O7+;5M3\+2VEE
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *AN/N+_ +Z?^A"I345Q_JQ_UT3_ -"% $U%%% !1110 4444 %%%% !
M0>E%!Z4 4M)_Y!D/X_S-65_U[?[H_F:K:1_R#(?Q_F:M#_7-_NC^M #Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I#2T4 ,B.84/JHI],B_P!4G^Z*?0 4444
M<?XFS_PDVC_]=8__ $,5V%<=XE_Y&;2/^NL?_H8KL:8D%-_C'XTZF_QC\:0P
M?G'U%.IC_P /U%/H **** "BBB@ HHHH **** *MO_Q]7?\ UT7_ - 6K55K
M?_CZN_\ KHO_ * M6: "BBB@ HHHH ****  ]*!0>E(* %HHHH **** "BBB
M@ HHHH **** "BBB@!#2T44 %%%% #2@)!(Y'2G 8HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFK0_US?[H_K572/^09#_ ,"_F:LJ?WS?[H_K0!)1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% #8_P#5)]!3J;'_ *I/H*=0 4444 <?XE_Y&71_^NJ?^ABN
MPKC_ !-_R,FD?]=8_P#T,5V%-B04W^(?C3J;_&/QI#!NH^M.IK=1]:=0 444
M4 %%%% !1110 4444 5;?_CZN_\ KHO_ * M6JK6_P#Q]7?_ %T7_P! 6K-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &Q_P"J3Z"G4V/_ %:_04Z@ HHHH X_Q+_R,NC_ /76/_T,5V%<
M?XE_Y&;2/^NL?_H8KL*;$@IO\8_&G4W^,?0TA@_;ZBG4U^WU%.H **** "BB
MB@ HHHH **** *UO_P ?5W_UT7_T!:LU6M_^/J[_ .NB_P#H"U9H **** "B
MBB@ HHHH #T-(*4]*!0 4444 %%%% !1110 4444 %%%% !1110 AI:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0U#<_<7_KHG_H0J
M8U#<_P"K7_KHG_H0H GHHHH **** "BBB@ HHHH *#THH/2@"EI'_(,A_'^9
MJT#^^;_=']:JZ3_R#(?Q_F:LK_KV_P!T?S- $E%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4&B@T -C_P!6OT%.IL?^K7Z"G4 %%%% ''>)?^1GTCG_ ):Q_P#H
MP5V-<=XE_P"1GTC_ *ZQ_P#H8KL:;$@IO_+0?0TZF_Q#\:0P;J/K3J:_4?44
MZ@ HHHH **** "BBB@ HHHH K6__ !]7?_71?_0%JS5:W_X^KO\ ZZ+_ .@+
M5F@ HHHH **** "BBB@ /2@4'H:0=* %HHHH **** "BBB@ HHK"\3:M=Z9#
M9P:?#'+?WTXMX!(3L4X+%FQS@ $T ;M%<G)?:YH>HZ>NJW=G?65[,MMNAMS"
M\4C [?XF!4XQZ\U._CG18;AH2;HA)O(EF6V<QQ/NVX=\87GU]: .EHK&\5WU
MQIWA34[VTD\JX@MV>-R <,!QP>#5?2/%NFZC<0V(>X6Y>+?&T\#1K< #YC&2
M &]>.W/2@#H:*P(/&&DW-]';(UP%ED,<5R]NZP2N/X5D(VD\'&#SCBLBR\;V
MUG>:G!JLMPYAOWB5X[5F2&/Y=N]E&%&2>6H [:BL35?%6G:/,T=REXP5!)))
M!:O(D:GNS*"!Z\]JS=3\1R6>OVQCD>;3GTV2Z,<$7F,Y#+M(P,G@]* .MHKD
M_ FK7>M:+]OO;FYEDE(8I);>4D9(SB,[1O7G[V3TZU<N?&>CVE[+;227!6*3
MRYKE+=V@B;IAY0-JD9&<GC- '045PUUXDNKCQ_'HD$U[;6T,2.WEV)<2N6YW
M,5.(\?Q CG/-7/%OBB\\.W6G"WM8[B&4227 (.\1Q@%MF#UP2?PH ZVBN?BU
MXW'B.TLH&B>RN-/-VLHZGY@!@YQC!J6S\5Z1>WRV<$\A=R1%(T++',1G(1R-
MKD8/0F@#;HK$N/%NBVUXUM+=X*-LDE$;&*)N/E>0#:IYZ$U4N=;U*]U>ZTK0
MH+8R680W%U>%O+4L,A55>6..O(Q[T =-16/:W]Y8:9/<^(GL;?R6YF@=O+9>
M,'#<J<G&,G]:?;>(]+NH+F:.YVK;+OF61&1D7LQ5@#@X.#CF@#5HK(L/$^C:
MI>?9;.^264J73 .) .I4]&QWQFF#Q9HAOA:"^3>7\H/@^67Z;-_W=WMF@#:H
MK$O/%VA6%W+:W.H1I-"P65,$F/(!RV!P,$<GCFI+3Q-H^HWS6-I?1RW !(49
MPX'4J>C8[XH UZ*P;3Q)9Q:):WNHW]H3.Y1&M@Q61@3PJG+$\5.WB?15MX)_
MM\;)/N\O8"S-M.&^4#/!X/''>@#7HJC?Z@+?0KK4K?9*([9YX^?E?"EAT[&J
M^E:PESX9LM9O7BMTFM8[B5BV$CW*&/)[#- &M16*/$FG7MG>MIUW'+<6\!E\
ML@A@,$@[3@X..M5/#GB_3M7L=/CDO[8ZE<6Z2/"AQ\Y4%@/<<\9R* .EHK)E
M\3:)!?FQEU2U2Y#!&C:0#:QZ GH"?0T^Y\0Z197JV=SJ%O%<LRJ(F<!B6^[Q
M[T :=%9:>(]%DO\ ["FIVK71<QB,2@DL.J_[W!XZU4T[Q9I>HZQ>:;%<1B>W
ME\L N#YORY)4>W(_"@#?HK+MO$FBWE]]BMM4M)KGD"-)5)..N.><=\=*9/XC
MTH3/:0ZC9O>@2;8&G )9 =P.,D8P<\<8- &O162OB"P@TFSO=0O;*W%PBLI6
M<,C$C/R,<;AWSCIS4TNNZ5!8Q7LNH6R6LV/*E,HVR9&1M/?\* -"BJ\-W;W5
MHMS;SQRP.NY9(V#*P]01UKF(O$NH7'ANSU&"TWS:C="*V58F98HV8A7DP>@4
M9)XZB@#KZ*XB]\:W>FZ+%JLNE2S)=7S6\%LH*2K&H8[F!!RQV$XXZBM@>)H)
M-3T2VMXQ+#JL4DJ3!\;0JANG?.?PH WZ*SUUW27U Z>NI6AO02/LXF7?D<XV
MYSG'.*2[\0:/87:VEWJEG;W+8Q%+.JL<].">] &C16#J.OO#JZ:5IUD;Z^,?
MFR*9?+2%,X!9L'&><  G@U;T^_O76X_M.P6R\D AQ.)(W'.2&P",=\@4 :=%
M4+/6]+U&.62QU&TNDB_UC03JX3ZX/'0TL&M:7=77V6WU"UFN-@D\J.96?:>C
M8!SCD<T 7345S_JU_P"NB?\ H0JM)K6EPWZV,NHVB7C?=MVF42'Z+G-1:AK&
MFVF$N=0M87$L:E99E4@E@0.3U(!Q0!J45434[&:[>TCO('N47<T*R NH]2N<
M@57M=61K&6[OO(M(XY70L;A60!3C);H/IVH TZ*I-K&F+9"];4+46C=)S,NP
M_P# LXK#UOQ3)87#)8V\=U&EHT[N&)^=B%A08ZEVS^ H ZFBH+229[&"2YC$
M<[1J9$!R%;'(_.HH-5T^ZN)+>WO;>:>/[\4<JLR_4 Y% %RBJJZC9/<+;K=P
M&=@2L8D&XX.#@9SP>M5KG7M.M=6CTR>X6.XDB:4;F 4 $#!.>#\PP* -.@US
M^D^)H+R\U&VNV@MGM[YK2(-* 9L '(![\]!FM>YO[2S"FZN88 YVJ97"Y/H,
MT 1Z3_R#(?Q_F:M*/WS?[H_K5+2Y%32(G)^4!FS[9-86B^+X]8O8TBM3'&]N
MUTSO)]R$.50GCJQ!..P[T =;17,6?BJ?4!'<V>AWTVFNX5;H,@W#.-P0G<5]
M_3FN@>\MHY5B>>-9&^ZA<!C]!0!/14,MW;P@F69$QC.Y@,9Z4HN83+Y0E0R8
MSLW#./7% $M%0M=0*X1IHPQ.T L,D^E*]U!$ZK)*B,W"AF )^E $M%1/<0Q@
M[Y%7 R=QQ@>M.$T;,%#@DC(&>H]: 'T5C:SKT6E2V<2QB:2XG\ME#X\N,#+R
M'@\*,$_4>M9]OXLDDTC1M2N--:"#4;@0G=)DQ!L^6YXY#8'I]X4 =312?PUF
MW&JK:/?-<PR16UI$LIG)!#@@D@ <Y&/UXH TZ*@M[J*[M8YX7W1R*&4^Q&?Z
MU!97YN8))9K:6UV2,F)B,D _>X)X- %ZBDW#%-\Q=VW//I0 ^BFAP1D4H.:
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M"@ $Y.!UH\M>.!QTXZ4 >42RV*>#=9TF^C!\237$V(=N9I)F;,;+@9(QMY'
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M#75Z;HD6G7^HWWFM+<W\HDD=@!A5&%0>P'\S5T6=N)I9A#$)95"2.$&YU&<
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M@!EKXFM+JXGMG@O+:XAA,YAN(BC-&.-P[$9]\U!;^,M+N-/;4!]J2S^01S/
MP$S.<!4'5FSQ@#K7/Z7H.IC7IKU]/U&*)M,EM\W]^+B0R%@<??8 'MCCZ58O
M?#.HW7@'1; 1,E[8-!+)"D_ELVP895<' ;!.#GKCF@#I-+U^UU2YGMD2XM[J
M *TEO<QE'"MG:WH0<'H:+SQ#96NH_8,7,LZA6E$$#.(E;(4L0.,X/O63X8TM
M8-0N;U]+U:UF:)8A+J5_]H9UR3@?.^ /?UJOXCL=2EUD7.CZ;>1:BJHD=_%<
M1B!USRLR%LD#+?PD\\&@#8O_ !7I^F3.MTMXL,3!);@6SF*,G&,MCG.1R,CU
MQ47_  E"CQ=-HC6T^U($D698G;+,Q&#@8"\#YLXZ^E<GXITGQ)K$6KV<EIJ%
MP[NWV(V]TD5J(N" XW LV0>&!YQT&371/!?V/CK[<NG37-I=64-J9863$3+(
MQ)8%@<88'@&@">R\46J:=!)<WAO9IYI8HOLMG(I<H3D!/F/&.3G!_&LSQ)XF
MD&HZ-96<US;Q7I,CR"R=G 7!4!2OKU&,CVK/M]$N;?P];0WFD:F;J&\N)H9K
M"9!+ 6<[3DMR&!]QQR*MC3=>GU'PI?:G#NGMDE%XZLF$9BH4'!Y/TXS0!T$G
MBC3;680W,ERG[T0&9[618_,/ &[;MY]>E27?BC2[*^ELY9IC+"%,OEV\DBQ;
MNFYE4@?C7$ZU9>)-6BO;2YL]1EF%\KQ%&C6V6 2*5(YW,<#Z@^E;5A_:7A_6
M]8A&C7=\E_=_:8+B$ILP5 *N68;=N/Q'2@#1TSQ;;ZAK&H6!AN(A;2A$D:"0
M*PV!B6)4!.IZGG@CK4]OXPT2YFMHX[J3%TYC@D:WD6.5AV5RNT^W//:L=[/4
M1K/B;3_L<R0ZL@:WO$QLC/D",[CG(.5&.*H0VVJZCH^@Z ^A3VCV$MLUU<2[
M/*018.8R"=Q;;C@< G.* .EF\9Z'!+=QO<S$V9<7!6UE81[>N2%Q_CVK1;5[
M%+BQ@:?][? FW4*3O 7<3P.!CN<=:Q?#>ERQQ^(8[ZV94N]2G=0X'[R)@H!^
MAP:P_!=K/]ON[F_;]QH<;Z7;N<88*V6<G_="#\#0!Z(3@9KG%\<^'Y)$1+V0
MAY?)\S[-*$5\XVEMN <^I_G6CHFJ-K.BVNHFUDMA<)O6*3!8 ]#QZCG\:\YT
MK^T-3\&-H%MI%RQN;N0K>Y7R53SR6<G.01C&W&>F.* .SM?$1@U7Q"-2G2.R
MT]X5C;:<C<@)'').3Q5Z#Q-I-S'=.EQ(GV5!),LL$D;*I!(;:R@D<'H*Y+5M
M#U2>Y\0SP6LQ!O;2YA"$!IEC4;@F>,\<9[U9BBO)/[1U;3++5VU:.S,,!U0*
MBOSG:%&,D>IXYZT ;&@>)-*N;3[.EPZ2PPF=UFA>+$>3\PW 9'N*LV7B72KU
MKB:&X<110K*TDL+QKLY^8%E (^E<7H-I>W&KPWMQ8:I<V@TJXAD^U(BF1RZD
MHH&,9YQGCK@TD=AJ]]I>KZ5I\>H_V8+)!;)J:A)5D#$^6I/)7 QD]..: .ZT
M[Q'I>JW!@M+AVE""0+)"\993_$NX#</<5+JFN:?HPA^W3LC3$B-$C:1W(&3A
M5!)P/:N9T.!+_7;2\FCU_P"TVD+A3?QK''&7P&7A1N/';(XJYKLLNE^)K+5Y
M+*ZN[06TENWV:(R-$Y96!VCD@XQ^% &C/XKT6VM;6X>\REVI:!8XG=Y .N%4
M%N._%21^)='EMK.Y2^1HKV;[/ P!^>3GY>G!X/6N:N;FYL?%=OXCN-*OOL,^
MF_9S''%YDMN_F;OF523R".F>1S65)H^HP:9!JKV$\:CQ!_:C6D:AI(X",?='
M\7\1 YYH [ZXUW3+1[Q)[M4:RC66X!!_=HV<$\>QJO;>*M$O9+B*VOEE>",R
M.%1N5!P67CYAGC*YKC-16^UBW\7W46EWT:75A$ELLL!#RX#=%_'H>?7%=)=6
M,H\7Z#-%;,((+6>-W5?E3(3 )QCM0!-HWC'2]5TF34'E^S)$I>82@@1J&(!W
M$ '..U6[3Q1HU[;W4T%ZI2U3S)MZ,C(F,[B& ., \UPSV=_>> Y-$BM+Y=0T
M^Z$LR>5CS%\YFPC,-KG;@CKVJTT-OJ5MK-_;2Z[>W?\ 9$UNK7MH(EY&=@'E
MJ6;/IF@#JE\8^'W@EG34HVCBD6)F56.7;.T+@?,3@],]*/[?BN9M,:RN;9K>
M[EDC/F[UD8JI)"#'4%3D''2LO6;:RA\-:0MW'?VXMC$\4MC 9'MY%0X)4*W'
M)'W3UK/2;5KU_"][J,$@:&\N6>1HC'^Z$;A)'7^#(QP<=: .D_X2_01?1V7]
MI1_:))/)1=K$,X."H.,$@]>>*'\8^'H[W[&^K6XN/-,)0D\."5*DXP#D$<UP
MOAV4J^@2:E]KCLH;F0V3QVW[MY)"RC=*&.5.XX.!GC.:M7FGW#> _%2"SF\^
M;5IW11$=SCSQA@,9/ X- '=ZYK%KH.DS:A=L1%&.@ZL>P'N:P+[QO9I!I-]9
M7D#6$]X8+J60']V!&SGGC!! ]>M;?B6"6Z\,ZG;P(7EDMI%11U8E3@5S%Q=)
MK2>$Y+:VN6C@U +*)K9T*%8'Y(8#@$CYNF: -ZZ\36<WA^75-*O;.>.-U4R2
MR%8P2P!!(!(//IZ5:F\1:1;:C%ITVH0)>R8"PD\Y/0>V?>N)UNTN6B\9"&VF
M8RW%F8\(?GQLSCUZ<FK%Y>/I?B64:(MX]Y=748N[&:T?R9. #*LN,*0H'\1'
M'2@#I_$FJW&DV=I/;+&QEO;>W?S,X"22!6(QWP:GNO$>C6.HQZ?<ZC;Q7<A
M6)FP23T^F?>LOQI'--ING"&-Y&&JVC$(I. )5))]@*Y"YMFADU_2M7U/4+<7
MEV[[(--,PGC8#:5<(>0!CKQCM0!V4WC;1(/$,NCSW2Q31*I+L0%+$XV>N:GT
M+Q=I.O"Y^R7*[K=W5E=ADJIQO&#]T]B:R/,&E_$,2W2S^1=Z?%;P2")F#2!^
M0=H^4\YYP.OI6!<PWEQX3\7:-;PW*:@-0GN1'Y3XDA,H;Y3C#97(P#GKQ0!Z
M'I^OZ3JOG?8-0M[CR3B3RWSM_P#K>].L];TS4+AK>SOH9Y4C65DC;)"-T/XU
MQVE+;7^JI>+J]W=W$-A)&D7]GF!40X^5CM'(('R]:W_!.GQ6/@W1T%N(939Q
M-*-FUMY4%L]\Y)H <^NE/$5W9LT4=E8V@FN9G/(9C\H'.  H)/U%4/\ A.;*
M\\.IJFFO&\GFQ))!*XW1AY GS 'CC)%&EHR^./$\<GS&6*V= ?[NQA_,5S5C
MY<OPVMM'EAD:^MKB%+N!X&X_TCOD8(QD]^* /1;#5].U+SOL5]!<>2VV3RW#
M;3[TEGK>EZC<2V]GJ%M<31??2.0,1^5<1XGT^\D\0:I;Z3%+&\OA\H@A^16<
M2G STW8R!]34F@_8K_5=%D357:>TB98[5=/,1C79@H[?PXQT.,D<9H Z?7=:
MDTN>QAA@:5KB1MYP<)&@W.>.^. .Y-9L?BVX.EZ9(-.:;4]4#26MDK[,1CG+
ML1\N%*YXZG@&NKV@\UR?B"<Z-XITO69H9'L/(EM)I(T+>26*LK$ 9Q\I!/;B
M@">T\4S1:D=/UZP72[AHFFA87(EBD1?O8;"X(XR".]8X\?R+X?;4Y)-+WSRI
M%:6XN277<^TF3CC ^;@5,US%XH\8V%U8 RZ?I<$_G7!0A)'E4 *N1\V ,G'2
ML::S!^'/AXBUS*=0MM_[OYB/-YSQTQ0!WD&L6]OI\$^J:AI\32CY7CG'EOSP
M5)ZU=GU&RM8P\]W!$I7<&DD"@CUY[<C\ZX+4MMAX[OWOI[.SM9K&**UDN[8R
M1E03O13D ')SCN*DT[1["34/"UN3_:%K!:7#123PE0?F7;\K=,9P,^E &G-X
MNNFU62UL;2.XB:YBMK>3>P\TXW2G.,81><]#TK8T[59KC6M2TVYB6-[5D>)E
M.?,B<<'ZY# _05J)$D:*B*%51@ #  KF[=9&^(]\Z./*338E<?[1=R/TS^=
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ML08C\35^.-8D5$4*B@!548 %/HH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH HG2[<ZNNJ;2+H0F L#PR9S@^N#T^IJ\.!110 4444 %%%% !1110
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MI?K,)2;V=;AV#X*2*JJK(>Q 4'ZUMT4 9NF:5)I[R/+J=]>O)@9N77"CV"@
M5#JWAK3]9O["]NU<RV+[X]K8!Y!PP[C*@X]JV** ,33_  OI^EZKJ&HVXD\^
M^;,FYN%[G:.V3R:KOX.L_P"R+"PM[N[MC82&2WGC9?,0G.>H(/WCVKHZ* ,B
MW\.VMO>:C=":=Y=0C2.8NP/"+M!''!P:ALO"EC8MIABDG/\ 9UJUK#N8<J0
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M4 %%%% !4%U_JE_ZZ)_Z$*F-17/W%_ZZ)_Z$* )J*** "BBB@ HHHH ****
M"@]**#TH I:1_P @R'\?YFK0_P!<W^Z/ZU5TG_D&0_\  OYFK0_US?[H_K0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-WILQO=9TNPU9+]WGEEMB;M)1*2 &,@)!7 &!C:<5UOQ'R/". P#&ZMP&(R
M?,'.* -'2_$@O=0DTZ]LI].U".+SC!.58&/.-P=25//O6YYT6&/F)A?O<]*X
M;7_#\EKX?\0ZQJ%^U]J$FFR0*PB$:1H 6PJY.,GDG)Z53U[3++2[#PZEM!:V
MUC-<*;MYH\QROY9V&;!!;YN['KB@#T42QE-X=2OKGBJUQ>21W%HD%NT\<SE7
MD1U B !.3DY/3'%<"^CV1M-3B7Q!I<<4]U!+%!%%BUBE7G8R[R"'V\CBC3]1
MCU"?P]Y.GVUF;?6+BW=;7!AD98),NA 'RG/Z4 =EXBUU=!T::_$0N&B>)#$)
M-I^>14SG!Z;L]*U?-12%=U#'H">M>+W1T0^ HY9FMQXB?4 )6)_?&07'S!CU
MV[>F>.E:]W:IJ.K^)8[Z[TJ&Y6Y*QRWZ'S8(MB[&B;<, ')X[YH ]1:6-/O.
MH^IJI<ZM9VFH6EE-*5FNRPA7:2&VC)R0,#CUKC[;1['5_%SQ:GY6I!-(@):1
M<H[$L-^T\9]#VS6':0Z?/!X)GU."VEC;[3#+-=(K JH8(&)Z@8XS0!ZUG-8N
MO^);+PZ+4WGFG[1)M7RUW%0.K'V&1GZU>M;ZTFGFM+:6-I+8*)(T_@##*_I7
M"ZQ%J.O>)-7%EIL5_:06IT[][=^2(W<!G(^5LGE1VZ4 >B!QLW,0!ZYI2Z@9
M+#'UKRZUO5U9?"=GKC#R(FN;:\BE;*2W,0"HK]CG#-SU-7[B+1IO%6D:>S0O
MHH@N&AB9]T+3A_F')P=HS@=!VH ]"+*!DL />C(]:X!H-*O/%]EI]Q)'/HR:
M67LX992\3R"0ACR<,57&/0&L6SN9%?172=VTR'Q'-!;2-(<&'8VT9/4 Y ^E
M 'K.1ZU!=.%B#$\!TS_WT*\VUJ_2Y'CF2UN2RQ):J'C?[C#@X-7K_1;/3?%5
MII]M&_V2_LI/M4;RLWFLDD9#')^]R1GWH [-=6AGL[6\M$ENH+EU5'A7. ?X
MCG&%'<U?W #DUY=IEM9VO@OPS/:A8IY]1L_/*.?F.\CD9X[U'-IL-WI/C34I
MGN/MEC>7#VLJS,/)* .-HZ#)Z^HH ]5W#UJ.>>.""29VVQQJ69O0 9->5:W,
M-2UG6+2:)+JXDL[>.U>>[CA6U=DR7 9@2,D'*@DX(KN=3E7P[X+N)88$G%I:
M$B/DJV!W[X_I0!'IGC&WU&\L8?L5W##J(=K*XD5=LX52Q. <KP,C(&:VM0O1
M86CW'V>XN I \NWCWN<G' KR99I_"$-M)YMO>S7D"KI-R)!Y=H[D;XPC-A4^
M;(8=A@U[!$=T:DL#D#D=#0!@Z9XOM=5NC;V]AJ:E9F@DDDMB$C=1R&.>*Z'<
M.YKB_"Y+:=XLP2/^)Q>8(ZC@5S:P-IWPYT>\M6E:?4I+>.\FDN74M&2>"_.P
M=%R!P#0!ZQN'K1D>M>=;9M M]6N[^W2STI[=1]CL-1>5O,+XW*2J[,Y .#[U
M3LTOQKFH:1"4T);K2C*HBOVN!$^\!9,D+M8YP<>@YH ]$TDXTR'/^U_,U:!
MF;)_A'\S7DK7PLO"=WIZV\]CJ%M+;23F.Z9XV4RXWJV<C/<'!^O6NAUF[=_'
M%Y!!=-M7P_*S)'*1M;><'CH<'@]: .\W#UI<UYO!9/IG@K2/$D-U>/<JMM=W
MADN'<2QD .""<8"N2/\ =%=#X2EFU*XUC6'EE>VN;HQVBLY*>5'\H91T&6W'
MWXH W;2]6\:X"Q3Q^1,T)\V(IN([KGJO/!'!JSD>M>97=W>26>HK]ONHB/%/
MV=9$E.Y(RJC:OH.3QTYKH-#@.E^--1TF"XG>R^Q17*Q32M)Y;EG5L%B3SM!^
MIH Z87ML]Y)9K.AN8T61X@?F522 2/0D'\J@TG5(M6L1=1*RIYCQX;KE&*G]
M17+V^GV[?$_46::X#BQMYP!<. 6\R0$$9P5X''3GWK!MK1]/\/6NL6]Y>K=?
MVPT97[0WEE#<,I79]W!ZGCKS0!ZID>M07U[!IUC/>7+[(($,DC8)PHY)P.37
MG$R:YK=UK[6B2F\@O'@MIQJ30K;!0-O[L#!!ZG/7-=?XG$C> =5^U*OF_P!G
M2%PIR-WEG./;- #K;Q787<4LD$.I,L<1F^;39UW*/[N4&XGL!DFMF"99X4E4
M,%=0P#J5(SZ@\@^QKCYSKEOX#U.>[O;7"Z5(]NUI&\3QL(B0=Q8\CU&.:KQV
MTNLZ[I5O/J&H1V[:,L[I;W3QAWR!DD'/?UH [S(]:,CUKSFTO?M>E:-974VK
M7=Y)-=PQ1VUUY1E2)RI:5\@G  [Y)/>JHO-2G\/QVHU&^@D3Q"UD)1/NE$63
M\I;^+ .,G/0&@#U#(]:-R^HKSJ\O+WP]/XHLK:]NIXK?38[N W$K2O$[;E.&
M;)Q\H-7M5M9O#7A>]U&RU?4;B<VRK_I-P95R64&0!NA )Z8'M0!V^165JWB+
M3-#DACO[AHWGW&-5B9RV.O"@^M8>B6FM6>OPE8=0&F20L+@W]\L[;Q]UDPQQ
MGG/0=*GU?_DH7AWGK!<\?\!% &[IFL:=K$#3:?>17"*VUBC<J?0CJ#[&KN1Z
MUYSX@U%])\3Z]?:2@::'1=\^W[HEW_*S#N0O/T%7]"M=9@U*SE":JUG+ PNG
MO[R.4,V 49 &)4YR. !@T =ON&>M&1ZUY;8/J$/@S2_$K:[?S7GGQ*T,DVZ)
MU:41E"O<X.<]<BI?$NKR6XU/5M*N-9FDL+M(Y',ZBU5@RAHO+W L,'!."<GK
M0!Z;N'K4<-Q!<H7@FCE0,5+(P89!P1QW!KE(;2XU7QEJR2:K?Q6]EY)C@@EV
M*2\?.?4<=/4FL+2[633?A_KVH6VH7PF1KM4S.2%*R-A@/[W')[\T >F;AZT9
M%<%_95\OB&STW_A(=5-O>VC7$Y\T;]Z%?N''R [N@]*IMJ^J-INE:6+B]F>;
M4;BUDGA=4GDCBW$ ,Q #' R>. : /2<CUHW#UKSJ^F\0Z5X6UQIC>VT4<L+6
M,UQ,DDP5G4,K%6.0#GKU!JV;2\M==GT5]9U&>WN],>Y:2613)'(KJ#L.W@$-
MTQ0!W*R)(H9&#*>A!R#5>VU&TO)[F&"=7DM7\N91U1L9P?PKF/AO8^1X.L;C
M[7<RB>($12,"D6">$ ' /?.:S;_5-36+Q0(;Z2-[?4K6*W?@^6K&/(QW')_.
M@#T+(/>ER*Y31UO=.\57.ESZE<W\,EHMTKW.TLC[BK 8 ^4\<=JB\370;58[
M.#4M82Z6 RBUTQ$^49QO<L,8SQC- '7Y%&1ZUA^&-1N-5\)V%]=8^T2P@N0,
M98<$URMGJ&KV7@.3Q)+JMQ=74D7E1PNJF-"90@;&,EA[GF@#T;(]:-P]:\_M
MKS6[,7J*NM26AL99&N-22-6BF5<KL*]CSQCC JI!+KYC\.3?V_.6UM-DX,:%
M8?W>\&,=FP",G/)SCM0!Z7D>M!(QUKSN;7-6TRSO])-\9KE-6@T^"\E +JDR
MJVYN@+ ,?TJU=)J.FZJ^AR:S=W-M>V$TZ32%//A>,KGD+C:0W<=C0!W$3*8D
M(((*CD4_.:\ML+V_T3P#X>%G=W<KZFT,0 1':!-I9A$N!S@8&[.*ZCPG<ZJ;
MK4+:]CU!K*/RVM)[^-4E;.[>K8X."!@XZ&@#J<CUHR/6N2F;4M:\3:G:6^JR
MV$&G+$(Q"BMYCNI)+[@<J.!@8^M97B76[NR:_N++5KZ:ZT\ O!!: VR< E9&
M(.<C/1LC(H T_$O_ ",VD'_IJG_H8KKP17E'BBXU#4?B':64-^UK L-M*A2-
M2P9I".I[<#/TK7M_$DM]HNF?;=9DM+V5Y8FCL+7S7N&C8@LO#;5XR>._6FQ(
M] R/6H);NW@G@BEN(HY)B5B5W ,AZX4=SCTKA;3Q+JFJ6&C6,=R8+R]N[B":
MZ,0!"1;LD*> Q&WMQSQ6M>MJ-A?:):W%\MT\]U+'Y[6ZA@OEL5]L@CJ,9I#.
MI8@D<]Z=D>M>9:1_;EGX8UF_L]2:62UOIV$#PKB38X+'.,Y(!&.G-=3I>O/K
M?B-TLI%.G064<LAQRTDOS)@^R@G\10!TM1M<0I.D+2HLK@LB%AN8#J0.^,BI
M!TKE=6 _X6+H'//V2Z_'[E '4Y'K2YKSJSU_Q -&L]<GOK>2&2^%L]JMN!E#
M+Y>=V<[L_A6]X[6<^$KR2&Y:#8 S84'<,CCV]?PH WY;ZUANH+66=$GGW>4A
M/+[1DX^E/FNK>W56FGCB#L$4NP7<QZ 9ZD^E<1KEOJ:^)?#-O'J2&Y(N?](>
MW' VCD*#C..!V[TIUO4'TR6*[^S3W-EK,5F96A&)%++AMI^ZV&ZB@#NLBEKC
MK36;\^*YK'4+Y;,^<PMK1K7Y+B(#AEESRQ].W3'>NQH K6__ !]7?_71?_0%
MJS56W_X^KO\ ZZ+_ .@+5J@ HHHH **** "BBB@ /2@4'I0* "BBB@ HHHH
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MW?B72+"[:UN=0ACF3&\')"9Z;B.%SVSC-7-2U"'2]+N=0G.(;>(R-CN ,\4
M<Y?>$;N34+Z:SN; 07P42I=6?FM& FT",[@ .X!! )-=!IFF1:9I%KIJ$R0V
M\*P@R<E@!CFLO3M0\27D=K=RZ=8Q6T^"8?/;S8T/<_+@G';]:JZ)XRLYVFM=
M2O[>.]%]/;)'C;P)66,'L"0._6@#8@\.:+;&8P:/I\1G!67R[5%\P'J&P.>O
M>K]O;Q6MO'!!$D4,:A4CC4*J@=  .@K)CUD0ZCK"WM[8K:V0C? )#PJ5R3(3
MQSU&*1O%6E-I]Y=07D;BUCWNI!# '[IP1G!/0]* -.*QMH!,(;>&,3.9)0B
M;V/5FQU)[DTBZ?9K8?81:0"TV[/($8\O;Z;>F/:L7P=JM[K&AQWUY>VUS),J
M.4@A,8A)4$H<DYQD<U'IFM:[JUS<O;6FG+907CVQ,DSB0A#@G 4C]: -2V\.
M:-9PS0VVDV,,<Z[9DCMU D'HPQR/K38O#.AV\+0Q:/8)&Z&-U6W0!E.,@\<@
MX'Y"HH?$%O%;74^H7MC%'#<M!OCE)52.BL2!AO45+:^(](O;&XO;?4;:2VM_
M];('&(_KZ4 0:)HFF0Z&;>+3[5(;C/G1B)=LG)'S#'/XU+9>'='L)W-GI=G
MQA\LE(5!*DG(SCH?Z#TJ#P_KNF7NG%;6_@E,"%Y0K\JI).2/3WJ>R\1Z/?ZH
M;2UU.UFN&C#B-) 21U_D1^= $FI:6\WAZYTS3Q!;[[<V\09/D0%=HX'8#M4^
MD:='I.DVEA%C9;Q+&#ZX')_'K4!\1:0-4_LS^TK7[;NV^1Y@W;L9QCUJO#XC
MLX=-6[U.]L;</-)$K)-E"58C )QDX'(['- %TZ-IQW@V4!#W'VIOD',O'S_[
MW YJ9;&W6^>]$$8N7C$;2@?,5!) )],D_G6)K'B7R--T^]TJ:VN8KJ]BMRX.
M]=K$@XP>M7]=UM-"TTW;Q/,Q=8XHD^](['"J/J: )KK1M/O+Z"^N+.*2Z@_U
M<K#YEYSC/IGFE.CZ>;-;3['#]G63S1'MX#[MV[ZYY^M8L_B/5=*FLCK.EP06
MMU*L/G6]R9/)=ONAP5'!Z9&:R9O'P37M4C&H:8EAIR?ZIR?.N&VY.UMV!AL+
MT- '37OAC1M1NS=W>FV\TY #.R_? Z!O[WXYK2N+2"ZLY+2>%)+>1"CQL/E9
M2,$8]*Y+PYXJOM4MK">:YTF5;R4J4A<H\/R;O+P2V]QW^[QVKH4U_29-3.FI
MJ5JUZ"08!*-^1U&* +4ME;S63V<D2-;/&8FC(X*$8Q],5'#IEG;SQ3Q6T:2Q
M0B!& ^[&/X1[<"H$\0:3)J1TY-2M3>C@P"4;\^F/6G_VWIGVU++[?;_:G=HU
MA\P;BR\D8]10!6N?"^CW=M';S:?$8XI'DCVY5D9SEBK @C)ZX/-20>'-)M8$
M@@T^"*))_M*(BX EQC<!ZUJ9^7-8NF>(8;V'5)KCR[6*PO9+5G>0;3MQ\Q)Q
MC.[I0!=?2;*2ZGNI+:-YIX1!*S#.^,9PI'<<G\ZHV?A+1+!)D@T^,K-&8G$I
M,@\L\[ &)PO3@<4E]XITVW\/76KVMY;7,4*MMV2C#.!D+GU]JQ!XTN3/I]D+
MS0WN[H/(\BW!\N-0!A3WW$DC\* .@TSPUIFD3^=9P2*^W8I>>20*OHH9B ..
MU/U3P]IVLR02WL#/)!D1NDSQLH/7E2#46MZ[)I3V-O!:&ZO+V4QPQ^8(UR!N
M)+'.!@>AJM/XAO;2&P>]T];-[B^%K(LDP=0I5FWJPZCY>X'>@#2LM#TW3K*6
MSM+&"."7/FIMSYF1@[B>6R/7-5M.\+Z;I5P)K5)\JI6-)+F21(U/4*K,0H^@
MK2MK^TO+8W%M=030C.9(Y RC'7D5';ZI874,LUO?6TL,0)D=)594QUR0>* .
M8\-^ ;'3+#3FOX$EOK4[SME8Q>9DX<)]W=C^+&:TKKP5H5Y<74L]F6^TMOEC
M$SB,O_?V [=W ^;&>*UAJFGEG47UL61@C#S5^5B,@'GJ<'CVIG]M:7Y(F_M*
MS\HML#^>NTMZ9SUH ?!IUO;WES=Q)B>YV^:V2=VT8'TXK-'A+25-_B"01WRL
ML\7GOY9W'+$+G"DGJ1BM2ZU&QLE1KN\MX _W3+*J[OID\TZ6\M8$#S7,,:LI
M8,\@ ('4\]N10!$=-MFOX;TQ?OX8FBC;<>%."1CIV%4I_#&ESV36CVY\LSM<
M*RR,'21CDLK Y4Y/8UJPSQ7$2RP2I+&PRKHP8'Z$4LDL<,;22NJ(HR68X 'U
MH QE\*Z<-+N-/D^U7$-P5,K7%U)*[;2"/F8DCD=JO-I5LVJIJ10FZ2 VX;<<
M;"02,=.H'-2QZA936S7,=W;O O659 5'XYQ3HKRUGEDBAN89)(_OHC@E?J!T
MH S]&\.V6@B9;$W CE(_=R3NZ( 2<(I.%&6/ ILGAC3I?MVZ-_\ 39HYYL2'
METQM(]/NBDUKQ!#IBPB$Q7$SW<%N\0D&Y!(X7) R>];#R)&NYW51D#+'')X%
M %4:; -5.I8;[281 3N.-@.<8^M4-3\+V&JWZWLKW4,_E^4[6UR\7F)G.UMI
M&1G/YFM:*Y@GW>3-')M.UMC X/H<41W-O*[I'/$[I]Y5<$K]?2@"OI^EVVEZ
M=%86B%+>)2J*6)P,YZ_C5>/P]I\6@'1!"7L2A3RW8G@DGKUZFIM1U>UT_3KJ
MZ,L;F"%IO+5QE@!_7I4.E:G<7>F+>7\,%INPP"S[QM(!Y) P>>E $%MX8M[>
M.6-[W4;A)(&MRMQ=,X"'K@>ON>?>IE\/V*KI:A9,:9_Q[?.>/D*<^O!K461&
M0.KJ5/0@\&F^?$5WB5-O/.X8XZT 95WX9TZ^2_2>)F%](DLQ$A4AT4*K*1RI
M 4<CN*;8>&;.PNIKPRW-W=RQ"%I[N4R-Y?\ ='8#Z#GO6OY\/R?O4^?E?F'S
M?3UIY( ))XH YFV\%:;'HJZ<TEX\*E'AW7#$V[+D@Q'^#&3TK7TS2AIIF;[9
M>W3RXW-<SE\8S]T=%Z]@,U;AFC>!&612I  (/%2;AG&1GKC- &'J'A>UU"_D
MO1<WMK--&(YC:7!B\U1TW8[C)P1@\]:KW?@G3KP7:-->QV]V0T]O%<%4=@H7
M<>^< =\''(-:6M:Q'I&B7NI*JS_98RYC5P,X[9[5<M+I+JWCE! +J&*YR1D9
MH \Q\4>'I)_B):3M)<06\D%O;QS0S!7)#D,/7H1R1UZ5V;>#=/1=/^QRW-B]
MA&T4,EM( =C?>#9!!R><GG-9WB<@>)M()P )8\G_ (&*WM/UD7^IZI9B(Q_8
M)DB+ELA]R!L^W7%-B117P9IT>FP6<,ES$;>X:Y@G67,L<C9R0S YSD]<YJQ%
MX=A22S:6[O+F6VG:X62>7<6<J5.>,8P>@ %;$LJQ(S,P 49)/85FR:S#]DL[
MNUBFO(;J1$5K=,[58_?.>BCO2&0VN@0Z9=75Q;37!BN9&D:T)7RM[8R1QD$X
M]<<FLWPGX9.F^%IK.:.6SN+PR&3RY<R1 Y" .,\JNT ^U=2[#*@D9)Z4_*@]
M1S0!':P?9;2&W\R27RD5/,E;<[8&,L>Y/<U3NM'@NM9LM49Y!/:)(B*"-I#X
MSD8SV'<5HYI 01D$$4 82^%+%=#CTD23_9X[@7 ;<-VX2>9UQC&?;I6CJFF0
MZOIEQ87!<13IM9D.&'N/>KF1ZBL[5=7CTI;9G1I!/<QVX"D<%S@$^U $$?A]
M!=Z?=SWMU<SV(D$;RE/FW@ [@% XQQC%13>%;.9;I3-< 7-ZEZ^&7AUVX XZ
M?*/\:T-7U--)L?M4D;2+YD<>U<9^9@N>?K5T$$=: ,*7PR+F_@GNM2O;B&WN
M/M,5O(R;$D&<<A=Q R< FMZDR/6ER/6@"M;_ /'S=_\ 71?_ $!:LU5MS_I5
MW_UT7_T!:M4 %%%% !1110 4444 !Z4"@]*!0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :XNUCUO
M0-5U.UMM(-]!>WAN8;D3(B1[@-PDR=V1@XP#FNTI,#TH \OUS1_$>HKJ=K/I
M][=3M=B2WN!>!;980P(41[A\V!SE>O.:O37NIVGC+Q2EAI$NH&:*V0>7(B^6
MWE'!8,1\ON,GCI7H6!Z5$EI;17,UPD$:S3;?-D"\O@8&3WP* //ET76]%LM&
MT[[/?7]C!9LDD>GW*P?OR<Y<EE)0 G&#^%+9Z3K&CVWA[4%TR2YDL%N8KBTC
ME4R!9&R&4L0&Z#J1P:]$!0D@$9';TI<#TH Y$6^IZAXHT'59].>U2*"Z69&D
M5C%NV[,X/4X/3('K6=I^D7=QX,U#PYJ&GS6C0"5XKQV3RV?S&=&0ALC!VGD"
MN_P/2F3P1W$$D,R!XI%*NI'!!Z@T <'H&KRV'A&^\77ML9;S49!(D ;!<<1Q
MHI]\9'^]7:7EI'JFE36MS'B.XA*2(>2,C!%2K96J6\,"VT0AAQY2;!A,=,#M
MBIL#&.U 'F.AZ+?^(/#^NK<RK]I^RG1[>4DG(CR&;/\ M,>?I6B(]5UY] LI
MM#N=.73;B.XN)I2FP&-2 J8)+!B?RKM[.RMK"U2VM(4AA3.U$& ,G)_4DU/@
M>E 'EKV&MV?A[5/#L.A7,[RWTDRW2N@B,;2;@1SG/;&*[KQ)IK:MX:O;%5_>
MR0GR_:0<J?\ OH"M? ]*,K0!Y)<>'/$=Q9QZDMI)'J.K23P7Z?+F&&550$G/
M(4(#_P "-=5J&D7":_(;6T8VJ:%+:QE0,;]PVI]<"NQXQFCY: .*T32KZVUW
MP]-);2)%;Z']GE9L?))E/E/OP?RK6O[.XD\;:5=K"6MXK6='DQPK$I@?7@UO
M@CM1Q0!YW?:7+;>(-<^V6FLS6NH,KQ'3G^60; I1P#P>.IXP>M$DZZ%XSTA8
M-,O98(]$\ORHP))8EWC&1GYL< XS7HFT>@JJ=.MFU-=0,(^U+$81)DY"$Y(Q
MTZ@4 >?V&D:IID6F:Q/ILT@74;FZFLHP&DA24$*0,\D<$@<\FGZEIE]K">(]
M233;B*.[2VA@@ECQ)+Y;9+E>W7 SS@5Z/@>E+@>E '*^*8KB.YT*]AM)KF*R
MO-\R0)N8*49<A1R<$CI5SQ/#/JW@S48;2%S//:-Y<3#:V2,@8/0]JW<#THP/
M2@#@IY;E[[PYKG]F7S6U@LMO<0-;L)8V=% D5.K $%21ZUJ>&H;FXU[6M8>V
MGM;:[>-(8ITV,^Q<&0J>1G..>>*ZG ]*7% ')0/-8>/=2\VTN6BOX(/)F2(M
M'E P8,PX7&1U]:QK;2[J+P!HD$EE)'<QZG%))&8R&7_2"23Z<'KZ5Z*0!SBH
M;G!1?^NB?^A"@#S2;3)(K[Q!IVIMK<=O?W,DJ)96HECN8W4?Q;&(8=.2.@KM
M?$&C'5?!MUI$3D/);".-I#SN&"N?Q S6Y@>E+C- '*Z5XIFEAL[.70M52^)2
M.=&M]J1=BY<_*5XSP2?:L>?2KS_A!=5@6RE-R^JR3)&(SN8?:MP8#K]WG/I7
MH.!Z48'I0!YEXCT74[S4/%<EK;3LKR:?*@5!^^6/EPF>&(ZXYYXJ_9V<-]=7
ME\ESKEY=C3Y8 UY:>4H!P=GW%RV>W-=]Q1@'L* ,?PM#+;^$M&@GC:.:.QA1
MT<8*L$ ((/?-8_ACP_$);^\N8;J&<:E-)&/.EC4KNRIV A2/J.:[# ]*7% '
MF\FFW$EM*K64LBOXF$NUHS@1[Q\V".5]^E:&K&^L=6\17>GV'G2FPMS&#$65
MW#.#Q_$0.<>U=O@>E!QTH \LT%;FZUB:X$U_>(=&FC,T]KY2[]^=B_*,]>^>
MO6K=KI\D.C>"0EHZ2PW$)D C(,8*/N) '&3C/O7=:3M&EPYQ_%_Z$:MJ!Y[_
M .ZO\S0!Q/AB[ATZ!M&O[2ZDU+^T)7;-J[*Y:4L)=Y&W&"#G.>*S8+J^TW1=
M.C5)+*.34+[SKW[$T[P#S7*[5P<;^F<=/K7I>!Z48'H* /*;>VNWT"3]S=R%
M_$XF!E@*,R$J=Y7 P#R>@ZUU_C:TN9]*M+FTMY+F6QO(;KR(_O2*K<@#N<$G
M\*Z? ]*"!WH X3Q!JD?BZ"RTG28;MR]U'+<R26TD2PQHVXY+ 9/0 #--:WF,
MWCPB"7][$OE_(?G_ '!^[Z\^E=[\I]*7 ]* //;:UN?L?@+,,F86_>Y4Y3]P
MPY]/QI_A&>&STF/1;RWFCUI;F8N6MF/[PLQ\W=C&"#US[5W^!Z4F!Z"@#R30
M]/9['2M-U'6;JVN;:^67[$-.RXE63.[?MSM;.=QXP376>%[-8_$'B>YFM0KM
M? I*Z8)78.A/;KTKK\#T%17-O'<VTEO(N8Y%*, 2N01@\CD4 4K?7+&YT;^U
M8VD-IACN\MB< X)P!D].U>=30W-WH%W>QB:.RE\1/=&0VQ?,. !(8R,LH;!Z
M=LUZC:6L%E:16MO$L<,2!$1>B@< 5-A>F!0!YE/917&E^)K^/61JL\UAM<16
M?EIN4'##&0SXXXYX%;<EE"WBOP[_ *(FS[#-N'E\9PF,\=:[(*H' &*,#TH
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M>];= !1110 4444 %%%%  >AI!2GI2"@!:*** "BBB@ HHHH **** "BBB@
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M]:NO:7-JND&TA=%D,T,F7Z8217/Z+3/[(G_X2R35M\?DM8BV"\[MV\MGZ<T
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M83,%0?=5'4.A/<@\DB@#MO\ A,)7O+:R@T:YGO+BS%XL:2)M5"Q W,3@=OS
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MNG\'W5[.NHKJ=M=6]ZUR97CE1O+12 %$;GAAA>W<F@#J:*** "BBB@"M;_\
M'U=_]=%_] 6K-5K?_CZN_P#KHO\ Z M6: "BBB@ HHHH ****  ]*!0>E H
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M0 8Q2;1G..:6B@!,#TH(&*6D- #8_P#5)]!3P .E,B_U2?[HI] "8%&T4M%
M''>)A_Q4VC^GFQ_^ABNPP,=*Y#Q+_P C-I'_ %UC_P#0Q784Q(3:*;@;Q]#3
MZ;_&/QI#$<#CZBG8![4C]OK3J ,_4=&LM4,+7,<@D@):*2*5HW0D8.&4@\BG
M:;I%EI2S?98W#3/OEDDD:1W.,<LQ)/%7J* $P*,"EHH **** "BBB@"M;_\
M'U=_]=%_] 6K-5K?_CZN_P#KHO\ Z M6: "BBB@ HHHH ****  ]*!0>E H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JE/I=K<:G:ZA)&3<VJNL+[C\H8 -Q^%7:* *4>F6T>J3:
MBJ$7,T2Q.V[JJDD#'XFLU_"&FM=R7$9NX/-?S)(;>ZDCB=O4HI )/?UK?HH
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MZU5TG_D&0_C_ #-6A_KF_P!T?UH ?1110 4444 %%%% !1110 4444 %%%%
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MSXITZ\TWP]/HL<+.;V601QB92N NV-SNYYR>G:@#O!THH'2B@ HHHH ****
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M@BC5V<(H9OO,!R:=@4M% ";11@4M% ";12XHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *AN?N+_UT3_T(5-4-S]Q?^NB?^A"@":BBB@ HHHH **** "BB
MB@ H-%!Z4 4=(_Y!D/\ P+^9JV/]<W^Z/ZU5TG_D&0_C_,U:'^N;_=']: 'T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !0:** &Q_ZM?H*=38_]4GT%.H ****
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M_75/_1@KL*X_Q+_R,ND?]=4_]#%=@.E,2"D_B%+2?Q"D,1^H^HIU-;J/K3J
M"BBB@ HHHH **** "BBB@"K;_P#'U=_]=%_] 6K55K?_ (^KO_KHO_H"U9H
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MT31HY5LJS(?F7KR*OZQJ6JP6'B+1=5FM[EAI$MU%/#$8^,,I4KD]^A]*U?\
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MRJ;*.VD\R*-C@-YF2"1P3QCK3;KQOJ!.H7MF]LUO9W+0)8_9Y&FN I 8A@<
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MILV@L+PR#2H9XN4YD\S;SUXQM_'-:NAZ0VD'4B9A+]LO9+L?+C9N ^7WZ=:
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M ./F[_ZZ+_Z M6: "BBB@ HHHH **** $/2E%(>AI10 4444 %%%% !1110
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MK?<,Y4KC.-I':K-S;:EK.H>(RIT\7-O=-%%/=WTD4EHH52C(JH0!SG.>><T
M>IDXI-WM7-^(Y+F+X?:@\LP:Y73V+2Q$@%]G)4^F:YJV73]/UOPO/I-[--)=
MQ2-=XG:3SHQ'DNV3U#8Q]: /2=PIKS+&C.YVJH))/85Y=977_$Y\.:C96J6=
MK?W3*KO?O+//&5;F1", 9Q_$<&M+1]'M-3LO$%[>-<3S)=W42;IW 1/0 '%
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MLDK2S-M.]64  DX[GC&: +]IH.EV)MVMK..-K=72)AU4,<L,^YYIQT33<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 AKSB707MI]3T^_T#5=3AO;J25)+2^*0NCG.'7S%VD?0YKTBD9@JEB<
M 4 <Q!IEU%XAUJ5;9EMI;""&%BV=S*),CKGC(ZUF6^C:@GA_P? ]I()K*ZB>
MX7C,8"L"3^)'2NY#9Z4I&10!Y?&^JWFE^)-%M-&FG%]J=U''=AT\J/,F&+Y.
MY=HY& <U?U;POJ=XNO6EO'_K=,M(()7.%D>-G)7\>!_P*NZM;&WLA*+:)8Q+
M(TKA1]YV.23[FK% '%1C4/$/B31[N;1+G3;731*\K7>P,[NFP*@5CD<Y)..U
M9WA/2[F/Q7<6<A#:=H7FQ6AX/S2G</\ OE#MQ[UZ,1D55M-/MK$SFVB6,SRM
M-*1_&YZD_D* .#BT#45\"Z98FQD-Q#JPF>/ RL?VAFW?3:0:N>(O#^H:M?\
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MBFZ'HVI0V_A+S[&Y3[->W4DRRIS$K;]N[''<<^]>ET=J ///&EE<1:[!'9*
M-?A_LZX(ZJ00?,]\)Y@KL;ZT$7ARXM+6,D):M%&BCDX7  J6?2K2YU&VOYHR
MUS:AA"Q8X3<,'C.,X[XJZ.!0!P^B:;>1>(]#GGLIE2'0A"[NF DFY?E/H<9K
M)L]-U'3H-.OI=,NI8++6;R22V2%BXC=F"2*@Y(&<\>O%>G44 <==M-K.N^'+
MR/2[R*WANYRYN+<H0/*8*Y!Y4$XQG!JCJ5K>V'C/5+N2;5H[2^MX1%+8V8N
M-@(*,-C%>3D8 !W&N_HH X"1M2TJ+2-/LAJMKI26.?.BL//N"X(Q&XVL$X]O
M;C%9^GVLUGX6TI[B/6+#5+<W!AN([%IBFZ1ODDC (PPP>@'H17I^*0C- 'F0
M37$URWUC5/M^GFZTR.-WL[03^7(&):-E*,5SD'IUXI;ZS@TK2--FL)-9M[Z
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MW0THI&^Z:44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[/3)5FA$$3(\SJ"%9R20,9Z#K^E.D\)S/X6U#1Q=('NKIYUEVG"AI0^"/TH
MV=8U>#1=)FU"<.\<8&%099R2  /<DBLB/Q+JL6H16&HZ*EM<7<3O9[+OS$D9
M1G8[;1L./0$=:T]>T8:WH4VG&9H6<*4E SM92"#COR!6;::-K5UK%K?ZW=63
M"R5U@BM(V 9F&"[%CUQV''O0!F?#:*XN-,EU2ZM4$]R[[KO[0TCS8D;(*D#
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MU"5P" ZG?P!Z_,*ZO4;5[W2;NUC95>:%XU9N@)&,F@#F4\:WA_L\OH5P%U-
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M:CXHTK3+U;*>69KEXA,D4-N\K,A)&1M!]#6%=Z+?/HGC*)+9FFOY9#;+D?O
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M:=36ZCZTZ@ HHHH **** "BBB@ HHHH JV__ !]7?_71?_0%JU5:W_X^KO\
MZZ+_ .@+5F@ HHHH **** "BBB@!#T-**1ONFE% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI/XJ6D_B'XTAB-U'UIU-;J/K3J "BBB@ HHHH **** "BBB@"K;_ /'U=_\
M71?_ $!:M55M_P#CZN_^NB_^@+5J@ HHHH **** "BBB@!&Z'Z4HI&Z&EH *
M*** "BBB@ HHHH ***H:UJ*Z1H]UJ+QF1;>,R% <;L=J +]%<9IOCTW-]IEO
M>Z/<V2:HNZTF,J2*_&1G!R/RKII-8TV&[%I+?VR7)P!"TRASGIQG- %VBJ5Q
MJ^FVC.MS?VL+1XWB255*YZ9R>,U+]OL\P#[5#F<9A&\?O/\ =]?PH L455_M
M*R'G_P"EP?Z.<3?O!^[_ -[T_&DCU2PFM_M$5[;O!NV^8LH*Y],YQF@"W10#
MD<44 %%!HH **** "BBB@ HHHH **** "BBB@ HI&Z5SI\86"Z+?:E)'<H+*
M9H)K<J/-$@. H ."3D8Y[B@#HZ*BAE$D*.RM&7 .Q\;AQT..]2;A0 M%)N!Z
M&DWB@!U%5-1O38V,MPEK<7;( 1!;J#(_(' ) [YZ]JR=0\41Z=)JR/:R,=.M
M$NFP0-ZMNX'O\IH Z&BJ&HZDNGZ-<ZBT;,L$+3% <$@#.*GL[I;NR@N5!42Q
MK( >H!&?ZT 6**3<*,C% "T50UC4TTC2+K49(WDCMXS(RIC) ],TMMJ(GOI+
M;[-<*$B603,G[MMW8-W(QR* +U%0W5P+:TFGV22>6A?9&NYFP,X [FLZ'78I
MM6MM.\BXCEN+,W8\Q=NT @;6'4-ST]J ->BLS5-8BTN6P26.1_METMLI3'RL
MP)!/MQ6B"* '45#=7=O96TES=3)#!&NYY'.%4>I-/65&4,K J1D$=,4 /HI
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MK39!);Y?G(##GUX8T <Q/XAU;2;3Q!:O=&]GL;BVB@N)(5WD3[>JJ "5W<8
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% "-TK)_X272_[&;5?M/\
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M)CF5'[,<# !.>X%9.AZ&T%A8:+JO]OM<6UPK>7%&OV?*OD2!]OW>Y^;/)XH
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M\I+9 OF;&QGYB N00>3@5<U#Q;Y1F2+2KR=K-8Y;T1E/]'SAMIRWS-CG"YH
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M@DMWB/G+*<83;W8Y&,>M4-(\12ZMXX:V1;NWMTT_?):W,6QDD\S&<?3'()%
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M%J'C235K^SM+FU%DD,0F0.R2!V.0"..#UKH'O+9+N*T>9%N)59HXR?F8+C)
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ME>HS@G!YKT?%)@>E $<R[K211U*$?I7GT%O<W7@[P]IQTZ[\^PO+1+E);=@
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MPW]B(Y$N'+);M$_\3#)((P>,^G-06.AZIJ^F6EQ>W<]GJ%E/(UE.\,?F>4>
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MS2:5K5GJ&H&YDU63S9)4B\O8VQ5&!D\#:"/Z]:<O@R,>&!I+WKFX$_VO[8$
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MI<\MHL,;K,ACX#$CS"3)G9QV&>#QTJ[HOB1-=E5[73[Q;-P_E7CA!')M;:<
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M HHHH 0]#2TC=#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCF29E>:W6.39EQR00.O7W[T >H9'K1D>M</+HUM<^-?[*>6[^P6^D(R0+=2
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M^"R:YM8$DNYIB_EAFSA% YZ#.<\5H^']:&MZ:+@Q>5-'(\,T8.0LBG! /<4
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M].LOL@EM9UW3S;L&)=ZH&QW&6&?K0!JR^'='GNY+N72[1[B3[\C1*2WN>.O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\<#'.Y@,?2M/6[S4!<SV1%U;VXL4$0M]/,[73$$%2Q4A<<#!QUSFN_P!1@4
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MW^FK8>)/"\>EVH@S:7<3&%-H \I2H8C_ &O7O7>8!HPIH \YT*:S/A.+2[:
MKXFALYAAX#YL=QL;<Y8CC<Q."3SFJ_AF*TN#X?MFU2*.\L=K&S2Q9)E<1D.K
MMD^IR2.:].P/2C '% 'E%Q8Q1_#O7[Q+4"]_M:61)1'^\R+D;2#UZ5T44EG8
M_$J_6ZC5'N[6 VI:/[[ OG:?7UKM=H]*,#TH \QC#:7H&D>(DB=OL%]<K.JI
M\S0R2NI_([34%]IU[9Z;X>NYI(X8Y[F6\OYIX6EC2:090NF1P,[1V! KU7 ]
M*-HQC% ''> +6**SOYX=0M[L3W&]UMH/*C1P #CD@DX!..]9MIH]WJ_BWQ;
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M]C;V\,.E:C*LQCE+I)A&4R(Q&7RS9R>IS0 :'XODL++4WO[74KFW@U*9)+L
M.D*;\*.6R0/]D'%:,.NK8>*?$\U[=2_8+.UM)%4DLJ;@^=J^IXZ=>*R_^$<\
M3+H^JZ(+:Q-MJ5W+)]I\\YBC=R6RN.6QC&/7M5S4O!U[J$_B15:%([^"T6V9
MFZM#DX;'09Q^9H WK#Q'%=Z@EC<65W8W$L7G0I<A?WJ#J1M8\CC(.#STJEJ_
MB*_L/%.GZ;!IDMQ;SPRR,4V;G*[?NDN  ,\Y'<8IFB:-)#JD%U-H%K9O#&RF
M<71E;<<9"#'W3[D'IQ4VNZ=J3>(])U?3X(KE;6.:&6%Y?+.'"X93C'!7F@!U
M[XNM[.:[6/3[ZZALN+N>!%*0G )!RP)(!!.T'%:YU&W.E'4D;S+<0F8,G.Y<
M9X_"N5_L?7M,BUVQL+2VN8=2N);B&X>?9Y32CY@ZXR0#R,9R.*UGTY='\"RZ
M<KEEMK!H@W<X0C- $%EXULKV:P!L[V"#4#MM;B:,!)&QG;P20>#C( ..,U8;
MQ3%%>PPW&G7\$,T_V>.ZDC C:0D@#&=PSC@E<5S6CZ;K6MZ7X7CN;:V@L[ Q
M7;3K)N,H5/D55QD'GG/IQ3#X8UR>\M'N[<S7,.I)<S7DE\S(\0DR D708&.,
M#IWH V]*\4P,\FG6]A?W$MJS+,\40V(<%AR2.O05G6OBR?4?#+ZA<K=:<RM'
MNGB@#*W[TKA06.>@!],UJ^#M-N;)=6FG "7=XTL)#9)7:%Y].0:PHO#^MMX2
MF\/O:(LD,D9283*5E7SF8GU'RXZT =/<^*+2WU&>QCMKRZDM@IN6MX2RPAAD
M;O7CG"Y.*K?\)-9Z<^KSWEY*\%K=1PL#" (B^W &.6'S YJM!::QHFMZL]KI
MR7D&H3+-%*)E3RVV@,),\XXXQG\*R-?TV_L8-9N1'$'O-9L7M=[?*^'C W8Y
M R* .HL?%=E>W,ULT%W;3Q0_:!%<0%6>/^\HYS].OM38?%MK-<M:M97\-SY#
M7$4,T!5ID'7;ZGD<'!K(EL?$.JZK<:I':1Z;/!8/;6HED5RTK$$ME<@+QQWY
MZ"J^AZ'J2Z_IM]/97L2002I/)>WWGNTC ?,%W, .O3!]A0!J:)XUBOO#K:KJ
M%K-9I$I+N8R8V^<J AZL> ,#N:U=-\06NIW4MFL5Q;W42"1H+F(H^P\!@.XR
M"*XU/#>L3^"TT*2Q:*?3[D3QR>>JI<@2,V%93N4X/4@8-=!X?L$74I;U]&U&
MSF$/D^;?7YN&8;L[0/,? SSGB@"W<:JEMXF^QO=,%%@UR;<0]@V-^_\ 3;^-
M,TWQCIFIW%K# +E5N@3;RRP,B2D#)4,1R0,_E534M*O9_&$U[';EK9M'DM@^
MX<R%\A<9ST[]*9'I-\ECX1C-N0]BRFY&Y?W>(67UYY('&: -#Q+XB;0$L"MI
M)<?:KI(6V(QV@]<8'+>@[\UEW?B?[#XHA$WVPVT^GF1+18&:3>'Y)4#((&>M
M:'BRTO+JRL9;&W-R]K?0W+PJP#.BDY"EB!GZD4EI:WD_BU=6EM)(('TT1E96
M4LC[\[3M8C./3CWH L-XKTM=.M+U)9)DO,BVCBB9I)2.H"XSD8YSC'>KNE:O
M::Q;236C/^[D,4J2(4:-QU5@>017"3>&-4%IHMPUK='[%/>>=!9W0AG*ROE2
MK!@.P)&X<'\*ZCPGI<6G6UW(EC?VLMQ/OD^W7 FED(  8D,P_7M0!GV7B>^;
MQU=Z3<QP?8#*T%NZ AQ(L:R$-S@Y#'MVI-3\67L/C.STFSA@:S-PEO=2N"6W
MNCN%7! & H)R#]X54U/PYJ%U'KMS;P!;U-2BOM/+,,.41 1UXSAEYQ3K?P_J
M45MX>DFB\V\_M1K[4&#+A"T;@_7&57C-  _BS56TC5;A$M%GM]6^P0%XF*;-
MZKEAO!)Y[$5K:5JVIKXDET/53:33"V%U'/:1-&NW<5*LK,V#GWYK D\.ZI-H
M6JVDEF^;C6_M"J) "T/F*2P(;CC)ZYKL=*T+3]',K64!5YB#)+)(TCOCIEF)
M)'MF@#'U3Q,FD>,UL[R=ELWT\2I&D32,TF]@<!03]T5I-XHTA=,M]1^UAK:Y
M;9"R1LS2'G@*!NSP>,=JRM4-]I_C<:I'I5U>69TX6Y:WVEE?S"W0L">WYUA6
M_A_5["RT:\EM[H-%/>27$%DZ&6(3-E<9X..AQSSQF@#LQXGTAM+;4OM8%JLO
MDL3&P829V[-F-V[/&,9K-OO&6GS:5?3Z??Q0R6;1B9[RTFV1[F P1A3D^W3(
MS7-:O8A+:UFLK748K^\U:*8?:BGG2,B'YD7.T8'4/CC/?%%]9W=]X;U_3Q::
MA+K4MQ;7$\<RQ*74R*%*"-F4#;$W!.>#ZT =EJ/B_1-)NI+6]O1'/& 701.Q
M4$9R=H/'OT%27OBK1M.\C[3>HOVB+SH0JLQD7CE< YZC@<U2CL;C^VO$TK6S
M;+F"%86('[PB-@0/Q-9>CZ7?PZOX4DFLY%2TT7R9V8#$<FU!M/OP: -N;Q%;
M7-EIUYI]_:BWN;M8=TL;G?DD%% P5;(_BX]:2X\:^'K.Y>VGU*-)8Y#%(-C$
M1MG'S$#"\]S@5@-I-_MA"6<FU?$QN< =(<GY_I2'2+]O#_CB(V4AFO+F=K=2
MO,JF-0I'MD'% '3ZIXITC1I!'?W@B8IYF C/M7ID[0<#W-3RZW9QZ*^K*Y:U
M5-X;8P)_#&>OM7G]X=1EU;5+:TBNWB^P6]O>?9(XI&3Y22I\QUPV">@;@_2N
M]T][:]\,6_\ 9I;[/):A8"X((7;@9S0!S3^/8KSP]8ZG:E+=WO+:*Z2525B1
MWP?F( / /(Z5TNF^(M*UB.>2PO(YE@QYO!78#R"<@<<=:XFVM[NX\%Z'I,NE
M7J3V-_:"Y22W8*5$GS$'HR@<DCCFK?B#1=1O]:\1I9P,HN](2*-R-J2.&;*9
MZ9QQ^- '5:9XETC6+E[>PO8YI44,5 (RO3(R/F''49K(\6^*H]&N["PCOK>U
MGN7)DEGB,@BC )W8!')( Z]ZIZ!;I=:OI<MP->-U90NH2ZM%CAAW* R[@B[A
MQ@8)' K3\0VMQ-XI\+S102/%!<3-*ZJ2$!B(!8]N: )[37%@@OIM3OK#RK61
M8S)"6&"57A@>A)/ &>HJPOB?1CI3:I_:$'V)6V-,6P WIZY]JY>>PB/_  D#
MZC;ZC%$VIQS0SVL#,Z%47$B@*<J"#V(JM+<:K.FC:QJ5I/<6=AJ,K,PM625X
MBF(YS%C.02>,>^* .ND\6Z%%ID6HOJ=N+25BD<F[[S#J .N>.E07_B&-K'3;
MS2YH+B"[O8K<R<L-K$@XP1S_ )Q67JNO3M_9MW:6]U::=-+()[O[ SS)P-I5
M-I8!CQDKVZ5D:9:78TY=UK>#/B59@)HMK^62#N( P/?  H ]#FO;>UE@AFF1
M)+ABL2L<%R!D@?@#44FKV$4ES%)=PH]K&)9U9P/+4YP6] <&LGQK8R7?A]KF
MW -UI\B7T&?[T9W8_$;A^-<E-:7>I^&(]?,$N^\U6._N5A0.ZVZ95,*<[L*J
MMCGOQ0!WNGZ_I6HZ:U[9W]O-;1C]Y*L@VIQW]*++Q%I&HVUQ<V6HVT\%MDS.
MD@(C &23Z=#^5<9!-']DUK6],DO=4O3;11R17-@T<3;2<'9L4N5&3@=JJ>;/
MJ4FOW$<MW=K)H,D:RO8M;J[_ #_(JD G&>.O6@#T2RUBPU&6>*RNX;AX"!*L
M;9V$],U@V?BAM3\77.FVU]IRVUL=IB(+33';EBIW   \'@]*U_#EK':>'--C
MC@6'%K$"H7!!VC.?Q)KG)[*ZN#XSCM(6%Q,H6 XV[CY('RD^_% %?6M9TW4/
M%^FP6=];SRPS(LB1RABIWCJ*OIXIO7_LXB* _:=7DL7^5OE1=_(Y^]\H]O:N
M/U"[L-1\0^$+?2[6:)K2:+S(VMGB\@ @$$L .>G&:VH(+@G1?W$H(\07+M\I
M&%Q+S[#FF)'<2:SIT.H1V$E];+>2#Y8#*-Y_"I?MMMNE/GQ8@SYIWC]WP#\W
MIQSS7FMR]JOA#5M#N+&1]>GGE'E^0S--(SDI(&QC &/FSQBK&O:??KKJ:.J.
M\6N0VZW4J@@ QD"4DCIE!BD,] NKV..%61XFD<%HE9P/,P,\'T]ZAM=6C;38
M+F]DM;>1XO-=5N%95'<AN,@9ZUP7AR#4;QIC?QR@:-8R6$1D4C>Y9LL,]?D2
M/GWJ;0=-AO)/!J7EF)$ATB5@DL>0K@Q8R#WZT >@F^MA:_:C<0BWQN\TN-N/
M7/2DMK^UO-WV:YAF"XSY4@;&?I7E-PTME86Z1P*R0^(;KRH94=XL#<5!1%+8
MYR, X/-=AX"^QFQU":*6W:ZGNFFN(H87B$)8#"A756QCG) SDT ;<.OV%S>7
M=G#.AN+8X92P^8[<\<\^]0^'-?CUS1;&[D,45S<0B4P*^2H^G7%8EBNFVOC/
M7()8H(KN4I); Q@,P\OYBIQZ@YK TK2K6V\)^#;R&TCBNVOH3),B8<[MV[)Q
MGTZT >FM>0).L#S1K,XRL9<!F^@ZU/7DL\-O,^M6FJ:AIUC>RWCN7N+9S<XS
MF-HFW#. !@*#Z5ZO$"L**S;F"@%B.OO0 ^BBB@"M;_\ 'S=_]=%_] 6K-5;?
M_CZN_P#KHO\ Z M6J "BBB@ HHHH **** $/0TM(>AI: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 5;?_CZN_\ KHO_ * M6JK6_P#Q]7?_ %T7_P! 6K- !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ H-%!H ;'_ *M?H*=38_\ 5K]!3J "BBB@#C_$O_(RZ1_UU3_T
M,5V%<?XD_P"1GTC_ *Z)_P"ABNP'2F)!3?XA^-.IO\8_&D,&ZCZBG4UNH^M.
MH **** "BBB@ HHHH **** *UO\ \?5W_P!=%_\ 0%JS5:W_ ./J[_ZZ+_Z
MM6: "BBB@ HHHH **** $/2EI#TI: "BBB@ HHHH **** "L#QEKK^'/#-UJ
M42*\R;5C5^FXD#GZ<G\*WZQ?%6@CQ+X>N=,\WRFEP4?&0K Y&1Z<8_&@#C-8
M7Q;X7T*/7YO$#7CQ-&US9R0(L>&(! (YZD"MV;Q];1ZP-*MM+O[JX,<4H\E
M0$< ECZ!01GZUEW^A^,_$>EQ:'JBZ=:60*_:+J"5G:4+R %XQD@'FMC3/#MW
M8^/=1U7RXEL)K2."':W(*[1C'8?+0!G:1XMMM/T[6KV]O+V[$6I-;112(NXO
MVCC ZCTS5X?$"SBLM1DO=/O+.[L(UEELY0I<HQ !4@[2,GUKG;GP!JUSH.I0
M,MO]I.L-J%O&TAV2K@C:Q'(R&-2'P;?W.B:Q#'X=L-.NKB!8HBEZTK2'>"<D
MC '% &W8_$2RO;]+;^S=1A$\+36CR0X%R%&2$'7/IZ_C57PIX\GU?3+FZO\
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MIH&B,CLP(4!@"=N"<XQS6;HR7^N:7K6I7D9-U9:<^DQJO.Z1%)D8?[Q('X4
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M< *2O(P35,^-+Z/23K4FC(FEQ3>5*_VC,@&_9O5-N"H/J0?:@#M<48KE=?\
M%%YH"3W<]E:M8PD?\O>)Y%) +(FW! STSG@U+>^(K^/7+K2]/TI;I[>!)WDD
MN/+7!SQ]T\\<=O<4 =+BC KF],\5Q:E=Z;&+9HH-1LC=02.W.X$;D(]0"#G/
MK6AH>K#7-,%_'%Y<+R.L1+;MZ*Q4-]#C- &I@&EKFCXBO;?4[.VO=+2"*[F,
M,;"Z#NIP2"R < X[$XJ]KNMC1X+<);275U=3+!! A WN03R3T  ))H UMHHV
MBN&\2ZGJ*Q:/+/ILD5RFK1H((9PPF&QL8;CC/J!TK6L?$ES=G4K9]*=-2L"@
M:U696#AQE2'X&/7TQWH V'TNTDU2+4GB)NXHS$CEC\JGD@#ISZU;VBN8_P"$
MJFMUU6/4---O<V%D;T1K.'$L>&Z-@8.5QT[BFV'BV6YU#3X+O2)[.#4D9K29
MY%;=M7>0P'W<C)'TH ZK&12;1[US6F^*)M3(NH-*D_LEGD07AF4<+G+E.NW(
M/.<^U0VOC(SMIT\VES0:=J4HAM;EI5+%CG;N3JH.#CD]J .K Q05!KG?%NK:
MEI-O9/I]NDIENHXG+.%X9@-O/KG&>U-N/$=Y'>0Z=!I#SZDT'VB:$3JL<"YP
M,OCDDC@8H Z/:,=Z7:*S="UF'7-/-U#')$R2-#+%(!NCD4X93BL ^-W<PS6V
MCSRV4]Y]CAN&F5-[Y()VGD#*D ]Z .ETK2;71M.BL+-66"+.T,V3R23S]35S
M KEKOQDMLUW/'IMQ/IUC*8;J[5U 5@0&VJ>6"D\GV.,T0>(=0G\87&G1V#2V
M2P0R+(&4;0S,"YYY4@# QG@T =04!&.:IZ5I-KHVGI96@<1*S-EVW,Q8DDD]
MSDUD^(=<O=)U'2(+:RDN([J<QR;-N6&QB%7+#!R <], ]Z+KQ2T=^]C::/?7
MES#$LMPL10"$-R%)+ %L=A^= '1%145PHV+_ +Z?^A"J^F:M;:UI4&H63,89
MEW+N&".Q!]"#7(^%_%'VC1](L)C<7NH3,SS2+AA"@F(#2$GC., =: .\VBC:
M,8KDX?']E,(ICIFI1V3W'V8WCQH(TDW%<'YLXR.H!'-6KWQ=#:WE[;V^F7]\
M+%0;F6V5"L9QG;\S E@.2!0!T6T8I-@K#MO%^EW5U)#$SE5LA?+*<;'BYR0<
M]1CFF6GC'3[VQTFZ@BN&&J3&&%-HW(PSNW<\ ;3G&: .@VBDV#WK/U76H=*^
MSQF">XN;ERD-O  7<@9.,D# '))-4H?%4%Q87$\.GW\ES;S>1-9+&IF1^.HW
M8Q@YSG&.] &_CC%-VBL!/&%@MAJ-U>07-DVGL%G@G5=X) VXVD@[LC&#UK,U
MWQ-<2>&KZX2PU/2YH#"P:XC +*TB@[2I()QD$=>>E '9[12;16+H_B6'5;Z2
MR:QO;*X6(3+'=QA#)&3C<,$]^QP13M6\26^EWL-@EI=WM[,AD6WM45F" @%C
MD@ <^M %S20#ID/X_P S5D*/.;_=']:X63QJ]KHFCSZ;8S3BXOOLTZM&-T?S
M$,F-PQ)Z=1UJ63Q5<VGC*17LM2EADTV*1+&*(,Z,7;+$9P.!Z^E '<;!2[1[
MU@MXPTQM+L;ZW6XN3?G;;6\*9ED(^\,$C&W!SDX%-/C/2H]*?4)Q<0)%.+::
M*2+$D,A[,OY=,]: .@*@TFP>]5-+U(:I9K<"TNK7)(\JZB\MQCOCTJU(C.C!
M7*D@@,.WO0 H0#I05!ZUPD'BG4YXK31E\O\ M[[:;:Y8)E41,,TNWT*D8]S6
MU=^--,LKJ>%HKR6.V;9<W,-N7A@/<,PZ8R,^E '0^6N<XZ=*4C(Q5"WUFSNM
M2DL(69Y4@2X) ^4HQ(!![]*RW\<:0FF6E^?M)CNY7AA18279T)!7;ZD@@>M
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M;/2K'3WN'M+6*%KF0RS%% WL>I/O61X8\1_VOIL$UX]O%<SS31QQ(<;PC$<
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M!(MM+81#SC T:S.&Y() SV&?:G:E/:Z;XXOKG6X&EM+FPCBM&^S-*#@MYD?
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M3ZG% '$Z]8:$/B/8RZM;V0BFL7.^X50'E61-O)ZL!T[UAS#1)=#UZYU<0?\
M"2I/,(S*1]H5P3Y C_B QMQCWKU.>TM[HH9X(Y?+;<F] VT^HST-1OIUG)=)
M=26L+W"<+*T8+CZ'K0!4T,W)LP;P 716+S@#D;_+7=^N:U:JVXQ=7?\ UT7_
M - 6K5 !1110 4444 %%%% "'H:6D/0TM !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -8X&:X/^W[Y
M-3TV6VU*\O;2YO\ [-(SVB1P$'<!L; 8X('.2#@UWI 88/2N?A\%:/#-;NBW
M16VF$T$37+E(FSGY5SC&: ,[3]4U.+Q UGK%U<V\\DT@M8/)3[-.F"5VR!=V
M[&"02#P>*IVGB6^T^SOWUBYNAJEM:2SFQE@1(GV_Q1NH^9>@^\3STKHX_"NG
M)>I=.]W,T;N\237+ND;.""5!/'!('IGC%):^$]-MY_.=KJZ<0M;K]JG:4)&W
MWE&?7 Y.3[T 8.DZGXBDNM*E+7=Y;W:DW7FVR1QQ93<K1D<X!P.2<@YI^EZO
MJS7%Q:7E[*FL"*5H[&XMU2&0C.TQR 99>F<DGU K:L/"EEIS1"&ZU P0@B&!
M[MS'&"", 9R1@\9)QQCI38?"&G1R^8\]_.ZPO!$TUT[-"C?>"-G()XYR3QUH
M J^%-4EO3/;WFH74E_$B--:W5LL+Q$YR1M #*3T//3K5/5?%-UH.H:Y;7;J_
MEVJ76GC;C.X^7L]SYA'_ 'U70:;H%KIMY->":YN;N5!&T]S)O8("2%'  &23
M5#7M!&L>(=%N)+<-!9.\SR;@.1C:N.XW8/\ P'WH HV]UKVHZO+I"ZFEI)86
ML37$Z0J[32N"> > HQZ<^HJM9>*M3GO- @E\I6N+NYM;HJG#F+(!7)X!QFNB
MU#PW:WVH'4$N+JSO#%Y+S6L@4NF<@$$$'&3@XR/6H9?"&F/IUC:0&XMOL#F2
MVFBE/F(QSDY.<YR<YSG- &+J?B;5+6/Q0T#Q;M.NK>.W#IQAUC)SZ\L:ZK38
M+^WM"NH7JW<Y8MO6(1@#TP">GK65%X)TN.QU"T\V[=+^5)IW>;<Q=<<@D=\?
M_JKHSPO% 'GD/B'Q&_AR3Q$UY9FW@N70VGV?!D192AR^[AL#CBM-M3UO5;S6
MO[.O+>TBTUO+C1X=YF<+N.XYX7G''UJGH'@@OI:)J\UXBF[DN)+$3#RG;S6*
M,<<XQ@X!P?2MJ_\ "-O=7=W/!?WMD+X 7<5NZA9@!CN"5..,C% '.0ZEJVNZ
MYX:OK>_6T%Y92R>5Y!=4(V;P?F&[)Z'M[TR[\9ZQ*^ISV(F8V5T\$5G'ILLP
MG"$ DRJ,*3S@=N^:ZFZ\+6CC3#:3W%BVG1F*!K<C_5D %3N!SD*.>M,/A98K
MRYGL-3OK&*ZD,UQ! 4VNYZL"RDJ3WQ0!1N=1U^_\0WFG:==6]E%!9Q7(,T!D
M?<V[Y2,C'3GTK'DU/6=;G\(7]OJ,=D;Z.3,0A+J'"G)(W#<.F >G6NXBT:VA
MU:ZU)6D\^YB2%P2,87.,<=>366W@ZU72],L[6\NK:33"3;7"%2XR""#D$'(/
MI0!035I+?4?% >>QLS:&W_TMX.NZ/DN 07/H,^@K+N]>NM0\/^*M.NKG[2(=
M,::.?[&]L2&5P1L;J.!@CKFNEN/"-G=-J+O<7(DO7@D+AAF-XA\K#C\><U'_
M ,(?%*FI&ZU&\N9M1M/LDTK[ 0O/*@* /O>E %B03OX(7[-*L,OV!2',>\#Y
M!GC([9'6N7\.WNI6/A?P[I]G):FZU-?W4KP$"")%RQ8!OG;GCIUKNULD72Q8
M!F\L0^3N[XV[<_6LA_"5J='TVQBN;B&33<&UN8R-Z$#'.1@@]P1@T 8][XIU
M;2+?7;2Z-O/?:=!%/#,L91)D<XY7)P001U]ZZG2O[26S:75)H))7.]5AC*B-
M2!\O).<'//&?05E'P=;26.HQ7%Y<SW>HA!<7;[0Y"'Y0  % 'H!WKI%7*X//
M&* .7T;5=;U.VCUF1[*/2Y=[BW\MO,6(9VMOSC<<#(QCWK//BC6X-!M?$]PM
MF-+G>/=:JK>8D4CA5??G!;Y@2,5LZ;X8?2YQ'!JUW_9J.[)8LJ%!NS\N[;N*
MC.0,U4@\$1Q6\%@^IW<FD6\HEBL65-H(;<JEL;BH/.,T 5K[Q!X@:XU\V,=@
M(-'<9\T,6F'EK(5X.%/)^;GMQQ5>34M7U#Q=I\EI<0QVMSIJ7(@E5R IECSD
M!@-_/!],UT0\/0A=;'GR_P#$V8M)P/D_=B/Y?P&>:IW/AGRIM+NK2_F@FLX4
MM"P16\V+>AP01P<J#D4 90\07-A9WSZ=I]F)Y->-D$R5$A; W,>?FSW_ $JS
M+XFU;3H]>M]0BM)+S3[+[9"\ 81NI#<$$Y&"/7D5H?\ ")6X4@7,W.J#4SP/
MO@YV_3]:FN_#5M>ZCJ5U--*5U"R^QR1@  )SR#Z_-0 RXUZ6WO\ 0X2D?EZA
M'+)*><KLC#_+_P#7KG+7X@W%R;&[1K![6ZN1%]D0L;B.-FVJY.<$]"1C@'K6
MW:>%)X]2T^\O=8N+PV"/'%&T2(NUEV\X')QWJ73?#EWI"Q6MEK$D>FQ2;DMS
M C,JYSLWG^'MTSCO0!S?B76]7UGPYXG-I;V@TNT:6S?S&;S9"O#L,<  G@=\
M'D5UUSJL.B>$_P"TYP6CM[5795ZG@<#\:R+_ ,$R7,>J6MMJ\]K8:G(TT\"Q
M*Q$C?>*L>0"0"1^HK?N](M[[1'TJZ#2020^2_."1C&?K0!SVE>*[R?5[&SNI
M=,G6]A9A]BD9F@=1NVMDG(QGGCD=*SK?QGXCETG3M5_LW3VM[ZX^RQ1"9E?>
M25#$D8"[ATY-=1INDZI9M$ESK)N;>)-BQ_9E1F&,#<PZGZ 54A\(1PZ'I.F"
M[<KIUVMTK[!\Y5V;:1V^]UH I-XJU2QMO$$6H6]HU]I5NMPIA9O+D5E) .>0
M>*GM/$.KQ:SI=IJUI:1PZFCF$V\C,T;*H;:V1@Y!ZBHO$^@R"P\3:C TD\]]
M8"%;=$R<JIQC'))STJQI?AJZ%]8:AJ>I/>&RB*VL1@$?E[EP2Q'WFQQG ^E
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M'C,T/GV[1B5!U*YZXS[&H;3QSHUY):^6UT(KIQ%#/);.L3.>B[B,9[?7CK5
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M2,@C/X4 ;<<B2H'C964]"IR#3J\PT6:]TKP'HILM1F5]3N(K4&4(RVH9FRR
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M9;J,K=/=Q3I)B6*5B<E6Q[G@@BE@\(:;'97]O</<WKWZ;+J>YD#22*!@#(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO<GY<]<<5Z'J>C:?K$*PZC9PW,:MN59%S@^H]*B'A[21ILNG#3K864IR\ C
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MT^4XPQR0,#)SQ5N'Q!I4^EOJ<=_";.,[7E+8"-D#:<\@Y(&#SS7,1:1*H\"
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MJ338%M7O$W*3SY@7(QNSCCJ:K:Q;B[O/$L6GPE5;P_$(4V$?+\Q"XZYQ@8H
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M"U:JK;_\?5W_ -=%_P#0%JU0 4444 %%%% !1110 'I10>E% !1110 4444
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M+YJE6<$8.[CITSWK4FU^/1I?$%Q!IWSQZA#%+(\[;/GC3]XY(.Q5!YP,<>]
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MPKU/:/2FX&\<=C2&5+;4;>ZNKJVBW^9:R!)=T949(!&"1@\'M5ZF,.F/6GT
M%%%% !1110 4444 %%%% %:W_P"/J[_ZZ+_Z M6:K6__ !]7?_71?_0%JS0
M4444 %%%% !1110 AZ4M(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "B@T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W'W%_WT_]
M"%2FHKGA%S_ST3_T(4 34444 %%%% !1110 4444 %!Z444 4M)_Y!D/X_S-
M6A_KF_W1_6JND_\ (,A_'^9JRO\ KF_W1_,T 24444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !0:*#0 V/_5K]!3J;'_JU^@IU !1110!Q_B3_D9](_ZZ)_Z&*["N
M/\2?\C-I'_75/_0Q784Q(*;_ !CZ&G4W^(?C2&#=1]:=36ZCZTZ@ HHHH **
M** "BBB@ HHHH JV_P#Q]7?_ %T7_P! 6K55K?\ X^KO_KHO_H"U9H ****
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M_A>U?PEX59])7[1/J(6[8PD,R%SG=WQC'6M*^T6XMW\>V>CV;Q*\-KY4<4>
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M, T44 & 1C%)@>E+10 FT>@HP!VI:* $..]&!Z4M% ";1Z"C ]!2T4 (% Z
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M/K]D+U;"6VM9 &@>1U)D7)&< G'3OZT 9[^"+(AX(;[4;>P<DM8PS[83DY(
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M_P"NB_\ H"U9H **** "BBB@ HHHH 0]*6D:EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DH)C8#
MJ0<5YW#IFMW/AK2_#L^D20&*:)YKOS4,:HC[\CG._C&,8]Z]&..]-=XHUW.Z
MJOJ3B@#S;7=+\2:I:ZC:W-M?7$S78:V,<R);+ '!7C(); [@\]ZU=0L]2C\0
MFXT2PO;6ZEN8_M,S2(UK/$, LRELAMO' !X%=MM!HP* .#.CS+;ZD+[2;R?S
M-8DNH'M)566(;5VR+EAZ8Q^E='X:_M5=( U<N9Q(_E^9M\SR]QV;]OR[L8SB
MMG:*,"@#R]M+UJY\(3^&&T6XBFN;IF6Z9D,21^;OW$[L@X' QZ5>NM*NK35=
M:CN;;6I[749S+&=.9"CJR*I1PV-I^4\],8YKT+ %& : /+[BPN4\2:G9Z;%>
MB!-+M[:5;;RG=5P_RL92!NP>JDC'6M73$34+S1=1TFVG;2AHT\$;R##*=R!5
M;W^4_E73:AX9T?5+HW-W9AYRGELZNR%E_NMM(R.>AK0MK6"SMX[>WB2*&)0J
M(@P% [ 4 <5#I%['X9\)6WV-UFM+V&2=0HS& &W$X^OZU%)I-Z?"WC*'[!(9
M[N\G>%-GS2J0NTCU[XKO]H]*,"@#S_4]-OY+WQ&T=G,PN/#Z0Q$+G?(!)\H]
M^1Q[U:O[.6"Y\)S?9C'%9P3>>Y4A81]GQAB/NC(_2NVVCTIKQ)(C(ZAE8$$'
MN#0!Y;X<9XXO#<^K)?+90R9LV2WC$7F29"DN'+E3NX^49R,YKK/&UM<W5OI
MM;>28QZG"[B-22JC.2<=![U;M?!NA6=S#/#:/N@;?"CSR.D1]50L5'X"MW H
M YBRM)?^$_U>[DMV$36<$<4Q3@\L2 W?GJ/I7+F*\M?"&H>%'T>_FU*XDE5)
MUMV,+[W+"0R_=& 1U.?EZ5Z?M'I1M'I0!Q%OI5POB/Q$9K>24-ID,$<[1G$I
M",& /?G&0*@LM-G@T/P4@L)4E@N$,RB$@Q QON+<?+DD=:[[ HP* .:\:P2K
MH\>J6P_TG2YENUYQE5^^/Q0M7-?V9?)X<TO69K66YEDU,:G>P1)N?8V=N%')
MVKLXZ\5WVJ:7:ZOI\MC>(SV\H =5=ER <XR"#VJVL:J@4#"@8 H \XU"WN/$
MMQX@O-.T^YAADTHVR/<0-$US+G(PK $X QD^M%O?R:KXA\'K!IFIQI8Q3)<2
M3V<D2(Q@V[<L!SD8].:](PM)A<__ %Z .:\"60L_"%@K6IMYBK&1&3:V[<>H
M/.>E1"Q6;X@:G--:AX_[,BC5WCR"2[Y /3IC(KJ\"C H \W\/6UTL'@H26TZ
M&&WN5D#QL/+X& ?3\:KVVDW/_"EH((;.1;I@K30K#^\<>=EAMZDD#IWKT_ [
M5%<X\M?^NB?^A"@#CM!>PU#Q+!>PW]W/<06C1,AL# BJ2IVN=H&X'H,^M/UV
M2#3_ !S9ZEJ<,CZ>+!X8I!"TBQRELD$ '!9>!],5VFT&C H \JL;V73=!:2V
MTK[+:S:VY#W=FS?8XRH(D\OJ#V'IFHC%-=:%XOEABGG5[BWGC;[*8S(HV%G5
M,=P">.M>M8%&T>E 'G6MWL5UX@T36H+AX-(\B:-+DVA=(I20/F4CY<@8!/I7
M2>#K>WM]$D^R7,MS#+<2RJTD!A W-DA5(&%SG'UKH=H]*  .E 'DUU?/J%QI
MZM#';7,6LHQL;>P93"!*07>3U(.<\ YK2N=*MY=&\>7$EF&N'N)E1V3+%1"C
M+C_@1/3O7H^!1@4 >;V\]O9Z^+CQ%$TL-QI$$=L9(6EW''[Q  #\Q/;J:Z#P
M GE^#+-!&\0$DV(W7:RCS7P"#T.*ZC:OI1M '2@#QD'3F\(:G816C'7Y]2D^
MS 0'S&;SCM=6QRJ@<D<#!]:U;^&,>)/$$&LZA:61NHXEC>[MO,\V+R\8C;<.
M0V[Y1SGFO0])53IL)(YY_F:LB-6N&)4'"KC/U- &++#Y7P^FA%Q)<[=,=1+(
MA5I!Y9P2#R"?0UR5OX?TPOX&C_LV+;/$[7/R9\P^1O\ WG][Y@#@^E>FXXQ2
M;5XXZ4 >7>;!I6E:Y"+*T:V'B Q(+Q/]&M@50[V Z+G/H,D4VPTZ/6;;Q1;6
M,UO(5:&YM9+./RH3,JY#(,GC*XSG!KU(QH5(*C!Z^]0S0AX)(XF\IF0J'4#*
M\=?PH Y/P9<'Q%J=]XG>,HLD:6=NK=551N?\W)_[YJE?R:+'XWUG_A*3;+$;
M:$67VS&PQX.\1YZMN[#FNPT32X=$TFWTZ!F:.!=H9NK'.23[DFKS1QN0656(
MZ9% 'C_BV^TZ:WUR&"#2;-X(%$9NE;[9/A%*M%D@A0,#//0YKI8["RU?X@Q?
M;[99S'H\4BK*,C<7/S8]1FNZ:&)CED4GIDBG;$W9VC=C&>^* .%T/3+!U\2Z
MF;=#=K=W"+,W+(NWH/3J?K7.KO:S\*+/+I<=J=)'E_VJ"8&D^7(X(&_&,9[9
MQ7K@10" H /7WIKV\+H$>)&0?PD9'Y4 >5QPP6Z>&[?4]3L;W0FO;HL\+$VJ
M<?NHRQ)! ;<!D^@YQ70^"#IG]O>(AH[*UD)(0FQB5^ZV=I_NYZ8XQTXKLS;P
MM'Y;1(8_[I7C\J5(D3[B*O;@8H \^O%T"XUWQ(WB.2 30A?(%P^TI!Y8PT8S
MUW%N1SFLR+4;SPSINB>(KY9WDN]/>TN ^=Q<9>$L#W.",^]>HRVMO,RM+!'(
M5Y4NH)'TS3WACD4+)&K@'.&&>: /+KO3KBPN?#NE:BUJZ-:RS.M](5AENV(9
MLE1@D;FP#Q5A]-!T+3=-GU&"XMI-<"*+&<E84*N?*W=>,D>O->C3VMO=1&*X
MACEC/59%# _@:%M+9(TC2")40@HH0 *?4>E &3>Z-I]MX6NM.CME6S2%R(03
M@=6_GS7":=IMJW@7PE&BO$+[4(_M!BD93)E) >0>,@8XKU8JK @@$'@@U$+2
MW"1H((PD1W1KM&$/J/3K0!PMWIFFGQA!HVI*D6D6]@7L8'F*H[[OG/7YB!C&
M>F<U@PF:\&CV;7,[Z;_;UQ;VLBS,K/;A3@;LY(^\,Y[5ZK=6%G?(([NU@N$'
M(66,.!^!I?L=IB(?9X<0G,0V#]WQCY?3\* /-SX;LS_PE<#-=+%IP\VR07+@
M0$Q[R5P?4#KTZ=S77R64NO\ @=())6$]S9(PD!*D2;00V1_M8-;?V2WS*?(C
MS-_K3M'S\8Y]>*D2-8HUCC5451A5 P * /,[37[_ %^"?5+<,LVDZ4V44G!N
MV!SD=#M"=/\ :J3PQ87_ -HT34H)[*-)EW74G]H22O=AER<H1C<#SP>,8Z5V
M7A[13H]A+#-,+BXGGDGGE"; [,?3)Q@8'X58AT/2;>]-Y#IMK'<GK*D2AOS_
M !H \\AN8_[2T;5=/A:WCO-1$8>749))IT)8,&B.0%SSUXXZ5N^$=,CN[[4=
M4N)[J6X@U&XBA#7#[(UW= H.#U[@UTT6A:3#<O<1Z;:I,[AVD$2Y+#H<^M6X
M;:"W#""%(P[%VV*!ECU)]Z ..\1Z187?CC13=M,JS6]QN*74D?*>61C:PQU.
M<=>^<5FS6]MJ5KXDU/4=2N8[NPFFC@"7;1"W5!F,[00#G@_,#FN\U#2=/U5$
M2_LX;E8VW()%SM/M5>[\.:-?WD5W=:;;37$6-DC(,\=,^O3O0!FK;WOB#X?0
MK-,\-]=6*/YB,5(DV@@Y&.]<K+XBU'4[2?6;1F4Z1I)9XU8D&ZD&&W*.NQ5)
MY_O5Z=C:F% &!P*QO#NA?V/8W,=P\<T]U<R7$S*FU27/3'H!@4 <[X?T[4K:
M[TW4869+6>$M>/+J+W'VC*9#*I!"G=S\N!C(]JS;6];^U="U/3QJ,=MJ-X(S
M+=7QD^TQE6_Y99(7D=L8KN+'PMH>FWS7MGI=O!<MG]XBX(SUQZ?A4=KX0\/6
M5T+FWTJWCG602*X!R&'<>G6@#(\,V;75W?:K=ZA=R-;WUQ'%&TQ6.- Q&"O0
M_CTXQ77QRI*BO&P96&0PY!JO'I=E%;3VZ6Z+#<,[2H.CEOO$_7-26=E;:?:1
M6EI"L,$2[41>BCTH Y;Q&K/X[\,KDA2MR,C@CY.QJ'X>60CL;V?S[ABM]<Q>
M6\Q9<"0\X/\ %[UUL^G6ES>6]Y- KW%ON\J0]4R,''X56M=!TRRU2XU*VM%C
MN[@$2R!C\V<9XSCL/RH YJ]N-9G\1:WI^G7ABD&EPO;!R-J2$L,C(."<8S6A
MX0O(Y!?6+F_COK0I]I@O)?,*,P)!5^ZM@GK^ K3FT#2[UIYKBT5Y+J%89FW$
M;E7D#@\8-2Z7HNGZ-'*EC!Y?FMOD9G9V<XQDLQ)/% '.6/VS7M5UMY=5NK3[
M#>?9X(H&"A%4 [F!!W;L]\C'2J8N+[5K/Q%J3:O=6<FG7,\%M'"P5(Q$,AF!
M'S9Z\Y&#72W_ (3T34]0^W7=D'N" &82,H<#D;@" V/<&F7_ (0T/4[QKNZL
MM\KD&3;*ZK)CIO4$!NG<&@#SB_U#4/$'BOP]YUW/9K/IMO<ND.%(=I<$@D9'
M_P!:MFQO=:&@Z9K4NM74LQU!+5XBB+&\?FF,Y4#J<9SUS6AXCL;9/&>DW2PA
M9SY<.X$_<$@(&.G7-=,OA_3$TZ*Q6V_T:*;[0B;VXDW;\YSG[W-,2.2EEU.^
ME\47 U^YM%TV=A;HH0(F(U;+9!R.>GUI+C6[C5+:U:&YU?[<=.2YD@L$C$<3
M,,AG9\=?[N>@Z5HP^!;&\U35[O6(!+]KNA)&(YW4-&%4!7"D _,"<'-:M_X4
MT?4;P7%Q;,)/*\EO*F>,.@Z*P4@,/8TAG-6NJZKKB>%%&I2V9U"TFDN3"B$N
M5V=,@[3R>1TR:7^U=7LM-^UM?27$6FZNUM=,ZJ&EMR0N6P,97<.1CI756_A_
M3+'^SC;VY3[ C16W[QCL1L;AR>>@ZYJ'5-$4>']6M--MHVFOQ(Q6:0[6D<8W
M'KCUP/2@"'PY?7FJ3:K>S2$V1NFALXRH&$C^5FZ9.6#=2>E8C3ZWJ%QXD>+7
M9;./39F%NB0Q$<1AOG+*25_Q/7C'6Z-IRZ3H=E8* ?L\*QDCN0.3^)R:YN+P
M/#>:GK-SJ?F[+RYW*L-PZ"2+:ORN!C(R#Q_B: (-/UC4O$NJ6UI'?R:=&NEP
M7LI@1"[R2=OG!^48["J!U*\OSH"7TRSW%IXA>U:=5"B4*C_-@<#(]*[#4/"^
MG7TT-P!/;7$,?DI-:RF-O+_N''4?R[41>&-+@MM/MX;<QQ6$_GP*';A\'DDG
M+?>/6@#FAK>IS+;V$%V(9KW5[BU%R(TS%&FX_*,8+8&,D&M&\GU?0;[29+G5
M6O;&:Z-M.7AC1AO'[LDJ!T8$<8^\..*T9_"FF7%DULR3*/M+7:2)(0\<K')9
M6'3J:S]<\,.WA&_TO3TENKB\<,TEU.6;<2OSDGT S@8Z4 7O"U_>:O976HW$
MF;>>YD^R1[0-L*G:#GJ=V"V3Z^E;]5M/M(]/T^WLX1B."-8U'L!BK- %6W_X
M^KO_ *Z+_P"@+5JJMO\ \?5W_P!=%_\ 0%JU0 4444 %%%% !1110 AZ4M(:
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** (;HS+;.;=4>8*=BNVU2>P)P<"O.+C4=6OOAB;K4(XIB
M7B9)$E^>4^<,@C: O3 YKTPC(KD$\(:@/#\NB/J<#6@D1K9A;$.BB3?ACOPW
MID 4 6;#Q#J9U6?2]0TN**[^R?:X%AN-X=<XV$E1ALXYZ<U!9^*[N76QI,]M
MIQNY8))42VO_ #-CKC]W)\N1G/7'X5<U7PPVIZI<7GVUH1-IKV.$7YEW'.\'
M/;TQ^-4=(\)7UCJFG7EQ<Z>%L8I(4BM+/R@X8 9)W'G@=J )? VJ:OJFC+/J
M4<;*7D"SB;<S$2,,%=H   QG)SBB^\9FPCUT2:?FXTV2)(H1-S<B7 0@[>,D
MX[]*M^'-$O\ 0DFLY+J":P$CO;A8BL@W.6(8YP<9QP*@U7PHVH^*K#5TN1'#
M"%%S;[<^?L+&,YSV9B: *^H^)UU"V>SM8 4N=&>_:?S,&)2,*-N.<G/.1TJ'
MP[XEOHXM!L;[2#;VU[ ([:X-R'=F6/=\R!?ERJD]3[XJ71?!DNDZ;JUJ;Q)G
MNXS;V[E,>5" P1#ZXW&K[>'IF'AP&9/^)4VZ0C(\S]RT?'IRV?PH S?^$]S&
M+]=/C;1S<B 77VL>8?GV;_+V_=W?[6<<XJ6^\97T%[JT-GH7VJ+2B#<2F["?
M*4#_ "C:26P3QP..O-5M/\'7VD%;.TBT::P68R)-=6Q:=%+;BO'!(YPV1VXX
MK3'AVX_XJ3,L9_M7_5=?D_=!.?Q&: -"YU@KX;;5[.V:Y_T87$<.[87!7=C.
M#@XJBWBZT\W3%1-Z7MJ]X[[_ /4PJN2QXYY(%:6DV#Z?HEE83%':"W2)BHX.
MU0#7&^#?#T<RZV\KM+:NTVG6A/&VW#-N _%B/^ B@#3@\:W!2RO;S17M=)OI
M5B@NC<!F^<_(7C ^4'CN>O-7%\6(VD:W?BT/_$JGFA:/S.9/+[YQQFLR/POK
MMU:Z;I.I75BVF6$L<GFQ!C+.(SE%93PO09.3G%17_A37S#KFGZ=<V"6&J2O.
M9)MYD1G W+@<8)'7MGH: -5O%5S)K4>F6>C27+&&&>27SU1(HW)!)SU(QP!U
M]L5KZG>W=G;*]EI[7LK,%V>:L84>I9N@_,U0TK1;FRUV>^E>)HY+*WMP%)R&
MCWY/3I\PIOBK1[O5;>S-HEO.+>;S)+2Y8K%<+M(VM@'H2",@C(H J1^-4&CW
M%U<:=+%>P78LOL:R*Y>8XVA6X&#N!R<5+-XJNK&R#ZCHDT%Y+.EO;6R3I)]H
M=AQM;@#H<YQC%9,?@O4ETNZ"2:?;7AU*/4+=($(A0JJC81UQP>1]<=JN7VD>
M)-7M+>ZN#I]M?V5VMS:P1LSH0 05=\ \Y/('''6@"Q=>++O3K&"6_P!!N8KF
M:Z6U2W29'WLRD@AAQCC'.,5:L_$<LNL6FE7FFR6EY/:O<LAE5Q&%?;@D<'/7
MBJ-UI.OZPFF2W_V&"2UU*.Z,4+LP$:J01N(^9LGT J76M(U;_A(K37-)2TEF
MCMGM7AN9&0$,P(8$ ]".F.: $'C.*2UW6]A-+=/>R6<-N& ,C(?F;=T5<#/-
M!\:00Z;=RW=E+#?6LR6[V0=7=I'QY:J1P=P(P?KGI6,G@K4X]-A:=--O;R#4
M)KHP2J1#,LF<@Y!VGG(X.,=ZM3^%[V]T1O)TK2=(OXKN*[ABM3N1VCY D8*N
M<\C@< T 3:;JM_?>.1#=V=W8;=/+-;2RAD)\P88%25/'?J.E1^)KB\D\7Z7I
ML>L7&G6LMK-*[P[!\RD8SN!&*NZ7I^N2^)O[7U2&SMT-H8%@@E,AC.\'EB!N
MS]!BG:KX=?4_%^F7\]O;W%A;V\L<B3 -\S8VG:1S0!ST$^KZQX2N]47Q!=1/
M8-<)%/;)&$O$3[LA!4]<=L"K+W&L:'X=M;M=8GO[W5&MX8%NU39 \G5OE )P
M,\'T%==JUB;G0+RQM8XU>2W:*-?NJ,K@#V%96J>'[J_\+6-E#,D-_9^3+"[#
M<@DCQP?8\C\: *&IIJ_A9++47UVYU&W-Q'#=PW4<8!#G&]"J@J02.,D5>\:W
MDECHMM<1/,NV^MMWD@EF7S!D #DY].]4KJQ\2^));2VU6PL].L()TGF,-V9F
MGVG(4#:NT$]<YK2\7Z??:AI$,>GB$W,=W!*HF8JGRR \XYH 6Q\4)<7%U:W.
MG7EI>01>>+>10SR19P&7:3GD8QU%%MXD^UWLNF76GW6GWC0-/"DQ4^9&#C(*
MDX.2.#R*Q+C0_$NKW6HZHZ0:5?\ ]GFRLUCG\P@EMS.6 &.>!QQUIFB^&=1@
M\11:BVEI91"PD@?=>F>225BGS,3VX/\ 6@"]X<UJ]B\&Z1(;*^U.ZF@+,R$9
MX/\ $[D#/ISDXJX?&VF?V=I]XD5W(M_*T,,4<67\Q<Y4CL<J1Z>O'-<_%X;U
MZTTO1;62V^W6UM:20SV,=WY*F4ME79@?F7'&.W4 ]*L:3X6U6SM?#T4L4"M8
MW]Q//LDR-C^9MQGD_>'6@#87QIIRZ=>W5U%<6TEE*L,ULZ9D#MC:H R&W9&,
M&I6\4PV^GRW6H:??6;1LB"&2,,TC.<*$VDAB?3/'?%8FH^&-6GO]<N[9("\E
MY:7=HLC_ "R&(#<K?W<X-2:[I>N^)]&Q<:7#:36UQ%/!;O=[O.V@[PS*,*#D
MX(STR<9X .ATW78M0O)K&2VGM+V%!(T$^W=L.0&!4D$<$=>HJ"\\46MKKAT=
M+2\N;P(LK+!&"%1B1N))  &/\,U6\.:4+._GN1H*Z<6B5/,>Z\Z1N22O!("]
M#UY]!4UMI=W'XVU'4FC7[)/:0Q(^[DLK.2,?B* &S>,+"%YF,%TUI!-Y$MZ(
MQY*/D Y.<X!."0" >]2:GXIMM+\]Y[*_:VMP#-<I!^[0'G.206 SR5!Q7-Q^
M%[BV:[L;C0#J-O+<O)'.+_RXRC-NPZ%N",]E.<"F>(= \0WW]N6XM9KN.Z3R
M[)EO_*@@39C#1Y&6SGL0>,D4 ;EOXGL[*.&QC@N[RZ$)G>.UBWE$+'!/3KZ=
M3Z51_P"$G:S\9:BCQW]S;&QMYHX(8&;RP=Y9B#C;VX/-5](LM:T>Z:_M=+&H
M)>6<4;JDR1M%+'D8RQ'R'/;)]C6O9:9?CQ3JM]/ BI<:?;QJ5<$>8N_</7@G
MJ: +;>*]-:WL9;;S[MKZ,RV\5O$6=D&,L1_"!D#G')Q49\8:6;:VEB%Q-)<S
M/!';QPDR^8@)=2O\)7!SFN8M/"^K6-IH,KV-Q.UO9O:W4%M>B&1,MN#*P8!N
MG(S6A)H2C25C'AF\#R7,DY,=^GVB*3  D\POU8=<,??- '76]R+NT69(Y(]X
MR$F0JP/N#7+R7^OZ3KVCVUY=V=\FHR-&\$-N8S$ N[<K%B2!CG(YK8\/0ZI;
M^'K9-58R7RI\^6!;V!8<$XQD^M<_HT.MMK3ZMK'A^[-_-^Z1EGMS%:Q9Z+^\
MR3W8XR?2@"37O%EY:>(;.PTZ.)H%NX;>\D=2<-(>$7_:VY)ZXR/6K4NHZWJ>
MLZK:Z3/9V\6GA$S/"9#-*R[L'##: "!WZUEZEX+U2""PCL-5N9PNI)<RF1(L
MJ2Q+2DD L1QP<_2K:0ZUX?UG59(--EU./4!')%+&Z+B54VD."1@' .1Q0!M:
M/JKZMX7AU(QB&66 LRC^%AD''XBL?POXRL[O3M*M[R>=KVXC"&>2!ECDEQDJ
M'QM+<= >V.M:^A:3/I7A2VTZ7:UPD!#[>F\Y)Q^)-83:%J/_  C'A*T^RGSK
M&]MY+E-R_NU56W'.>>2.F: -J[\8:39W$T4KW!2W8)//';2/%"Q[,X4J.O//
M'?%7X=9L;C59],BE+74$2S2(%. C=#G&#T[&N*_L_6-/\/:SX<31I;J2]DN/
M(NT9!$RRD_,Y+9!7=Z<X&*L1:7J7AKQ%]L@L;C4HY=,AM$:)E&)(^/GR1@'K
MGF@#=G\9:+;VUI.\\K+>%UMUCMY':1D.&4*%SG/0=^U2-XKTP31PC[6TCI&[
M!;.5O+#_ '=^%^0^S8([US6AZ-J<<OA.2ZLGC:U-XUR,@B(OG;GUS[58U^WU
M :X;C1;'4H=2+1@S(R_99T!Y\T$]AN[ \#% ';DX&:S?[?T[[)?W+7 6+3V9
M+HLI!C*C)XQD\$=.O:C3M534KS4((XVV6<WDF3.5=MH)Q],X/O7'>(]*NCXR
M2PM<?8]=$;7@'51"V6/_  (%1^% '377C#1K3RQ)-,S/$)RD5M)(R1GD,X52
M4'^]BKL>N:=-<V<$5TDCWL;2V^SD2(N,D$<=Q7.[KSP_XBUJY.DW5Y%?^4\#
MVJAN53;L;)&WGG/3FLVTTK4- _X1F]GLIYEM()X[B.V D:(R'<HQD9 Z<4 =
MW9:C:Z@;@6TH<V\S02\$;77J.?K5)O$^CII\E^]ZBVT<YMW=@1B0'&W&,YS6
M=X)@O(X-7FO+.:T:YU&6=(Y<9VMC'0XK!U;PS>ZEXBO=*:!QH]TS7QF7@++Y
M)CVY]=Q#T =7K.N06=O=QPWUK#>0V_VC]_EE1,XW,%YQ63JGB"_M1K9BEA/V
M328;N+"9'F,9<GU(^1>*P(M(UB]\%^(+W4+.0:K>VL5NL)3YR(D R._S,6.*
MTM4TV]DMM=5+65O-T&W@CPI.Z0>;E1[\B@#M;>X!TV*YF95!B61V/ '&2:S[
M+Q5HFHF7[+J$+^5&96R2OR#J_.,K[CBJ^O:==ZAX$N+"U&+J2T554G&2 ,K^
M.,5B:O+-XD\'WNEZ7IU[;72VBC$T)C52&4F$%L9) (XR/>@#I[#Q)I.IR/':
M7L;NB>85.5.S^\,@97W'%-L/%&BZG<BVLM0AFE92R*#C>HZE<_>'TS7-6$,4
M]^+NWFUR[OK6UD6..^@$<2D@?(3Y:YR0.A(XJEIKWNH:YX<N9QJ$DT!D^TB2
MS$,-NQC(VK\H/7CJ1P.: .TM/$>DWUXUI:WT,LZACM4\$*<-@]#@]<46'B31
M]4NVM;'4()YE4ML1LY4'!(]1GN*X7R+^XMK[1/#[7S64UI.-M[;M$;20_=1'
M(&022,#.,9S5_04MKNZT9)IM9^V60XMY;,1QPL(]K N(P"OT8YXH [+4M9T_
M1XDEU&[AME<[4\QL%SZ =2?I48U_2CI1U0:A;&P'_+QYHV=<8SZYXQZUE>*;
MZ[LKC31$7AMG=Q/=Q6IGDBP/E"J <;O7!Z5RT,%Q'IEM?3VEW-:V^O27,R26
MY#F,@XD,8'."P; 'X4 =TOB?17TUM174[0V2ML,WFC:&_NGW]NM)_P )1H?V
M%+W^U;/[*Y95E\X;25&2,^H SBN9U:\MKK4='UV+3[EM,M+N4W+_ &5@S$QA
M5EV8W, >,X[>G-6+N6TUN^\/3VMC*;4ZE([F2U*!L0OAR".A.,$]30!U%MJU
MA>.J6UW!*SPK<*J2 DQM]U\>AP>:IRZW&]YI@M)[&6WO'==YN0&;:/\ EF/X
MSD<C/%86HWD6A>.Y+VYBG%M<::EO 88&?=(LC'8-H/.".N*Q='M[A(O F^WF
MC,=S>&0-&04R'QN]* .^'B'1VO([-=3LS<RYV1"==S8)!P,^H(_ TE[XBT;3
M;D6]_JMC:S$;@D]PB''K@FN'&FQKX)EF%B%NCK&_?Y7S_P#'UC=G&>G?TK-U
M2:-]4\2VMW/';V$U\HGG-E+.\85$/RN@*CIT.-N30!Z7J>L1V'A^ZU>%!=10
M6[7"B-QB10,\'G@^M8D'BS5&EAM[K0%@GO(6DL=MZ'29@ VPMM!0X(Z@BK7B
M=DE\!ZJ;<AXWT^0IM'!!0XQ4>A>'D1K#5+F_O+N>.V"PI,RA(0RC.U5 YP.I
MS0!5TSQ7KE]JDVG?\(U$C6C1+<M_:(.Q74,"!L^;CG%6/^$HU.[FNFTCP\]Y
M:6\C1>>]TL/FLI(8(I!S@@C)(!J/PZI'C+Q22N!FTP<=?W(K/T7Q/I?AG2WT
MK6)WMKVUFE'EM$Q,REV*LF!\V010!UNCZQ;ZWI<5_;!@CY!1AAD8'!4^X/%6
M!?6I@\\7,)AW;/,$@V[LXQGIG/%8/@BQN++P^TEU&8I;RYENS$PP4$C9"GWQ
MBN$;4[2V\&?V!)(1J8U5=UOY9RH%R&R>, 8QS[T =3XGO+:/Q3I6^XA4B6-"
M&D P=X..O6NDGU_3K75H-,FN%2YFC:102, #'4]NO%>3>)+*"[\=Z_YT$<G^
MI52ZYQ\@Z?\ UJVK<Z=;WG@V^U>.$0RZ8R/+.@8-)M3:&)')ZXIL2.OU7Q+<
MZ;9W%Q+IRJ(KZ.V0&X4^8C%1OX^[UZ'T]ZWVE1)$#, 6R "<9->9:H!]C\0D
MY"_\)#;]O^N5==XTT^6]\/22VH'VRR87EO\ [\9W8'U (_&D,WWE0,%+ -UQ
MFB.XBE!,<B. <$JP.*\OOI)-7T#5?$\:3"WOKF"([.&6RC($F._)WDU=F339
MO%-HGA5;3RO[/N/MPLU4(5* 1!MO!;=T[]: /1?-4@'(PW0YZT@FC+8#KGTS
M7F5OJ^GRZ%X+TV.Y1[Z.ZM_,C7EHMH*L&_NG/'-;WA'3+.34]<U"2VB>\CU6
M=(YG4%HQ@<*3TSDYQUH [.BBB@ HHHH **** *UO_P ?5W_UT7_T!:LU6M_^
M/J[_ .NB_P#H"U9H **** "BBB@ HHHH 0TM(U+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14-U
M(L-M)(\BQ*BEB[=%P.I^E<!I_B"[C\3:9$E]J=[8WZR;I+NU2*)]J;@T) !Q
M['/7K0!Z+17&>'YM6U'3(?$4^K/Y<H>5K%8T,0C&=J@XW!N!DY_"E\/MK.H:
M1;Z[/K#'[3&TKV@A3RE7!VA#C<".,DDY]* .RHKS>+5M?B^'C>))M6\RYEBB
MV1"% D?[Q5STR21G/;G@#%=#K.M7.G:_9Q*=UH;&YN)8U4$L8PI'/XF@#IZK
MWM[;Z?;/<W<J0P)C<['@9.!^I%<+H>O:W=7&CW##4;F.]P;M'L/+@B5E)#1O
MC. <#DG(K,UN[UO6/ NH:R^H1):R3E!9"$8$0F"#YOO;\C)[8XP* /49YH[>
M%YI9$CC099W8 */4DU5BU?3I[>2XAU"TD@BYDD292J?4YP*Q_B#D> =9QU^S
MGO6-I&F'4M>TV\AT)]/LK>T:*X>=44W6X !=H)R <G)H ZQ?$.BRR+''J]@[
ML<*JW*$DGH ,U--J-A:3I#/>6T,K_<CDE56;Z GFN5T/3;/_ (3#Q/\ Z#;L
M(9+<Q#RE^4^5GCCCD4WP9I&GZKX5-[J-I#<W6H/(]T\R!F)W$8R>@ XQ0!W
M.1FH;6[@O(VDMY4E179"R'(#*<$?4$$5SGP[EFD\'PK*S,(9IHHV8YW(LC!>
M?IQ^%<Y9W>MZ/X?OM7M[RV^PVVHW!:T:'YI%-PP<E\\'DX 'US0!Z:3Q5=;R
M!KQ[02H;A$$C1Y^8*20#CT.#^5<1XF\37NFO>W%GK%N[6JK(MBEB\G& 2)9
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M#+-Y:*I_B+8/'X5R.H^+K^?POX@DLQ:I?::GSRP7'F1[2FX.AV\D<C:1VZT
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MQ2YF\X(=RC+!%(^; ]QS34\06LWB%)(/M,B2:.;U/WV(BN_IL_O?[7X4 =6
M!1M&*Y33O%\]Y+IQFT:>VM]10FUE>9268+NP5'0$ X/MT%.\):WJNK2WPOK(
M)%%<RQK*)%^3:1A,#KU/- '4[11@5C/XBMXM2U6SGC>(Z? EP78C$D94DE?I
MM(-4(O%<]VEFEAHUQ/<W%L+MHGD1!%&Q.W<Q[G!P!GIVH ZG'%)M%<_:>+;.
M\BTYD@G5[RZ>T:-P T,J*Q8-SVVD<9K2L]4BO-1O[)(W5[)T5V.,-N4,,?G0
M!>(!I-H]ZP+OQ=964&M2303A]*91+'@;I P!4KSC!SCG'(J.[\46LMO$D*71
M6YTZ2^\V':#%&%Z\_P 1)P.O- '2;11@5Q$.H27&M:&T%W<M;SZ)/-B9_F<Y
MBVLP'!;D\BMWPO/))X2TRXG9Y9&M59F)W,QQ^IH VMHHVBL&V\3&74K:SN]*
MOK$W0;R'N-F'*C)!"L2#CG!%5%\<02R6AATJ_EMKRX-O;W(\L)(03D@%@0/E
M)Y'.* .IVBC:*YZ?Q.;?4T@N-)OX;62X%LEXZJ$+DX'&[=M)Z''-5H_$MIIB
MZW<W-Q>SQ6E[' ZNBD1%RH 3')7Y@>>>M '5;11M'O6-I/B.+5+^:P>RN[*Z
MCC$PBN54%XR<!A@GOV/(J35=;.F2K''IE_>ML+L;:,%44>K,0,^PYH U-@/K
M7/3^#;&9KQ%N[Z&UO9&DN+6*4".1FQN_AW#..Q%/F\8:>MCI]Q;17-W)J";[
M:W@0&1UQDD@D  =\FB?Q;:PQV@6QU"6[N@S)9I#^^4*<,6!(  /?/.>* -R*
M".&%(8E"1HH55'0 < 4_&*YZ[\965JUK%]BU&6YN8//BMX[8F0@'!!7L15T>
M(+,Q:I)ME TS/VC*\\('XYYX- &E&/W2_P"Z*7:*YYO&%@EK8M!;WEY+=6RW
M2P6L6]UB(!#,,\=?Q[5L6&H6^JV$5[:.7AE&5)&#]".Q!XH M8%)L&<UYK:^
M)_$,>A)X@GOK:>#[<;<V)MPC,OF^6-C@]>0>1V-:%W+XJC\3VND1:_:C[1!)
M.':P'RA2!C&[GKUH M>)!_Q5.D_]=(__ $,5UYB1\;@#SGFO+==U#4M0\:V6
MEVMS"DEB84N+MH=V^5B#\J9  '7K79>'=6OIK_4=(U4P/>V#(3- I594<95M
MIS@]CS3$CH/+3!&T<G)XJ"^MVNK.>V65HFEB=!(HR5R,9'TJ.+5[.;4+NQCD
M8W%HJM,NTX4,,CGH?PK/F\7Z+;Q6<S7+$7D1EME6)F:4<<* ,YY''6D,OZ?I
MT&F:9:V$"XA@4(OO[FK45O# &$421ACD[5 R:YK4O&MA!I%KJ-FLEPDUVEN5
M\IPR'< P8;20PST/7M5B76?-N1]FNU5'L99D@DMG60LI WY;& .F",G- &XM
MI;JQ98(PS-N)"C)/K]:D2-(\[%5=QR<#&3ZUD:3JN/!UEJVHR];)+B>0+G^
M%C@?TJVVKV"M8J;A<WW_ ![  GS/EW9'M@9S0!>HK%B\6:)/=+;QWH+O(8D?
MRW$;N/X0^-I/L#5P:Q8&*]E^T#99,5N#@_NR%#'/X$&@"]14=O/'=6\<\+;H
MY%#HWJ",@U)0 4444 5K?_CZN_\ KHO_ * M6:K6_P#Q]7?_ %T7_P! 6K-
M!1110 4444 %%%% "-TI:1J6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KB".Y@D@E0/%(I1U/0@
MC!%85EX/TZRN[2Y62]D:SS]F6:Y=UB!7;@ G&,5T).*C6>-VVJZL< X#9XH
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M&9DC=I P95."0!NX)':M?P_IVIVM]JE[J8MQ)>R1NJP$D* FW!)'/U[UT%%
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M_P#'U=_]=%_] 6K-5K?_ (^KO_KHO_H"U9H **** "BBB@ HHHH 1J6D-+0
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M\\9Z=<"N@L] M['6%OX'=52R2R2'LJ(20<]<\X_"J=UX2AN(;E1=S1SR7_\
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M;!/7 ]ZZBVF6YMHIT^Y(H=<^A&:P6\/SM;>(HO.3.J,QC/.(\QJG/XC-;=C
MUM86\#D%HXU0D=#@8H L4444 %%%% %:W_X^KO\ ZZ+_ .@+5FJUO_Q]7?\
MUT7_ - 6K- !1110 4444 %%%% "&EI#2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UW6-"['"@9
M)]*R;/Q/IE[>QV<;SI-*I:(36\D0E ZE"P ;'M6A??:18SFS"FY$;&(-T+XX
MS^->?Z?IVMWFMZ!=WEKJK2P&0WLUVZ!(W:,C$:J?NY[@>E &CXH\;VT.F2+I
M%XWVM;F.%9/(9HV.\!U5RNTG&> <UKZSXKTS3_M=H;LK>10ECMC9EB)!V[V
MVKGW(KCIM/UE?!<'AQ="NGN(+I2]P-OEE1*&\P'=EB1V^M:TL.HZ=/XEM1HE
MQ>MJ3F6"6/;L<&,+M<D_+@B@"WI?B&;[!I-S?7D3&?2A=RP+ QD=L+E@5XQ\
MV,8[U):^*UU7P_!?V\B6,IEA607$+LHWN%V@X&2>@(Z$C-4M&T?4(;KP\9;6
M1%M]"-O*Q_@D_=_*??@_E56"UU";P/:Z1_9UXEW9W=J'WIP0MPK,RG/S *,Y
M]Z .JO/%.CZ?=26US=[9(@#*5C9EBSTWL 0OXD4Z_P#$^CZ9(L5W>QQRM&)5
MC +,RDD @ '/0]*Y9([[1H?$FGR:/=7<VHW<T]M)%'N2974 !FZ+MZ?-CCI5
MG0]!O-.\4Z:]S$\L=KH"6C7! (\T.,@'UQ^E '6VNHVE]8I>VLZ36SJ761#D
M$=ZQM$\9:9K37BH_E&V9R3)D QJ0-^2  .1P>:;X)L9[#P\;>>!H6%U.RHRX
MPID8CCTQ6%<66H76B>*-#6RN!=37$UQ"SQD1S(S*P4/]W)&1C/K0!U>G^)]'
MU2Y%O9WT<LQ4LJ8*EE]5R!N'N,U9U'6+#28T>_N8[=7)"ESC) SCZX%<J&EU
MWQ!H#VNF7EK'II=[B2XMVB"93:(U+#YL^JY''6K/C&9;?5O#DS6LMT([MV,<
M2[VP(V^8+WQUP.>.* -J/Q+H\NFR:@FH0_98FV/(3C:WH0>0>1QU.14#^([&
M\TB^N],O;5FM4+.9MRK'QGYQC<!@>E<I+)K _MS6M-TZYABO;FV1!+:EI5C0
M;9)A"1DL.P(S\N<56CM+^YA\8S^7J<_VK3(4AFNK/R9)V42@X144YY'!&>E
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M?XFP3C\@:\ZTB^DC\&^'+.WU:ZL[F2!G^SV5JL\TBAN&Y4A5'J0,Y'-.FO\
M4M:TCPRTMT(M0&JRP&X,(ZQ^:FXIG ;Y>G3)]* /0KV_MM.M'NKJ01P)C<Y'
M R<58!R*\RU[4M13P_XJT?4+O[:]@+8QW)14=UE((#!1C((/0>E7[S7-7O\
M4M473[R[M5T^0P10P6 G6=PH/SL5) )(  (P.<T =\3B@'(K)N'NK_PSYAD?
M3KF6W#N=H8PG;EAAACU%<?I%_JVF^#O#\46H^;-JK0P0--"N+52A)(QC><#^
M+J: /1Z*YO2;K4[/Q!)HNH7HU!?LHN8K@QK'(/FVE6"_*?8@"ND'2@ HHHH
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M4'#?CFK<FBV$ERUPT \QK8VI(.!Y6<[<56NM8EB\1V^F1Q*Z2V<MQNS@Y1D
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M2-_6EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD2:A?P65[(9+FSB=1'(3][DKN4'N%(S5N;PY"VKVNHVUW<6DMO +?9#MVR1
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M_NC^M #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH- #8_\ 5)]!3J:G"+]!
M3J "BBB@#C_$G_(SZ3_UT3_T,5V%<?XD_P"1FTG_ *Z)_P"ABNPIL2"D_BI:
M;_$/QI#!NH^M.IK=1]:=0 4444 %%%% !1110 4444 5K?\ X^KO_KHO_H"U
M9JM;_P#'U=_]=%_] 6K- !1110 4444 %%%% "-V^M+2-V^M+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1]:=36ZCZTZ@ HHHH **** "BBB@ HHHH K6_P#Q]7?_ %T7_P! 6K-5K?\
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MW%_WT_\ 0A4U0W'W%_WT_P#0A0!-1110 4444 %%%% !1110 444&@"EI/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB3_D9M)_ZZ)_Z&*[ =*;$@IO\8_&G4G\5(8C=1]:=36[?6G4 %%%% !1110
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MZA#U"J  1[UZ&O2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I#2T&@!$^XOTI:1/N#Z4M !1110!
MR'B/_D9M)]/,3_T,5U]<AXD_Y&;2?^NB?^ABNOIL2"F_Q"G4W^(?C2&#=1]:
M=36ZCZTZ@ HHHH **** "BBB@ HHHH K6_\ Q]7?_71?_0%JS56W_P"/J[_Z
MZ+_Z M6J "BBB@ HHHH **** $-+2-VI: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU:'^N;_=']: *D&DVEOJ4^H11E;JX55ED+L=P7H,$XXR?SJ:]L;>_A$-PF]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %13_<'^
M^G_H0J6H;C[@_P!]/_0A0!-1110 4444 %%%% !1110 4444 4M*_P"0;#^/
M\S5H?ZQOH/ZU6TK_ )!L7X_S-6A]\_04 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "@T4&@!$^XOTI:;'_JU^@IU !1110!R'B+_D9]*_WT_]#%=?7(^(<?\
M"3:5_OI_Z&*ZZF)!2?Q#\:6D_B%(8C=1]:=2-V^M+0 4444 %%%% !1110 4
M444 5K?_ (^KO_KHO_H"U9JM;_\ 'U=_]=%_] 6K- !1110 4444 %%%% "'
MI2TAZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGZ,* )J*C\^+_GJG_?0H\^+_ )Z)_P!]"@"2BH_.CZ^8F/\ >%*)8ST=?SH
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M<_ZN?_P)E_\ BJ** #_A&],_YYS?^!,O_P 51_PC>F?\\Y__  *E_P#BJ**
M%_X1S3/^><__ (%2_P#Q5*/#NF_W)_\ P*E_^*HHH /^$>TX=%N!_P!O<O\
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MH_\ XBD.GW'_ $%;S\H__B*** $_LZYS_P A:\R?]F+_ .(IW]GW'_06O/\
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,[?\ @6:OBBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exhibit101-offerletterda002.jpg
<TEXT>
begin 644 exhibit101-offerletterda002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M=?U+29<VUW*H7DQL<J3[BCZHI?!*X_K37QQL>\45R'AGQM!K$BVETH@O",J
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M($,[9NK8!7/]\=FK@?'!*>*KH@=2I_2HPD'"LXLO%24Z2:.Z^'7'A<#TF?\
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MU.O_ !\O_N+_ #- $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444&@"*U_P"/
M2'_KFO\ *I:BMABUB![(/Y5+0 4444 <?XEQ_P )1I'_ %T3_P!&"NP'2N/\
M2 _\)/I'_71/_0Q784V)!3/^6@^AI]-_C'T-(8-V^M.I&'3ZTM !1110 444
M4 %%%% !1110!5M_^/J[_P"NB_\ H"U:JM;_ /'U=_\ 71?_ $!:LT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'M0:#2F@#SG
MQ5\GC_2W.""8A@]OG->B@UYW\1H3#J&GWJ<-@KG'0J01_/\ 2N^M)A<6L4ZG
M*R(''T(K>IK3@S"GI.2)C6/*=VM*!V(_E6N>E8UOB?6FDZ[<X(],"O-Q.KBO
M,UET-H5#>?\ 'E/_ -<V_E4PJ&]P+&X)!($;<#Z5UK<;V/GYP-YX]1BOH*U_
MX](?]P?RKY\8DLV#SSP*^@[3_CTA_P!Q?Y5Z&.VB<."WD2D5R'CSP[_:FE?:
MX$!NK4;N."Z=Q_45V%-(##!KAA)PES([)Q4HV9X)HVJ3Z)J<5Y"#^[."O9E[
MC_/>K?BN[2^\02W41'E2*CICK@J#S6CX[\/KI&J"Z@3_ $2Z)(7^X_<?3G-<
MID[AR!GG@\"O8I\M1JJCR:G-#]VSUWX=*5\+J#GF9^_TKCOB)C_A*I,G_EBA
MZ].M=E\.L_\ "++G_GL^/TKC/B'D^*I>?^62<?G7)0_WEG35_P!WB=3\,N-%
MNL_\]_\ V45W%>2^$_&-IX?L)+>:VFE+R[MT>, 8'J:WQ\3]/(_X\+S_ ,=_
MQK*M1J.HVD:T*U-4TFSNLBBN&_X6=I@ZV5YSTP$_^*J1/B7I;.%-K>*#W*I_
M\567L*O\IK]8IO2YA?$72#;:K'J4?W+D;7 _O*!_,?RJKX$UT:3JAM+A@EO=
MD#<QX5^<?GT_*O2M1L+37](>"4AX9TRCJ>G'#"O&=:T:ZT._:VN%SC[DFW"N
M/45V4)QJT_92W.2O%TJGM(['NZG(%.S7D_AWQ]=:=&EM?QM<VZJ K X=,=O<
M?K7<6?C+0[R$/]OCA)_@F.P_K7'4H3I[HZX5X35TSH,TA( KG[OQGH5I&6.H
M1RD?P1?.3^5<9K_Q!N;Y9+73(C;PG(:5B"[#T&#Q13H3F]$$Z\(+5D?Q U];
M[4$L+>0-!;D[R.0S_P#UOYT[X=:2;K5GU!T'EVZX7(_C(X_(9_2N=T?1KK7+
M]+>V4\\R2?PJ,]37M&CZ7!H^GQVEN#M4?,QZLW<FNRM.-&G[*.YRTHRK5/:2
MV+X&*6BBO./0"BBB@ HHHH **** "BBB@ HHHH **** "H+K_5+_ -=$_P#0
MA4]07?\ JE_ZZ)_Z$* )Z*** "BBB@ HHHH **** "BBB@"GI7_(-A_'^9JP
MO^O?_='\S5?2O^0;#^/\S5A?^/A_]Q?YF@"2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *#THH- $<'_'O%_N#^525'!_Q[Q_[H_E4E !1110!R'B/_ )&C2?\
MKHG_ *&*Z\=*Y#Q'_P C-I/_ %T3_P!#%=>.E-B04W^,?C3J;_RT'T-(8-U'
MUIU(W;ZTM !1110 4444 %%%% !1110!5M_^/J[_ .NB_P#H"U:JK;_\?5W_
M -=%_P#0%JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 (>U*:0TM '+>.]/-]X<ED1<O;$3 >H'!_0_I4/@'5A>:&+1V!EMCM
M[E/X3_3\*ZN:&.>&2*1 R.I5E/0@UY*_VCP7XK(4,;?.5']^-CT^HZ?@*Z:2
M]I!T^NZ.:J_9S4^G4]4N[@06S/W[?6J.CP ^9<X&6. >_O5&741JPC>T(>)A
ME#Z_6NAMXEAA"*.!7D0;JXAOI'\S9/F=^A(*;,GF0O'DC<I&1VI]-=@B,QZ
M9KMV+//9/A@C _\ $V;)'>#/;_>KT"%1'"D8(.U0/RK+C6;469VD98E. %XS
M4S:=Y:AH9G5AW9JREBJM57M=$0IQC\*-&DS6?J#/':)AV+!@-W<TT:<65?\
M290<9SGO4NK+FY8QN5<DU;3(-8TV:SN!E)!P>ZGL17#CX7,0<ZL <8R(,_\
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M0 4444 %%%% !4%U_JE_ZZ)_Z$*GJ"Z_U2_]=$_]"% $]%%% !1110 4444
M%%%% !1110!2TC_D%P_C_,U87_CY?_<7^9JOI QID/X_S-6%_P"/F3_<7^9H
M EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "@T4&@".#_ %$?^Z/Y5)45L,6L(/78/Y5+
M0 4444 <AXC_ .1GTG_?3_T,5U]<?XC_ .1HTG_KHG_H8KL!TIL2"F_\M!]#
M3J;_ !CZ&D,5NWUI::W4?6G4 %%%% !1110 4444 %%%% %6W_X^KO\ ZZ+_
M .@+5JJUO_Q]7?\ UT7_ - 6K- !1110 4444 %%%% !1110 4444 %%%% !
M1110 55U*Z:RTVZNE7<T,+R!?4@$XJU5'68WET:^BB0O(]O(JJ.I)4X% '"6
M7Q UN&QTG4]4TZS.FZE,(4DMY6\Q&)(Y4CGH?RKJ9/&?A^'4?L,FJPK/O\O&
M#M#YQ@MC;G\:YWP5X'LX-'TR^U6"[;4(<LL%S*Q2!MQQMC)P/7IWKEM;M/$V
MKQ7-G>VFKM<)?B18(84%J(<\,"!DM^/>@#T2RU^8:_KL5]?Z>+"Q",H7*R1
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M CG<RD\E@>,CIU]ZR4\6:CJHT2R\ZYMGN+%KJYFL+<2R,5?8 H(8 9!).#V
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M!L+GS#$R8RKCKT/7CI5>V\9:B/#<_B"^L;2&R566)%G.^23>$&<C"J3GW&*
M.YHKF/#_ (H_M/4GL)I],GF,/GJ^G7/G( " 5;T(R/K73T %%%% %6W_ ./J
M[_ZZ+_Z M6JK6_\ Q]7?_71?_0%JS0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !@>E)@>@I:* # ]*3%+10 A&<<48'H*#UI: $P/2EP***
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M5W_UT7_T!:M55M_^/J[_ .NB_P#H"U:H **** "BBB@ HHHH **** "BBB@
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M(JW!!Y\B0!7^N#M/X5SE[%</INB7<D<*0ZK?RW=W]L!$)+#]RLF.V-H ]0*
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M03QQJ4P75(3%+:&Y\D:;':2-,T>_9O$HXS_%MV]!UH ]'Q4-U_JA_P!=$_\
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MV%<?XDQ_PE&D_P#71/\ T,5V%-B04S_EH/H:?3/^6@^AI#%;M]:=2'J/K2T
M%%%% !1110 4444 %%%% %6W_P"/J[_ZZ+_Z M6JJV__ !]7?_71?_0%JU0
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M:M55M_\ CZN_^NB_^@+5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3M;22]@TO['+"L\=D7,4F\<E&4E00,;L=O>@#L9-<TN+35U*2_MDLGQMN#*
MC9Z8/2J&B>(8M:UG5+>VD@FM;586BFA?=OWJ2<D<<$5R4EA#80Z1J$1O[K2X
MM5EN;D36I4J67 <1A0=H;G..];/A)XKCQ5XBO+6SEM[2X%LT9DMS%YI"OE@"
M!U- '5WE[;:?;O<7D\4$"?>DE8*H_$U@Z?XML[W6]0A2YM&TZVM(;@7:2@J=
MS.#D],#:/SJ'QS$QBTFYDB>:QM;^.6Z1(R^$ /S%1R0#@US%Q"FL7_C"32K&
M58;O2XQ$WD%!.X+Y*@@9SP/>@#TIK^U62",SQ;[@$PKO&9 !D[?7CFLV\\3:
M?':SO9W=E=7$4/G"'[4B93.,DGH/<UR<&IV^I^)O!\=HD[BSAG29V@=%1O(Q
MM)('/!R*@MM-AB^$-_)'9*MW)!-O81_.Q+GVSV'Y4 =[/KFFV40:^O;:U.U6
M82S*,;NG?O@_E4USJEC9VRW-U=P0P-C;))(%4YZ8)KD++3;6\\;.UW91S(NB
MVX3S8PP!W/G&>^*YC3IY[;2_"6^V662."[Q#<Q.Z\28'RJI8$+T;!&..] 'K
M-I?VE_&TEG=0W"*<%HI X!].*HWWB32M/U.'3KJ\BBN)49P'<  #U)Z9SQZU
M0\#164'A\16=Q#.1*YF:*,QA9"Q)7:>1C.!GL!67XI72[/QKHM]JL5NMFT$\
M<DTT0*E_E* DCKUQ0!MV'B:UGU#4+2YE@MS;70MXB\H!E)16X![_ #8XK5NK
M^TLE5KJYA@#'"F60+D^V:\^N=)TZ\M_'5U/8023QLYBE9 63$"L"I[<\\52N
MY8EUQ)M<O-.@MIM+MQ;RZI!YD3G!WA"64*V2">YXH ]6!W*".AJO/?VEL6\^
MYABVXSOD"XR<#.?4YK.\)VZ6OA73X8[\7\21X2X"E0ZY., D\8X_"L2]TNPU
M3X@7L=];17"KI,95)!E1EY 3CIGW[=J .N%Y;F<0":,S%=XCWC=M]<=<4K7<
M"S)"TL8E?)5"PW-CK@=Z\PTK3[6U\/>#-1AA47LM]&LEQUD=65@5+'DC  QT
MXJ">?1ET+Q$-::+_ (2/[5,(Q+_Q\ DXA\KN%QMQMXH ]7DN(H@QDD50N,EF
M QGI5+4=3M;:XL[.5]L]U*!$N#\VT@GGMQ7%V>DP:MXVO(M<MDN98](M2Z2<
MKO)<,<>O7GM6':1Z?/I/@B\U<0R0EIX)9KH Y"D[%8GTQQ]* /3;#7([[5]4
MT\0E&L'C4N6SOWKNX]/2M3/&:\U&C:5JNO>,I)[:.801PB$Y.$_<Y!7'0\#!
MZUVGAB9Y_"VDRRNSN]I$S,QR2=HY)H CG\0.OB-=&M;![B18EFN)/,5!$C,0
M#@\L>"<"MG?[5P,FFVK?$K5Y8[2)KF+34GA.SD2Y(W#W[5C0-I2^$M$U"TN%
M;Q)-<P9=9"9Y)BX\U'[D8W @\ "@#MI?%T$)N0;27]QJ46GGYARS[<-]!N_2
MNBW>U>879'FZK@\_\)1:?EF.G/\ V1>#Q7<:_< 7UK=RK"992C01!1Y1CYXS
MZCJ: /3-U!; S7E%[>ZGI%K97EP7^U:UHD=H1N.3=\ $^A(?GZ>U7O#PN;C6
M].\/SSRN=!:=YGR?WG(6'=]5<G'M0!Z#8WOVZS2X-M/;E\_NIUVNN#CD59W5
MYA;1&_MO"UK<33-'+J%ZLNV5EWJ&D."0<XXJOJ-S)I5AXCT^*>6.RMM6MHXT
M\\H!&ZHSIO)^13D\YP,T >E:4<:;#^/\S5A6'VA_]U?YFN*^']HOF:A?(BQ0
M2LJ6\(N1*44?>. Q"Y/;V]ZO^,6GLTM=7MVD']GSQ23*KD!H22KY'0X!S^%
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M\I]^1Q[UVN>,UXSKF3KLH'/_ !4:?SAKV4_</TIL2&6]S#=PB6WE26,D@,C
MC(.#R/>G_P 8^AKS/2M8US1/"0U1([%M+M[F17BPQE=#,0S YP"">F#TJ]JG
MCF>/4=32SN=.A33LH(KH,9+EPNY@I!&T?P@D'FD,[\]OK2U5LKH7VGVUTJLH
MF19 K=1D9P:Y+Q/XMO?#]S.[WFC+'%M=+-W8W$R<9(Y !Y.!@T =O17$W'C*
M]@AUI/LT37=L\'V*/!'FK-@1YY]<@X]*M6?BFYU.]T^&PAB<3::;V?>2 C'
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MZVL);B2[F6)'N(XU9NA9E4 ?B36D#F@ HHHH **** "BBB@ HH/2B@ HHHH
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M2X%SJ<5TZ?8!N#>:IW%MW(0 <>BXXKOTBBB=V2-%9SN<@ ;CCJ?7@5)OZ^U
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MCV=A#$TB>6QQGY/[HST7V'%0VOA'0K&[BNK;38(IX6+1R*#E,@C ]!R>.G-
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M[S1Y4%]=IJ&H2L\4FVU:0&/)4X 7;GZ<U@VFG72>&/!D36<JS6US"TR;"&B
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MBB@ HHHH **** $/:EI#2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA)6,%MQ?+#))(7CL!WKL\BCB@#E;+1M:O-1TR?6Y++R],RT8MBS&:0H4WMN
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MELYZ<5V61GWH&#TH \<N]*O[?3?#=E):R)<I=HS1$C('VDMG\L&O8Q]VN/\
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M8>4O*UN+>-"HQ&H.3CZG'Y4 6;#4+34[?[197$5Q#N*[XVW#(.",UB>(MO\
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M@+?[49)]C7&=J_N^20.3CTXSZBMBWT.*WUMM465C(UJEL4P-N%).?KS4>M:
MVK7%E<1W\]G/9LS1/" >6&.01@C':@#F[GQM?:1#?6-_':MJ5O=PVL4RAEA?
MS065V7)( 4$D9.<8!YK8\-Z[=:A>WEG<SVUWY*)(EU:PM&C!L@J0Q/S#'KT(
MJ,^";>6SF^U7L\VHRW$=T;\@!UE3A"J_=  XQC&":V-,L;ZT,K7NJR7Q? 4-
M"D83&<XVCDG/?TH S_$FJWFG-;+;ZAI5BDF[,E]N9F(Q@(@(SWR<\5E6_B_4
MM3TG25L(+1=2OYY8=S[FA019WOC@D$#@>_6MK5O#\M]JUKJEI?M9W<$;PA_*
M60%&()&#T.0.?YUGKX*-OIMI#:ZI+%>V=Q+<0W;1*W,A.Y67@$$'';\* .<E
MN+N)_&DNJVMG-<1Q6BNBEO)D&#@]00.^,\>IKK[#7+FY\7:MHS11""RAADC<
M [B7!)SVKGM:\/W-AIFK*)K[5K_63$F1 -J%".NWA5P>_I6]?>&9Y];DU33]
M4>PDN8EAN@L*N9%7."I/W6YQG!X[=Z ,5_&NI-I6BSC^S;-K^*222[N]XMXR
MIP$Z\$Y[GL:L3W_B(^.+6U@FL1 ]AY[0L7*D;E#'(ZMDG!Z8/(JRWA*^BT*U
MTBSUI8[:*%H91/9K,)03G/)&#S[CVJ7_ (1.:UNM+N-,U/[.]C:BS;S8!*)8
ML@^HPV5Z\]>E &+<?$4K)/=02Z4+*WG,+6LUSB[E ;#.BYP.^ 0<XZBK^H^(
M-5OKK5[32K.TDMM/CVW#32LK2,R;MJ8! P/7J>..M3P>$]0TV>9=)UB&VL99
MS,8);(2LA8Y8*^X8&>F0<9I;SPG?MJ.HW.FZTME%J2J+F,V@D.57;N0[AM)'
MJ#0!/X%!'@+1\<G[*I&361I?B?4[+3-<U#588I+6RNYT!CF+."I $:KL&5R?
MO$YYZ5U.A:5_8N@V6F>=YQMHA'YNS;NQWQDX_.L-O!L\D>L64FJ*=,U&22?R
M5M\212.0<A]V" 1G&V@">#Q!JEMJ5C;:UI]K;1Z@Q6!X;@N8W"[MC@J.2 >1
MWXQWJ_XAUE]#TA[]+;[25>-/+#[<[G"]?QJA:^'-3EU"PN=9U6&\2PRT,<5M
MY6Y\%=['<><'H.,UI:]I+ZSI9LTN!"3+%(6*;N$<-C&1UQ0!DWWBN\TV2PL[
MJQLX]2N]["-KW$4:*,Y:0IG/L%_&N>\2>(+K7_#R06UM;@_VDEE=J+O*EL@A
M58+\R,#R>,>AKJM=\.2ZCJ=AJ=I/!'=6@=-EQ%YD<J,.5(R"/K45QX;O+VPM
MX+J[M%DCOH[K_1[8HH5?X0-QR?\ :_2@#G8;^U\,>)]3N+B%;:VL]&A+6\+E
MPI\QL*I(!/)QG ZUNV7C$OJ$5KJ%M:V_G6[SQ/!>"; 0 LKC VD Y[C@\\4:
MOX+76=1U6>>Y"PW]DEL J_-&RL6#Y[\XX]JFL- OH_W5X-*$'DM$[6MJ4DER
M,9SGY>_ S0!6TKQ#K-_H\%Y#HD:VL\!>WE:[&>%RI==OR@]L;O>K?@G4]2U;
MP[;W>I)%N=<K*C@F3DY)4* O;IFH/#FBZU8Z;86%S?VDFGV\/EC9 1+*I7"@
MDG"XXZ9SCM5_PQI%YH>F+IUQ-!+! -L#1J0Q7)/S9[\CIZ4 9=QK.MIX^.F0
MVT,MG]C\WRS.%/\ K #)G9G(Y&W./>L?0_$UWHVF7<T^G22Z<FJSQRW?G#*;
MIRH(4\E1D9Y'MTKI[[1;X^*K?6;&:WP+8VLT<ZG[I<-E2._!ZUGS^#[J7PA?
M:,+J$37%\UTLF#M ,XDP?? Q0!@>+/$ZQ^+8H[>U-P-.,9N&\T)SD-M7/4X^
MG6O1;&^AU#38+ZW),,\0E0D<X(R.*\Q\4>&#%XZCNHK?3KM;^:-V2\BSY;Y"
MGG!R#@<<=Z]0M(#;Z?#!MB1DC"XB3:@('8=A[4Q(P=/\37NJVLMU::0SVP5_
M*?[2FYF4XPR_PYP?ZXJAI7B^[7PQ:ZGJUB_F3!$@\EE)NI'.%"J#Q^-3:?X<
MU!?$HU6:*QLL1NEP;)W_ --) PSJ0 N.O5C[U3C\+:R?#]EI<LUFL^E7$<]C
M.K,1+Y;9 D7'RY!QP3ZTAFJGBU(KBYMM5L9=.GMK8WA5W5U>(<$JRGJ#U'N*
M@O=?N[WPUJDSZ3?6"G3YIX)W9>@0XS@Y1N00#_2J]UX9U37[F\N]8-K:/)I\
MEA!%;.TH0/RSEB%R>!QCIWJT;3Q'?:!>Z9?0Z>A>QDMTEAG9C+(5VAB"@V#K
MQ\W6@"3PIX@&J6UK:PQ33K!:1"XO"1L\W:,IGJS#OCI6AKFO)HALU-K<7,EW
M*8HXX%#,6VENA(XX_"LSPOH&H>')5M5EBETV2%':,N<P3@?/LXY5CSVP?K3?
M&)NQJ?AQK%(I+H7KE$E8JK?N9,@D XR,\X- $C>-;:WTN^N[RSN;>6PECBN+
M9@K.I<@ C!P1\V:1]=>;4-%\^'4=/:ZN9(T@94Q(!&6S)U(&!VYSUK.N_#&K
M:IIVKS7*VL.H:A- 1$DK,D<<3*<;]H)) /\ ".U;>M:3<:CK&AW41C\JRGDD
MFW,02K1LHV\<G)% #;+Q4M_<#R--O&L3(T:WVU?*)7()^]G;D8W8Q3;;Q?;W
M,EJ_V&\CLKN7RK>\=5$<C<X_BW ''!(YJCHND:SIE@OA^2TM'TM#)']K%R1(
M8F+$#R]G#<X^][^U9^B>#I=,>SM[C0M/G^S.O^G?;'!8*>'$>W&[IQG'O0!V
MNHZC;Z7I\U]=R;((5W.V,_D.Y/0#U-9MAXF2[OX;.XTZ^L99XS)!]JC51(!U
M PQP0"#@XJ7Q+I,FMZ#<V,,HBF<*T;L,@.K!AGVR!6;!9ZUJVM:?>:I86]C%
M8*[ )<>:TCL-O&%&% Y]?:@"'3?'%A=W22"SU!+:\N4ACN7A B\PJ %)SGDC
M&<8]Z[&N"LO#NH)X8L--*1_:+34;::4;^ J.KG![\5W@H 6BBB@ HHHH ***
M* #M0*.U H **** "BBB@ HHHH **** "BBB@ HHHH 0]J6D-+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 (<XXKC;3Q==:BNNP?8KF!K-I8XIA$0%
MVIN&\D\-D]/I79UQMOI>IV=YXEMC8F6#4I9)X;A9$"C,07:P)W9R,=,4 2^&
M_%UO?6FDVMQ]K%U=6Z[9IH"B3.J@OM8CD]?0'M5UO%^EK<;"UP81-]G:Z$+>
M2),XVE\8Z\9Z9XS6>=$O_LOA!!"-VGNAN?G'R 0E3WYY(Z5BZ;X3N;.U.F7V
MF:C>1+<NRR0:B$@9"Y8,T9<8(SR IY]: .T\0:P-$T>6]$1FE!6.*$'!DD9@
MJKGZFJMLOB4&"2YU#3&)93-;+:LI .,A7\P\CUV\^U2^)=)FUC0I+:V=8[I'
M2>!GY&]&#*#['&/QKF[^ROM:O-/D;PK]CU&*Z@EN+UGA*A$.6 <'>P(& ,>F
M<4 ='!XKTVYU:3386N)+B&1HIBELY2)E&?F?&T9[9/-%CXJTV_OH[./[5%-*
MI>$7%K)")0.I4LHS_D]*HZ%INI:?%XE?R5CN+K49I[3>00ZE%"DXZ#(/!K"T
MO3=8G\0Z#>7=MJQ>V,OVR6]F0H':)A\BJ<;<\9 [B@#HX?'.@W%RD,=W)\\O
MD^8UO((UDR1L9RNT-QT)_F*;8>,(+WQ/>Z*;.[1K=D1)?L\I#D@D[ODP@XX)
M.&[5@1Z%J ^'QLFLI/M8U+SA& -VW[3NW=?[O/TK9L8[S3_'>JO)87$EKJ0@
M,5S& 438C [N<B@";Q-K.IV.L:-INF&U62_>4%[A&8+M7/0$46?B*ZMM9FTG
M7([>&9+8W<=Q Q\N2('#<'E2#57Q9#>1^)O#NI6^GW-W#:-.9A;J&9=R@#@D
M=ZKR6VM:CK-YXB@T\VLD&G26UC;W)&^5R=VY@#@#( P30!N6OBS2;QI4BFF$
MB1&8));2(SH.K(&4%Q_NYJKH?C73M7T>3496-HD2EY?-#!47<0#N*@'..@]:
MP]#M=1F\6:=J%PNM2*EM,DTE^J*J.=GRHJ@$#@]<CBJ<.EZE+X$.A/8WD5W8
MW2S.4  E43EOW;'@G;R,\9Q0!W>EZY8:PTBV<[,\>"\;QM&X!Z':P!P>QZ&M
M.N*T.**WOKW55'B*[FAM2O\ I\:+O .[8@"J2V?PYZUU]I.;FTBG:*2$R(&,
M<@PRY&<'WH FHHHH **** "BBB@ HHHH **** $-0W7^J7_KHG_H0J>H+K_5
M+_UT3_T(4 3T444 %%%% !1110 4444 %%%% %+2/^07#^/\S5E?^/B3_=7^
M9JMI/_(,A_'^9JPH_P!)<_["_P S0!+1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 )M'I2T44 %%%% !1110 4444 %%%% !
M1110 444AH CM?\ CTA_W%_E4M16W%K#_N#^52T %%%% ''>)!_Q5.D'_IHG
M_H8KL:X_Q)_R-&D_]=$_]#%=@.E,2#%,(_>+]#_2GTW_ ):#Z&D,&'(^M+@>
ME(W;ZTZ@!,"D>*-V5G16*G*DC.#[4ZB@ Q2;1Z4M% !@4F!2T4 )@>E&!Z4M
M% %6W'^E7?\ UT7_ - 6K55K?_CZN_\ KHO_ * M6: "BBB@ HHHH **** "
M@444 %%%% !1110 4444 %%%% !1110 4444 (:6D/:EH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J"[_P!4O_71/_0A4]077^J7_KHG
M_H0H GHHHH **** "BBB@ HHHH **** *6D_\@R'\?YFK"_\?+_[B_S-5])_
MY!D/X_S-6%_X^'_W%_F: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%(: (
M[7_CTA_W%_E4M16W_'K%_N#^52T %%%% ''^)/\ D9](/_31/_0Q78#I7(>)
M/^1GTC_KHG_H8KKQTIL2"F?\M!]#3Z9_RT'T/]*0QQ[?6EI&[?6EH **** "
MBBB@ HHHH **** *MO\ \?5W_P!=%_\ 0%JU56W_ ./J[_ZZ+_Z M6J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#2TA[4M !1
M110 4444 %%%% !1110 4444 %%%% !1110 445C-XL\/KJ1TYM8LUO%?RS"
MTH#;O3'K0!LT4F12%U&,L!G@>] #J*J)J5I)J<VG)-F[AC65X\'A6) .>G8_
ME5K(]: %HIK.J(68X4#)-0V5];:C8P7EI*);>= \<@!PRGH>: +%%)D>M+GC
M- !129%&10 M%)D49% "T4F1ZU#!>6US+/%!.DDD#;)54Y*-C.#Z<4 3T49%
M07E[:Z?:R75Y/'!!&,O)(V%4>YH GHJ"TO;:_M8[JTGCG@D&Y)(VW*P]0:D6
M6-L[74XZX/2@!]%)D>M&10 M%)D49% "T44F10 &H;K_ %2_]=$_]"%3&H+U
MUC@#.P51(F23@#YA0!8HI-P]:,B@!:*** "BD)"@DG '))H5@P!4@@]Q0 M%
M%% !112$B@"GI'_(+A_'^9JPO_'R_P#N+_,U6TI@--ASQU_F:LJ1]ID_W%_F
M: ):*** "BC-% !129%&1ZT +1129'K0 M%&<T4 %%%% !1110 44F11D>M
M"T4F12T %%%% !1110 4444 %%%% !12$@49'K0 M%&110 4444 %%%% !0:
M*0T 1VYS;1$=T'\JEJ*V_P"/6+_<'\JEH ***0D#J: .0\2<^)](_P"NB?\
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M#FGGP=I1O=6NC&_F:I$8K@;^,$8.WT)Z_6@#+D\17#VNJWC:E!:6:7PM+5S
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M5TB[T>34PU@TAFM (,26\F_S Q;=\V&/3 JQ'X5N[V[-UX@U".^=+>2VA6"
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M*RV[JV9))!@$# ;)/7-2ZCJ=KINE^-].N92+VYDF>& *2[H\(PP'=1W/0=Z
M.Y34;."[NEFN[>-C*@ >0 DLHV_G@X]<5IJ<UP6D:?:7OC_47N;:.9HK"UV>
M8FX*2#R > >*[T#% "T444 %%%% !1110 AZ4M(>E+0 4444 %%%% !1110
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M386W,2Q&WYL$GI6LT4FA^(="@M+^\NEOS*MS'/<-*' 0'S!N)VX./NX'S=*
M.SR/449'J*\PTV;4O^$2TCQ ^KW\MXU_'$ZO)F-HFG\LJ5QCH<Y.3[TMQ?\
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M+$C1LB+@[CC=EN>01CB@#OK>=+F".>)MT<BAT;U!&0:9%>VT]Q/;Q7,4DT!
MFC5P6C)&1N';(YYJOH7'A_3?^O6+_P!!%<EK&M:A9-XMDM9T22T-KY!$2G:6
MQG/'S?CG':@#K])(&F0Y/K_,U97'VF3_ '5_F:XSP[=ZG:>(+73+K4/M=O=6
M,ET T*H8F60*0NT?=.[OD\=:Z?4KA;2SOIVNDM1'!N\^1=RQ_>^8C(SCT[T
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MDC!R\C<KM;H01SGC@'.*?_PEWD0:D+[3WM[VPM_M36ZRA_,BYPRL..H(]B*
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M[UR\CU#45CG4PPZ.MW'B/'SDO\W//8<&N@TFYENM$L;F4AI9;>-W.,9)4$T
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MWP5IE_<74DKWBQ79W7%M%<LD4C8QN*COP*T;SQ!IUAJ-M875U''/<*SIN8
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MO#K,$-C<H8VB>RWNBD8.UPX'Y@UOD\9%8,_C+1+;4)[*>[:.6 [96:"3RT.
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M.UC0+!;&=I[:*1]0CFD8.Y(^1V;<20,XPQ^@KI_$?AJ74QI=U#!9W4VG%O\
M1+L9BG5E *DX.#P"#@\CI716J*EI"% P(UQCZ56_MS2A=?93J=E]HW;?)\]=
M^[TVYSF@#F+GPG<7VC%1HVB:?=I<QW*6\(WQ2;>-LIV+G@D=..*>/#]]<Z-J
ML/\ 8&CZ5<7-LT$0M)-Q;.?O,(UP/;!KM.U% 'GOB*RF'C+PQ)\NVW 1^><E
MD QQ[5/?>#KVYT\GR;::>'59KU+>20A)D<M\I8#Y3AL]#@BK7B3_ )&G2/\
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MGDDCBFV[FBP&&&!XS]*S;+PH8[^2[U+4;C4G\AK:$3JJB.-OO#Y0,D\98^E
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MEQ$C'!S^9KB=)UR\;Q9%JDUS*VDZK+):6\1SL0H<1M[;BLE 'HF!2]*Y._\
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M_2@#D-2T+2](\3Z0NGV$%N!(I_=I@\N,\_A77ZEX?TG67B?4;"&Y:+.PR+R
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M8$$?G4,?A;1(M)GTN/3XULIVWR1 G#-QSG.<\#GVK'A\674ENDAMX>=;;3"
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MUZ]1R.* %LX;B&SCBNKEKJ91\\S($WG_ '1P*Y9? CHD5JNKS#3X;S[9';K
M@)??OPS]6[X^O.<#'7S3QP!3+(B!F"@LP&2>@^M2#I0!@_\ "-K]FUV'[0W_
M !-F8L=H_=;HPG'//3-5)?"EU'>B[TW5I+&1[2.TGQ K[U3.UES]UADX/(YZ
M&NIK/@UBVN+F_A0L!8L%FD;A 2NX@'V!&?K0!#X;T1?#N@P:6L[3B(N?,9<%
MMS%N1^-5(_"L'V_7;B>4S1:PB))"R\(%0KUSSG-6M,\3Z1K%Q)!I]['/(BEF
M"@@8!QG)&"*CL_%NAW^H_P!GVNI02W62!&I/)'7!Z'\* ,Y/"-Y;/IEQ9ZL$
MOK*T^QM+-;"1)X^,;EW Y&,Y#5=FTG6I;%(#J]L\AW^=YU@K12!N@"!@1C_>
M.>^:T=-U6WU6.9[<M^YG>"0,,%70X(_SZU>H Y"'P=/I]GHR:9J0AN-,61!)
M-!YBR+)RP*AACGI@\=*TK?1CI]YJEX9Q)_:%U#+MV8\O 1<9SSTSVK2LM1MM
M129K9RXAF:%\J1AU.".:DNO]4O\ UT3_ -"% '*Q>#KO3[;27T[48UOM-65%
M>6',<J2-DJRALCM@@]JLW6@ZU,FFW7]J02:G9RR2&22WQ$P<$;=JMD8!&.23
MCGK7444 <A+X8U*VU6^O-.FTUDOF621+RU+^5(%"ED(;D'&<'\ZEN/#NJ0ZQ
M_:FE7UK#<3VJ6UT)H"4.SHZ*&&",G@G'O755G:KK=AHL<3WT_E^:Q5 $9F8@
M9. H)X R: *_AK1Y]"T1+">X%Q*LDKF4+MW;G+9QVZUF:YH?B#5[6]TW[?8#
M3[HE2S6[>;&A/W1\VTG' )Q]*ZF*59H4E0Y1U#*?4'I3Z .77PY?6GB1;^QN
M+?[+):16D\<RDOM0MRI'<@XYK/7PAJ_]D1>'7OK4Z+&XR_E'SWC#;A&>=OMG
MT[5W%% '*PZ%K.EZMJ$NE7-E]DU"X%Q()XV+Q-@!MN#ALXSSC%5&\&7D>I7>
MK6EU%'J37QN8'P=IC*JK1/Z@[?P/-=A<7$5K \\\J11(-SN[!54>I)Z4]7#Q
MAU(*L,@@Y!% &*;>[NO"LMO9.D5S-"\<<C9PA)(S^&<UB77P^TX:<L&FQ);Z
MA;)"\%SN;B1"3N//?'ZUTFE74'V6&V\Z/S]A?RMPW;=Q&<=<>]74_P"/F3_<
M7^;4 <G?>"WO_%XU269?L,D8:XM\??E5&C4_3:Y_(52T_P "ZE:>&-7L#J(6
M_NQ'%%<(2-L4:JJ(3UZ @X]37?T4 <)I_A.^CU>:_:PTO3DDT^2U\BSR<NQ!
MW,VT9Z>F?K6A>^&[V;P=I>G0R0B_T\6[H6SY;O& "#CG!YKJZ* .5TO3-;E\
M6G6]4BM88S8FV6"&4N4.\-DL0,YP>PQQ4_B'0)M?U/38IB1IEN[3RA)FC=I
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M='?K6C0 4444 %%%% !1110 A[TM(>E+0 4444 %%%% !1110 4444 %%%%
M!1110 44AI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DB+)&R,,JP
M((]17D5S>ZA"%M8Y9#_PBTCS3#!RZ"1=F?4>46_*O8*B-M 3(3#'F48D^4?/
MVY]: /-Y)YKS0$UEW8?VCK]N\6"1B$2JB?F%S^-7]-L=(MO$GB?$,,=W'(#"
MI/S;6@!) /7)W_K7<-:V[1I&T,9C0@JI484CH0/:F/I]G)="Z>UA:X"[1*4!
M;'IGK0!YII&G0:9HG@K4[9ITN[F>".5VF8AXWC;*D$XV],#M7;^+[&YO_#5V
MMDSK>0@3V[(<'S$(8#\<8_&M7[#:B.&/[/%Y<!!B7:,(1P,#MBI)U=HF6,@.
M5(!(R : /,+[6+O5M%U[Q183W,,2QPV5LZYRD>]3-(!Z_,1G_9]JU4MM.TKQ
M7H]OH4SM]IMYC<QI<M(&C"960@D\[L#=[UU6A:+#HNA6NF+B18H]KMMP'8_>
M./<YJ:QT;3-,:1K&PMK9I#ES#$%+?7% 'FMGJH7X=^%HCJ#&\EU&)2#,3(V)
MCN!YSQT.:[WQ5:3WGA?4([5I%N5A,D+(Q5MZ_,O/U%61X>T873W0TNS\^1P[
MR>2NYF!R"3CJ#6ECC% 'DA\8W*ZJ/%/FRC2C";(QG)7S1#YN<>N_*_A6M:V=
MQ;ZMX8TVZNKMS/IMV]R#.X+.WEDY(/8L<>G:NT_L#2/L/V+^S;7[+YGF^3Y0
MV;_[V.F?>K+V-K)=Q73V\;7$*E8Y2OS(#C(![9P/RH \JMK"UA^%(N(9IUFG
MEC1_W[.%(GQ\JDD*?H*Z$VLF@ZWJ-K:W][)#)I,EPRW%R\I613@,I8Y4\]O0
M5TZ>&=$0W)72[4?:7628>6,.P.02/KS]:MS:;9W$SS2V\;RO$8&<CDQGJN?2
M@#S^P6XU=O"-G/JFH)'<Z)YMQY-TZ-*VV/EF!SG)/.<_G72^")[B71[J&XN)
M;@VM]/;))*VYRB-A<GJ3CN>:UH-&TVUDM9(+2.-K2'R("HQY<?'RCVX%36=A
M:Z>DJ6L*Q++*TS@=W8Y8_B: ..U7SM.\4_VCJD^H'3Y+B*.VEM;MECA)P-DD
M0(#9;/.&Z]L53O;V]CTC6;Z/4+A+FQUMOLJ&1B)N$ AQW!W$ =C]*ZZ3PKH<
MVK?VI)IT37F\2>82<;AT;;G&??&:E_X1_2O/2;[&GF)<M=J=QXF(P7QGKB@#
M@+J)M9\,V.IWE]=FXNM7B\V)+AT%OF4+Y87/RE0.OKDUK:MJ[^"]68375Q/8
M3Z>Y@6>1I&$\9Z GDE@P_*NGF\-Z1/;WD$MDC17D@EG7<0&<8PW7@\#IBL[5
M/"\=Z-&LX8H%TZPN1.Z2$LQ"@[5&<YR3SDT :?A^VNK70K.*]GDGN_+#322-
MDESR?P!./PKSZ:6=OA=JTZOF:YU*83[@2 #/L(/?&T"O4UX%85AX>2 :O9W,
M<,VFWTS3)$0<C>!O4_B,C'K0!S6MZEK>FV]YI-W+9W$=QI%S-"]I T1B**!@
M@L>/F&/I5FZ6V70?!BP+'N%Q:^3M]-GS8_#-='IOAC2-)>5[2TVO*@C9I)&D
M)0=%RQ.![5#9^$-$TV]CO+2RVRQ;O*!D=EBW==BDX7/L* *GA\"+Q;XEBC&(
MS+#(1_MM'R?T%,U.>^U#QO'HL5_-96L=A]K9K<*'D8OM R0>!UZ5H>']'GTV
M74KF[='N;Z[>=BA)"IT1>0.B@5/JGA[3M8FAGNHY!/$"J2PRM&X4]5RI!P?2
M@#BM)OA8Z)+!-J=Y]JGUB>-391H9;EAG( ((4=R>,4V36M7M=+U*XFN[HQ:-
MJ<)D698S*]N0I97V\$C=G(]!76#P;HD=A%9P6KV\4,YN(C#,Z-&Y&"58'(X-
M5[[PW:Z=X?U2VTJT#RWI!9)Y682.<+\S$D_6@#*DU77]8BURZT24M#!<1VUO
M&@3<RK@RLI;C<<X&>.*W_#&H0W^G2&*]N[EHI6207D82:)AC*, !T^G?O4>E
M>&+>U\+6.D2M(AMU5C)!(T;>9R68$8/4FM+2]&L]'AECM$?,TAEE>1R[2.>I
M)/)H YXS:IK6M:W#!JLEA;Z<R0Q+"B$O(4#EGW*?E^8# QT-<U%>7WB+5_ N
MH37LUO/<QW6[RE7:K(F"R@@_>QWSQTQ7<ZAX5T[4+R>Z8W,,MR@CN#;W#1B9
M0, , >>.,]:G7PYI:7&ES1VY1M+5TM KD! RA2,=^ .M %?Q;?W.D^$=0O;6
M39<01;D<@'!R.W2L'5=2U?1(=+LI=2N;JZU.9F>6&U5VA14W,L:@<\XQG/&?
M2NPU/3;;5]-GL+M6:WG7:X5BI(^HJ#5-%M-5MX(I_-1K=Q)#+$Y1XV QD$>Q
M(_&@#CI?$/B"UTJZC"SH\E[!:V-WJ%N(VVR$ EE& 2O/. #Q5W7[[6/#>GQ@
M:G)>R7EU%;0NULIDAW9W$!0 YXX&.OK6U+X8M+K29M/OYKN]25E=I)YB7##D
M%2,!<$9X J(>$+&2TDAO+B^O)'='$\\Y,B,F2I4C 7&3T'?F@#GIM9UJ+2?$
M3NMX]K!9&>VGO[,1L'P<H5VA6' /3O5JX\47.B3ZA]OD\R(:;'>VB! .<;60
M8QGYBO\ WU6W_P (W')IUY97>H:A>)=Q&*1IY1D*<_=   //7&:-4\*Z9J[:
M>UVDC&Q(\K#8R!@[6]1\H_*@#F;#5-2MG1)FB^T1Z ]R["-<B4,<\XZ9[=*D
ML]8URUN_#UW?7L,\>KB..2!(0JQY0LI4]<\<YXYXK<M=!M+M/MLAE$LUF]FV
MU@!Y98DXXZ\U)-X=MI1ID0>4'2E1K;YAR54J-W'/'IB@#D[;Q-J^IZE:);:N
M!-/J,D$MC# C^1"C,-^['(PHYS@[N*[C6[HV&D3W'VV"SV ?OYT+HO('(!&2
M>@YZD5P^DZ'K^GV]E8VUKJ%I<PW :6?[8IM"F_<X6/<3@C( VCKUKNM8TFWU
MO37LKHR*A975XFVLC*058'U!'>@#G/"OB.YO_$-WI<MU-=PI;)<1SSV;6TG+
M%2"I R.F"!Z\UHZ[JE\->T_1--FB@GN8WFDGDCW[(UP/E&1R2>_%3:7X<CT[
M5Y-3DOKV\O)(! TERRD;0<X 51CFIM8T&/5+FUNX[F>SO;;<(KB#:2 >JD,"
M"#0!ESWNN?VA8Z(EU:)>212SSW:P$C8K *%0MP3N&<DC@UFWGBG6K?3[BV"V
M;:I;ZK%8ERC"*19 &5L Y!PPSR>AK<G\+^:MI+'JE]'J%JKJM[E&=U8Y*L"N
MTC..,#&!61K7A1H=$MK.Q:[GGGU2*YNKK</-)S\TF>@P ,8Z8H CO=>\1Z7/
MJ6G.UG>7\5B+^V:*W90RA\.A&X\^AS6MI_B*75O$EO:V!C;3Q8+=3NR'=N?[
MB@YP.,D]:L:9X>&GW=SJ%U>7&H7DT8B\V95!6,9PH"@#OD^IJCX!T232-'ED
MG@E@FNIF?RI3EHXQ\L:'Z*!^= %W7]2U"'4M.TK2_(2[O?,<S7"EDCC0#<=H
M(R?F&!D5R/B35=9N?#>O:;=26@N=/DA6:2.)MD\4F"N%+?*?7)/>NUUG1#JD
M]K=07<MG>VF[R9XU#8# !E*G@@X''M6<W@V*32]1M[B^GFN]1=)+B[90"Q0@
MJ HX  &,4 :^EVMS;:2D<AM1<E22T$)2//8[<GV[UYS<-K,W@'Q6U]?Q7$"7
M%U%MV/O#"7'RLSG">BXX'>O5P,*!Z5R4W@N26RU>P&JRBQU%I9/),*DQ/(P8
MD-U/0X'O0!'8ZUK6FZC:6NMI9_9KFTDFC:V#9B,8!*L23N^7N .:S=-\>7=W
M<Z9<&73Y+6_G6/['$'-Q K'"LQS@]LC QFNLNM$2[U*PNY)25M(I(C&4R) X
M .?RJCI/AW4='^S6=OK3'2[<_NX&ME,FW^X7ST_#- $_C/4+C3?#%S/:2B*=
MBD22G_EGO8+N_#.:ALO"VEZ1Y-]&;G[1;J7>8W+L9?E.=^3AO7FM?5]+MM9T
MNXTZ\0M;SIM<#J/<>XZUDV6A:Q'(D5]X@>ZLHP5$0ME1I%QC$C<Y_ "@#+'B
M?7(;*UURZM+--'N)441(S>?&CG"N3]WN"0.QHU+Q3K=L^LSVMC9O8Z3+B9I)
M6#RIM5B% X! )Y/'2ID\'7IBMM-N=9:;1+:19(K<0!96VG*H\F<%0?0 G'6K
MUWX8:YT[Q#:?:MO]K,S!MG^KRBKZ\_=]J *]EK^JKXALK#5;2V@CU&"2:T$,
MC.Z;-I*N3QG#=15.T\6ZRUM9:I=:?:)I<]R+5F25C*&,A0/C&-N<<9S6W<Z&
M\^O:/J7G@+IL4T?E[,[_ #%49!SQC;[]:YGP_P"&=6O=(T^*_O\ 9ID=P;G[
M$UKMEW+(652Q/W<@-TS[T :&N>*[_1+YGG72OLB2*OV?[6?M3JS ;PN,8YSC
MT!J>^\0:S_:FIV6F:;;S?8 DCO+,5WJ4W;0!SN/;M5"\\"W\_P#:$$6H6BVE
M[>&[<O:%I@2P;9OW?=XXXZ5O0Z')%J>LWGVA3_:*(JKL.8]J;>3GGU[4 5=-
M\6)?WED#;&*SO;#[9#.S\Y!&Y".Q .<TS2UE\3W&E^(I%,%I#'(]K!D[F+$J
M';CH4 ('O6%XA\+S6_A;PYI%O)))>V\RVJW$,9'R,A60GKM&W^0KT"WM8K.Q
MBM;9!'%%&$C4=% &!0!AZ!K]SKCM*MM;):99>+G=-&P.,.FW@GKUXJ/Q1<W3
M7.EZ/:73VK7\Y66:/[ZQ*I9@I[$\#/:F6/AV_'B2'6+Z:R$D4+Q,;2!HVG+=
MWR3T[#GGO5[Q#HDVKQ6LEI=?9+ZSF$UO,4W*#T*L,\J1P: *CV]IX-T^[U%K
M[4KB!4_U%S=--N;/&TN202>.N/:GP>([N'5K33]7TY;-[U7-L\<YE5BHW%6^
M4;3CGN#@^E07N@ZUKFG7=IJU]9HCQKY"VL+?NY5((<ECD\CIQ^-.AT/6+S6K
M'4-9N;1A8(_D16JL \C#:7;/3C. /4\F@""R\97-TFGW4NCM%I][<?9DG%P&
M97R5!*X^Z2#SG/M7/0RW%[J?BW4=1MIB=/20+)!?-&\*K$3L3&!R,G/8UTT'
MA>YB\/Z3IYN(C)97BW+O@X8!V; ]^:1?"]RMMXJC\^,G62_E'!_=[H]GS?CZ
M4 $7B64/9:=IFG37T_V".[E#W 4I&1@ L?O.<'TSW(K'\,>)C8^&;"-XI;F_
MO;RX2*)Y,$;78DLQR  .._M6G'X;U;3-2BO]+FLC(^GQV=PMP'QE/NNN.O7H
M<?6LZ/P%>1Z5I22O8W=W8W,TKQSH?)G60G(/!(/0C@]* -<^,XX]-O;B:PF%
MS93QV\]M&X<Y<C:5/1@0?;TXI_\ PD]P\E]8R:9+;:C#:_:H87F1O,CSC=D'
M (/45 ?#5S+HTUJEEI5A(]U#,$M 0NU&5CN.T9/!QQ5VXT":?Q8^J^8@@;3#
M9;>=VXONSTZ8]Z ,B/Q#<W'AW0KO4X[VUDN;RUB62WEC G9^Y'.$/<<'TK5U
M+Q-+I4X:ZTFY2P,ZP?:_,3&6(&[9G=MR>N/PK,7PWK5SH.C:;=?8XVTR^MI0
M\<C,)8XCR>5X)]/UK,U+P/JM])>B6&QN9YKH3IJ$TK>8L88$1JFTA< 8R#0!
M8?59+2X\62RW-\L%LEEY:P.-T>Z,9V!LJ,D\\<UHQ^)]5/BC4-.32)[FVMK>
M%P4>-7&[?\QRXR#M& !D$'/:J]WX7U"[M_$+1-"3J:6A@RQ'^K4!L\<=*U(]
M-U*S\6RZC!#!-:WMO##,6D*-$8R_(&#NSO\ :@"6/Q5:S:=I-W'!,S:G(L<4
M/&]202V[G^'!S]*WQTKSSPYI2)XTU>X\]&T[2IIF@ 7B.6;#2#_@.,?\"KK_
M  ]?W>IZ0EY>6OV9I78QISDQY^0D'H2N#B@#SCQ#K=[!\4H8IY5.FP36\9R
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MAG!1<8<9ZG[QK(9].U7Q#)IU['I,=PVM/(UW>3KY[(DAQ$(R,\@!1SC!SUH
M]GW^U&[VK@=)TJWF\1>*;Z.WCFOK2X M-XR(G\D8*CL3QDCTK)\.6JW=GH=]
M%>Z1!J F5IYBS&YF?D21N#U))/!]* /5-U&[VKR*ULIM4L[R::]TNTU9-1;=
M>7,C"Y@99 0@']W;P!G&#6K?Z79ZIK'C22[C\U[2")H<L<1-Y).Y?1N!SUH
M](#@TNZO-[*TBLK[PC?6V\7E_#(;F8N2]P3%N^<D_-STSTK/T*TN=0M=-U)+
MO2K?4?M8,]T\[_:';?AHF7'.>FW.!Q0!Z7I38TR'OU_F:1+^V_MJ2P\W_2A;
MK*8\'A-Q&<].M>96NFVUWX=\8ZC,9#=6=S</;.)&!@9%W KZ'/7'6M>.STZX
M^(\,E[%%YDVD0SAF.W=*).O7D]* .[O-1M-/$)NIEB$\JP1;OXG;HH]S5<:Q
M&?$#:1Y3^8MJ+GS,C;@MMQ]:YWX@V=O<V^B/<)N5=5@1FR1M1CSG'3.!S5:?
M0M,O_&Z6+JS6<.D+LC29@#B4CD@Y/Y]: .[W<=*@N;^VLUC:YF2)9)%B0L<9
M=N /J:\XL-06^T30M+GMY=1O9'N%A2:Z:&,I&2"9&&2Q Q@8-48XTOO"=NMY
M(95MO$)M4*W+NJ1F7&T/D$CL"1GITH ]6O+M;.SGN74LL,;2%5ZD 9XIFG7Z
M:CIMK>QHR)<1+(JOU (S@U2O[:&Q\,7EO;J1#':R!07+'&T]SDG\:XO2;0Z0
M/!=Q:W%SYE\OE7(DG9E=/)+ ;3P,$#& * /2]U .:\ODNG?4M,U73;>\BM[G
M54@-[/J#%I@7*LODY("\$#H>.E:L(DTGQ8)M6:YN%O;PI97L-TQ0$@XA>+.
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MD,4]OK2TA[?6EH **** "BBB@ HHHH **** *MO_ ,?5W_UT7_T!:M55M_\
MCZN_^NB_^@+5J@ HHHH **** "BBB@!#TI:#THH **** "BBB@ HHHH ****
M "BBB@ HHHH 0TM(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0
MG%9EQXBTRWTQ-1-TDEK))Y<;PYD\Q]VW:H7)8Y!&!Z&@#4HJ&VN4NK9)XPX1
MQN ="K#Z@@$?0U4TW6[#5GE6RF,HC)!<(P0X)!VL1AN01P30!HT444 %%%%
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MI%V\]?D7I5RO,M/U6PO-2\)6]M<Q2RQE6<1G.S_1U7!]#G/'7BO3: "BBB@
MHHHH **** $/2EH/2B@ HHHH **** "BBB@ HHHH **** "BBB@!#2TAI: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!&8("6( '4FF^:GR_,/FZ<]:
M9=6\=W;2V\R!XI4*.I[@C!%>0F]NT^SR^8W_ !2)"3^CYFV?^B5S^- 'J][J
M'V0P!+::X\V986\H ^7G^)LGH/ZUB7'BQ;>-W^QL=FJIIN!)W8J-_3_:Z?K7
M,JLCZ'I.JRLWG:IXABN<YY$9+!!_WP!3;\@V=Q@@Y\60?^A1T >GCA:QKW7F
MAUZ'2+:RDN9VA\^1E=5$<>[;GGJ<]O:MD=*X>73K5OBC<2"W5I5TI9T.3_K/
M-(S_ "H [8.O3/('3O3MPS7DXEL8_!FFZS;7C/XDGGA5I///FO*7'F1E<] "
MWRXP!71Z=8PW?B#Q%J%Q)<-)9W@6!/.?9'B%#D*#@DY]* .UW#%&X5Y-X.9=
M:O\ 16+A;BV1I[N5M2$CW3$?+^[#[N#R=P&,8YJ3S=W@%O$,E[.GB)IL;A<,
M"LPDQY(3.,8XVXZ4 >K4FX XID)9H4+_ 'BHS]:X[Q)/!>:Y-I\=O<2SP6?G
MR.=0>VBA4D@,-N<MP><?C0!TMUJ\%KJUEISI(9;M)71@!@", G/_ 'U1HFKP
M:[I,&HVR2)%-G:)  >"1_2N+T6\GO;GP9=7,K32M8W9=VY+D;!U_K6W\.B#X
M&TTCNK_^AM0!U!8"DWC%8?BBUO[RS@CL)L.LP>2W$YA-P@ZH'7D>OX5S5EK/
MVS7/"0LI;V&U>6]BN()YRQWHGW6.3OP<XY- 'H6X5GZMK-MHUO#-<K(4EG2!
M=@!.YS@?A7#ZCJ]R8]86'4Y8[>778;,SQRY\J,HF\(W\/.1QT)/>K/B[2X+/
M1H;."_NW\S4K7(EN#*\.6P"I;)&>OIQ0!WX.:"=H)/05RFB12Z9XOOM,2\NY
M[0VD<ZK<SM*R.68'#,2><=*ZB94>WD63[C*0V3CCO0!EV?BC1]0NEM[2[\UW
M)5"(V"N1UVL1ANAZ'M6E!=07*;X)4E3)7<C!AD'!''<&N,LX[[PO=Z?H,T\=
MWI-XSV]I(N4N+?Y2P!(X8  _,,&L/2Y9=%^']UJ-C=7"S37TMLIDF+K$&N2F
M_:<C< <D]Z /5-P-17-S':VTMQ)G9$A=L#)P!DUQ&I7-WX4UFRAM+R]OH[JT
MNI98;F8RD-%'N5P3]W)XP..>E3:;;SS>$DUF?5[NZEN=/:>>(R Q.6CSA5Q\
MH&>WXT =?8WL.HV%O>VY)AN(UEC)&"589'%6*\]^'5_=Z@EO#=7+6RV-C!'%
M8#'[Q"@Q.QZD'H .F.:]!;.TXZXH R+[Q5H6FW9M;S5+6&=<%HV<97/KZ5>E
MFCGM8Y8G5XW>,JRG((W#D&N8^'T<$_A!9YE62YN9IFO6<99Y-[ AOP 'TKFK
M*XOHM'\/:?IUZ]K:76K7$$;H%;]RK,5VY!'&./PH ]4=UC7<[!1ZDXJ"34+2
M&\@M))T6XG#&*,GE\=<?2O-_$CWS:-XHTFXU.>ZBLFMY(I#LW8D/,;D+R 1G
MH#TKH;FXN=&UC1+3[9<W4;I<22M-L)8+'N R%&,=L8H ["BO-QJVM)X.M?%3
M:P[32R)(UIM00&-GV^6!C=G'?/6K-_=ZW<WGBJ6#6I[:+2E62WBBC0@MY(<A
ML@DCCIQU/- '?T5P6HZWJB1:;J-Y=7=GI<UC'(]Q9Q(ZQ3M@DR@@G9@C&..N
M<5W43!XU8,&! (8=Z 'T5R7B/498]4%K;ZIJ*3"W\P6FGVJ2,/F(\QV8$;>V
M.,X-9MGK>MZS;^%TBU 6DFH6LLETZ0JQ.W;RH/ /7U'/2@#OZKB]MVOGLA*I
MN4C$K1]PI) /Y@_E7"-XDUF*SETU;H->?VV-+CO6B4D(1NW%<8SCCIBM'1+>
M\M?'VH17E\;UAI\.R5XPC;=[\';P><\X% '2Z2?^)9#^/\S4=KJ^G7=[)%;7
M]K-(%7*1S*Q')[ T_2_^05%]&_F:\?TBU$^FZ%";&"T\[4 4U8$;PRS2'9@#
M(+<J,G''X4 >W YHK@-0\1:O=:KK$6G74L"Z:WEPP1Z>TXN) NXAV .T$\#&
M.YJ74=?UB.\TYKFZ_L6TGM(I#)+:>:GGM]Z.1L_(!P.V<]: .YR,XIDT\5O&
MTDTBQQJ,L[L  /<FN/TN'56\=:PQU<M;Q"%C"8%PRL'(4'/&/7OWK.34-9O_
M  )J6LZG=6ES ;:8)9M:J5RCD!FR>>AXZ=.] 'H@8-R.1ZT9YQ7'_;]<U37+
MJPTJ\M;&&PAA9C);^897<$X^\,*!CIS533GUD?$#5EGU&/RX;:WEEC$+,NT[
MLJGS<'@_-CGCB@#O*9--';PO-,ZQQ(I9W8X"@=23V%>=6/C75+J2SODD>:*Y
MG"-81Z;-^[C+8#";&TD#!/:GZOJFO:UH/B6\MYK.+3+=+FV%L\9+R*JD.^\'
M@]<#&/7UH ]$5U= ZD%2,@@Y!%->5(QEV"CU8XJOI?\ R";3_KBG_H(KF?&.
MDSW=W8W[:6FL65LKK-ISD?-NQAU#?*S#!X/KQ0!UZR*X!4@@]"*=7FTE[+-?
M>%8_"]W'8V,SW$8MWA?;&Z(Q974,,@$8"]CSTK;_ +7UW4[_ %&WTJ:RC33=
ML4KW$#-Y\VW+!<,-H''//6@#KJC,T8F$)=?,(W!,\D>N*XNP\7ZCXB&FP:/%
M!;7%Q:-=3R7*EUC"OLV@*1DE@><]*KZ[K-QHWB32KF]@CDU![":&..!B4DF:
M2,*H)Q@'KDT >@454TXWGV&+^T#";O;^]\D$(#Z#/-6Z "DW>U+WKSW5VL'\
M=7T>IV^H7,"VD)CCM1,VTDMDD1GCMUH ]!ZBHH[:&.XDG6)%FE55=POS,!G
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M^]&KZ?\ VKI%S8>>\ N$,9DC^\H/7'X5E^&_$CZ]]I5[&YMVBED4,\152%;
M&3_%ZBMNYG%M:R3%)'"+G;$NYC]!W- "06D5M:1VL:@11H(U7L% QC\J?'!'
M"FR)%C7^Z@P*X>Z\97%WX'.K11SV,Z/"79HB$P9 #M)'S#&:Z+3O$^G:D]Q&
MC3P26Z"61;F%HCY9Z. PY7@\T 6[6V@6[NBL,8Q*&&%'!V+S]:OUSVD^)M,U
M'4I(8))0UP1) 9(719E"KDH6 !_R>E=#0 4444 %%%% !1110 AZ4M(>E+0
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M#!5SA<@GIBM.VU&RO49[6ZAG5#AC%(&"GWQ3K:]M;P,;6YAG"'#&-PV#[XH
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M5JRS1P1M)*ZHBC)9C@#ZF@2HRA@P*GH0>#0!S\?@C1HKE) MP88Y?/2T:=C
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MW\/:Z/#NHP>0L0:YAGL=/DNC)Y2HRLR;R.,E3CJ!6CXC_P"1HTC _P"6B?\
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MJK;X^U7?_71?_0%JU0 4444 %%%% !1110 AI:0]*6@ HHHH **** "BBB@
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M,NW/7%:-X7U?0CJ<DTBKJ.O1"%HW^[$K^6I7TSM)S[UZ)_9%@'NV%G #>?\
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MLFI:[>ZC;&-HOL\JHBE6&#NV*"W!/6@#%M]=\1:=IVAZIJ$UG-::C-!"]I'
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M:/ _('\J -O3]1M=4L([RSE\R&0':<$'@X((/(((P0:R(/%5O-XGN]%,$ZM
ML963RG(=F+ C[N !MZYP<^U'A&RFL=-O$GMV@DDU"ZE"L,95I6*D>VTBJZBZ
ML/'EY.UC<2VU_;6\<<\2@JC(9-V_GC[X- %;PYXTM)[>*WU._!OI+J6$'R\*
M#O8(A8#:&( P#R?QK:OO%&D:==26]S>!9(@IEVHS"$'H7(!" ^^*Y0Z)J'_"
M P6:V+B[&J).T>!D+]IW%O\ OGGZ4RZTM[;5M<@O1K?E:C,9(SI\2/',C(J[
M22I*L,$<D#&* .PFU9;;5)UFN[=;2*S^TLN&\Q1DY;/3;@?6I-,U[3-9,O\
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M?9T"@Q;6:7!"CCITXX[5SMO-<W&B^%([R6S?3\W*9U#+1%T9A&K^N%&!GN*
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MYNUMX[*_26"4A3E;A"<$'/W6"MQC- ':T5B>&-4N]9TEM0N%18YII/LP4?\
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M8&,\#OCM0!T:NCYVL#@X.#T/I3J\[\-ZU+#K6JZ/I]ND]Y+J]S/.7;:D,6X
ML<=22, #ZG%=GK=^^F:%?7R+N>W@>10>Y )% %_<*BNN85_ZZ)_Z$*XM?# /
MAC^TYM1OFUK[-]H^W"Y<$-MW !<[=O;&*6W\5ZE?V^C6MM8PRW5Y81WCR2R>
M6B$.HY !."3V]: .YR* 03BN#N_$^L7UKI[6=O#;7":K]BNHFF)!<9^4$+RA
MZYZ^U7KK6+?2-?OKJ^MRLT&DK<321SLRX#L-BJ<#.>_!.: .OHKEXO$FIV]U
MIJZMI<-M!J+^7$\-P9&C<C*JX*CJ >03@U5_X3'4!!)?-I,8TV&]:SEE^TY<
MXE\K<J[>F<9!(/7TY .RHKG(?$=S=>([K3(+:V"VLBI)YUSLE<%0=Z)MY49]
M><&NB% "GBDR*#TKB+C6[K1+KQ7;SS/*88EO;-6.6 =2NT>P=>/K0!V^X&C<
M*\ZAU34X?!T^C37TIUN.^73?M&[+EG8$.#_N,3^%6=<UF^TBW\2R:?YSW-FD
M#&2XN-R("I^9$*D#IR.Y.<T =?I7_(-A_'^9JRH_TF3_ '%_F:X*>_U)/^$7
MG_L[?=&:8+;Q7 (?*-@EB  .YX.,=ZZG0=7DU9KSSK4VMQ:R"":(N' 8<\,.
MH(8'H* -FBL+7/$$FE:C8V%OI\MY<WJ2F%4<*,ILSN)Z##9S[>]5+SQ<\%Q/
M;V^G/<S6D2R7BB95,9(SL7/WWQV&!TYH ZBBN:D\7)+);QZ992WSS60OOE98
MP(B>#ENYYX]N<4L?B:[NM+LKVRT6>=;N+S@3-&B(AQC+$]2#P,?7% '24'@5
MRS^-8#I&FW]O8W5PVH3M;QP)M#AP&R#DXZH1U]Z?<>*YH[Q+&'1KRXO5MQ<7
M,$3QY@4G !);#-P> 3TH Z4$&EKGO!%W-?>%+:YGEEDD>2;+2DEL>:X .?08
M'X55?Q'JJ>-GTA=)EDM! K[U:/=R^WS,E_N=L8W<=* .KHKE#XWAS)<)IEZ^
ME1R^4VH@+Y8.[:6VYW%0<@D#M74AMP!'(- "C&3Q2X'I7F%OXEU8+'=0:XMY
M?2:BT']C^7&2T8F*G&!N7"?-N/'%=;J'BN.RN[F"'3[R]6T4-=RVRJ5AR,X.
M6!)QR0 <"@#H<#THVC.<#)[U@7'BN!+Z.TM+.[OW:V6[8VRJ0L39"M\S G..
M@R:K6_BJYE\67>CMI5WY403;,L8(&=WS-\W"G'!ZT =32;5QC:,>F*Y*7QE#
M>Z/J5S:PZC:Q6UO)(;QK8%59#@A03AF'IT]ZN7?BNWL9(+9;6_OKAH%FD%K;
M[S&AZ,W.!GG@9- '0[5W;L#/3.*;Y,0W?NT^8Y/RCDURMOXTDG\52Z2-)OC"
M%C*3"$Y&XD;F!Z)[_I5N+QCITUY'"D=UY$LOD1WIA(@>3.-H;UR".F,T =#M
M7=NP,XQG'.*1T25"DB*ZGJ&&0:Y/Q!XRMK6TU>VM?M1N+:WD4W44!:*&782J
MLW8YQ[>M=!I$TMQHUC/*VZ62WC=V/<E030!<6.-#E44' 7@=AVJ.2U@DA,#P
MQM$>J%05_*N3TK6=8U76;U%U&PMQ:7CPMI\D!,IB4X#;MV<D<@@$5>TSQ9'?
MZG?VDMK<6Z6TA FDB95VA Q+DC"]^O48]: .ACBCA0)&BH@Z!1@5'<VD%Y$T
M5S!%-&>J2(&'Y&L>R\7Z9?7,42&XC2=MMM-- R1W!QGY&(P?Z]LU(GBG39=2
M:RC>9V67R3*MNYB$F<;-^,9_'';K0!IO96\ML;:2WA: C!B9 5Q].E-33[2.
MT%I':PK;CI$J (._3&*YWP[XH6>W6'4KH&\GOKB"WC5"694<@<*. !U)X]ZZ
MR@"$VT1G$YB3S@I02;1NV]<9]*R=3\-V]^^GA4@C@M;EIWA\H%9-RL",=.2Q
M)ZYJUJ.N6.ERI'=/+O92X6*WDE.T=20BG ]S4,_B;2+>SM+N2^007>?L[!6;
MS.,X  SGVZ]J +2:1I\>GM8)86JV39!MUA41G/7Y<8ID&A:7;6\MO!IMG'#*
MGER1I H5UYX(QR.3^9J"#Q-I5S%!)'=_+-/]G7=&RD2_W&!&5/LV*O1WUO+?
M3622@W$**\B <J&SM_/:?RH <;*W+POY$6Z#(B.P9CR,';Z<<<5G:5HGV#5-
M4U"5XY)[Z8-E%V[8U&%7W/4D^]6=1UFQTORQ=S[&E)$:*C.S8Y.%4$\?2LB_
M\56]AKEDLU["FFW%D\X?;DNP90NW')X)XQ0!KZWI<>M:-=Z;*<)<1%"<9VD]
M#^!P:L6,4UO86\-Q*)9HXU5Y ,!B!@G%4I?$.EQ:?#?-?1?9ISB%U.[S#Z*!
MR3["@>(M);3UOQJ%O]E9_+$I; #>AST/UH NW=E;WPB%S"DHBD65 XSM=3D,
M/<5!J6C:?K$*Q:A:1W"*=R[ARI]0>H_"JI\4Z*+&*].HP_9YF*1OS\Y'4 =3
MC%23>(=)@TV+4)-1MQ:3'$<N\8<^@]3Q^E #;#0M,M]/L8H;*%$MB)H@JXVO
MC&[Z\GFK_P!B@^W?;?*7[28_*,G?;G./SIFFW,-WI=M<6\BR1/&"KJ<@C%5+
M[Q)H^FW2VM[J5M!.0#L=P" >A/I^- $G]A:<;%+(V<?V9)1,L?8.&W!OKGFE
MDT/3Y1*'MD(FG6YDY/S2+C#?4;1^58'B'Q6]IKVGZ197UC;/,K2337*%PHXV
MJ ".6R<'/:NEO[PV.F75WMW^1$TFW.,[03C/X4 <;XJTRSNO%NGO/;I(TZI!
M+NYWQ[\[2/3D_G71:;X3T?2;E+FSL]DZ*461I&=@I_AR2>..G:N&N/$5]J&O
M>&+B_P!-BMDU!T,#17'F<9##<"HQQGH37HK:UIL>H"P?4+5;L](#* _L,>M-
MB103P?HJ6]Q +1O)N)%D>/SG*A@VX;1GY>>>*;J7A+2=5U W5S#+YLB[9?+G
M>-90.@<*0&'UK3DU;3XKY;&2^MDNW^["TH#G\.M9^F^*M)U2\NH8+R#=:NZ-
MNE7Y@H!++SRO/7V-(9<_L>SCU&"^2+9/# ;:/:Q"K&2#C;TZJ*GLM/@T]9EM
MU*B:5IG!8G+L<D\^]4KW6X%4?89K.ZD6:))4^U*FP.<9)YY]!WJ]+J%E!<1V
M\UY;QSR?<C>50S?0$Y- &7J7A+3=4U%K^8W<<[HL;M;W<D.]1G (5AGJ:?+X
M5TI](BTM+8PVT3B2/R'9&5Q_$&!SGW[U+8>(=/U+4+NR@G4S6TIB92RY8@ G
M;SR!FKL-]:7$LD4%U!+)']]$D#%?J!TH R[7PKIMI%?(J2R?;DV7+33,[2#!
M'))SWJ(^#].:QMK9I+QVMI?.@G:Z=I8FQCY7)R!CC'3VJQK?B"WTNS>2&2">
MXCEBC:#S1N >14R0,D?>S6NSA8V=C@*"2: *>F:7%I<<J1S7,IE?S'>XF:1B
M< <9Z#CH.*I^)M,N-9TK^SH2HCGF03L3C$0;+8]SC'XU7TSQ/+JA@FBTB\33
MYRWEWC&/;@9PQ7=N ..N/RK1TS6;+5DE:TF#^5*\3@\'*G!_#WH T%4*H &
M*PE\)Z>(;ZW)F:TO=QDMVD)12QRQ7NISSG/';%;,5S;SEA#/%)M.#L<''Y4C
MW$8WA9$9T&2H89H P])\.V]GK$MX]S=W5Q"!#$]S+NV*54D#@<\#GKQUKHJQ
M/#FK+J]@-0,8A-T5<1E]V/E'&>,UMT %%%% !1110 4444 !Z44AI: "BBB@
M HHHH **** "BBB@ HHHH **** $-+2&EH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &R1K*A1U#*1@@C((K%L?"UGITD1MKF_6*$DQV_VMS$N>P7.,
M>@/ [5MLP12S'  R:P]0\2VUKH4&KVR_:;>>6)$.2F0[A<\C/&?2@!T'A72[
M9;40Q.CVT[7"2ASO+MG<6;JV<\@]:9%X3L[:;=:W5_;0&7SC;07#)%O)R>!R
M 3U .#GI6X&'<TNX>M %&TT>UL[B^FC#%KYQ),&.03M"\?@*H:=X4M=,G1H+
MR^^SQ;A!:-.?*B!!! 7N.> 2<=L5JV.H6NIV4=Y9S"6WD!*. 1G!QW^E6-P]
M: .>F\(02:=;6$.J:E;6L%NML8H95Q)&!C#94\XZD8/O3KCPE;/=1W-E>WNG
M3) MN6M'7#QK]T,'5AQZXS[UO[AZT;AZT 0VEM]EM8X/-EEV+C?*VYF]R>YK
MG]1\$VVHRZA_Q,]1M[?4.;FWA= CMM"YY4D< < X-=,2!UHW#UH S;;0[>UU
M:34DEE,TEM';%21M"H20>F<\^M<WKWA4P^"H="TQ9[AUN4,4K, \.9,LY( Z
M MTKMMP]:A2[MI;J:V25&GA"M)&.JAL[<_7!_*@ L[:.SLX;:%0L42!$ &,
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M'0'D\]A70%04VGD$8- ' Z%'KDQTG5(9-3E-SM>]^U749@:-E))1 QVD'&,
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MJOB1];_L:T?2_/BLEN)II89-I?)&% ?H2!].>M; T$O/IEQ<W]Q<3V#R.))
M@,A<$<A5 X!XP!TJ1-%CC\0SZP)F\R:V6W,>!@ $G/UYH YFP\4Z]-#I%_=6
M^G+8WUPMK)%'O\Q&.5W!B<8W \8Z8YJ-/$$^EV&JS6-A8I*=?:TVA642EMHW
ML<_>.>3[=*WHO"T46DZ;8"YD*V-T+E7*C+D,6P?^^J@E\&P202Q?:Y!YNJ_V
MFQVC[W'R?3CK0 RUUS6(K[4M+OQIQO8+5;J&9-\<)5B5P^22,%3D^E4+3Q5J
M5]=7VF)=:3<S"Q:Y@N[,L8UP0I5AN)SR""#6IK?@^#7+G4)IKJ6/[99QVI"
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M1(]SOB0JJ*JC)X'Z9-:2>*=-;3+N_=Y88[1MD\<T++)&W& 5//.1C'7-<O\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28%+2'I0
MR #R(\?W1_*GX%1VW_'M%_N#^52T )@48%+10!QWB,#_ (2G2/7S$_\ 0Q76
M);01S/,D,:RR8WNJ@,V.F3WQ7*^(A_Q5&D_]=$_]#%=>.E-B04S \P<=C_2G
MTW^,?0TA@P''UI<"D;M]:=0 FT>E&T>E+10 F!1@4M% "8%&T>E+10 FT>E&
MT>E+10!4MU'VN[X_Y:+_ .@+5NJMO_Q]7?\ UT7_ - 6K5 !1110 4444 %%
M%% "&EI#2T %%%% !1110 4444 %%%% !1110 4444 !HH-% !1110 4444
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M6@ HHHS0 4449H **** "BBB@ HHHH **,BB@ HHHS0 4444 %%%% !1110
M4444 %%%% !1110 4AI:0]* ([;_ (]8O]P?RJ6HK;_CVB_W!_*I: "BBB@#
MD/$7_(SZ3_UT3_T,5UXZ5R'B,?\ %3Z3_P!=$_\ 0Q77CI38D%-_C'T-.IO_
M "T'T-(8I[?6EI#V^M+0 4444 %%%% !1110 4444 5;?_CZN_\ KHO_ * M
M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%% "&EI#2T %%%% !1110 4
M444 %%%% !1110 4444 (:6D-+0 4444 !Z4444 %%%% !1110 4444 %%%%
M !1110!1UG3X]6T:\T^3[MQ"\1/ID8KS'4;F]\0Z/I:V[.;G2+!KV4#@FXC?
M8 ??,<E>MFLG3_#MAIEWJ%Q;1G??OOFW-D=^!Z#D\>] '-I<KJ^KZIK:*KPV
M.E+%"&&07D3S6X^FP'ZU#;'4K[6_#,D.H?9?M&D&4QQP+L7B+("^^>/3'%=-
MI?A?3M(T:XTJT21;:XW[\OECN&#S], 4V7PO:NFG"*XNK>33X?(AEAD 8QX
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M]WJT=UK^H1JMS.L=JN!_#$.2#[NS'\!0!T6I^(-+T;8-0O(X&D!**V2S =2
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MU.34EAQ=R1"%I-QY4'(&,XZFN8O?&=W;OJS0:))/;:5(5N)O/5<J%#':.I8
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MO[;_ (FD%NVD272)?W"RN'5@ P(8E>#T]J;8SZCJ[^%;1]5O84N]*DFN7BD
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M QRJD\XSR>:U* "BBB@ HHHH **** $-+2'I2T %%%% !1110 4444 %%%%
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M)Y]1N["%1<R0*\<V4^4G@D]&P#D=L&L6STUK7Q7X>6*.Y:UMM(>(2SK\W&T
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M#Z'^E/IO\8^AI#%/;ZTM(>WUI: "BBB@ HHHH **** "BBB@"K;_ /'U=_\
M71?_ $!:M55M_P#CZN_^NB_^@+5J@ HHHH **** "BBB@!#TI:0TM !1110
M4444 %%%% !1110 4444 %%%% "&EHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CGMX;F,
M1SQK(@96 89&0<@_@0#4@&!110 4444 %%%% #!$@=G"@,V,D#DX]:?110 4
M444 )@5!=#]TH_Z:)_Z$*L5!=?ZM?^NB?^A"@";:*-HQBEHH 3:*-HI:* $V
MBC:*6B@!-HHV@4M% "$9I"HQ3J* *.E ?V9#^/\ ,U851]I?_<7^9J#2?^09
M#^/\S5A?^/E_]Q?YF@"3;[FC:*6B@!-HHVBEHH 3:*-HI:* &[![TNT4M% "
M;11M%+10 FT9S5.^TR&_GLII6D5K.;SXPA !;:5P>.F&-7:* &[![T;!3J*
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M M%-W4NZ@!:*0-FC/- "T5!/>6]M+!'-,D;SMLB5C@NV,X'J<"ILT +1110
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M%X[Z;SY\R-DR8 W*<Y4@*,8QC%16F@66CAY+9[MWD>,,UQ=23<!A@#>QQ^%
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M*17-YJ4ME-*T(Y51)SM[-\H/U'IQ3[C6]<T^+7(3>BY?1I89S(85W30,,NA
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MOILYEWPV[++<91E+.Q/WN?\ Z] &AX4U77]2OM234(+7[/!=R1;TF):-AC"
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M4D$I A";L8(P,8YSFN@M%@U7Q)KTNLZA- ]GY*11+=/ ($V;MXP1G)+<GTH
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MUC>'-1L[O1[<V\TQ&6CVW4A:4,I(92226(/&<GZFMF@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ;L <N ,GJ>].HHH **** "B
MBB@ I#TI:0T 1VW_ !ZQ<8^0?RJ6HX/^/>/']T?RJ2@ HHHH X[Q)_R-&D?]
M=$_]#%=C7'^(Q_Q4^D?]=$_]#%=A38D%,_Y:#Z'^E/IA_P!8OT/]*0Q6ZCZT
MZFMU'UIU !1110 4444 %%%% !1110!5M_\ CZN_^NB_^@+5JJMO_P ?5W_U
MT7_T!:M4 %%%% !1110 4444 (:6D-+0 4444 %%%% !1110 4444 %%%% !
M1110 AI:0TM !1110 4444 %%%% !1110 4444 %%%% !1110 8HHHH *3'-
M+10 =J;MIU% ";:IVFEVME=W=U"A$]VX>9V8DD@  <]  .@XZU=HH 0C-)MI
MU% #=HI=HI:* (Y8(YXGBE4-'(I5E/0@]16#;>#=.MI;?,]]/;VC*]K:S7!:
M* J, J.IQVR3CMBNBHH 3;2;/>G44 )CBDVBG44 (!BD* G-.HH ;M%-$$8D
M,@10Y&"P')'UJ2B@"(6\0E,HC42$8+[1DCW-(;6!IA,88S*!@2;1N ^M344
M9NN:/'KFEM822O$IDCDW* 3\CJ^.?7;BKD-I!;AA#%'&&.Y@BA<GU.*FHH K
MQ6%I!*\L-M#'(_WG1 "WU-0W-G;K#'B",;)D=<(.&+#)'H>:O5!=?ZI?^NB?
M^A"@!G]GV?VK[5]EA^T_\]O+&_\ [ZZTKV%K);M;O;PM Q):,Q@J2?;I5FB@
M"D-'TT6AM/L%M]F)R8?)783_ +N,5/!:PVL*PV\211+PJ1J%4?0"IJ* */\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&B@T 1P#%O&/\
M9'\JDID/^HC_ -T?RI] !1110!R'B/\ Y&;2/^NB?^ABNOKD/$?_ ",^D_\
M71/_ $,5UXZ4V)!3?XQ]#3J:?]8/H:0Q3V^M+2'M]:6@ HHHH **** "BBB@
M HHHH JV_P#Q]7?_ %T7_P! 6K55;?\ X^KO_KHO_H"U:H **** "BBB@ HH
MHH 0TM(:6@ HHHH **** "BBB@ HHK#UOQ9IGA^[M[6]^T--<*SQI# TA('7
MH* -RBL_2=9MM9LS=6R3K&&*8FB:-LCV89[U>W4 .HINZLK7/$-MH(LS<0S2
M?:[A;=/* .&;N<D<4 :]%-+=/K1N]J '44FZC=0 M%-#9[4Z@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J"Z_U2_P#71/\ T(5/4-SS&O\ UT3_ -"%
M $U%%% !1110 4444 %%%% !1110!3TK_D&P_C_,U87_ (^'_P!U?YFJ^E?\
M@V'\?YFK"_Z]_P#='\S0!)1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>E+2'I
M0 R#FWC(_NC^525'!_Q[Q?[@_E4E !1110!R'B+_ )&?2?\ KHG_ *&*Z^N0
M\1_\C/I/_71/_0Q77TV)!3?XQ]#3J;_&/QI#%/;ZTM(>WUI: "BBB@ HHHH
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M *M?^NB?^A"IZAN>(U_ZZ)_Z$* )J*** "BBB@ HHHH **** "BBB@"EI/\
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MK;37+C*QHV2>,\?AVIT/BO09[\6,6J6SW1+CR@_(*9W9],8/Y5YEHT%SK/\
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MYD(!(ZD'G)YY% 'HJW4#R"-95+E ^S/S;3WQUQ59;VWO[036S[T$P3.".5<
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MPOXM1LX[J*.>-'&0L\31./JK $59S6'K=W-X>\(WEW$[W4]K S(TV"6;L6P
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MT?Q/J%_'H#2B &_FN(Y=J$?+'NVXYX/RC- '70016T"001I%$@VHB*%51V
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MTL33;0ZOOP V.N&^E=_@>E&!Z4 >.Z_HFI7FL-=W=ND%]J5S;LMJ)0PC1'0
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M,=1,6MHGV'5)K*T2ZMWLD<+(&W J5)8Y&W/!Y!KH=3T8:WX?6QDG:$D1NLB
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M+B"0IN4.IR,CN.U9EWH6LZC:Q2W6IVJZA;7*W%JT-N1$A (*L"Q+ @G/(]J
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M:'LWF:X"HVR<FV?_ $<YQB3CY.>.:MZAXKTS3KU[*5YI+I(Q*88(&D8H<_,
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MC[^ 3G..V* /1\CUHJC"+\ZC.TSP?8BB^2JJ?,#?Q;CT(]*O4 5;?_CZN_\
MKHO_ * M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%% "&EI#2T %%%%
M !1110 4444 %%%% !1110 4444 (:6D-+0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1BBB@ Q1110 48HHH ,4444 &*:Z+(I5U#*>H(R*=
M10 8HQ110 48HHH *,444 %%%% !1110 8HHHH ,"C ]*** $(J&Z_U:_P#7
M1/\ T(5,:AN?]6O_ %T3_P!"% $V*KI8VT=_+>K"@N94"/(!RRCH#^9JS10
M8HP/2BB@".:&.X@DAE4-'(I1E/<'@BF6=I!86D5K;1B*")0D:+T50, "IZ*
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MT2-+6:^9F9W9F =A@MSGIZ=*T]-TR/3=)M].B+-%!$(@6.20!CDU<;J/K3J
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M7+'>!YF_=\OMC;U]ZW[>83VT<V,!U# 'MD9H EHI,CUHW#UH 6BDR/6C(]:
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M@ HHHR* "BDR*9-<0V\1EGE2*->KNP4#MU- $E%(&4G (SZ4M !136=44LS
M =23TIV>,T %%(KJXRK!AZ@TM !13=Z[MNX9],TZ@ HI"0.II: "BBB@ HHS
MFB@ HHHH **3(I: "BC(HS0 449!HH **,YHH *0TM(: ([;_CUB_P!P?RJ6
MHX!B",>BBI* "BBC(% '(>(A_P 5/I/_ %T3_P!#%=>.E<CXB_Y&C2O]]/\
MT,5UPZ4V)!3?XQ^-.IO\8^AI#%/;ZTM(W;ZTN0: "BC-)D>M "T444 %%%%
M!1110!5M_P#CZN_^NB_^@+5JJMO_ ,?5W_UT7_T!:M4 %%%% !1110 4444
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MQ)Z:1:C_ -&5U&N,8_ %ZX)!73F((ZC]W6O+IEE/Y_FV=O)YZ".;=&#YBC.
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MF6:"UE5$9SU8?*2I/?:12W_A*UOKZYNEO+ZU-VBQW26TP19@O SP2..,@@T
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MM3>)IIECVJHC(*JJYX&,]2>M %&]\0Q:-KOB>2+3D>ZA2R1"K$-<R2[E16[
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M=@ H'<GM2QRI+&LD;JZ. RLIR"#T(KSNPCU.ST/Q3=/J?VB.WFNAY$ELFUY
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MGK6]HNJ3ZK/J4FV(6<%R8+=ESE]H&YB<X(W9 QZ4 ;/%&!7%:UXLNM)NI_\
M2]*F6&=$-DFXSE&('WMV W.<$8]ZLWFL:])K&I6>FP6 CLH4FW7&\E]P)VX4
M\?=//;T- '68%,22.0'RW5MIVMM.<'T-<DGB?4-4ETRUTFWM8[B[L?MTC7)8
MI&F0-H P223C/M^%/\"F9K75VGB6&8ZG+YD:MN"MA<X/>@#JH,?9X^<C:/Y4
MUI[=0^Z:,",@/EA\N>F?2N,U#Q;<Z1)&K3Z.Z+)&AM!.?M!C8@;O0'D';C\:
MQ?$:_P"@>/C@',]J.G^Q'0!ZEM%)@5SWC/4[C2O"=Q/:/Y=PS1PQOC.PNZKG
M\,TZV\/Z?HJK?BXO=]LC/+))=R.)!@[BP)(/KT[4 4/$0'_"4Z3_ +Z?^ABN
MOP*\HU'Q+>3ZEH.LW=C#!I]S+$8U65FE1&<;6<8QSZ \5T%UXQU2(ZS<0Z3!
M)8Z3<&.>0W!#NH )V+C&0#DY('3%-B1UNH:;9ZK:/:7T"3P/C*-[<CZ53TOP
M[I.BS,^GV:Q/(,,Y9G8CTW,2<>U9MAXDOY-8AL=1TR.V%U:O=6Q2;>P"XRKC
M  ;# \$BJ-KXTU![33=4N]&6'3+QTA\P7&Z16<@!]N/N9..N?:D,[1@./K3L
M"N5UKQ3=:->1FYLK86C3K$/]+'GL"0/,6/;RHSZYINH>+;Z'5-5L['16NAIJ
M)+-*;@("I0/@ C.[&<#IQUH ZS:#1M%8&G^*8+V_AMFA,*3V"7T,C./G4_>&
M.Q7BK^AZH=:TB#4?LY@2<;XU+;B4S\K?B,'\: -# HVBEHH 3:*@M+&VL(/)
MM8A''N9\#N2<D_B35BB@!-H]*-HI:* *MO\ \?5W_P!=%_\ 0%JU56W_ ./J
M[_ZZ+_Z M6J "BBB@ HHHH **** $-+2'K^%+0 4444 %%%% !1110 4444
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M4 5;?_CZN_\ KHO_ * M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%%
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M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%% "&EI#TI: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "H;G_5K_P!=$_\ 0A4U07/^K'_71/\ T(4 3T444 %%%% !
M1110 4444 %%%% %+2?^09#^/\S5E1_I#_[J_P S5?2O^0;#^/\ ,U87_7M_
MNC^9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVE2(;%R=SL%'ZFKP.17)_$5F7PO&47>_VZVVKG&3YJG&>U8JZIJ$_@>]U?\
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MW3;J6YMM9BNTAO4A>TBL6,:HSA2IEY <;L]1Z8JUI$.IMX_UO.J PQB!GC,
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M.XLK?6K>UM2X))8'#OD'L3@?0YS5C3YM:FU'Q-'>W-K/9P.5:(H_0P@@+\W
MP1GU.>E ';@@C(.1ZTM>;Q>,EL=)T'3[9M.TQKC3UN3+=%C#$HX"*,Y)//?@
M ]:OKXWEN-$L[J-;2 S74EK+=2LS6\14'#9&"0W&,D=>M '<T51M[MTTK[5=
MF$LL9=S Q9"!SE3WXKFHO%.K#3K/6KC3K9-*NY8U"K*3-$CMM5V&,'DKD \
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M%U.(R0&.Q<'+< YQQQU.:SI_&EE9>)&BN[M8]/>QCG@S$V]F9FSP!NZ =N*
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MA?P%:%C<2R6$<UVUOYA4EF@<M'CU!/;%20WUK<HSP7$4J)PS(X8+]<4 5/\
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MUE?RRNEU)(0\*R'+ IM^8CG'-:UEX?ELO$]O>1[?L<&EK9+D_.65\_RKHZ*
M.;\4:?J5W<6$MI!]KM8B_GV?VDP>82!M.X=0.>/>L6/PMJHT^PB>W@22'71?
MND<I*K%\W0GD]1Q7?4C,%&30!R4_AR6\U7Q2;M0EEJ=G!#'*&!(*+("<=B"P
M--^'MO=2:-)JNH/YEU>E ''1HD7:A'U^9O\ @5=3'+;:A:;HVCGMY01D896'
M0U)##';PI%"BQQH JH@P% [ 4 <3J%U?V?Q&N9;#3FOR=*B#Q)*J,/WKX(W<
M$9ZU27PGJ6GV&D7#6;7LL#3O=VUK<F%LRMN^1LKG& ,9&:[]+>$737 B03E
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MUS4BTLLD-[9"6SC;+ 7 8)L7TSN0X^M;_A;0O^$?T:.T9D:=G:69D&%+L<G
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M'WKI;+P;8V4]D_VJ^E6P;-I')-E(1@C: !R,'J<GWJ>7PEI<NIZC?LLAEU"
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MRJ##%GY4.T#)Q_/K61<>%-062_@TW6!::=J$C/<0FVWR(6&'\M]PQGW!QVH
MAA\3ZG?3Z7:Z':6TRW6GQWGF74I38IX(. <GH..];GB'5I]%TR*YBMA<2O<1
M0B+?MR7<+P?QJMI'AZ.PO[&]@EVPPZ<EFD.W)P"#NW9]O2F^-[>XNM%MHK8R
M+*;^V(>--YC_ 'J_-CIQUYXXH H/XQN](GO;?Q%9Q0RPVOVN(V<AE61-VW;D
M@?,"1VQS5FU\0:O!J5A;:WI]M;1:AE;=[><R%'"[MK@J,$@'IGFJLG@RYU=[
MZ?7]02>XN+7[)$;6(QK"@;=NP2<L2 3VXQ5FUT#5[G4K"XUN_M9XM/RT"6T#
M(7<J5WN6)YP3P.,F@#SZQFCANO"(9'_>:A, WFE0#YK')'\0XKT72O$.H:O(
M+FVTQ&TAY&CCN!<?O#@D;]F,;<CUS[5R%UX9FTW5_"UK).LAL[II78 _,'<\
M#T^]75Z)H>MZ(8M.@O+$Z-#([(#"QFV,2P3.<<$]<=*8D5;'Q1#9Z)ID5M&\
MEQ>R3+"MU<\ ([;F>0]OP/4"GMXWA%CYIM3]J2]%BT0F78LC $,9.FP@@Y_2
MH&\%7"6&DE#97%UI[S9BN4+0S)(Q)!XR",C!P>E: TC48].,"Z;H/[R4F2T6
M-DB:/ X+8/S9[[<8[4AF]933SVJ275N+>4D@H) XZ]01U!_"L3QO?7-AING/
M:SR0M)J5O&Q0\LI?D?0^E9^EV6L>'HM*TBW$<HENY)[C"NT5O!G.Q6/.<D8S
M[\8%;/BG19];M+"*!XU:WOX;EO,)P50Y(&.^* +6K:JND003S1L\4EQ' S*1
M^[WMM#'/;)&?K6>/&.FC4-8M"7#:7%YLC'&' '(7W!P/J15_Q!I(UOP]>Z<"
M%>>$JC-T5^JD_0@5Q<_@#4;BVL=UU MQ*\W]IL"2)$DD5V"<?[  SC@T :=[
MK N&OY4>_@EDT$W0A,@$<8.[!P.0_OZ"I=)N)V\0:-&9Y6631B[JSD@L&3YB
M/7D\U-J?AV\O-8U*[A:!8KG2#8QJQ((?+')X^[R/\*FL-$N[77[&]=HC##IG
MV1P"<E]RGCCIP?\ "@#I**** "BBB@"K;_\ 'U=_]=%_] 6K55;?_CZN_P#K
MHO\ Z M6J "BBB@ HHHH **** $-+2&EH **** "BBB@ HHHH **** "BBB@
M HHHH 0TM(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P-?O%MM8T
M")DF)N+MHPT=P8PI\MC\RCAQQT/3K6-+XZO(K6YOCH3-IUK=M:S2K<C>2'VA
MD3;@CIG)&">^,UT.L:,^IZEH]VLJH-/N6G*E22^49<#GC[V?PK*;PE,?#=[I
M0N8]UQ?-=!]IP 90^W'K@8H D@\472S7]KJ.E"UNK:S-ZB)<"021\\$[1M;(
MP1R/0FJ<?C2]<:<[>'IA'J:9LMMPI9FQG#C&%&.0<G@= >*TM0\/S7>L7MZD
MR!;C3&L@I!R&))W?3FFKX<G6/PVIEC)TD 2'!^?$6SC\>: (!XUB@TJ\FOK-
MH+VUN5M'MED#!Y6QM"N<#!SG)Q@ YI8O&UI"FHC485MY;&W%RZPS+,KQDD94
MC'.1C!QU'K534O!$FHIJA>: O<7\=[ LD>] 44+M=>X(R#]:>WA W>C:G8OI
MVD:6;N 1*^GPC<#URQVKD9QQ^M %>76=2N_&?AR"YL+K34E%PY0SADE7RL@-
MM/WE/8CC/!J_I.N7+>'K.:PTZ^U%II)5)FG0% KD99CCTXP#Q38]%UV\\0Z/
MJ>HO91QZ>DJF& LVXNFW=DCOZ=O4U1C\):G::=I4.RVODM'G,MG+*4BD+N65
MB=IR5!Z$=Z ':IXUO6TK3KO3--E#RZ@MI<12M'N1@VTQ_>QD]B.!WQ6M/XGG
MBFBLX-%NKG4/(\^>V26(&!2< %BVTL>< $]#60/".I0>'4MX?LGVR#5!J$4:
M$I$0'W;.AV\9[&I+_P .7\VL#63H^G7TUQ;I%<6L\Y B92<,C[#G@X/ Z4 %
M[X@-_JGA6]L#<&UN?M+/;@[6<K&?E89QD,",>M:T/BVRN-.TF[@BFD.I2K%'
M$H&Y#R6W?[N#GZ543P[<+J/AZXBM;2T@L#.TMO WRJ9%P O SR3D\5E>&-('
M_"<ZJT4WF:=IDL@MX^R338:0?AR/^!4 ='KU\+2^T93<7,7GW@BVPA2KY4G#
MYYQQVYJC)XZMXY)F.E:B;.WN6MKB\"+Y4;!]F?O9(SUP#C/-:&NZ7<ZA>Z/+
M $V6EX)Y=QP=H5AQZGFLF?PUJ#^$=7TU/+^T7=Y-/'E^-KR[ADXXXH K/K,\
M_CV]@N(M2ALK*&-@4E58DY<F5P&Y4@ =">#P*TK3QO:W#VSRZ;J%M8W;A+:]
MF11%(3]WHQ8!NQ(&?:FS>&I[O6-?>8JEKJ6GQVBLARP.UPQ(_P"!#%4$T77[
M[3=+T2^L[:WM+)X6ENX[C>9A%C;M3:-N2!G)X]Z -FU\607NJW%C;Z;J#K;3
M20SW/EKY4;(,\G=W[8'<9Q5"'XAZ=,EM-_9NK);W:_Z-*UMD3/C/EJ 22WZ'
M!YJ[H>DWEC'KBW"1@W>H33P[&R"C*H&?0\&LVT\-:C#H_A.U98_,TR=9+GY^
M,"-EXXYY84 ;VB:_;ZVMP(X+BVGMG"3V]RH62,D9&0"1R.>#6;;^)YY_%=WH
M[:3>>3%L F"+A<[OF;YONG'&!GK5K1]+N;/Q)K][,BK!>R0M"0V20L>TY';F
MH!::E9>-+F[BL?M%C?0Q(\PE5?(*;NJGELY'2@#)\*^,U.E6D>J"]=Y;B2 W
MK0GR0YD(1"WKC SC'J<UO7OBW3[&YFB:.[E2V.+J>& O';\9^=OH<G&<=\5@
M1>&]43P/8::UL/M46HI.Z!UX07&\G.<?=YZU5OO#-Y%JNJJ^C7^I6M[*94>V
MU5K9"&4!D>/>H[=<'(H [35]9ATK0;K56'F10PF10#]_T /N<?G67I47B:4V
MU]=ZA8>1, \EDMJ08U(Z"3=R1[KS5O5M!34O"<VBQ#R%:W$4>26V%0-O/?!
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MZB-411<JYW[#<E-N?[I7^'I6AJ4=S!K-]X0MU*0:I=17,3)_!"V3./;!C/\
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M'MFJ=[JVJ:/I>K6%O>7$S1:G#903RLK2HDJ(Q^9L D%B 6/I0!Z%;'-K$?\
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MM4 %%%% !1110 4444 (:6D/2EH **** "BBB@ HHHH **** "BBB@ HHHH
M**0TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3$ACB+%$52QRVT 9/J:?10 4444 %%%% !1110 4444 %%%%
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MI V21Z4M !112 @T +1110 44$X&:0'- "T444 %%%% !1110 4444 %%%%
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MVO[26UNH5F@E7:\;C(8>AK,@\):);VES:K9F2&Y0)*L\KR[E'1<N20!V Z4
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M.O4'I5+3-1\0W-WXA2_2TDLK>1HV$=PP:/\ <JVU/D&0=V22002:O:UX=O\
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M+ )#;*&(X<KD\8Y#$'.>*M&*[D3Q9HD<,\6H7DTL]N_E-Y;H44#Y\8&<$=:
M.NT_Q)HVJW3VUAJ,%Q,JEBB-R0#@D>HSW%9>L^,M.MHYX+#4+2;4(98D: MD
M@-(BMP#U ;M[5B:"+6_O=*0WFKM=V,3;;::P$20$QE2K,(P,<\<\X%9:3QIX
M2T_09-+NWU6UO(C/MM6Q"PF!,A?&""#V)^]0!Z#KWB"P\.V"W=_+M5G"(@(#
M.2>V2.@R?H#0WB?0X]*CU-]5M%L9&VI<&4;&/H#ZU4\:1N_A6Z,<+RF-HY"D
M8RQ"R*QP._ -8E[JEDOB;2M?F69]'-G-#'+]F<B*8N.2NW(R 0#C^= ':VEY
M;7UK'<VD\<\$@RDD;95A[&IZY;P<FX:M>0V\MO87EZTUK'(A4E=JAGP>0&8,
MP'O74T 5;?\ X^KO_KHO_H"U:JK;_P#'U=_]=%_] 6K5 !1110 4444 %%%%
M "'O2TA[TM !1110 4444 %%%% !1110 4444 %%%% !12&EH **** "BBB@
M HHHH **** "BBB@ HHHH **** .;\2ZZ=$U71?-N4@LKB25;@L!R F5QWZX
MZ<G-:%MXATFZTR748KZ+[)"2)9&.T1D=0P/(/L:H:W9377BGP[*+=Y(8))GD
M<+E4/EX4D]N>E<MJFB:I.OB*2&SNE4ZW!<B..,;IXD2/<4#?*QR,\]2* .YM
M?$.E7D%Q-#>Q^7;C=,7RGEKUW$-C P#STJ*#Q%INHQW*:?>QRSPQ&0QX(;&.
M&P>2/?I7,)]K4:GK.GQ:Q?:FEEY4?V^Q$"D;L[0NU"Q')Z<],U!8)J=WXC-W
M(NJW*)I4\8GNK#[.#(2IV ;0?SSWQGF@"]IGCRV%CX>74Y$%QJ-N99I/NB,A
M<]/<Y JS9^,[.#6M9M=6U&TMH;>>-+;>P0E2BDDY/3+=>V:QK2VGTFV\"7,^
MGWGE6EI)'<+';.[Q2/&H 9 "1SD=*N)ILT@\=SR:?,7NE*P;H3F91!@!>/FY
M)Z=Z .ZWKLWY&W&<^U9MKXDT2]EFCM=6LIGA4M(J3J2JC@D\] >,]*HW=G>O
M\/FL[7>MZ=.$: \-NV 8Y[]JQTUJU'AIHM+T&YN+RRL<"WELG4(0%!C)8<GO
MM&<@?2@#J;#7](U4RBPU*UNC$,OY,JMM'J<'I[TVV\1:->>;]FU6RF\F,2R>
M7.K;$(R&.#P,<YKB=.GN+KQ(UV+B>\5-'G3[2+ VZ%MR':N>21_GO33I,R?"
M'2X+>UD4[8);I(X=SE=P9\IU;U([XQ0!WNGZQINJH[Z=?VUVJ'#F"57VGWP>
M*NDX&:X31YK'^U[K76UB2[^S6)2798&% @.[DXY(P<#WKJ+R>74?#$\^FEA+
M<6C/;$C:=S)\OT.2* )(-=TFYOGL8-3LY;M,[H$G5G7ZJ#D4_P#MC3?MB6?V
M^V^U.S*L/FKO8J,L N<Y'>O/8Y;*_P!(\,Z3I-K-'J%K=P2S1^0ZFWV',I<D
M#&>1[YKHO!^G6ZWFO7KVJ"Y?59P)67YBHX&">W)_.@"]JVO_ -E^(=.M9Y+>
M&QGAGDFFF.W9L"XY)  ^8YS6J-2LFL1>K=P&T*[A.)!LQZ[LXKD_%4EA!XRT
M"?4HP;2&*<F1XRR1N=@4L<8'U-<SY%R+!+Q&:STF;Q!/<H\]LTD:1%/W;M'Q
M\A<$C/ R#0!ZG;:C9WMJ+JUNH9[<\B6)PR'\1Q3;;4[&\A>:UO()XD)#/%(K
M!<=<D'BO-=3LI6\.ZQ<V6KPZE#=7D#7GV.S*QA01O( 8[\C&[!Y -7UAM)Y-
M7U&VUJPO93I$D,D5A:^6I'52Q#L,CD =>: .]BO[2>8PQ7,,DJC)17!8#UQ4
MD]Q#;Q&2:5(XQU=V  _$UYY9Z5::=/X$>TM(X)9 PF=$PS9AR=Q[\UI^,FMU
MUWP^VK,BZ*LLK3F;'E"4+^[WD\8R3U[T ;NGZS]MU?5+/RU$=F8MDJMD2!TW
M9JU<:C$-.NKFU>*<P(S85Q@D G!(SBO+[E+7^R/%)T./R].DU"V$AA1MODD+
MYA ')0Y.<$#'3BM2"VLX7UG4K#5='D4:1(DEKIB;5;:"5=L,<'J* .XT75HM
M5TJRNOD26XMXYVA#Y*;E!_KUQ5T7,)E,0E0R#J@89'X5Y5I,6AA_!K:&EO\
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M*^!9&@^'MC*?WC+%(_'\7S,:Q$N]73PM9>*FUJ=[B62)WM0%\AHW<+Y87'!
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M-S86UZES'L:6^GF3D'*,Y(/'M6 /#^I[+M3;<R>(1>IAUYAW [NOMTZUW-%
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M@SLQ( W,QSSQTR>G6L"3PYJ?_"+^++)8D-QJ-[<3VR^8/F5PNW)[=#Q7<T4
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M<UF6/AO58+/PS%):,'LM3FGN,RJ^Q&\P@DYYSD>_->B44 <3J%C>V'B>_O\
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M^ %8FVC* \$#TZ#\J .&\-V&FZGH]E?7&IW']JWR.)3]N?+2%6W)LW8PO)
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M 4444 %%%% !1110 44&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX00-$H\B"(;268D$,2I.0<G)X H Z_2V']FQ<^O\S4KRQP/-+*ZI&D89F8X
M SR:X6SU74M1L;V"RNWMDM)?L<=S(T:*) 1ND<X.3D\(  >^,\=M/+';+)+.
MXVJB[CCJ<GH/4^E %;2_$FEZS<S6]G.YGA 9XY87B;:>C ,!D>XK5)Q6%I=L
M)]8N=6G01W+QK"D)QNACY8;L?Q,3G'.,#WS7N=7EN-:U*W%T;*QTN%6N)P%R
MSLN[&6! 4+@GW(H W;J]M[&W>XN9!'$F,L?4G 'N22!BFV>H0WT+RQK*H21H
MV$D94AE)!Z]LCJ.#7$VLFH>(=5\,I=3RQM':'4+J((H&[[L9((R"<L<9_AX'
M&:U_%D=QJ-SINA0S/!#?.[74B'#&)%R5'U)4?3- &Y9:M9:C+(EI,9A']Z1$
M8Q_0/C:3[ Y%7:P/"EY)=6=Y$VPQV=W):PNB!0Z+C!P.."2./2M^@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "@]**#0!%;'-M$?]@?RJ6HX!BWC'HH_E4E !1110!R'B+_D9])_Z
MZ)_Z&*Z^N1\1?\C-I/\ UT3_ -#%=<.E-B04W^,?0TZF_P 8_&D,4]J6D/:E
MH **** "BBB@ HHHH **** *MO\ \?5W_P!=%_\ 0%JU5:W_ ./J[_ZZ+_Z
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MT %%%% !1110 4444 %%%% %6W_X^KO_ *Z+_P"@+5JJMO\ \?5W_P!=%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC#:#?QY;I\K<?7CC\: -FBL@^)]%!Q_:5MG&?O\ %*OB;16Q_P 3.U'UD H
MUJ*RQXCT8_\ ,4L_^_HH_P"$CT7_ *"ME_W^7_&@#4HK,_X2'1CTU2S_ ._R
M_P"-*/$.C$X&J6?_ '^7_&@#2HK-_P"$@T?./[4L_P#O^O\ C2C7M)/_ #$[
M/_O\O^- &C16?_;NE'IJ5G_W^7_&C^V],VEAJ-I@=_.7_&@#0HK._MS2\_\
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MH **** "HIQE!_OK_P"A"I:AN#B-?^NB?^A"@":BBB@ HHHH **** "BBB@
MH/2BB@"II?\ R#HOQ_F:LC_6M]!_6JNE'.FPGZ_S-6%;,[KZ*#^IH DHHHH
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M=]BO,D?VK-]?*CS_ .@T44 'V*\ _P"0I,?K%'_A2?8K[/RZK)^,*'^E%%
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M_%_MBNS67+ ;>OO1138D2;N>E-S^]4>Q_I112&*YQCZT\T44 %%%% !1110
M4444 %%%% %6W_X^KO\ ZZ+_ .@+5JBB@ HHHH **** "BBB@!G;\:?110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exhibit101-offerletterda003.jpg
<TEXT>
begin 644 exhibit101-offerletterda003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M 6**** "BBB@ HHHH **** "BBB@"EI'_(,A_'^9J=#_ *5(/]A?YM5?2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY5-0 4444 <?XE_Y&?2.?^6B?^ABNPKCO$O_ "-&D_[\?_HP5V(Z4V)!3/\
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M?\@>]_ZX/_Z":[([CELSP.#!FCQG[PKZ&C_U:_05\\0#]^C<<L,<]J^AHO\
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M HHHH **** "BBB@ HHHH I:3_R#(?Q_F:L+_P ?#_[B_P S5?2?^09#^/\
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M"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *#12&@!L/^HC_P!T?RI]1P'-O&?5
M1_*I* "BBB@#D?$?_(RZ3_UT3_T,5UPZ5R/B/CQ-I'_71/\ T,5UU-B04W_E
MH/H:=3?XQ^-(8I[?6EIK'&/K3J "BBB@ HHHH **** "BBB@"K;_ /'U=_\
M71?_ $!:M55M_P#CZN_^NB_^@+5J@ HHHH **** "BBB@!&Z&E%(>AI: "BB
MB@ HHHH **** "BBB@ HHHH **** $-*:0TM "4"EHH #2 4M% "  =*6BB@
M!"*3'M3J* &XS2XI:* $HI:*5@$Q1BEHI@-Q2XI:*0"8S012T4P$Q1BEHI )
MBDP/2G44 (*3:#VIU%,! *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 0U#=?ZI?^NB?^A"IZ@NO]4O_ %T3_P!"% $]%%% !1110 4444 %%%%
M!1110!3TK_D&P_C_ #-3K_Q\R?[B_P S5?2?^09#^/\ ,U87_CYD_P!Q?YF@
M"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXSWH OT5&)D,C1JZEUZJ#R*Q?^$E_P!.U*/[)_H>G B>Y,HSD('P%ZG@CG-
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MJ-MJ4!GM)1)$'9"V".0<$<T 6J*** *MO_Q]7?\ UT7_ - 6K55;?_CZN_\
MKHO_ * M6J "BBB@ HHHH **** $/2E%(>E** "BBB@ HHHH **** "BBB@
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MOE1)G1)&XY9 0">.XH Y37KZYM?%8T6/4I(;'49(7N9=S%K9B3^[5L_+YFT
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M ./J[_ZZ+_Z M6JJ6O\ Q\W?_70?^@+5N@ HHHH **** "BBB@ /2@4AZ4M
M!1110 4444 %%%% !1110 4444 %%%% "&EHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "N;O/"KMJD]_I>JW>ERW)!N5@5&24@8W;6!PV.,BNDHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=I)X5,F9G=002, $D+]!B@#KR<4;A7%65NNMZSK=Q?ZE=Q26-V(H$BN6C6!
MJD':#@[LG[V:SY$.I6?B?5;O5+N*[T^>>.V$=PT:VRQCY#M! ;=U.X'- 'HN
MZC=7GEJMWXDU;3XM1O+N&.70H;J:"WF:,-*2>3C!&,YX(Z#.<51L'O+?0/#^
MOOJ=]/?7%[';R>;,2C1EF7:4&%[ YQG/>@#U'=67/K]M;ZO<Z<\4YEM[-;QV
M1-P*%F7  Y)^4\8]*XN^C:Z7Q=>S:Q>P2:=,QM4CN6582(E8-M!YR21@Y'7
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ME%%% %6W_P"/J[_ZZ+_Z M6JJV__ !]7?_71?_0%JU0 4444 %%%% !1110
M'I10>E% !1110 4444 %%%% !1110 4444 %%%% "'M2TAI: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K/BTB&'6KG4XY'$ES$D<L?&UBI.&]<X)%
M:%% $,ML'@EC1C$9%(WH!D$CK]:@TK3+?2-+M]/MMWE0($4MU/J3[D\U=HH
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M10 5!=?ZM?\ KHG_ *$*GJ&Z_P!4O_71/_0A0!-1110 4444 %%%% !1110
M4444 4M)_P"09#^/\S5A/^/F3_<7^;57TG_D&0_C_,U87_CYD_W%_FU $M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4AZ4M(>E $=M_P >L7^X/Y5+4<'-O'QC
MY1Q^%24 %%%% '(>(_\ D9](_P"NB?\ H8KKZX_Q(?\ BIM(_P"NB?\ H8KL
M*;$@IO\ &/QIU-_C'T-(8K=OK2TA[?6EH **** "BBB@ HHHH **** *MO\
M\?5W_P!=%_\ 0%JU56W_ ./J[_ZZ+_Z M6J "BBB@ HHHH ****  ]**0]#2
MT %!Z444 -C#A?G()R>0,4ZBB@ HHHH *R?$NI2Z1X<O[^$#S((2RY&1GM6M
M574;"#4]/GLKE2T$Z%' .#@T <=X;\)6\EGIFN3:IJDFI2+'<23&Z;$F0"5*
MGC9VQZ51D\?ZX^CS^(K72K5]$AFV8:9A,Z9P6'&!S6OI'A/6M):WM$\22OI5
MLZE(# OF%0<["_7;V^E9W_"N[U+)]%AUUD\/R2;VM?(!DQG.T2>G H 6[\<:
MY/K6IV.C:5:SQ64"7!FFF*?(T8?ICD_-Q]#2GQ[?WUGH":3IT4FH:JDC[)I"
M$C"$AN1UY!_*M:U\("TUC6KV*Y CU&V2W2(I_JMJ! <YYZ5DI\/[VTT_0S8:
MLD.I:4)$6=H-R.KL205S[XZT <D]Y)'X9\3S:C8*9CK*>9 MP5VL>H#+R<?K
M746.L>)9/B7=:>%A:R2%"87F.V.+(^=>.6P>GO4DWP[N9="U*P?5_-FOKQ+M
MIY(N01][@'N<X]*U9?#&H1^,DUVQU*.%'A2&YA>'>752/NG/&<"@#F-"\5#2
MO"^_3].WWM]JDEM;V[W+%2_'S%FY Y'&/RK3E\=ZKIO]L66K:=;1ZE8VGVN(
M0S,T<RYQCID8_P >F.5B^'3PZ##:1ZELOK6^:]MK@1Y4,<8#+GD<"G-X#O=0
M35[K5]3BGU2_MOLR21Q;8X4'/"YR>GK0 FD^.-8NM;TBTU'2(+:VU:%I;9X[
MC<P 4MEACOCI[BK/@_QAJ/BBX>4VUC%9*SJ46Y)GC(Z;E(Z&IT\'S)J7AF[-
MZI_L>V:!U\O_ %I*;<CGCU[U7TOP?J,?BN+7=4O+%Y;=&16L[;RFGR",R\D$
M\]J .WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"Z_U2_P#71/\ T(5,
M:ANO]4O_ %T3_P!"% $]%%% !1110 4444 %%%% !1110!2TG_D&0_C_ #-6
M5_X^'_W5_F:K:3_R#(?Q_F:LK_Q\/_NK_,T 24444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !0:*#0!%;_P#'M%_N#^52U' ,6\8_V1_*I* "BBB@#C_$@_XJ?2/^
MNB?^ABNPKD/$?_(SZ1_UT3_T,5UXZ4V)!3/^6@^AI]-_C'T-(8I[?6EI#VI:
M "BBB@ HHHH **** "BBB@"K;_\ 'U=_]=%_] 6K55;?_CZN_P#KHO\ Z M6
MJ "BBB@ HHHH **** $/2EI#TI: "BBB@ HHHH **** "J6JZM9:)ITE_J,W
MDVT> [[2V,D < $]2*NTUXTD4JZJRGL1F@#F;/XB>%;^]AL[;5E>>9PD:>3(
M-S'@#)7%=/NKSWP>L<-_XRN%@222'4I3&NT=5+$ >E<XVJZK'X%M/%2Z_>R:
MG+=X^S^=B)_F(\L1].@ST[T >MZCJ5GI%C)>WTZPVT>-\C=!DX'3ZUGZ3XNT
M'7;I[73-1CN9T7>R*""!Z\CWK)^)Q_XH#4<_],^_^VM4=6;7-,\"ZE=2W=DK
MK:Q_9WL86B>/D9))8YX],4 =Z6Z4NX5Y+]GUP:IX:@'BC4\:U:L]PQ8'9A5;
MY!C"\'&>O>JU[KFM6'@_48QK5P9;/6Q:QW3L#((P"<,>_O0!ZW?7T.G6%Q>S
M[A#!&TCX&3@#)IFF:E!JVFV]_;;O)G02)O&#@^M>5ZO<ZEI.IZIH[:U<:I:7
M6BRW+^>0Q1@OWACH#Z#CFI-)O;^^/A+P[%J,^GVDNEBXEDMSMDE/S?*K8X^[
MGCUH ];W"C<*\@FUSQ!9:+J-U%JES<KH.K>4S\$SV_ VN>Y!QS[TW5O%.M7.
MEZ_KVFZG-'9+?Q6EDJ@8POWF ([\?G0![#N%+GC->7QV/B(^-)O#W_"77_DM
M9"\>;RTW@[MNU>,*,\\=N*SAXQU^?PKX:A6>Y>[OYY8YYK94\Z14; 5=V%#'
M/4^E 'L.<TA.!FO);[6_&.E>%M1FN7O;5EO85LYKM(C*8VSE6"Y!Q@<^]6+J
M;Q#;Z[J&@7'B&>YCETEKKSF@C4QL#R% '0C(Y[&@#U%'5UW*<CUIU>:^!=*U
M=OAY'_9NNFW:X -N'MT*VV';<!_>S[]*]&@#K"BROO<* S 8W'N<4 24444
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MA'3^'M6[%=V\TDL<4\;R0L%D56!*'&<,.QP0>:8]]%'?Q6967S)$:0,(F*
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M"UFMW\F(JK%V4@C).,!<>]5H/"TL&AZ7I_VM6:RO%N6?9]\!RV,9XZUU.**
M.0'A?4;*\O6TZ[L/LUW<-<L+RT,CQLQRP4A@".XR*GNO#^J)K-Y>:5J<-M#?
MJ@N$E@WE&4;=R<@9QZY%=11B@#*\.:4VAZ!9Z8\HE:WCV&0#&[G.<?C3=4TE
M]0U;2;Q9E5;"9Y60KDMN0KQ^=:]% '(?\(C-_P (G?Z-]K3?=7;W'F[#A09
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M5D_\)-HAMY+@:O8^3&VQW\]<*WH>:M2:G8PP1S37MND<@)1VE4*PQG@YYXH
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M+%OOED5_P^]C\*TRRJ,LP ]S0 M%8^N:[_8XM8X[<W-S=S"&&(.$R<9)+'H
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M;65S/):?9KJU6<H%(<LI1B#G&X@Y SU]JKVGA?48H;26>2!KM]8_M&Z",=B
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M4: "BBB@ HHHH **** $/2EI#2T %%%% !1110 4444 %%%% !1110 4444
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M:(1O.J'.Z10< ,<]>]4W?4-)\0-I4^JW&H07FF3SM]H"9CD3 R-H&%(;I[4
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MA]IR%) !QT!/0]*S=9N=5F\)^(+*XU22232[Z.$3B-%:=&", W& 07ZC&<4
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M9=O+4G*ICVYR1UXSCEFF^-FGO]/AN[>TCBU%6:$PW0D>$A-^V1<#!(]/I[T
M=7;VT%G:Q6UO&L<$*+'&@Z*H& !^%2X%><ZQX@U;5O#]O=C2E@TVYO[?R9TN
M=SA!.F&=<#AO8G&>:]&7@4 <?XC'_%4:1Z>8G_H8KKP%ZUR'B0_\51I'_71/
M_0Q533M-?7/$/B5I=3U.%[:\$5NT-Y(JQCRU/"9V'GGD4V)'9?V=:'4O[1,(
M-WY7DB4DDA,YP/3FI_XU^AKBM.\7WT6@:>9;,ZA?RWLFGML<1[W3?\W3 !V<
M^G-;-EK\T_B)-'N;#[/<"Q%U(5FWA26V[!P,_7]*0S>/;ZT8%<HGC":[L+&2
MSTMI;N\N)HHX&F"J!$S!F+XX' [=ZT_#NM7&MVL\MQI_V)H9FA*&82'<IPW0
M#N* -G%(0#6$_B&X?Q!<:79:;]I%J8A<R&=4*;^054CY@!R>1W R:B_X2:ZG
MU.>"PT:>[M+:;R)[E957:_&0JGEL9Y_3- '1;1Z4;17,V?B][N\OA_94L=A8
MRSQ7-ZTJ[4,9/1>K9 [=,TEEXP>:YL1>Z7)96VH9%K,\RL6."P#*.5)4$CZ<
MX- '3[1Z48%<O%XR,K0W(TN7^R)I_(COO-7DD[0VSJ%+< _CC%1WWC62UDU+
MR=$NKBWTV4I=3K*BA%"AL@$Y;@]!0!UA S1M'I7-3ZW##XAE*FZD TDW842#
MR2H8]!C[Q]<XQ2:?XP^V7EE'-I5U:6U^I-K<2LN)&"YV[0=R\9QD<XH W;<#
M[5=_]=%_] 6K5<5#XT=M0#6VC7,UE>7@MX;HRH@9@N#\I.<?*Q'KCBNT!SVH
M 6BBB@ HHHH **** $/2EI#2T %%%% !1110 4444 %%%% !1110 4444 (:
M6D-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %5CIUDT-Q"UG;F*X)
M,Z&)=LI/4L,<Y]ZLUF+X@TI]1^P)?P&[WE/)#98$=1B@"2^T32M2\O[;IMI<
M^4,1^;"K;1Z#(X%)=:'I5Y9Q6EQIMI);Q?ZN)H5VI_NC''X5';>(=)O;L6MM
MJ%O+.<X17SNQUQZX]J6'Q!I=S=/;07]O),F[<JOG&WK^7?TH +CP_I-U9PVD
MVF6K6\'^IC\H 1_[N.GX4R;PUHL]I#:R:39F"$DQ((E 3/7&.F>_KWJPFL:>
M]G;W:WD!M[EU2&4-\KL3@ 'N2:YR7QO%IL&L7&IF/9::E]CA2/Y6=<1\\GDC
M>2?84 ;=UX:T:]:%KC2[20PJ(X]T0PJ#HN/[OMTHO/#>CZA<+<7>F6TTRJ$#
MM&,X'0>^.WI1)XET:*&&635+18YANC8RC##.,CVSWK41@ZA@00>01WH JP:9
M9V\\4T5M&DD,/D1LHY6/(.T>W _*L^70WN?&,&LS"'RK6V,4 7[Y9C\Q;CIC
M@<]S5^]U6QTX9O+R"W!4N/-<+P" 3S[D?G4">(]&D>W1=5LBUS_J0)US)VXY
MYYXH T)HEFB>)U#(ZE6![@UDV7A71--O$N[/2[>&=%VHRK]WUP.@)[GO6FMY
M;M+-$L\1DA ,J!AE,\C([55GUS2[6"*>?4;2.*89C=YE <>H.>10!1M-"D3Q
M??ZY/Y/[V".WMPF=P4<L6XZDX_ 5NN@="C*&4C!!Z$5C'Q7I"Z[_ &0U["MQ
MY2R F10IR<!0<_>/7'I6W0!AVGA'0K&]6[MM,@CF4[D(&0A_V1T7\*6/PGHL
M.HB]CT^)9@YD')VJYZL%^Z#[XJO'XJ@C\0ZOI]_/:6L-D85BDEE"&0NFXCDX
M_*MBZU*RL8EFN[NWMXF.%>60*#]"3S0 QM)LG2]1K=2M[_Q\#)_>?*%Y_  4
MITRU:6TE,"^9:*5@.?N C!Q^ %689H[B-98G5XW&Y74Y##U!%.=UC1G=@JJ,
MDDX % '*:!X*L[&&">^M(GOHYGE+*Y*;B[%7V]"P! SC-7KKP=HM[<7$L]H6
M^T-OEC\UA&S?WB@.-WOC-7&UNSFT^[N;"[MKLV\;.1%*' (!(!P>.E5]"\16
MVKZ;92//;)>SVZS/;+*"R@C/3.<4 :$>G6T5W/=)%B:X1$D;/W@N=H_\>-8&
MO^%5OM!L-%L;>);.*ZB9PY^Y$IRVW/4GI^)K2TSQ/I.KSW,%I>Q/+;R-&R[A
MEMN,LHSRO/7I5N+5+2ZCF-E<V]TT0.Y8I5;!]#@\?C0!;50J!0, #  KG[GP
M7H]U/<22PS[;B3S985N'6)I.#OV XW9'7%:5MJD<FG0W=T8K4O'YC(\RL% Z
M_,#@CD<CCFK*74$EN+A)HVA*[A(&&TCUSTQ0!(ZEHF4=2,5R'A?P/;:7INE/
M?1NU]:1@F/[0SPI+C!=4)VAO<#J:ZN"[@N81-!-'+$>CQN&7\Q6:/$,3^(K;
M2H465)[:2<7"2 J-K!2N!UZ^M %FWT>TMK>ZMTBW0W4CRS(YW!B_WNO:LVV\
M+V>E/#+!<7[+$ZK%#+=R/'&-P& I..G3TKH2<5B6&M)J]DTIC$++>& (7!+;
M)=N1]<4 -\8:5<:SX:N+"T17EE:/Y6;:" ZD\_0&DT[PEI^GO<2![J>:>(P&
M6YG:1TC_ +BD]!6ZTB(0&=5)Z9.,UB:MXB-AJ]GI5M;+<WETKR!6F$:JBXR2
M<'GG@8YH A?P9I96T$+7=L;6#[,K6]PR,\0_@8@Y(S2R^#=,;3[.S@^T6HLY
M&DMI;>8K)$6)+8;T.2,>E;XE3(5F4.?X<\TID13@NH/N: ,&;PC8RVMK&)KV
M.:U+F*[2X;S@7^]ESG.>^>*L)X=M!!9Q2274_P!DN/M,;S3L[%^>23U')XZ5
MK;TW[-R[O3/-.H S3HMH9-2?:^[45"3_ #=0%V\>G%9LW@VQ9+/[-<WUE-:0
M"V2XMI]LC1#^%B00P[\BNCR"2,CCK2&1%7<74+ZD\4 92^'K82Z=*\UU+)8%
MVB>68NS%P0=Q/)Z_A4-QX4L+JVU>"5IRFJR"6?#@$,%505XXQM'K6YD<<CGI
M[T%@,\CB@#*\-VGV+0H(/M$]Q@L?,G8,QRQ[@"N=C\&?;]5UN6\N;^VBN[G+
M007 $=Q%M ^8<XSAAV.*ZK2"#ID6"#C/\S5E>+AS_L+_ #- %&'1;>WU4ZA%
MO63[.ML$! 144Y&!C^M87B#PL[^#AHNF))([7*,DKR &',FYGSQG )X')Z5T
MUUJ-K9& 7$RI]HE6&+/\3GH/T-620,<CF@#%N/#_ )EM9PVFH7M@EI%Y*+;.
MH4K@#D,". .#VJ&S\'Z;8RV+Q"4BSMI+9%=@0ZN<L6XR23_,UT!) SQ5>*^@
MGN9[>*9&E@*B5 >4R,C/X4 85IX,M[6U:R.H:A-I_E/"EG),/+1&&".!DX'3
M).*?IWA*.POK*Z?4K^Z>RB,,"S.NU5( Z!1S@#GK71U2U?4H]'T>\U*9&>.U
MB:5E3&2 ,X&: $T?2XM&TR*P@=WCCW;3(03RQ8] .YK,D\+[;N]GL-4O;!;U
M_,GCMRF"V,%EW*2I/<CK6[#*)H4D' =0P_&HS>VZWR633(+ET,BQ9^8H" 3C
MTR1^= &)?>#K+4I[Z>[EGDFN8DB20L-UL%Y!CXX.[YL^M177@[[3/>2KJU[#
M]OB2*\$>P>;M7:#DJ2N1UQUSVKJ** ,BPT&'3[BUFCEE<VUBEDH8C!5<')XZ
M\537PA;+H$>D"XF\I+I;K>0I8L)/,QTZ9KHZ* .>N_"D%W]LW7$R_:KV*\;&
M.&CVX ]CL'YT:IX3MM6U"]NKB>9?M>G_ &!T0@ +N+;@?7G]*Z&L\:O VO2:
M. _VB.W6Y8X&W8S,H[]<J: ,JQ\*R6^JV6HW6I2W4ME"T$*>4D:!" .BCKQU
MJ/\ X0YCH4VC/J4KV32*\2F-=T0$F_&?XN>.>U=310!S-WX6N&NK^73M4DL8
M]1(-U$L*N"=H4LA.-K$#KSZXJS9>&+;3]1L+FV=DCLK-K2.'J"K,K%C[_*/S
MK2OM0@T]86G$N)I5A7RX6D^9NF=H.![G@=S3FOH%2X82(_V?/FJA!*D#.".Q
MQ_.@"#2],&F0W"+(9/.N9+@Y&,%V)Q^&:1-+5=6O-0\QBUS;Q0%".%"%SG\?
M,/Y5-INH0ZIIEO?V^[R;B,2)N&#@],BDL-2M]2%Q]G,A^SS-!)OC9/G7KC<!
MD>XX- &;!X:2#3=%LQ<N1I;JZMM&9-JLN#Z?>K,3P3,D(LQJI&GK>"\6(6R[
MR^_?AGS\PS[ ^YKL:* .,NM$6^^),%V(9Q%;VRS3.1B-Y066/'J0&<G_ (#7
M57]FFH:;<V4C,B3Q-$S)U (QQ5>ZUFRL]+.I-,LEJ"J^9$=X.6"C&/<UH Y%
M '+:=X4O+74-+N;G5(IH]-B>&"&*T$0VLH7GYCSQ[#V%,M?"FIZ?H,&E6FKV
MIB7S?-^TV'FK)O<M]W>,8SCJ1[5UM% ')6_@ZYTIK.;1M4\B>"U%HYN8?.25
M Q8$@,I!!)QST/2MG0M(.CV3Q27#7$\TKSSS%0N]V.20!T'H.?K6I10!RUWX
M<U=?$&H:KI6L0VQOHXXY(IK3S H12 P.\<\D^E1-X+:VCTI]/NH?M&GPM ?M
M4'F1SJQ!;< 00<C((/&372:CJ%MI6GSWUW(8[>!=TC!2V!]!S5B-Q(@<=",B
M@"GI=K<VEH([J2W>7<23;P>4G/0;<GIZYYJO!I#Q>(;_ %0S!DNH8HA%MQMV
M;N<Y[[O2M:B@#D=.\+7^DNMM:2:8UBLID1I[0M,BEMQ3(8 ]2 >WH<5#JFA:
MK8PZW)8ZA!#87OF7,H:$F6-MF&"$''. <D<<]:[2D(!% '%V&B:DUMH>KZ9<
MVT-RFEQVDJ7,;.NP@-D8(.X'L>OJ*FM/"%W;Z;I5K)?1R266J/?R2>61Y@8R
M'&,\'YZZ/4M2M-(LGN[R41P)@%L$DDG   Y))XP*?97L6H6D=U 6,4@RN]&0
M_B& (_&@#(T_0<Z!J%C<RY346F=BG!591T^H!JKH^@:G8/;P7']DM:VZ>7YL
M5L1-* N 2<X4],]<^U;4>HVT%Q8Z?))BYN(2\2;2=P0+N.>@QN%:% '"'PCX
M@;2[71_[3L1IUG/%)&1"_F2HCA@K<X7&.V<G'2NOMH[Y;JZ:YFB>!G!MU1"&
M1<<[CGDYS4MW=V]C;-<74\<,*XW22-A1DX'/U-3 Y&: ./\ $?\ R-.D_P"_
M'_Z&*6+1/$EAJVL3:?/IH@U&<2B6?>SQ?(%^Z!@]/44>(_\ D:-)/_31/_0Q
M78#I38D<M!X4>SAT*&"X5UT^Z>XG>08:8LC@L,=]SYQZ=^*-4TG5T\41ZSI'
MV.21[0VDD=RS*%&[<'! .?IQ]:ZFF_\ +0?0_P!*0SRZ_P!'GTB'P]IFH:A:
MP3)+>3-<NS1Q99\C#*5*M\XQS_>ZUUG@>Y$ND36\=K!%#:SM"DMLS-%/SDNI
M;D\YR><G/-='-$DH D4,,C@T]5"C &!0!R'B+0]6U?4T^SV=A#LD1H=569EN
M(5!!*[0OS9Y&-P'/(I]MIGB#2-1O8=.BL9;&]NVNO/FE8/#NQO78!\W3@[AU
MKJI98X8GEE=4C0%F=C@*!U)/:B&5)XEEC=7C<!E93D,#T(/<4 <YIWAR>/2=
M=L+IT4:A=W,B-&<[4DZ9]ZSM$\.WUK/:P7GAS0D6W&&U"%AYCD*0&5/+^5CQ
M_%ZUV%K>6]XKO;S)*J.T;%#G#*<$?4&IZ ."T?PK>:1]GTX^'M$NK>"7*ZC(
MX$I3=D$IY9^8<?Q=16C+X=OGTWQ5 /*\S5)7:W^;L8E4;N..0?6NE-U"+I;8
MRH)V0NL>?F*@X)QZ9(J>@#CV\.:B=0,V(2IT+[!G=SYN3[=/>II=$O1#X9^6
M,?V:0UQ\W3$17Y>.>?I72W%Q%:V\D\TBQPQJ7=W. JCDDGTIRLLBAE(*D9!'
M>@#R#PY<"QDL+Z9+>^BFOPL40O6$B/(<>9Y&"H8 \C/'/O7L*UGVME:IJ-Y,
MMO$LID'SA &^Z.]:- !1110 4444 %%%% "&EI#TI: "BBB@ HHHH **** "
MBBB@ HHHH **** $-+2&EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=@_?#I\WK0!P\FJ:A/I2:J+RX6.^\0V\4(5R +<2JF%]F"DGUS5K2=.BBO\
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MK:'4+R]17$]VJI*=QP0HP,#M0!Y5JOB2XU*X\*W4]T;(W-FMS+)!&'(?>N,
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M ,M$_P#0Q77TV)!3?^6@^A_I3J;_ ,M!]#2&*W;ZTM(>WUI: "BBB@ HHHH
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M5UXZ5R'B/_D9])_ZZ)_Z&*Z^F)!3?XQ^-.IO\8_&D,4]OK2TA[?6EH ****
M"BBB@ HHHH **** *MO_ ,?5W_UT7_T!:M55M_\ CZN_^NB_^@+5J@ HHHH
M**** "BBB@!#TI:0]*6@ HHHH **** "BBB@ HHHH **** "BBB@!#2T44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1160_B*S274UV3NFG%!.T41
MD^9AG:JKDD@$$X'>@#7HK,N=;@MUNL0W$CVUO]I94A;YEP3A21@MQTSFKEI=
M17MI#<P,&AF02(P[@C(H GHK'U/Q1I6D7GV2\FD$WE^:5C@>3:F<;CM!P/K6
MA8WMOJ-G%=VDJRV\JAD=>C"@"Q115'4=5M]+-K]HW?Z3.MO'M&?G;.,^W% %
MZBBB@ HHHH **** "BJNH:A;Z792WEV_EP18WMM)QDXZ#W(JR#F@!:*QK_Q5
MHFEWRV=[J5O#<''R,W(STSCI^-6[?5;2ZO[BRAEW3VZ(\BA3@!L[2#T.<'I0
M!>HHHH **J76HVUG=VEM-)MENF*0C!.X@9/TX'>EN=1MK.:WBN)EC>YD\N)3
M_&V,X'X"@"U10.E% !1110 5!=?ZI?\ KHG_ *$*4W4*W"VYEC$S*66,L-Q
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M]0@)PH_W<5>LM-L].65;2!85FD:60+_$YZG\:M44 9UQH6G76J0ZG+;YO(0
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M J"Z_P!4O_71/_0A4]077^J7_KHG_H0H GHHHH **** "BBB@ HHHH ****
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M!:M55M_^/J[_ .NB_P#H"U:H **** "BBB@ HHHH #THH/2B@ HHHH ****
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MLSX@@GP+J>.2%0@>OSK5==*U*ZU.+7+U;>T%I8R10QP2&1V+#JS%5QC P.:
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MD6)DWF,\8SNXW9S^%..L>)=2CU*]TZ+4WGANWCM88Q (-J$#:^XAB3SD]NU
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M$$\QF"_-@$A!CYL9YR15>;Q;<$:C-8:3)>6FG2-'/*)@K,R\ML7!W8]R/;-
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MQP3754 %%%% !1110 4444 (>E+2'I2T %%%% !1110 4444 %%%% !1110
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M?Q-=NFEVB:B+]85%R(/LX<$_ZO.=N.G6JTWAS2KB&]AFM$>.^D$MP"3\[@
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M?C&?>@"/X@.R>%V*!6?[3;[5)QN/FK@9[57/BC4](OKVVUV"T81V#W\4EF&
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M)M"D.".5XSQSVQ6?<^%[^UT.RTZVTY9[NVMBD&I07?DO#*Q);/?9G''.>>*
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MHHH **** *6D_P#(,A_'^9JPO_'S)_N+_,U!I7_(-A_'^9J=?^/F3_<7^9H
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MB39G.-O&?7ZUR\/@MH[*+37U25],BF$JP&%-QP^\ OC)&<<XS[UUE% #$B5
MVU5!8Y; QDU!'I]I#<O<Q6L"3O\ ?D6,!F^IQDU:HH J2Z98S7)N);.W><KL
M,C1*6V^F<9Q4JVT2RF58D$A4(6"C)4=!GTY-344 4I=)T^>T%I-8VLEJ#GR7
MB4IG.<[<8ZU+;V=O:;A;P11!B"PC0+G P,X]@!^%6** *E]IECJ2HM[96]RJ
M'<HGB5]I]1D<4@TRS58E%I;@1.9(P(QA'.<L..#R>?>KE!H SI](T_4K6!;^
MPM;L1J-HN(EDV\=MP.*NP016T*PP1)%$@PJ(H55'H .E$ Q!&/\ 9%24 0"T
M@$LTHAC#S "5@HRX' !/?@]ZK7.B:9>6<5I<Z=:36T./+BDA4JF!@8&,"M"B
M@#A?$6FV0UG2; 6EN+/<B_9Q$-FW>.-N,8KM;:VAM+9+>WB2*%!M6-%PJCV%
M<KXC'_%4:3_UT3_T,5UXZ4V)&9+X?TF;41J$FFVKW8(/G-$"V1T.?4>M13>&
M]'N-36^FTRU>Y^\9&C!)(Q@GU/O6Q3?^6@^A_I2&5_L%L+J2Z$">?*HC>3'+
M*,X!]N342Z/8);VD"VD0BM&#P*%XC8 @$>G4U=;J/K3J .4TSP180W-U=:C:
MVMS<R7TMU$^#PK-E0P[D>^<=JWSIEHUQ<3M;QM)<1K%*6&=Z+G (]/F/YU<H
MH R=/\-:1I5P;BQL8X9=NT,"3M7T7).T>PI(O#.CPI=I'IT 2\_UZ8RK\YZ'
M@<G/%:]% &38^&])TX3"ULD7SUV2;R7W+Z'<3Q[5%8^$]$TVZBN;73HHYHB3
M')DDKD8P"3P,$\=*VZ* (+RTBOK2:UN$#P3(8Y$)^\I&"/RK.T[PQI&E7C7=
ME8I%,RE 0Q(12<D*"<*"><#%;%% '/:+HQM/$6NZG((Q+=S1JHCZ!%08_$DY
M/X5T-5;?_CZN_P#KHO\ Z M6J "BBB@ HHHH **** $/2EI#TI: "BBB@ HH
MHH **** "BBB@ HHHH **** $-+2&EH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &LNY<9(]Q7,Q>#S+J8O-6U2;4C'#)!"DD4:;4<88,5 +' ]N_%=
M110!SNE>'=0TR6&-O$%S<:? NR.UD@C!VXP S@9.!].E,T[PI-IDPAM]9N1I
M2R-(MB8DP-Q)*[\9V9)X_6NEHH Y!/ S)!%IO]LW!T2*82K8>4G0-O"%\9*
M]O3C-:<?AR..;7)/M#'^UL;QL'[O$>SCU]:W** .5?PA/!<V5UI>K/9W,%BM
MC(Y@602QKT.">&!R0??H:@M_ K65IIZVNIE[FQNI;B.2Y@$BN9,YW*".>>H(
MYKL:* .23P2PL7@EU1YI9-434GF:( EEVY7 P!G;^M'CS1SK.F6EM")%NOM2
M+%+&.8U8%7)/8;"WZ5UM&* *MO9I:V$=I;_NTBC$<>!]T 8%85MX6N7UH:IJ
M=]!-.EL]J#;6QA,BMCF0[CN(QQT STKIZ* .,3P5>C1;'3Y-4MI1ITZ2VF^T
M)4A0<"1=_P W7J,8Q3V\%7$UEJ\=UJHDGU*6&5I$@V+&8RIP%W=/EQU_.NPH
MH Q=?T.;5OL,UK=I;W5E.)X6DC+H3@@AE!!(P?45)K.B#7=!FTRZG*-*BYFB
M7!5P0P8 D]P#BM:B@#E8_#.K7&K6^H:GK,<K0P20+';VQB W#!<$L3N_3IP*
MIZ;X'N[*71P]_9_9]+E+HL-EL>7Y67+MO///8>OX=M10!R+^#KB:TU?3I+^+
M^S[Z5[B(" ^;#*S!@=V[! (SC'XU?TS2=5MI2;BXTT*(BBFULC&Q;LQ)8_E6
M_10!5TZ&[@L(8KZY6YN57$DRQ[ Y]=N>*M444 %%%% !1110 5#<_P"K'^^G
M_H0J:H+K_5+_ -=$_P#0A0!/1110 4444 %%%% !1110 4444 4]*_Y!L/X_
MS-6%_P"/A_\ =7^9JMI7_(.A_'^9JRO^O?\ W5_F: )**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ I#2TAH ;",0H/]D4^H[<YMHB?[@_E4E !1110!R/B+_D9M
M)_ZZ)_Z&*ZX=*Y#Q%_R,VD_]=$_]#%=?38D%-_C'T-.IO\8_&D,4]OK2TA[?
M6EH **** "BBB@ HHHH **** *MO_P ?5W_UT7_T!:M55M_^/J[_ .NB_P#H
M"U:H **** "BBB@ HHHH #THI#2T %%%% !1110 4444 %%%% !1110 4444
M (>U+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-US
M$O\ UT3_ -"%35#<_P"K'^^G_H0H FHHHH **** "BBB@ HHHH **** *>E?
M\@V'\?YFK"_Z]_\ ='\S5?2O^0;#^/\ ,U87_7O_ +H_F: )**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ H-%!H 9#_ *B/_=%/ID/^HC_W1_*GT %%%% '(>(O
M^1GTG_KHG_H8KKQ7(^(O^1FTK_?3_P!#%=<.E-B04W^,?0TZF_\ +1?H:0Q3
MVI:0]J6@ HHHH **** "BBB@ HHHH JV_P#Q]7?_ %T7_P! 6K55;?\ X^KO
M_KHO_H"U:H **** "BBB@ HHHH 0]*6D-+0 4444 %%%% !1110 4444 %%%
M% !1110 &BD-+0 4444 %%%% !1110 4444 %%%% !1110 4444 (<]JXOPI
MX_3Q)JD]A)9&UE53)#^\W>8H;![#!''K7:-TXKPRTT_4](\.6'B"SLKC[=:7
MT\;1;&#-'(,9QC. ?;O0!Z!9>/XK_P 9R:#!:%HU,B"Z+X#,@RPQCID8SFM3
M2O$T4VBC4=8EL-/4R-&"+U)(S@X^^,#/MVKA]&\/SZ-XN\-Q/#*S_P!FS27$
MI0D><^\MD^N3BLNWL[6/P%H\E]/<Z?<P7=Q+;N]FTT1;=TD7&!GC'XXH ]>?
M6M*CLH[V34K1;63[DS3*$;Z'.#2RZQID%I'=S:C:1VTGW)7F4(WT.<&O)YIW
M,OA35O$.BK!I"1S":VCM28HW.=K&/'&[Y3R*FU\VQUS0=0A@6R\/FVD6 W&F
MM+%$Y9LDQ9&-PVX- '=ZQXG-AJV@VMJD-Q#JDS)YPDX50!RN.O6F^'/%:ZQ9
MZG=7H@LXK.]DM@YDPI5<8))Q@\UP5C81VE[X,6TNYKVU_M&Y=)&M6@" A/E"
MG.%R"14-O>'3O".K22Z;;W,;^(7#F\B+QPJ0/WC*.H']: /7HM5T^>U:ZBOK
M:2W0X:595*@^YSBGPZA9W$SPP7<$LL?WT20%E^H'2O#9PAT?QK]E:)[61;1H
MS;VI@B?YQDK&<X],_C70+I<>E>+?#0TBV2":?2I6<H,>9)Y9(+GOR1UH ]17
M4+)[HVJWEN;@=8A(-X_#.:)M0LK>989KRWCE;[J/( Q^@)KQ/P];65T-,MI]
M6MM/UV*^W.AL'-VTA<\-)NY4YZD8J2[ET>.V\4VVOV[2>(I;EQ:"2)FE8?\
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MWM[5IK"/3X9;2&XOY+=MK#E\@$LPX&3TQ[U9$-W/J7AS1=:OV>,VL\LOD7#
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M&2*+:.&8G)SC/8=Z .ER/6ER*\[M-8UW4CX=MH]3\A[];WSY1 C']VPVD C
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MCEC62-U9& *LIR"#T(-.R/6N%M-6U>ZN/#^G6+V=I'=:0MU(WV?<(SA<!%#
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M8GC^V10%H8IMN0I?&,YQ[ ]:W]0U673/"LFI>4\\T5L)-J(6W-MZD#MGK[4
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M#H58<@^X-71-&9O*WKYA7=LSSCUQZ5#<:C9VDL<5Q=P0R2':BR2!2Q] #UH
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MO( #W)X/)Z8K>:6-,[G5<#)R<8%4[W5K/3Y[2*XEV-=R^3",$[FP3^ P#S0
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MF74+6+5I8M/U"5I;B%H$=_F # .W(X''!([=*Z:VL;>UC"10J/W:QDXY95&
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M!I]ZN6*]67 4D="0 ,$],5<MM-LK*ZNKFVMHXI[I@\[J,&0@8!/K0!:HHHH
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M_7O_ +J_S-5]*_Y!L/X_S-6%_P"/A_\ =7^9H DHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D-+0: (X.+>(?[ _E4E,A_U$?^Z*?0 4444 <AXC&/$^D?]=$_
M]#%=>.E<CXB_Y&?2?7S$_P#0Q774V)!3?XQ]#3J;_&/H:0Q6[?6EI#V^M+0
M4444 %%%% !1110 4444 5;?_CZN_P#KHO\ Z M6JJV__'U=_P#71?\ T!:M
M4 %%%% !1110 4444 (>E+2'I2T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A.*R8O$-I+!+.%F$4
M=W]D#^62'?(7(QGY<Y&?8UISEE@D9?O!21]<5P=O<3VGPZT*6TF99)+FV$CH
M<%M\PW@_7)S]: .GO?$=I8VUQ<2+.8[:=()B(C\A8@;N<94;ADBMD$$9%<3>
M32W6D>-XKB9I(HA(L:,>$'D X'XG-=-H<DLV@Z=),")7M8V<'LQ49H NS2I!
M#)-(<)&I9CC. !DU@_\ ";^'MY3^T/G !*^3)D ]/X:Z&N<M/^2@ZJ/^H=:_
M^AS4 :>F:O;:JUV+8L?LMP]M+N7'SJ 3CU'(K0S7E7DWUMI?C+6+/5+JVEL]
M5N'ABCQY98!"2P_BR,#!Z8S6EJ&IZEJOB*XLXH]6\B"SAECCTV6*-M[@DLQ=
ME) Z8&1P: /0Z*RO#K:D^A69U=-FH>7B<<?>SUXXYX/%<]<0W^K>,-;LQK=W
M9VUK!!)'' X4AV5OFSC.!CD=#GF@#MLCUHS7FUIJ&JZ])X7A?5+BT^VV5P]R
MT&$:4H5 (]">N1V)K4BCOM7U?5[<ZS=VD6E^7!"(64%F,8;S),CYNO0\<4 =
MK52;4;6WOK:REG1+FY#&&,GEPHRV/H"*X73?%5] -(U75+D?8+ZPF$B[0$6:
M++;AZ;E#<>U3V&IZ\+GPG'=W1\[4HKN>>-D4 ?('C0\9&W(''ISF@#N;BYBM
M;66YGD6.&)#([MT50,DG\*+>XBNK>.XAD62&50Z.IX92,@BO/X-6U*STK55U
M*_OX-;BL+B7R9XX_)=D4D20D#!4<<9SZBK-AJ&JZ]J-AIO\ :<MDBZ1!>SR1
M+'YD\DF1QD$!002< <D4 =Y1FO-1K^MW%C96B:@([L:[)I4EV(5/FHJO\^W&
M >AXXR/3BKPN_$,*^(=*M;R2_O++R7MIGCC$I1QEAC 4L,'&?6@#O*,U@^%K
MU;RUN!_:%U=2QR;9([N%8I8#@?(P 'USCOU-5=;O-0N/$UAH=C>&Q66"2YEN
M$17<A2 %4,"!G=R<&@#>U#4+;3+22[O)TAMXQ\SN>!V%.LKV"_MEN+=F:)LX
M+(5/!QT(!KS+Q+<ZG<>'M3L+K4&E?3M3@B\]8U4S*Q1EW#& RY[8SBO3+2WE
MMK..*>Y>YE48::15#-[D* /R% $TTT<$#S2,%C12S-Z #)J*SO(;ZSAN[:02
M03QK)&XZ,K#(/Y5P&FZ?>1ZGXQE;5)V6-F$D9CC FS#P20N1C(Z'M4?AZ?6]
M*TKPA-)J@GL[Y(;<VAA55C0Q90AOO;A@9R<'TH ]"M+ZVOE=[6XBF1)&C8QL
M"%93@@X[@]JLUYZNJZS)I-Q);/*J)K-Q#<36ELLDL<*LP!"8Y.=N3@G'-=?H
M%TEYHT$Z:@NH*V?]($83=R>"HZ$=#TY'04 7+J]M;&(2W5S#!&3C=*X4?F:@
MFO;66P%U'<1/;AE;S5<%<!ADYZ5S=K;0:E\1=5:]C28V-M"MJDB[A&&R68 \
M D@<^U<]X@LDT^Y\76FFR+;6\NGQW4L<: J'R01CL64?UH [H>*M#-B;T:I;
M&V\P1>:'X+$9 'J<<UK0S1SPI+$ZO&ZAE93D$'H:\LNK36$'@F+^V1F8YA)M
M%Q"?)XR,_-@$C]:T;OQ+K%U>:LNGSW*'39#!'#%IKSBYD49.YU!V9/  Z=:
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MIO\ &/QKG[CQC8I%8FQM[K4I;V(SPPVBJ6,8ZN=Q4 9(')ZU535II/&=J?\
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MOW=M'>6DUM*NZ*9&C<9QE2,'^=1W^HVNF0K->3"*-I$B#$$_,Q"J./4D"K5
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M\YXR 1^-"Z3KMIX7\R%;B/4+V_\ M5^L#)YJQL3E4)^7( 4?GBNZHH \UNM
MU6ZTGQ0D>G7BF]6W%NES<"223;C))W''3IFK6M^'-4U"^\1M! P6XM+0098
M3-&6+)U^@YXYKT"B@#B+/^T-3\;V5^=(N+6UMHI4DDF*A@S)'Q@$_P!WK[UV
M]5;?_CZN_P#KHO\ Z M6J "BBB@ HHHH **** $-+2&EH **** "BBB@ HHH
MH **** "BBB@ HHHH 0TM(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH @O':.UE=(O-948B/^^<=/QKS?3[F>^\1>&+@1JLD;2">*"Q:);7=&?W98
M]>G3VS7IQ /6C:* /*YM,5/AY=3QV92]_M9I XB_>9%U@'.,_=_2K][+86FJ
M^*8M:LWFN+K:;0?9S(9H_+ "Q\=FSD#H3FO1=HHVB@#SW3DDU'3/!NB'<(X[
M2*^O%(P=L:KL4CW<@X_V35BZFL-/\;:O/K\8,$MM$+*2:,NFP*1(B\$!MW)'
M4Y%=C'I]K%J$]\L?^DS(J.Y8GY5S@#TZG\ZL[1Z4 >7Z9I$LDW@BVU*U9XA]
MK<0SJ3Y:;0T:L#W QP>F/:O1KBV_XELUO JIF)D15& .,# JU@"EH \GM=2M
MI=!\%:6%E-Y:ZA;_ &B$Q,#"5W##<<')X!ZU/>:9;S>'O&UY)9H]VEW.892F
M77 !&T]1SZ5ZAM6C H \RU(,/%%PVHWFGVL4UC"L#ZE:&9&7!WJIWJ <]1U/
M%2PZ/!+K/A"QNI$U.UCL;G]Y+$0LF-FTE6)]NN>E>CF-&&&4'!SS2[1Z4 >3
M:KI\"^%M2MDM(S%;^($6",QY$:-)'N"CL#DY XYK7N(=&L?&MY%K\%E%I:V<
M2Z:EPBB!<9,@4'Y0V<=.<5Z#L7^Z/6FO%%( '16 .0&&: /*[&Q6]NO"-M>1
M,]C+>:@8()@>;?:S1A@>HP!QTQBM:=/#UMXHU.#Q"ME'%';PI8I=!0BQ '(B
M!X!S_=YZ5WYCC+*2HROW3Z?2D>"*4J9(T8KTW#./I0!Y;J:6]SXBUB+4;K1K
M>-HXUM#J\;9$)C&#$2PP0=V<<YJQJ5Q;J;#2KYM'NKB/3D<ZEJN=DRDD8B7.
M2W&2<YY'6O29+>"7'FQ(^.FY0<4K6\,A4O$C;?N[AG'TH \ELY[.XTKP%)KD
MRM;&*<2O.Q"\  ;SZ< '/'K3I3$VD:R-/<?V/_;EJ++8?W?WH]^P]-N[.,<=
M:]7-M RA6AC*C( *C SUH%O L8B$2!!T7' _"@#R.ZCN;Z]U]+^_T2TNEO7$
M<VH.R7$*#'EM$<C"],8ZG/6O5) XTEM[AV$)RXZ,=O6IGL[:619)+>)W7[K,
M@)%3%01@CB@#QW2?['_X1WPO+ITRG7VO(0RQR9EV[OWBL,YV;,^W2M?,\&N2
M>"660PW&HB\C;)P+7F5ESZ;U*_CBO15L[:.7S4MXEDQMW*@!QZ9]*HQ:,J^)
M)]9DE,DCVZ6\2%>(E!).#[D_I0!%XLOK?3?"U]=74$L\,:#='%(4+98#[PZ#
MGD^F:Y;PS(L/Q N;2 6$4#::)'@L)S)&&$@ )X'S;3SQR,5Z"R*Z%'4,I&""
M,@U!;Z?9V@ MK2"' (_=QA>#UZ4 <QXH-M+XDT2TU24)ILBS,5D?;'),-NQ6
M.1G@L0#UK)U :0^N:+8?:@^@M%*\"B<F&6<2J"I;/S *6PO0?A7?7=E:WT!A
MN[>*>(]8Y4#*?P-5;_3+"?3ELY;*WDM@Z*(6B4H!N'&,8H \Z-VT%C<FVNW_
M +'M/$=NL,OFDJD7R[P&_N!B1UK3U;4XKGQ!XE%E>"40Z"P(CDR$?Y^F.,XQ
M7>"PL_L?V/[+#]EV[?)V#9CTV],5%#I&FVT9C@T^UBC*>652)5!3^[@#I[4
M>?Z]H6GVG@?3[PB2626YLI)IIIF<MF1=Q))Z88CV%>@VD-O;62QV6WR4!V!6
MW#\ZEELK6>U-K+;Q26Y7:8F0%2/3'3%%K9VUE;);6L$<$$8PD42A54>P' H
M\QGFB/@Z;7$OYO\ A(A=D+B<EQ+YV!"$SC;C VXZ<UMZ#IUN?B'XCE,9\V(6
MSJ=YX9D;=W]ZZO\ L/2?[2_M'^S+/[=_S\^0OF>GWL9JS'9VT5Q+<1P1I--@
M22*H#/CID]\4 <UXK82ZIH5A<W,D%A<W$@F*2%/,*H61"PQ@$]L\XQ6;?Q6,
M6KZ-H\>HS+I4TL[N%NF(:50"L1?.0.2=N:[2]T^SU*W-O?6L-S W6.:,.I_
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M3Z=&[1HB ;F *K]T,,X8#WS3K_PIH>IWANKO3XY)BH5SD@2 = P!PV.V<XH
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M.@S"29(#;6WFH'F"A@<D$A6YZ4 =G13(F+Q*S*5) )4]1[4^@ HHHH ****
M$-0W7^J7_KHG_H0J<U!=?ZI?^NB?^A"@">BBB@ HHHH **** "BBB@ HHHH
MI:3_ ,@R'\?YFK"_\?#_ .ZO\S5?2?\ D&0_C_,U87_CX?\ W%_F: ):***
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M#Q0 456N=0M;.SGNYYD2" %I7)R% ZYJ6&9+B%)HF#1NH96'0@\@T 24444
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M?$0_XJ?2?^NB?^ABNN'2N1\0_P#(SZ3_ -=$_P#0Q77#I38D%-_C'T-.IO\
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M:K</%%"X$98!,EEQ\V1QS6I<7^KZYKM];1?VDJ6D$/E+87$<.'= Q=MQ!;T
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MM9S$T,LI%RZ  B55Q@J2?_KYXIWC"[NXK6PLK6X:W?4;V.U:9#AD1LEBI['
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M^2WN]/@%PT*R!UDC.<,C=^A'.,&G6GBII=1M[2\TVXLOM<#W%LTCJV]4P6!
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M%[K;2QE#+J#.I(^\NQ,']*Z"@ HHHH **** "BBB@!#2TAI: "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#Q6E=>#(0L-NLI^PKI?]E[3]_#2(=V>G04 3V_BJ^WZ?+?:.UK9:@ZQP2_:
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MC:Q)&3S0!LCQ*JW=I#<Z=?6J7<ODP2S*F&?!." Q9<@'&1527QO9PBZD:QU
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M;<Q6JZ;#;Q@ONVE6;Y<]3@$<T ,E\;Z/!<7$,DEQ_HTIAN)%MW9(6SCYV P
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M\F@,L'R^0ZRL,HBXXP#P<YXJ2\N-5FM/%>I1ZU=0#2[F06T*!=@*1(Y#9!+
MD].WXT >A;A2UP6IZEJ<5[::G?37UMHTEO$XEL=A6"0\MYP()*\CD# KNU;=
M&&!R",@^M "YQ6;?:]8:??VUC,TK7-QRD<,+2$#(&YMH.U<G&3Q7)&]U;4-%
MUGQ FLRVK6<MPMO;*J&)5B)&'!!+%MOKQD8I-/6XOOB3'=&ZN(C)I$4[1X4@
M O\ ZOD=/U]Z /0-PQGM5:ZU&ULX(YIY0(Y)$B5ASEF8*HX]R*9J432Z7=1I
M*\1,3?.@&1Q[@BO/+.VNU^&6CF'4&+37-GY/FQJ5@/G+T  )YQP3VH ]/R*
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MO6M\0$E;P5JC13^3L@+,=H.Y>Z\],^M &]->V\$]O!+*JRW#%8D/5R 6('X
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M+1;6PU74-1A,AGORAFW-D?(NT8';BK.H6$&IV,UG=)O@F0HZ^H-6-PI0<]*
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M4FF3Z?JAAN+*Q%@7D@$@=.#N R-K9'T]0:Z*;4;6"_MK&20BXN5=HEV,0P0
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M>,GBO0"RC&2!FEP/04 <_P"%[6>U_M87$/E-)J,LBKD'*'!4\>HYKH:JV_\
MQ]7?_71?_0%JU0 4444 %%%% !1110 AI:0TM !1110 4444 %%%% !1110
M4444 %%%% !12&EH **** "BBB@ HHHH **** "BBB@ HHHH **** ,GQ/\
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M[I\TTR7%RTP+)MVOR3MSN(XP#BLW2M3?PWI?A[4III3IUUHBQF$R':LT<7F
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MNIKNZC:5)7$]PS;RO*@_[.><47'A;3+E;Y'C<)>RK/*$D*XD7&'7'1N!S[4
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M6C6Y=I[NP:W,<@(&T?*H(()/<C'6KMIX1TRST"?14$KVLY)D,DA+GICYO8
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MNK/[*V( BQC)/R@'..>A)Y[]J@?PI>VEQ8W6D:G%;WD%BME(T\!D25%Q@X#
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M>&+*"!/[:M;^W%T! ?,B;?\ /O;'&3ZGFI]0@$]EXCC>-FCD\16ZL&!^8$Q
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MBQPE>7BQQUS\PYX'I0!Z3D>M&1ZUY[#I<6IZEX:LM2NUU&,:;*SR(Y\NXP4
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M<L8E))/7B@"SD>M&1ZUYG<:E(E_IVK:<-5:VFU$0O=75V/+E5F(*+%G[OH<
M\4ZZ2]N=+\4:L-8U&*73+V86L:381-BJW(_B!R1@\ 4 ;7B1E7Q1I1/]]/\
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MI[R[O+8W0@1U7RX\]68G'4@ =ZQ]$UMY+;[1-)J$1N->\A4) 90<X1P<X7U
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M6.XB:)BO4!A@_P ZS[KPW;W6BV>G&:9#9^6UO.I^='085O3/U&#DULE@HRQ
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MTRS-HF0/W@(49/H?E_6M_(]:7K0!PFO:!+;-:,@N[BW?5)+RXD@C#R0AXV7
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M0 4444 %%%% !1110 5#<_ZM?^NB?^A"IJAN!F,8_OI_Z$* )J*** "BBB@
MHHHH **** "BBB@"GI7_ "#8?Q_F:L+_ *YO]T?S-5]*_P"0;#^/\S5A?]>_
M^Z/YF@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM!H CMSFWB/J@_E4E,A
M_P!2F/[HI] !1110!R'B(?\ %3Z3Z>8G_H8KKQ7(^(O^1FTG_KHG_H8KKATI
ML2"F_P 8^AIU-_C'XTABMV^M+33U'UIU !1110 4444 %%%% !1110!5M_\
MCZN_^NB_^@+5JJMO_P ?5W_UT7_T!:M4 %%%% !1110 4444 (>E+2&EH **
M** "BBB@ HHHH **** "BBB@ HHHH 0TM%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %0W/^K7_KHG_H0J:H;G_5K_UT3_T(4 34444
M%%%% !1110 4444 %%%% %/2O^0;#^/\S5A?]<W^Z/YFJ^E?\@V'\?YFK"C]
M^Y_V1_6@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#THI#0 RW_X]HO]P?RJ
M2H[?_CVB_P!P?RJ2@ HHHH Y'Q%_R,VD_P#71/\ T,5UPZ5R7B'_ )&;2?\
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M<0QV,*Q"87 15P!(,8;'KP*AM=&$6O7>L32B6XFC6",!-OE1#G;U.26).>*
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MV!Z (O&/^^C6M0 4444 %%%% !1110 AI:0TM !1110 4444 %%%% !1110
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M>'_$.G"YB\S4[F6>-\'"!]N ??BH[_PO>C6I]1L8=*NA=(BRQ:A$3L91C<C
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M>K<4V--2T'Q'K4\6CSW\>HM%);R0,G!5-I1RQ&T#&0>1R:LQZ==?;O%$K6S
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M6W_X^KO_ *Z+_P"@+5J@ HHHH **** "BBB@!#2TAI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,
MT53U6_BTO2KJ_F_U=O$TK?0#-5='U-[JSLUO7@CU":V6X>W0X*J?0$YP.F:
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M9(SR!0 L/^HC_P!T4^J.FZE9ZC;[K.YAG"85S$X;:WH<=*N,ZJP4D GH,]:
M'4444 <EXAQ_PD^E>N]/_0Q76CI7(^(?^1GTK_?3_P!#%=<.E-B04W^,?C3J
M;_&/QI#%;M]:6D/:AF"XR0,G R>M "T444 %%%(3SB@!:*** "BD+8H!S0!6
MM_\ CZN_^NB_^@+5JJMO_P ?5W_UT7_T!:M4 %%%% !1110 4444 (:6D-+0
M 4444 %%%% !1110 4444 %%%% !1110 &BBB@ HHHH **** "BBB@ HHHH
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MQQZ<7 *^4S*'"?[!.[VQ7I&J:%:WWAJXT=(DA@>$QQK&-H0_PX],'!K3$2
M;1@=!Z4X].* /,+&^U'Q$+O4UB<7>C:5);*,8(O""'*XZX"C\Z9"FB01^%I_
M#KQ'5)[F+SVB?,LD>/WOF\Y^N>AKO="T2/1;*6'SFFEFG>>65EP79CGI[# _
M"KT5E:PS2316\22R??=$ 9OJ>] 'F-WJ-E:>!_$ME<W,*7;:G<*L!<;R3*",
M+UZ<UOVVE6NH_$&\ENXO-^R6=I+ K,=J-F3YL>O'%=;)IMC+,\TEI \KKM9V
MC!8CT)]*F6&))6E6-!(P"LP R0.@)_$T <UXSLA?6-K%Y]EE)_,-K?3&.*Y
M4@JQ'/&0W0C(YKEBFA:K+X4O)+".VM'FN;>19GW*NU'PH?.-NX$CGZ5Z5=6%
MI?1"*[MH;B,'.V5 XSZX--FTVQN+9;::S@DMUQMB>,%1CI@=* /-/&%S9W$N
MM/9V=JMQI\*J;NZOGCDC;9N7[.HS[<C;D^M:<EG%K_B:S:_>62/^RK:<QK(R
M(TAE^\0I'(SQ7:S:1IT\RS36%M)*J[ [Q*6"^F<=*)[.VC"21P1HX,<895 (
M4,,+]/:@#D/"&GZ;:^)O$0"I'<Q7Y$2&0[@AB0YQGG)+<U-KZ6U]XXL-/U68
MKIPLGGCB:4QI)*' R2",E1R!VZUUG]G67VW[;]EA^U8V^=L&_'INZTE[IECJ
M4:QWUI!<HIW*LJ!@#^- 'FNGW&EIH\]KFXOX;K76AMS]J9!*=HQYCYR4Q]<\
M=:ISQF3PSXIM+DQ^5I]S"T45O<O)'!D+N ; ) YX(XKU272--GMGMI;&V>!V
MW-&8EVD^N,=?>ECTK3XH)8([*W2*5=LB+& &&,8(QR,<4 <)KD6==T/1]/2*
M?3)8II1#->NL<T@QP7&XG .0OO[5T7AAIM)T9H=6O[0C[6\=L5NC)M0GY(R[
M $L.1Z\"M-_#^D/IZV#:;:FT0[EA,0V@^H'K5>Y\-V$KZ>J1)#:64IF6VB0*
MCOC"DX],D_6@"MXTCN4T$ZC9NZSZ=*MV$5R!(JGYE..N5W?CBN3U'5KR[L]9
MUVUNI8[*YNH+"&5'(\J $"24=ADL1N]J]&U&&:XTVYAMV1)I(V5&<94$C@D=
MQ5/2-#MM-\.VVCE5F@BB\M@ZY#^I(]SF@#D;Z)M%U^/3]%N+ETN]-N&GB:X>
M8J57Y)!N)*DGCCK3K/4W/ACP4&O7^TW%Q"'_ 'I+R#:V[/.2,XS[UV&F:#I6
MC*XTZP@MO,^]Y:8)_&HH/"^AVMT;F#2K6.<R"7S%C&0P[CTZT 8>NW%QI_AS
M3]5@F=!8W22S*I(#Q%RK@COPV?J!7)CQ-J+3:N3/<?\ $^C"Z6%)_=GS6A^4
MYX."K\>N:],L[6"[T5;>XB62&161T8<,"3Q3%T+2Q/:K]AAQ8J#:_+_JCD_=
M].@H XK6FFC7QM9FXF>&WTBW$:/*S $K(&.">IP,GK6WHH7_ (2W/?\ L6VX
M_P"!/703:)IMP]X\UG&[7D:Q7!(_UB#. ?IDU)#IEG!=&YB@59S$L.\==B]%
M^@R: .8UBVDU3QQ!IKZA?06IT]IGCMIVCW$2 #)'/?MZ5A1ZOJEUI.B:=)/=
MRB>]N;>5X9Q%-*L);8OF9&,X&3G)QUYKT8Z?:F_%\85^U"/RA+W"9SCZ9JG-
MX;T>?3_L$EC&;;S#*$Y&UR<E@1R#DDY% '$ZA<^(]%T.XMW^T0V]Q?PP6K2W
M2R3QQ/\ ?'F9/.>%)/&:L7$OB#P_I>N7<,=['9QV7F0+>72W$B3 X+ [F.W!
MS@]P?I76V_AG1[;39]/2R5K6?_7)(S.9/]XL23T'>DL/#.D::LZVUI_KTV2F
M61I"R_W26)..>G2@#C_[-_L_Q7X4;^U+R\-QYTC"YF\SYO*Y9<] <]!QTJ_X
M_L!<W'AYS=W4._4XH,0S% -P;YA_M<8!]S6Y8>#]!TRYBN;6P"3PDF.1I'<I
MD8P"Q.!@].@J]JFD6.M6?V2_A\V'<' #E2&'0AE((/N#0!RBV]SJOB:_T:75
MM2MK32[:'RC#.4DF9P<N[XRV,8^N:V/!^H7>I>'DEO)UGFCFEA,ZC E".5#_
M (XJ2]\':%J"P"XLW)@B\E'2XD1BG]UF5@6'L2:U;:TM[&UBMK6)8H(E"HB#
MA10!YQ<7FK6_A:]\1IKET;BRO9DCMBX,147!78XQEB1P/3C&*Z"U%[J7B_4M
MVJ7D-K8F"2.VB("L63)#9&2..GN?:C1_ VGV[_:=1MDEO!=RW *32>6V969"
MR9"E@".2#C'6NE@TZUM[VYO(HRL]UM\UMQ.[:,#CH./2@#@5U'5Y_"-QXN36
M)XKA&D=;1MOD"-9"/+*XSD@?>SG)].*LZAXFU'3)]<T]YP;V7R9-*WJ,_OOD
M"XQSM8$]_>M]O!6@O>-<M9N2TWGM%Y\GE&3KN\O=MSGGIUYJ]>Z!IFH:E9ZC
M=6^^ZLR3 ^]AM)]@<'\<T <7JOB'5M#E\11B[:X:RL;7R6>-!B1SM:0X'KSC
MIQTJ::&\TSQCH+W>IS:ABUN7_>H@92$!.-H'![ CCUKJ[CPYI5U-?RSVWF-?
MPK!<Y=L.@! &,\=3R*JV'@[1].OX;Z)+F2YA0QI)/<R280C&W#$C&* .=TS5
MO$UW;:3J4?VRZ%U,C7$!AA2!(7ZE&^_E01U)S_+HO%=_>6=E8PV$XMY[V]CM
M1.4#^6&R20#QGCC-.M/".F6,B?9FO(H(Y/-2V6[D$2MG.0N>F>W3VJ]JVD6>
MM67V2]1FC#K(K(Y1D=3D,".010!PU[?7_AWQ'K-W/=G4)+;1P\+RHJ,29, -
MM & >X XK1.I:QHU]H)N]2-_%J;F.>,Q(HC8IN!C*@' Z<D\5LVO@_2+6>[G
MV3SS7D)@N7N)VD,JGL<GC\,4MAX2TS3[NVN4-S,]HACM1/<-((%(P0H)].,G
M)]Z *'A^;6=3L8-:GU8B.<N_V,0)Y:IR  <;MPXY)(]JS;#Q+JD_@/2M3EN
MUW<7L<,LGEJ,J9BI&,8Z<5T5GX4TZQO%GMWNUC25IDMOM#>4CMG)"Y]SQT'8
M55'@71A)&<W?E13_ &B&'[2WEQ/NW$JON?7/MB@#&U#5=?V>)KV#4UA@TB4^
M3%Y*GS,1JQ5R1G;R>F#SUJ>'6]7T_4M*EOKQ;JUU.TEG,2Q!?(94#@(0,D8.
M.2:Z%_#FGR0ZM$5DVZH2;G#]<J%X]. *>=!LOM&FSXDW:=&T4 W<;2H4Y'?@
M"@#D-'\2:[J!TR_7[;-%>3+YUM]@(ABB;/S++C)*\<DD'T%)=:WXE.G>(-4@
MO[=8M(NY56W:WSYJ)R0S=N.F/QKI[#PQ!ILD:VM]?QVD;[X[3SOW:G.<=-V,
M]LXJ0^&;#^S-5L 9O)U-Y'G.[G+C#8..* ,"%=1N/B+(\>H>7$=/BF,9A#?(
M7.4Z]>OS>_M56Y\67EKJUF8=2^WP3ZDMG+''8.L,89MH FQ@LO&>>>>!BNHG
M\.V\FK6VHQ3W,$\,0@?RV&)8P<A6!![]Q@UGQ>![*);> 7U\;.TN5N;6U+KL
MA8-NQ]W<PSD?,3C/&* ,W3AJ:7GBJ2;48[B""1PUO);Y5SY*D<D\#D C'//K
M2:9K6J:HNB:5ITEM8L^CPWUQ+Y&X+N  1$R !G/T&*WSX:B_M"_N4O;I(K]2
M+BV4KL9BFS=]W<#@=CC-5SX0@B33FL;Z[LKJQM5LTN8MC,\0 &U@RE3TSG%
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M*** "BBB@ HHHH 0TM(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJV/%-F;(W'V/4]XE\DV_V)S+NV[N@'3'?./>@#8\F/<S;%RW4XZ_6E,:E@Q
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M9=0MTM9SB*4N-KG!. ?H#^59NH^--(L_#\VL0SBZBC.P1QG#%_[I!^Z<>N*
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MV "1^E4?#EM:W$6@VLVIP6VH6<ZR&T33V6X##(97;=T.3EB,<BO5=OO05XH
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M.GVEOL\FVAC\M2B;(PNU2<X&.@S3)M*L;FWDMYK.WDAD8N\;Q JS'J2.Y]Z
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M&*>WUI:0]OK2T %%%% !1110 4444 %%%% %6W_X^KO_ *Z+_P"@+5JJMO\
M\?5W_P!=%_\ 0%JU0 4444 %%%% !1110 AZTM(>M+0 4444 %%%% !1110
M4444 %%%% !1110 44AI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/H:=3?XQ]#2&*W;ZTM(>U+0 4444 %%%% !1110 4444 5K?_CZN_P#KHO\
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M.E-B04W^,?C3J;_&/QI#%/;ZTM(3T^M+0 4444 %%%% !1110 4444 5;?\
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M:=0 4444 %%%% !1110 4444 5;?_CZN_P#KHO\ Z M6JJV__'U=_P#71?\
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M(9)XR9(=WENKE67<,'!!!Y%7** .=L]#E&IV<DT-M;VFG>8+2"!BP);Y0[9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "H;G_5K_P!=$_\ 0A4U17 R@_WU_P#0A0!+
M1110 4444 %%%% !1110 4444 4]+_Y!\/T/\S5A1^^8]MH_K5?2_P#D'1?C
M_,U:'^M;Z#^M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH ;#_J(_\
M=%/ID(Q!&/\ 9%/H **** .2\0?\C/I?^^G_ *&*ZT=*Y+7_ /D:-+_WT_\
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M!6\.Z>PVD7)'O=2__%4#P[I^,8N<=,?:I?\ XJBB@ 'AS3E(*BY!['[5+_\
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M0!'_ &_?JW(MB ?^>;#_ -FIP\171W?NH>G'!_QHHH 9_P )'=QM\T4+#'&
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A?_71?_0%JU110 4444 %%%% !1110 TGY\>U.HHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit101-offerletterda004.jpg
<TEXT>
begin 644 exhibit101-offerletterda004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *@N_P#5+_UT3_T(5/5>[_U2_P#72/\ ]"% %BBB
MB@ HHHH **** "BBB@ H-%!H I:3_P @R'\?YFK"Y^TR>FQ?YFJ^D?\ (,A_
M'^9JPO\ Q]2?[B_S- $M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&BB@"*V&+
M6$?[ _E4M16O_'I#_P!<U_E4M !1110!QWB3_D:M(_ZZ)_Z&*[&N.\2'_BJ=
M(_ZZ)_Z&*[&FQ(*9_P M%^A_I3Z8?]:OT/\ 2D,<W;ZTM(W;ZTM !1110 44
M44 %%%% !1110!5M_P#C[O/^NB_^@+5JJMO_ ,?5W_UT7_T!:M4 %%%% !11
M10 4444 (>E+2'I2T %%%% !1110 4444 %%%% !1110 4444 (>U!8#O0>U
M,FA69-K*#2=[: .WCU'YTH8$5B7FES1J[PDN ,@$\BH+/4WM RSAS&/0$E<#
MH!WKB^N.-10JQM?J3S6W.BW4FZO&==\0:EXDU3R(5F2(,5AMDR"?=O?^5=/H
M/P_956XU>=V?KY"2' ^I[_A7JRH\L>:3,HU^>5HK3N>@!LFES4%M:PV<(AMX
M4BC'14&!63XNGE@\,7TD,CQR!!M9"01R.]8Q7,TD:RERJYN9I<UX =:U7J-4
MO?\ O^_^->B^ /$CW\+:?>3L]Q'EHV<Y+K]?:NBKA9TX\QA3Q4:DN4[JBD'-
M+7,=(4F:#T->'ZGK6IIJMVBZE=JHG=0!,P &[ZUM1HNJVD8UJRI)-GN.:3-9
MNAR22Z#82.S,[6Z%F8Y).T=:\DUO6-2CUV^1-1NT5)V"JLS #GIC.**5"523
MBGL*K75.*D^I[;FC->!-KVK[N=4NU!_Z;M_C35U[5B__ "%+S_P(;_&M_J,^
MZ,?KL>Q[_GVHS7@/]O:L>!JE[N]//;_&K%GJ6N7MU%:P:E>O-*P5 )VY]^M)
MX*2U;0UC(MV2/=Z*R]%T^33--2*>YEN)C\TDDDA;YN^,]JY[Q)X^MM,D>TL%
M%Q=*=K,WW$/]37-&$INT=3IE4C&-Y:':%L"HVN(E.&E0'W85X5?:_JFIR,;J
M_G9&.=BOA?R'%5XM.U&Y9GBLKJ7W6%F_7%=2P32]Z5CE^N)OW5<]_$JL,J01
M[&G Y&:^??,O;&165[BU<$X^\A!KI-(\?ZII_EI=-]L@SR)/O@>Q'7\:4L%.
MUXNXXXR-[25CU^BLS1M=L=;M3/:2[L8#(?O*?0UIYKD::=F=:::N@HHHI#"B
MBB@ HHHH **** "BBB@ HHHH **** "J]W_JE_ZZ1_\ H8JQ4%W_ *E?^ND?
M_H8H GHHHH **** "BBB@ HHHH *#THH- %'2/\ D%P_C_,U97_CZD_W%_FU
M5M(_Y!</X_S-6$_X^I/]Q?YM0!-1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $-K_QYP?\ 7-?Y5-4-K_QYP?\ 7-?Y5-0 4444 <=XDX\4:/\ ]=$_]#%=
MB.E<=XD'_%4:0?\ IHG_ *&*[&FQ(*8?]8OT/]*?3#_K5^A_I2&*W4?6G4UN
MWUIU !1110 4444 %%%% !1110!6M_\ CZN_^NB_^@+5FJMO_P ?=Y_UT7_T
M 5:H **** "BBB@ HHHH #THHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0]J6D/;ZT'I0 '&":\]O?$]O/XI>QBCS"/W8=.2T@)ST[=JZ+QCJQTGP]<21
MMMGE'E1?4]3^ R:YGX=: &#ZS.OJEOG]6_I^=5+#4ZM&3J+T]3GJ2;FH1^9O
MZ%86%OJ4TRP*+N0?ZT\D@#FNG KG[Z%[.\$D38!Y'H#GD5N6TJSP)(O1AFN'
M"3EK2GO'\C6.FA*>E<_XTX\)Z@1C.P=?]X5T!KG_ !G_ ,BEJ&#_  #K]17?
M3^->HJOP,\9M+62]O8K:(J9)6"KGN33[:ZN-*U".5,Q7$$@.#D$$'D$5;\-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "@T44 16O%I"/\ 8'\JEJ*U_P"/2'_<7^52T %%%% ''^)?^1GT@_\
M32/_ -&"NP'2N/\ $O\ R,^D?]=(_P#T8*["F)!3#_K5^A_I3Z9_RT7Z'^E(
M8K=OK3J:W4?6G4 %%%% !1110 4444 %%%% %6W_ ./N[_ZZ+_Z M6JJV_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+;R6M_9:G$V#PF?1E.Y<_K^5=MH]^FIZ7;W:'B1 3['N/SJOXDTC^V=$N+4
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MM)_Y!D/X_P S5A1_I#G_ &%_F:KZ3_R#(?Q_F:LK_P ?#_[J_P S0!)1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(>E+0: ([?BVB_W!_*I*C@.;>,_P"R/Y5)
M0 4444 <AXC_ .1GTC_KHG_H8KKZY#Q'_P C/I'_ %T3_P!#%=?3$@IO_+0?
M0TZF?\M!]#2&.;M]:6FMV^M.H **** "BBB@ HHHH **** *MO\ \?5W_P!=
M%_\ 0%JU56W_ ./J[_ZZ+_Z M6J "BBB@ HHHH **** $/2EI#TI: "BBB@
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MC0,4SU..>U-$VH$_\>\8XYY]J+)5).5]>WH(-4)^RIGKN'2F7,;P>7=0Y)4
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M6\RAXWP1N'K@\UY7XBN]1U7QZ\ NY;);'R$B154@NV&);(^8<XX/:NZ\!<^
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MBBB@ HHHH **** "BBB@ HHHH *R=,T8Z9?ZG*DVZVO9Q.(2O^K8J W.>02
M?SK5)Q7(Z7KOB76)YY;2RTE;&&\DMR99Y!+A&P3@(1G\: .G6PLUM#:+:0"V
M.081&-ASUXZ4K65HYE+VT+&5/+DR@.]?[I]1R>/>N?U#Q?#HMK>W&H-;2+%=
MB"..UER^#C[X; # ') [4MUXPLK?5]/3[7:#3;FWFD-PS?Q(R* #G'\1XZ\4
M :']C9\1IJC2*8X;;R((0F/+R<L<Y[X4=.U:CHDB,CJ&5A@JPR"*I#6=.;31
MJ2WUL;(_\MQ(-G7'7Z\4V/7=,FLI+V._MFMHFVR2B0;4/H?0\B@ M= T:QN!
M/::38P3 $"2*W16&>O(%6%TZR2"&!;.!88&#Q1B,!8V'0J.Q^E1V.J6>IPO-
M8W4-S&CF-FB<, P .,CZC\Z1=7L'LYKQ;RW-O 6667>-J%?O GMB@"CXD\/)
MK6AZE96PAM[F^C5'GV<G!XW8Y.*O66C:9I\DLEGIUI;R3?ZUH854O]2!S45Y
MX@TG3Y5AO-2M()7 *I)*%)![X)Z5;%[;FZ2U\^+SWC,JQ[AN*9QN ].>M $%
MQHFE7-C'8S:;:26D>"D#0J47'3 Q@4R[TM5T"XTW2HK:TWPM'$!&!&F1C.T?
M6KEO<PW2NT$J2!'*,4.<,.H/N*J7^NZ7I<R17^HVEL[\JLTJJ2/7!- #;#0K
M*TT&UTF2".XM[=$4+*@8$KSNP>^>:O?9;?[2;GR(_/*>69=HW%<YQGKCVJK>
M:SI^GQJ]Y?6UNK*7!EE"@J,9(R>1R/SJ2ZU*VL].>_EFC%LB;_,+ *1VY/'/
M'YT 17.AZ5=6 L9M.M7ME.Y8C$NU3G.0.QSWIT&C:9;6\5O#I]K'##)YL:)$
MH"/_ '@,<'WZU@R^-[2?0K+5-/>!DFN((YDE<;H%D(SNP>"!_*M^RU:PU*%Y
MK*]MKB*,E7>*0,%/N0>* )C9VQFEF-O$994$<C[!N=1G"D]QR>/<U%I^EV.D
MP&#3[2&UA+;RD*!1GIG ^@IMCK.FZG(\=C?VUR\?WUAE#%?KBH-=UR+0[6*1
MH9)YIY5@MX(\;I9#T SP.A.3TQ0!=NK"TO?*^U6L,_DR"6+S8PVQQT89Z'WI
M(["TAO);R.UA2ZF $DRQ@.X'0$]3BJEE?ZE+,R7^EK:H$WB5+A9%SQ\IX!!_
M C@\U)9:WIFHRR166H6MS)']]890Y7Z@&@!)]!TNYT]K"73[=K1G,AB\L!=Y
M.2V!WR2<^]2P:996K%[>UBB=HEA)10"47.U?H,G'UJ)==TI[A8$U*S:9E+!!
M,N2!U.,^QI\&KZ?=6TES;WUK+!%GS)$E#*F.N2#@4 3V=G;V%G':VD*0P1C"
M1H,!1["A;2!;Q[L0H+AT6-I,?,5!) )] 2?SJ&WU:PN[B2WMKVVFFB_UD<<H
M9E^H!R*2WUG3;J[:U@O[66X7[T4<RLP_ '- #8M&TZ$7@CL;=5O'+W"[!B4G
MJ6'>H=.\-Z1I,[365A%%(R["^23MZ[1DG X' XJP=9TX726QO[43N2$B\Y=S
M$'! &?7BIEO;=UE99XF6$E9"'!"$=0?3% &?8^%]%TZ]^UVFFP13#.UE'W,]
M=HZ+GVQ4.M^%]%U65;F\TZ"6?<BF3&UB-PX)&,CZULI.DL2RQNCQL-P=6R"/
M7-4+C5]/D41QW]JSY23:LRD[=P.[KTQWH +GP_I5WI\-C-I\!M8<>5&%VB/'
M3;C!7\*;!X:TFWLA:16$2PB99]O)S(I!#$YR2,#KZ5:BU.SFM6NHKNWDMUSN
ME20%%QUR<XIL>L:?-;-<17]J\*L%,BS*5!/0$YQF@!S:9:-?2WC6Z-<2PB!W
M/.Z/).TCICDU3L/#.CZ7=&YLM/BBEP0&'.P'J%!^Z/88K2:YB25(FD02."40
MG#-CK@=ZH:GXAT_2+JTM[VX2)[IRB;F  X)R<G@<=: )/[$L/LBVOV5?)2<7
M"IDX$F_?NZ]=W-.FTFRN+F>XEMU::>#[/(^3EH\D[?IDFGRZI8P"$S7MM&)A
MF(O*H\S_ '<GGJ.E.N=1L[/_ (^;NWAXW?O) O&<9Y/K@4 4;WPQH^HB%;K3
MXI/(C\J,\@A.FW(.2/8\4DOA;19KR.Z?3H3*FW'4+\OW<KT.,#J.PJ[)JMC$
MX22]MD8L$ :502Q ..O7!!Q[T^._MIIY+>&XADGC^_$K@LOU'4?C0!8(]*Q9
M_"FC7%ND+V0"H[R+L=E(+G+<@YY/:K-KJ\4EC'<7306K.6 4SJP^4G/S X/
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MS+;;O*;/W=PP?TJ07ENURUNL\1G49,8<;@/7'6E%S$T;2"6,HN0S;A@8Z\T
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M#4(=2LTNX%D$3YQYL;(W!QRI (Z5Y^^@ZG+;1W;6,D9N_$L%\;; )BA! +,
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M/[/2^^W(+>23RD8JP+OZ*N,M^ KC=1L;S5-*UN\BTRY6&_U*T:*"2$B1T21
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M444 %%%% !1110 4444 (:6D-+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %(6"J22 !R2>U#=*XO2-:OKJXN8-4NXH;I8YBVF2VFT[03M*N3\ZXQD
MC(Y[4 =G'(DJ*\;JZ,,AE.012D UYO!XGGBT[0+5+S3]&AN---TT_D#RPRX
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MEBDAQD,5*YYX[]._2MJB@#F8?#J:=I.K-=RW&J75\C&YD=5#R@*0$50, 8X
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M]'B:&.62'>KJR!6RNX<\ CGMWJZWAN.:+6XKB8R)JIRXV ;/W83CUZ9K>HH
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MB6/=C&< #/Z5@7'@V&X\4W.KR3@PSP&-K;R^/,*[-^<]=O'3OUKJ:* .,L_
MIM?!NH:$=0,D]Z,279B[8"J-N>RJ!UK4;0[R+Q"FJ6E[%&KVZ6]Q#) 7WJK$
M@J0PVGD]0:WZ* .-M?"K77@U]+^U@&:[:Y\SR\XS-YFW&?PS^G:MW6=,_MC3
MK_3_ #3%]H@">8!G:><''>K&D_\ (,A_'^9JPO\ Q\R?[B_S- &&-"O[B_T6
M]O;V!Y=.:4LL5N5$@=-@ZL<8SGOGVJI=^#GN&U"5;U$GN+Z.]@8P;EB9% P0
M3\P.#GIUKK** ,G2;/4+9I6OFL3N "+:6YCQC.226.<\<<8]ZR-4\)75YK5]
M?07=J!>VX@;[1;>:T  (S&=P SGD>O-=;10!Y_\ V-J>F:QX>L-.NXO.LM,E
MC,DL),<H!0;3@Y7/7@YX[U7USP_>:=I^CQQW0DU"YU]+J:Y$!*+(P/.S/W1@
M#KVZUZ/MYS1MYS0!QMUX1U'4[366U"_@^VZC D"F&$B.!$.0 "<MDDG\:UM9
MT:ZO3IUS97$<-Y82%XS+&71P5*LI ((SGKV]ZW:* .6@\+37)UFXUB>*>ZU6
M 6[K"A6.*,*0%7)R>6)R:IVG@N[C\*7^FW.H+-J-Z5,UV5)$@7 56&<D;5 /
MU-=K10!Q4?A&^>/5#+_9EL;S3&L8X;* HD>=V">>>OH*WHM&!\+1:)<MO46:
MVKNHZX0+D5KT4 <A'X;UF[.EVNJ7MHUCITB2J8(V$EPR#";\G"^IQG-;&B:5
M+I:WXE='^TWLMRNT'@,1@'WXK7HH Y^72M2C\5_VK9R6Y@F@2"XCF!W *Q.4
MQW^8]:SKGPE>3>"_[$$\(G%R9O,.=N//,F/7.#BNQHH XR7PE<VVJZA=65KI
M%W'>R^>5U"$LT3D -@@'*G&<<?6NCO+!KK1+BP'EQM+;M#E5PJDKC@>GM6A1
M0!PMMX1UF:RT33M1N;%+/29HID-L',DIC^Z"3@ >M23>%]:73K_1+>[L_P"R
M[R61Q+(C>;"DC%G0 <-U."2.M=M10!PNJ>"KBZO+H1P:9<P3VJ0027L9=K/:
MNW]V,8YSG@CGUQ6OI7A^YL-6M;N26)HXM+CLB%SDNIR3]/UKHZ* .)OO#6N?
M8=8TNPFL19ZE)++YLV[?%O'S+@9!YSSGC/2MZ?1/M?A Z'/)C?9BV9U&>=NW
M-;%% ')IHNN7UQI2:I)9I;:;()LP%F:YD52JDY V#G.,GFM'P]H\VD6][',Z
M,9[R6X79GA7.0.>];=% ')-HVN6/BG5M6TX6,J7Z0H!<2,ICV+C. ISG/J.E
M02>#KO\ LVUC-S%/>_VM%J5W.4V"0J^2 .>@X'TKM** .?L] 91X@BN]K0ZG
M.S *3G8T:H0?3H:R/#_A.32I+.&7P_H1:UVC^TD0>=)@8#;=F0QZD[O6NWHH
M Y31M,U[1C_9T4=E)8"X:5;EW8.(V;.S9C[W)&[./:JO_",:G)I>KZ*PMDM;
MB=[FWN@Y+;S('563'0$')S^%=K10!RL.F:UJ>N:=?ZM#:6J:=O*)!*93,[#;
MNR0-HQVY/-2Z?I%]I_@V'3#:V=U.BE7@G8^5(I8DJ3@]CW%=+10!R&BZ3KFC
MV%V;6"VA\^Y1X;!KAI([:/ #A6P.O)  P*ZXTM(: ([7_CTA_P!Q?Y5+45O_
M ,>T6/[@_E4M !1110!R'B/_ )&?2?\ KHG_ *&*Z\=*X_Q&?^*ITG_?3_T,
M5V IL2"F?\M!]#3Z;_RT'T-(8-V^M.IK=1]:=0 4444 %%%% !1110 4444
M5;?_ (^KO_KHO_H"U:JK;_\ 'U=_]=%_] 6K5 !1110 4444 %%%%  :*#TH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0]J6D/:EH **** "BBB@ HHHH
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MB@ HHHH **** *>E?\@V'\?YFK"_\?#_ .ZO\S5;2?\ D&0_C_,U97_CX?\
MW%_F: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI:#TH CM_\ CVB_W!_*
MI*CM_P#CVB_W!_*I* "BBB@#D/$?_(SZ2?\ IHG_ *&*Z^N0\1C_ (J?2?\
MKHG_ *&*Z\=*;$@IO_+0?0TZF_QCZ&D,5NWUI:1NWUI: "BBB@ HHHH ****
M "BBB@"K;_\ 'U=_]=%_] 6K55;?_CZN_P#KHO\ Z M6J "BBB@ HHHH ***
M*  ]**#10 4444 %%%% !1110 4$9HK"\7ZXWASPW=:E&BO+& (U;H6) &?;
MO^% &YM%)M%<AHUEXNA>TU'4_$$-U:LA>YLQ9JNT%20$8<D@XZ^]36/CNQNM
M0L[*;3M4LC>,5MI+RW\M)".PYS^8H ZK:*-HKF#X\TD:!>ZR8KL6UG<&WD78
MN\MD#@;NG/K3KCQO80ZM)IT-EJ5W+$L;3M:V^]8=X!7=SGH<\ T =&R#(^M+
ML%<KJGC_ $K3+ZYMC;:A<"S*BZFM[??'!GIN;/\ +-::>)],EUNVTF.21[FY
MM_M,15"4:/L=U &L8D( *@@=B*/*3:5VC:>HQ3P<T4 ,$2#H .,<>E((4#%@
MH#'J0.M244 ,\I,,-HPW48ZT[  QVI:* &")!G"@9ZX'6@1(JE0H /4 4^B@
M",PQL I12!T!'%+Y2?-\H^;KQUI]% $9AC*[2BE1_#CBE\I"FPJ-O3&.*?10
M!&L$:_=0+QC@8XH2&.+.Q%7/)P,9J2B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN>8U_P"NB?\ H0J:
MH+K_ %2_]=$_]"% $]%%% !1110 4444 %%%% !1110!2TG_ )!D/X_S-6%'
M^D.?]A?YFJ^D_P#(,A_'^9JRO_'P_P#NK_,T 24444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2'I2TAH CMCFUB.,?(/Y5+4=N,6T0]$'\JDH **** .0\1G_BI]
M)]!(G_H8KKQTKC_$?_(SZ3S_ ,M$_P#0Q78#I38D%-_Y:#Z&G4W_ ):#Z'^E
M(8K=OK2TUNH^M.H **** "BBB@ HHHH **** *MO_P ?5W_UT7_T!:M55M_^
M/J[_ .NB_P#H"U:H **** "BBB@ HHHH #THH/2B@ HHHH **** "BBB@ K$
M\6Z%_P ))X=N=,$OE/)@H^W.U@01QZ<8_&MNB@#B-+E\=ND6GWFG6-K'%$R/
M?"?>7(0A2J <'=MSGT-<WI_A7Q7-J>A3ZC8R>;87GF7%W/J9G,JYSE8R<(,<
M8'/M7K=% 'D-]X2\6)I&M^'[33K>6SN;IKJ.[>X4%QD$(%Z@YQR<#@^HK1U_
MP_K]QK:SZ/HS6EYB)?[6AU (K*%&X2Q?Q8(QWX ^E>FT4 >4WOA75['6-7#:
M+=ZQ9:A)YL9@U9K903]Y9%W $9/7!P!^7::?%J&GZAI^GPZ/!%I4=F TXFWM
M$X_Y9C/)'OWKH2,XI: $'2EHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**#Q0 44@.:"<4 +10#D44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7"1V\,\_F06<4ID2W3:!M!('4@G &!F@!7\5VR:/>Z@UO.&M+DVKV^5WM)N
M '..=P(YZ&JFI^+XXA?>1IUY=6VG2J+NYB*!4((8@ L"Q ZX%9EYHXNOBBD,
M<JFV,<6I74..1+'N1">W.0?^ 5+>:+KMC;ZQI^GQV<UGJ5P9(II9"K6YD(W;
MEQ\PSTP: .@LO$EI?:PFGVXD<R62WJ2X^4HQP/?-6-(U>+6;!KN!)$19I(</
MC.4<J>_J*YQ/#FIZ)J=C=Z-%;70BTU;!UN)#'@J<A^ <CKD5K>$=+O='T+[)
MJ#1-<FXFE9HC\IWR%@1Z=>E %5O'6F)I.G:A(LR1WMU]E5#C=&P8JQ;GH".:
M=JWB.W U*V62\A:PGMDDFA"\F1EPHSVY&[V/'-8UUX(O+K5M6!DA739H9VLU
M7ADGE";F(QV*9_&K4'AC4QX1FMKC[.=6NKY+NX96.PD2JV,X[*H% %NP\2:G
M=>+-8TJ33)!:VGEA)5:/,892=S_/DAL C R,\@51\+^+I/[&T6/4+6_(NL6X
MU"7:4>7GC[V[G&-V,5I0:7J%CXRU*_BABFLM3CB#N9=K0F-2OW<?,#Q5-?#=
M^/"6@Z:5B^T65S#+,-_&%8DX]>M %Z[\8PP-?20Z?>W5G82&.ZNH=FR-A]X8
M+!FQGG -7[7Q!:7NM2:7#O:1+5+H2#[C(Y(&.^>*YQ]&U_3[+5](TZVM9[74
M)Y9(KF2;:81*<N&7&6QDXQZC-2#0-3T+6XKW1K>"[C;38[$I--Y?ELA)#]#E
M>>0.: 'WWC*Z,VC-ING2SP7MS+!(#L#$IO!5<N,'*YR>,>]='J+ZD^@SOIL*
MKJ+0YACG885R.C$'''L:Y&+P[K5IHNARK%;SZAIM]+<R0K)M657,F0I/0_.#
MS7=0-(]O&TT8CD*@L@;<%/<9[T <)'?:OX=\/7FHW+--L6*UL(FFRKDD#>^!
M]XN3GV %=!96>LVUPDEWK/VC:@,\?V50K9W<)C!&#ZEJAO\ 1SKOA$V"2"*5
MAOBD(R%=7RIQZ9%0VUUXIN;@V\^G6=HXB"RW/VC>&.&P44#(Y_O>G>@"Y:^)
MDFU&ULKK3[ZR:\#?97N%4"4J,D8#$J<<X8"D;Q78IX>;6F2?[,MQY!&T;MWF
M^5TSTW?I7,:1X:U>/5-$NKJP*364K&[NYK\S-.3&R[E!)P,GH<'D<4E[H7B1
MM#N?#\&G6[VQOS<+=-< ;XS/Y@ 7J&'?M@<9- '61^(X[C59K*VLKR=;>803
MW$:KLB<C.#D[CP1D@$#-5;CQG8VSRR>1=/8P3_9YKY%!BCDR!@\Y(!."0" :
MSM3TG5KGQ)%=6&F_8IUN%:34(KH".:$'E9(P068CCD''K6?#X4DM'N;&Y\/O
MJD4EP\D=R+[RX]C-N ="V<C)Z*<XH VKRP\37>L.\-X]M9O=QX5'4^7 @RQ]
MRY.,=@,UOZIJMKH]@]W>.RH"%"HI9F8G 50.I)JZ%"@ =!6!XKTRZU&PMWL4
MC>ZL[J.ZCCD;:)"ASMSVSF@!;3Q3:W-Q/;36]W9W4,!N/(N4"L\8_B7!(/YU
M/HFO1:[ T]M;W26^ 4EFCV"0'NO.3BL,V&L:SK,FJ7>F'3T@L);6&"25'DE>
M3!))0E0/E '-=#H%I-9^'].M;E-D\-M&DBY!PP4 C(H J_\ "4Z?_8]YJ3><
MD5I*\,J,F'WJ<8 SSG(QZY%0WWBZSLKFX@%O>W)M0&NVMX=RVX(W?,<^G.!F
ML#4](DG^(\5E&ZFQN3%J5S'DG:\.5'';<2GUV^U6GM-:TBYUR&STG[?%J4K3
M03)+&@C9EP1)N(. >F >* .DMM<L[N]@M;>1I&GM1=QN!\K1DX!S^-49_&.F
MV]G]I<7/E_;)+'"Q[F,J%@0 /4J0/PK$L]%U7PLVC/9V#:F(-.-G<+%*B%7W
M!@07(^7)([D =*;I6A:S':V!O+)4F379KR55E4A8WWG<#GD9;Z^U '86^I1R
MZ9]OE2:UB"LSK<+L9 ,YR.W2J&G^*;+4+R*U$5W;O<(9+=KB$QK.HZ[<_4'!
MP<5<UW3FU30;ZP1PCW$#1JQZ D<=*Y;1-+9]2L)+_P /ZI#<V8)^T7&I&:%&
MVXRBF1LYZ?=&/:@#0/C_ $9,,XO4@\QH6G:V;RUD!(VD^IQQC/4#KQ5F+QAI
MSV.HW3QW< T^/S9XIX2D@3!(8 ]00#^592:)J7_"*VEF;3_2(]4\]DWKQ']I
M+[LYQ]TYQUJ'Q?8W$=IXLO7B(MI='$:OD<E=Y8=<\ B@#>T_Q9INH:A%91&Y
M1YT,EN\T#(DX'783UQ_]<9%9^C^*5A\,65WJ<LMQ=W,LL<4<,19Y2KL,!0.P
M YZ57LAK&L:MHANM'>QATU6DFFDD1ED<IM CVDD@YSDXJGIVEZMI%AH5\=-F
MG>Q:\2>VC9?-V2OE67) )&T<9SAN* .BA\8Z1+'$QEEB9[I;-HY8F5XI6Z*X
M[9QUZ>]6K_Q'IVFO=K<S,OV2..28A"0@D8JO3W'Y<US!T:^U.P\3ZC>6S6#7
MZ1O:Q2,-\9A4E'?!(!+8./05FIIVJ:]\-=5OO(,NIZQ*DXB3"_*I15'/^RF?
MQH Z@>.M&+/'F\$XP8X/LK^9,ISAD7'*G!YXQCG%7&\5:2-*MM12X>6&Z?9
ML<3,\C<_*$QG/!SZ8YQ4$EA<MX\M;[R6^S+IKQ-(,8#F12!^0KE'\/:C'I&E
MSRV5]_HE[=--#93&.?RY&;#(5(/IP#R": .R_P"$KTA=)EU*2Y>*W@E\F;S(
MF#1/D##+C(ZBJW_"::;+8ZA-;FX::SA\XPR6\B,RG[K $9*D]QT[XK ;1-_A
MJ\DL=*U5;BYO+>1EOYO,ED".OS'+$@ 9'//%;NI:9<W?B6Z=(B(IM'>W$Q^Z
M'+G _7- %[PSKT?B'2(;Q8I(I&C5I$:-U4$C.%9@-P]Q52/Q/9VR7[WNH)*(
M;\VB+#:R*RO@$1XRQ=O<8'TQ3O!3W">';6PNK"YM)K*)('\Y0 [ 8)4YY''7
MWKGFTPK;Z[_:.DZC)%)K+3PO9?ZV,;1B5,$'KD<9//IF@#N++4(+ZP^UPB81
M\Y$D3(XQU^4@&L71O&5CJ:7K2B6W%JTI9I(9%01H?O%F4 ''.W.15CPH^JOH
M@.K"42^:_E>>H64Q9^7S O ;'I[=ZYJ?3[^[T?Q%H":?=)/+<S7,,Q7;%*"X
M<*'SU/(]N] '46/BG2=1EE2"XD4QQ>=B6%XRT?\ >7<!N'TJ&#QMX?N+":_C
MO7^R0^7OF:WD5!O.%P2O/)YQT[XK"TBTANM3AN6TW7Q>6]K(GF7S'RXBP *#
M)^;..HR.*6;3KMOA5IEBME-]JCBLP\'EG>"KQELCVP2: -@>//#K!\7LA=2/
MW0M9?,((R"$V[BN!U Q4TNO03W>BO9:C;_9=09]BM"[-. N?E8$!2,9.X'TJ
MO]DE_P"%@/=_9W\@Z5Y8FV?+N\S.W/KBN<TG2]0A3P4)+*Y7[+<79GW1D>4"
M' +>F<C% '5)XV\/27B6J:AF5I?)_P!2^T29(VEMN <CH3S3[[Q=HFG7<EM=
M7C(\9"R,(9&2,GH&<*57J.IKG/[-O/\ A!Y+?['-Y_\ :GF^7Y9W;?M.[=CT
MV\Y]*S_%LVL7L>NZ=+#JK2,I6QM[2W!@EBV@[G?!YSG(R.@P* .ID\96,?BL
MZ&R2Y$:GSA'(?WC-M"X"].AW9QS[5<;Q9HBZF-/-\/M!E$(Q&Q3S#_!OQMW>
MV<UBS22:7X\MKN6RNY(+O3X[59886<+()#PV/NC!SD^E<[INF)%91>'M8.O_
M &A+K(@@AW0/F4LL@D"$ <@G+ CF@#K]3\7Z7I5E-:F]1=0BM=RJ49E5BOR!
MF PN3C )&:T]*U(S>&K/4KUPI>T2>5@IP,H&8X_/BN(\Z32K7Q#ILFCWMQ<Z
MENFMVB@+I,KQ@<MT&T\'/X9KJ+.*1?A[!#(A25=+5&63*E6\KH?2@">Q\8Z!
MJ5[%9VFHI+-,NZ,!& ?C) 8C!('49R*L_P#"0Z3_ &7)J?VU/L<<GE-+@X#;
MMF.G][BN$T2];5]-\(:9;:=>)+9>3//-+"4C5%BQN#GAMV1C&3ZXJAJ#75IX
M0U+PT-,OY+Y=0,H9+=FC\HSJX<,!@Y&.!DY[<4 ;WB76=/3QOI5B;I/M2S1*
MT6#D;F!';TKIX/%.BW-Q/!%?HSP*[.=K!<+]XAL8;'?!.*X74H9$^*EQ*T+B
M.0VH5]G#8QD ]^U6-,:9Y9=&T-=0.F36TXFMKZU:,63L#M5'91N&XD8RV/6F
MQ([Q=9TY[:SN5NHS#>,J6[\XD+ D ?4 U2_X2G1#JZZ<-0C^T[S%MP<;^/EW
M8QN]LYKB].O99]*\):2-.OTN;"\A%V7MF5(2JNN-Q&#GGD9'N*JZQ?:AJ;_9
MKD:B+N+5$(LH;(B!(EF7$GF;.21SD-WZ8I#.^U'Q9H6FW!@N]3@AF601LC$Y
M4X!Y].".>G-5[[QGI&GZ_%I5Q<HCO'O,A/"DE=J_B&R/I61+9,T?CEC:L7GR
MJ'R\F0?9EQCCYN2?QS4%E<'29/"5W>P70B_L?[,[1P/(5D(B(#!02.AZ^E '
M3>(/$MCX<M[>6]?'GRK&H!YP2 6^@!R:?-XIT2VT^"^GU*!+:X&87)/SCV'4
MU2\:!_["BG2&646]Y;SNL2%FV+*I8@#DX -8\VJVUGXOB\0W,-T=,NM.\F&X
M%K(QC<.205"[EW CJ.<4 =M:7MM?VL=S:3I-!(-R2(<@BJ \3Z(VJ_V6-3MS
M>[MGD[N=WIZ9]JR_!%M+%IE_</#)#%>W\UU!%(NUEC8C&5/3.,X]ZY34M0O]
M5,45T;I;J+58R=/BLCMA19 /,,FTYR"#D$=3[X /5:*** "BBB@"K;_\?5W_
M -=%_P#0%JU56W_X^KO_ *Z+_P"@+5J@ HHHH **** "BBB@ /2B@]** "BB
MB@ HHHH **** "BBB@ HHHH **** $-+110 4444 %%%% !1110 4444 %%%
M% !1110 4444 !.*R1XDTQKTVB3,\WVG[+A4)S)MW$ ]\#J>U:K5B0>&=,L+
ME+ZVMF^TPF9XRTC'YI3E^"<<D"@":Z\3:'8WHLKO5;2"Y.!Y4DRJW/3@FK5O
MJEI=:A=6,,A:XM0AE7:0 '&5YZ'CTKF?A]:VESX-626&.2:[DE:\WJ"9)"YW
M!O7TYK.FM+V3Q5XJDL=2FL%MK>!E6"-"681$KG<#P,'@8SGVH ]#HKA1K<^I
M:;HK_P!I7T5[=:>+AK:PMU8L2!EV+ A0">G'XU336];U&S\)VZ:D]K/J$EQ%
M<3")"2(T;G!& WR_3)Z=J /1J*\VN/$6L6&C:O:/?R236>JQVB7GE*TOE-M.
M=@&&8 D<#WQQ39_$&L:;I.MZA#J-Y>6XFAM;"2Y@5>7*AG VJ6VD\=CT]Z /
M2ZKM?6JWR6+3QBZ=#(L18;BH."0/3FN;T"YU@:\\$SZC<Z<]N7\V^MTC:.4,
M!@%0,@@GMQBIM4OKB#QA;6\;JL9TRXE.4!(963!SC/<\"@#I2,TUY$BC9W8*
MJC)). !7 :9J/B"*S\.:K=ZRURFI3I!+;&!%0*ZG!! SNXYYY]*T_&P%S-H.
MG3G%C>:@J7*GHX"E@A]B0.* .CM-5L-0+BSO+>XV?>\F57Q]<&KE<YKRV?A_
M1[K6+.PM5O+>W,<3B,+@$C )'\.<''M6:+G6M!UG18[S5WU*'4G:&57A1/+?
M86#)M ..",'/'>@#LA&J,S!0"QRV!UIP8'ZUYY:ZIXA_LFTUV761)$VH1VQL
MQ;J$:-IQ$<MC.X9SP0.*NZ':7R>,-?D;5KETBDC+1&--KAD) /RY&..F,XYH
M [>D=E1&=CA5&23V%>;VFO>(+;P1;Z]<ZDEQ<Z@(8+>)H56.%G8*') R3C)(
MZ5JM<ZMHVMP:;>:G)J5O?6LS!I(41XG09.-H *G/0]* -\^)='%M:W)OHQ#=
M1-+ YSAT5=S$>P'-:%K=0WMK%=6TBR03('C=>C*>0:XCPMX<LM7\%:+-=F1G
M.FI!PWW4/+ >A8<$]<5W$4:00I%$H1$4*JCH .@H >3BH(KVVFNY[6.9&N(
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M: +VD_\ (,A_'^9JPO\ Q\R?[B_S-<'HOB:\BU+3+5M2L;R&[F>!X;>%AY#
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MXWO=P^TL2050C@$8'J>>E '5T5PVL^.);/4=2M[>XTN$:>!NBNY2);AMNXA
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MNKA+:",MM!=L\L<'  !)^E9]WXBU;3XH+>ZTR!M2NK@06T<-SF*3C<7+$ @
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M_P#0%JU0 4444 %%%% !1110 'I10>E% !1110 4444 %%%% !1110 4444
M%%%% "'M2TAI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I",C%*3B
ML.U\5Z;>W:P6R7DB-*85N%M7,)<9! ?&.H(STH @G\%:3-<S2HUY;QW#%I[>
MWN7CBE)ZEE![]\8S6C'H5E%<7TZ*P>]C2.;YN-JJ5&/3@FM'<*H6.JQ7U]J%
MJB.K6,JQ.6QAB4#Y'X,* ,U_!FG&.Q2">]M39VXME>WG*,\0_A8]QQ]:FMO"
MFFV@TL1"8#3'D>WR^<%PP;.>O#&MO(HW T <9XD\+YADEL;6:Y^TZA'=7D23
M!)&55Q^[8D;3P.XXSS4>E:!-?S:I;WUI?0:'<Q(L=I>W/FR"0')<$,Q7^''S
M=1FNVRM&Y10!E:5H)TRX:9]5U&])38JW4P95&1T  YXZGFIKG1K:ZU6/49&D
M\Y+>2W4 C&UR"?Q^45H;A1D$<4 8Z>&K)--TNQ#S>5ILJ2PG<,DJ"!GCGJ:L
MZOHUIK=@UG>*QC)#*R-M9&'1E(Z$4:3JT&K1W+P+(HM[A[=_, &64\XYZ5?W
M 4 <];>$+=89X]0U'4-46:)H6%Y-E0AZX50!GISUXZT:;X0@L;Z"ZN-1O]0:
MU4K:K=2 B $8., 9..,MDUT.X>M(SA5+'. ,]* ,9?#%FNB1Z5YDQ@CN5N58
MD;MRS"4#ITR,?2E/AR(>(7U>*]NHFE4+-;HR^5*0" 6&,Y /8^E:-C?P:C9Q
MW5OO\J3.W>A4\''(/(Z4^>[M[6(RW$\<,8(!>1@H!)P.3ZGB@#)C\*:<OA6/
MP[)YDME'&(U+M\XP<@@CH0>AJ/3_  K':7;W=WJ=]J-T83 DMTR_NT/4*%4#
M)]<9K?W U5N-2MK6[M;:4N)+IBL6$)!(&3DC@?C0!'HVE0Z)H]IIEN[O%;1"
M-&?&X@=SCO5.2SOI_%T-V9)(K"VMF4(K\32.><K_ +(4=?6MK</6C(ZT 96N
M:$NLBV=;VXLKBUD\R&>WV[E)!!&&!!!!]*;!X=A@O-2NOM,\DFH0QQ2EL<;%
M*@C ZG/-:^X"C<* .9/@R*&WTX6&J7ME<V-N+9;B+83)'QPX92IZ9Z59?PPD
MYTE[K4;NXFTV=IUEDV;I6((PV% QANP'05N[AC-)O'^10!0L=(BL=0O[R.61
MGO9%D=6QA2%V\8_K527PX#XD.LP:A<6[21I'<0(JE)@N<9)!(Z]C6WN%)N%
M'.+X-M$\-V6B_:K@PVEPLZR?+N8B0O@\8QDXZ5%<^%I;:6\DT[6;NRAO;A99
M(41&".6&60L#M)ZGK74%A4-T08E_ZZ)_Z$* &7FGP:AI\UC=+YL$T9CD#?Q
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MNGZUK@@T$@4 <A_PA4EK%I366HJMUIQG\MYK<.C"5BQRN1@C/!!_G2GP4ZZ
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MS$HP!ST;&0>U2W?AW5KJ6QU1[^S.KVAD !MSY#(X *$9W<8R#GJ3769%!P*
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M/2B@ HHHH **** "BBB@ HHHH **** "BBB@!#2TAI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!KD*N20 .I-<"TW_"*W-C)H^HQ7FD7]Z(OL&5=D
M,C$EH6') .25.?J*[\C-9EOX=T:TOC?6^E6,5T<_OH[=5?GKR!0!YU>7,$DU
MMK&G6C6Q?64@^U2Z@[32_OMCKY7(V8SQG@<XK3NKVUMIO$Z7<4TRW&K6]O''
M!,8B[M%'@%U((''-=A_PC.B?;)+O^R;'[1(0SR?9UW,P.0<XZY .?:K$^C:=
M<Q7,4]C;2)=$-.KQ B4@8!;U( ')]* /-]]Q86OC6R0BVCM[."2.""\:98'8
M/NVL0",X!Q_C6K?:5#X:TW2M?M)[P_9YHY+W?<O()4D 1V*DD<;@W &,5UEO
MX;T:TMI;:WTNSCAF01RHL*@2*,X#>O4]?6DU_2)-4\-W>E6DD5NT\/E*S)E4
M!X/'TH SO!IGN].NM6N&E8ZC<O/$LC'Y(>D8 [#:,^^:Y#6KM)#-KFEQ7<30
MZK';F[FOW&YO-5658>5*8)&..F:]0MK:.TLX;6)0L<2*B@=@!@5DS>#_  ]<
M7TEY-H]F]Q(=SR&(9+9SGZ\=: .6O]/&J:MXMDN+R]'V%(WMTANGC6-O)SN^
M4C)R.AX]J6T=O$^IZ3;:K>7"P_V,EYLAF: R2L0&<E"#P.V<<UW']EV?FW4G
MV=-]V LYQ_K !@9_ XJG>>%M$U"UMK6[TV":&U7; KKG8,8P/:@#(^'84:1J
M.R<SK_:4X$K-N+@$#)/>N6U"&X;1_$VN+J-\MYI^IR"UVW#A(P'7(V9VL#GH
MP/MBO3=.TRRTJ!H+"VCMXF<N4C&!N/4XJ%]"TR2UN[5[.,P7DAEN$.<2,<9)
M_(?E0!Q^R/PUK[YOK]K*?2)KFY,L[2G>A7YUW'Y3ACP,#I571Y9;'Q3HPMX+
MVTMM4MIW>.[OFN&E"JK(Q4D[#R>GKCM7>S:18W$ZS2VT;R"%H,L,_NV^\N/0
MXJEI_A'0=+N8[BRTR"&>/.R10=P!&",^F.W2@#B;9KG48O!MG-?7:1WDEZDY
MCF96=55CM)SGMC/4=L56U6 2>&=>L+F>XE@TO6(8[5I+A]R1LT7RLV<MC<<;
MLGOU%>DQZ%IL+V;1VD:FS+M;D9_=E\AL?7)ILF@:7-#>PRV43QWS[[E6&1*W
M')_(?E0!S&L6E@EY:^'K:#5KR6.!K@0QZC)$$3<1O>0MN)SP!D_2L_1=5U"Z
ML?!$D]W+))/<7,<[;O\ 6!0X&['7[HKK)/!GA^6"""33(62 %8^3D G)&<Y(
M).<&KEOH&F6L5I%!9Q1I9LSVZJ,"(MG.!^)_.@#@4AN(/#L>OKJ5\]W'J9C0
M-.QC6,W)0ILZ$$'J<GTKKO&2WD?AR:]L7D%S8LMTJQL1Y@0Y93ZY&>*T3H>G
M&P-B;5/LWF>;Y>3C?NW9_P"^N:M72NUE,D00R%"%#_=)QW]J /.]3\17MS::
MUKFG7<D=K']GL;9L912Q4R28]1O S[5J3Q2>'=?TVSLKV\GBOH+@S1SS&4[D
M0,)!N/R\\8''/2MCP_X:M]*\*0Z+<)'.FPB<%<K(S<MQZ9-6-.\,Z5I,YGL[
M7;.4\H2/(TC*G]U2Q.%]AQ0!Q\6L7S>!O"ERU[)]INM0MXY7+?-(I=MP/KP.
M:U_#\%SJ7B'6;FZU&\:.ROVBM[=9-L:KL4G(_BZ]#TQ6@O@K0$N8[A=/7?%+
MYT0\Q]L3[MV47.%R>2 !FM:TTZUL9+J2VB$;W4OG3$$_.^ ,_D!0!RGB*\O;
MCQ9;:/&EZ]G]C:XDCLY5B>1MVT?,2#@=< ]QVJC<W'B.WT[1;2]NI[2XN-7-
MMYH9&D:W*/MW8RN[&.?4 UV&I:%8ZM+%-=1OYT.1%-%*\4B ]0&0@X/IFF)X
M<TQ(;2(0$K:W'VF(M([,)><L23DGD]<]: .-:'4O-\36@US45BTB,2VA#C<"
MT>[YFQEP".A]?I5A;B_UO4M/BEU.XMH9M+M[F2.V(7?(9 "02"1U[>U=@=%L
M6DOW, W7ZA+D[C\X"[1WXX..*YW4/!UM/K=M.\>VRMK.*U@\J9XY8R)!T92#
MC:<=: ,:QU.ZOY/#J7DQN);?6KFW$Y',BHC@,<#KSV]*;_:.J3>!KOQ:=8N(
M;Q)'DC@!'DJJR%1$5QSD#&>N3UKN(O#NEP1V$<5JJ)I[%[8*Q&PD$$]><Y/6
MJC^"]#DN&F:T;#S>>\/GR>2TF<[C'NVDYYZ4 <UJGB74-+GUO3VF?[3=Q0RZ
M6#RRM+^[*CUVOS^-$]WJUQKFIZ6DFK3+IMM D+V;QJS2LF3)(6(W9/0<C@\5
MT6J:"^I>*](OY8H#;:>DC!B?G,C8VC&.@P3G/7%7+WPWIVH7OVV5)H[HIY;2
MV]Q)"SKZ,48;A]: .0EU;Q!/J&CZ3J$5ZDW]G&XO$L'C6223.T<D@ #&3M/?
MTKK?"[:F=%0:NL@NED=09=N]D#'86VG&[;C..]+<>&=,N8K1'BE5K-"D$L4\
MD<B*0 1O4AN<#/-7["QATZU6V@\SRU)/[R1G8DG))9B2>?4T >96R7]EX3U_
M6K36+FWEM-1NY(H%"F+B8DJP(RV[/X9XJ_<ZOK.JZMK4=LFK+]C98;5+'R@B
M/L#;I Q!.2P]1@>M=(W@;0&D=C:2%9)C<21?:)/+DD+;MS)NVDY/<=AZ59O/
M"VFWM]+>,+F&>90LS6UU)#YH'3<$89^O6@##WZQJ>OV-A/J$^G;M+%Q<Q6X7
M)DW;2 Q!QR>WH*QCXHUB33]$L3)=237%W<PS3VB)YTJ0D@;0V%!/&?IQUKT"
M'1[."]CO(XR)X[<6RL78_N\YQR>>>_6J;^%-):S6V$#HL<[7$;I,ZR1R,22R
MN#D9)/?':@#@-1.J3^!;M;TWT5O%>P_93.$621"RY#8SG#9P>O3.:W[U[R/Q
M1=Z0=0N6MQH9E,C!-Y<2-SG;Z<5K:?X:T^X\/"SN/M$\4KB1S-<2,Q93P02>
M.@X&!6D=(M)-;EU!T)N&M5MR2QP4W,<8SCK0!QFFQ:Q:?#_19].NKZ:)TA>X
MC@6-I8X=G*Q KZXZY/I76Z%=1:EH2R6U_//G<GG3*JRHV3\K+@89>F".W-00
M>$;*ULA:VUYJ4,:-F+R[R0&(=-HYQM]B#^@K2TS2K72+/[+:(4CWM(Q9BS.[
M'+,Q/))/>@#S72;R_P!&\+7]U:ZC*9KG6'LU:94*QLTN#*1MR6(SUXR1Q712
MW>J:+XB33&U*>^@NK":93,J>9%(@ZC:HR#GH>];H\+:5_9%SI;6[/:7$K32*
MTC$[RV[(.<CD C'3%,L_"MC9S37#27-U=2PF W%S,7<1_P!T'L/I0!4\%?VC
M=:%:ZIJ&J2W<EY;I)Y;(BI'Q_#M /3KFL3Q7KEW8RZK-INJ:G+/9J'\J&T1K
M:#"@E9&*Y)/4\Y&1Q7;Z?I\&F:=;V-L"(+>,1QAFR0!TR3UK&O\ P5IFHR7A
MEDO$AO#NN+>*X9(Y'P!N*CO@#V..10!-K]_<VO@J_P!1MG,=RED\T;* =K;<
M@X/!YK!34=8TF?1;RZU62^BU%&,ULT4:JA\LR Q[0#QC')/6NC\0Z;-=^$]0
MTVR7=++:/#$"V,DK@<U1T/P;::<+&YGDN9[JWMQ&B33F2.$E0&" _B/IQTH
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M[2DDDL]M:FXE15P $0 \DGDD$ "M)?#*MJEO>76I7MTMK*TMO!*R[8V8$=0
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M,'[VXXY]#758VJ%Z]*XSPEX;2";7I9HI4M[J:2V@BE0J4@#.2!GG:2[8]@*
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MBB@ HHHH ****  ]**** "BBB@ HHHH **** "BBB@ HHHH **** "BD-+0
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MJ3QYI]WX?U6]TNXMY+NR25A \JL6"'&_"G)0\8/O6_I^MZ;J4CP6FH6EQ<1
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M*** "BBB@ HHHH 0TM(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D(R*6B@"IINFVVE68M;5"D0=WP3GEF+']2:MT44 (1D52TK2;31[:2
M"T0JLDSS.68L6=CDDD]:O44 %%%% !1110 4444 4-3TN#5H(X+DR>4DR3;4
M?;N*,& /J,@''M5X#%+10 48HHH **** "C%%% !5+5=-AU?2[G3[@N(;B,Q
MN4.&P?3WJ[10!'!"L$$<*?=10HSZ 8J2BB@ Q6/J.CP7&K6NJR-(9K8".),C
M8NYURV,=>,=:V*@NO]4O_71/_0A0!%9Z9;6=U=W42'S[MP\KL<DX& /8 #I[
MGUJYBBB@ Q69K.B6^M16ZS22PR6TPGAEA8!D< @$9!'<\$5IT4 9.FZ#%I]_
M-?O=W5Y=S(L;37+*2$4DA0%  &23TYK6HHH ,48HHH ,#TK"NO#?F:I<W]IJ
M5W9272JMPL00A]H(!&Y3@X/:MVB@#)\-64.G>'K.TMP1%$I5<G)ZGK5Z.)%O
M9I BAF103CD\M46D_P#(,A_'^9JPO_'S)_N+_,T 2;%((*C!ZC'6EP ,8XHH
MH 8L,2#"QHHSGA0.?6G!5!)"@$]3CK2T4 1QP0PY\J)(\G)VJ!FEDABF"B6)
M'VG(W*#@^M/HH C>WADC,<D,;(3DJR@@GZ4OE1[67RUVL,,,<'C'/X4^B@"%
MK6W>$0O!$T0Z(4!4?A4B(J*%10J@8  P!3J* (C;0&X\\PQ^<!CS-@W?G3Q&
MBNSA%#-@%@.3CI3J* ,K6-&768[6*64K##<).Z 9\S:<A3Z#.#^%7;JRMKV$
MPW=O%/&>=DJ!A^1JQ10!7:SMWM3:M!$UN5VF(H-A'ICIBFQZ;910&&.SMTB*
M>646, ;?3&.GM5JB@!%4(H50 !P .U5O[/L_MIO?LD'VLKL,_EC?M]-W7%6J
M* *$&C:9:W;W=OIUG#<O]Z:.!5=OJ0,U,+&V%LUL+>$0/G=$$&UL\G(Z<DU9
MHH @-I 9HI3!%YD2E8WVC* ]0#V' J,:;9A2OV2WP9?/(\L<R==_3[V>_6K=
M% %9K"U:*>(VT)CG),R&,8D)X)8=^ .M0SZ+IMS/#//IUG+- ,0R20*S1CT4
MD9'X5?HH SYM$TNYMH;:XTVSF@@QY4<D"LL>/[H(X_"I6TVS=;A&M+<I<8,R
MF,$2D #YN.> !SZ5;HH S[30]+L+>6WLM,L[>&48DCA@5%<=.0!S4PTZT5+=
M!:P!+7_CW41C$7&/EX^7CCBK5% %>:S@N)(9)H(I7A;?$SH"4;ID9Z&FMI]J
M[SLUK 6N%"S$Q@F0#@!O4<GK5JB@#-T[0=+TAG;3M.M;4OPQAB"DCTR!T]J;
M'X>T>(SE-*LE-PP:;$"_O"#D;N.<'GZUJ44 9=WX>TB_O%O+O3+2>Y7&)9(E
M9N.1DXYQ^E,OO#.BZE<&>]TJTN)6 #/)$"6 Z;O7\:UZ* *J:?:)>F\6VA6Z
M,8B\X( VP'(7/I[5:-%!Z4 16O\ QZ0_[B_RJ6HK;_CUB_W!_*I: "BBB@#D
M/$?_ ",^D'_IHG_H8KKQTKD/$?\ R,^D_P#71/\ T,5U]-B04W_EH/H:=3?^
M6@^AI#%/;ZTM(W;ZTM !1110 4444 %%%% !1110!5M_^/J[_P"NB_\ H"U:
MJM;_ /'U=_\ 71?_ $!:LT %%%% !1110 4444 !Z44&B@ HHHH **** "BB
MB@ HHHH **** "BBB@!#2TA[4M !1110 4444 %%%% !1110 4444 %%%% !
M1110 449Q4'VVU\WROM,/F9QLWC.?3% $]%)D4;AZT +129'K4/VVV-Z;/SX
M_M(C\TQ9^;9G&['IGB@">BBB@ HI,CUHR* %HHR*3(]: %HI,BER* "BBDR*
M %HHHH **AENK>!T2:>.-I#A [ %CZ#UJ7</6@!:*8)8VD:,.I=<$J#R/PIV
MX>M "T49IAD3?LWC?C.W/.* 'T4=J3</6@!:@NO]4O\ UT3_ -"%3U!<_P"K
M7_KHG_H0H GHHHH **** "BBB@ HHHH ***#0!2TK_D'0_C_ #-6%/\ I+_[
MB_S-5])(&F0_C_,U84_Z0_\ NK_,T 2T4F1ZTN<T %%%&0* "BDR/6EH ***
M* "BBB@ HHHH ***3(H 6BBCI0 44F1ZT9% "T444 %%%% !12;AZT;AZT +
M1110 4444 %%%)N'K0 M%)D4M !1110 4AI:0]* &6YS;1'I\@_E4E1P?\>T
M1_V!_*GY'K0 M%%% '(>(_\ D:-)_P"NB?\ H8KKZY#Q'_R,VD_]=$_]#%=?
M38D%-_Y:#Z&G4W^,?0TABGM]:6D;M]:6@ HHHH **** "BBB@ HHHH JV_\
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MF&3GL>M 'HN1ZT9'K7G>IQ7D7B:+0+5-2N[*"Q^T")-3:*5F:0@LTI;>P7
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MQIJRC[5 B2.IXX8L!@]S\I_3UJMH>OQ:S8I.RI!(\DD:PF0$G8Q7(Z9Z9Z4
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M;\.B7-H=2CLY[+2;:XL&0)#>-)LFS@2_,HQP<9'M78QZ=916 L([6%;,+L$
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MA:2_N ZW"%20P3/RGC(( XK9\+1S:U8Q:Y<ZG>I<274I^SK.1$BJ[*(BG0X
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M!!:_8I(E1&VAMT@=@6R3Z8P..:Z:3P9H<UP\TEHYW2^>$\Y]BR9SO5<X!SW
MJ>]\,Z=>WKW9%S!/( LK6UP\7F@= VTC- #;F.ZO/";B\+VMTUKNF\E@"KA<
MD \C&>/I7(V,MUIWA+PW:VFHW*'59H86F<JWD(5)(CXP"<8&<UZ*EO$EN(-F
M8@NS:W/&,8.>M8D?@[2(]-;3O)F:UWJZ(]PY\EESM,9S\F,]L4 9^B3W5CXV
MU'16NYKNU^SI<H\[!GC;A2I.!D'MGTKL*Q-$T6TTN[OGA\V2>1T$D\\K22,
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M$&0I,[;709 /&.,]":D\0:?J&KZAI&MFPU2WAA$T4L%K,J72*V-KC:V,?+R
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M:"YMIHR7CD!R!E3R,$8K&6:X;PWX<O(M-U!I-'EB^U0/:R)(5\HHQ16 +8W
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MKO\ ZZ+_ .@+5JJMO_Q]7?\ UT7_ - 6K5 !1110 4444 %%%%  >E%(:6@
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MZ5-<?9H[\E-K-NV@[0=VTMP#B@#J=HHVCK7*W?CA+:?4%CT>_GBTZ0K=S1[
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M;2(BA6&0I9@ 6VCIGTS6GKVAKK=M %N9;6YMIA/!<1 %HW''0@@C!/!K7HH
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MYO)+B.]VHKB,(T4:8\M1R<[<=>]:VEZ;JUK<(U[>V4\2+MQ#9>4[GU9MY'X
M5M+(K.RA@2O! /2GT <II/@F#3-2U&Y>X,T%RCQ0V^S:((W8LZ@YYR3UP.@J
M+3O#FI:-!9V8O+&6RM9(U61[/]^ZAA@%@V >GS8[=*["H+K_ %2_]=$_]"%
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M.@ZC-X$\2V,=F[75U=3R01@C+@N"IZ^E8FKV^IWVN>(%M8;R;3"(X;Y;.2%
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M)5GD&)%65A')\I7+)G!."1R*J6G@W1;*ZMYXH9B+8EK:*2=WC@)ZE$)P.IH
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MC%=P:A#%%>V5P8)O)),;' 8%<\X((KF5N=9L_%GBV;2+:SE$;02S&XD920(
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MBU#5)9UD-Q'%#"@3'E(FXGGN26)_ 58TC2(-'MYHXG>1YYWN)I7QN=V.23C
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M!_"7BVU6T<W%W=W#VZ8&9%;;@CGOBN[HH \]UGPYJ>IQZM!#;NK3:1:Q1EB
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MR7")J(U(AK;_ ):+_I(;)7J!CN>.1ZUZ.WA_S/$,&JRWTS);*PM[4(BQQEE
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M=%_] 6K5 !1110 4444 %%%% "&EI#2T %%%% !1110 4444 %%%% !1110
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M)KV.ZM-,TW2GO)Y=/CNT:6Y" *3@[VP3G@<@')/05N7MA)<>&Y].5D$LEJ8
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M **** "BBB@ HHHH **** "BBB@ HHHH *S]/UB#4KB^B@23;9S>0TC#"NX
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M;KN9KB954X]P !@5Q5CXAOTU?16CU._U"TOKAH))9[-8H)!M8AHL -QM]P:
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MW";( @B*G#)C)W*=PQGG@UEZ1K&JZC;>'](TR>VT]Y-)2]GD6V#*HX4(B9
MSG\.E '=B]MOMPLO.3[48_-$6?FV9QG'IFK%>?W46N3>.[.&&]M(-0_LE_.N
M!"73;YHY5">IXZDXYZUT?A35[G6-#\^\$?VF*:2"1HN%9D8KD#MTH W:C2)(
MW=E55+G+8&,GU-<)<>(?$D>CZCKB2V)M-.N)5:U\H[IHT<@Y<GY3CI@'D>^*
MU8M4UC4?%3VEG/:PZ?;PP7$F^(M(X?/R YP.!U[<=: .JHKS:V\=ZE>*FI6Y
M\RW>Y,2Z>EA*6\O?MW^<!MW8&[&,=JTKCQ9J5MI^I6I2WDUJ"_2S@15(5_,(
M,;$$YQM)SS_": .WHKS^]\9:DVI:HED\<::<QC6%K.65KIU&6 9>$YX'7U]J
MTWUC7-1U2*TTTVMHKV$5VQNHF=T+%AMV@CT'7&.?I0!UF><4H.:\[FUG6M8M
M/#%Y:WD%G)<7+12IY3,ID5),DX<93Y?NGOCGBM277=3A\2+IUU?6-E&/+$7G
MVSXO"0-VQ]VU3G("\GCO0!V%%87B75[K18;*[C5&M3=)%=[E)*QMQN'I@X_"
MLBY\6WRW&K?9HH)(H;R+3[3<"-TS8W%CW4$]O0T =I17'R:WK6EZE)INHO9S
MRRV4MU;W$,31J&3&492Q)Z@YS5J+Q!=O9>&9BD6[5'59@ <*#$S_ "\^JB@#
MH9[F&UB:6XE2*)>KNP4#\32PSQ7$2RPR+)&PRKH<@CU!%<?\08[F:#18HFA\
MN35($9)8RX9LG;D9'RC!R._'2I+2_P!</B*?1;./38K>PBMWFD\M@"'!RJ*#
MQG!QZ>] '845Q$OBC61I-UXBBBM&TF"1P+9@PF>-'*,^_. >"0,=.]37OB#7
M)+[4X]+ALC!8V\=SNG+9<,I;8 .F<'GMZ&@#L:*X_3O$FKRW6C37MM:1V.KY
M\A(V)DB_=F1=Q/!R!T'3WK2\2ZS>:2-.2Q@BGFO+H6ZK*Q4#*L<Y /I0!KW-
MI!>1K'<0QS(K!PLBA@&!R#]0:G' KA[GQG?Z-'JD&KVUM]KLUB>.2%RL4@E;
M:I)897!Z]>E+I?CC[5J-QI[76G7DRV;W<<MC(60;3@HV>0>1SW&>E ':NZQJ
M6=@J@9))P!34ECF0-&ZNIZ,IR#7G'B/4M<U?P$+R[MK"&VO&MRL2R.S;&8<-
MQCGC\":VH+W4K>\70-)T_3+>XMX!<7!&X0)O8X5  "2<$D\?C0!UEM_QZQ?[
M@_E4M<,GC*_;2]*6UTV,WUQ>-I\L4LORQR(""=P'(XSTZ>]79]9\1#55TF"S
MTXW:VBW$DKS.(P2S @#&3T'YT =83BD# ]*X>U\9:K);:9J5UIUM#IU[<+:D
M"<M*KG(W=,;=P(QUI)?$+Z3_ &JUEIR/*-8CM2K3L!(753NR<A?O=!Q0!:\1
MC_BJ=(_ZZ)_Z&*[ =*\E\1^);ZQ\0$:K9VXNM/CCN0+:4E)$+<#Y@""""#78
MZ5KFLW'B%=,O8=-"_9!=,]M.SD G '(]?TZ4V)'4TW_EH/H:Q7U[[+XCFTR[
M58X_LGVJ"7)^<*<.#[C@_0UD6WBS4M173(+/3H/[0O;9[LK+,1%%#NPI) R2
M>. .YI#.Q;J*@@T^VMKRYNXH@L]SM\YP3E]HPOY"N9/C&9(;99[#RKO^U8]-
MN(O-RJ%AD.K8Y&"#T%7+_P 3/97>M0?9=PTVP%Z&WX\SACMZ<?=Z\]: .CI&
M8*,GI65H=_?ZC8+>7EI%;),JR0JDN\["H(W<#!^F:Y/Q+XCO]2\-Z^]G8*=/
MMC):M<?:,2%E."RKC&T'WS0!Z%17/:5KK2ZO_8K08:#3X;GSM^=V[(QC'MUS
M6+=>*M6O(O#MW86\445[=O$\;SXWD!QM)V' ^7.1],4 =UUJ*"U@MM_DQ)'O
M<NVQ0-S'J3[UR<_B.#1KW7[JZMY1):06\DJK<%U9F! 55( 7GC/?K4MKXSS>
MFTN[>#S7MGN8A97(N,A/O(< 8;GZ&@#K:*P] UJZUJS2]:WMX[:5 \;PW7F_
M56^48([]?2MR@"K;_P#'U=_]=%_] 6K55;?_ (^KO_KHO_H"U:H **** "BB
MB@ HHHH 0TM(>E+0 4444 %%%% !1110 4444 %%%% !1110 A[4M%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 A&:QM(T5M,EU.)I$EM+JY:>.,K
MRF\#<I]1NR?QK9;I6/8:TG]G17.IW-A;O([J#'<!HSM)Z,<9.!SZ<T )?Z&H
M\.7.D:0L%BLT;1KM3"H&/S$ =\$_C6E:V<5G90VD(VQ0HL: #H ,"DLK^SU*
MW%Q8W4-S"3@20N'7/U%0W.MZ59726MUJ-I!</]V*2958_0$YH JP^%-$@OEO
M(M.A2='\Q" =JM_>"] >3R!FK+Z'IKV5W9M:1FWNY&DGCQQ(S<DGW.!3[O6-
M-L"1>7]M;D ,?-E5< \ \FI4OK222*-+F)GE3S(U#@EU_O#U'/6@#B=5\%WM
MUJ6I2+:Z/>I>ME+B]#>;;#;M"J I! ZCE>36XO@W1YH;7[=;B[N8($@>>0D&
M8*/XP#ANYYSUK<BNH+@R"&9)#&Y1]C [6'4'T/(XJ :OIIN$MQ?VQF<D+&)5
MW$@X( SV(/Y4 <EJ?@Z4:M%<6>GZ7?V:6JVL5I?LRK;@$DE2%;.>^>>.M:FG
M^$+0^'K+3]55+J6V9G21"R&,LQ.$.=P !QUZ"MRWU*QNUD:VNX)ECXD,<@;;
M]<=*2UU2POBXM+VWN#'PXBD#;?KCI0!5B\-Z5#;0VZ6W[N&<7*;G9B)1T;).
M2?K5D:59BZNKD0_OKM%2=MQ^<*" /R)_.G1ZE8RS+#'>0/*R[E19 6(]0,\B
MA]3L8Y1$]Y LA;8$:0 EO3'KR.* ,^?PGHUQ:VMNUH46T3RX&CD9'C7T# YQ
MQTS4\/A_3+=+-([; LW:2#+L2C,"&.2><Y/7/6K5SJ%G9[?M5U#!O^[YL@7/
MTS3IKVUMAF>XBB!7=EW"\<<\]N1^8H J2:!IDJZ@LEJKC4 != DGS,#:._''
MI4^GZ;;:99BUM0XB!)P\C.<GW8DU91UD171@RL,@@Y!%07-_9V:JUU<PP!CA
M3*X7/TS0!5M_#^F6OV/R;8)]B+M;_,WR%\[N_.<GK5FWTZUM+BZG@CV2W3B2
M9LGYV"A<_D *?)>6T*!Y;B)%(+!F< $#J?I39[ZW@T^6]:13!'&9"ZG(*@9R
M* *DWAW2[@WWFVP;[<R/<?,?G*8V]^,8'2G3:!IEQ]M\ZU207J*EPKY(<*/E
MX]LU'H&J2:GI-G<W210W5Q")S CY*JW3WZ8S[U)/J?EW]M;PQ"=)79))%E0>
M40,X()R3[#I0!DWWA&)-'U"WTVXG%W<6S6\<EU<22JBG^'#$@#\*R=)\-7XU
M:TDETR#2[."%XIXX[YI_M0*[0-N  .^3S74:#J[ZK;W0N(EANK6YDMY8U)(!
M4\$9[%<'\:T'NK:.=('FC663[B,P#-]!WH Q+'P9I%A=VMU$MRTEH3]G$MP[
MK"""NU03@+@]*U=/TRVTNU^S6JE8O,>3!.?F9BS?J34\ES!"&,DT:!<;BS 8
MSP,_6G>8A.-PSC.,]J .;N/ 6B737(D6Z\FXD,S6ZW#B)9"<EPF< UM6VEVU
MI>WEY$&$UVRM*2V02HVC [<5<W YYZ<4WS8PX3>-Q&0,\F@#FY? >B22L[+<
M^7YWGI;B=A%')G)94S@$D?J:Y?4?"^L";4O)T\+=W5V9(=3BOVB6(,PVGRAW
M Z]<GFO3!*C [6#8.#CL:@NI8S!N# A9$W$<XPPH BN--AU'2GL+\>?%+&(Y
M<\;^.365:>"-*M+U;SS;Z>Y6%X!+/<L[!&&" 2>, <8K:L-0MM2L8;VU<O!,
MN]&*D9'T-3K*CJ&5@RGN.10!AVOA#3('GDF:YOGF@-LS7LQE(B/5!GH#4FF>
M&+;2KA)8KW495C4K'%/=,Z(#Z _US6A=7;P/ (K:2X#RB-S&5_=#^\V2.![9
M//2K'FIOV;ANQG'?% &=J^@VFLF!YGGAGMV+0W%O(8Y(\\$!AV(ZBJO_  B&
ME?V4=/V2F-IUN9)#(3)+(K!@S,>2<@?E5G3M9&H:KJEDL)0Z?*D98MG?N0-G
MVZUIEU&,GKQ0 21K+&T;@%6&"#W%<W9^!M+LKBSE2XOW6RDWVL4ERS)#P1A1
MZ<UTA<=._I5:PO'N[432VD]HVYAY<^W=P<9^4D8/7K0!E7'@_3+BQ^R[KB,K
M=-=QS1R8DBE8DEE/;J>*:_@ZQDL8H'NKY[B*4S1WK3DSJY&"0QXQCC&,>U=!
MO%*6% '*Z9X0TR3PY-:2FXE-XXDN9WDS)(RMD9/;&!P!BM2;1+.ZU[[?,K-(
MEH;;83\C(Y);(_"K.E,!IL/X_P S5A6'VJ3_ '%_FU '/V7@FPL[FV<WE]<6
M]FV^TM)Y0T5N<8&T8R<=LDX[5JZ5HUOI!O3;O*WVRZ>ZD\QLX=L9QZ#@5H;A
M1N% '*S^ K"=KE/[0U)+6XN/M36J3 1"3=N)QMSR1T)(]JFO_!=K>W]Y>)J6
MI6LEY@7 MY@JR*%"[<%3@8'4<\GFNDW"H+NY^S6DLZPRS&-"WEQ+EWQV [F@
M#'O/"5G<)9"TN;O3GLXS#$]FX4^6<90Y!&#@>]10^#HK/2X[&PU?5+,),\OF
MQ2J78L<D-N4@CZC/O700R^9$CE63<H.UNH]C[U#-J5I!?064DNVYN S1)M/S
M!<9YZ#J.M &*W@G3TL[.*TNKVSN+0N8[N"0>:2YR^XD$-N/)R*U],TXZ;:>0
M][=7C%BQFN6#.<_0  >P%.M+_P"TW%U$;:YA^SR!-\T>U9.,Y0]QVJWN% &%
M)X2TZ77KO5W,K375N;>2,D>7@@*3C'4A5'T%16O@S3[3PNV@1SW)MF;>TK,#
M(3N#=<8[ =.E=$&!H% &;<:);W&L1:F\LHFCMWMPJD;2K$$D\9SQZUEMX*MH
M[?35L]1OK.XT^W^RQW,)3>\?'#94@],]!S72EP*7<* ,:R\-P66IV^H"\NYK
MB&T-KNG<-O4MN+,<9)R/I[59T?1H-%M);>"2619)GF)D(SESDC@#BKY88ZU1
MTS58=36Y,2R+]GN7MGW@#+(<$C!/% '):;X+EO[>_CU"^U""TN+Z626Q#+Y<
MJ^82O49 (Z@'FNLMM'AMM6NM01WWW$<<90XVJ$SC'_?1K0W"C<* .=L_"CZ<
MS16&LWEM8F<SBV1(R%);<RJQ4D*3GCW/-2S^%+.?Q5%KS2R>;&@7R0!L9E#!
M7/&<@.0*W=PK.LM8M[W5M2TY%D$VGM&LI8#:=Z[EVG//'KCF@#/?PL\6H7UU
MINKW5@+Y@]Q'&B,-P&-R[@=K'OU^E:%OI"P:H;\W$LDK6J6S;\<A23N.!U.[
MZ5HY%&X4 <T/!T<6DV5G;ZA/%+97#7$$X520QW9!!X(PQ%/O_"LNIE8;S6;J
M6R\R.5H#&@)9,8PP&0"5R1[GD5T6X4;A0!E>)H%N?#.HPM;R7&^W<"*(99CC
M@#WSBLK3_":S^"K32[R:>*Z^6X>=2#(DY;>6!((R#Q74[ABH[:[M[R!9K:9)
MHF) >-L@X.#T]Z ,2W\+!K^2^U2_EU"Y:W-LNY%1$C/7"CN>Y]NU5K+P;+;3
MZ6TVMW5Q!IC9MX&C15QM*C=@9) .,\?2NI+ 4;A0!F:SHJ:PMB'F:+[)>1W8
MV@'<4S\OXYI;71TM=<U'5!,S->I"C1E>%\L,.O?.ZM+<*-PH Y.7P7));SZ8
MNK2IHT\YF>U6(;P&;<R!\\*3GMG!QFM5=!1;K59A.0+^%(=NW_5A59<CU^]^
ME:^X49% &&GAJ-;?0(?M#$:1MVG9_K<1F/GGCKFJ/C2SN;PZ)%:M)'(-11O.
MC3<8OE;YB.F,XKJ=XQFEW"@#D?\ A##=QZE+J6H-+J%\8R;B"/8(?+.4V*2>
MAYY)SFM.VTW5Y(IHM2U.WFC>%H@L%KY?7C<26.3[# K:W"F3W$5K!)/,VV.-
M2S'!. /I0!AW7A@7/A6UT/[45%N(1YNSD^60>F>^*34= O#K;:QI.H):W4L
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MZ .C'B:WDUR;28;6\FG@=5F>.,>7&&4$$MGIS]?:KVH:BU@(]MG=W3.<!+=
MQ'N22 /Q-4M(TV>TUK6[F10(;J:)H3NR2%B523Z<@U5\3V>I75SISVJ7$]G$
M[FYM[:Y\AW.!L.[(R <Y&1U_"@!\WC'38-*AU"1;H1R71LS$(29%E!(*E1SG
M*D<9II\::?':W\UQ#>6[6!C-Q%+#AT5SA7QGE?<=,&L"U\,:O'I5O$]JB2#7
MUOW3S_,VP]3\QY)'YG%;TV@M>Z_K;W<(-A?:?#; EA\Q!DW<=N&'- &M_:UO
M_;::4"S7)M_M!VKE53.T$GW/3Z&J^H^(K6POUL%AN;J\,?FF"UBWLJ9QN/0
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MXI)+=HKD2@E%W,K?*-IQZ9%*GBMG\/Z/JOV+']HS11^5YO\ J]^><XYZ>@H
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MEB94M71)Y3,JL"P!!5#R5 /)R.G&:MZYK<>C0P?N7N+FYE$-O!&0&D<^YX
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M&ZOHU#3(NV%#_'(QPH_,BLWP]K=TFF:DFNSJ;O2I7%S+Y>T&/&]7P.VPC\J
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MSA!+Y!@,1\[S<X\O9UW9[?TH V]B;2FQ=OICBJNHV*7]C<VNXQ"XB,3.@^8
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MI( Z 9/<UZ3X?MI;+PUIMM<1>5-#;1I(F0=K!0",CCK6%XC7_BJ=).!]]/\
MT,5V Z4V)'(V5OJ.G^*]<+:=-+:ZD8Y([E'38FV/:0P)SG(';O5(:-?KX8\)
M6OV1Q<6=Y;R7"*RYC5<[B>>>O./6N[P/2F$#S!QV-(9YW#H=Q96^HZ5>V.KW
MD,]U)(CVTZK%,CG/.6&TC.#GTXKT2-=J!<8  &*5@...].QB@ HHHH ****
M"BBB@ HHHH JV_\ Q]7?_71?_0%JU56W_P"/N[_ZZ+_Z M6J "BBB@ HHHH
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M^G37\@BMM+@E4I&@W,1+OZ@\-M&1V[8JP'DTW0='MFUK46FNMGE)!;Q/*PV
M[%^3 48R21]370)X?TZ-[EA!Q<VZ6TJER08T!"C\F//6J8\'Z>+2U@$U\#:,
M3;S"Z?S(P5"[0V?NX&,?UH X[5I[_4O"V+V\N1):ZTEL&,<09QO3:SC:0&&?
MX<#US6YK6J7>A:E;PO/+>10Z9/<NTB('D=)(B.54 <$C@ <UKIX0TE-)N-,6
M&3[-/-Y[9F<N)./F#$YSE0>M/DT*TB>WG8S2S1)]G#S2ERR/(K,#GKDJ* .>
M.H:UI^D:-K<VJO=&]F@6>T$4?EA93TCPN[(R.K'.#5:;4M?DT_Q)JL6KM$ND
MW4X@MQ A1TCP=KDKDY' P0?K726G@W2[2YMI4^TO':,7MH)+AVBA)[JI/OWS
MCM5L>'=/%AJ5EY;>1J3R27(WG+%QAL'M0!HV\GFVT<G&74-^8KG/$%[+_:45
ME;:G?Q7#0M(+>QMDD/7[[LZD*O;'&:N6FARP^([C4Y91Y0MH[6VB1CP@Y);M
MDG]!UYIVH>&;'4K\7LCW$4YC\F1K>9H_-CSG:V.H_6@#F;76-8U:#PM"M^UI
M+?QW NI(XD+,8P.5# @$D'U')XI%UW6?[/GT];P->KK9TN.]>-<A-JOO*@;2
MV"1TQGM74VGAK3K'^SO(C=?[.61;?YR=H?[V?7\:BG\):7<6=[:R1R;+N[^V
M2%9"&$WRX92.GW10!DZ/;75I\1;V*ZOGO2-+B,<LB*K[?,;AMH )SGD =:H>
M*],FU/QPALV O[32C=6F3@"59AC/L<D'V-=3I?AJQTK4IM0A:XENYXQ'++/,
MSEP#D9ST_#%6SI5L=:_M;#?:OL_V;.[C9NW=/7- 'G=EXK7[1XF\1V\/SKIU
MLPBDS\D@W*58>S=?I70?:=:TB_T-KK4Q?1:C+Y,\3QHOEL4+ Q[0#M&".2>H
MK7C\*Z7'/J<HM\C4UVW498[7'.<#MG)Z4RQ\*65E=VUR9KNY>U4I;?:)BX@4
MC!"CZ<9.30!R5GJ^N6_AT:T-11H8M1:V%IY"[6C\\Q\MUW>A'''>NFU'7I(A
MJD5OI]^)X+5WCE>W(B9E5B,-[FBQ\-V-SX8&G.)?L\D[7# /SO,A?KZ9K>,8
M>:13T**"/^^J .;\)Z'I<W@_2Y9;.">2:&.ZDED0,SRG#%B3SG<?PK-FUG7+
MK2=:UZUO8H8+"698+3RE99%B)#>8WW@20<8(P,=:V8?!EE;,(X+S4(K(/Y@L
MDN"(@<YP!C(&>V<4ESX)T^YFN\W%W':WLGFW5G'-MBF<XR3QN&<<[2,T 9QU
M/6]7UI[73[R.QMQID%YEH [AW,F!SV^49],=LU2TOQ%KLVG:#K=U<V[V^HW2
M6LEI'#@*&)4.&ZYR,^F#BNSCT>VBU.;4$4B>6W2V// 1"Q  ^K']*IP^%=/M
M]*T[34\W[/I\RS0Y?G<I)&3WY)H Y^\U/Q$]GK^H6M_;PPZ7<2K% T /FA &
M(=B>.#@8JK-XOU'4[^YCLGNK2*"VADC%OI[W1>21-_SE00% P,#!/)K0M_!?
MVV[UAKZ>\@@O+UVDMXI@([F+"XW#!(YST*D]ZV+CPM"VH/?6-[=Z;/*BQS&U
M*;9%7A05=6 P.,C!H YIY=:U/Q#X;G>YDTV>>RED> P9\M@%W ACDYSWZ57\
M3W-W)IOB%(+E+=;;4[="T,0#.&6(_,1R2"V??&.E=?>^&HKQK"47MY#<V2E8
M[B.0%V5@ P;<"#G YQGTQ3;GPG875KJ=O(TQ749EGE(?!5U"@%>.,;0>] %"
M[NKK2M9TJ*[FCNW^QWDLLQ@5';9L( QT'S8/K5"+6?$$&B:;XAN;JVEMKJ2$
MRV20X$<<K!5V-G)8;ESGKS71Q^'H_M%E<75W<W<UK%-$'F*YD$A7=N"J!_"
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M44 (:6D/2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMH6E*Q?WVV@X'\\'TJE=^-M'2PL[C?<G[6!+;QBVD\R55=0=JXR3R#CN.>E
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MV:Z=I-Q#JD-K##%J$%VBHN -RRJ3EE!SQAL]L5T/BW3[S4_"-S96L8ENI!&
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M,=!BD:.-F#LBEEZ,1R* /)+BW%Q<>(+:_P!8TS3WEEQ_IUJ6FV;1Y;1-Y@X
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MBPCD1B">5!(((]#0!EV'C(VVA@S:<T=W!?1V4\#2_=,C##*V/F&&!Z"M2_\
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M* "BBB@!#2TAI: "BBB@ HHHH **** "BBB@ HHHH **** $-+2&EH ****
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MX8<!5Z*?7UI#.N/;ZTM9>DW=_>VQGOK%;/<P,4?F[V*D?Q<<'VYK4H ****
M"BBB@ HHHH **** *UO_ ,?5W_UT7_T!:LU5M_\ CZN_^NB_^@+5J@ HHHH
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M9Q7.JBPLX%E=[PVL9+[=VP9F;&. O3W/YT 6H_#/D:6MA#K&JHJN&2;SU+J
M,;>5QM]B*=;>%K*UTZYM8Y;L273!Y[OSSY[N.C%_48Z=/:I="UY-:M))C&L#
MI=36XC+Y+>6Y7(^N,UJ/,D;*KNJECA03C)]J ,73O"UM9:C_ &A<7-WJ%X$,
M237CAC&AZJH  &>_&35N?1+276+?5-A%Q;Q/&@& I#8)R,=>!5]YDC4L[JH
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M#W1<W TB.Y=HY7 ,HDP2,$?+QTZ>U9>G^=J%AX+LYKZ\6*Z-VLWES,K2!3D
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M'Z)?W4T\]M)F=@T\:3ND<Q'=T!"M^(J^-)L5U5-2$(%VD'V=7#'B/.<8Z=:
M.7\:V NM=\- W=U!OO&C!ADV[?W;G(XX/;/I5>729[OQAJD$6K7ULL-A!EX7
M >0C?@LQ!]"<=\UU^J:/9:S#'%>(Y\J02QO'(T;HXZ%64@@\FE@TFSMKJ2YC
M1_.EB2%W:1F+*F<9R>O)Y[T <'_PD&IZG!X=LV>^/VNP-U<-8;5FD(PH )(
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MZ[8Z+=S[;2*&6YN0(V?YBNR,?*#CEF;\*ZC3M'&G.[M?7]X[X!-U/O  ] ,
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M %T7_P! 6K55;?\ X^KO_KHO_H"U:H **** "BBB@ HHHH 0TM(:6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HI#2T %%%% !1110 4444 %%%% !1110
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M3R%DU&$S0>=QC(W+\VW."3ZUV?@NTAMM(N([;4+6]MVN7*?9(RD473**"S<
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M23>;IFHRV\"AYKF*$&-%QG.206QWP#BM*YU""VTJ74B2]O'"9\IR64#/'X4
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M@;O+49_"GFWB:59&C4R+T8J,CZ&L32?%.EWL4D2R2PM;0"9_M$319CQ_K!N
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M1HS:<U^;U4MXY5BD9U*F-R0 &!&5ZCKZU/INOZ9JTTL-E="26(!G0HRD*>A
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MIN$N%N;JTC"30J?+5B<X.,Y]^M=;9>&+6TU-]1DNKR[NI+<VS/<2 @H2#C
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M,&]Y Z[BN<C'0\]>1Z4_Q7KMSIE[I=C;-)%]L,IDFBMFN'14 /RH <DDCDC
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MV27J*MU%$JG?@8!!8':<<9'\Z+#PC:V,6G1>?++'9VDEH%8#$BN1DG'T[>M
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M27O-/M8K75XR;5HYV9T;9O7>,="/3I6@FC:M<6%_:ZCJ-DZW-N\"&VLS%L+
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M'3H9(&-Q"S13(YSC .00<8/UH W?#.M+K6E[RJ)-;R&"98Y/,4,O=6[@\$'
MJKI?B&]U74[J..UM%LH)I(6;[4?/4H2,M'MX!(XYZ$&M#0;:\M]*B2]-KYQ
M.+:(QHHQP,$DFL;_ (1O4[OQ3:ZK>S:?&EHTFQ[6)EFF1@0$D).,#KW_  H
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M5Y5W-#&+JRCDD1B##$P4.R_W>">15OQ)8:/:>&-1@TVZ;<YMA(B71<H/-&&
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M0(;B:.(.X12[ ;F/0#/4GTKS71&O[6U\&ZD=7U"XFU)ECNEGN&='4QD@;2<
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ML %63_:W9Z\]:7PK'<:GJVGZ=>H2/#,3Q2'L\N=D;#_MFI/_  *O1%B5<D
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MWBK[GC%\\G2;<GZ_/7H;6D#N7>&-F*[2Q0$D>GTIS6\;;]T:-O&&RH^8>AH
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MJ]&33;.-X72VA5H$*1$1@>6IQD+Z#@<4G]FV8@B@%K#Y4+!XTV#:C#H0.QH
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M8[4/<66K->-!YBY>,N_0DXSAAU-=7?P3ZEX=NH!'Y-Q<6SH$=@=C,I&"1[T
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MD-+0 4444 %%%% !1110 4444 %%%% !1110 AI:0TM !1110 4444 %%%%
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MC(3#AEDPIXR O;'/J35.SU;6;^W\'6T.IFV;4H;EKF5($);8 1@$8!ZC\>E
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MC:><\9'O5S2?$%Y]MTZQO]*%FE["S6KB?>3L4$AU"@(<'. 6Z&@#J:*!THH
M*:Z+)&R-]U@0><4ZB@"MI]A;Z9916=I$(K>)=J(#G _&K-%% !1110!5M_\
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M]P(4B>VN=GG($(=6 Z#..>#Z&M:[\)V$\5F+:2XL)+./R8)K-]CHG&5Y!!'
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M6$>-'N=7M$@$:E48[T$C)Z GN.O->HV^G65I9FTMK2"*W((,21@*>W0<59)
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M).09!Y@;<"0 .JG'' -0Z@-2U#Q7?V$.K3V=K!8PS@0JNXR%I!G)!X^49'?
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M]CU(X%4HH-8M/$&FW]S9M>/)IRVMS);,H$<NY26PQ'R]>F?I65)INMIX8O\
MPLFD.[SSRK%?>8GDF)W+;VYW!@">,=1UH ZB^\4V5C>O:>5=W,L2*\WV:W:0
M1*>A8C^0R:S8_$Z6&JZXVH7$C6T5Q!%:Q)'N9F>,':H R23S4-O;:GX;U?56
MMM)N-2BO?+DADCD1=K*NTJY8@@< Y /6J5WH&K1^)K_Q':V@>ZAN(W@@=QMN
M(S$$D )/RL.<-QTQT- %YO%XTWQ'K4%^;N6"!87CCAMR_DH4R[,5' SZGZ5J
MZIXET^UM[0JTMS)=!98(K6(R/(@926  Z<CD^M48M-O#J/BB=[9PE[!&MON(
M^?$1!&.W)QS67:6&IZ%+H]X^FSW4:Z;#9S)$R&2%U<-T)&0>G!["@#8OO$0N
M[;1[G2;H^7/J26\RE<,!AMR,#R",#/>J_B3QM96>E:M'9W$HNK:)T6X2$M$D
M^W*H7P5W9QP:S[70=498+J6T:*2XUX:@\ =28(MI'S$'&>A.,]:K7%GK%MX8
MUWP]'H4]U<7,UP\4P9/*=)&+!BQ/WAGIC.0* .NN?$MEIRQ0W#3S7)@6:2.W
M@:5D3^\P4<#K1>^+-(L8;.5[HR)>Q-+;>2AD\X#;G:%!R?F'Z^E<Q=Z-=6?B
M2[O9H]8:UO+6!$.FN,JZ*5*,,YQSD'IUS5VTT)K75_"AL[*YBL;*VNE83LK/
M"7";0Q!/)PW3- &Y'XGTZ6]2TC:=Y3L#[;=R(BX!4.0,*2".#5W4M3M=)LFN
M[V<10J0I8@G))P  .22>PKEM1@O(_%4<^CVFH6UU)<I]J.T&UN8A@,['/#!>
M!T.0.HK3\56EW,FF7=K:F[^Q7BSR6ZD;G7:R_+G@D;L\^E #;GQC8C2-1NK;
MSOM-I$7:VDMW6121\I*$9VD]^GO1X1U"XO?#R7]W?7-U(ZAY/-MQ'L.T$A %
M!*\\=?J:QKFRO];U/6M5AT^YMXGT=[&!)U"23.26SM/('0#-=5X=MY;3PWIU
MO/$8IHK9$>,_PD#D4 <Y/XT:^\+:W<V2S6]Y:13M&S0MM&PX#990,_[/6MG1
M_%&FZM+':0W#-<^2)/FB91(.A9"0 PSZ5SDEM?GPKXET3^S;O[3)]JDB<)^[
ME#L2NUL\DYZ>QK1O]*NIM?T"2*!UBBLKB*60#B(LB@9_$4 6M&\3Z7+';6B7
M#;I':*.0Q,(Y'!.55R-I/![U9U_69-'2/[/"LUW=RQVUNC-M4NQ;EC_='4XK
MBO#FC!K#2=.U&#Q"9;29'V*%^RJR,2'#X V]\9S[5U/BS3KNYDL+^Q@,]QIU
MS'<"$, 9$^8.!GC..E %VREUVT:636[C2VM%C+F:W1XC&1UR&9@1C/.1TZ4^
MP\3Z5J5TEM;7+>9(A>(21/&)5'5D+ !A]*QM9O+OQ/X?U#3[/2+^!WMR=UY'
MY(9P01& 3DYY&>GOS4"F?7=;\.M%IE[91Z87EN&GA,07,101J3][D]LC H V
M1XT\/F5$.IH ^0'96" @$D%B, X&<$Y_,58MO$^DW=E=W<%X##:#,Y:-E*#&
M<E2 <8[@<UQTFBWO_"!:7:G3Y#<+JD<LD0BRP7SB22/IU/I5GQ%;31:CXJN?
ML\BV\NB(HEVX5W!DXSW(!'Z4 =18>)M(U*\-I:7R2S;2X&T@.HZE6(PV,]B:
M2T\4:/?WJVEM?)),^?+^5@LF.NUB,-^!-<NKSZQJGA[[%I%S:_V6KRS-<1&-
M1F/:(U;[K9)!X]*S[;^V=1UGP]<W:ZHUS#>;[JW-F([>TS&XPK;<D<CG<0?Q
M% ':OXMT..[^R/J40F\TPD$'"OG&&.,+SP,GGM5Z/5;*4792Y3%FQ6XSQY9
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MT6ZDLK= \UP)$&!WVJ3EL=ZRY=7BL_'=[=W%TR6$6AI.06.T9D;Y@,XS@8H
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M^SN)+F"QMH9I/OR1Q*K-]2!5;5==LM(*+<&9Y&&X100M*^T'EMJ@D#WK-O\
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M30$D,;71U<R6]O-<M(L:;&VQF0C)^N#C/?%:-WX;UG6H]4O;M;:TO9VMOLL
M?S400.74.V!G<S-GC@8ZUVCQV\SJ72-WB;<NX E#CJ/0X-2X% '('3]:U77[
M/5;ZQMK0:=!,L, N?,\Z210#DA1A./<]\"LZ#PWJWV?6(+>Q73;&XL7ABL/M
M7FH9C_&O9%QQCC/H*[R2:"%D$LL:&1MB!F W-UP/4\&I, T <F^EZG8^)+#4
M[:V2ZC&GBQFC\P(8SO5M^3U'!X'/2J1\.:I;B"]@AA>YM-6GO%@:3 ECDW#
M;LV&SS7<_+4-O=VMV'-M<0S!&VL8W#;3Z''0T <1J>@ZSKMGK]Y-9):7-Y8K
M9VUJTX8X!)W.P^4$D]LXQUYK<N]*NYO%6A7R(OV>TAF29BW(+* ,#OR*Z$8/
M2C H YSQ'::FVKZ1?Z=:QW7V-I6EC>4(2&7&%)[^G;W%8\VB7EUI/B?4M3B2
MQGOU6:*+>&,'DK^[9F'&<@,<9KNSCO3)[>&Y@D@GBCEAD4J\<BAE8'J"#U%
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MUZ0OV?:)-WF[LYZ#IC.376:59W$'B[6IY(F$,T=N(I#T?:A!Q]#70X'I3?\
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M!'-=3;>%]&LUE%OIT$?FQ&&4@<NAZACU/XU;.EVA:S8VZ9LL_9_^F>5V\?\
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M?W<1<R7LBR2[FR 0H48].!5'7-/NIM9T/4K2,2&SF=95R ?*D7:Q&?0[3^%
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MHHH **** "BBB@"K;_\ 'U=_]=%_] 6K55;?_CZN_P#KHO\ Z M6J "BBB@
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ML)YIKHROI$%P2+J0;G# =,]..1T)-4;S5[N#P#XEF:_F6YCU6>&&0RD.H$P
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M[_ZZ+_Z M6JJV_\ Q]7?_71?_0%JU0 4444 %%%% !1110 AI:0TM !1110
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MO]VI5HXRGG,1G@<[<]>: -:?3=/N;-;2>RMY;9<;87B!08Z8&,"G+I]DMO)
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M; <;O?UYJ]KFK_V1I%Y>(B2RV\)E$1;&0/Y"KMO=17 (21&=0-ZJV2I/8^E
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M:%=L<,"1H/0!0!5(^';,Z=%8_O?)CNA=+\_.\2>9^6[]*T[4YM83_L#^52T
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M<E%&3E ?<C%2^+(M+T?4C=6TFD_:8K01#2;N,8FCWLW[D#G>3GH#[UZ)Y:8
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MZ9KO;'3++2[9;:PM8K>$'(2-<#/K5>]\.:-J%X+N\TVVFN I7S'0$D8QSZT
M<G!:'Q)J]C#J-S=&&3189Y(X9WB#N3U.T@]ZW? US/=>%H&N)6E>.22(.YRQ
M57*C)[G '-;,.FV5O*DL-NB.D(@5E'2,=%^E/L[*VL+<6]I"D,0)(1!@9)R?
MUH GHHHH **** "BBB@"K;_\?5W_ -=%_P#0%JU56W_X^KO_ *Z+_P"@+5J@
M HHHH **** "BBB@!#2TAI: "BBB@ HHHH **** "BBB@ HHHH **** "BD-
M+0 4444 %%%% !1110 4444 %%%% !1110 4444 07<DD5K+)"J/*J$HLC[5
M)QQDX.![XKDM-\8O+J\EC//IEZ/LLERLFFS%]A0C*,#GGG@\=#Q73:SIJZQH
M]WITDC1I<Q-&73JN1U%<O-X6U*W1[Z2[BO9;;3Y[6"TMK86X8, 0,[FP?EZ]
M.>@H ;IOBC6+W5-&B9=+$&IQ-<!(G=I(D !P>Q/.,XQFG:?XNU&3P]<^(+VT
MM8["))-B)(?,D=6*CKPH)&.?KTK,\+0R6%]ID.FQ>8641Z@9-)^SE%"]?,VK
MN.[ [YY-=+:^$XX?"#^'Y[AI$<./.C381N8L"!D\@G]* ,NP\<I_:26M]<Z5
M.LL$LX;3KGS?)\L;F5_PS@\=#Q4.G>/S>7FFLTFE/;ZA($6W@NPUS;[@2I=?
MRR.,9]JW[/1M4 EAU34+*[MI(6B9(K'RF;(QEF,C9XSP .M0:1X>U72%M;5=
M4M9-/M0$1#98F* 8"F3?CTYV]J ,B?QEK4-C?ZH-*M7L+*]>U=1*1++B38"O
M&!@D=>O/2KA\67FF7]]:Z[:6\1@T\Z@IMG9OD#;2AR/O XY'7/2K$GA!I/#N
MH:4;T W=\UWYOE?=S*)-N-W/3&<_A4^I^%8M5UFXO;B<^3/IK:>\*K\V&?=N
M#9]NF/QH S-'\:F^UFRL9YM(E-ZK%$L+P3/ RKNVR#OQGD8Y%-M?%NKR6=IJ
M4VF6J:=+>?9&*SDR<R% X&,  ]LY^E:ND:+J]A-"+F_L)[>)=H\NP\N5^, E
M]Y'UP.:8OA5AX<MM)-XI,-TMSYOE?>Q-YFW;G\,Y]_:@"MH^I:Y<^+M9LYA:
M&SMI8U(WMN163(VC')/?-:5[K_\ 9_B"+3[B +;RVDEPEQN_BCQN4C_=.<Y]
M:9;Z'>6?B:\U*VO(A:WVQKB"2$L^Y%VC:VX #IU!Z>]-\5^&G\264,,5X;.:
M)V(E";LHRE67&1U!ZT 9VG^.6O\ 3-.F73MEY=WXLVMFE(,8Y8OG;SA,-C Z
M]:SM0US4+>QB?2K?R<Z^]K+YETS&3]X1CYE.%8YX'W<#&:V[7P@+7Q:VL+<C
M[,$REKL^[+L5"^<_W5 QCN:CN?"=U+I,MO'=QK<KJK:E S(2@/F%PC#.<<D9
M% %"YOM:B\<1B#389KJ3207B^U%8HSYIYW;<GTX7O72Z%K/]MZ'%J$=N8I'#
M!H6;[C@D%<XYY'7%06>CWJ^($U>\G@:4V MI(XE(7?OW9&3T[5-X;TB31-'6
MRED61A+(^Y1@?,Q;^M '&?VOKNH>"_$K7\,7E1?;$2=9\LC*Q CVA!D#G#9Y
MP.*Z'3O$MXE_;66JZ2+&.>W>:&7[2).$ W!Q@;3@YZFJY\*ZFFFZ]I,=W;&R
MU SRPNRMYD;RG)![%1SSUYK5OM"DO=5TVZ:11#:PS121]WWJ!Q^5 &7:^.'N
M%L;LZ;&NFWLXABF%V#*-QPC-%MX!..^1GI5SQ7?7446GV%E<&VGU&Z6W\\#)
MC7!9B/? P/K6?HOA/4-&^RV:1:-+9VS#9=R6Y^TL@.<$=-W;=GWQ6WXAT236
M;*%8+G[+=VTRW%O-MW!77/4<9')!&10!3DLK/PG:W&JO?ZB]K#"QEAN+EYPQ
MR,$;R2#VP"!STIMMXGOX[ZP@U;1A8Q7Y*02)<B4A\9"N HP2,]"1Q3)]$U[6
M].N['7+JPCMYH#&%LHWW;\@ARS'L1]W'?K20Z#K=]J.G2ZW<V1M].;S(EM0X
M,TF,!FW?=P,\#/UH ICQY?FS34!X<=]/:Y-J)H[M68MO**57;R"P Y(Z]ZMM
MXQNK2#6#J.C_ &:XTVU6[\I;D2"5#NQ\P48.5(Z?G2+X5NQX8CTLSPF9=0%V
M7 .TK]H\W'UQQ]:K>,=+FCL/$FJ%D\J;21;JH)W94N23_P!]"@"]9^*[R34]
M/MK[16M+?458VLWV@2$L%W[74#Y25Y')IW_"47MOJ]G::EI"VD%Y,8(I1=K(
MX?:2-R < [>Q/453TO1M;OKK2+K5+FT%II\>^ 6RL'F=D*AG!X7"D\ GGO69
MIW@75;>XTH3KI6-/NQ.]ZBL;B[Z\N2.#STR?PQ0!J7'C>Y@2\NO[#D;3K&Y,
M%S<_:%&W#8+*N,MC()Z=>]6+WQ;#!;ZZ;BV:-]'D1F7?DRJ<,I''&>F/6HKK
MPM>S>%M<TL2P>=?W,LT3$G:H9@0#QUXK-\4:8+OQOI5O"P'VM$:_CVYW112*
MR$G_ 'CMY[&@#?U_5K^T\&W6IVUMY5VMJ9=C.I\D[<DG(P=OZXJI;>*K^/1M
M/>ZT>5M1O"J6]NLR9F^3<7)Z(,9.#6YK&G?VKHMYIQ;8+F!XMV.FX8_K7-KH
MWB$V&DW/D6,>HZ4VR.'SV:.>/9L.6VY4GJ.#B@#:T;7VU.ZN[&ZL9+*_M-IE
M@9PXVL"596'!!P??CFJNH^*I+:_N[2PTR2^>R17NB)5C";AD*N[[S8&<#\Z=
MH6E:@FJW^LZJ(8[N[5(UMX&WK#&F<#<0-Q)))X%96J>&;R/Q#>ZC;Z+I.LQ7
MP0E+Y@C0,J[<@E&R".W'2@"AKFKS:WK_ (;2RMKR?3+V"2X407?V<S<+SPP(
MV9S@^O'2H="UN2WO?$&M:O9WR1VEU)")/M>]8\;%6 1!L%LM]X#'/7-=*-!N
MAK7AV[2WM((+"VFCFB@.U$9U4 (,?=R#Z=JH/X.O+K0O$>GS20H^H:F][;L?
MG7&490X^J8(]* -&U\6[;V6TU;3Y--E2U-VN^59 T:_>Y7H1Z5 ?%6J3Z/<W
MT7AVYBC^S--;22S1X?TW#.5XYP>P]:@M?#L]]'>P7OAO1])6:UD@%Q9N))"6
M&./W:X'7C)[5:TVU\1SZ:^F:I;6$$*VK0?:(9V=I6QM#;=HVC&<C)H N^%M6
MO]8T>&ZO]/-J[QHRMYBLLN1G< "2H]CS5;4?%-QI5WF\T6YBTWSUA-Z94(RQ
MP&V [MN>]6/"L&K6>B066JVMO#);(L*-#.9!( ,;C\HV_3GZUR>H^$-=O)+Z
M*2SLKAI+P7$>HS7+-((PX81JA7Y<#C@XXH V]>UJ]T'P4VH6-NLTL?&6(VH"
MWWB"1GL,#GFGR^*[NT:R2?0+L7U\'6*U26-CE.>6!V@'/4GC'-2ZII$NN>"+
MG3H75)9HSY9;IN#9 /L2*9#9:O>ZWH]_>6=O:M:),LT<=QYHPP 4@[1GIT[4
M 3:AXGO-/MQ<OX>O6MXX1-=2"2," 8RPP6RY49SCTHN_%?EW<-K8:7=:A//:
M+=Q+$RJ"A..2Q 7\>N<5A^)/#.LZEJ6JE+*WOH+N 1VLEQ>,BVAV8;$>""2>
M<UM:7H=Y::U:74HC\J+24M&VOSY@8$_AQUH :?&MK+9:=)86<]W=ZAO\BU5E
M1LQ_?#,Q !'UY[5>N]:O((+=H-"O+F:1 [QJ\:^4.X+,P!/L,YKFHO#>HVWA
MZ'3KC1;6_P 33R%A=^7)"S.2K(V..#S@@CWILGA[Q'Y>GI? ZQ#'9&.6%KTP
MKYY;(9N/G &%SUXSB@#=;QC92:=87-C;7-[+J 8VUO$H#MM^]N).% Z$DU5O
M_%=Y!JFF00:->&.Z\W>CJJR$IV7+8[9ST((P:S=-\.:YH>GZ#/!:075U8)/#
M/;><%RDC[LHQ&,C X.,YK1O[?7YY=&U8:7"UW:M-YMFER.%<87#D $\#/UH
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MI)Y]9A\3>);G2'LD2%())/M2.Q?$9.T $8SSR<_2@#OZBEN(H'C666-#(VQ
MS ;F]!ZFN47Q!JFL7-E::,MK:RRZ?'J$TUVC2JJR9"H%4KSP><]NE4;K5IM4
M_L,W4*175MKOV:81G*EE1^5[X((- '=3SQVT32S2)'&HRSNP4 >Y-/&" <YS
M7FGBG5M;U3P9X@O$CLETA4F@6,[Q,0IVE]V<=0?EQT[UH:EXPEM]4FTZTO-.
MM6LHD,AO58F9BN=JA2,<8YYZ]* .[(S2D9KBF\2ZQJ%[I-KI5M;1-J&GO=EK
MH,?)(*CD#!8?-C''459AU^]D\3OI<DMA;&%U4PS!A)<*5!WQGI@'<,8/3J*
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M** *MO\ \?5W_P!=%_\ 0%JU56W_ ./J[_ZZ+_Z M6J "BBB@ HHHH ****
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MCPR-5M-%TVULU%I;W<;2$,!Y<*@@@>N1Q75[0%"@<4BR*XRI!'J#0TJH5#,
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M]<GLQ)'Z$5NZA81:CIMS8REUBN(FB<H<':1@X/T-2V]O%:VT5O"NV*) B+Z
M# % 'DS-9GP0=)%O_P 58;K)C6,B?[1YN[S,XSMQSNZ8X]JZS1K& >/]>F:W
MCW+';E&V#@E3D@^_>NPV+G..?6EVB@#BO%0TRV\7Z#>:G#;K:LLZ233Q@J6V
MC:&)'UQFLN?1["^D\=W-Q9Q32!@(I"F2H%LA&WTY[CTKT@HK=1GOS2[%QC%
M'E3RDZ]:2ZM<Z=#;RZ/ +>34XB\1)'[P [E 8\=>2*[CPE!':^&;*"*^%[$B
MD).%*AEW'& 2>!T_"MMHD88901Z$4H0#I0!Y!:Z/I\G@C0KMK2,7,VKI')*
M0[JTK(RDCG!7C'2M+7=/&FR^+K72(/L\;:=:RF*W4@??=7( [[%[5Z:(T  "
MC Z#%&Q<DXY/!H \\T"&PEUR.[L-7T3 LGC-KIL10NF!M,@W'!7W'<BL6ST3
M3SX3\#RBV02WES%'<.,AI49&W(Q!R5(4#'3 KUQ8D7[J 9]!2^6F -HXZ>U
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M;W4D=S+>+&KJ<;1L&!C\Z -*BBB@ HHHH JV_P#Q]7?_ %T7_P! 6K55;?\
MX^KO_KHO_H"U:H **** "BBB@ HHHH 0TM(:6@ HHHH **** "BBB@ HHHH
M**** "BBB@!#2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5!=?ZI?^NB?^A"IS4-S_ *L9_P">B?\ H0H FHHHH **** "BBB@ HHH
MH **** *>E_\@V'\?YFK"C]^Y_V1_,U7TK_D&P_C_,U87_7-_NC^9H DHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTB_>0,,CZBI:\H\*W]UI.AW&JR6-C<7E[J#VMO)&")9)7E((=B/]6",_05U
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MV:3?8)4AWO/L5G(!<$X.-H(]:RE\="'3-5EN+>&>YTT1L_V*?S(Y%<@!@V.
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M:RH^X1[<8^\!\V>@Z5UUGH;HVNK<NIBU*<N-A.0AB5"#[_*:VTC6-0J@*HZ
M# %.H X6/PUKL^E:=H5Y):+I]E)&7N8F8R3HARJ[",*>!DY/3BK,WA*YD\8C
M4!/'_932I>26YSN-PB% ?3&,'KU%=C4<\\5M!)/,ZQQ1J6=V. H'4F@#A'\&
MR6^H:@1H6DZI%>7#3I-=MM:'=U4C:VX9Y&#WK2ETO6]-UN]NM(ALI+>^CB5A
M*[)]G=%V[@ #N7';BNJAF2XA26)@\;J&5E.0P/((I] '&Z -2T&/0O#I2"61
M8I9+UU)Q&F?E(/N3^AK1\1:7?7-]I6IZ<D4MSI\KMY,KE!(CJ58;L'!Z=JZ
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M".,RV]DZ2&6[@M#/(K<80#!VY]<'I3_ L$]OX>=+B*>)S=SL%GC"-@N2"5'
MSUXXKIJ* "BBB@ HHHH JV__ !]7?_71?_0%JU56W_X^KO\ ZZ+_ .@+5J@
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M_$UR-IIIMM!\:3?;KV3RI+J/;)+E7^3[S#'+>]>F06\=M!'!$H6.-0JJ.P'
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M<V\_VB&\,@,J/SR.-N,$C;C&.U2Z/X<MM&NKN[CN;JXN+O:9Y+B0,7*YP>@
MZ]!@<# % '*:*-1'C:\']I@0QVD<K1F#(*;W^4?-P>/O?I3X?$.O2:#_ ,).
M9[7[*VV0V(BZ0[ROW\YW8YZ8[5NV'A^&2^M]9BNKF"<Q>5*D>W9,H8D!LJ3W
M[$57C\#V*S"V^V7ITR.19TT\NOE!MQ;&<;RN>=I;'M0!I>(M4N=,T<36BHUU
M+-%;Q>9G:&D<("<=AG-9NHW^N:+;PP27UG=7-[<16]M(T!C$9.=Y90WS  9
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M9SGVKJ_&3M%X,U5T)#"V;!'7I7/R>$-;31Y= MKVQ721,9H69&,N#)YGEGL
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M** "BBB@ HHHH **** *MO\ \?5W_P!=%_\ 0%JU56W_ ./J[_ZZ+_Z M6J
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MNFP)86M'7R.,G>S   ?7GMFN0MM+9/AW9,;-DO9=6BE=A$1(";D?,>,\+^E
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MJULF<_\ 3,G^M '4DXHK@]4U?6+[5]9M["YOH/[."QP1VMLD@DE*;LN6!XY
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M#O"46-/L_&X9)8@9.<C/M5^7Q;J.C:9JB:F(+F\LKJ.VCEC0HLOF %6*C.,
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MW9LEM %\WS@3E>N.,$YSC%3VWB/SUOHFTZ[6^LMOFV@VLY#?=*D-M(//?L:
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MU)JA>>%M%U"[DN;JPBEED $A;.'P,#<.A([$UL44 1P01VT$<,2A(XU"(HZ
M#@"BXMX;JWDMYXTEAD4JZ.H(8'L0:DHH PH?!^A0VUQ;K8*T5PGER"1V?Y,Y
MV@L20N>PP*TI=-M)[B&>6%6DA1XXR1T5L;A^.T?E5NB@##M/".BV5Q!/!9X>
MW8M!NE=A%D$80$D*.>@X]JL2>'M,DTMM-:V!LVE,S1[FY?S/,SG.?O<UJ44
M>?W_ (0O9KS5!]AT^X:^G:6/4'F:.2W! "C:JY)7'7<,UT4OA73KP02W?GM=
MQPK"]S#<2022@#^(QL">><'/6M[ ]** *T5C!#8BR1,0!/+"Y/W<8QGK52U\
M/Z;9RV4D$!5K* V]N?,8[(SC(Y//0<GFM2B@"I8Z;:Z=]H^S1E#<3-/+EB=S
MMU/)X^@XK.?PGI3:BUZJ3QN\PG>..YD6)Y <AR@;:3D#MSWK<HH YZ;P5H\]
MS)*T<XCEE$TMLMPXAD<<Y,8.WZCH>^:TX=)M;?4;R^C5A/>)''*=QP0@8+@=
MOO&KU% &!-X0TR6PL;56NH18EOL\L,[)(F[AAN'KFM*UTNWL[JZN8]YDN=GF
MEF)SM7:/TJ[10!SJ^"M)693FZ-LDWGK9FX8P!]VX'9GL>0.@]*T[/2+:QU"_
MO8=_G7S(TV6R,J,# [<5?HH P[WPO:W>H27T5Y?64\P G-I.4$H' W#GG'<8
M/O2ZIX5TS6([%+Q9G^QD&-O-.6''#'^(' )SUQ6W10!CZIX<M]3O(KU;J[LK
MR)#&+BTD"L4)SM.001GGD4H\/6X;3GDN;J:2P=WC>63<SE@0=Q(YZ]L5KT&@
M#G_^$6L+NUU/SGF(U98S. P&PJ@52G'&, \YYK6TZS:PLH[=KJ>Z*#'FSD%S
M]< #]*GA_P!2F/[HI] &,]G?3>*X;OSC'86]NZ"-9#^]D<CDKTPH48/7YNW=
M?$?ANT\36$=I=O+&(Y!(KQ'# X((SZ$$@_6MBB@#SS6]!L[?XA:=J<8=99/+
M4H,!1A@,].N,#\*Z.?PI!-I5S9+=S1&:\-ZLRA2T<A?>,9&" ?6J/B+_ )&?
M2?\ KHG_ *&*ZX4V)&-::!Y&L0ZI/?SW-TEG]D9G55WC?NW$*  ?IQ56V\*6
M]K]CC6XE86U]+?*2!RS[LK]/G/Y"NCIO\8^AI#,#_A%8%T/4=*%U+Y=_-)*[
M[1N4N02!^5:U[I\=_IEQ83$^5<0M"^.NUEVG]#5H]OK2T <]9>%WM_[*-SJD
M]TVFNS0EHT7*F/RPIP.PYSU)I;[PE::@NIB2:5#?2QS;TP&B>, *RGURH-=!
M10!F:=8:C;3M+?:NUX"@18Q D:@_WN.23]<>@%:=%% !1110 4444 5;?_CZ
MN_\ KHO_ * M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%% "&EI#2T
M%%%% !1110 4444 %%%% !1110 4444 (:6BB@ HHHH **** "BBB@ HHHH
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M_H"U:JK;_P#'U=_]=%_] 6K5 !1110 4444 %%%% "&EI#2T %%%% !1110
M4444 %%%% !1110 4444 (:6D-+0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !4%U_JE_ZZ)_Z$*GJ"Z_U2_\ 71/_ $(4 3T444 %%%%
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M@+5JJMO_ ,?5W_UT7_T!:M4 %%%% !1110 4444 (:6FMUIU !1110 4444
M%%%% !1110 4444 %%%% "&EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *#10: &1?ZE/]T4^F0_ZB/_ '1_*GT %%%% '(^(?\ D9])_P!]/_0Q
M775R/B+_ )&?2?\ KHG_ *&*ZX4V)!3?XQ^-.IO\8_&D,4]OK2TA[?6EH **
M** "BBB@ HHHH **** *MO\ \?5W_P!=%_\ 0%JU56W_ ./J[_ZZ+_Z M6J
M"BBB@ HHHH **** &GK3J1J6@ HHHH **** "BBB@ HHHH **** "BBB@!#2
MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#<_ZM?\
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M "BBB@ HHHH **** "BBB@ -%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %0W R@'^VG_H0J:H;C[@_WT_]"% $U%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** &1?ZI/]T4^F1?ZE/]T4^@ HHHH Y37O\
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M@N=.N?*7.KWI_>)_#%_>'^Q110!+_9UUG_D,WO\ WS#_ /$4O]FW?_09O?\
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=EV[AG_69_I110!H177G2%=NW SUSZ5<%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit101-offerletterda005.jpg
<TEXT>
begin 644 exhibit101-offerletterda005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%8NA>)=/UV(_9Y,3*!OB;[R_XCW%;6:Y'%Q=F=<9*2N@HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** $-07?\ J1_UTC_]#%6#4%W_ *E?^NL?_H8H GHH
MHH **** "BBB@ HHHH **** *.D?\@N'\?YFK"?\?4G^XO\ -JKZ1_R"X?Q_
MF:L)_P ?4G^XO\S0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4&B@T 0VG_'
MG!_US7^535#:?\><'_7-?Y5-0 4444 <;XEX\4Z1_P!=$_\ 0Q795QWB7_D:
M-(]?,C_]&"NQIL2"F'_7+]#_ $I],/\ KE^A_I2&*W4?6G4U^WUIU !1110
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M?@1Z'\/1CPG <8_>/Q^-<+\03CQ;<D8XC3C\*[OX? ?\(K"1WD?^=<)\0/\
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M\T]$**** "BBB@ HHHH **** "BBB@ HHHH *@N_]2O_ %UC_P#0Q4]07?\
MJ5_ZZQ_^AB@">BBB@ HHHH **** "BBB@ H-%% %+2/^07#^/\S5A?\ CY?_
M '%_F:KZ1_R"X?Q_F:LK_P ?#_[J_P S0!)1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %!HHH AM,_8X,]?+7^535#:_P#'G#_US7^534 %%%% ''>)?^1GTC_K
MHG_HP5V(KCO$O_(SZ1_UT3_T8*[$=*;$@IA_UJ_0_P!*?3#_ *U?H?Z4ABOV
M^HIU-;J/K3J "BBB@ HHHH **** "BBB@"K;_P#'U=_]=%_] 6K55;?_ (^K
MO_KHO_H"U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO-1Z04444 %%%% !1110 4444 %%%% !1110 57O/]2O_76/_P!#%6*@NO\
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M** "BBB@!#2FD/:CG- 'FVNYC^*%DS 8)AQZXY'\Z]*%>;>/ ]CXGT[40N5
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M(9TVN>A'>KP-9\$<\]T)I4"*@^4=ZT *J@Y.+OWT".PM%%%= PHHHH ****
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M?]=$_P#0Q784V)!3/^6B_0_TI],_Y:#Z&D,5NH^M.IK=OK3J "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***#0!%:\6D/^XO\ *I:C@_X]X_\ ='\J
MDH **** ./\ $G_(SZ3_ -=$_P#0Q78#I7'^(_\ D9])_P"NB?\ H8KL*8D%
M,_Y:#Z&GTS_EH/H:0Q6ZCZTZFGJ/K3J "BBB@ HHHH **** "BBB@"K;_P#'
MU=_]=%_] 6K55;?_ (^KO_KHO_H"U:H **** "BBB@ HHHH #T- H/2@4 %%
M%% !1110 4444 %%%% !1110 4444 (:6D/:EH **** "BBB@ HHHH ****
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MG3-#>ZE;0RKC<C/\RYY!([#WZ5/>ZYINGP13W=[!%'+_ *IF?_6<9^7UX]*
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MK][.[9CGVZ]* -.BH6NH4<(TL:LS%5!8 D^E*\\<94/(BECA0QQD^@H EHI
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M75(;O4+ZR16$MFR+(2.#N4,,?@:NGI0!';?\>T7^X/Y5+45L<VT1]4'\JEH
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M3>R>=%%?--#H\6JR7(FCL7*^9YK!1YX;:5W$<[<GI[UZZ5&",5ST?@W3$C2
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MC[5%;F".0AB/ER3NP">_/2K>Y9K34I;N6&*_;0I+>WM(K26)G54)+?O ,D9
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M:39AK7Q%K@>XDU"SNKQ;7,K%$P#@!<X/)[@UUT?AC0H;Y[V+2;1+IW$C2K$
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M8'I1K%G!8:]H5I:QB." QI&@YVJ&  YKIY-"TV75AJKVY^VA0ID61EW  @9
M.#C)ZBFQ(X'P_;SZ;X4\,ZG!J-Z6FNHH6A:7,7ENQ4KMQCWSUSWJ]*^MZ@NN
MQ6-U-(UOJX7REEV.T 1"T:,?NDYZ_P LYKL8]"TR+3K6PCM0MK:.LD,>YOD9
M3D'.<GGUJM<^&=)N)),VS(9IS=.\4KHWF[0NX$$$';QQ2&,\-WT%YI.83> Q
M3-')'>G,L3@\JQR<]>.3P>M8*M>>!WMDBEAN] N[P1QQ])H&E?(P>CKDGW^M
M=98Z79:59BTLH!'#O+E=Q8DL<DDDDDGU-4+7P;H-G<030V)!MVWPHTTC)$WJ
MJ%BH/T% '*PW/B#5+2\U"Q-\]^EY*L&)T6U54D*[&0MD@A>21G)XK7M%NM>U
MG66GU2[LUL9U@ABMI0H3"ABS @ALEN_'%:LWA+19KJ:=K5U,\GF2I'/(D<C>
MK(&"D_4<T^_\+:/J5X]U<VK&610LNR9T$H'0.%(#8]Z ,31M/\OQ5X@E%[>'
MRI(V"F8E6W1YY'?';TXK/T._U#6K3P[8W.I7,2W%E+<SRQOMEF97"A=V.!AL
MG&#QUKL#H.GG6#JGD,MVR[79)74.,8&Y0<' )ZBH9/"FCO96=H+5DCLL_9C'
M,ZO%GKA@<\_6@#E)M4U2.TU2PCU*8FSU:WM8KO ,FQ]A*L<88C=CI]:Z#1_M
M-EXGO=,>^N+NW6VBN$-P0S*S%@>0!QP#CMVJ_#X<TJWL%LH[0" 3BXQO8EI
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MQJLVIZQKGF"X1(9HU2&<8,1V<C'3KZ<&LZ;P[?VK:)J>F:3:03:?+.7T^.8
M,DHP2'( WXP?S&:U?#5AJUOJ.KWNJPV\3WDJ/&D,F\*H7&"<#D4 7X==MIK_
M %*S6.82:>%,I(&#N7<-O//'TJ@/&5G)#IKP65].^HP&>"**,%B!C@\X'WNY
MQ[U0N],UZQUW6+G2[.WN8]3CCVR2S[!"ZKM.X8R1CD8_2LJ"TU?0[WPK:V]G
M#/=VVFRQSP&;:2H,>=K'C.<=>* .E3QGISZ=]J\JX$HN?LAM"@\[SO[F,XSW
MZXQSFE;Q?916^I275K=VLNGP?:)H)47>8\$[EPQ!Z$=>M8(\*ZQ\FM&. ZJN
MJ&_^R>8-FPIY>S=C&[;SGIG\Z=JGA[6==37;V>S2WGN-+:PL[8S*S'.22Y'R
MCDC&#0!O6'BRTOM1@LC9WML]S$9;9[B(*LRCKMY)Z'."!6AJ&IFP\L)87EV[
MYPMM&&QCU)( _$UF2:1=G4_#LRQCRK%'68EAE<Q[1]>:B\46&I7=WI[P17%S
M8QE_M%O;7/D.['&PDY&5'.1GO0!(_C33$L;6Z,5V?M%R]JL2PYD65=V4*COE
M2/RIR>,=-^Q:A<SI<6K:>5%S!-'B1"WW> 3G.>,&N?LO"^JQ0:.'M4C:WUF6
M\E03[PD;;L$,>6ZCWJ;5/#>J7&H>)KB&"-A=-8RVH=QB5H"&*GT!*XY]: +=
MMXBN+_QS8V2Q7MG ;.626WN8@I8Y7:V><\9Z'ZUM:EK]OIU]%8B"YNKN2,RB
M&W3<P0'!8Y(&,_C6+9PZQJ?C2QU>YTIK&S@M)8<23(S[F(/(4GCCC\>G%.\8
MV$U[)']GTJ]EN4B/V:^LKA8Y(9#GALL#LZ9ZCVH V[?7;2YUB32T$HNH[=+E
ME9, (Q('XY'2N:UCQ8AO= N+26=K*YN)HY(DBW/*T9P !@G[P[8I%LM>TGQ&
MFK/8G49+K3(K6;[.ZJ%G1B<G<1A#GJ,].E9<>EZYIMCX;NGTLS3V=U<R7,,4
MJ\"20XVDG!SG@?RH Z6Y\66=QHUQ=07,EE);W*6\RSVQ9XW8CY2F1USUZ<YJ
MY?\ BFQT^XN(&BNIVM4#W+6\!=85(S\Q'MS@9..:XG6K*]31M:U>_M3:MJ6H
MVACMF*ET1&506P2-QYX^E7;[P_);^(-7DNM,U?4+6_D$L;6%Z8P,J%9'7S$'
M;@\\?2@#J;SQ7I]K-;PQK<7DT\/GI%:1&5O*_OD#H/3U[533QE')X@ATZ.PO
M7AEMEF646[YRQ &1CA1GDGH>*SX["]\-ZY%>V.CS7-C+I\5KY,,BM);LA) )
M9AE?F.3D]*M/_:D/B>PU672)G6>Q%O,D#HQMW+J3N)(R!SR,]* -+Q!XA_L)
M;,_8[BX^T3K$?*C9MH)YZ \^@[TEQXKL8)8H!;WLUW)#Y_V:*V9I43U=?X?H
M>:9XJ@N9=/M);2U>ZDMKV&=HHR-S*K<XR0,X/K66C:GIOB.[UH:+=W%MJ5K"
M&CB,?G02(&^1@6 P0V<@GF@#IK#5;74].2_LW\V!U)! .>.H(Z@^U4T\4Z9)
MIEAJ"2.T%_*L-OB,EF<DC&.HZ'/IBJ_@_2KK2M#*7R".XGN);EX@VX1EV+;<
M^PQ7/:1I<@\=3Z=A?[/TN62^A"MT>8#:I'M^]/XB@#H9_&NDV\TJO]I\B&7R
M9;M;=S CYQ@R8P,$X)Z"M*/6+2:]NK1')EM8TDEP#@*P)&#WZ&N)>RUF#PM?
M>%H]'GEFGDECCO-R^1LD<MO9L[@0&/&.HJ\UOJ.A:[?&#2[J_2\LX8HI(F7:
MKH&4[RQ&!R#GF@"]:>+=+LM*TS>TSM?1-+;)%"SM(,C@ #.?F''UK:GU*UL[
M>:_N9/)MUA5V:08VCGJ/7VKC?#VDW\4W@V:2U<):6$T5PW&(V(4 '\C6UXTT
MFYUG0KNVM-QG4PRJBMM+['+8![$XXH MQ>+--DCNF*W43VT7GR0S6SI(8_[P
M4C)'TJ9/$NER-$$N5*R6OVSS/X5A_OL>@'U]#7-Z9;"VN+G4X]/\175U%9NB
MKJ$@8,20?+4$]21UQCCK659^%-5L]*U?2VMD+ZO9^:LD8PL$N23 3V4;N#TZ
MT =KI_BO2]2NX[6!YDDF0R0>= \8G08RR%@-PP0>.QI+7Q;I-Y=&""65AEU6
M;R'$3E02P5\;21@]^U<MHNDQW&HV#7$7B3[;;1.-UX_[BW9HRK '^('H-N>U
M:'A*XNK/1[+P]<:->07-K$899O+Q!\H.'#YYW>@YR3G% &^GB/3)-.L;\3_Z
M/?2+%;ML/SLW08QQT[UFP>,(;U]7@CCD@DLV=4EE@D*85 Q9OE&,9^[G)Q[U
MRUG#J)T7PUH;Z/?K/INH0M=2M%B-55CR&_B&#GCIWQ6R?M-O?>*[%["\+7V^
M>WE2$F-QY"KC=TSE<8H V5\46%KIVGRW5R)[B[A$D:6L#LTHP"65 "V.>_2I
MF\5:*FG0Z@U_$MI+(8DD((^< DJ1C(/RG@UR6E1WWA^YT?4KO3;N:W;1H[23
MR86EEMY%.<%1S@Y[ \BH(-'U)K>RNWL)D^U>)1??9W7YH82K#+ =/7\10!W>
ME:[8:R)OL4K,\)"RQNA1T)Z95@",]146I>)=+TJX6WNIV$Q3S/+CC:1E3NQ"
M@X'N:HZ=:S1>/-;N3 ZP36MJ%D*X5V7S,\]R,C]*H27$WA_Q=K-Y<Z;>7-O?
MQ0FWDM8&FY12I1MOW>3D$\<GF@!=>\7QQ76C0:=>((=1WR&Z6W:?"*I(V@=2
M2,>WI727&I6VEZ<MS?7 5 %!D*D;F/HO)R?2N(TK2-0M+[P>TMG,@2XO9I4V
MY%NLBL55B.!U ^M=3XKNK^STE9=/60OYR"5X8?->.,GYF5.Y_.@"]INLV6K)
M*;24LT3;)$9&1D/7!5@"*J:AXKT72KAX+R]5)(P#(%1GV ]-VT'&?>L'PDMR
M_BK6KMUU%[:>& Q37MOY1DQN!XVCTZ8SC'M6'JK2MJOB>.0W@TR>X1;N2ULQ
M, JQIGY]X*MCJ-I X/>@#N[KQ3H]E'$]Q>*GFQ><B[&+;/[Q &0/<TZ\\3Z/
M816\EU?PQI<)YD)SGS%X^[CKU' ]:XV:7['XEO=5-WJ,.GZG! UK<V=F)U=0
MN-C9C8J><@<9S5[3M-2UUCPJMM!=M:06=P%>YAPZ9VD;Q@;3UXXH Z9/$>DO
MI)U47\'V$'!F+8 .<8.>^>,=:2+Q+I,]A<7L=[%]GMSB9FRIC/\ M C(ZCM7
M!W6GWR6$]R+:[2*U\1R7+B.'<XB(($B(P.[!(/0YYQ4UY!9ZEH/B2^L[O4=1
MN)[:.*1YK3RU?:3@* B[B.<]: .O'C#0#;M<#4X#$LGD[@3\S]<+Q\W /3-1
M7WB6"33+.]TJXAN(YKZ&V9ADA=SA6!'!!'OTJKXDU&?1[?25MU^S6CR;)[F.
MV,IME"'!"@'&3QG!%<OIZS2VE]($NI!)XCM95>6W,;.I,9WE0!@'KTH ]+GO
MK:UDMXIY5C>X?RX@W\;8)P/? -1G5K$&\!N8A]B&;GYO]5QNY_#FLCQO:33>
M&I;BU5C=64L=U#L^]E&!./JNX?C7GTUAJJA9UAF'_"4AHY3@L8E:?>"P[?N7
M(]L#TH ]*N?%V@VCQI<:I;1M(BR ,_.T]&/H#ZFGWFMPV&H,+JYM(K-+4W#,
MSGS!\P&['39SU]:Y'Q/JDJ7>KZ-*7M(?LBK:QP61E:\RAR"V" !T[8]:ETBQ
M6_N],M;E)!%-X:\F3(P1ED!'UH [:34[.*:VADN8EDNL^0A;F3 R<>O%5;/Q
M)H^HWK6=GJ-M/<+DF..0$X!P<>N#7!Z=8ZIK-M=Q,)8[O2-,?3H&92H:=BP+
M XY^54Y']XU8\-RZ=>2Z!;2:I=_;;$#%D;+9Y;",JRLVS@<GOSQ0!VUMX@TF
M\O19VVHVLUR5+"*.4,V <'@>AXI-0\1Z1I,RPZAJ-K;2L-P224 X]?I[UD^
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MZD\R65[;W+0MMD$4H8H?0XZ5Y>;B7_A&+W0]-ELM2AATH-'=V2?O4C#*&CD
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MS/,*9R>Q^:D?Q+JUA=WMI?Z=#-=16)O;>.SD9M^#@QG(SG/<#GTH Z_ H8J
M68@ #DFN+_X3-K;PQ-K,YT^Z&Z..)+2<C#L<;'+#Y<9R3Z9XJ"3Q6U_!J^DS
M&QGD&F2W"36$_F1XP04/HPX/N* .[!5@"""#R".]5KAHWCPKABLJ @'.#N%8
M^E/-#X%LY;3R_.6Q1D#Y"Y"#KC-<9X6O)-*\*:+]FTJSDU+5Y%"3*VUI0K;F
M>9MN>/QZ]J /2+O2;"^NK:YNK9)9K8EH6;G8?7]*N8%<?=^,+O3++61?Z?$M
M]IL23;(IBT<T;' () (Y!X(K>TJXU.ZM&EU&T@MI6.8XXIC)\N/XC@<_3(H
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M;ZAJ-W<1%B+: R,<$Y)/"CMU(S0!URQ1IG:H7/7 Q2"&-?NH!]!BL!O$%OJ
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MS)<PW"E3)O?=UR,$?/Z<]^M._P"$*BDT[4H;F_GN+S47C>XNW10QV$%5"@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 5;?_CZN_\ KHO_ * M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%%
M"'H:4444 %%%% !1110 4444 %%%% !13#(H;;D;O3-/!R* "BBB@!#2TAI:
M "BBB@ HHHH **** "BBB@ HHI%;- "T444 %%-# L1W%.H **;O&<=_2G4
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M7^52T %%%% '(>)/^1GTC_KHG_H8KKQTKC_$G_(T:1_UT3_T,5V IL2"F?\
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M-MISW4-TS%MC(&8K@@*6< $=3GC!XK!\+))HOB&RM[N.UNI;ZW9(9K>_EN3
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M)K/!-]]KWQ[E! =$))R>."!C-6(O"]W/X)U?1YML4]U-.T1+;@ SEESC\,T
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M!D\V0IO7(]R,]Z] \'62V5O?B.^L;F*2X+B.Q7;% 2HRH&XXR?FQ[T ;=O\
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M&.E1RN&:Y%NDOD/=_9V\@/G;@OC'7C/3/>M/4=4MM*L7O+N7RX5P,@%B22
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MDH3S5'0,"#SVR,'WIMSX/T^2QL+:TEN; V&?L\MJ^'4'[P.0<@]\UT&X4N:
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M.>&$DTQM(BTQ/M&HDI%?12Z9Y;PH1\V9<+]W &3G<?7->K;A0,&@#F#X3/\
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M.I6WF2WML8+:1=1-P8%"ABNPHN%.!R"W0<UU^L:;=77B;P]>PQJT%G).9F+
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M+>YT^R9M,G6SN/$?VB.WEA(VPD'YF7^$$@GGUKU$]OK2T >>G1HI/$GC9C8
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M*>X$"Q"^!N@"VU9#'CH?3.<<^U4-7T:__P"$C\,_VGJ$-U-:3@EX[<QAU.%
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MT7_T!:M55M_^/J[_ .NB_P#H"U:H **** "BBB@ HHHH 0]*6D/2EH ****
M"BBB@ HHHH **** "BBB@ HHHH 0]J6D/:EH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J"Z_U2_]=$_]"%3U!=?ZI?\ KHG_ *$* )Z*
M** "BBB@ HHHH **** "BBB@"EI/_(,A_'^9JPO_ !\R?[B_S-5])_Y!D/X_
MS-6%_P"/F3_<7^9H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 AJ&YYC'_71/\ T(5/4%U_JE_ZZ)_Z$* )Z*** "BBB@ HHHH
M**** "BBB@"EI/\ R#(?Q_F:LK_Q\/\ [J_S-5M)_P"09#^/\S5E?^/A_P#=
M7^9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "@T4'I0!'!_Q[Q_[H_E4E16Y
MS;1'_8'\JEH **** .0\1G_BI])'_31/_0Q77CI7(>(_^1GTG_KHG_H8KKQT
MIL2"F_QCZ&G4W_EH/H:0Q3V^M+2'M]:6@ HHHH **** "BBB@ HHHH K6_\
MQ]7?_71?_0%JS56W_P"/J[_ZZ+_Z M6J "BBB@ HHHH **** $/2EI#T-+0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I#TI:#0!';_P#'M%_N#^524R$Y@C(_NBGT %%%% '(>),'Q/I'_71/
M_0Q77CI7(>(^/$VD?]=$_P#0Q77TV)!3/^6@^AI]-_C'T-(8I[?6EI#V^M+0
M 4444 %%%% !1110 4444 5;?_CZN_\ KHO_ * M6JJV_P#Q]7?_ %T7_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC"ZOQJ&GPW>EW5RMDUQ%<6A;8N#AE8$DYP>#GGTK8N_!L%Y+K+R74@.I2PS
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M0,0<CDG/'/\ ]:@"C%XUU&+PRNOZAIMI!:W"QBUC6Y)8LQQER5PJ]\Y/%7M
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M0 5!=?ZI?^NB?^A"IZAN?]6O_71/_0A0!-1110 4444 %%%% !1110 4444
M4M)_Y!D/X_S-65_X^'_W5_F:K:3_ ,@R'\?YFK*_Z]_]T?UH DHHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 AI:0TM !1110 4444 %%&:* "BBB@ HHHH **** "BBB@ HHHH
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MU*^OY]+E1X;.3RE0KT<*0H/()ZM0!U-QXMTFVOY+-I9GDB94F>*!W2)FZ!F
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M#P!B@#M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "H+K_5+_ -=$_P#0A4]077^K7_KHG_H0H GHHHH ****
M "BBB@ HHHH **** *6D_P#(-A_'^9JRO^O?_='\S5?2O^0;#^/\S5A?]>_^
MZ/YF@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *#10: (X/\ CWC_ -T?RJ2H
M[?\ X]HO]P?RJ2@ HHHH Y#Q'_R-&D_]=$_]#%=?7(>(_P#D9M)_ZZ)_Z&*Z
M^FQ(*;_&/H:=3?XQ]#2&#=OK3J:W;ZTZ@ HHHH **** "BBB@ HHHH JV_\
MQ]7?_71?_0%JU56W_P"/J[_ZZ+_Z M6J "BBB@ HHHH **** $/2EI#TI: "
MBBB@ HHHH **** "BBB@!",C%4%T+2DOC?+IUH+L\^<(5W_GC-:%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AJ&Z_P!4
MO_71/_0A4]0W7^J7_KHG_H0H FHHHH **** "BBB@ HHHH **** *6D_\@R'
M\?YFK*_\?#_[H_F:K:3_ ,@R'\?YFK*_\?#_ .ZO\S0!)1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)SGVI:* "BBB@ HH
MHH #TXIJ,S("R%"?X3C(_*G44 %%%% !1110 4&BD/2@".V_X]8O]P?RJ6HX
M.+>,?[(_E4E !1110!R'B/\ Y&;2?^NB?^ABNOKD/$7_ ",^D_\ 71/_ $,5
MU],2"FG_ %@^A_I3J9_RT'T-(8K=1]:=2-V^M+0 4444 %%%% !1110 4444
M 5;?_CZN_P#KHO\ Z M6JJV__'U=_P#71?\ T!:M4 %%%% !1110 4444 (>
ME+0>E% !1110 4444 %%%% !11574=0MM*L)KV[<I;PKOD<*3@?0<T 6J*R-
M,\3:7JUU]DMY9$N?+\T03PO"Y3^\%< D>]:] !1110 45R'B'51:^*(9',QM
M-%TVXU2Z2+DN2"D:X[\"8\]P*D\.>*M2UN:V:?18H[*[A,L5W:7RW*(1@[),
M*-K$'MD<$4 =717-^#Y9+^+5=7>1F2^U"4P GA88\1+@=@?++?\  JP(+=?&
MNN^(;K6+^[BT72+MK&&T@NGMT+(BM)+(R$%N6XYP * /0Z*\XTC7M*\/V'B*
M[T?Q+%KVF65F;R&P-[YTT!0'<OF$D[#\N,YP<UH'QWJ,=G9-/X=,-YJDNW3;
M9[U,RQ[-[22-C$8 ZCYCR!0!V]%<5_PL*.TLM5_M/3FAU+3C"#:6\XF%QYQV
MQ>6^!G<W'(&,<U8LO%FJCQ/8:%K'A\6,U[#+-'-%>":/"!<KG:#N^89'0<8)
MSP =;16#XSUJ30/"E]>VXW7A40VB=WG<A(Q_WT1^ -8G@)[S1K[4_".IWTUY
M<V0CNK:XG<L\T$@YY/)VR!Q^(H [FBN1C\=))X%TWQ-_9[!;V6&(6_F\IYDH
MCSNQSC.>E5;SQUJBW6NQZ;X:-W#HLI6YE>]6+>HC5_D&TY;!/!P.G/.  =Q1
M7+W'BF_N8=/DT+1&O8[RS6]^T74_V>&-& *J7VMESG[H' YS68OQ',NBZ9=V
M^B2S7E[J4FF&T2X7]W,@?.'QAERG7C@Y[8H [NBN=\.^)+K5=3U/2M2TP:?J
M.GB)W1+@31ND@)5E;"_W6!!':NBH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ****  U!=?ZI?\ KHG_ *$*GJ"Z
M_P!4O_71/_0A0!/1110 4444 %%%% !1110 4444 4M)_P"09#^/\S5E?^/A
M_P#=7^9JMI7_ "#8?Q_F:LK_ ,?#_P"ZO\S0!)1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4456MM1L;R66*UO;>>2$XD2*56*'W
M /% %FBJO]I6)O\ [#]MMOMF,_9_-7S,>NW.:F>XACFBA>:-99<^6C, SXY.
M!WQ0!)152UU33[Z:2&TOK:XEB_UB13*[)]0#Q2_VE8?;_L'VVV^V8S]G\U?,
MQ_NYS0!:HJ-[B".>*!YHUEESY<;, SXZX'?%06NJ:??2R16E];7$D7^L2*97
M*?4 \4 6Z*K?VC8_;_L/VVW^V8W?9_-7S,>NW.:;=ZII]A)''>7UM;O+Q&LT
MRH7^@)YH MT57N[ZTT^#S[VZ@MHLX\R:0(N?3)J:.1)8UDC=71AE64Y!'J#0
M ZBBB@ I#TI:0T ,M_\ CVBQ_<'\JDJ. 8MXAZ(/Y5)0 4444 <AXC'_ !4^
MD_\ 71/_ $,5U_:N0\1?\C1I/^^G_H8KKQTIL2"F_P#+0?0TZFG_ %@^AI#%
M;M]:6D;M]:6@ HHHH **** "BBB@ HHHH JV_P#Q]7?_ %T7_P! 6K55;?\
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MK6U]M\18_P"0+8_^#%O_ (U3?M_B/_H!V/\ X,C_ /&J .4F\$Z]JT/B&_U
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M#UT?]N#4O_"61_\ 0%US_P  'H Z"BN?_P"$LB[Z-K@_[<'II\6P#KI&M_\
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M>PQ\MDS/O$*]BH# @C@YJ*[TCQ!-/8:C;S:A#K%M UO+=-';M'<1D[L-%Y@
M((!!!'?K6SX1T=]&M+M9X[MKNZN#<W-U<F/=/*PP2 A(4 * !V&.O- '1444
M4 %%%(>E $=OD6T6>NP9_*I:CMSFVB/J@_E4E !1110!R'B(_P#%4:5_OI_Z
M&*Z\5R/B+_D9])_ZZ)_Z&*ZZFQ(*:?\ 6#Z'^E.IO_+0?0_TI#%;M]:6D;M]
M:6@ HHHH **** "BBB@ HHHH JV__'U=_P#71?\ T!:M55M_^/J[_P"NB_\
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M0 4444 %%%% !1110 AZ4M(W2EH **** "BBB@ HHHH **** "BBB@ HHHH
M0TM(:P_$NL7.F0VEO811R:A?3B"W$I(13@DLV.< #M0!NT5@V-MXBMKV%KO4
M[.\M6!\X?9S$R''&P@D'GUIEKXTT2[>?RIY?*MT=YIVA81Q[?O MC&>^/>@#
MH:*P].\6:5JD[0Q23PR"+SU6YMWAWQ?WUW 96H;'QMHVH7T%I;F]+W W0LUE
M*J2+_>#%<;??I0!T5%9/B/5CH^ASW<05[CB.!&Z/(QVJ/S(JEI'B56\-3ZAJ
MS)%-8-)'?>4I*HR$@D#DX(P1]: .CHK/;6K!9K"$S$/?J6MAL/S@+N/TX]:S
M;?QSX?N;N*VBO6+RR>4K&%PF_. I;& Q]"<T =%16)>>+='L+]K.XGE5T94>
M06\C1HQZ!G"[0?J:-3\7:)I%V]K>WA2X1%=HTA=R%.<'Y0>.#D]N_44 ;=%1
M6US#>6T5S;R+)#*H='4\,IY!%2T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!=?ZI?\ KHG_ *$*
MGJ"Z_P!6O_71/_0A0!/1110 4444 %%%% !1110 4444 4]*_P"0;#^/\S4Z
M_P#'P_\ NK_,U!I7_(-A_'^9JPO^O?\ W1_,T 24444 %%%% !1110 4444
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M ):#Z&G4W^,?0TABMV^M+2-V^M+0 4444 %%%% !1110 4444 5;?_CZN_\
MKHO_ * M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%% "&EI":6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HI#2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5!=?ZI?^NB?^A"IC4-U_JE_P"NB?\ H0H GHHH
MH **** "BBB@ HHHH **** *>E?\@V+\?YFK"_\ 'P_^ZO\ ,U7TK_D&P_C_
M #-6%_U[_P"Z/YF@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6D/2@!EO
MS;1?[@_E4E1V_%M%_N#^524 %%%% '(>(_\ D9])_P"NB?\ H8KKQTKD?$?_
M ",VD?\ 71/_ $,5UU-B04W_ ):#Z'^E.IO\8^AI#%;M]:6D;M]:6@ HHHH
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M_P!=%_\ 0%JS0 4444 %%%% !1110 AI:0]*6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HI#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5!=?ZM3_ --$_P#0A4]077^J7_KHG_H0H GHHHH **** "BBB@ HHHH
M**** *6D_P#(,A_'^9JRO^O?_='\S5;2?^09#^/\S5E?]>_^Z/YF@"2BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#4-S_JU_P"NB?\
MH0J8U#=<1K_UT3_T(4 3T444 %%%% !1110 4444 %!Z444 4]*_Y!L/X_S-
M6%_U[_[H_F:KZ5_R#8?Q_F:L+_KW_P!T?S- $E%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4'I10: (X/\ CWC_ -P?RJ2HX/\ CWCQTVC^524 %%%% '(^(O\
MD9])_P"NB?\ H8KKJY#Q%G_A)M)_ZZ)_Z&*Z\4V)!3?XQ^-.IO\ &/H:0Q3V
M^M+2-V^M+0 4444 %%%% !1110 4444 5;?_ (^KO_KHO_H"U:JK;_\ 'U=_
M]=%_] 6K5 !1110 4444 %%%% "&EI#2T %%%% !1110 4444 %%%% !1110
M 4444 (:6@T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MAJ&Z_P!4O_71/_0A4]077^J7_KHG_H0H GHHHH **** "BBB@ HHHH ****
M*>E?\@V'\?YFK"G_ $AQ_LK_ #-5]*_Y!L/X_P S5A?^/A_]U?YF@"2BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5!=?ZI?^NB?^A"IZAN?]6/\ KHG_ *$* )J*** "BBB@
M HHHH **** "BBB@"GI7_(-A_'^9JPO_ !\/_NK_ #-5]*_Y!L/X_P S5A?]
M>X_V5_F: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAZ4 ,MSFVB)_N#^
M525' <V\9_V1_*I* "BBB@#D/$?_ ",^D?\ 71/_ $,5U]<AXB/_ !5&D_\
M71/_ $,5U]-B04W^,?0TZF_\M!]#2&*>WUI::W4?6G4 %%%% !1110 4444
M%%%% %6W_P"/J[_ZZ+_Z M6JJV__ !]7?_71?_0%JU0 4444 %%%% !1110
MAI:0TM !1110 4444 %%%% !1110 4444 %%%%  :*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%U_JE_ZZ)_
MZ$*G-070_=+_ -=$_P#0A0!/1110 4444 %%%% !1110 4444 4M)_Y!D/X_
MS-65_P!>X_V5_F:KZ5_R#8?Q_F:L+_KW_P!T?S- $E%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4&BD- #81B%!Z**?3(3F",YSE13Z "BBB@#D/$7_ ",^DC_I
MHG_H8KKQTKD/$7_(SZ3_ -=$_P#0Q77BFQ(*;_&/H:=3?XQ]#2&*>WUI:0]O
MK2T %%%% !1110 4444 %%%% %6W_P"/J[_ZZ+_Z M6JJV__ !]7?_71?_0%
MJU0 4444 %%%% !1110 C=*6D/2EH **** "BBB@ HHHH **** "BBB@ HHH
MH 0]J6@T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AJ&
MY_U:_P#71/\ T(5,:ANO]6O_ %T3_P!"% $]%%% !1110 4444 %%%% !111
M0!2TK_D&PCZ_S-65_P!>W^Z/YFJVE?\ (.A_'^9JRO\ Q\/_ +J_S- $E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#'U=_]=%_] 6K55;?_ (^KO_KHO_H"U:H **** "BBB@ HHHH 0TM(:6@
MHHHH **** "BBB@ HHHH **** "BBB@!#2TAI: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *@NO\ 5+_UT3_T(5/4%U_JE_ZZ)_Z$* )Z
M*** "BBB@ HHHH **** "BBB@"GI7_(-A_'^9JPO^O;_ '1_,U7TK_D&Q?C_
M #-6%_X^'_W5_F: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "H+K_5+_P!=$_\ 0A4QJ&Z_
MU2_]=$_]"% $]%%% !1110 4444 %%%% !1110!3TK_D&P_C_,U87_CX?_=7
M^9JOI7_(-A_'^9J=?^/E_P#=7^9H EHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"@T4AH CMO\ CVB_W!_*I:BMO^/6+_<'\JEH **** .0\1\>)])_ZZ)_Z&*Z
M^N0\2?\ (S:1_P!=$_\ 0Q77]J;$@IO\8^AIU-_C'XTABGM]:6FMV^M.H **
M** "BBB@ HHHH **** *MO\ \?5W_P!=%_\ 0%JU56W_ ./J[_ZZ+_Z M6J
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M6FMV^M.H **** "BBB@ HHHH **** *MO_Q]7?\ UT7_ - 6K55K?_CZN_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "@T4&@".'_41_P"Z*DID)S"A'=13Z "BBB@#D?$?_(S:
M3_UT3_T,5UPZ5R'B/_D9])_ZZ)_Z&*Z^FQ(*;_&/H:=3?XQ]#2&#=OK3J:W4
M?6G4 %%%% !1110 4444 %%%% %6W_X^KO\ ZZ+_ .@+5JJMO_Q]7?\ UT7_
M - 6K5 !1110 4444 %%%% "'I2TAI: "BBB@ HHHH **** "BBB@ HHHH *
M***  T4AI: "D%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (
M:BN?]6O_ %T3_P!"%2FHKGB,?]=$_P#0A0!-1110 4444 %%%% !1110 4'I
M110!3TK_ )!L/X_S-6%_X^'_ -T?S-5]*_Y!D/X_S-6%_P!>W^Z/YF@"2BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0TM(: &PG,$9_P!D4^HX/^/>/_='\JDH
M **** .1\1<>)])_ZZ)_Z&*ZX=*Y#Q'SXFTC_KHG_H8KKZ;$@IO_ "T'T-.I
MO\8_&D,&[?6G4UNWUIU !1110 4444 %%%% !1110!5M_P#CZN_^NB_^@+5J
MJMO_ ,?5W_UT7_T!:M4 %%%% !1110 4444 (:6D-+0 4444 %%%% !1110
M4444 %%%% !1110 AI:0TM !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %077^J7_KHG_H0J<U!=?ZI?^NB?^A"@">BBB@ HHHH **** "B
MBB@ HHHH I:5_P @V'\?YFK*_P#'P_\ NK_,U6TK_D&P_C_,U97_ (^'_P!U
M?YF@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(>E #8?]1'_NBGU';_\
M'O%_NC^524 %%%% '(^(P/\ A)M)/_31/_0Q775R'B+_ )&?2?\ KHG_ *&*
MZ^FQ(*;_ ,M!]#3J;_RT'T/]*0Q6[?6EI&[?6EH **** "BBB@ HHHH ****
M *MO_P ?5W_UT7_T!:M55M_^/J[_ .NB_P#H"U:H **** "BBB@ HHHH 0TM
M(:6@ HHHH **** "BBB@ HHHH **** "BBB@!#2TA[4M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA4YJ&Z_U2_\ 71/_ $(4 34444 %%%% !1110 4444 %%%% %+2?^09#^/\
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MHHH **** $-+110 444@H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J"Z_U2_]=$_]"%3U#=?ZI?\ KHG_ *$* )J*** "BBB@ HHHH **** "
MBBB@"GI7_(-A_'^9JPO_ !\/_NK_ #-5]*_Y!L/X_P S5A3^_8?[(_F: )**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ H-%(>E #(/^/>/_ '1_*I*CM^+:(?[
M_E4E !1110!R/B,_\5/I/_71/_0Q77#I7(>(_P#D9])_ZZ)_Z&*Z^FQ(*;_&
M/H:=3?XQ]#2&*W;ZTM-8=/K3J "BBB@ HHHH **** "BBB@"K;_\?5W_ -=%
M_P#0%JU56W_X^KO_ *Z+_P"@+5J@ HHHH **** "BBB@!#2TAI: "BBB@ HH
MHH **** "BBB@ HHHH **** $-+2&EH *04M(* %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *@NO]4O_71/_0A4YJ"Z_P!4O_71/_0A0!/1110
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M%%% !1110 4444 %%%% !1110 4444 (:6D-+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%%  :AN?\ 5K_UT3_T(5-4%U_JE_ZZ)_Z$* )Z
M*** "BBB@ HHHH **** "BBB@"GI7_(-A_'^9JPO^O?_ '5_F:KZ5_R#8?Q_
MF:G7/VA_38O\S0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!HI#TH ;",01C
M_9%/J.W.ZVB)ZE!_*I* "BBB@#D?$?'B?2?^NB?^ABNN'2N0\1G_ (J?2/\
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MHHH I:5_R#8?Q_F:M#_7-_NC^M5M*_Y!L/X_S-6%_P"/A_\ =7^9H DHHHH
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M_P C/I/^^G_H8KKA38D%-_C'T-.IO_+0?0TABGM]:6D/;ZTM !1110 4444
M%%%% !1110!5M_\ CZN_^NB_^@+5JJMO_P ?5W_UT7_T!:M4 %%%% !1110
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M%(>U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%U_JE
M_P"NB?\ H0J8U%<_ZM?^NB?^A"@":BBB@ HHHH **** "BBB@ HHHH IZ5_R
M#8?Q_F:L ?OF_P!T?UJMI7_(-A_'^9JRO_'P_P#NK_,T 24444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0:*0]* &P\PQ_[HI]1V_P#Q[1?[@_E4E !1110!R/B,
MG_A)M)_ZZ)_Z&*ZZN1\1?\C/I/\ UT3_ -#%=<.E-B04W^,?0TZF_P 8_&D,
M4]OK2TA[?6EH **** "BBB@ HHHH **** *MO_Q]7?\ UT7_ - 6K55;?_CZ
MN_\ KHO_ * M6J "BBB@ HHHH **** $-+2&EH **** "BBB@ HHHH ****
M"BBB@ HHHH 0TM(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "B@T4 % HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "H;G_5K_ -=$_P#0A4U0W/\ JU_ZZ)_Z$* )J*** "BBB@ HHHH ****
M "BBB@"EI7_(.A_'^9JRO^O;_='\S5;2?^09#^/\S5E?]>_^Z/YF@"2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *#THI#0 RW_ ./:+']P?RJ2HX?]1'_NBI*
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M1110 4444 %%%% !1110 4444 %%%% "&EI#2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5!=#]TO_71/_0A4]0W7^J7_KHG_H0H FHH
MHH **** "BBB@ HHHH ***#0!3TH8TV'\?YFK"_Z]O\ ='\S5?2O^0;#^/\
M,U87_7M_NC^9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/2EHH CM\_9HL
M]=@_E4E,BXA3_=%/H **** .1\1<^)M(]I$_]#%==7(^(O\ D9M)_P"NB?\
MH8KKATIL2"F_\M!]#_2G4W^,?0TABMV^M+2-V^M+0 4444 %%%% !1110 44
M44 5;?\ X^KO_KHO_H"U:JK;_P#'U=_]=%_] 6K5 !1110 4444 %%%% "&E
MI#2T %%%% !1110 4444 %%%% !1110 4444 (W:EI#2T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5!=?ZI?^NB?^A"IZAN>8A_UT3_T
M(4 34444 %%%% !1110 4444 %!HHH IZ5QIL/X_S-6%_P!>W^Z/YFJ^E?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-S_JU_ZZ)_Z$*FJ&
MZ_U2_P#71/\ T(4 34444 %%%% !1110 4444 %%%% %/2O^0;#^/\S5A?\
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M_D&0_C_,U97_ (^'_P!U?YFJVD_\@R'\?YFK*_Z]_P#=7^9H DHHHH ****
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M %%%% !1110 4444 !J"Z_U:_P#71/\ T(5.:ANO]4O_ %T3_P!"% $U%%%
M!1110 4444 %%%% !1110!2TG_D&0_C_ #-6%_X^9/\ <7^9JOI/_(-A_'^9
MJRO_ !\/_NK_ #- $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&B@T ,AY@C_
M -T4^HX/^/>//]T5)0 4444 <CXB_P"1FTK_ *Z)_P"ABNNKD?$7'B?2O]]/
M_0Q774V)!3/^6@^AI]-_Y:#Z'^E(8K=OK2TA[?6EH **** "BBB@ HHHH **
M** *MO\ \?5W_P!=%_\ 0%JU56W_ ./J[_ZZ+_Z M6J "BBB@ HHHH ****
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M[@B$$@]>>AX'/%;#D!23T'-<3H>ER>(-/U/4'N9(+;5[ARP11YC0K\BKN.<
M@'H,\\$4 =G!<PW5O'<02"2*50Z..C C(-29%<-J6LV]E#JT*3/:V6C0+##!
M"Q5Y)?+W#H<D %0!WYSTJ."\U&.;3[&_N;J\9M,$X6S?#S3$_,68$$ 9 '(!
MYZXX .QTH@:;#^/\S5A3_I#_ .ZO\S7!:=?:E;KINC32SS7!LVO+IO.122#M
MV!N,)G))&3^==1H"2VVE1F]U!+MQ'O>X#94C<QX;N .,GTH GFUZUAU-=/\
M)O9)BRJ6BM)'C0G&-S@;1P0>36D2!UKE!9"T\;VLVE7+M%>1R3:A"9C(A&!L
M< D[3NX&, C/I6AK=]=+JFEZ7:/Y37C2/)-@$I'& 2%!X).0/;)- &TSJJEB
M0 !DD]JHV&KP:B^((KCRS&)$F>(JDBDD @GZ9QUP0>]<3J5]=ZKINJ:;:75Q
MY,VHI86L@8$MT\X;L9*@!^>O!&:Z3Q)=3Z+X2E^P9,X6.VA8X^5G98PQP,<;
ML].U &HNKV<FH-8Q2&6X3_6"-2PC_P!X] ?;K5X'(S7'>';>71/$3^'[>Y>Y
MLHK%9Y/,5=T4K.1RP )W ,><GCK78B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@".V_P"/
M:+_<'\JEJ.#_ %$>/[HJ2@ HHHH Y'Q$/^*GTG_?3_T,5UU<CXC_ .1FTGC_
M ):)_P"ABNN%,2"F_P 8_&G4W_EH/H:0Q3VI:0]OK2T %%%% !1110 4444
M%%%% %6W_P"/J[_ZZ+_Z M6JJV__ !]7?_71?_0%JU0 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-R/W:_\ 71/_ $(5
M-44_W%_WT_\ 0A0!+1110 4444 %%%% !1110 4444 4]+_Y!L/X_P S5A?]
M>_\ NC^9JOI?_(-A_'^9JPO^N;_='\S0!)1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %!HHH 9#_J(_]T4^FQ_ZI/\ =%.H **** .1\0?\C1I?KO3_ -#%=<.E
M<EK_ /R,^E_[Z?\ H8KK:;$@IO\ &/H:=3?XQ]#2&*>U+2'M]:6@ HHHH **
M** "BBB@ HHHH JV_P#Q]7?_ %T7_P! 6K55;?\ X^KO_KHO_H"U:H ****
M"BBB@ HHHH 0TM(U+0 F:6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*?[@_P!]?_0A
M4M0W'W!_OI_Z$* )J*** "BBB@ HHHH **** "BBB@"GI?\ R#H?Q_F:LC_6
MM_NC^M5],_Y!T7X_S-6!_K6_W1_6@!]%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4&B@T ,AYA3_=%/ID/^IC_W13Z "BBB@#DM>'_%3Z8?]I/_ $,5UM<IKO\
MR,NF_P"\G_H8KJZ;$@IO\8^AIU-_C'XTABGM]:6D-+0 4444 %%%% !1110
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M0 4444 %%%!Z4 5-,_Y!T7X_S-6!_K6_W1_6JVE'.FPGZ_S-6%.9W'HH_F:
M)**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!"\_[Z7_  I?[/E'34;O\T_^)HHH 7[%-CC4;K\D_P#B:3[%/_T$KO\ */\
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+[#&,"IA110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit101-offerletterda006.jpg
<TEXT>
begin 644 exhibit101-offerletterda006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M-5;?_CZN_P#KHO\ Z M6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,K#H0>]>.^.,_P#"5W7&/N^GI71?#[Q&&']CW+X?K;EO3NO^%<[XWX\5WA'
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MO_KHO_H"U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:,!;@ 'YESP?P[^WTKS9000??T[U[%&<:J4^IYM2#IOEZ'KGP\'_ !3/&?\
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M%$@2-%"JHZ #M6E>K&,?90(I4Y.7/(DQ2T45PG6%%%% !1110 4444 %%%%
M!1110 4444 %077^K7_KHG_H0J>H+K_5+_UT3_T(4 3T444 %%%% !1110 4
M444 %!HHH I:3_R#(?Q_F:LK_P ?#_[J_P S5;2?^09#^/\ ,U97_CX?_<7^
M9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D/2EI#0!';_\ 'M%_N#^52U'!
MC[/'CIM&/RJ2@ HHHH Y#Q)_R,VD?]=$_P#0Q77UQ_B3_D9M(_ZZ)_Z&*[ =
M*8D%,/\ K5^A_I3Z9_RT'T-(8YNWUI:1NWUI: "BBB@ HHHH **** "BBB@"
MM;_\?5W_ -=%_P#0%JS56W_X^KO_ *Z+_P"@+5J@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0]J4TAI: ,CQ)IO]J:#=VRKND*
M;D'JR\C]1BN3^'NKB(S:3<':Q8O$#US_ !#],_G7H1Z5Y3XPTJ;0M=35;0E8
MIG\P,!]R3N./7K^==%&THNF^NQC5O%J:/1=5N?+MO+7[TG'T'>DTB );&3:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "@T4AH CMN;6(_[ _E4M16W_'K#_N#^52T %%%% '(>)/\ D9](_P"N
MB?\ H8KKQTKC_$G_ ",^D'_IHG_H8KL!TIL2"F?\M%^A_I3Z9_RT7Z'^E(8Y
MNWUI:1NWUI: "BBB@ HHHH **** "BBB@"K;_P#'U=_]=%_] 6K55;?_ (^K
MO_KHO_H"U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI?\ KHG_ *$*GJ"Z_P!4O_71/_0A0!/1110 4444 %%%% !1110 4'I10>E
M%+2?^09#^/\ ,U97_CX?_=7^9JMI'_(,A_'^9JPO_'R_^XO\S0!+1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %!HH- $5M_QZP_[@_E4M16_P#Q[1<8^0?RJ6@
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M44 %%%% !1110 AJ&Z_U2_\ 71/_ $(5,:ANO]4O_71/_0A0!/1110 4444
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!=?ZI?\
MKHG_ *$*GJ"Z_P!4O_71/_0A0!/1110 4444 %%%% !1110 4&B@T 4M(_Y!
MD/X_S-6$'^DR?[B_S-5](_Y!D/X_S-65_P"/A_\ <7^9H DHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "D/2EHH BMO^/6+_<'\JEJ*U_X](?\ <7^52T %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !110: (K7_CTA_W%_E4M16O_'I#_N+_ "J6@ HH
MHH X_P 2?\C-I'_71/\ T,5V Z5Q_B0_\5/I'_71/_0Q784V)!3/^6J_0_TI
M],_Y:#Z&D,<>H^M+36ZCZTZ@ HHHH **** "BBB@ HHHH K6_P#Q]7?_ %T7
M_P! 6K-5;?\ X^KO_KHO_H"U:H **** "BBB@ HHHH 0]*6D/2EH **** "B
MBB@ HHHH **** "BBB@ HHHH 0]J6D-+0 4444 %%%% !1110 4444 %%%%
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MHH **** $/2EH/2B@ HHHH **** "BBB@ HHHH **** "BBB@!#VI:0]J6@
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MS56W_P"/J[_ZZ+_Z M6J "BBB@ HHHH **** $-+0:* "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 4444 %%%% !4%U_JE_ZZ)_Z$*GJ"Z_U2_\
M71/_ $(4 3T444 %%%% !1110 4444 %%%!Z4 4M)_Y!</X_S-6%_P"/E_\
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M HHHH *@NO\ 5+_UT3_T(5/4%U_JE_ZZ)_Z$* )Z*** "BBB@ HHHH ****
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MJOI/_(,A_'^9JPO_ !\R?[B_S- $M%%% !1110 4444 %%%% !1110 4444
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MBMV^M.IK=1]:=0 4444 %%%% !1110 4444 5K?_ (^KO_KHO_H"U9JK;_\
M'U=_]=%_] 6K5 !1110 4444 %%%% !10>E% !1110 4444 %%%% !1110 4
M444 %%%% "&EI#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 &H+K_5+_ -=$_P#0A4]077^J7_KHG_H0H GHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !4%U_JE_ZZ)_Z$*GJ"Z_U2_]=$_]
M"% $]%%% !1110 4444 %%%% !1110!2TG_D&0_C_,U87_CX?_=7^9JOI/\
MR#(?Q_F:LK_Q\/\ [J_S- $E%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&BB@"
M*V&+2$?["_RJ6HK7_CTA_P!Q?Y5+0 4444 <?XD_Y&?2!_TT3_T,5V%<AXD'
M_%3Z1G_GHG_H8KKQTIL2"F_\M!]#3J9_RT'T/]*0Q6ZCZTZFMV^M.H ****
M"BBB@ HHHH **** *MO_ ,?5W_UT7_T!:M55M_\ CZN_^NB_^@+5J@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\C1I'_71/_0Q78#I38D%,_Y:#Z'^E/IG_+0?0_TI#''M]:6D/;ZTM !1110
M4444 %%%% !1110!5M_^/J[_ .NB_P#H"U:JK;_\?5W_ -=%_P#0%JU0 444
M4 %%%% !1110 AZ4M!Z44 %%%% !1110 4444 %%%% !1110 4444 (:6D-+
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :ANO]4O_71/
M_0A4U077^J7_ *Z)_P"A"@">BBB@ HHHH **** "BBB@ H/2BB@"EI/_ "#(
M?Q_F:L+_ ,?#_P"ZO\S5?2?^09#^/\S5A<_:I/38O\S0!+1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH *#110!2TC_D&0_C_ #-6%_X^'_W5_F:KZ1_R#(?Q_F:LK_Q\.?\
M97^9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBD- $=M_QZP_[@_E4M16W
M_'K#C^X/Y5+0 4444 <AXD_Y&;2!_P!-$_\ 0Q77UR'B3_D9M('?S$_]#%=?
M38D%,_Y:#Z&GTS_EH/H?Z4ABMV^M.I#V^M+0 4444 %%%% !1110 4444 5;
M?_CZN_\ KHO_ * M6JJV_P#Q]7?_ %T7_P! 6K5 !1110 4444 %%%% "'I2
MTAI: "BBB@ HHHH **** "BBB@ HHHH **** "BD-+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%%  :@NO]6O\ UT3_ -"%3U!<\1@_]-$_
M]"% $]%%% !1110 4444 %%%% !1110!2TG_ )!D/X_S-65_X^'_ -U?YFJ^
ME?\ (-A_'^9JPO\ KV_W1_,T 24444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'I
M2T4 16PQ:Q =-@_E4M16O_'I#_N+_*I: "BBB@#C_$G_ ",^D?\ 71/_ $,5
MV%<AXD_Y&;2/^NB?^ABNO'2FQ(*;_P M%^AIU-_Y:#Z'^E(8'J/K3J1NWUI:
M "BBB@ HHHH **** "BBB@"K;_\ 'U=_]=%_] 6K55;?_CZN_P#KHO\ Z M6
MJ "BBB@ HHHH **** $/2EI#TI: "BBB@ HHHH **** "BBB@ HHHH ****
M$-+2&EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"Z_U
M2_\ 71/_ $(5/4%U_JE_ZZ)_Z$* )Z*** "BBB@ HHHH **** "BBB@"EI/_
M "#(?Q_F:LK_ *]_]U?YFJVD_P#(,A_'^9JRO_'P_P#NK_,T 24444 %%%%
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M44 %%%% !1110 4444 (:6D/:EH **** "BBB@ HHHH **** "BBB@ HHHH
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MXO\ ,U7TG_D&0_C_ #-65_U[_P"Z/YF@"2BBB@ HHHH **** "BBB@ HHHH
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M+2'M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAIU-_C'XTABGM]:6D/;ZTM !1110 4444 %%%% !1110!5M_^/J[_P"NB_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+K_5+_P!=$_\
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M*I* "BBB@#D/$G_(S:1_UT3_ -#%=>.E<AXCQ_PD^D?]=$_]#%=>*;$@IO\
MRT'T/]*=3?\ EH/H:0Q3V^M+2-V^M+0 4444 %%%% !1110 4444 5;?_CZN
M_P#KHO\ Z M6JJV__'U=_P#71?\ T!:M4 %%%% !1110 4444 (:6D/2EH *
M*** "BBB@ HHHH **** "BBB@ HHHH 0TM(>U+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&Z_U2_\
M71/_ $(5-4%U_JE_ZZ)_Z$* )Z*** "BBB@ HHHH **** "BBB@"EI/_ "#(
M?Q_F:LK_ ,?#_P"ZO\S5;2?^09#^/\S5E?\ 7M_NC^9H DHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "@]**#0!';_\>T7^X/Y5)4< Q!&/]D?RJ2@ HHHH Y#Q
M'_R,^D?]=$_]#%=?7(>(_P#D9](_ZZ)_Z&*Z\=*;$@IO\8^AIU-_Y:#Z'^E(
M8-V^M.IK=OK3J "BBB@ HHHH **** "BBB@"K;_\?5W_ -=%_P#0%JU56W_X
M^KO_ *Z+_P"@+5J@ HHHH **** "BBB@!#TI:0TM !1110 4444 %%%% !11
M10 4444 %%%% "&EI#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5!=?ZI?^NB?^A"IC4-U_JE_ZZ)_Z$* )Z*** "BBB@ HHHH ****
M "BBB@"EI/\ R#(?Q_F:LK_KW_W5_F:K:3_R#(?Q_F:LK_KF_P!T?S- $E%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4'I10: (K;FUB_W!_*I:BM?^/2'_ '%_
ME4M !1110!R'B3_D9](_ZZ)_Z&*Z\=*Y#Q'_ ,C/I'_71/\ T,5U]-B04S_E
MH/H:?3?^6@^AI#!NWUIU-;M]:=0 4444 %%%% !1110 4444 5;?_CZN_P#K
MHO\ Z M6JJV__'U=_P#71?\ T!:M4 %%%% !1110 4444 (:6D-+0 4444 %
M%%% !1110 4444 %%%% !1110 AI:0]J6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ H/2B@T 16^?LT6>NP?RJ6H[<8MHAZ(/Y5)0 4444
M<AXC_P"1FTC_ *Z)_P"ABNO'2N/\1_\ (SZ3_P!=$_\ 0Q78"FQ(*9_RT7Z&
MGTW_ ):#Z&D,4]J6D/;ZTM !1110 4444 %%%% !1110!5M_^/J[_P"NB_\
MH"U:JK;_ /'U=_\ 71?_ $!:M4 %%%% !1110 4444 (:6D-+0 4444 %%%%
M !1110 4444 %%%% !1110 AI:0]J6@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "H+K_5+_UT3_T(5/4%U_JE_P"NB?\ H0H GHHHH **
M** "BBB@ HHHH **** *6D_\@R'\?YFK*_Z]_P#='\S5;2?^09#^/\S5E?\
MCX?_ '5_F: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/2BD- $=O_Q[1?[@
M_E4M1P8^SQXZ;1_*I* "BBB@#D/$?_(RZ3_UT3_T,5U]<AXD_P"1FTG_ *Z)
M_P"ABNO%-B04T_ZP?0_TIU,_Y:#Z'^E(8X]OK2TC=OK2T %%%% !1110 444
M4 %%%% %6W_X^KO_ *Z+_P"@+5JJMO\ \?5W_P!=%_\ 0%JU0 4444 %%%%
M!1110 C4M(U+0 4444 %%%% !1110 4444 %%%% !1110 AI:0TM !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %077^J7_ *Z)_P"A"IZ@
MNO\ 5+_UT3_T(4 3T444 %%%% !1110 4444 %%%% %+2?\ D&0_C_,U97_C
MX?\ W5_F:K:3_P @R'\?YFK*_P"O?_=7^9H DHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "D/2EI#0!';?\>L/^X/Y5+4<'_'O'_NC^524 %%%% '(>(_\ D9M(
M_P"NB?\ H8KKQTKD/$8_XJ?2/^NB?^ABNO'2FQ(*;_RT'T/]*=33_K!]#_2D
M,5NWUI:0]OK2T %%%% !1110 4444 %%%% %6W_X^KO_ *Z+_P"@+5JJMO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+5J@ HHHH **** "BBB@!#2TAI: "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH *AN?\ 5C_?3_T(5-4%U_JQ_P!=$_\ 0A0!/1110 4444 %%%%
M!1110 4444 4]*_Y!L/X_P S5A?]>Y_V5_F:KZ5_R#8?Q_F:L+_KF_W1_,T
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M*** "BBB@ HHHH **** "BBB@!#2TAI: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *@NA^Z7_ *Z)_P"A"IZANO\ 5+_UT3_T(4 34444
M %%%% !1110 4444 %%%% %/2O\ D&Q?C_,U87_7O_NK_,U7TK_D&P_C_,U8
M7_7O_NC^9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 A_I2TAI: "BBB@ HHHH **** "BBB@ HHHH **** "BD-+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%U_JE_P"NB?\ H0J>
MH+K_ %2_]=$_]"% $]%%% !1110 4444 %%%% !1110!3TK_ )!L7X_S-6%_
MU[_[H_F:KZ5_R#8OQ_F:L+_Q\/\ [J_S- $E%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4=J*#0!';_ /'M%_N#^525%;_\>T7^X/Y5+0 4444 <AXCQ_PDVD_]
M=$_]#%=?7(>(_P#D9])_ZZ)_Z&*Z^F)!3?\ EH/H:=3?^6@^AI#%/;ZTM(W;
MZTM !1110 4444 %%%% !1110!5M_P#CZN_^NB_^@+5JJMO_ ,?5W_UT7_T!
M:M4 %%%% !1110 4444 (:6D-+0 4444 %%%% !1110 4444 %%%% !1110
MAI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** $-+2'M2T %%%% !1110 4444 %%%% !1110 4444
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M^525' <P1G_9%24 %%%% '(>(_\ D9M)_P"NB?\ H8KKQTKD/$?_ ",VD_\
M71/_ $,5UXZ4V)!3?XQ]#3J9_P M!]#2&.;M]:6FMU'UIU !1110 4444 %%
M%% !1110!5M_^/J[_P"NB_\ H"U:JK;_ /'U=_\ 71?_ $!:M4 %%%% !111
M0 4444 (>E**0TM !1110 4444 %%%% !1110 4444 %%%% "&EI#2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** $-+2'M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5#<C,:_[Z?\ H0J:H;K_ %2_]=$_]"% $U%%% !1110 4444 %%%% !1
M110!2TG_ )!D/X_S-65_X^'_ -U?YFJ^E?\ (-A_'^9JR#^_;_=']: 'T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB?\ H8KKATIL2"F?\M%^AI]-_C'T-(8I[?6EI#V^M+0 4444 %%%% !1110
M4444 5;?_CZN_P#KHO\ Z M6JJV__'U=_P#71?\ T!:M4 %%%% !1110 444
M4 (>E**0]*6@ HHHH **** "BBB@ HHHH **** "BBB@!#2TA[4M !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 (:ANO]4O_71/_0A4QJ*Z
M_P!4O_71/_0A0!-1110 4444 %%%% !1110 4444 4]*_P"0;#^/\S5A?]>_
M^ZO\S5;2O^09#^/\S5E?^/A_]U?YF@"2BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *#12&@".V.;6(^J#^52U%;#%K"/]@?RJ6@ HHHH Y#Q&?^*GTG_KHG_H8K
MKQTKD/$?_(SZ3_UT3_T,5UXIL2"F_P 8^AIU,_Y:#Z'^E(8YNWUI:1NWUI:
M"BBB@ HHHH **** "BBB@"K;_P#'U=_]=%_] 6K55;?_ (^KO_KHO_H"U:H
M**** "BBB@ HHHH 0TM(:6@ HHHH **** "BBB@ HHHH **** "BBB@ HI#2
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &H;G_5K_P!=
M$_\ 0A4U0W7$2_\ 71/_ $(4 34444 %%%% !1110 4444 %%%% %/2O^0;#
M^/\ ,U87_7O_ +H_F:KZ5_R#8?Q_F:L+_KW_ -T?S- $E%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 AJ&Z_U2_]=$_]"%3&HKG_ %:_]=$_]"% $U%%% !1110 4444
M %%%% !0:** *>E?\@V'\?YFK"_Z]_\ ='\S5;2O^0=#^/\ ,U97_CX?_=7^
M9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "@T4'I0!%;?\>L7^X/Y5+4=O\
M\>T6?[@_E4E !1110!R'B,_\5/I(_P"FB?\ H8KKZY'Q&?\ BIM)_P"NB?\
MH8KKJ;$@IO\ RT'T-.IO\8^AI#%/;ZTM(W;ZTM !1110 4444 %%%% !1110
M!5M_^/J[_P"NB_\ H"U:JK;_ /'U=_\ 71?_ $!:M4 %%%% !1110 4444 -
M-.IK=Z=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5!=?ZI?^NB?^A"IZ@NO]4O_ %T3
M_P!"% $]%%% !1110 4444 %%%% !1110!2TG_D&P_C_ #-65_X^'_W5_F:K
M:3_R#(?Q_F:LK_Q\/_NK_,T 24444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2
MTAZ4 1VQS;1'_8'\JEJ.WXMHO]P?RJ2@ HHHH Y'Q%_R,ND_]=$_]#%==7(^
M(^?$ND?]=$_]#%=<.E-B04W_ ):#Z'^E.IG_ "T'T-(8X]OK2TC=OK2T %%%
M% !1110 4444 %%%% %6W_X^KO\ ZZ+_ .@+5JJMO_Q]7?\ UT7_ - 6K5 !
M1110 4444 %%%% #3WIPII[TZ@ HHHH **** "BBB@ HHHH **** "BBB@!#
M2TAI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 (:6@T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 AJ&Z_P!4O_71/_0A4QJ*Y_U:_P#71/\ T(4 3444
M4 %%%% !1110 4444 %%%% %+2?^09#^/\S5E?\ 7O\ [H_F:KZ5_P @R'\?
MYFK"_P"O?_=7^9H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T4AZ4 ,@_X]
MX_\ ='\JDJ. YMXS_LC^524 %%%% '(^)/\ D9=(_P"NB?\ H8KKJY'Q'_R,
MVD?]=$_]#%=<.E-B04W_ ):#Z&G4W_EH/H:0Q6[?6EIIZCZTZ@ HHHH ****
M "BBB@ HHHH JV__ !]7?_71?_0%JU56W_X^KO\ ZZ+_ .@+5J@ HHHH ***
M* "BBB@!IIU-/>G4 %%%% !1110 4444 %%%% !1110 4444 (:6D-+0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "&H;K_5K_ -=$_P#0
MA4QJ*Y_U8_ZZ)_Z$* )J*** "BBB@ HHHH **** "BBB@"EI/_(,A_'^9JRH
M_?M_NC^9JOI7_(-A_'^9JPO^O?\ W1_,T 24444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2&EI#TH 9;C%M$/]@?RJ2HX.;>/_='\JDH **** .0\1_\C/I'_71/
M_0Q77BN0\1_\C-I'_71/_0Q77TV)!3/^6@^AI]-_C'XTABMV^M+2'M]:6@ H
MHHH **** "BBB@ HHHH JV__ !]7?_71?_0%JU56W_X^KO\ ZZ+_ .@+5J@
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MBBB@ HHHH **** $-+2&EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J"Z_U2_P#71/\ T(5/4%U_JE_ZZ)_Z$* )Z*** "BBB@ HHHH
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M/_=%/ID(Q"@_V13Z "BBB@#D?$?_ ",VD?\ 71/_ $,5UU<CXC/_ !4VD?\
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M -=$_P#0A0!-1110 4444 %%%% !1110 4444 4M)_Y!D/X_S-65_P"/A_\
M=7^9JMI/_(,A_'^9JRO_ !\/_NK_ #- $E%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4&B@T ,A_P!3'_NBGTR$Y@C/JHI] !1110!R'B+CQ/I/_71/_0Q77CI7
M(^(_^1FTG_KHG_H8KKATIL2"F_QCZ&G4W^,?0TABMV^M+2-V^M+0 4444 %%
M%% !1110 4444 5;?_CZN_\ KHO_ * M6JJV_P#Q]7?_ %T7_P! 6K5 !111
M0 4444 %%%% #3TIPIIZ4X4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEI&[?6EH **** "BBB@ HHHH **** *MO_Q]7?\ UT7_ - 6K55;?_CZN_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "H+K_5+_P!=$_\ 0A4]077^
MJ7_KHG_H0H GHHHH **** "BBB@"AK=Z^FZ)>7L>W?!"TBA@2"0,@8!'6LVV
MU;4(O$%II=\MN[W%HT[>0K Q,I PV2?E.< \<BG^(8)M1-CIHBE-O+<H]S(B
M_*(TR^#]655_&C5;%M/T'49-$M M^\1VF-<NS8P.3U('3)H U/[1LO/$'VN'
MS2VT)O&XGTQZ^U,;6-,27RFU"U63.W:9E!SZ=>M<I' )M9TYCI]W9:786<KQ
M32C:P=_E);/0X#<<DE@34'A](+HZ19W1FM)].$GV:TN(&B>=MI&\EOO?*22%
M)Y))- '5Z7>VR6<$#7$0F;($9<;B<D]/I2ZKJMIHUM/>WDOEQ(JCW8DG"J.Y
M/:N5\)VTMY;67VZTO1-!*\TJO 8XO.RV7W,27ZD#:< 8X&*V-=LS<>(-(FEB
MDDL[9GED"(7Q(!B,D#GNWXXH U-,NKN]A^TS1PQPR -$J2;V _VB.,_3(]S5
MR2Z@A9%DE1&<X4,V-Q]JQ?#%E-;6M[/+&T*WEW)<10,,&-&Z9'8G&XCL36!<
M6=[>:7J]J89FUC4KMX=SJP6"%7VHP..%"#</5B>_0 Z2]UI1J\&D6,D#WTJ/
M(0[96-5Q]X#G))  ^I[<R7NK_P!EVEJ+N,RW\^$2VMOF,DF,L%SCY1R23C &
M36=X?A2ZUK5M3\K&R5;*%F7DB('<P^K.P_"JFJVL+>++J\U*U^TQ)IRQ6D1A
MW;V+,7"YX+<+^!H ZBR:Z>(M=I$DA/"Q.6 'U(&35JLCPQ976G>&]/L[UMUS
M#"JR'<6Y],GKCI6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !0:*0]* &P\P1X_NC^5/J*W_ ./:
M+_<'\JEH **** .0\1''B?2?^NB?^ABNO%<AXC_Y&;2/^NB?^ABNO'2FQ(*;
M_P M!]#3J:?]8/H?Z4ABMV^M+2'M]:6@ HHHH **** "BBB@ HHHH JV_P#Q
M]7?_ %T7_P! 6K55;?\ X^KO_KHO_H"U:H **** "BBB@ HHHH ::=333J "
MBBB@ HHHH **** "BBB@ HHHH **** $-+2&EH **** "BBB@ HHHH ****
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M!(D&%')_4]3[U/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4&B@T ,A_U$?\ NBGU' ,0
M1C_9%24 %%%% '(>)/\ D9M(_P"NB?\ H8KKQTKD?$0SXGTD>DB?^ABNN'2F
MQ(*9_P M!]#3Z;_&/QI#%/;ZTM(>WUI: "BBB@ HHHH **** "BBB@"K;_\
M'U=_]=%_] 6K55;?_CZN_P#KHO\ Z M6J "BBB@ HHHH **** &GI3J:>E.%
M !1110 4444 %%%% !1110 4444 %%%% !12&EH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#^/\S5D#]ZW^Z/ZT /HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!DH_LO4L_\A^[_ ._,7_Q- &SFC-8W]F:D#_R'KH_6"+_XFC^S-4[:[/\
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MZK<#_F#7_P#Y"_\ BZ -*BLS^U9_^@/J _"/_P"+I?[6EQSI5_\ ]\H?_9J
M-*HK@X1?]]/_ $(52_M=_P#H%W__ '[7_P"*J&YU9C$O_$NOA^\3K$/[P]Z
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MJ:** "BBB@ HHHH **** "E-%% !VH[444 )VH%%%  *4T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#<?ZL?[Z?\
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MR6LZ:/\ A)M/4W=XP#)C=,3CYQ76#2\#_C_OOQE_^M1138D._L^0=-0N^?\
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=#_V>K%EKEY<SB-U@ /=4/^-%% '0]J>*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372546786176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEOGENOMICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2897368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9490 NeoGenomics Way,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Myers,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">768-0600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock ($0.001 par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NEO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,578,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001077183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372547117248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 275,609<span></span>
</td>
<td class="nump">$ 263,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">142,306<span></span>
</td>
<td class="nump">174,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">118,842<span></span>
</td>
<td class="nump">119,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">24,432<span></span>
</td>
<td class="nump">24,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">15,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,622<span></span>
</td>
<td class="nump">8,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">584,996<span></span>
</td>
<td class="nump">605,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment (net of accumulated depreciation of $138,863 and $131,930, respectively)</a></td>
<td class="nump">102,845<span></span>
</td>
<td class="nump">102,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">93,784<span></span>
</td>
<td class="nump">96,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">399,477<span></span>
</td>
<td class="nump">408,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">522,766<span></span>
</td>
<td class="nump">522,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,306<span></span>
</td>
<td class="nump">5,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,124,178<span></span>
</td>
<td class="nump">1,134,743<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,709,174<span></span>
</td>
<td class="nump">1,740,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">22,712<span></span>
</td>
<td class="nump">20,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">32,891<span></span>
</td>
<td class="nump">40,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">17,964<span></span>
</td>
<td class="nump">15,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of equipment financing obligations</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">6,934<span></span>
</td>
<td class="nump">6,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Pharma contract liabilities</a></td>
<td class="nump">6,067<span></span>
</td>
<td class="nump">7,557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">86,606<span></span>
</td>
<td class="nump">89,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">536,037<span></span>
</td>
<td class="nump">535,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">67,319<span></span>
</td>
<td class="nump">68,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities, net</a></td>
<td class="nump">31,715<span></span>
</td>
<td class="nump">34,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">13,035<span></span>
</td>
<td class="nump">13,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">648,106<span></span>
</td>
<td class="nump">652,079<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">734,712<span></span>
</td>
<td class="nump">742,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, (250,000,000 shares authorized; 127,200,491 and 126,913,992 shares issued and outstanding, respectively)</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,167,051<span></span>
</td>
<td class="nump">1,160,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,834)<span></span>
</td>
<td class="num">(3,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(189,882)<span></span>
</td>
<td class="num">(159,087)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">974,462<span></span>
</td>
<td class="nump">998,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,709,174<span></span>
</td>
<td class="nump">$ 1,740,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372547101040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 138,863<span></span>
</td>
<td class="nump">$ 131,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">127,200,491<span></span>
</td>
<td class="nump">126,913,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">127,200,491<span></span>
</td>
<td class="nump">126,913,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372546810800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 137,220<span></span>
</td>
<td class="nump">$ 117,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">82,406<span></span>
</td>
<td class="nump">78,937<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">54,814<span></span>
</td>
<td class="nump">38,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">61,549<span></span>
</td>
<td class="nump">66,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,395<span></span>
</td>
<td class="nump">7,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">16,259<span></span>
</td>
<td class="nump">16,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">89,887<span></span>
</td>
<td class="nump">90,260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(35,073)<span></span>
</td>
<td class="num">(52,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense, net</a></td>
<td class="num">(1,467)<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">114<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(33,720)<span></span>
</td>
<td class="num">(53,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(2,925)<span></span>
</td>
<td class="num">(3,753)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (30,795)<span></span>
</td>
<td class="num">$ (49,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">125,026<span></span>
</td>
<td class="nump">123,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">125,026<span></span>
</td>
<td class="nump">123,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 114,869<span></span>
</td>
<td class="nump">$ 98,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">67,292<span></span>
</td>
<td class="nump">65,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">47,577<span></span>
</td>
<td class="nump">33,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">22,351<span></span>
</td>
<td class="nump">18,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="nump">15,114<span></span>
</td>
<td class="nump">13,670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">$ 7,237<span></span>
</td>
<td class="nump">$ 4,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549398592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (30,795)<span></span>
</td>
<td class="num">$ (49,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>OTHER COMPREHENSIVE GAIN (LOSS):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive gain (loss), net of tax</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (29,730)<span></span>
</td>
<td class="num">$ (51,779)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544972288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,108,277<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 1,123,628<span></span>
</td>
<td class="num">$ (638)<span></span>
</td>
<td class="num">$ (14,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for ESPP</a></td>
<td class="nump">971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">6,480<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation expense - ESPP</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">11,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="num">(2,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,408)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,722,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">1,075,004<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">1,142,133<span></span>
</td>
<td class="num">(3,009)<span></span>
</td>
<td class="num">(64,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,913,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">998,023<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">1,160,882<span></span>
</td>
<td class="num">(3,899)<span></span>
</td>
<td class="num">(159,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for ESPP</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="num">$ (147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock options (in shares)</a></td>
<td class="nump">75,028<span></span>
</td>
<td class="nump">75,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">$ 751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance fees and expenses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Stock-based compensation expense - ESPP</a></td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense - options and restricted stock</a></td>
<td class="nump">4,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,795)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,200,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 974,462<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 1,167,051<span></span>
</td>
<td class="num">$ (2,834)<span></span>
</td>
<td class="num">$ (189,882)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544656480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (30,795)<span></span>
</td>
<td class="num">$ (49,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net&#160;cash&#160;used in operating&#160;activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">9,048<span></span>
</td>
<td class="nump">8,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">8,783<span></span>
</td>
<td class="nump">8,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">4,758<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">2,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible debt discount</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issue costs</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of assets</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other adjustments</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(1,187)<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,722)<span></span>
</td>
<td class="num">(2,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax liabilities, net</a></td>
<td class="num">(3,035)<span></span>
</td>
<td class="num">(3,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(7,250)<span></span>
</td>
<td class="num">(5,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">4,101<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,692)<span></span>
</td>
<td class="num">(29,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(6,756)<span></span>
</td>
<td class="num">(16,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">40,425<span></span>
</td>
<td class="nump">36,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(9,927)<span></span>
</td>
<td class="num">(8,219)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">23,742<span></span>
</td>
<td class="nump">12,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_RepaymentsOfEquipmentAndOtherFinanceObligation', window );">Repayment of equipment financing obligations</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">6,403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">12,429<span></span>
</td>
<td class="num">(10,931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">263,180<span></span>
</td>
<td class="nump">316,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">275,609<span></span>
</td>
<td class="nump">305,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet', window );">Increase in other current assets for the sale of assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable</a></td>
<td class="nump">$ 1,174<span></span>
</td>
<td class="nump">$ 1,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Gain On Sale Of Property Included In Accounts Receivable, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_RepaymentsOfEquipmentAndOtherFinanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of Equipment and Other Finance Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_RepaymentsOfEquipmentAndOtherFinanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549364832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business</a></td>
<td class="text">Nature of the BusinessNeoGenomics, Inc., a Nevada corporation (the &#8220;Parent,&#8221; &#8220;Company,&#8221; or &#8220;NeoGenomics&#8221;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#8217;s Clinical Laboratory Improvement Act, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372551385152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, except for new accounting standards discussed under Recent Accounting Pronouncements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in the Company&#8217;s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim unaudited Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations presented in this Quarterly Report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, impairment analysis of goodwill, and restructuring reserves. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Restructuring charges</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring charges relate to a restructuring program to improve execution and drive efficiency across the organization. Restructuring charges consist of severance and other employee costs, costs for optimizing the Company&#8217;s geographic presence, and consulting and other costs. For further details on the Company&#8217;s restructuring activities, please refer to Note 8. Restructuring.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#8220;ASU 2021-08&#8221;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years </span></div>beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted this standard as of January 1, 2023 and there was no impact on its Consolidated Financial Statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372550093200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#8217;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets and are included in cash and cash equivalents on the Consolidated Balance Sheets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of March 31, 2023 and December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,682&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,392)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,452)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $1.0&#160;million and $0.9&#160;million of accrued interest receivable at March 31, 2023 and December 31, 2022, respectively, included in other current assets on its Consolidated Balance Sheets related to its marketable securities. There were no realized gains or losses on marketable securities for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at March 31, 2023 and December 31, 2022. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of March 31, 2023 and December 31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,553&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the three months ended March 31, 2023 and 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other liabilities, and other current assets and liabilities, are considered reasonable estimates of their respective fair values at March 31, 2023 and December 31, 2022 due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, and long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and, as such, these are considered Level 3 fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372550102960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of goodwill by segment at March 31, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:56.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,477&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. The following table summarizes the amortization expense for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense related to amortizable intangible assets for each of the following periods as of March 31, 2023 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372548199696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2028 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, the Company completed the sale of $345.0&#160;million of Convertible Senior Notes with a stated interest rate of 0.25% and a maturity date of January 15, 2028 (the &#8220;2028 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2022. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the first quarter of 2023. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended March 31, 2023. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the second quarter of 2023. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $17.41 on March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,500 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2023. The interest expense recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,400 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2022. The effective interest rate on the 2028 Convertible Notes is 0.70%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2023, the estimated fair values (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $258.8&#160;million. At December 31, 2022, the estimated fair value (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $218.2&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">2025 Convertible Senior Notes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2020, the Company completed the sale of $201.3&#160;million of Convertible Senior Notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025 (the &#8220;2025 Convertible Notes&#8221;), unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2022. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the first quarter of 2023. The last reported sales price of the Company&#8217;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended March 31, 2023. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the second quarter of 2023. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $17.41 on March 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $37,600 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2023. The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $36,800 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2022. The effective interest rate on the 2025 Convertible Notes is 1.96%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of 1.25% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.</span></div>At March 31, 2023, the estimated fair values (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $186.8&#160;million. At December 31, 2022, the estimated fair value (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $169.6&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372548158064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $4.8 million and $12.1 million for stock-based compensation in general and administrative expenses </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Statements of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s plans for the three months ended March 31, 2023 is as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347,719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,142&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award granted during the three months ended March 31, 2023 was estimated as of the grant date using a Black-Scholes model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 - 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% - 4.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.6% - 65.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.66</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was approximately $12.2 million of unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of approximately 2.1 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Awards</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock activity under the Company&#8217;s plans for the three months ended March 31, 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was approximately $15.5&#160;million of unrecognized stock-based compensation expense related to restricted stock that will be recognized over a weighted-average period of approximately 2.3 years.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Modification of Stock Option and Restricted Stock Awards</span></div>In the first quarter of 2022, upon the Chief Executive Officer&#8217;s departure from the Company and in accordance with the terms of the Chief Executive Officer&#8217;s separation agreement, 237,960 previously granted time-based vesting stock option awards and 142,302 previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $5.9 million of incremental stock-based compensation which consisted of $2.3 million and $3.6 million for the acceleration of stock option awards and restricted stock awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the three months ended March 31, 2022. There were no such amounts for the three months ended March 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372548226560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s two reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s specialized diagnostic services are performed based on a written test requisition form or an electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharma Services Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other contract research organizations (&#8220;CROs&#8221;) to provide research and clinical trial services. Such services also include validation studies and assay development. The Company records revenue on a unit-of-service basis based on the number of units completed towards the satisfaction of a performance obligation. In addition, certain contracts include upfront fees and the revenue for those contracts is recognized over time as services are performed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional offerings within the Pharma Services portfolio includes Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data. Informatics revenue is recognized at a point in time upon delivery of retrospective data or over time for prospective data feeds. The Company negotiates billing schedules and payment terms on a contract-by-contract basis, and contract terms generally provide for payments based on a unit-of-service arrangement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, Pharma Services incurs sales commissions in the process of obtaining contracts with customers. Sales commissions that are payable upon contract award are recognized as assets and amortized over the expected contract term. The amortization of commission expense is based on the weighted average contract duration for all commissionable awards in the respective business in which the commission expense is paid, which approximates the period over which goods and services are transferred to the customer. For offerings with primarily short-term contracts, such as Informatics, the Company applies the practical expedient which allows costs to obtain a contract to be expensed when incurred, if the amortization period of the assets that would otherwise have been recognized is one year or less. Contract assets and capitalized commissions are included in other current assets and other assets on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded within other current assets on the Consolidated Balance Sheets.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other assets on the Consolidated Balance Sheets. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other long-term liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized related to Pharma contract liability balances outstanding at the beginning of the period was $1.8&#160;million and $3.1&#160;million for the three months ended March 31, 2023 and 2022, respectively. Amortization of capitalized commissions was $0.2&#160;million and $0.1&#160;million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services segments (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial Insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-Pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,869&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372548261872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company embarked on a restructuring program to improve execution and drive efficiency across the organization. This program is a framework for identifying, prioritizing and executing operational improvements. Restructuring charges incurred consist of severance and other employee costs, costs for optimizing the Company&#8217;s geographic presence (&#8220;Facility Footprint Optimization&#8221;), and consulting and other costs. There were no such charges for the three months ended March 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:40.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Other Employee Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility Footprint Optimization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consulting and Other Costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of facility related assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments and other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,008&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments include non-cash asset charges related to Facility Footprint Optimization costs.</span></div>The Company will continue this restructuring program in 2023 and expects to incur additional restructuring charges of approximately $3.0&#160;million. The Company estimates these additional restructuring charges to be comprised of approximately $1.0&#160;million in severance and other employee costs, $1.0&#160;million of Facility Footprint Optimization costs, and $1.0&#160;million of consulting and other costs. The Company&#8217;s restructuring activities are expected to be complete by December 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549144192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each interim period, management estimates the annual effective tax rate based on forecasted pre-tax results of the Company&#8217;s global operations and applies such rate to its ordinary quarterly earnings to calculate income tax expense related to ordinary income. The tax effects of items significant, unusual and infrequent in nature are discretely calculated and recognized in the period during which they occur. These discrete items often relate to changes in tax laws, excess tax benefits/deficiencies related to share-based compensation or adjustments to previously reported tax expense/benefits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing available positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred income tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.</span></div>A cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome. Cumulative loss in recent years is commonly defined as a three-year cumulative loss position. As of March 31, 2023, the Company&#8217;s U.S. ongoing operations were in a three-year cumulative loss position. Management determined that sufficient objectively verifiable positive evidence did not exist to overcome the negative evidence of the Company&#8217;s U.S. cumulative loss position. Accordingly, the Company&#8217;s estimated annual effective tax rate applied to the Company&#8217;s pre-tax loss for the three months ended March 31, 2023, includes the unfavorable impact of a valuation allowance against the Company&#8217;s deferred income tax assets expected to be created in 2023 for additional U.S. net operating loss and tax credit carryforwards as well as Switzerland, China and Singapore deferred tax assets. Management has however determined that sufficient objectively verifiable positive evidence does exist to overcome the negative evidence of the Company&#8217;s U.K. cumulative loss position. The reversal of U.K. deferred tax liabilities will provide a sufficient source of realization to support the full recognition of the U.K. deferred tax assets and therefore no valuation allowance has been established for those deferred tax assets. Accordingly, the Company&#8217;s estimated annual effective tax rate applied to the Company&#8217;s pre-tax loss for the three months ended March 31, 2023, includes the favorable impact of recognizing the U.K. benefit.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372548226560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents both basic earnings per share (&#8220;EPS&#8221;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock options were exercised, stock awards vested and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury stock method based on the average market value of the Company&#8217;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#8217;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations (in thousands, except net loss per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:59.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:59.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#8220;Capped Call Transactions&#8221;) with option counterparties pursuant to capped call confirmations at a cost of approximately $29.3&#160;million. The potential effect of the Capped Call Transactions were excluded from the calculation of diluted net loss per share in the three months ended March 31, 2023 as the Company&#8217;s closing stock price of $17.41 on March 31, 2023 did not exceed the conversion price of $85.75 per share. The Capped Call Transactions are not reflected in diluted net loss per share as they are anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372550094864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments an Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#8217;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in U.S. District Court for the district of Delaware, alleging Inivata&#8217;s InVisionFirst&#174;-Lung cancer diagnostic test of infringing two patents. Natera then filed a second patent infringement complaint on December 20, 2022 against Inivata Limited and Inivata Inc. alleging that RaDaR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> minimal residual disease test infringes one patent. The litigation is approaching the discovery stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2022, a purported shareholder class action captioned Daniel Goldenberg v. NeoGenomics, Inc., Douglas VanOort, Mark Mallon, Kathryn McKenzie, and William Bonello was filed in the United States District Court for the Southern District of New York, naming the Company and certain of the Company&#8217;s current and former officers as defendants. This lawsuit was filed by a stockholder who claims to be suing on behalf of anyone who purchased or otherwise acquired the Company&#8217;s securities between February 27, 2020 and April 26, 2022. The lawsuit alleges that material misrepresentations and/or omissions of material fact were made in the Company&#8217;s public disclosures in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The alleged improper disclosures relate to statements regarding the Company&#8217;s menu of tests, business operations and compliance with health care laws and regulations. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney&#8217;s fees and expert fees. The Company believes that it has valid defenses to the claims alleged in this lawsuit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company made an offer to remedy a dispute and the dispute is now in pre-litigation non-binding mediation.&#160;As a result, the Company has recorded a liability in accrued expenses and other liabilities as of March 31, 2023 on the Consolidated Balance Sheets based on the offer to settle this dispute, which reflects management&#8217;s best estimate of the minimum probable loss associated with this matter.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) of the Company&#8217;s internal investigation in November 2021. The Company&#8217;s interactions with regulatory authorities and the Company&#8217;s related review of this matter are ongoing. The Company has a reserve of $11.2 million in other long-term liabilities as of March 31, 2023 and December 31, 2022 on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#8217;s best estimate of the minimum probable loss associated with this matter. As a result of the internal investigation and ongoing interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. The Company was notified on June 30, 2022 that the Department of Justice (&#8220;DOJ&#8221;) will be participating in the investigation of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, DOJ, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#8217;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, exclusion from participation in federal healthcare programs or other losses or conduct restrictions, which could be material to the Company&#8217;s financial results or business operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372550093200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsThe Company has Pharma Services contracts with HOOKIPA Pharma, Inc., an entity with whom a director of the Company, Michael A. Kelly, was a director of until April 2023. In connection with these contracts, the Company recognized $0.2&#160;million of revenue in the Consolidated Statements of Operations for the three months ended March 31, 2023. Revenue recognized in connection with these contracts for the three months ended March 31, 2022 was immaterial.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372550093200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under two reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#8217; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes segment information for the three months ended March 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:63.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,073)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,028)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,795)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,408)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549398208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, except for new accounting standards discussed under Recent Accounting Pronouncements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#8217;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, impairment analysis of goodwill, and restructuring reserves. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Sales and Marketing Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three months ended March 31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring charges</a></td>
<td class="text">Restructuring chargesRestructuring charges relate to a restructuring program to improve execution and drive efficiency across the organization. Restructuring charges consist of severance and other employee costs, costs for optimizing the Company&#8217;s geographic presence, and consulting and other costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#8220;ASU 2021-08&#8221;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years </span></div>beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted this standard as of January 1, 2023 and there was no impact on its Consolidated Financial Statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372542101664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring and Nonrecurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#8217;s marketable securities accounted for as available-for-sale securities as of March 31, 2023 and December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,682&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,392)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.180%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,452)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at March 31, 2023 and December 31, 2022. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Year or Less</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over One Year Through Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over Five Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,400&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of March 31, 2023 and December 31, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Yankee bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Municipal bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,553&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549129792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amounts of goodwill by segment at March 31, 2023 and December 31, 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:56.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Classes of Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,477&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization<br/>Period (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademark - Indefinite lived</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Asset Amortization Expense</a></td>
<td class="text">The following table summarizes the amortization expense for the three months ended March 31, 2023 and 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles included in general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense related to amortizable intangible assets for each of the following periods as of March 31, 2023 is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Intangible Asset Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372720712880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company&#8217;s plans for the three months ended March 31, 2023 is as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,214,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347,719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,142&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Stock Option Award Granted</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award granted during the three months ended March 31, 2023 was estimated as of the grant date using a Black-Scholes model with the following assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 - 5.5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% - 4.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (%)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.6% - 65.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield (%)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.66</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted stock activity under the Company&#8217;s plans for the three months ended March 31, 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372548242272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma capitalized commissions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma capitalized commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current pharma contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term pharma contract liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pharma contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded within other current assets on the Consolidated Balance Sheets.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Recorded within other assets on the Consolidated Balance Sheets. </span></div>(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services segments (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Client direct billing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial Insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Medicare and Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Self-Pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Clinical Services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,869&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372550156000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:40.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance and Other Employee Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility Footprint Optimization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consulting and Other Costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of facility related assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments and other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,008&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments include non-cash asset charges related to Facility Footprint Optimization costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372548244368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculations (in thousands, except net loss per share amounts):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:59.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET LOSS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:59.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372546805904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text">(in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:63.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,073)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,028)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,795)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,408)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544355104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Amortized Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 145,682<span></span>
</td>
<td class="nump">$ 179,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3,392)<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">142,306<span></span>
</td>
<td class="nump">174,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">37,054<span></span>
</td>
<td class="nump">56,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">36,704<span></span>
</td>
<td class="nump">55,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">3,357<span></span>
</td>
<td class="nump">5,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">6,010<span></span>
</td>
<td class="nump">12,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">12,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">12,804<span></span>
</td>
<td class="nump">12,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(902)<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">11,902<span></span>
</td>
<td class="nump">11,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">21,433<span></span>
</td>
<td class="nump">25,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">21,142<span></span>
</td>
<td class="nump">25,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="nump">62,136<span></span>
</td>
<td class="nump">63,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,696)<span></span>
</td>
<td class="num">(2,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Fair Value</a></td>
<td class="nump">$ 60,450<span></span>
</td>
<td class="nump">$ 61,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372541733056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">$ 93,386<span></span>
</td>
<td class="nump">$ 111,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">48,920<span></span>
</td>
<td class="nump">63,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">142,306<span></span>
</td>
<td class="nump">174,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">29,416<span></span>
</td>
<td class="nump">40,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="nump">14,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">36,704<span></span>
</td>
<td class="nump">55,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">3,573<span></span>
</td>
<td class="nump">6,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">2,363<span></span>
</td>
<td class="nump">5,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">12,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">11,902<span></span>
</td>
<td class="nump">11,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">11,902<span></span>
</td>
<td class="nump">11,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">21,142<span></span>
</td>
<td class="nump">23,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">21,142<span></span>
</td>
<td class="nump">25,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">One Year or Less</a></td>
<td class="nump">33,083<span></span>
</td>
<td class="nump">35,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Over One Year Through Five Years</a></td>
<td class="nump">27,367<span></span>
</td>
<td class="nump">26,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Over Five Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Total</a></td>
<td class="nump">$ 60,450<span></span>
</td>
<td class="nump">$ 61,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372543254832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">$ 142,306<span></span>
</td>
<td class="nump">$ 174,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">36,704<span></span>
</td>
<td class="nump">55,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember', window );">Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">12,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">11,902<span></span>
</td>
<td class="nump">11,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">21,142<span></span>
</td>
<td class="nump">25,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">60,450<span></span>
</td>
<td class="nump">61,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">406,671<span></span>
</td>
<td class="nump">408,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">36,704<span></span>
</td>
<td class="nump">55,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">12,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">11,902<span></span>
</td>
<td class="nump">11,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">21,142<span></span>
</td>
<td class="nump">25,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">60,450<span></span>
</td>
<td class="nump">61,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">263,367<span></span>
</td>
<td class="nump">196,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">36,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">321,188<span></span>
</td>
<td class="nump">281,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">36,704<span></span>
</td>
<td class="nump">55,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">12,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">11,902<span></span>
</td>
<td class="nump">11,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">263,367<span></span>
</td>
<td class="nump">196,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">85,483<span></span>
</td>
<td class="nump">126,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">21,142<span></span>
</td>
<td class="nump">25,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">60,450<span></span>
</td>
<td class="nump">61,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">36,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Yankee bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=neo_YankeeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372546762336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 522,766<span></span>
</td>
<td class="nump">$ 522,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">458,782<span></span>
</td>
<td class="nump">458,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 63,984<span></span>
</td>
<td class="nump">$ 63,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544355232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 522,766<span></span>
</td>
<td class="nump">$ 522,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">458,782<span></span>
</td>
<td class="nump">458,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 63,984<span></span>
</td>
<td class="nump">$ 63,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544967856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Classes of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total cost of intangibles</a></td>
<td class="nump">$ 501,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">101,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">386,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">399,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Trademark - Indefinite lived</a></td>
<td class="nump">13,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">143,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">58,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">84,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">310,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">38,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 271,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Marketing Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 31,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 27,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 2,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangibles, net</a></td>
<td class="nump">$ 1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortization Period (years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372543584688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization of intangibles</a></td>
<td class="nump">$ 8,783<span></span>
</td>
<td class="nump">$ 8,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Amortization of intangibles included in cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization of intangibles</a></td>
<td class="nump">4,853<span></span>
</td>
<td class="nump">4,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Amortization of intangibles included in general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization of intangibles</a></td>
<td class="nump">$ 3,930<span></span>
</td>
<td class="nump">$ 3,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549104320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 26,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">33,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">33,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">33,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">226,824<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 386,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372543120416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - Convertible Debt<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>day </div>
<div>Rate</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>Rate</div>
</th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>USD ($) </div>
<div>Rate</div>
</th>
<th class="th">
<div>May 04, 2020 </div>
<div>USD ($) </div>
<div>Rate</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent) | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible notes, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtContractualCouponInterest', window );">Interest expense, contractual coupon interest</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAccretionOfDebtDiscount', window );">Interest expense, accretion of debt discount</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts', window );">Interest expense, amortization of debt issuance costs</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on Convertible Notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">0.25% Convertible Senior Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value of debt</a></td>
<td class="nump">258,800,000<span></span>
</td>
<td class="nump">$ 218,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtContractualCouponInterest', window );">Interest expense, contractual coupon interest</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAccretionOfDebtDiscount', window );">Interest expense, accretion of debt discount</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts', window );">Interest expense, amortization of debt issuance costs</a></td>
<td class="nump">37,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on Convertible Notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value of debt</a></td>
<td class="nump">$ 186,800,000<span></span>
</td>
<td class="nump">$ 169,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember', window );">1.25% Convertible Senior Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion price on applicable trading day (as a percent)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days (in days) | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days (in days) | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtAccretionOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Accretion Of Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtAccretionOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Amortization Of Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_InterestExpenseDebtContractualCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Contractual Coupon Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_InterestExpenseDebtContractualCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544246784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense (gain)</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period (in years)</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average recognition period (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Accelerated vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment', window );">Incremental stock-based compensation for accelerated vesting</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchaseProgramAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to adjust previously recorded stockholders' equity balances to the actual aggregate amounts paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchaseProgramAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372546849680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">4,214,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">338,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(75,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(347,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">4,130,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">754,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">10.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">20.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">15.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 29.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549087712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average fair value/share at grant date (in dollars per share)</a></td>
<td class="nump">$ 5.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">54.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">65.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549079120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1,994,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">213,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(33,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(89,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,085,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">23.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">12.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549100000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Pharma contract liability, revenue recognized</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract commissions</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544005216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract with Customer, Asset, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current pharma contract assets</a></td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="nump">$ 1,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Long-term pharma contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Total pharma contract assets</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetCurrent', window );">Current pharma capitalized commissions</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Long-term pharma capitalized commissions</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Total pharma capitalized commissions</a></td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current pharma contract liabilities</a></td>
<td class="nump">6,067<span></span>
</td>
<td class="nump">7,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term pharma contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total pharma contract liabilities</a></td>
<td class="nump">$ 6,067<span></span>
</td>
<td class="nump">$ 7,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549054320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 137,220<span></span>
</td>
<td class="nump">$ 117,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">114,869<span></span>
</td>
<td class="nump">98,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Client direct billing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">76,823<span></span>
</td>
<td class="nump">65,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Commercial Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">21,355<span></span>
</td>
<td class="nump">18,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Medicare and Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">16,587<span></span>
</td>
<td class="nump">15,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services | Self-Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 22,351<span></span>
</td>
<td class="nump">$ 18,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_ClientDirectBillingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_ClientDirectBillingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_CommercialInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_CommercialInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_MedicareAndOtherGovernmentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_MedicareAndOtherGovernmentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=neo_SelfPayServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=neo_SelfPayServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372546723344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Activities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 1,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">4,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of facility related assets</a></td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments and other adjustments</a></td>
<td class="num">(2,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 4,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Restructuring incurred cost statement of income or comprehensive income extensible enumeration not disclosed flag</a></td>
<td class="text">Restructuring charges incurred<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Current liabilities</a></td>
<td class="nump">$ 4,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveNoncurrent', window );">Long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">4,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=neo_SeveranceAndOtherEmployeeCostsMember', window );">Severance and Other Employee Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">3,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of facility related assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments and other adjustments</a></td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=neo_FacilityFootprintOptimizationMember', window );">Facility Footprint Optimization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of facility related assets</a></td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments and other adjustments</a></td>
<td class="num">(564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=neo_ConsultingCostsMember', window );">Consulting and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of facility related assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments and other adjustments</a></td>
<td class="num">(346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph 210-10-S99-1(SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=neo_SeveranceAndOtherEmployeeCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=neo_SeveranceAndOtherEmployeeCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=neo_FacilityFootprintOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=neo_FacilityFootprintOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=neo_ConsultingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=neo_ConsultingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372543584848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restructuring - Narratives (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and Related Cost, Expected Cost</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=neo_SeveranceAndOtherEmployeeCostsMember', window );">Severance and Other Employee Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and Related Cost, Expected Cost</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=neo_FacilityFootprintOptimizationMember', window );">Facility Footprint Optimization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and Related Cost, Expected Cost</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=neo_ConsultingCostsMember', window );">Consulting and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and Related Cost, Expected Cost</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=neo_SeveranceAndOtherEmployeeCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=neo_SeveranceAndOtherEmployeeCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=neo_FacilityFootprintOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=neo_FacilityFootprintOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=neo_ConsultingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=neo_ConsultingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544885808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS</a></td>
<td class="num">$ (30,795)<span></span>
</td>
<td class="num">$ (49,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Basic weighted average shares outstanding (in shares)</a></td>
<td class="nump">125,026<span></span>
</td>
<td class="nump">123,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">125,026<span></span>
</td>
<td class="nump">123,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income (loss) per share (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income (loss) per share (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372546458864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Shares (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember', window );">Capped Call Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember', window );">2028 Convertible Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible notes, conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 2025 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,538,000<span></span>
</td>
<td class="nump">5,538,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 2028 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,215,000<span></span>
</td>
<td class="nump">5,215,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=neo_CappedCallTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=neo_OnePointTwoFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372544919360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 20, 2022 </div>
<div>patent</div>
</th>
<th class="th">
<div>Jan. 20, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember', window );">Patent Infringement Complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ContractualObligationLineItems', window );"><strong>Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents allegedly infringed upon | patent</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember', window );">Federal Healthcare Program Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_ContractualObligationLineItems', window );"><strong>Contractual Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_ContractualObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_ContractualObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_PatentInfringementComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=neo_FederalHealthcareProgramRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372549413152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Pharma Services contracts with HOOKIPA Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related party</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140372543044672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 137,220<span></span>
</td>
<td class="nump">$ 117,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">82,406<span></span>
</td>
<td class="nump">78,937<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">54,814<span></span>
</td>
<td class="nump">38,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">61,549<span></span>
</td>
<td class="nump">66,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,395<span></span>
</td>
<td class="nump">7,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">16,259<span></span>
</td>
<td class="nump">16,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">89,887<span></span>
</td>
<td class="nump">90,260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(35,073)<span></span>
</td>
<td class="num">(52,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense, net</a></td>
<td class="num">(1,467)<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">114<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(33,720)<span></span>
</td>
<td class="num">(53,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(2,925)<span></span>
</td>
<td class="num">(3,753)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(30,795)<span></span>
</td>
<td class="num">(49,408)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">114,869<span></span>
</td>
<td class="nump">98,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">67,292<span></span>
</td>
<td class="nump">65,267<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">47,577<span></span>
</td>
<td class="nump">33,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_IntangibleAssetsAcquiredAmortizationExpense', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember', window );">Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">22,351<span></span>
</td>
<td class="nump">18,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">15,114<span></span>
</td>
<td class="nump">13,670<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">7,237<span></span>
</td>
<td class="nump">4,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_neo_IntangibleAssetsAcquiredAmortizationExpense', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_neo_IntangibleAssetsAcquiredAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Acquired, Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">neo_IntangibleAssetsAcquiredAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>neo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=neo_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>neo-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:neo="http://neogenomics.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="neo-20230331.xsd" xlink:type="simple"/>
    <context id="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ide298903e2814b3691a9fe4a01ba981e_I20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07ed7276d306438c829d302392f7b033_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i78f22d3306074426850c066c83f4fad2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idbe390f745ed4eca957b49e083feac70_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1863049f937940c499e969956396ab07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2707608d9f224b6ea1ad5d5d7f84d1b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i876d38822e24498d879a3ab240be09a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i035f530335b749e188af838868c59214_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b1caf8ef350438b9c76c704b6ea7ba7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib2722299e2e54f68a4514ccee1e3eb82_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3bfee91888ba4bbe8c107385485e0364_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaba385e087f94defb90c20be01b30692_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3537e2b2319b47afafdc2563a4fe34c9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id0b5e4798787448caf33060025f52e51_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie2f9e943825942a7b01c83b2eaacb3d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i79595b9a231b4236a3065c84f3b094e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i312ff0fa5d2e4b28aa9a59ff81523b57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cf5dc7a570d4b40afef1ad9a2c2afa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie714ae56c66b4a099f1db8dc8c6474fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i245e7c47a46c401abe4388c05022edc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifdd1f4fdbef9465d8834bed27b491755_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d22b4cf5a3440539edd117dd9c35a86_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67d2ec838c7d43b1814352266b3a6fe5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id1ec944b9e4b458fa0a2f3458676f6d7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6bba56276d3c4175888b91c4ac33bc23_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id8925c88775946e58ab40caee41543ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f5ac7b5971d4ab4bfc8063f863485f2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id3231ed75cf147cd8562dc1eb6475ade_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id3df88625d7d4b79abc18906edfac694_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a32a8c1adf04752a2088e1fe8031686_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea924912a062451a84ce6ae2de1bc5cf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id2f7b461087345aaa9abd14ef4c75f71_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b89e92263f34f90963302abcacb623e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia0c598cbef0946909ac15453b1e078f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1dc66208c4d42149ee22af031b70b4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc02f25dbebc48aca77b271035670aa4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2d34acf37be43769a927e85ccbd4413_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32af5f3b41c84510a781dc62b89f0fc9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c94fefd79994ed59ea8010c5f2f1990_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i004aaabb0349419fb34c1f104c808679_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20fd8019e30e4ef59757dfbd552fefeb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if7f72321e8d346c1b9be055441f0522d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia61de5d25d8d448a888213f0ef7c3c93_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i76d77419ee434f6d947c0e5684e90599_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id75d7c777de1492c9afb624404e70f75_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieb2da309f705473cb33d6513d2d19040_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i86086c5acace448bb8b6dabbe453c7be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9cef6dfefe3f46798762dc09c193dcd0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i26e671e8e2cf407bb994e16200e27c76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6ed5d50e23774aa184b8e4f93485b926_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifda741ccd246402297be5d1bebec2777_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie6ed3e307ef849bfba217e3b1fcfa083_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c3929fc1b70423592f232d6a018be6a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id65fc87ebe854a83bcf13322733d9557_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i98f3e45c8ce247d9b943649f14ba658f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8cf7e134e204d52adbadf5546e01d3a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3247270c4bc14b0aa820a377e20562d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iedde0d2d8fe34264951d0503e5c197b9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75a9a7f37116407f959fe7f724da7dad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idc3fd0f9e99e4320b6637e1380b3bce5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i029abd7f614f43d5a623df347ff6580e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if10ce274df2c4249b4324db839548e83_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icfc449c252d24578be1789efa8d675cc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7dfd45837ded4c3d8128215042b47480_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic4e227c6d3ee48169e743fbe4f36fe59_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i35ccb7220b1d436480b06a47fc83f4ee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if17f174d18f64b4991198db92b4c8ae0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if8ca769c06f34caab7a01fa701dd33ae_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i850e29d393ab4d448d3e09260828b223_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia7838cdae8934aa7bf7358f76022d88d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie39ff6c2d66a41949d09b075c81e15de_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93fb5da9266349929735ffd80af05646_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i29826c914306440c8b40afad7d4e56ec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6d59563f70954f8497c1438ea92e442a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8144c05b43464394a4a6145a9a634b35_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie54945d1251c4441a2ac49774ce617f9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d2cf2340a864d6998bf33d1d77a4392_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i82eca2166b614d8eb21a538228c7f1e7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i262590bf4922435bbe6f1bac3c1def5e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec9562a1c78e4bddbc52f9bef81cbed5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0dba6ced43c849c9b749eb64351e67f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacc7421b8125439e8a22041f284e8ebc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d558e5bb5fa4d8cbbe97eca0573db11_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i516b4da2b0b24ab4a71025b9383c4617_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8f6f6af9b184accb1eaff0152baad1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bcfd50343e7421882cf69bfe1e791f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04a302973b364b1588a1306eed18fe90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief43d0a3f2004fddb2988edc9ffc1db7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7dbd954120a4a10b873c3b2d48c8d49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c0a5c00a8a5486f9c09d4373fd16f53_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3aa409a34fd4aeeb322282e6be87924_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57d9ad9c26cc4a97894893e214f893f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59835bdf1de54dc3a48328b7959328f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5dee9db4a6134911883daae2b127b1bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib768cc7d37f345a5b55d7bb1727a8e78_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">neo:YankeeBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied859b3bfe82436e90e318d8e56a78e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i215f68b232644561b266ba62b04dfd65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c3fb5fa062e447e8d199b4b11655520_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i463acfa7a3c04bef8a12ae1f93cb16d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e2fd1c3e7e64fb7b43f4cbbe181cd25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a646025d4924bfdb1a9695ebcdf84bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3bfade97a184c86b6180bc197f2e725_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1749cb686d884db7a9db215233a80ff9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2d2220b415e487cb212f61ed9379605_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64302d40674f4f668abac29df75dbd08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia10b30abc40c456a88f7a33b38bddab3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c9283a1102d45bbb21af57e2510969a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b4c1be3902041dea01bb81350a399fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f9a7584dfdd402fbb79771f6d4e5a9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf8c26fd3116483f97d7f3c916a5aadd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e51fb83d6764e358db23f5748f2e935_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d782115f910461ebaa72bdf726eb86b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i404c6343a4ff4c68abad1297de44d068_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63c3cbd76eb2472ea8dc34f7fb98f41d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33036807c49d4896a9d79aecfb8f9205_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14bfd72886cc4c9aaf201e65540075bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a2868dd906c41e081be0d5635abba54_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ee14aadf28745e58a865d5fcc44e840_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id753f0b755d344a0b0bdf1feb8643feb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d9561a855e94d8eaf7a7d262bd98518_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i373380b438ca40aea3be8180eff81a98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide4d19a07e4d4c6b8fa3f9a7a166e31c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieff90c10aa6e47e395b6fced1a0dabfc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c1ab8ebd44e43e58d7c8ba3e808b947_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if1e1858214854850becd063395aada4d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd160d8807e0436c83ea5c0c12b91fc8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i71c657c0e98341bbbc4ddc31647ac2b6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib0ff16f279754224a25c4ced6f282de9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e9d62bddb1f4f688e043921e3f5282a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc32c676c0194721a3de605c721c7774_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b5e9af89b9f4994b751ddbc6c96ae25_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib997aee08c8e473bb492e4695716145d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5af4eb0b49b046e8b55345cc060257f8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d2008a400814d3fb508d405fef19e64_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie573780cd0664b138a05a0e5835aced1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1a1bb85243b8446f88ff933b1b86f31f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia00db418b1f6455fb09b2677268bc6e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic69d55a1ed4a4e4e9dadc2f09c415671_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9932df4812244904b018651543ab7697_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic50858980989426ebbf9e3e896cff83b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib23b6c43131945bf975f36256bb931eb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i489270e3fa944888970ab2fee62822f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8d3f64016074292b7c1e2da1f2c9ed2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icdf7019ad564417a87f14091ba7ee081_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83abff9eb9764eda9517f9f96b3a9e85_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69c1f4bb1df84121b986b7e6c99816e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7df8ca34dc349b6a74c42cd48d424c1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4f505f6d5c4d49cdac4ad18e9a62c42a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i821b3f256d5440b6bea9447ea968ec92_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6d88d8c28f9b449184647686d36c0f4a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iba4fa73897df4f2f8b41c9cf59104254_I20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="i61fa222768e04a5282a731261a6c92db_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icbc5630007bf4025ab16a7d4dbffd844_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8528ca596729487298c1867438155cae_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i40ba8428c60f458195216b9cdad76629_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5dae2c2009134637be004106df1ea18f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic91661eeb2ac4b54baf73ff541a0d067_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82b9d072356745b8a8360da4654cefcb_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b7b175d56e84a4eb34fc4843d19177f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6906beeb9ed54b49b24795b298297e33_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2aa31d2ad384df88f27d19c894362af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ef92042d6eb4a88aa6d7e9f6a975c9a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2e92033c77f541ad96bf59d87f798f51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2da554b61949435884736cf902fdd198_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e8dfcc988724045b9e80d0e895dc241_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic55a517d33ae4df6997fc44f609d4dfa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie26129e32e0847b28250bb921ab579d5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9c010ac793694faaa7a1d1b387f6224b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2ed6ecf9b84046808c7c599bf940501d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i37155bb755b5477e8fbeac7342fd0122_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5be18713caa049f98bd25ee684a48d54_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:ClientDirectBillingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie0d2caa28bcd47f08e1eeac2e9fde476_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i91a0583c3c0842779bca3dd6c45d8eae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:CommercialInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i029263e85dca4857a798b85580af5632_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic451e6718033441284f8fab001983ece_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:MedicareAndOtherGovernmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0934976619bb435f972eb14ee73bc235_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie0f79cb85f8e47b78073f6f575ba7ce5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">neo:SelfPayServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">neo:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if4c752dcd1ca45ff827097c99008c859_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:SeveranceAndOtherEmployeeCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99667b42ce8d4309bbdc2e318c38ed7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:FacilityFootprintOptimizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id986d81110f2465fa821ef6a63bd6657_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:ConsultingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:SeveranceAndOtherEmployeeCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:FacilityFootprintOptimizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:ConsultingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia5ea221a5e49464f94ac854559238414_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:SeveranceAndOtherEmployeeCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic9cb7bbbb4784cb198eec618ef26686a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:FacilityFootprintOptimizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifbec686c7a42479b9a9e4877006b5814_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">neo:ConsultingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7ef7183b65cb4f2f9f4adf9f0a5bb5b6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifdb4dbfbf647436ebf637a1b3d7cc7d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief61d5bc03a04fc793734af9dc810aab_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibe85cf00c6914ff48f891eb304bfa59f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ca7d72eb0dc4c1794a0c06f7f6fa78d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i61b3ab81b6f5476ea3f286adedb2c683_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:OnePointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i207470ae354943faa9001607fe4529a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad53f6ac95fd426b9947f85a93074c2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">neo:ZeroPointTwoFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if650c426e70e4f4a8a39d610bfaab9b5_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="ifa8cf70c5a204e4ba1dd0ff819094a7a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">neo:CappedCallTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic233566287de4d36bb1a6bb64acf5924_D20210120-20210120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-20</startDate>
            <endDate>2021-01-20</endDate>
        </period>
    </context>
    <context id="i52bebd24ded945888e4e9c5d03543ea8_D20221220-20221220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:PatentInfringementComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-20</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="i7d357522f0b4460a9c80ae8413a0dce2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d234e06879f4d25b290bf7fa83aa615_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">neo:FederalHealthcareProgramRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i954166d7487547128bc5b533688dd6d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001077183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">neo:PharmaServicesContractsWithHOOKIPAPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>neo:day</measure>
    </unit>
    <unit id="segment">
        <measure>neo:segment</measure>
    </unit>
    <unit id="patent">
        <measure>neo:patent</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF8zLTEtMS0xLTE2NzU0NQ_0f96bc16-fb2a-4bb2-b02b-340f85d32afe">0001077183</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF80LTEtMS0xLTE2NzU0NQ_2d98b125-48bc-4db6-85be-24687ab0d124">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF81LTEtMS0xLTE2NzU0NQ_1c98e454-fe09-492d-b977-fea2e33becea">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF82LTEtMS0xLTE2NzU0NQ_828937ea-ef98-4db5-9fb7-ae7c3b2f12c4">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180L2ZyYWc6M2Q1MmVhNzVkNzA4NDQ2YTk1NDVkNGJiMzk0N2E4YjkvdGFibGU6ODY5YTc2ZmM4YWE4NDc2ZTk1NGI0YWFmNGQ2NmQ3MmQvdGFibGVyYW5nZTo4NjlhNzZmYzhhYTg0NzZlOTU0YjRhYWY0ZDY2ZDcyZF83LTEtMS0xLTE2NzU0NQ_e3bab8ba-a346-426f-9e5b-ec0b39d64cc4">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y184NQ_800b66c1-8a0c-420c-9a42-8d8e7e80791d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6OTk3Y2E5M2I3ZGM4NDMyZDhhZTdlYWY5N2ZjYmI3M2MvdGFibGVyYW5nZTo5OTdjYTkzYjdkYzg0MzJkOGFlN2VhZjk3ZmNiYjczY18wLTAtMS0xLTE2NzU0NQ_b47703b9-06d5-41d7-93ec-055880182705">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xMjE_c2aaee65-a75a-4a8b-a0d8-a96e8aacb85c">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6MDEzM2EzNGVhMzQwNGQ4MzhhZmFkN2NiNjVhYTgxZmQvdGFibGVyYW5nZTowMTMzYTM0ZWEzNDA0ZDgzOGFmYWQ3Y2I2NWFhODFmZF8wLTAtMS0xLTE2NzU0NQ_00f3fd63-765c-4c06-8241-6af4178ba948">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yMTU_72c05c78-fe23-488a-a97e-62c9e90c1055">001-35756</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yMTg_02f7543a-02b2-4c63-93e4-f6c3b9a0b109">NEOGENOMICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18wLTAtMS0xLTE2NzU0NQ_5ec8eef5-d7ad-4804-a642-a831bddfea73">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18wLTMtMS0xLTE2NzU0NQ_6871d7e0-7088-4f13-8268-abb4997302e6">74-2897368</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18zLTAtMS0xLTE2NzU0NQ_ccfd564b-987c-4a95-b115-3ccc4d25a4d9">9490 NeoGenomics Way,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y18zLTEtMS0xLTE2NzU0NQ_43f1ae2b-0088-4f4e-bb2f-de08cb989fb9">Fort Myers,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y180LTAtMS0xLTE2NzU0NQ_34b1e42a-b42d-485f-bfe1-08d507d03235">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6YzJmYTY1NTc4ODcwNDVkNjk1ODVlNDZhNDMxNzBjOWMvdGFibGVyYW5nZTpjMmZhNjU1Nzg4NzA0NWQ2OTU4NWU0NmE0MzE3MGM5Y180LTMtMS0xLTE2NzU0NQ_c9a00190-1a29-49bd-8faa-38fa683cc94a">33912</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yODE_48a82dfa-0b87-4593-8b65-10746833ea30">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18yODQ_e61f0460-baa3-4ca9-80b4-231aaad1a6e9">768-0600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6NmUzNmU0MWY1MTE4NDdhNjhmYTBjYzAzZTA2MTAyY2UvdGFibGVyYW5nZTo2ZTM2ZTQxZjUxMTg0N2E2OGZhMGNjMDNlMDYxMDJjZV8xLTAtMS0xLTE2NzU0NQ_1f0cdf23-382b-4bf3-aced-690525be14d1">Common stock ($0.001 par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6NmUzNmU0MWY1MTE4NDdhNjhmYTBjYzAzZTA2MTAyY2UvdGFibGVyYW5nZTo2ZTM2ZTQxZjUxMTg0N2E2OGZhMGNjMDNlMDYxMDJjZV8xLTItMS0xLTE2NzU0NQ_be536784-4f39-4627-8e76-21e2d09e5044">NEO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6NmUzNmU0MWY1MTE4NDdhNjhmYTBjYzAzZTA2MTAyY2UvdGFibGVyYW5nZTo2ZTM2ZTQxZjUxMTg0N2E2OGZhMGNjMDNlMDYxMDJjZV8xLTQtMS0xLTE2NzU0NQ_e86b449c-9c3f-436c-b16f-8e7f4a5992b6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y183NTE_1cd39586-2e08-4fdb-bb72-2a8f3a122dab">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xMDc1_8d275d90-fb58-4381-b525-a46daa40f7ac">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6ODdiMjRiZmIyYmMwNDNjYWE4NDBmOTY2ZjMyOTFhNWUvdGFibGVyYW5nZTo4N2IyNGJmYjJiYzA0M2NhYTg0MGY5NjZmMzI5MWE1ZV8wLTAtMS0xLTE2NzU0NQ_0b95d3c2-cc32-45a0-917f-48b5c2902065">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6ODdiMjRiZmIyYmMwNDNjYWE4NDBmOTY2ZjMyOTFhNWUvdGFibGVyYW5nZTo4N2IyNGJmYjJiYzA0M2NhYTg0MGY5NjZmMzI5MWE1ZV8xLTQtMS0xLTE2NzU0NQ_26ebc3b3-7745-4b29-a258-6755a42add28">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGFibGU6ODdiMjRiZmIyYmMwNDNjYWE4NDBmOTY2ZjMyOTFhNWUvdGFibGVyYW5nZTo4N2IyNGJmYjJiYzA0M2NhYTg0MGY5NjZmMzI5MWE1ZV8yLTQtMS0xLTE2NzU0NQ_344359a8-a4d8-46c1-b760-58f197b97699">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xOTE4_5a3524d5-9d1e-4c5e-8c91-e3f88c0629f2">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ide298903e2814b3691a9fe4a01ba981e_I20230505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xL2ZyYWc6MWIwMDg3YTVjN2Q3NDU0OThjOTMwOTg2NTYyODI3NWMvdGV4dHJlZ2lvbjoxYjAwODdhNWM3ZDc0NTQ5OGM5MzA5ODY1NjI4Mjc1Y18xODUw_8f6fb5ff-bf5d-4303-92e1-20fca5894b83"
      unitRef="shares">127578138</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMy0yLTEtMS0xNjc1NDU_5bc931c9-9d9b-45da-966d-69362b226e9f"
      unitRef="usd">275609000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMy00LTEtMS0xNjc1NDU_552d5561-dba8-4af6-ba46-5f557471e735"
      unitRef="usd">263180000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNS0yLTEtMS0xNjc1NDU_3d0aee65-f295-4c78-8860-14800a838a93"
      unitRef="usd">142306000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNS00LTEtMS0xNjc1NDU_4a7647b6-5a6e-487e-9079-087010f55ce8"
      unitRef="usd">174809000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNi0yLTEtMS0xNjc1NDU_3f94ce4b-9e4e-48a6-b3d3-43c8a3e58874"
      unitRef="usd">118842000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNi00LTEtMS0xNjc1NDU_4ccf5fa5-05a3-45b1-b988-0b9c4a8c6b93"
      unitRef="usd">119711000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNy0yLTEtMS0xNjc1NDU_a226c791-ad8f-4d29-8a58-0ec14be6fd2a"
      unitRef="usd">24432000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNy00LTEtMS0xNjc1NDU_1c9079da-e991-42a4-9220-a0daf30db3cb"
      unitRef="usd">24277000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfOC0yLTEtMS0xNjc1NDU_7a6ecc71-2095-40c7-a1b7-8475e81fcacd"
      unitRef="usd">16185000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfOC00LTEtMS0xNjc1NDU_eddf52ae-7944-4fc2-a3a4-06fc9399a707"
      unitRef="usd">15237000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTAtMi0xLTEtMTY3NTQ1_bd5f8551-3e37-4dc6-adf0-ffb70dad92b7"
      unitRef="usd">7622000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTAtNC0xLTEtMTY3NTQ1_ed73fb8e-bfd7-41f4-a32e-65fe7cdeeaaf"
      unitRef="usd">8077000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTEtMi0xLTEtMTY3NTQ1_a7876481-2fd1-4b24-b5e4-dd34badc3f25"
      unitRef="usd">584996000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTEtNC0xLTEtMTY3NTQ1_e45d3880-4d40-4a04-aef1-4d3f00bedc9a"
      unitRef="usd">605291000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246M2E5NTUyNDM3YTY1NGNkNmI1NTdmNDcwZWYyNTVhOGJfNjM_ba48864c-e3bd-4961-a4f7-62d4f892340d"
      unitRef="usd">138863000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246M2E5NTUyNDM3YTY1NGNkNmI1NTdmNDcwZWYyNTVhOGJfNzA_e9fb6b8d-4847-4f2e-a799-3dbcdb8407ca"
      unitRef="usd">131930000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItMi0xLTEtMTY3NTQ1_d13f20e2-3e5f-44d0-8fdd-70412260b0a4"
      unitRef="usd">102845000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTItNC0xLTEtMTY3NTQ1_ce125c68-061e-46ca-8741-9d4991708031"
      unitRef="usd">102499000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTMtMi0xLTEtMTY3NTQ1_cfc70912-91a7-451b-9737-8c1743ec35af"
      unitRef="usd">93784000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTMtNC0xLTEtMTY3NTQ1_9c08d1d7-8714-4b98-9259-4ce70e9ab8aa"
      unitRef="usd">96109000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTUtMi0xLTEtMTY3NTQ1_57163e0b-d355-47df-aa23-c8f19b5aec34"
      unitRef="usd">399477000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTUtNC0xLTEtMTY3NTQ1_296eb2b8-48e4-4f46-92cd-b222b2c7b5e8"
      unitRef="usd">408260000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTYtMi0xLTEtMTY3NTQ1_1218b664-a13e-481c-b475-41182df96841"
      unitRef="usd">522766000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMTYtNC0xLTEtMTY3NTQ1_5afa49a0-4ef9-4b6e-b424-edd042a722d8"
      unitRef="usd">522766000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjEtMi0xLTEtMTY3NTQ1_ce4ae0a9-f264-4342-978c-9479194064f3"
      unitRef="usd">5306000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjEtNC0xLTEtMTY3NTQ1_7603ff3a-18f9-4b9b-bd30-15c541c613ff"
      unitRef="usd">5109000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjItMi0xLTEtMTY3NTQ1_908a2bd2-9ffc-4413-8a97-4f75883c978c"
      unitRef="usd">1124178000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjItNC0xLTEtMTY3NTQ1_c66febe2-1e51-4227-963b-1ee2406fef5e"
      unitRef="usd">1134743000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjMtMi0xLTEtMTY3NTQ1_5189001b-2615-4293-96b3-0ff490531810"
      unitRef="usd">1709174000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjMtNC0xLTEtMTY3NTQ1_0ce1c7ab-6a5f-44d5-88db-74ccc6471381"
      unitRef="usd">1740034000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjYtMi0xLTEtMTY3NTQ1_6a0a4221-204e-43b9-9b31-834860d9058e"
      unitRef="usd">22712000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjYtNC0xLTEtMTY3NTQ1_5bcdcc23-3ce0-469b-ae21-d8b84c85f17a"
      unitRef="usd">20510000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjctMi0xLTEtMTY3NTQ1_5b6dcc81-e61c-4455-8c0a-fc9506bd364c"
      unitRef="usd">32891000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjctNC0xLTEtMTY3NTQ1_0a287ec2-b338-407d-8c84-4eaea5227343"
      unitRef="usd">40141000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjgtMi0xLTEtMTY3NTQ1_32ecb73f-8aaa-4053-b704-279c6944ace4"
      unitRef="usd">17964000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjgtNC0xLTEtMTY3NTQ1_f3d52c19-dbbe-4646-9303-594d6eb17d6f"
      unitRef="usd">15070000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjktMi0xLTEtMTY3NTQ1_fdd88853-d96c-45d7-95c7-87c3b2f0a604"
      unitRef="usd">38000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMjktNC0xLTEtMTY3NTQ1_b2755a40-21b2-41f9-b764-113a3cebed1a"
      unitRef="usd">70000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzAtMi0xLTEtMTY3NTQ1_87cee8e2-5156-40c5-8ef1-4ccdcec0b238"
      unitRef="usd">6934000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzAtNC0xLTEtMTY3NTQ1_a5fd3cb3-e097-4f21-b68a-b85bf516d858"
      unitRef="usd">6584000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzMtMi0xLTEtMTY3NTQ1_f211e5fd-9ce5-421c-9afa-452d4958085d"
      unitRef="usd">6067000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzMtNC0xLTEtMTY3NTQ1_9dcd315f-76a8-4b09-80e3-ae7fee9c4498"
      unitRef="usd">7557000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzQtMi0xLTEtMTY3NTQ1_7d69c2bc-e56a-4c8f-8ba5-83dce5a32be0"
      unitRef="usd">86606000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzQtNC0xLTEtMTY3NTQ1_d453f42d-e9c6-4776-be3f-5e15239305a9"
      unitRef="usd">89932000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzYtMi0xLTEtMTY3NTQ1_a8b5931e-bee9-499c-aca6-c606076ab2e8"
      unitRef="usd">536037000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzYtNC0xLTEtMTY3NTQ1_ee5ec29b-7459-44fc-813d-859bca58d7eb"
      unitRef="usd">535322000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzgtMi0xLTEtMTY3NTQ1_88df0e93-da9f-49a9-a8dc-fd7609a678d2"
      unitRef="usd">67319000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfMzgtNC0xLTEtMTY3NTQ1_788227a7-8f7c-40cb-a889-9431b5274b69"
      unitRef="usd">68952000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDEtMi0xLTEtMTY3NTQ1_9272280f-ac81-4d28-a358-853e48eef4e1"
      unitRef="usd">31715000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDEtNC0xLTEtMTY3NTQ1_25eb5c7a-9da5-40cf-aae5-062eafc92748"
      unitRef="usd">34750000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDItMi0xLTEtMTY3NTQ1_1e08ccd1-ed05-41db-8645-66de5cf56eb2"
      unitRef="usd">13035000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDItNC0xLTEtMTY3NTQ1_0c1ce738-8471-4d94-9924-c0c32cec8343"
      unitRef="usd">13055000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDMtMi0xLTEtMTY3NTQ1_0511b5d9-2aee-4f9a-b769-bfa877441cf3"
      unitRef="usd">648106000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDMtNC0xLTEtMTY3NTQ1_c6fb88f4-1b6e-4c07-9596-dbefcdcc4e7a"
      unitRef="usd">652079000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDQtMi0xLTEtMTY3NTQ1_cf646798-ffb0-4dd4-8963-6c0bba2e1aab"
      unitRef="usd">734712000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDQtNC0xLTEtMTY3NTQ1_c3f95156-3ff1-459f-9ef5-59dff7d9680b"
      unitRef="usd">742011000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDUtMi0xLTEtMTY3NTQ1_d935d85e-ebc4-43b6-b9c1-826bebe27cd4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDUtNC0xLTEtMTY3NTQ1_819b8937-611a-452d-9f7d-0ebf58ae6899"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMTg_762f93f3-fcec-4899-9b9a-8a84e2a5255f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMTg_83392568-96e8-4bb4-9f9b-82259f7cda0a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMzM_0ce7df19-7eec-4d04-8acd-aaa6e246431e"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfMzM_97fdc5eb-d62f-4c69-888e-bbac9e4ba230"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNTU_7bf1fcc5-6100-438b-8798-4d68891e6283"
      unitRef="shares">127200491</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNTU_982c9308-cf2a-4eb1-ab83-22bbcc3f686d"
      unitRef="shares">127200491</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNjI_b8670134-d43c-4179-b4a9-7850b6b9b6da"
      unitRef="shares">126913992</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMC0xLTEtMTY3NTQ1L3RleHRyZWdpb246YzY5ZjliZWU4MjAyNGJiN2E2MGUwZjRlNDFkMWY1MTBfNjI_ca1cf557-67ce-4894-9920-02867bd86f97"
      unitRef="shares">126913992</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctMi0xLTEtMTY3NTQ1_57cf3f8a-59e8-4c16-bf3a-7fdacc9d0e36"
      unitRef="usd">127000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDctNC0xLTEtMTY3NTQ1_c4b9528f-f779-47f5-bcb7-5f517210eb1a"
      unitRef="usd">127000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDgtMi0xLTEtMTY3NTQ1_89af1e16-39d6-4cde-9a90-2bae8e38ae61"
      unitRef="usd">1167051000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDgtNC0xLTEtMTY3NTQ1_9d87bd29-9b9b-4306-9436-779503dfb41c"
      unitRef="usd">1160882000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDktMi0xLTEtMTY3NTQ1_4352c6ab-e807-43ed-b306-9a26cc638423"
      unitRef="usd">-2834000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNDktNC0xLTEtMTY3NTQ1_d26951f7-a9f9-40a5-8473-2e719498097c"
      unitRef="usd">-3899000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTAtMi0xLTEtMTY3NTQ1_6b1aae06-65ad-4c11-8c20-a09075eb9fc4"
      unitRef="usd">-189882000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTAtNC0xLTEtMTY3NTQ1_28c579a9-0c4f-4656-ae28-6f18e4d3f7c1"
      unitRef="usd">-159087000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTEtMi0xLTEtMTY3NTQ1_f965dc36-7fd5-4ca9-aa69-df98a546df03"
      unitRef="usd">974462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTEtNC0xLTEtMTY3NTQ1_cb015538-835c-4df6-9ea9-2cebf7f3099b"
      unitRef="usd">998023000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTItMi0xLTEtMTY3NTQ1_3de77bc8-411f-4c97-a0f2-ee8bba0b260c"
      unitRef="usd">1709174000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xOS9mcmFnOmQ0MmUxMzc2NGU0NzQwNzZhYTE1MTkyMmNlZWU2MzYzL3RhYmxlOjc0MTVmOGRlMjhlZjQ5ZDM5Yjg4M2ZhMjhiY2U3MzBhL3RhYmxlcmFuZ2U6NzQxNWY4ZGUyOGVmNDlkMzliODgzZmEyOGJjZTczMGFfNTItNC0xLTEtMTY3NTQ1_e4c1c68a-6fa5-4ef8-887c-b3ba8d2239ee"
      unitRef="usd">1740034000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMy0xLTEtMS0xNjc1NDU_135f1747-f423-40c1-ab85-4cf9508a2d42"
      unitRef="usd">114869000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMy0zLTEtMS0xNjc1NDU_af3fce82-4739-4c23-84e9-22328d849f99"
      unitRef="usd">98791000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNC0xLTEtMS0xNjc1NDU_2f4b617d-e21c-46ee-83ab-e3569dbaa6e6"
      unitRef="usd">22351000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNC0zLTEtMS0xNjc1NDU_7141825e-5ebd-4492-b1a0-72cada340efc"
      unitRef="usd">18378000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNS0xLTEtMS0xNjc1NDU_db8829d9-e110-40e2-9fa9-c2375eb180c0"
      unitRef="usd">137220000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNS0zLTEtMS0xNjc1NDU_86a0ea6c-1157-46cc-9828-a7e4e54cc3f0"
      unitRef="usd">117169000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNy0xLTEtMS0xNjc1NDU_e47cb1d5-5afe-410c-89ef-fbc637e23d5a"
      unitRef="usd">82406000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfNy0zLTEtMS0xNjc1NDU_84bca0e3-ee2e-4eeb-b37b-deea0e49f099"
      unitRef="usd">78937000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfOS0xLTEtMS0xNjc1NDU_4439f81d-aca7-4245-9ffd-2bd1ee88c306"
      unitRef="usd">54814000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfOS0zLTEtMS0xNjc1NDU_dbbcd18e-71d5-4150-b61a-eed129e341a7"
      unitRef="usd">38232000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTEtMS0xLTEtMTY3NTQ1_5b965920-1972-481b-89e1-073441002557"
      unitRef="usd">61549000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTEtMy0xLTEtMTY3NTQ1_85a867b9-fdb7-4626-b63e-7f98f1cf7e28"
      unitRef="usd">66248000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTItMS0xLTEtMTY3NTQ1_ce2da932-0316-470a-a70e-7c3cc5933b76"
      unitRef="usd">7395000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTItMy0xLTEtMTY3NTQ1_9cdf1354-5f28-4fb7-b56d-f2fa35874edb"
      unitRef="usd">7713000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTMtMS0xLTEtMTY3NTQ1_9cc24f35-40f5-4049-9e37-fd997526534a"
      unitRef="usd">16259000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTMtMy0xLTEtMTY3NTQ1_71d3ecd1-5a5a-4470-8c04-20b170b6e229"
      unitRef="usd">16299000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:RestructuringCharges
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMS0xLTEtMTcyMDg0_4880c224-39d5-4229-83be-747ddada2099"
      unitRef="usd">4684000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMy0xLTEtMTcyMDg3_2f2553d8-1c3a-4ec2-b219-e71d712a83db"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTQtMS0xLTEtMTY3NTQ1_a57ce70e-3bf9-4201-b8ac-c7782be3c22b"
      unitRef="usd">89887000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTQtMy0xLTEtMTY3NTQ1_96e367db-37fc-4cd7-8e1a-533cc99c3183"
      unitRef="usd">90260000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMS0xLTEtMTY3NTQ1_d3618c6f-d616-4cfb-9076-5625143d7740"
      unitRef="usd">-35073000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTUtMy0xLTEtMTY3NTQ1_d624831c-bb07-414c-9908-7a19cc6b6749"
      unitRef="usd">-52028000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTYtMS0xLTEtMTY3NTQ1_f77e0466-9253-403e-b195-c0f201e05a98"
      unitRef="usd">1467000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTYtMy0xLTEtMTY3NTQ1_04319ed1-42be-4470-aaa6-eb86a1f46af7"
      unitRef="usd">-1301000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTctMS0xLTEtMTY3NTQ1_f1638474-9a50-4b05-889c-7f93ebe0ed77"
      unitRef="usd">-114000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMTctMy0xLTEtMTY3NTQ1_7b3d2464-2ff1-4ddc-aa92-92a17af69938"
      unitRef="usd">168000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjEtMS0xLTEtMTY3NTQ1_77c8fd0d-43d6-4e6f-bdb3-334eb8a93678"
      unitRef="usd">-33720000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjEtMy0xLTEtMTY3NTQ1_6fa525ea-0115-4b80-88c2-c8458ea8df83"
      unitRef="usd">-53161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjItMS0xLTEtMTY3NTQ1_826a3157-f431-4b40-9715-bc9e47d42f8a"
      unitRef="usd">-2925000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjItMy0xLTEtMTY3NTQ1_c4d45d99-137f-464c-b9d6-274321e54425"
      unitRef="usd">-3753000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjMtMS0xLTEtMTY3NTQ1_154c5601-d62b-4c07-b500-85185541b341"
      unitRef="usd">-30795000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMjMtMy0xLTEtMTY3NTQ1_78d0dbbd-8582-4ab2-96a8-0285f3ea817d"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzEtMS0xLTEtMTY3NTQ1_dc7a037c-ab76-4ded-ada8-146fa08a780c"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzEtMy0xLTEtMTY3NTQ1_ebf0a8bc-886c-4c1a-a811-bd2ab651be0e"
      unitRef="usdPerShare">-0.40</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzItMS0xLTEtMTY3NTQ1_924c053b-1e72-4728-99f0-2ad73eb26948"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzItMy0xLTEtMTY3NTQ1_89fad222-631d-4412-9b44-9dd2f3fcee3a"
      unitRef="usdPerShare">-0.40</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzUtMS0xLTEtMTY3NTQ1_083248af-b360-4859-ad47-92edc6cd6db0"
      unitRef="shares">125026000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzUtMy0xLTEtMTY3NTQ1_967ba903-1f72-4a98-bf43-da0b08eb3201"
      unitRef="shares">123630000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzYtMS0xLTEtMTY3NTQ1_5102ff0d-f773-46af-8dea-a5f039133ea9"
      unitRef="shares">125026000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yMi9mcmFnOjY0MjgzZGJmMmIwYTQ4YzBhZThkMzAxNWRmZDE0MzQxL3RhYmxlOjVhODFlYzcxNmUyYjQxZTdhNDVjZjNiMzY4NDAyOWJlL3RhYmxlcmFuZ2U6NWE4MWVjNzE2ZTJiNDFlN2E0NWNmM2IzNjg0MDI5YmVfMzYtMy0xLTEtMTY3NTQ1_43e9940c-26a7-4124-aa7a-9116f6a201fb"
      unitRef="shares">123630000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMi0yLTEtMS0xNjc1NDU_20f41089-30aa-4324-ae8f-bd06fd95fe4a"
      unitRef="usd">-30795000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMi00LTEtMS0xNjc1NDU_6e8eb65f-e55f-4bb9-aeb0-dccc5afc992d"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfNi0yLTEtMS0xNjc1NDU_4d37a016-307b-4937-aacd-9be4745d1fd7"
      unitRef="usd">1065000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfNi00LTEtMS0xNjc1NDU_b1cc1c42-7067-4d76-b0d8-1b754a534a93"
      unitRef="usd">-2371000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfOS0yLTEtMS0xNjc1NDU_17cbfaf8-8a2b-4c6a-b6fa-8417563f6823"
      unitRef="usd">1065000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfOS00LTEtMS0xNjc1NDU_db6154c2-28f9-4248-bf06-2816fd11ce77"
      unitRef="usd">-2371000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMTAtMi0xLTEtMTY3NTQ1_5612af4f-900c-4d93-907c-f9473c894cc0"
      unitRef="usd">-29730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yNS9mcmFnOmZhZmQ4NjUxN2Q1NDQ3YWQ4NmQ2NmY5MTM5YWZiZWM5L3RhYmxlOmI2NWEwYTQyYTQ2ZjQ0N2JiYjc0YjA5MGQ1ZGVhMmZkL3RhYmxlcmFuZ2U6YjY1YTBhNDJhNDZmNDQ3YmJiNzRiMDkwZDVkZWEyZmRfMTAtNC0xLTEtMTY3NTQ1_52dc042a-a1cb-4df9-9370-1fcc915ed21d"
      unitRef="usd">-51779000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i2707608d9f224b6ea1ad5d5d7f84d1b1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi02LTEtMS0xNjc1NDU_77d168ee-4579-4a19-a40b-dfad1ac05224"
      unitRef="shares">126913992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2707608d9f224b6ea1ad5d5d7f84d1b1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi04LTEtMS0xNjc1NDU_a5308337-6b0b-4945-92eb-0d394b50ab1e"
      unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i876d38822e24498d879a3ab240be09a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xMC0xLTEtMTY3NTQ1_209d9084-ad54-4e70-988a-d739f17a56f9"
      unitRef="usd">1160882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i035f530335b749e188af838868c59214_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xMi0xLTEtMTY3NTQ1_d764d640-0b68-4388-b969-42a243b2bdde"
      unitRef="usd">-3899000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b1caf8ef350438b9c76c704b6ea7ba7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xNC0xLTEtMTY3NTQ1_0cab2750-d58b-4fc1-9127-f890313e52e5"
      unitRef="usd">-159087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMi0xNi0xLTEtMTY3NTQ1_39619022-5127-4216-87af-9f84aae543aa"
      unitRef="usd">998023000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMy02LTEtMS0xNjc1NDU_a14e4043-6375-4405-8fb9-a50a81f65304"
      unitRef="shares">96733</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMy0xMC0xLTEtMTY3NTQ1_e19e947f-63ef-468b-ac9e-09c8bf15e99a"
      unitRef="usd">811000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMy0xNi0xLTEtMTY3NTQ1_1a292cd5-3982-43ad-b5c8-e9ab0c2cc4ae"
      unitRef="usd">811000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNC02LTEtMS0xNjc1NDU_3ece2fca-5643-4e53-a7d0-96b1b023bd0e"
      unitRef="shares">114738</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNC0xMC0xLTEtMTY3NTQ1_419fb858-19df-4d6b-a977-dffb684b315e"
      unitRef="usd">-147000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNC0xNi0xLTEtMTY3NTQ1_3ad5acb4-626c-4372-be84-f414188f5265"
      unitRef="usd">-147000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5b06745c2b124586ba94969fbcef0d37_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNS02LTEtMS0xNjc1NDU_1b88c0ae-5221-4c03-af3a-97aaf3b6adaf"
      unitRef="shares">75028</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNS0xMC0xLTEtMTY3NTQ1_48f815be-a1c9-4677-b349-4fb9c97da64e"
      unitRef="usd">751000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNS0xNi0xLTEtMTY3NTQ1_5b8fd7d5-e9ea-4ecd-bfe5-e09b59a771eb"
      unitRef="usd">751000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNi0xMC0xLTEtMTY3NTQ1_575b577c-d610-4158-ae7d-d5155c62f0b0"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNi0xNi0xLTEtMTY3NTQ1_f5cf3dda-7fb9-4afc-bae2-a83959c53526"
      unitRef="usd">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNy0xMC0xLTEtMTY3NTQ1_1bc064ba-e357-4d11-a03a-20b5e3b796d4"
      unitRef="usd">275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfNy0xNi0xLTEtMTY3NTQ1_513c8dad-2304-433f-a5cb-700c59762ae8"
      unitRef="usd">275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a96e1e629b841478bbb4b75ddbccdd6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOC0xMC0xLTEtMTY3NTQ1_3ed9d52e-d3e1-4e7c-999a-15d4a15c4300"
      unitRef="usd">4483000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOC0xNi0xLTEtMTY3NTQ1_e6843bcd-f367-484c-b977-bc795e610285"
      unitRef="usd">4483000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib2722299e2e54f68a4514ccee1e3eb82_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOS0xMi0xLTEtMTY3NTQ1_b222691c-7140-4932-bfdd-d83a4a346752"
      unitRef="usd">1065000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfOS0xNi0xLTEtMTY3NTQ1_81bee72d-8233-429c-8962-1872515358ac"
      unitRef="usd">1065000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3bfee91888ba4bbe8c107385485e0364_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTAtMTQtMS0xLTE2NzU0NQ_35699244-40e7-494f-95e8-369a859d0c6e"
      unitRef="usd">-30795000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTAtMTYtMS0xLTE2NzU0NQ_d31180e6-0222-4f09-b2de-3deeafb8fac6"
      unitRef="usd">-30795000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iaba385e087f94defb90c20be01b30692_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtNi0xLTEtMTY3NTQ1_c3d1a3bb-5278-4043-8bee-b46aa35cca7c"
      unitRef="shares">127200491</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaba385e087f94defb90c20be01b30692_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtOC0xLTEtMTY3NTQ1_e3a78a2c-1ae0-4a6a-a410-8379dd9445ae"
      unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3537e2b2319b47afafdc2563a4fe34c9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTAtMS0xLTE2NzU0NQ_7934c582-7925-403e-a21c-3fa51b77a953"
      unitRef="usd">1167051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0b5e4798787448caf33060025f52e51_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTItMS0xLTE2NzU0NQ_48654c14-c9d9-463c-b7fa-c69b63f96a46"
      unitRef="usd">-2834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2f9e943825942a7b01c83b2eaacb3d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTQtMS0xLTE2NzU0NQ_efb5402a-1bef-4143-9495-65c9421e553a"
      unitRef="usd">-189882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOmFjZTg3NmNkODI3MzQwYTBhMTBlOTM2NjA0NGE5OTYyL3RhYmxlcmFuZ2U6YWNlODc2Y2Q4MjczNDBhMGExMGU5MzY2MDQ0YTk5NjJfMTEtMTYtMS0xLTE2NzU0NQ_09fb7597-b520-4eca-8490-db1267fec650"
      unitRef="usd">974462000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i79595b9a231b4236a3065c84f3b094e4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi02LTEtMS0xNjc3MjI_ac7f7d5b-f79d-405c-a0aa-e63b31fc9a20"
      unitRef="shares">124107500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i79595b9a231b4236a3065c84f3b094e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi04LTEtMS0xNjc3MjI_1ea76774-089b-46fb-9172-3467cf0bc66d"
      unitRef="usd">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i312ff0fa5d2e4b28aa9a59ff81523b57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xMC0xLTEtMTY3NzIy_5fbaf557-3623-4b31-9bcc-56a93ad40625"
      unitRef="usd">1123628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cf5dc7a570d4b40afef1ad9a2c2afa0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xMi0xLTEtMTY3NzIy_bb156ea8-9a90-4f1a-8054-8e874b83ef0e"
      unitRef="usd">-638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie714ae56c66b4a099f1db8dc8c6474fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xNC0xLTEtMTY3NzIy_a05f5dc7-b997-4c12-bf65-f89bfc35a791"
      unitRef="usd">-14837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i245e7c47a46c401abe4388c05022edc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMi0xNi0xLTEtMTY3NzIy_5dc58ce0-9e90-479a-8f52-5f41d121cc3b"
      unitRef="usd">1108277000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMy02LTEtMS0xNjc3MjI_a0d2e076-9db0-4691-b264-435dad9f1dd2"
      unitRef="shares">47853</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMy0xMC0xLTEtMTY3NzIy_0dd4aca1-f474-4a9b-ba10-f910ba402f70"
      unitRef="usd">971000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMy0xNi0xLTEtMTY3NzIy_8cd1c851-2549-43a4-9454-4afd97c754ae"
      unitRef="usd">971000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNC02LTEtMS0xNjc3MjI_adc685a7-adac-4e39-8c62-8ee343156277"
      unitRef="shares">100253</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNC0xMC0xLTEtMTY3NzIy_0afdefb8-005d-45fb-8624-3698e9376342"
      unitRef="usd">-1049000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNC0xNi0xLTEtMTY3NzIy_0c3db3ee-fb35-4a82-8f98-642f8931d064"
      unitRef="usd">-1049000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS02LTEtMS0xNjc3MjI_7036d4fe-bbd1-487f-bd6b-c54f0e2f293b"
      unitRef="shares">466609</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i17cc40b5dd8f475da9967febdb818974_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS04LTEtMS0xNjc3MjI_fd1492f0-abff-451e-8ef1-9c4f68387fa9"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS0xMC0xLTEtMTY3NzIy_d1c91250-28c3-4abb-b9ea-14cd6c95d5b1"
      unitRef="usd">6479000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNS0xNi0xLTEtMTY3NzIy_4c99fa3a-d46e-4ac6-90de-3f6db695af0d"
      unitRef="usd">6480000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNy0xMC0xLTEtMTY3NzIy_76c65ab3-ee25-4d0f-bae6-db742b83ed21"
      unitRef="usd">249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfNy0xNi0xLTEtMTY3NzIy_62da73cf-4b98-45f2-963d-d4fa94870bac"
      unitRef="usd">249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f29a20fd62743bfb1fc8c0d319d8dbd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOC0xMC0xLTEtMTY3NzIy_e09573f5-3654-48e1-a025-117f8d33a13b"
      unitRef="usd">11855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOC0xNi0xLTEtMTY3NzIy_09f402f8-e061-44de-a7a4-d784ec0ba962"
      unitRef="usd">11855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifdd1f4fdbef9465d8834bed27b491755_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOS0xMi0xLTEtMTY3NzIy_6ab93b2a-952c-449c-8d12-db4da32487a2"
      unitRef="usd">-2371000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfOS0xNi0xLTEtMTY3NzIy_03903097-37c7-41fa-b0c3-a817f447a699"
      unitRef="usd">-2371000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i2d22b4cf5a3440539edd117dd9c35a86_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTAtMTQtMS0xLTE2NzcyMg_e58a7507-0c4d-4fd1-a6cc-f948cafaef7e"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTAtMTYtMS0xLTE2NzcyMg_f3b7d644-4f19-4b60-a52e-1b6026579ef3"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i67d2ec838c7d43b1814352266b3a6fe5_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtNi0xLTEtMTY3NzIy_33521879-5415-4164-8927-2df248eb94b7"
      unitRef="shares">124722215</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i67d2ec838c7d43b1814352266b3a6fe5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtOC0xLTEtMTY3NzIy_6ed1c1ef-ec92-41e7-a9ac-191de87b7dcf"
      unitRef="usd">125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1ec944b9e4b458fa0a2f3458676f6d7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTAtMS0xLTE2NzcyMg_c4a2873e-d90c-4041-855e-076881c7f283"
      unitRef="usd">1142133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6bba56276d3c4175888b91c4ac33bc23_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTItMS0xLTE2NzcyMg_fe633e71-5eb9-43b0-932a-4199bcb36f7a"
      unitRef="usd">-3009000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8925c88775946e58ab40caee41543ef_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTQtMS0xLTE2NzcyMg_519ae376-a754-4502-8294-366f28086051"
      unitRef="usd">-64245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f5ac7b5971d4ab4bfc8063f863485f2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18yOC9mcmFnOjIwNDg3YTc2OGNkZTRkZDhhNzIzNDM2ZDlhNmRjMzM0L3RhYmxlOjVjYWRlODU2OGViNjRmNDU4ZDA4MmRjOTI1OTI0N2MxL3RhYmxlcmFuZ2U6NWNhZGU4NTY4ZWI2NGY0NThkMDgyZGM5MjU5MjQ3YzFfMTEtMTYtMS0xLTE2NzcyMg_1ca25585-1cf2-42c3-b1c6-0f49eabd5485"
      unitRef="usd">1075004000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMy0yLTEtMS0xNjc1NDU_ca19906c-8572-4b35-98b4-7fbe9a974f84"
      unitRef="usd">-30795000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMy00LTEtMS0xNjc1NDU_8b399075-ad8a-41e7-b0db-f4266703280e"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNS0yLTEtMS0xNjc1NDU_df22972d-c66e-45ae-9691-81cfc618841e"
      unitRef="usd">9048000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNS00LTEtMS0xNjc1NDU_e3645c43-2f47-4475-bbf4-cf217a23a92b"
      unitRef="usd">8395000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNi0yLTEtMS0xNjc1NDU_ea837c63-9f46-420d-b4fb-1c3cdd828659"
      unitRef="usd">8783000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNi00LTEtMS0xNjc1NDU_f656615c-c317-4283-a867-ce1a4572ea00"
      unitRef="usd">8490000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNy0yLTEtMS0xNjc1NDU_b4efb194-13ab-4d57-99d7-d0dc166b50e6"
      unitRef="usd">4758000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNy00LTEtMS0xNjc1NDU_6cb93d14-1bb1-4978-ad9b-d601fef3a5a5"
      unitRef="usd">12103000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOC0yLTEtMS0xNjc1NDU_5422f6af-0aa2-446d-b41d-c4938e91ecbe"
      unitRef="usd">2330000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOC00LTEtMS0xNjc1NDU_912c7868-dcca-4e76-bbb7-5ae42ecfdbc9"
      unitRef="usd">2653000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOS0yLTEtMS0xNjc1NDU_9d83c037-a18c-455c-9d51-8076797503c0"
      unitRef="usd">669000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfOS00LTEtMS0xNjc1NDU_1c43bf34-6760-44d7-a9c6-f30041d0d6fc"
      unitRef="usd">661000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTAtMi0xLTEtMTY3NTQ1_e8c9a959-6fbd-4464-bdbe-083c25babeb1"
      unitRef="usd">46000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTAtNC0xLTEtMTY3NTQ1_e1e72fa9-f58b-4b97-9a1b-e50d8cb9cc63"
      unitRef="usd">45000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTUtMi0xLTEtMTY3NTQ1_fa910f31-bc70-42c4-a6ed-c649c80e30b6"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTUtNC0xLTEtMTY3NTQ1_fc3e9bf9-49bb-483b-9ebb-d706b6c62564"
      unitRef="usd">2048000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTMtMi0xLTEtMTc0ODE4_5d8b5a8c-e44d-4e98-a99e-d3749c060d5b"
      unitRef="usd">923000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTMtNC0xLTEtMTc1OTM3_3fa646af-f125-4af1-9309-c60015602f6d"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTctMi0xLTEtMTY3NTQ1_9c5224f7-09e8-42fd-b195-cc08aebbc385"
      unitRef="usd">-31000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTctNC0xLTEtMTY3NTQ1_2359d14c-7000-475b-b124-8dbf31f8698d"
      unitRef="usd">1126000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTktMi0xLTEtMTY3NTQ1_762b8e22-b07c-409e-b88f-307c272bfdd7"
      unitRef="usd">-870000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMTktNC0xLTEtMTY3NTQ1_84b64c52-0a76-46f3-b1b8-ca194848382f"
      unitRef="usd">-1334000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjAtMi0xLTEtMTY3NTQ1_9a92a8f3-2f00-46db-b56b-d226d21aedb0"
      unitRef="usd">200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjAtNC0xLTEtMTY3NTQ1_2fd4609f-9a56-4570-b18a-490d613f86bd"
      unitRef="usd">445000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItMi0xLTEtMTY3NTQ1_2f2ebead-572f-4784-8048-7bc64705452a"
      unitRef="usd">1187000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItNC0xLTEtMTY3NTQ1_877c9deb-d58a-4b0b-b9d2-1f7be4a034f4"
      unitRef="usd">2044000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItMi0xLTEtMTc3NDY4_a0a78806-ff2b-467b-a329-12a7a42b8c57"
      unitRef="usd">-1722000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjItNC0xLTEtMTc3NDY4_697834fa-fb88-454e-a41e-88cdd4b9dcba"
      unitRef="usd">-2832000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjMtMi0xLTEtMTc3NDY4_2b9b0c09-adcf-4e89-8f16-4f52cd3c4a10"
      unitRef="usd">3035000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjMtNC0xLTEtMTc3NDY4_4a91f81e-fe5f-48b0-ac5a-d08c3b905c09"
      unitRef="usd">3765000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtMi0xLTEtMTc3NDY4_d9c62145-f69b-493a-9b0e-ed0ba3dfb157"
      unitRef="usd">-7250000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtNC0xLTEtMTc3NDY4_fc8d84b0-eab8-4d65-9e2a-08a779e5ec6a"
      unitRef="usd">-5985000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtMi0xLTEtMTY3NTQ1_2bacde25-6d88-4c57-9b1b-7d490af53e0c"
      unitRef="usd">4101000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjQtNC0xLTEtMTY3NTQ1_cf0741bb-13ff-47f6-b1eb-3391e15f41ce"
      unitRef="usd">2680000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjUtMi0xLTEtMTY3NTQ1_39ba5361-7215-45e9-9727-4fbd05156266"
      unitRef="usd">-12692000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjUtNC0xLTEtMTY3NTQ1_1242f56c-4a63-4d57-87a6-1d56072f0c00"
      unitRef="usd">-29040000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjctMi0xLTEtMTY3NTQ1_de30eb93-d2ac-488a-bd6b-684153372506"
      unitRef="usd">6756000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjctNC0xLTEtMTY3NTQ1_ca4eaa3e-1f94-41b6-a02a-e9f9ca95e8b7"
      unitRef="usd">16167000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjgtMi0xLTEtMTY3NTQ1_a3539fe6-6283-40b9-a9f3-9d185e9c3ecf"
      unitRef="usd">40425000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjgtNC0xLTEtMTY3NTQ1_7fac4859-3921-4f0c-a488-f10ea51f6bc9"
      unitRef="usd">36438000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjktMi0xLTEtMTY3NTQ1_4020a56b-61ba-4b4a-b886-20bc9fbd5639"
      unitRef="usd">9927000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMjktNC0xLTEtMTY3NTQ1_b5d27dfc-8fa4-4eef-a9dc-a64efd0ac8bf"
      unitRef="usd">8219000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzMtMi0xLTEtMTY3NTQ1_5ca1138b-ceb7-4697-abc4-214425694d1b"
      unitRef="usd">23742000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzMtNC0xLTEtMTY3NTQ1_7317abe7-d0ad-447b-a7b0-20f1c870ff3e"
      unitRef="usd">12052000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <neo:RepaymentsOfEquipmentAndOtherFinanceObligation
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzUtMi0xLTEtMTY3NTQ1_a3617a34-6afe-439e-8542-c4eb803aa172"
      unitRef="usd">32000</neo:RepaymentsOfEquipmentAndOtherFinanceObligation>
    <neo:RepaymentsOfEquipmentAndOtherFinanceObligation
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzUtNC0xLTEtMTY3NTQ1_b7c02e39-135c-4a70-ace1-618f5fa4303b"
      unitRef="usd">346000</neo:RepaymentsOfEquipmentAndOtherFinanceObligation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzYtMi0xLTEtMTY3NTQ1_060f93be-c614-400c-b3eb-132a3b3e35ca"
      unitRef="usd">1411000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfMzYtNC0xLTEtMTY3NTQ1_57b25107-c8df-4e39-8777-df29498d9f42"
      unitRef="usd">6403000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDEtMi0xLTEtMTY3NTQ1_25caed04-614c-4e55-8a41-c5792a9f04ab"
      unitRef="usd">1379000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDEtNC0xLTEtMTY3NTQ1_874a956d-aff4-408a-b2cd-cb02d691a90a"
      unitRef="usd">6057000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDMtMi0xLTEtMTY3NTQ1_8e30ed8b-26b9-40b5-8425-2efbb5b14396"
      unitRef="usd">12429000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDMtNC0xLTEtMTY3NTQ1_e57a7b3c-6fae-4906-a74f-a2948a57e4b5"
      unitRef="usd">-10931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDQtMi0xLTEtMTY3NTQ1_347256a5-74ea-42fc-8829-1919221faf2a"
      unitRef="usd">263180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i245e7c47a46c401abe4388c05022edc4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDQtNC0xLTEtMTY3NTQ1_f8be3f91-74a6-4d62-9a70-8bb1f2006a35"
      unitRef="usd">316827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDUtMi0xLTEtMTY3NTQ1_7ce4548c-5e51-4d9d-b2b5-95fed2ad8178"
      unitRef="usd">275609000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f5ac7b5971d4ab4bfc8063f863485f2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjY4YjM4Y2Y0MWVmODQ1ZTA4YmY4MDk5YzQ1MWYxNTVlL3RhYmxlcmFuZ2U6NjhiMzhjZjQxZWY4NDVlMDhiZjgwOTljNDUxZjE1NWVfNDUtNC0xLTEtMTY3NTQ1_0a13901c-c98d-4218-a19e-b0104e39c027"
      unitRef="usd">305896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfOS0yLTEtMS0xNjc1NDU_8c83a232-58a5-43da-b1ac-25dd7c4e51a3"
      unitRef="usd">432000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfOS00LTEtMS0xNjc1NDU_1f3d1776-e695-4fe7-85d0-62e90dc1373a"
      unitRef="usd">442000</us-gaap:InterestPaidNet>
    <neo:NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTUtMi0xLTEtMTY3NTQ1_caf764bb-f4dd-4946-862d-d26cb18609c1"
      unitRef="usd">0</neo:NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet>
    <neo:NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTUtNC0xLTEtMTY3NTQ1_6077a853-2f66-4def-a9fb-036fd339e23b"
      unitRef="usd">12098000</neo:NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTYtMi0xLTEtMTY3NTQ1_2cb2e64f-f0c9-43de-b03e-60147de8f6dd"
      unitRef="usd">1174000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zMS9mcmFnOmQ1ZGUzNDA1MmFlMjRmMzU5YzNiNGNmZjQyYzEzNzJkL3RhYmxlOjBkNWEwMTYzZDA3MjQ5Y2M5ZGYzNGRmNmNiNDM0ODdkL3RhYmxlcmFuZ2U6MGQ1YTAxNjNkMDcyNDljYzlkZjM0ZGY2Y2I0MzQ4N2RfMTYtNC0xLTEtMTY3NTQ1_6f90963c-c0f6-449d-bab0-3593eca37529"
      unitRef="usd">1061000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18zNy9mcmFnOmRhODM1YTMxZWIxMzRiYTQ4MGY5ZDRkNDc3MTIzN2E3L3RleHRyZWdpb246ZGE4MzVhMzFlYjEzNGJhNDgwZjlkNGQ0NzcxMjM3YTdfMzE2NA_05de81bb-4208-4556-b0de-bdbe42f8f2a5">Nature of the BusinessNeoGenomics, Inc., a Nevada corporation (the &#x201c;Parent,&#x201d; &#x201c;Company,&#x201d; or &#x201c;NeoGenomics&#x201d;), and its subsidiaries, operate as a certified, high complexity clinical laboratory in accordance with the federal government&#x2019;s Clinical Laboratory Improvement Act, as amended, and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories as well as providing clinical trial services to pharmaceutical firms.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MTE_68a8c172-2e11-43a1-bbc1-4fa5a50ab054">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022, except for new accounting standards discussed under Recent Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain information and footnote disclosures normally included in the Company&#x2019;s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim unaudited Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations presented in this Quarterly Report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#x2019;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, impairment analysis of goodwill, and restructuring reserves. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Restructuring charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring charges relate to a restructuring program to improve execution and drive efficiency across the organization. Restructuring charges consist of severance and other employee costs, costs for optimizing the Company&#x2019;s geographic presence, and consulting and other costs. For further details on the Company&#x2019;s restructuring activities, please refer to Note 8. Restructuring.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#x201c;ASU 2021-08&#x201d;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years &lt;/span&gt;&lt;/div&gt;beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted this standard as of January 1, 2023 and there was no impact on its Consolidated Financial Statements.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MTI_ef47b560-8124-437e-8000-bd2dfce14397">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim Consolidated Financial Statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. All intercompany transactions and balances have been eliminated in the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the Company are the same as those set forth in Note 2. Summary of Significant Accounting Policies, to the audited Consolidated Financial Statements contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022, except for new accounting standards discussed under Recent Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MDY_dd084d47-3d7b-4866-a6d9-f029a6fa2117">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management&#x2019;s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, impairment analysis of goodwill, and restructuring reserves. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MDk_f322f5fe-0982-4692-a331-bca895ee2802">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing expenses are primarily attributable to employee-related costs including sales management, sales representatives, sales and marketing consultants, and marketing and customer service personnel in the Clinical Services segment. Advertising costs are expensed at the time they are incurred and were immaterial for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMzg0ODI5MDczODE5MA_9a707dca-89b8-47e7-957f-4029775d480e">Restructuring chargesRestructuring charges relate to a restructuring program to improve execution and drive efficiency across the organization. Restructuring charges consist of severance and other employee costs, costs for optimizing the Company&#x2019;s geographic presence, and consulting and other costs.</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180MC9mcmFnOjAwNmQzYjQ3MTJjOTQ2Mjc4YjUzMGY1YTA5ODFhNTUzL3RleHRyZWdpb246MDA2ZDNiNDcxMmM5NDYyNzhiNTMwZjVhMDk4MWE1NTNfMTE5MTA_86b473ee-3aae-4952-b34f-82bbfe3f8d45">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (&#x201c;ASU 2021-08&#x201d;). This update amends guidance to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. ASU 2021-08 is effective for fiscal years &lt;/span&gt;&lt;/div&gt;beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted including adoption in an interim period. If the Company early adopts in an interim period, the Company is required to apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The amendments in ASU 2021-08 should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted this standard as of January 1, 2023 and there was no impact on its Consolidated Financial Statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzMg_d1f00605-25c6-4b6e-a1b5-e1b49ac60366">Fair Value Measurements&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy has been established based on three levels of inputs, of which the first two are considered observable and the last unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices in active markets for identical assets or liabilities.&#160;These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly.&#160;These are typically obtained from readily-available pricing sources for comparable instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs, where there is little or no market activity for the asset or liability.&#160;These inputs reflect the reporting entity&#x2019;s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets and Liabilities that are Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets at fair value on a recurring basis, including its marketable securities and certain cash equivalents. The Company considers all securities available-for-sale, including those with maturity dates beyond 12 months, and therefore these securities are classified within current assets on the Consolidated Balance Sheets as they are available to support current operational liquidity needs. The money market accounts are valued based on quoted market prices in active markets and are included in cash and cash equivalents on the Consolidated Balance Sheets. The marketable securities are generally valued based on other observable inputs for those securities (including market corroborated pricing or other models that utilize observable inputs such as interest rates and yield curves) based on information provided by independent third-party pricing entities, except for U.S. Treasury securities which are valued based on quoted market prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#x2019;s marketable securities accounted for as available-for-sale securities as of March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $1.0&#160;million and $0.9&#160;million of accrued interest receivable at March 31, 2023 and December 31, 2022, respectively, included in other current assets on its Consolidated Balance Sheets related to its marketable securities. There were no realized gains or losses on marketable securities for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at March 31, 2023 and December 31, 2022. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of financial assets or liabilities into or out of Level 1, Level 2, or Level 3 for the three months ended March 31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, accounts receivable, net, accounts payable, accrued expenses and other liabilities, and other current assets and liabilities, are considered reasonable estimates of their respective fair values at March 31, 2023 and December 31, 2022 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill, and long-lived assets in connection with periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs and, as such, these are considered Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzNA_6efe5277-d67a-4400-b3dd-70c0a5753d9c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the amortized cost, gross unrealized gains, gross unrealized losses and fair values of the Company&#x2019;s marketable securities accounted for as available-for-sale securities as of March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC0yLTEtMS0xNjc1NDU_d7ba26fb-0d07-44be-8c9f-79811358e092"
      unitRef="usd">37054000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC00LTEtMS0xNjc1NDU_ab9faaca-00d0-4205-867b-aafb2df1d218"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC02LTEtMS0xNjc1NDU_f8951c62-5af6-41c3-b44f-fc3939137fdd"
      unitRef="usd">351000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNC04LTEtMS0xNjc1NDU_68579518-d583-4896-96ae-1467f985bec0"
      unitRef="usd">36704000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi0yLTEtMS0xNjc1NDU_ea2d3a2e-ca0d-424f-8349-4246e79cce27"
      unitRef="usd">3357000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi00LTEtMS0xNjc1NDU_c7fcc4b7-b122-446e-aca7-6ba45d7607fa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi02LTEtMS0xNjc1NDU_04338877-c1eb-43cc-83ce-3a6d38a4aa58"
      unitRef="usd">78000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNi04LTEtMS0xNjc1NDU_00aa60a1-31d8-489c-a13f-ea3df728efa8"
      unitRef="usd">3279000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy0yLTEtMS0xNjc1NDU_9d8445a7-e260-415d-b5b6-28bb540d8dbf"
      unitRef="usd">6010000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy00LTEtMS0xNjc1NDU_359acff9-a2be-4cc8-b347-0cbd8dd218f3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy02LTEtMS0xNjc1NDU_fb310984-641c-434a-ad6f-3a4c9fb964dd"
      unitRef="usd">74000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfNy04LTEtMS0xNjc1NDU_2576de50-4985-4a1e-b455-99d7fed4648e"
      unitRef="usd">5936000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC0yLTEtMS0xNjc1NDU_a102f27d-30b0-4819-a96c-ec3875cc3af1"
      unitRef="usd">12804000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC00LTEtMS0xNjc1NDU_7ae6297c-c90d-4a7f-af20-d00ec33bcb86"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC02LTEtMS0xNjc1NDU_18e69962-59e6-47aa-8dac-2c18bbc986d0"
      unitRef="usd">902000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOC04LTEtMS0xNjc1NDU_f58e9230-cf38-4e73-add4-08bd59314e8c"
      unitRef="usd">11902000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS0yLTEtMS0xNjc1NDU_00bc019e-5649-4f81-b4aa-6dbb8508f603"
      unitRef="usd">2888000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS00LTEtMS0xNjc1NDU_c68733d1-4761-4856-9979-4114e51f2aac"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS02LTEtMS0xNjc1NDU_8365b6d4-a4f6-45a6-9235-5797f109706c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfOS04LTEtMS0xNjc1NDU_7cbd4dd8-1ae4-4ba2-aa1a-a28903f8e0d3"
      unitRef="usd">2893000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtMi0xLTEtMTY3NTQ1_df1046ee-6dec-4f9b-b8f0-49b1d827883f"
      unitRef="usd">21433000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtNC0xLTEtMTY3NTQ1_e5a014e2-6606-43bf-aaee-7b371be58f7c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtNi0xLTEtMTY3NTQ1_cdbdb9bf-e80a-416c-b9c5-329d4624122d"
      unitRef="usd">291000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTAtOC0xLTEtMTY3NTQ1_63ece9e9-e184-47c2-a2a4-9ca2805331ed"
      unitRef="usd">21142000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtMi0xLTEtMTY3NTQ1_baf5ef01-a98b-46cf-b576-4f17ee1b7abf"
      unitRef="usd">62136000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtNC0xLTEtMTY3NTQ1_62c927f4-fc94-4500-b32c-b79d29b688db"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtNi0xLTEtMTY3NTQ1_6d554a56-310c-489b-b9c5-cf96c1582000"
      unitRef="usd">1696000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTEtOC0xLTEtMTY3NTQ1_b58f970a-b3eb-433d-be5e-f6a61ff26d54"
      unitRef="usd">60450000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItMi0xLTEtMTY3NTQ1_4c323b44-7552-475c-bf06-4ea040d8dbcf"
      unitRef="usd">145682000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItNC0xLTEtMTY3NTQ1_6419e34e-10cc-4ba1-a4e3-bfd02c05df2f"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItNi0xLTEtMTY3NTQ1_e813a0a7-c05f-407b-8e31-5acb7a4c911c"
      unitRef="usd">3392000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjA2NTYwMTgyNDI1ZDQ3ZDZhMTM2MDYzMzg3NTdjMjM2L3RhYmxlcmFuZ2U6MDY1NjAxODI0MjVkNDdkNmExMzYwNjMzODc1N2MyMzZfMTItOC0xLTEtMTY3NTQ1_ec70ff91-a107-4dfb-9852-c3e5df3c550f"
      unitRef="usd">142306000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC0yLTEtMS0xNjc1NDU_c042803c-7e92-4d23-bb2d-d3454f0690f1"
      unitRef="usd">56426000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC00LTEtMS0xNjc1NDU_e4f15301-d35a-4b04-b1a4-6966ecf3ff59"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC02LTEtMS0xNjc1NDU_1ad54598-1fe0-4a91-a550-5ba9c1e9008f"
      unitRef="usd">651000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNC04LTEtMS0xNjc1NDU_fd4c198f-07ca-4075-a83e-3b58e4b490b7"
      unitRef="usd">55775000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS0yLTEtMS0xNjc1NDU_48983f28-2d85-49f0-8576-1b9d48decfa8"
      unitRef="usd">5358000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS00LTEtMS0xNjc1NDU_4c5dfb5e-a29f-4462-b77e-ced819d118a9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS02LTEtMS0xNjc1NDU_417b5c8b-f9b3-43f8-9ae4-6f2e734e3fea"
      unitRef="usd">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNS04LTEtMS0xNjc1NDU_81e54165-dbb1-4162-a2d3-dfd2f73bdb82"
      unitRef="usd">5266000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi0yLTEtMS0xNjc1NDU_7c8af31d-f454-491c-b046-820c29822b04"
      unitRef="usd">12485000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi00LTEtMS0xNjc1NDU_f024a090-5929-4242-8812-7895526d7e1f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi02LTEtMS0xNjc1NDU_dfce57b8-140a-415d-9231-4588c8be8a0a"
      unitRef="usd">116000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNi04LTEtMS0xNjc1NDU_44307aad-c146-4e7c-9c38-2256caa583e3"
      unitRef="usd">12369000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy0yLTEtMS0xNjc1NDU_f5d325c8-73fd-4f7b-a069-01d06037c6b5"
      unitRef="usd">12841000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy00LTEtMS0xNjc1NDU_54fa24e4-8bb6-42d8-a128-5ace81d1dd9e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy02LTEtMS0xNjc1NDU_fdef5de0-364f-4909-bff6-676f9ce9d325"
      unitRef="usd">1030000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfNy04LTEtMS0xNjc1NDU_656c9a6d-36ed-4a8c-8657-acfc3c97c0cb"
      unitRef="usd">11811000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC0yLTEtMS0xNjc1NDU_e4f150f0-ec7c-478c-babd-ee6a2f195f97"
      unitRef="usd">2846000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC00LTEtMS0xNjc1NDU_c4b2f4fa-883d-40a9-bd1d-782bf7f00e6c"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC02LTEtMS0xNjc1NDU_f98230f3-5568-407c-a513-2d59d3647fdb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOC04LTEtMS0xNjc1NDU_03d8cb7f-6dcd-497f-9693-a72f9f05675d"
      unitRef="usd">2854000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS0yLTEtMS0xNjc1NDU_5a01fabe-1f61-4978-b26d-c0feba2b185a"
      unitRef="usd">25544000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS00LTEtMS0xNjc1NDU_797cc571-b95d-4b3e-960c-c0622b50a82a"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS02LTEtMS0xNjc1NDU_b5b85bd5-0f6a-458d-8acf-959caa2af734"
      unitRef="usd">427000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfOS04LTEtMS0xNjc1NDU_a45beb1f-7cf2-42e0-9ede-277b464c1ddb"
      unitRef="usd">25119000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtMi0xLTEtMTY3NTQ1_ec195096-f805-42e5-9c21-fae543037229"
      unitRef="usd">63748000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtNC0xLTEtMTY3NTQ1_0ce79a2c-7d6b-41e1-b643-1eab24451783"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtNi0xLTEtMTY3NTQ1_6d38e0ac-ac1c-420c-b7c7-f93f4fa74ac2"
      unitRef="usd">2136000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTAtOC0xLTEtMTY3NTQ1_4a71d057-66c9-4b83-bf8f-d005f462adf7"
      unitRef="usd">61615000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtMi0xLTEtMTY3NTQ1_508c6fee-c9c2-4832-b856-011dc7876ab0"
      unitRef="usd">179248000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtNC0xLTEtMTY3NTQ1_48e3b48c-71cf-4411-9a8a-58298ba6ae71"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtNi0xLTEtMTY3NTQ1_1d483200-a308-4fa6-b95b-1df5177d3284"
      unitRef="usd">4452000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjdlNmM3ODI4N2VkNTRkNWViYTU0YjkxMjQyZjQ2Yzk3L3RhYmxlcmFuZ2U6N2U2Yzc4Mjg3ZWQ1NGQ1ZWJhNTRiOTEyNDJmNDZjOTdfMTEtOC0xLTEtMTY3NTQ1_06a98c38-177e-421f-b56b-33cbdfff4221"
      unitRef="usd">174809000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNTQ5NzU1ODE4MTA2_bd1dfa2a-6b6b-47a4-87ec-2af20c1101f8"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNTQ5NzU1ODE4MTE0_3308f20c-01c7-46a9-b34a-943f1fb65580"
      unitRef="usd">900000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzMA_a276286d-8071-4e42-876a-11d9a08e2af5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the fair value of available-for-sale marketable securities by contractual maturity at March 31, 2023 and December 31, 2022. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;One Year or Less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over One Year Through Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over Five Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC0yLTEtMS0xNjc1NDU_7f8937f7-5874-4a1b-8179-55c0ff27cc0d"
      unitRef="usd">29416000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC00LTEtMS0xNjc1NDU_cb411fb2-a4bd-41d4-9638-0ac9e9e8124a"
      unitRef="usd">7288000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC02LTEtMS0xNjc1NDU_04295acd-b14d-4872-a72c-9066ad214136"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if7ad453d5b0e40f2a0ea7e47d5cdf9fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNC04LTEtMS0xNjc1NDU_fa4ba8a4-2baa-4a90-90b1-6e43df4dde88"
      unitRef="usd">36704000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi0yLTEtMS0xNjc1NDU_fb48105d-99aa-4fd6-a6cb-fbebb0f5b84b"
      unitRef="usd">3279000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi00LTEtMS0xNjc1NDU_6d16fba7-5739-4bda-81eb-5fd99cb70f4b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi02LTEtMS0xNjc1NDU_82a850a6-c6a6-433d-a184-fbc04ba808ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id3231ed75cf147cd8562dc1eb6475ade_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNi04LTEtMS0xNjc1NDU_c3fa673c-c742-442b-9304-c849778f4a68"
      unitRef="usd">3279000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy0yLTEtMS0xNjc1NDU_8b10f1ea-1878-485e-8c13-26fccaf7836c"
      unitRef="usd">3573000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy00LTEtMS0xNjc1NDU_f9424ec0-634e-41e2-aa92-10d4bae21275"
      unitRef="usd">2363000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy02LTEtMS0xNjc1NDU_288696a7-0d0b-4e31-9d2c-8365ab5da257"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id3df88625d7d4b79abc18906edfac694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfNy04LTEtMS0xNjc1NDU_2e07fe29-30e3-4b52-929b-e6ef54b370ec"
      unitRef="usd">5936000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC0yLTEtMS0xNjc1NDU_5db006b8-0e75-43c1-9f7a-6448a4ed5fad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC00LTEtMS0xNjc1NDU_ffecc07a-6a55-435d-b04c-3a8a4b4e1cc3"
      unitRef="usd">11902000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC02LTEtMS0xNjc1NDU_f60d8a67-5699-4ced-88b7-ed12f1f7be31"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3a32a8c1adf04752a2088e1fe8031686_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOC04LTEtMS0xNjc1NDU_c259755e-e2ff-4f6d-9ed8-6066d4b79e73"
      unitRef="usd">11902000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS0yLTEtMS0xNjc1NDU_1ac7eafd-c33e-49f3-9143-429e16997466"
      unitRef="usd">2893000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS00LTEtMS0xNjc1NDU_7e8a4b34-5575-4455-85f5-5da30754b244"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS02LTEtMS0xNjc1NDU_2989a010-b193-4934-b06d-1918d5ac1ee6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iea924912a062451a84ce6ae2de1bc5cf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfOS04LTEtMS0xNjc1NDU_abea24fa-3bb6-4157-96c6-cc1e6cd46aa0"
      unitRef="usd">2893000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtMi0xLTEtMTY3NTQ1_1e4f82e0-0316-4772-af94-126a90160e1d"
      unitRef="usd">21142000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtNC0xLTEtMTY3NTQ1_b43d1ae9-65ee-4218-a52d-404eeb213ef0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtNi0xLTEtMTY3NTQ1_a1018442-53f6-497f-b026-756ec6b21f2b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id2f7b461087345aaa9abd14ef4c75f71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTAtOC0xLTEtMTY3NTQ1_adaa0d6f-9c09-4b06-9433-53e4dfae40d8"
      unitRef="usd">21142000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtMi0xLTEtMTY3NTQ1_942a4f2f-7702-45e9-939e-91dd282939e1"
      unitRef="usd">33083000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtNC0xLTEtMTY3NTQ1_d962a4d0-10ad-404b-9012-59386dd63ca3"
      unitRef="usd">27367000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtNi0xLTEtMTY3NTQ1_d9b3b2fb-8609-4002-a6d1-92bb70102306"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i0b89e92263f34f90963302abcacb623e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTEtOC0xLTEtMTY3NTQ1_67a76c23-ea47-4df1-9a3a-002d37865d07"
      unitRef="usd">60450000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItMi0xLTEtMTY3NTQ1_78945ca6-4f28-407a-abbe-1d094de97403"
      unitRef="usd">93386000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItNC0xLTEtMTY3NTQ1_25b16239-3dc7-483f-bda1-948e8051a5a7"
      unitRef="usd">48920000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItNi0xLTEtMTY3NTQ1_cbc246ea-caad-4a48-a34b-2514ffa513b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmQ4OGVhZjAyZmU5ZTQ0NTJiMmQ1YzczOTMwMDNmMjZjL3RhYmxlcmFuZ2U6ZDg4ZWFmMDJmZTllNDQ1MmIyZDVjNzM5MzAwM2YyNmNfMTItOC0xLTEtMTY3NTQ1_d5035a56-ce74-4dd9-be19-1ebf9641dd0a"
      unitRef="usd">142306000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC0yLTEtMS0xNjc1NDU_17567811-6dd3-4f91-8d46-7635f0b743a0"
      unitRef="usd">40795000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC00LTEtMS0xNjc1NDU_89032835-ae00-4f29-af2d-07e347b4078e"
      unitRef="usd">14980000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC02LTEtMS0xNjc1NDU_c1ffa56b-703b-4c1b-bd17-8eeae2113089"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia0c598cbef0946909ac15453b1e078f6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNC04LTEtMS0xNjc1NDU_e9440e97-28bc-4002-8c38-07788c69326f"
      unitRef="usd">55775000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS0yLTEtMS0xNjc1NDU_38bd1d58-f211-4f82-b219-4b5a7695f7ed"
      unitRef="usd">2734000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS00LTEtMS0xNjc1NDU_505bcc56-b02c-4002-b549-bf1fc931c74b"
      unitRef="usd">2532000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS02LTEtMS0xNjc1NDU_133fe962-aada-4f15-9a4a-a53c9be213da"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic1dc66208c4d42149ee22af031b70b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNS04LTEtMS0xNjc1NDU_7e1019b5-41a3-4ce7-af05-9591c2eb8747"
      unitRef="usd">5266000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi0yLTEtMS0xNjc1NDU_14e312c6-cb0f-47f0-b906-fc7492cb851d"
      unitRef="usd">6470000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi00LTEtMS0xNjc1NDU_fd33b7d1-6a04-449c-8c95-3eb74c1be2ef"
      unitRef="usd">5899000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi02LTEtMS0xNjc1NDU_832ee970-bcb3-48e5-be98-0560c75a4254"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="icc02f25dbebc48aca77b271035670aa4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNi04LTEtMS0xNjc1NDU_8a87e218-7d9e-48a2-b09d-6ad51baaf35c"
      unitRef="usd">12369000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy0yLTEtMS0xNjc1NDU_40819585-e428-4f30-8c18-d1c9e3620fa1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy00LTEtMS0xNjc1NDU_7464d490-10e4-4669-828b-c7819eb4b00f"
      unitRef="usd">11811000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy02LTEtMS0xNjc1NDU_5ecf180a-ffc0-44bc-96a6-f380756ffa8a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie2d34acf37be43769a927e85ccbd4413_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfNy04LTEtMS0xNjc1NDU_1ab6a8d5-ecd8-4eab-b098-11bb6181b383"
      unitRef="usd">11811000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC0yLTEtMS0xNjc1NDU_e3737886-7552-43ec-be68-b500b26d081f"
      unitRef="usd">2854000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC00LTEtMS0xNjc1NDU_bb29c6b9-7e55-4c28-8a26-e83cc12c9582"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC02LTEtMS0xNjc1NDU_295c469d-4e10-49e4-b8c0-4bff88673ac2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i32af5f3b41c84510a781dc62b89f0fc9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOC04LTEtMS0xNjc1NDU_d72edce5-c9ea-4b87-a575-5832a966352e"
      unitRef="usd">2854000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS0yLTEtMS0xNjc1NDU_41ef8d79-a262-449b-952b-e8e33b631a48"
      unitRef="usd">23179000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS00LTEtMS0xNjc1NDU_f45d7afb-f24a-4f11-bba3-d2d73468ff2c"
      unitRef="usd">1940000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS02LTEtMS0xNjc1NDU_764619d3-3a1c-4d9d-90e0-2d8514df295d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i2c94fefd79994ed59ea8010c5f2f1990_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfOS04LTEtMS0xNjc1NDU_b57fb4ec-0476-4826-96f8-83e5330634ed"
      unitRef="usd">25119000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtMi0xLTEtMTY3NTQ1_ffbf06d6-f05d-4074-a022-168ef38abb3a"
      unitRef="usd">35377000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtNC0xLTEtMTY3NTQ1_a87b11fe-0cdb-4f02-86e5-d1ae48d44759"
      unitRef="usd">26238000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtNi0xLTEtMTY3NTQ1_f12b13d4-34f1-45f9-a09e-2d25fff4d190"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i07a2e76c2edd4887bdc9fefd38d7fad9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTAtOC0xLTEtMTY3NTQ1_28ded449-bd0b-435a-8605-d760cb956bd6"
      unitRef="usd">61615000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtMi0xLTEtMTY3NTQ1_4fa1f7f8-4b9b-4e2e-ae77-224901c46aa0"
      unitRef="usd">111409000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtNC0xLTEtMTY3NTQ1_1cbe2000-46b4-49e9-bfc5-a31405b2cf0f"
      unitRef="usd">63400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtNi0xLTEtMTY3NTQ1_c85a4485-0452-4c5f-973f-3e18d1cfc9a0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOmFlZTI4ODIzNjIwMzQ1MzZiNjRjMWM3MWFkZDU2MjQ3L3RhYmxlcmFuZ2U6YWVlMjg4MjM2MjAzNDUzNmI2NGMxYzcxYWRkNTYyNDdfMTEtOC0xLTEtMTY3NTQ1_4861be5e-0ec7-459b-b105-977dc361b0ef"
      unitRef="usd">174809000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RleHRyZWdpb246MTBlMzE1YjQ3MThlNDY2OTg3N2MxNWZmYTI5MWY0MDNfNDEzMQ_ee0bed04-dfea-42da-b38d-7006b7660162">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s cash equivalents and marketable securities accounted for as available-for-sale securities that were measured at fair value on a recurring basis based on the fair value hierarchy as of March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Yankee bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i004aaabb0349419fb34c1f104c808679_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC0yLTEtMS0xNjc1NDU_2c205d5c-42a6-435a-ba2d-7c73de3bfe57"
      unitRef="usd">263367000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20fd8019e30e4ef59757dfbd552fefeb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC00LTEtMS0xNjc1NDU_68fc5a2c-2927-4b0a-bacd-07de08b41b97"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7f72321e8d346c1b9be055441f0522d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC02LTEtMS0xNjc1NDU_ee7879d7-a2b3-4071-aa5e-99c1652ab3a4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia61de5d25d8d448a888213f0ef7c3c93_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNC04LTEtMS0xNjc1NDU_fe80ce37-8733-4511-87e8-d0da17b59380"
      unitRef="usd">263367000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i76d77419ee434f6d947c0e5684e90599_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi0yLTEtMS0xNjc1NDU_dcdea882-fa09-4b21-9211-224310b4d576"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id75d7c777de1492c9afb624404e70f75_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi00LTEtMS0xNjc1NDU_44c16367-eb8c-47fa-b847-3c0967194623"
      unitRef="usd">998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieb2da309f705473cb33d6513d2d19040_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi02LTEtMS0xNjc1NDU_8924cccb-0e7f-44ab-9f6b-e1c74ec36ac3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i86086c5acace448bb8b6dabbe453c7be_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfNi04LTEtMS0xNjc1NDU_0097f86e-2a5f-4d4a-aa79-0037805c1b12"
      unitRef="usd">998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i9cef6dfefe3f46798762dc09c193dcd0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC0yLTEtMS0xNjc1NDU_3317f57a-ae27-4ab2-88f1-b5430809f3bc"
      unitRef="usd">36704000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i26e671e8e2cf407bb994e16200e27c76_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC00LTEtMS0xNjc1NDU_b1c7428e-1984-49bd-a811-148135214310"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i6ed5d50e23774aa184b8e4f93485b926_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC02LTEtMS0xNjc1NDU_aff5bce9-7bcc-474b-ab8c-270785a7985c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ifda741ccd246402297be5d1bebec2777_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfOC04LTEtMS0xNjc1NDU_009b584b-3303-4925-ba02-91b9d9ea382f"
      unitRef="usd">36704000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie6ed3e307ef849bfba217e3b1fcfa083_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtMi0xLTEtMTY3NTQ1_2699ac29-0281-43a4-ab86-662b2fa40de1"
      unitRef="usd">3279000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i0c3929fc1b70423592f232d6a018be6a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtNC0xLTEtMTY3NTQ1_3bf0e05e-87c7-43b0-9ae4-99e864351001"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="id65fc87ebe854a83bcf13322733d9557_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtNi0xLTEtMTY3NTQ1_29fd498f-0983-409c-9e80-be120ea85180"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i98f3e45c8ce247d9b943649f14ba658f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTAtOC0xLTEtMTY3NTQ1_4e5923ce-26c8-4119-9df4-77c063916a2f"
      unitRef="usd">3279000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib8cf7e134e204d52adbadf5546e01d3a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtMi0xLTEtMTY3NTQ1_f067b368-09f3-4865-96e2-c6161af1873d"
      unitRef="usd">5936000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3247270c4bc14b0aa820a377e20562d6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtNC0xLTEtMTY3NTQ1_ebad6272-21f0-445d-9def-7987983f98d4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iedde0d2d8fe34264951d0503e5c197b9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtNi0xLTEtMTY3NTQ1_87fc5f7d-d444-4a9b-a65a-28cfa0bc14f0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i75a9a7f37116407f959fe7f724da7dad_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTEtOC0xLTEtMTY3NTQ1_0d1b288d-515e-4dd1-95c0-13784ad9bf05"
      unitRef="usd">5936000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="idc3fd0f9e99e4320b6637e1380b3bce5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItMi0xLTEtMTY3NTQ1_6ed1f451-f934-40db-b2af-c6529f1a90b2"
      unitRef="usd">11902000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i029abd7f614f43d5a623df347ff6580e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItNC0xLTEtMTY3NTQ1_948f17b8-ba7f-4824-9015-b1083b8dea08"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if10ce274df2c4249b4324db839548e83_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItNi0xLTEtMTY3NTQ1_02776113-56b8-4866-9ede-7b5adde199c8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="icfc449c252d24578be1789efa8d675cc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTItOC0xLTEtMTY3NTQ1_f19d4646-c5bc-4bdd-9959-d4d7c368822f"
      unitRef="usd">11902000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i7dfd45837ded4c3d8128215042b47480_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtMi0xLTEtMTY3NTQ1_4e8c885a-6b89-4b1d-a060-37861a891b4c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ic4e227c6d3ee48169e743fbe4f36fe59_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtNC0xLTEtMTY3NTQ1_a18bda19-363c-4508-88ad-595bd3f916e7"
      unitRef="usd">2893000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i35ccb7220b1d436480b06a47fc83f4ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtNi0xLTEtMTY3NTQ1_1b2d6d9b-89b1-4e27-8783-eb890216862d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if17f174d18f64b4991198db92b4c8ae0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTMtOC0xLTEtMTY3NTQ1_17be809b-d825-49be-8c57-e32d1cf8a844"
      unitRef="usd">2893000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if8ca769c06f34caab7a01fa701dd33ae_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtMi0xLTEtMTY3NTQ1_ba3ba1a5-62f2-4a33-bb12-4be6fa3b604b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i850e29d393ab4d448d3e09260828b223_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtNC0xLTEtMTY3NTQ1_7b63de4d-f39d-4b79-a0e2-d706686d31f8"
      unitRef="usd">21142000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia7838cdae8934aa7bf7358f76022d88d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtNi0xLTEtMTY3NTQ1_8d33183d-2154-4769-90d8-a858eec3cb58"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ie39ff6c2d66a41949d09b075c81e15de_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTQtOC0xLTEtMTY3NTQ1_0314397c-d1b9-41c2-a53a-721250fb4fd8"
      unitRef="usd">21142000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i93fb5da9266349929735ffd80af05646_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtMi0xLTEtMTY3NTQ1_2ffc6003-6957-4fc0-91e9-b5944e07bcb9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i29826c914306440c8b40afad7d4e56ec_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtNC0xLTEtMTY3NTQ1_2b81287b-3273-474c-9e74-c8bcc876701b"
      unitRef="usd">60450000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i6d59563f70954f8497c1438ea92e442a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtNi0xLTEtMTY3NTQ1_cf2c8df2-1987-4c6c-b298-f766ed42e014"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i8144c05b43464394a4a6145a9a634b35_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTUtOC0xLTEtMTY3NTQ1_b3dfe93d-8049-488e-b6da-a2d117c1815a"
      unitRef="usd">60450000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie54945d1251c4441a2ac49774ce617f9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtMi0xLTEtMTY3NTQ1_96ee056e-7939-475f-850c-7fb0e95cf2e7"
      unitRef="usd">321188000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4d2cf2340a864d6998bf33d1d77a4392_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtNC0xLTEtMTY3NTQ1_2089ce61-76e3-4dbb-ba5b-0c389e4e29ab"
      unitRef="usd">85483000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i82eca2166b614d8eb21a538228c7f1e7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtNi0xLTEtMTY3NTQ1_0293ed07-610f-47e0-aa65-7c56c81355ea"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i262590bf4922435bbe6f1bac3c1def5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjY0MjBmOGRiNTc0MTRlM2Y4MmJjODgzZjQzZTFmYWYzL3RhYmxlcmFuZ2U6NjQyMGY4ZGI1NzQxNGUzZjgyYmM4ODNmNDNlMWZhZjNfMTYtOC0xLTEtMTY3NTQ1_1e08d461-00bc-4aca-9f9d-69f64f36fd4c"
      unitRef="usd">406671000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iec9562a1c78e4bddbc52f9bef81cbed5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC0yLTEtMS0xNjc1NDU_7c156af3-ed47-4ff2-924d-49b20c77e0dc"
      unitRef="usd">196749000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0dba6ced43c849c9b749eb64351e67f3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC00LTEtMS0xNjc1NDU_60b69692-2549-4c47-8e50-20e8095af767"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iacc7421b8125439e8a22041f284e8ebc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC02LTEtMS0xNjc1NDU_7b901eae-eb25-4e6e-a57d-2afa8cf61c1b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0d558e5bb5fa4d8cbbe97eca0573db11_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNC04LTEtMS0xNjc1NDU_74d7a7b7-23e3-47a5-8902-a28dc2173fb1"
      unitRef="usd">196749000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i516b4da2b0b24ab4a71025b9383c4617_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi0yLTEtMS0xNjc1NDU_43741d67-412c-49f8-87cd-4a5febeee76b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id8f6f6af9b184accb1eaff0152baad1b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi00LTEtMS0xNjc1NDU_aaf9a075-3604-495e-adf0-47a78077596f"
      unitRef="usd">36965000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0bcfd50343e7421882cf69bfe1e791f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi02LTEtMS0xNjc1NDU_957c3511-b0cc-4b47-b16e-5168f7cc3065"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i04a302973b364b1588a1306eed18fe90_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfNi04LTEtMS0xNjc1NDU_552f75fd-afd3-43d4-91ae-63643ef9ad00"
      unitRef="usd">36965000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ief43d0a3f2004fddb2988edc9ffc1db7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC0yLTEtMS0xNjc1NDU_c149d086-735f-4a71-a151-3c41a20192b2"
      unitRef="usd">55775000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if7dbd954120a4a10b873c3b2d48c8d49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC00LTEtMS0xNjc1NDU_38d5ee8a-83f9-48e4-812c-010d3dfad5a4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i0c0a5c00a8a5486f9c09d4373fd16f53_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC02LTEtMS0xNjc1NDU_5764710e-943e-4520-ac4a-9d9e174b982c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib3aa409a34fd4aeeb322282e6be87924_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOC04LTEtMS0xNjc1NDU_b5cf637e-8346-48c2-bd2a-9dafb4937007"
      unitRef="usd">55775000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i57d9ad9c26cc4a97894893e214f893f0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS0yLTEtMS0xNjc1NDU_bbd4f7b8-0304-45eb-befb-686c72f874e6"
      unitRef="usd">5266000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i59835bdf1de54dc3a48328b7959328f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS00LTEtMS0xNjc1NDU_0d9cd879-4d87-4319-9181-70719d263cf5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i5dee9db4a6134911883daae2b127b1bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS02LTEtMS0xNjc1NDU_ccc40910-b497-4ec3-a143-f5f6ec9a5490"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib768cc7d37f345a5b55d7bb1727a8e78_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfOS04LTEtMS0xNjc1NDU_e30705d2-7c2b-4db3-9c9e-acfe32d2ffef"
      unitRef="usd">5266000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ied859b3bfe82436e90e318d8e56a78e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtMi0xLTEtMTY3NTQ1_ef356e15-d407-4c1f-9c2c-4bc5fe3fc362"
      unitRef="usd">12369000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i215f68b232644561b266ba62b04dfd65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtNC0xLTEtMTY3NTQ1_414101dd-a863-415a-a0ad-47c90c3de5ea"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i1c3fb5fa062e447e8d199b4b11655520_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtNi0xLTEtMTY3NTQ1_f269496e-d6b2-4809-8aad-9eb9eb0da140"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i463acfa7a3c04bef8a12ae1f93cb16d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTAtOC0xLTEtMTY3NTQ1_75749e0e-fef8-4e55-8ebf-138d62bfca0e"
      unitRef="usd">12369000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i4e2fd1c3e7e64fb7b43f4cbbe181cd25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtMi0xLTEtMTY3NTQ1_b29e0f27-07bc-4d65-9712-bf776b6203ad"
      unitRef="usd">11811000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i0a646025d4924bfdb1a9695ebcdf84bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtNC0xLTEtMTY3NTQ1_1d9f34d5-cfa1-4fd2-9702-40e99793e6da"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="if3bfade97a184c86b6180bc197f2e725_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtNi0xLTEtMTY3NTQ1_37d55dca-88be-45f5-a13c-ed39301992c0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i1749cb686d884db7a9db215233a80ff9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTEtOC0xLTEtMTY3NTQ1_fb910002-3cee-4989-859e-eb03f3140522"
      unitRef="usd">11811000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ib2d2220b415e487cb212f61ed9379605_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItMi0xLTEtMTY3NTQ1_811af86f-a76e-4ce9-8732-276c62d247b8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i64302d40674f4f668abac29df75dbd08_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItNC0xLTEtMTY3NTQ1_4c37bdb4-1c2c-4821-bcfd-5e52bd41f203"
      unitRef="usd">2854000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="ia10b30abc40c456a88f7a33b38bddab3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItNi0xLTEtMTY3NTQ1_feeb4305-6e62-4076-9351-bfee3fd00a22"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i3c9283a1102d45bbb21af57e2510969a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTItOC0xLTEtMTY3NTQ1_58dd8115-f96d-4ae3-b83f-28a87c19a9d4"
      unitRef="usd">2854000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i0b4c1be3902041dea01bb81350a399fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtMi0xLTEtMTY3NTQ1_52be9883-7f85-440c-bafb-0047f8a5b2f2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i7f9a7584dfdd402fbb79771f6d4e5a9b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtNC0xLTEtMTY3NTQ1_7cf0c278-bab1-48af-8957-63405bd1f71c"
      unitRef="usd">25119000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="iaf8c26fd3116483f97d7f3c916a5aadd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtNi0xLTEtMTY3NTQ1_3a9d00a3-08c3-4aa5-ab6e-bf64be86dd1e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i1e51fb83d6764e358db23f5748f2e935_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTMtOC0xLTEtMTY3NTQ1_937a6249-8679-4c83-8628-a707429cc228"
      unitRef="usd">25119000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i8d782115f910461ebaa72bdf726eb86b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtMi0xLTEtMTY3NTQ1_41eb5956-da1a-4941-b930-3fd279c92bad"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i404c6343a4ff4c68abad1297de44d068_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtNC0xLTEtMTY3NTQ1_a9d3a7dc-096f-40c3-86bc-5073b3d0a5ae"
      unitRef="usd">61615000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i63c3cbd76eb2472ea8dc34f7fb98f41d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtNi0xLTEtMTY3NTQ1_8c5855b0-04dd-4f66-800a-99c0621b6230"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="i33036807c49d4896a9d79aecfb8f9205_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTQtOC0xLTEtMTY3NTQ1_51a0eb3b-a29a-43e5-b5a4-8cf430f2cbfa"
      unitRef="usd">61615000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14bfd72886cc4c9aaf201e65540075bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtMi0xLTEtMTY3NTQ1_b19f3ab6-09ed-4d3f-9318-6d993b804944"
      unitRef="usd">281970000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a2868dd906c41e081be0d5635abba54_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtNC0xLTEtMTY3NTQ1_6efae6e9-40a5-4a88-a88f-5be09fa3de6f"
      unitRef="usd">126553000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5ee14aadf28745e58a865d5fcc44e840_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtNi0xLTEtMTY3NTQ1_f0583e19-1116-42bb-a452-e8dc44550194"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id753f0b755d344a0b0bdf1feb8643feb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M180Ni9mcmFnOjEwZTMxNWI0NzE4ZTQ2Njk4NzdjMTVmZmEyOTFmNDAzL3RhYmxlOjNhYWI1YjA1MWE2MTRkMGNiNDgwYjIxY2VjZmU2ZjI0L3RhYmxlcmFuZ2U6M2FhYjViMDUxYTYxNGQwY2I0ODBiMjFjZWNmZTZmMjRfMTUtOC0xLTEtMTY3NTQ1_0e80035b-edcc-4931-be66-919d384992b3"
      unitRef="usd">408523000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTcw_604e240c-9903-4a4b-88f3-6fd3db5b3d57">Goodwill and Intangible Assets&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amounts of goodwill by segment at March 31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. The following table summarizes the amortization expense for the three months ended March 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense related to amortizable intangible assets for each of the following periods as of March 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfMzI5ODUzNDg5MDUzMA_38c500f3-cd06-49be-8a83-85fc82c590df">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amounts of goodwill by segment at March 31, 2023 and December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i9d9561a855e94d8eaf7a7d262bd98518_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMS0yLTEtMS0xNzY0MDI_ce6ea594-a0f0-4bad-9dba-265f0f8ccf29"
      unitRef="usd">458782000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i373380b438ca40aea3be8180eff81a98_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMS00LTEtMS0xNzY0MDI_e52c6ac7-22ba-4df2-904d-59c0e726241b"
      unitRef="usd">458782000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ide4d19a07e4d4c6b8fa3f9a7a166e31c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMi0yLTEtMS0xNzY0MDI_54b49748-bac8-43b8-808a-4f35dd6015ab"
      unitRef="usd">63984000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ieff90c10aa6e47e395b6fced1a0dabfc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMi00LTEtMS0xNzY0MDI_32a3e5cf-9e06-41c3-b93a-2811880f53b5"
      unitRef="usd">63984000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMy0yLTEtMS0xNzY0MDI_96ef8931-19bd-40d7-8723-a938611f728d"
      unitRef="usd">522766000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU3ZTJkNTliNTcxYjRjM2FiMzQ0NThlYTA5Njg3YzczL3RhYmxlcmFuZ2U6NTdlMmQ1OWI1NzFiNGMzYWIzNDQ1OGVhMDk2ODdjNzNfMy00LTEtMS0xNzY0MDI_5e0e2c08-fb19-42b4-9a44-accaf35991c5"
      unitRef="usd">522766000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTcz_bc2cf519-5298-491f-a66b-db1a75f45d32">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization&lt;br/&gt;Period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademark - Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8c1ab8ebd44e43e58d7c8ba3e808b947_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozNjQ1ODYyYWIyMzA0YjQ5ODg0MmU0ZTJiMGYzNzk5OV80_cf628014-7a82-42cc-8ba1-3a570230db0f">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if1e1858214854850becd063395aada4d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozNjQ1ODYyYWIyMzA0YjQ5ODg0MmU0ZTJiMGYzNzk5OV85_d424cc33-3d3a-404d-83ec-b7a0208cca62">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idd160d8807e0436c83ea5c0c12b91fc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC00LTEtMS0xNjc1NDU_5f1718e7-b94a-4830-99dd-67abb6b740fe"
      unitRef="usd">143101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idd160d8807e0436c83ea5c0c12b91fc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC02LTEtMS0xNjc1NDU_979b6d5f-1ada-4c3f-a319-9bbb2e88a83a"
      unitRef="usd">58117000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idd160d8807e0436c83ea5c0c12b91fc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNC04LTEtMS0xNjc1NDU_a832a6b8-7e31-431f-a405-69ff71381e7e"
      unitRef="usd">84984000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i71c657c0e98341bbbc4ddc31647ac2b6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozZjg4YzJjMjA5ZDU0ZmI5OWU5ZGYxZmU2OTdkNzUzZl80_27c2e94a-a296-49ba-908b-50acb638322d">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib0ff16f279754224a25c4ced6f282de9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjozZjg4YzJjMjA5ZDU0ZmI5OWU5ZGYxZmU2OTdkNzUzZl85_7f3c3add-b64c-48a7-8a0c-f3f9201d191d">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS00LTEtMS0xNjc1NDU_a633c5bf-f9a2-46e3-bb5a-e0cb545705a7"
      unitRef="usd">310226000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS02LTEtMS0xNjc1NDU_a2227e20-fb91-4aee-8554-70e83f49c396"
      unitRef="usd">38447000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebb3c5f7ba6b42c780987cc3d46a71ac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNS04LTEtMS0xNjc1NDU_b1212035-42f8-4234-8100-85273f4c407a"
      unitRef="usd">271779000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3e9d62bddb1f4f688e043921e3f5282a_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo3ZTdjMjI2N2ExZDM0OTEyODkzOWRjNWQ3YTc3MDhhOV80_30800bf5-e231-408a-af60-13076d1c42fa">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifc32c676c0194721a3de605c721c7774_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi00LTEtMS0xNjc1NDU_5b8f9423-123d-4d69-902b-97a0d0446998"
      unitRef="usd">549000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifc32c676c0194721a3de605c721c7774_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi02LTEtMS0xNjc1NDU_49713346-9ead-4cd4-8090-559440039bb7"
      unitRef="usd">273000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifc32c676c0194721a3de605c721c7774_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNi04LTEtMS0xNjc1NDU_7ed6fc37-5cf6-4a45-a691-a122fb49215f"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6b5e9af89b9f4994b751ddbc6c96ae25_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo2M2M3ZGFjOWM2Njg0ZmJmOWRlODg3NmRlNDRlZTRiOF80_b2a46d40-47fd-43c5-9d99-f3dee0dc4298">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib997aee08c8e473bb492e4695716145d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy00LTEtMS0xNjc1NDU_56fe4694-be32-4d8f-8491-9d425eb9e004"
      unitRef="usd">31473000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib997aee08c8e473bb492e4695716145d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy02LTEtMS0xNjc1NDU_8d8295c7-55bf-4034-a6e2-481466871c43"
      unitRef="usd">3748000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib997aee08c8e473bb492e4695716145d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfNy04LTEtMS0xNjc1NDU_9f321d40-5055-4382-9477-4add2ba875ca"
      unitRef="usd">27725000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5af4eb0b49b046e8b55345cc060257f8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjphYmJmYTc1YTc5MDQ0MzgyYTdmOTZjNmMxNTFiY2EwZF80_f3c39b9a-a0c2-49d5-a446-655dc82e5702">P2Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC00LTEtMS0xNjc1NDU_649af00d-6a73-419f-b8e5-55f6ed5df4ad"
      unitRef="usd">2584000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC02LTEtMS0xNjc1NDU_086b7318-7561-4861-8de0-4f8366e2a182"
      unitRef="usd">1318000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3bfc6ab17e564ca7a2c4b71407f2ddc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOC04LTEtMS0xNjc1NDU_cf5f18c3-6b28-4486-aefb-8e2bdfdd16cf"
      unitRef="usd">1266000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7d2008a400814d3fb508d405fef19e64_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOS00LTEtMS0xNjc1NDU_1aca561f-4ae4-440a-b3ee-f8ba5171bea1"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7d2008a400814d3fb508d405fef19e64_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfOS04LTEtMS0xNjc1NDU_fdcff29d-82a1-4d09-a899-c87fa7c32b86"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfMTAtNC0xLTEtMTY3NTQ1_74c7da16-ec18-4122-8b5d-e8a33cff6164"
      unitRef="usd">501380000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfMTAtNi0xLTEtMTY3NTQ1_5ca78655-3142-49d2-924f-ce7b6d13c57a"
      unitRef="usd">101903000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOjU5NjQ3MjliNzE4NjQ1Y2RiYWMzYmYzM2RmYTIxMWIwL3RhYmxlcmFuZ2U6NTk2NDcyOWI3MTg2NDVjZGJhYzNiZjMzZGZhMjExYjBfMTAtOC0xLTEtMTY3NTQ1_7edab79f-8085-4082-be7c-68a79050a469"
      unitRef="usd">399477000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie573780cd0664b138a05a0e5835aced1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpmNTIwNzRiMjg1ZDY0YzRjOWNiZWIwM2M3YTY4ZTFlZl80_a1a37609-4a23-4af0-a6d9-3bbbb9e087a3">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1a1bb85243b8446f88ff933b1b86f31f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpmNTIwNzRiMjg1ZDY0YzRjOWNiZWIwM2M3YTY4ZTFlZl85_45b1515a-8105-4503-b282-c889d5889f3e">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia00db418b1f6455fb09b2677268bc6e7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi00LTEtMS0xNjc1NDU_1f3eda1f-06ff-45b3-a9f3-ad67a5227f87"
      unitRef="usd">143101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia00db418b1f6455fb09b2677268bc6e7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi02LTEtMS0xNjc1NDU_94d6cae9-3dca-448e-9b98-0e65c70e3be7"
      unitRef="usd">55645000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia00db418b1f6455fb09b2677268bc6e7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMi04LTEtMS0xNjc1NDU_eb7abe8b-c83e-49fc-9de7-2b61ce9d3806"
      unitRef="usd">87456000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic69d55a1ed4a4e4e9dadc2f09c415671_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjoxNWVmOTYwNGQyZDY0NGYzYmViZjQwOGU2NGZlZTg1NV80_2c33b8eb-5b62-4248-b498-a179134376ea">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9932df4812244904b018651543ab7697_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy0yLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjoxNWVmOTYwNGQyZDY0NGYzYmViZjQwOGU2NGZlZTg1NV85_0958f4af-437a-4393-897b-c8b407717e4a">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic50858980989426ebbf9e3e896cff83b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy00LTEtMS0xNjc1NDU_194c5c80-627b-46a1-9d65-9dcce6654d2e"
      unitRef="usd">310226000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic50858980989426ebbf9e3e896cff83b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy02LTEtMS0xNjc1NDU_ed43cebc-4029-4871-843a-6db1471bbc61"
      unitRef="usd">33117000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic50858980989426ebbf9e3e896cff83b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfMy04LTEtMS0xNjc1NDU_c6effee6-27a7-4426-8491-c824b03d92f2"
      unitRef="usd">277109000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib23b6c43131945bf975f36256bb931eb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC0yLTEtMS0xNjc1NDU_5803d2e7-92c5-40bc-ba92-445c8dc436b8">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i489270e3fa944888970ab2fee62822f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC00LTEtMS0xNjc1NDU_0009e7ba-9830-4671-91f3-04f3acc1042c"
      unitRef="usd">549000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i489270e3fa944888970ab2fee62822f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC02LTEtMS0xNjc1NDU_d0b99082-fed5-41da-b8a5-8d38b2f73f45"
      unitRef="usd">238000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i489270e3fa944888970ab2fee62822f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNC04LTEtMS0xNjc1NDU_b0636414-41ec-4e37-afdb-a1c5e0b16b0f"
      unitRef="usd">311000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id8d3f64016074292b7c1e2da1f2c9ed2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS0yLTEtMS0xNjc1NDU_ab646d1d-2359-4d8d-8701-b0334ee9afbf">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icdf7019ad564417a87f14091ba7ee081_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS00LTEtMS0xNjc1NDU_d9439cd0-f927-4221-9196-a02fd566b4a9"
      unitRef="usd">31473000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icdf7019ad564417a87f14091ba7ee081_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS02LTEtMS0xNjc1NDU_0405c6b6-edf9-4009-a6cc-99cbaac58924"
      unitRef="usd">3223000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icdf7019ad564417a87f14091ba7ee081_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNS04LTEtMS0xNjc1NDU_d56aae11-e287-40b0-8813-fe77e0fef592"
      unitRef="usd">28250000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i83abff9eb9764eda9517f9f96b3a9e85_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi0yLTEtMS0xNjc1NDU_d630045d-b789-458f-871b-4255f7770d36">P2Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi00LTEtMS0xNjc1NDU_6644a273-6bfa-421c-a90e-41783bc16e1e"
      unitRef="usd">2584000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi02LTEtMS0xNjc1NDU_27903812-d27f-44c6-8694-6c8795f33ed6"
      unitRef="usd">897000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ide5eeab7f30f4daaba0f8a48626a7b00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNi04LTEtMS0xNjc1NDU_b0b11fc4-55eb-411e-8481-0d2ee0a4ad79"
      unitRef="usd">1687000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i69c1f4bb1df84121b986b7e6c99816e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNy00LTEtMS0xNjc1NDU_1ac17b54-186a-49e1-b547-1c41442fdf3f"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i69c1f4bb1df84121b986b7e6c99816e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfNy04LTEtMS0xNjc1NDU_f242de3f-640d-430c-bb4e-93c3d26d81c4"
      unitRef="usd">13447000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfOC00LTEtMS0xNjc1NDU_e4bcb7d9-5404-493f-bcab-1617a4d78857"
      unitRef="usd">501380000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfOC02LTEtMS0xNjc1NDU_c22e161f-b202-445e-b326-409d44b02fa3"
      unitRef="usd">93120000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY5NDRmMGQyYzI1YzRjZTU5ZDdhMzI5YTg5ZmRkOGFiL3RhYmxlcmFuZ2U6Zjk0NGYwZDJjMjVjNGNlNTlkN2EzMjlhODlmZGQ4YWJfOC04LTEtMS0xNjc1NDU_e4fdf060-7416-4dcd-b14a-07d90e54252b"
      unitRef="usd">408260000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <neo:ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTc0_9078af27-fd29-4c67-b657-0de3a41f37d2">The following table summarizes the amortization expense for the three months ended March 31, 2023 and 2022 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles included in general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</neo:ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic7df8ca34dc349b6a74c42cd48d424c1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMi0yLTEtMS0xNjc1NDU_a150959c-aabf-4c96-aa5b-bc765b73ad84"
      unitRef="usd">4853000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4f505f6d5c4d49cdac4ad18e9a62c42a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMi00LTEtMS0xNjc1NDU_3c8dda46-8a8d-478b-b0ae-07d8e740fad6"
      unitRef="usd">4853000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i821b3f256d5440b6bea9447ea968ec92_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMy0yLTEtMS0xNjc1NDU_acdd0966-2472-4894-8114-b79418eacf13"
      unitRef="usd">3930000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6d88d8c28f9b449184647686d36c0f4a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfMy00LTEtMS0xNjc1NDU_a4c09d56-d32e-40ba-b42e-c1a88319e3be"
      unitRef="usd">3637000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfNC0yLTEtMS0xNjc1NDU_8f3bbd76-81a9-451b-9dbf-47250be3f5ea"
      unitRef="usd">8783000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmYzNzUzMmEwMThiZTRkZTg5MzE4NmY0YjI0NDU3ZWE2L3RhYmxlcmFuZ2U6ZjM3NTMyYTAxOGJlNGRlODkzMTg2ZjRiMjQ0NTdlYTZfNC00LTEtMS0xNjc1NDU_c283eb50-121f-4512-9d8a-39dd90e44085"
      unitRef="usd">8490000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RleHRyZWdpb246MTU1MjkxODNjNWMzNDlhMWIyYjI4ZWI0MTgyNDYyYjRfOTY5_3160ae36-de01-4de5-9e30-c697cf788b9c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense related to amortizable intangible assets for each of the following periods as of March 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMC0xLTEtMS0xNjc1NDU_d4a0d1ad-15ad-4b5e-9670-5ce0e48d5c79"
      unitRef="usd">26350000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMS0xLTEtMS0xNjc1NDU_5cc96473-0536-464e-b54f-57f28975adc8"
      unitRef="usd">33447000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMi0xLTEtMS0xNjc1NDU_18aae685-4b2a-4c3d-8c31-bec1ee58b8a4"
      unitRef="usd">33343000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfMy0xLTEtMS0xNjc1NDU_5d27e0cf-a692-4269-9d5f-c87bd74791d4"
      unitRef="usd">33308000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfNC0xLTEtMS0xNjc1NDU_b8023219-6c74-4580-acf8-874a056de0e3"
      unitRef="usd">32758000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <neo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfNi0xLTEtMS0xNjc1NDU_ec7a191e-5760-4479-8223-8fe59b6574c7"
      unitRef="usd">226824000</neo:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181Mi9mcmFnOjE1NTI5MTgzYzVjMzQ5YTFiMmIyOGViNDE4MjQ2MmI0L3RhYmxlOmY4NTZmOWI1N2M0ODQwNmVhZmY0MDBhMWViNTdjYzE4L3RhYmxlcmFuZ2U6Zjg1NmY5YjU3YzQ4NDA2ZWFmZjQwMGExZWI1N2NjMThfNy0xLTEtMS0xNjc1NDU_2ae2f2ff-76ef-4dc6-8249-132e9bff559e"
      unitRef="usd">386030000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTUzMA_00014295-2f4e-44f4-b8c1-464533c42016">Debt&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;2028 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2021, the Company completed the sale of $345.0&#160;million of Convertible Senior Notes with a stated interest rate of 0.25% and a maturity date of January 15, 2028 (the &#x201c;2028 Convertible Notes&#x201d;), unless earlier converted, redeemed, or repurchased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2022. Based on the terms of the 2028 Convertible Notes, the holders could not have converted all or a portion of their 2028 Convertible Notes in the first quarter of 2023. The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2028 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended March 31, 2023. Based on the terms of the 2028 Convertible Notes, the holders cannot convert all or a portion of their 2028 Convertible Notes in the second quarter of 2023. The value of the 2028 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $17.41 on March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,500 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2023. The interest expense recognized on the 2028 Convertible Notes includes $0.2&#160;million, $0.4&#160;million and $8,400 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2022. The effective interest rate on the 2028 Convertible Notes is 0.70%, which includes the interest on the 2028 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2028 Convertible Notes bear interest at a rate of 0.25% per annum, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2023, the estimated fair values (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $258.8&#160;million. At December 31, 2022, the estimated fair value (Level 2) of the 0.25% Convertible Senior Notes due 2028 was $218.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;2025 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2020, the Company completed the sale of $201.3&#160;million of Convertible Senior Notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025 (the &#x201c;2025 Convertible Notes&#x201d;), unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended December 31, 2022. Based on the terms of the 2025 Convertible Notes, the holders could not have converted all or a portion of their 2025 Convertible Notes in the first quarter of 2023. The last reported sales price of the Company&#x2019;s common stock was not greater than or equal to 130.0% of the conversion price of the 2025 Convertible Notes on at least 20 of the last 30 consecutive trading days of the quarter ended March 31, 2023. Based on the terms of the 2025 Convertible Notes, the holders cannot convert all or a portion of their 2025 Convertible Notes in the second quarter of 2023. The value of the 2025 Convertible Notes, if-converted, does not exceed the principal amount based on a closing stock price of $17.41 on March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $37,600 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2023. The interest expense recognized on the 2025 Convertible Notes includes $0.6&#160;million, $0.3&#160;million and $36,800 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended March 31, 2022. The effective interest rate on the 2025 Convertible Notes is 1.96%, which includes the interest on the 2025 Convertible Notes and amortization of the debt discount and debt issuance costs. The 2025 Convertible Notes bear interest at a rate of 1.25% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, which began on November 1, 2020.&lt;/span&gt;&lt;/div&gt;At March 31, 2023, the estimated fair values (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $186.8&#160;million. At December 31, 2022, the estimated fair value (Level 2) of the 1.25% Convertible Senior Notes due 2025 was $169.6&#160;million.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iba4fa73897df4f2f8b41c9cf59104254_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTA0_e8855579-9d5d-46f1-94f1-e3220c36ed67"
      unitRef="usd">345000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba4fa73897df4f2f8b41c9cf59104254_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTY2_db725fe8-3dbf-4ee5-8e3a-ad03eb8ca6dd"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzg2_66d53fc8-f27e-4eb2-aef8-3b2c41647cb7"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDU1_b00baba0-4efb-4c31-a877-bcdc1ae4ab33"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDcw_9bd7222b-de22-4604-b7de-a5672cc07608"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNzkz_d87e0e3c-2aab-4715-89f1-f3321dd30fe0"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfODYy_a9a6c41b-876a-4d40-a39b-ff764288ef1b"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfODc3_453a7b23-ac7a-4f7d-b474-0fd4acfd9a48"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTIxMw_b670899e-b6ba-4f81-99c6-32651eb29698"
      unitRef="usdPerShare">17.41</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i8528ca596729487298c1867438155cae_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTI5NA_deadddda-4e6d-4a3b-940c-8812e83b9a97"
      unitRef="usd">200000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i8528ca596729487298c1867438155cae_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTI5OA_63862fa7-d243-4d52-850e-74317c9bf9ff"
      unitRef="usd">400000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i8528ca596729487298c1867438155cae_D20230101-20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTMwNQ_136f31e8-ed74-472c-8e4d-57428255074d"
      unitRef="usd">8500</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTU0OA_0bc156aa-8315-4941-83ad-92d92b0df8cb"
      unitRef="usd">200000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTU1Mg_53526671-c2a9-40e9-b6ef-50bfc1a83b8a"
      unitRef="usd">400000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTU1OQ_bcdecea7-d597-421c-b775-dae661dca3ce"
      unitRef="usd">8400</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i40004c5a1d9b4098b12b6e4129f7da74_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjI5NA_b1f24756-b4af-4b99-839d-54fcc47c57bc"
      unitRef="number">0.0070</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjQ3Mw_c6a7976e-9243-413e-9151-ed8bdb4f84c4"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjYzOA_6904ba22-4d65-432a-8a57-9ad0365b288d"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i40ba8428c60f458195216b9cdad76629_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjY3OQ_36be30ff-929f-435d-95d0-feeeeecc3e7f"
      unitRef="usd">258800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5dae2c2009134637be004106df1ea18f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjczMg_da8831d1-2f4a-4988-9690-4921afcb94cc"
      unitRef="rate">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic91661eeb2ac4b54baf73ff541a0d067_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjc3Mw_01ef6e80-0cb2-4b50-a212-716f2e6ad082"
      unitRef="usd">218200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i82b9d072356745b8a8360da4654cefcb_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjg1Nw_7aba2dd5-f940-4950-a52a-abf28e557903"
      unitRef="usd">201300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i82b9d072356745b8a8360da4654cefcb_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMjkxOQ_30cc93f2-3c8f-4a79-a69a-6602e0ed5d4e"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzEzNQ_f297bafd-043b-4e17-843c-ba4409744a41"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzIwNA_83d86da8-f5fc-46e2-a74e-e2c9d1c5b07d"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i61fa222768e04a5282a731261a6c92db_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzIxOQ_c31e50db-70dc-44b6-93e7-47d152bff657"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzU0Mg_49cf3e4c-f7d5-4c9f-8cf7-e9dfe184f0ea"
      unitRef="number">1.300</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzYxMQ_cad98951-dbe7-420d-94b6-3e29e1d23a82"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i36a2f0b698fa4cdda3a4893d9a8fae96_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMzYyNg_b6e1d639-7c3b-4ddb-93b6-94944112da32"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfMTA5OTUxMTYzNDEyOA_b670899e-b6ba-4f81-99c6-32651eb29698"
      unitRef="usdPerShare">17.41</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDA0Mw_9b796511-be7e-4a44-866c-d229900e398f"
      unitRef="usd">600000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDA0Nw_86fac9e3-85ed-4536-8afd-d4481c98f64e"
      unitRef="usd">300000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="i2c486d1066f44cb0808768d4b09223a9_D20230101-20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDA1NA_46cdcfeb-c2b8-4772-b9ba-c965e769f121"
      unitRef="usd">37600</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <neo:InterestExpenseDebtContractualCouponInterest
      contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDI5Nw_a36d37a2-c449-452a-831d-bd99bc2497ac"
      unitRef="usd">600000</neo:InterestExpenseDebtContractualCouponInterest>
    <neo:InterestExpenseDebtAccretionOfDebtDiscount
      contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDMwMQ_58409099-88a1-4ae0-8c28-5b656a90beb2"
      unitRef="usd">300000</neo:InterestExpenseDebtAccretionOfDebtDiscount>
    <neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts
      contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNDMwOA_6e8f8433-a4bc-4002-bd1b-a7d15f858dd6"
      unitRef="usd">36800</neo:InterestExpenseDebtAmortizationOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ie2e9f81c2baf4fc685fb0f972b17a645_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTA0NA_2c1cba43-aa57-446f-a611-b89c36780954"
      unitRef="number">0.0196</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3b7b175d56e84a4eb34fc4843d19177f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTIyMw_b1e28858-bc5d-4a99-a01f-6a8c94960cdd"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3b7b175d56e84a4eb34fc4843d19177f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTM5MQ_2cd957ab-163a-42e0-901d-5b1c9b07f14f"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6906beeb9ed54b49b24795b298297e33_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTQzMg_dabf66a5-a1eb-4ef5-9f19-32139ecf30ae"
      unitRef="usd">186800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic2aa31d2ad384df88f27d19c894362af_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTQ4NQ_ca48584a-2c65-477b-975c-9b134c87011a"
      unitRef="rate">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1ef92042d6eb4a88aa6d7e9f6a975c9a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M181OC9mcmFnOmZhODg3OGZhZmJhNzQyOWVhYmEwOTY2YWRkZWEyZDg2L3RleHRyZWdpb246ZmE4ODc4ZmFmYmE3NDI5ZWFiYTA5NjZhZGRlYTJkODZfNTUyNg_e2c29a86-0234-4f50-875c-fe839a30d0f5"
      unitRef="usd">169600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc2Ng_e19b30b0-03f4-469d-8fad-874e0071fb9f">Stock-Based Compensation&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded approximately $4.8 million and $12.1 million for stock-based compensation in general and administrative expenses &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the Consolidated Statements of Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s plans for the three months ended March 31, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,214,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award granted during the three months ended March 31, 2023 was estimated as of the grant date using a Black-Scholes model with the following assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% - 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.6% - 65.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, there was approximately $12.2 million of unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of approximately 2.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted stock activity under the Company&#x2019;s plans for the three months ended March 31, 2023 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Restricted&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,085,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, there was approximately $15.5&#160;million of unrecognized stock-based compensation expense related to restricted stock that will be recognized over a weighted-average period of approximately 2.3 years.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Modification of Stock Option and Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;In the first quarter of 2022, upon the Chief Executive Officer&#x2019;s departure from the Company and in accordance with the terms of the Chief Executive Officer&#x2019;s separation agreement, 237,960 previously granted time-based vesting stock option awards and 142,302 previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $5.9 million of incremental stock-based compensation which consisted of $2.3 million and $3.6 million for the acceleration of stock option awards and restricted stock awards, respectively, within general and administrative expenses on the Consolidated Statements of Operations for the three months ended March 31, 2022. There were no such amounts for the three months ended March 31, 2023.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfNzM_00821d02-de0b-469a-a4cd-3f04926fe3ec"
      unitRef="usd">4800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfODA_d5726440-1036-43c2-9deb-759009c753f6"
      unitRef="usd">12100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc2OQ_d03e2ee3-e597-4303-b1e7-b230bbfb3a19">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company&#x2019;s plans for the three months ended March 31, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,214,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMS0yLTEtMS0xNjc1NDU_50f8beb0-d705-4128-ab86-7b87d8d75eeb"
      unitRef="shares">4214617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMS00LTEtMS0xNjc1NDU_81b60d67-790b-4e35-ad12-776b8606bafe"
      unitRef="usdPerShare">16.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMi0yLTEtMS0xNjc1NDU_d162a761-d043-4d30-a499-5b8a597bc27a"
      unitRef="shares">338792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfMi00LTEtMS0xNjc1NDU_5603bae3-6688-4b4d-b2b5-9d84cde4c320"
      unitRef="usdPerShare">10.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNC0yLTEtMS0xNjc1NDU_1c283ff0-6784-4ed9-9860-4acc1edcb66c"
      unitRef="shares">75028</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNC00LTEtMS0xNjc1NDU_aa76aa56-11c5-4986-b2b9-bafd69cc1c2f"
      unitRef="usdPerShare">10.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNS0yLTEtMS0xNjc1NDU_5fee0394-a3e0-42c9-b752-947e5690911e"
      unitRef="shares">347719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNS00LTEtMS0xNjc1NDU_8861882e-8574-4dbc-8157-f2288c6f79d5"
      unitRef="usdPerShare">20.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNi0yLTEtMS0xNjc1NDU_8e3bf385-a06d-4482-aae0-e23a69c95a2e"
      unitRef="shares">4130662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNi00LTEtMS0xNjc1NDU_3fe026d4-ba15-4a6a-b94d-6e84ed17cc73"
      unitRef="usdPerShare">15.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNy0yLTEtMS0xNjc1NDU_fde426f5-712f-4306-a22a-4644997e8ff1"
      unitRef="shares">754142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjk5ZTdjMjkyNTEzNzRkNWZiZDJlMmY3YWZjMzE1ZDkyL3RhYmxlcmFuZ2U6OTllN2MyOTI1MTM3NGQ1ZmJkMmUyZjdhZmMzMTVkOTJfNy00LTEtMS0xNjc1NDU_869c7bd8-7fae-4eb5-bbef-8ceb6b1a1726"
      unitRef="usdPerShare">29.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc3MA_8a48ed79-bd24-4168-bba4-889353e7fb08">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award granted during the three months ended March 31, 2023 was estimated as of the grant date using a Black-Scholes model with the following assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% - 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.6% - 65.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMS0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjplN2U0NmQ1NTQ0NzI0MjAzYmZkNmIwYjZmZmI0MjIxMV80_c6b7c4fc-4a4e-47fe-854d-034ab3809fa3">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMS0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjplN2U0NmQ1NTQ0NzI0MjAzYmZkNmIwYjZmZmI0MjIxMV85_2bb031e1-afe2-4e8f-b1c7-076bcbbde45c">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMi0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpkMmJlMzhkYzI3NWE0OWJlOGUwNjI2ZDBiOTg0MmE0MV80_ac846ca6-780b-4748-8b02-84117484f5e3"
      unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMi0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjpkMmJlMzhkYzI3NWE0OWJlOGUwNjI2ZDBiOTg0MmE0MV85_36ba975d-8877-47b9-ba52-6d6af90c0c97"
      unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i21c62002c90b4ea2b8250f7f2aa7718f_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMy0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo0OTk3Y2VhMDQxMTA0ZjE2YmUyYjc5NjZhMWZjZjVjNF80_f10c7cb1-5475-4a02-921c-b09d51209dc1"
      unitRef="number">0.546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i04c340e22785477bbb4b4b4fb7e3e91f_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfMy0xLTEtMS0xNjc1NDUvdGV4dHJlZ2lvbjo0OTk3Y2VhMDQxMTA0ZjE2YmUyYjc5NjZhMWZjZjVjNF85_84f4cefe-93dd-453f-80f6-cc1abf605012"
      unitRef="number">0.657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfNC0xLTEtMS0xNjc1NDU_fc14b1ef-2f34-4050-96ec-96f60682e0e7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjU1MzljZjYxODZlNTQyOGZhNzY1NmMwYzFmNjhlNmQwL3RhYmxlcmFuZ2U6NTUzOWNmNjE4NmU1NDI4ZmE3NjU2YzBjMWY2OGU2ZDBfNS0xLTEtMS0xNjc1NDU_f44709c5-4889-4c89-99aa-37943aa34466"
      unitRef="usdPerShare">5.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfNjYx_adf67db4-cb7d-4a01-94fe-d4e2f926da29"
      unitRef="usd">12200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfODEw_5fb309c4-d099-4023-8ab6-0e2fe80409b9">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjc2NA_45013e64-733e-40a0-944a-c07d891a214e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted stock activity under the Company&#x2019;s plans for the three months ended March 31, 2023 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Restricted&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,085,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2e92033c77f541ad96bf59d87f798f51_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMS0yLTEtMS0xNjc1NDU_83488a52-66ba-449e-b223-ec0974c6aede"
      unitRef="shares">1994861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2e92033c77f541ad96bf59d87f798f51_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMS00LTEtMS0xNjc1NDU_5ec93c87-00b8-434e-aa67-30fe3b74428f"
      unitRef="usdPerShare">12.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMi0yLTEtMS0xNjc1NDU_d80fe961-a7fc-44e3-a5f2-9d201ccfa4fd"
      unitRef="shares">213710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMi00LTEtMS0xNjc1NDU_bdba5991-7519-4cdc-b6a4-0e010d09d7e3"
      unitRef="usdPerShare">10.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMy0yLTEtMS0xNjc1NDU_5a4509da-e31f-4e5f-bf7b-0ef5f0019661"
      unitRef="shares">33607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfMy00LTEtMS0xNjc1NDU_2a6f0efb-0780-4bed-8e70-0e8debe18916"
      unitRef="usdPerShare">23.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNC0yLTEtMS0xNjc1NDU_f247bbfa-f5aa-44d8-8459-c918d2d42fab"
      unitRef="shares">89836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNC00LTEtMS0xNjc1NDU_ac10863c-eda9-4d34-83de-01e80578f4dc"
      unitRef="usdPerShare">12.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNS0yLTEtMS0xNjc1NDU_b97b789e-53cf-44d1-a027-5511f17ca478"
      unitRef="shares">2085128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RhYmxlOjNiYTUzZjBjZDNlZjRiYjhiNjJmZmVhMjQ3NjQxNTYzL3RhYmxlcmFuZ2U6M2JhNTNmMGNkM2VmNGJiOGI2MmZmZWEyNDc2NDE1NjNfNS00LTEtMS0xNjc1NDU_bc6d6021-3824-4eb8-b848-ee8373bedb99"
      unitRef="usdPerShare">12.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0f07db1e4bb04bc9bda5f569a0adfbd8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfOTkw_3dde4b37-d9ee-413a-ac89-b69750729ac1"
      unitRef="usd">15500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2da554b61949435884736cf902fdd198_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMTE0Mg_e5c5f4a8-ca7d-435a-b9ec-e8e6acbbf2ec">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="i9e8dfcc988724045b9e80d0e895dc241_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjE2NA_263cf25f-c6ad-47a9-9792-3d0c67c1c1d9"
      unitRef="shares">237960</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="ic55a517d33ae4df6997fc44f609d4dfa_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjIyOQ_a24d11c3-aeb1-44c4-8b6b-87104825feb3"
      unitRef="shares">142302</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="ie26129e32e0847b28250bb921ab579d5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjQzMA_8cca2e50-ab22-4012-92c6-ca7d7b04f7d3"
      unitRef="usd">5900000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i9e8dfcc988724045b9e80d0e895dc241_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjQ5Mg_d86599c7-c155-4f8b-b6ec-2d3b25bcedd0"
      unitRef="usd">2300000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="ic55a517d33ae4df6997fc44f609d4dfa_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjQ5OQ_08742551-0bca-46e1-b05a-466caf062f54"
      unitRef="usd">3600000</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i9c010ac793694faaa7a1d1b387f6224b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjcxOA_2d0e77ee-9553-49a9-b562-fe681699e1ce"
      unitRef="usd">0</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:AcceleratedShareRepurchaseProgramAdjustment
      contextRef="i2ed6ecf9b84046808c7c599bf940501d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M182Ny9mcmFnOmQzOTUyZjFiMWRjNzQ5NGY5MjY1NDI2Y2VkZDQ2NzA5L3RleHRyZWdpb246ZDM5NTJmMWIxZGM3NDk0ZjkyNjU0MjZjZWRkNDY3MDlfMjcxOA_f51c335f-e9c4-45cb-bbdb-505dbb3eb7bc"
      unitRef="usd">0</us-gaap:AcceleratedShareRepurchaseProgramAdjustment>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNzIxOA_3862503c-c7cd-4a37-ad65-3b6ea81090b3">Revenue Recognition&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s two reportable segments for which it recognizes revenue are (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s specialized diagnostic services are performed based on a written test requisition form or an electronic equivalent. The performance obligation is satisfied and revenues are recognized once the diagnostic services have been performed and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. Revenue is recorded for all payers based on the amount expected to be collected, which considers implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive based on negotiated discounts, historical collection experience, and other anticipated adjustments, including anticipated payer denials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pharma Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Pharma Services segment generally enters into contracts with pharmaceutical and biotech customers as well as other contract research organizations (&#x201c;CROs&#x201d;) to provide research and clinical trial services. Such services also include validation studies and assay development. The Company records revenue on a unit-of-service basis based on the number of units completed towards the satisfaction of a performance obligation. In addition, certain contracts include upfront fees and the revenue for those contracts is recognized over time as services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional offerings within the Pharma Services portfolio includes Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data. Informatics revenue is recognized at a point in time upon delivery of retrospective data or over time for prospective data feeds. The Company negotiates billing schedules and payment terms on a contract-by-contract basis, and contract terms generally provide for payments based on a unit-of-service arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts collected in advance of services being provided are deferred as contract liabilities on the Consolidated Balance Sheets. The associated revenue is recognized and the contract liability is reduced as the contracted services are subsequently performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are established for revenue recognized but not yet billed. These contract assets are reduced once the customer is invoiced and a corresponding receivable is recorded. Additionally, Pharma Services incurs sales commissions in the process of obtaining contracts with customers. Sales commissions that are payable upon contract award are recognized as assets and amortized over the expected contract term. The amortization of commission expense is based on the weighted average contract duration for all commissionable awards in the respective business in which the commission expense is paid, which approximates the period over which goods and services are transferred to the customer. For offerings with primarily short-term contracts, such as Informatics, the Company applies the practical expedient which allows costs to obtain a contract to be expensed when incurred, if the amortization period of the assets that would otherwise have been recognized is one year or less. Contract assets and capitalized commissions are included in other current assets and other assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most contracts are terminable by the customers, either immediately or according to advance notice terms specified within the contracts. All contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma capitalized commissions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded within other current assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Recorded within other assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Recorded within other long-term liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized related to Pharma contract liability balances outstanding at the beginning of the period was $1.8&#160;million and $3.1&#160;million for the three months ended March 31, 2023 and 2022, respectively. Amortization of capitalized commissions was $0.2&#160;million and $0.1&#160;million for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered various factors for both its Clinical Services and Pharma Services segments in determining appropriate levels of homogeneous data for its disaggregation of revenue; including the nature, amount, timing, and uncertainty of revenue and cash flows. Clinical Services categories align with the types of customers due to similarities of billing method, level of reimbursement, and timing of cash receipts. Unbilled amounts are accrued and allocated to payer categories based on historical experience. In future periods actual billings by payer category may differ from accrued amounts. Pharma Services relate to contracts with large pharmaceutical and biotech customers as well as other CROs. Because the nature, timing, and uncertainty of revenue and cash flows are similar and primarily driven by individual contract terms Pharma Services revenue is not further disaggregated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services segments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Client direct billing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Medicare and Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Self-Pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Clinical Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODI2NDUy_7e9cfdcc-76bf-459b-95ba-9f64df8df276"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNzIyMQ_30a992c2-65e2-4c8c-8c5b-89a8623bc882">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma capitalized commissions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma capitalized commissions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term pharma contract liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total pharma contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded within other current assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Recorded within other assets on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMS0xLTEtMS0xNjc1NDU_8d34feaa-4375-4814-8e0a-6c55cb01b635"
      unitRef="usd">1121000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMS0zLTEtMS0xNjc1NDU_b47a8635-8778-4c8b-b3a7-c266965cf38b"
      unitRef="usd">1898000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMi0xLTEtMS0xNjc1NDU_1fb4f5d5-f8c5-4840-a940-2544c52c0f1a"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMi0zLTEtMS0xNjc1NDU_5b4aa348-2a57-42e2-8c97-a09fb0a732b1"
      unitRef="usd">31000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMy0xLTEtMS0xNjc1NDU_ad46efec-2c4a-4336-b1b4-d2d8c318fcd5"
      unitRef="usd">1121000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMy0zLTEtMS0xNjc1NDU_ecf0b137-e13e-4caf-b45c-88be9e1eda11"
      unitRef="usd">1929000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNi0xLTEtMS0xNjc1NDU_e4ff9976-fe7e-4f47-88e4-70db624ca7ed"
      unitRef="usd">912000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNi0zLTEtMS0xNjc1NDU_ffe78b55-e70f-4bd3-aa4b-cb73ec268d7f"
      unitRef="usd">800000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNy0xLTEtMS0xNjc1NDU_f2cbfcfa-b26c-46dd-b04a-521a2165a12b"
      unitRef="usd">632000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfNy0zLTEtMS0xNjc1NDU_35a86b7d-2837-4d5f-8e33-7a9c2305207d"
      unitRef="usd">715000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostGross
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfOC0xLTEtMS0xNjc1NDU_bdf3fb3e-1429-4878-9aa0-e7550be61676"
      unitRef="usd">1544000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfOC0zLTEtMS0xNjc1NDU_6dbfec09-1221-4ba4-b11b-951bea21fc72"
      unitRef="usd">1515000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTEtMS0xLTEtMTY3NTQ1_1919a6b1-a325-421c-bf37-725beb01eaf5"
      unitRef="usd">6067000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTEtMy0xLTEtMTY3NTQ1_65879f34-5b4f-4bb7-abc4-979a9daee00b"
      unitRef="usd">7557000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTItMS0xLTEtMTY3NTQ1_62017bb8-0744-4396-9f80-675edf68a915"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTItMy0xLTEtMTY3NTQ1_fcfcc197-2dd8-44ce-96ec-eabe2db1c2c8"
      unitRef="usd">19000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTMtMS0xLTEtMTY3NTQ1_e79e49fd-ce43-41af-ac9e-64508e04f51f"
      unitRef="usd">6067000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOjE4NjZiYjQ0NTEyMTQ0MmI5YTg4YjM0ZjhkY2RmNjJjL3RhYmxlcmFuZ2U6MTg2NmJiNDQ1MTIxNDQyYjlhODhiMzRmOGRjZGY2MmNfMTMtMy0xLTEtMTY3NTQ1_5a6d120f-adbb-4517-bf5d-749b88ca1c30"
      unitRef="usd">7576000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODM4MDMw_0f36942d-884c-4a95-abda-7b8d03491af7"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODI0Njgx_58e7b5f0-5aab-49b9-8f41-27fb95ab0353"
      unitRef="usd">3100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODM4MDM3_67013cc3-a575-4e37-81a7-2c2be53e1f9d"
      unitRef="usd">200000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNTQ5NzU1ODI0Njkw_52185709-9b87-4bb1-bbc5-509258d8ba60"
      unitRef="usd">100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RleHRyZWdpb246YzdmYWVhOTI2MjNiNDMzZTg3NmNjZmY1ZDhmYzE3NzJfNzIxNg_4838d4f1-64fd-4a08-bcc1-67594dcd494f">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the disaggregation of revenue for both the Clinical Services and Pharma Services segments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Client direct billing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Medicare and Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Self-Pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Clinical Services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i37155bb755b5477e8fbeac7342fd0122_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfMy0yLTEtMS0xNjc1NDU_2725892c-18c6-4b6c-a4aa-8a41c163a334"
      unitRef="usd">76823000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5be18713caa049f98bd25ee684a48d54_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfMy00LTEtMS0xNjc1NDU_a87e076f-9ef5-4a73-9819-c41826d42d44"
      unitRef="usd">65014000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie0d2caa28bcd47f08e1eeac2e9fde476_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNC0yLTEtMS0xNjc1NDU_41674f17-36cf-43a6-af39-44ab9a0d8e25"
      unitRef="usd">21355000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i91a0583c3c0842779bca3dd6c45d8eae_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNC00LTEtMS0xNjc1NDU_c09d3660-1b82-4b73-af23-7c2622a4a616"
      unitRef="usd">18288000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i029263e85dca4857a798b85580af5632_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNS0yLTEtMS0xNjc1NDU_0b72e44f-e8ac-494a-acb7-f1f5559dfaeb"
      unitRef="usd">16587000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic451e6718033441284f8fab001983ece_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNS00LTEtMS0xNjc1NDU_d2484db9-bf43-449c-8ae5-84af0b68f05a"
      unitRef="usd">15465000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0934976619bb435f972eb14ee73bc235_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNi0yLTEtMS0xNjc1NDU_959295e4-2f41-44e8-afd6-11deb99d79ce"
      unitRef="usd">104000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie0f79cb85f8e47b78073f6f575ba7ce5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNi00LTEtMS0xNjc1NDU_ff27c15b-a7e2-48cf-a8d1-ba83abe08c84"
      unitRef="usd">24000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNy0yLTEtMS0xNjc1NDU_48069bcc-5f25-4f9a-9f4b-af1c5ee74f9c"
      unitRef="usd">114869000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfNy00LTEtMS0xNjc1NDU_317c08c8-7fd2-4616-a707-5eaf6951035e"
      unitRef="usd">98791000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOC0yLTEtMS0xNjc1NDU_e9e7d35a-87fe-4210-b890-1cbce81719d7"
      unitRef="usd">22351000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOC00LTEtMS0xNjc1NDU_50f754cb-52cf-45a5-910a-48720b1a311a"
      unitRef="usd">18378000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOS0yLTEtMS0xNjc1NDU_2eff7533-1223-4e5b-add3-05533ade4000"
      unitRef="usd">137220000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183MC9mcmFnOmM3ZmFlYTkyNjIzYjQzM2U4NzZjY2ZmNWQ4ZmMxNzcyL3RhYmxlOmEzYzQ3YzVhNTg4MDRkZTliMTNiMDRhMDZjZTQ0MGJiL3RhYmxlcmFuZ2U6YTNjNDdjNWE1ODgwNGRlOWIxM2IwNGEwNmNlNDQwYmJfOS00LTEtMS0xNjc1NDU_13d64218-679b-4dc6-9ef5-c948c7fa0fa5"
      unitRef="usd">117169000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF8zODQ4MjkwNjk4NTk1_ca0f4c40-1d13-4a1d-8944-eb683e2abd87">Restructuring&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company embarked on a restructuring program to improve execution and drive efficiency across the organization. This program is a framework for identifying, prioritizing and executing operational improvements. Restructuring charges incurred consist of severance and other employee costs, costs for optimizing the Company&#x2019;s geographic presence (&#x201c;Facility Footprint Optimization&#x201d;), and consulting and other costs. There were no such charges for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the Company&#x2019;s accrued restructuring balance (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Other Employee Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Facility Footprint Optimization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consulting and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of facility related assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments and other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments include non-cash asset charges related to Facility Footprint Optimization costs.&lt;/span&gt;&lt;/div&gt;The Company will continue this restructuring program in 2023 and expects to incur additional restructuring charges of approximately $3.0&#160;million. The Company estimates these additional restructuring charges to be comprised of approximately $1.0&#160;million in severance and other employee costs, $1.0&#160;million of Facility Footprint Optimization costs, and $1.0&#160;million of consulting and other costs. The Company&#x2019;s restructuring activities are expected to be complete by December 31, 2023.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF8zODQ4MjkwNjk4NTk2_003b8b27-3f5b-4a43-8b27-e63c3e21ecbb">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the Company&#x2019;s accrued restructuring balance (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance and Other Employee Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Facility Footprint Optimization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consulting and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of facility related assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments and other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments include non-cash asset charges related to Facility Footprint Optimization costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="if4c752dcd1ca45ff827097c99008c859_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTQtMS0xLTE3MTg5Mg_bdb62da6-510c-4236-b454-33387d1fa0f0"
      unitRef="usd">559000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i99667b42ce8d4309bbdc2e318c38ed7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTYtMS0xLTE3MTg5Mg_e08af3a4-36df-4dc0-8bb4-693ad4fa8f06"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id986d81110f2465fa821ef6a63bd6657_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8xLTgtMS0xLTE3NTQ4Mg_7d589b78-a2ea-4cbf-960e-8e503afdc024"
      unitRef="usd">960000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i07ed7276d306438c829d302392f7b033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTE0LTEtMS0xNzE4OTI_0f68b98f-a5ed-439e-bf82-de8579145d46"
      unitRef="usd">1519000</us-gaap:RestructuringReserve>
    <neo:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTAtMS0xLTE3MTk5Mg_b8cf4641-7eb6-4077-988b-0a6764f9ed19">Restructuring charges incurred</neo:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTQtMS0xLTE3MTg5Mg_8cd60543-6666-40cf-b28c-261e01aeb5f8"
      unitRef="usd">3105000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTYtMS0xLTE3MTg5Mg_cd78a629-6e7e-4398-b61c-28b0303b66fd"
      unitRef="usd">913000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8yLTgtMS0xLTE3NTQ4Mg_f8eac49b-6285-4582-8f4b-304ec4337b11"
      unitRef="usd">106000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTE0LTEtMS0xNzE4OTI_6077f7b8-0647-42fb-bed8-daa774214d4d"
      unitRef="usd">4124000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:AssetImpairmentCharges
      contextRef="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV80LTQtMS0xLTE3MTg5Mg_a4354446-ef28-40ef-ad0d-62f9d6e2465f"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV80LTYtMS0xLTE3MTg5Mg_afbdc660-4fc0-47b5-8f32-97ad22532952"
      unitRef="usd">560000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8zLTgtMS0xLTE3NTQ4Mg_86e35f10-141d-48eb-98d8-bd070c8342ff"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV80LTE0LTEtMS0xNzE4OTI_36b107fa-ee4f-48f4-9777-ad6b32b14024"
      unitRef="usd">560000</us-gaap:AssetImpairmentCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i7715d3824b3d43cb9b9cbd602560d1b1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTQtMS0xLTE3MTg5Mg_71ffed7a-6590-4320-b54e-bb2873be967e"
      unitRef="usd">1285000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i1f412c375eb94c48a0cf24a80d009bb0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTYtMS0xLTE3MTg5Mg_97c8a78b-23f5-4481-a5df-da5b650f6f2b"
      unitRef="usd">564000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i722da61b1b7a4808923d32a61c1d6f9e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV81LTgtMS0xLTE3NTQ4Mg_03449d8a-cf17-422f-8660-b16ecb6a914e"
      unitRef="usd">346000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTE0LTEtMS0xNzE4OTI_3426811c-4d32-4b2f-b6e3-4d2ed263e8e4"
      unitRef="usd">2195000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ia5ea221a5e49464f94ac854559238414_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV83LTQtMS0xLTE3MTg5Mg_4a0bb92f-b15c-4518-8025-69538f407b98"
      unitRef="usd">2379000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic9cb7bbbb4784cb198eec618ef26686a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV83LTYtMS0xLTE3MTg5Mg_b21cd7dc-4e3e-43ab-b138-77ff527c6fce"
      unitRef="usd">909000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ifbec686c7a42479b9a9e4877006b5814_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV82LTgtMS0xLTE3NTQ4Mg_40f18b5d-6fba-417e-87a3-10615d767e8e"
      unitRef="usd">720000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV83LTE0LTEtMS0xNzE4OTI_c7d68873-0464-4c1f-81a5-f306921207b6"
      unitRef="usd">4008000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserveCurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV84LTE0LTEtMS0xNzE4OTI_cc77a38b-4f22-495a-9ade-fd1d5ca3679c"
      unitRef="usd">4008000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveNoncurrent
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV85LTE0LTEtMS0xNzE4OTI_7f654af7-b598-40ef-83a8-d81e5a5b08bf"
      unitRef="usd">0</us-gaap:RestructuringReserveNoncurrent>
    <us-gaap:RestructuringReserve
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGFibGU6YjU1YzdhZWQwODgyNDI3OWI1ZWUyZDM0NGYzMmI5ZmUvdGFibGVyYW5nZTpiNTVjN2FlZDA4ODI0Mjc5YjVlZTJkMzQ0ZjMyYjlmZV8xMC0xNC0xLTEtMTcxODky_57dfb45f-52ad-44e1-8b07-53535609576d"
      unitRef="usd">4008000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="iec351bfb82464fa9ba1cbdf2b89bd464_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxMTg_41c0e9f2-0930-42ca-a784-b478c38f98e3"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ia5ea221a5e49464f94ac854559238414_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxMzI_3552c953-999b-4a62-9d98-ed875247f949"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ic9cb7bbbb4784cb198eec618ef26686a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxNDY_46942fda-941c-4506-b739-2ca32f34f188"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ifbec686c7a42479b9a9e4877006b5814_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M18xMTExL2ZyYWc6YzUzOTE5NDk1M2FlNGZkODlmYTA0NzRmOTMzMDM1NzgvdGV4dHJlZ2lvbjpjNTM5MTk0OTUzYWU0ZmQ4OWZhMDQ3NGY5MzMwMzU3OF81NDk3NTU4MTUxNjA_5020d934-2081-4446-8225-ae34362ea6d8"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183My9mcmFnOjljZDgyYWRhNTY2MzRmMmI4NDI1ZDcxMWNiN2I3YTY0L3RleHRyZWdpb246OWNkODJhZGE1NjYzNGYyYjg0MjVkNzExY2I3YjdhNjRfMjAzMA_072244c2-fe2c-425c-85b9-27a323491b07">Income Taxes&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of each interim period, management estimates the annual effective tax rate based on forecasted pre-tax results of the Company&#x2019;s global operations and applies such rate to its ordinary quarterly earnings to calculate income tax expense related to ordinary income. The tax effects of items significant, unusual and infrequent in nature are discretely calculated and recognized in the period during which they occur. These discrete items often relate to changes in tax laws, excess tax benefits/deficiencies related to share-based compensation or adjustments to previously reported tax expense/benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assesses the recoverability of its deferred tax assets as of the end of each quarter, weighing available positive and negative evidence, and is required to establish and maintain a valuation allowance for these assets if it is more likely than not that some or all of the deferred income tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion that a valuation allowance is not needed.&lt;/span&gt;&lt;/div&gt;A cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome. Cumulative loss in recent years is commonly defined as a three-year cumulative loss position. As of March 31, 2023, the Company&#x2019;s U.S. ongoing operations were in a three-year cumulative loss position. Management determined that sufficient objectively verifiable positive evidence did not exist to overcome the negative evidence of the Company&#x2019;s U.S. cumulative loss position. Accordingly, the Company&#x2019;s estimated annual effective tax rate applied to the Company&#x2019;s pre-tax loss for the three months ended March 31, 2023, includes the unfavorable impact of a valuation allowance against the Company&#x2019;s deferred income tax assets expected to be created in 2023 for additional U.S. net operating loss and tax credit carryforwards as well as Switzerland, China and Singapore deferred tax assets. Management has however determined that sufficient objectively verifiable positive evidence does exist to overcome the negative evidence of the Company&#x2019;s U.K. cumulative loss position. The reversal of U.K. deferred tax liabilities will provide a sufficient source of realization to support the full recognition of the U.K. deferred tax assets and therefore no valuation allowance has been established for those deferred tax assets. Accordingly, the Company&#x2019;s estimated annual effective tax rate applied to the Company&#x2019;s pre-tax loss for the three months ended March 31, 2023, includes the favorable impact of recognizing the U.K. benefit.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMjAyNA_0d9a6986-be81-421c-b036-be680b33a30c">Net Loss Per Share&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company presents both basic earnings per share (&#x201c;EPS&#x201d;) and diluted EPS. Basic EPS excludes potential dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if stock options were exercised, stock awards vested and if the 2028 Convertible Notes and 2025 Convertible Notes were converted. The potential dilution from stock awards is accounted for using the treasury stock method based on the average market value of the Company&#x2019;s common stock. The potential dilution from conversion of the 2028 Convertible Notes and 2025 Convertible Notes is accounted for using the if-converted method, which requires that all of the shares of the Company&#x2019;s common stock issuable upon conversion of the 2028 Convertible Notes and the 2025 Convertible Notes will be included in the calculation of diluted EPS assuming conversion of the 2028 Convertible Notes and the 2025 Convertible Notes at the beginning of the reporting period (or at time of issuance, if later).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculations (in thousands, except net loss per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET LOSS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the 2028 Convertible Notes offering, on January 11, 2021, the Company entered into separate, privately negotiated convertible note hedge transactions (collectively, the &#x201c;Capped Call Transactions&#x201d;) with option counterparties pursuant to capped call confirmations at a cost of approximately $29.3&#160;million. The potential effect of the Capped Call Transactions were excluded from the calculation of diluted net loss per share in the three months ended March 31, 2023 as the Company&#x2019;s closing stock price of $17.41 on March 31, 2023 did not exceed the conversion price of $85.75 per share. The Capped Call Transactions are not reflected in diluted net loss per share as they are anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMjAyNw_02892cf9-18c7-403b-bd82-d44096f43468">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculations (in thousands, except net loss per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET LOSS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMy0yLTEtMS0xNjc1NDU_aaa6f58a-49dd-4ddd-97b1-48a957dbbf69"
      unitRef="usd">-30795000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMy00LTEtMS0xNjc1NDU_ce41fc0e-f14b-47e9-a85e-66c190bb1275"
      unitRef="usd">-49408000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfOC0yLTEtMS0xNjc1NDU_707c3b20-1da6-41c9-86d3-f251f6102f97"
      unitRef="shares">125026000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfOC00LTEtMS0xNjc1NDU_b7bc6760-c9ab-467b-b511-149aa12574fc"
      unitRef="shares">123630000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTMtMi0xLTEtMTY3NTQ1_f7640f00-eda9-4d24-9b8e-4a569acc6580"
      unitRef="shares">125026000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTMtNC0xLTEtMTY3NTQ1_d28b0513-8d03-4b57-9b84-d218948a2c76"
      unitRef="shares">123630000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTUtMi0xLTEtMTY3NTQ1_e2794ca1-3a1d-4997-a3d8-119612193fc0"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTUtNC0xLTEtMTY3NTQ1_fdf25283-9c2e-4d9b-9221-91981412a03c"
      unitRef="usdPerShare">-0.40</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTYtMi0xLTEtMTY3NTQ1_09be69c3-9618-4b69-ae56-41f10c3aa9ab"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOmY3NmU5YzllNDMyMDRiMTY5YzUwOTJlNTcxODVkNGQ0L3RhYmxlcmFuZ2U6Zjc2ZTljOWU0MzIwNGIxNjljNTA5MmU1NzE4NWQ0ZDRfMTYtNC0xLTEtMTY3NTQ1_4f3d95c1-053a-4685-ae69-48ef6c24c1d4"
      unitRef="usdPerShare">-0.40</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMjAyOA_34e50eba-12e0-4903-a4e4-6fef5cbef545">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ef7183b65cb4f2f9f4adf9f0a5bb5b6_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMi0yLTEtMS0xNjc1NDU_233ab3f9-60f1-4ccd-b11e-7392a49731c7"
      unitRef="shares">13000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifdb4dbfbf647436ebf637a1b3d7cc7d8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMi00LTEtMS0xNjc1NDU_2efd1d49-b9ab-4b71-9c26-5c1b37453a2c"
      unitRef="shares">467000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief61d5bc03a04fc793734af9dc810aab_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMy0yLTEtMS0xNjc1NDU_b64db7b9-a6ff-4df7-8700-5981562a0215"
      unitRef="shares">942000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe85cf00c6914ff48f891eb304bfa59f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfMy00LTEtMS0xNjc1NDU_c703b71c-4a07-4116-8d3c-645387459dfe"
      unitRef="shares">137000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1ca7d72eb0dc4c1794a0c06f7f6fa78d_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNC0yLTEtMS0xNjc1NDU_aecc3815-b8b3-4aa8-a51f-d06731207646"
      unitRef="shares">5538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61b3ab81b6f5476ea3f286adedb2c683_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNC00LTEtMS0xNjc1NDU_151a774d-9912-4f8b-9927-967f6989291e"
      unitRef="shares">5538000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i207470ae354943faa9001607fe4529a7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNS0yLTEtMS0xNjc1NDU_6e685c07-d73b-494d-b8ec-66715b49a522"
      unitRef="shares">5215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iad53f6ac95fd426b9947f85a93074c2e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RhYmxlOjExNTMwMDBjYjBlZjRiYzJhYWQ1ZDFiMWFiYzE3ZDA2L3RhYmxlcmFuZ2U6MTE1MzAwMGNiMGVmNGJjMmFhZDVkMWIxYWJjMTdkMDZfNS00LTEtMS0xNjc1NDU_385243fc-0775-4e18-bdd0-8012fe11b4cf"
      unitRef="shares">5215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="if650c426e70e4f4a8a39d610bfaab9b5_D20210111-20210111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMTY4Mw_ad7060f9-f4b4-41c6-a926-1eb3358d3620"
      unitRef="usd">29300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="icbc5630007bf4025ab16a7d4dbffd844_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMTA5OTUxMTYyOTgyNw_b670899e-b6ba-4f81-99c6-32651eb29698"
      unitRef="usdPerShare">17.41</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ifa8cf70c5a204e4ba1dd0ff819094a7a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M183Ni9mcmFnOjBhMmNhZmE0YTcyNTQ3MzU5NjhmOTIzZmIyNTZmMzZhL3RleHRyZWdpb246MGEyY2FmYTRhNzI1NDczNTk2OGY5MjNmYjI1NmYzNmFfMTkwNw_86c1a15b-fed5-4fe3-8464-3e07c3ad5628"
      unitRef="usdPerShare">85.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfMjc4MA_a46a834f-804e-49da-9d12-4c8256edbce2">Commitments and Contingencies&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2021, Natera, Inc. filed a patent infringement complaint against the Company&#x2019;s newly-acquired subsidiary Inivata Limited and its subsidiary Inivata, Inc. in U.S. District Court for the district of Delaware, alleging Inivata&#x2019;s InVisionFirst&#xae;-Lung cancer diagnostic test of infringing two patents. Natera then filed a second patent infringement complaint on December 20, 2022 against Inivata Limited and Inivata Inc. alleging that RaDaR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; minimal residual disease test infringes one patent. The litigation is approaching the discovery stage. The Company believes that it has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2022, a purported shareholder class action captioned Daniel Goldenberg v. NeoGenomics, Inc., Douglas VanOort, Mark Mallon, Kathryn McKenzie, and William Bonello was filed in the United States District Court for the Southern District of New York, naming the Company and certain of the Company&#x2019;s current and former officers as defendants. This lawsuit was filed by a stockholder who claims to be suing on behalf of anyone who purchased or otherwise acquired the Company&#x2019;s securities between February 27, 2020 and April 26, 2022. The lawsuit alleges that material misrepresentations and/or omissions of material fact were made in the Company&#x2019;s public disclosures in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The alleged improper disclosures relate to statements regarding the Company&#x2019;s menu of tests, business operations and compliance with health care laws and regulations. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney&#x2019;s fees and expert fees. The Company believes that it has valid defenses to the claims alleged in this lawsuit, but there is no guarantee that the Company will prevail. At the time of filing the outcome of this matter is not estimable or probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, the Company made an offer to remedy a dispute and the dispute is now in pre-litigation non-binding mediation.&#160;As a result, the Company has recorded a liability in accrued expenses and other liabilities as of March 31, 2023 on the Consolidated Balance Sheets based on the offer to settle this dispute, which reflects management&#x2019;s best estimate of the minimum probable loss associated with this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Regulatory Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the assistance of outside counsel, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (&#x201c;OIG&#x201d;) of the Company&#x2019;s internal investigation in November 2021. The Company&#x2019;s interactions with regulatory authorities and the Company&#x2019;s related review of this matter are ongoing. The Company has a reserve of $11.2 million in other long-term liabilities as of March 31, 2023 and December 31, 2022 on the Consolidated Balance Sheets for potential damages and liabilities primarily associated with the federal healthcare program revenue received by the Company in connection with the agreements at issue that were identified during the course of this internal investigation. This reserve reflects management&#x2019;s best estimate of the minimum probable loss associated with this matter. As a result of the internal investigation and ongoing interactions with regulatory authorities, the Company may accrue additional reserves for any related potential damages and liabilities arising out of this matter. The Company was notified on June 30, 2022 that the Department of Justice (&#x201c;DOJ&#x201d;) will be participating in the investigation of this matter. At this time, the Company is unable to predict the duration, scope, result or related costs associated with any further investigation, including by the OIG, DOJ, or any other governmental authority, or what penalties or remedial actions they may seek. Accordingly, at this time, the Company is unable to estimate a range of possible loss in excess of the amount reserved. Any determination that the Company&#x2019;s operations or activities are not in compliance with existing laws or regulations, however, could result in the imposition of civil or criminal fines, penalties, disgorgement, restitution, equitable relief, exclusion from participation in federal healthcare programs or other losses or conduct restrictions, which could be material to the Company&#x2019;s financial results or business operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="ic233566287de4d36bb1a6bb64acf5924_D20210120-20210120"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfNTQ5NzU1ODE5NDI2_58a7892a-ce49-4b01-ac1c-7c116aaaed8c"
      unitRef="patent">2</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="i52bebd24ded945888e4e9c5d03543ea8_D20221220-20221220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfNTQ5NzU1ODE5NDMx_9d4000eb-a24f-4275-8c74-b847f416e238"
      unitRef="patent">1</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7d357522f0b4460a9c80ae8413a0dce2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfMTI2MQ_ab8e92a3-f1cf-4e09-8c28-3ebbe5dd5a8f"
      unitRef="usd">11200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7d234e06879f4d25b290bf7fa83aa615_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184Mi9mcmFnOmY0NTExOTI0Y2MxMjQ0ZGQ5ZDljNzAzM2I1NmFlZTkyL3RleHRyZWdpb246ZjQ1MTE5MjRjYzEyNDRkZDlkOWM3MDMzYjU2YWVlOTJfMTI2MQ_efd5a65b-e56c-43d2-a7b4-40524b9ce0be"
      unitRef="usd">11200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184NS9mcmFnOjBhMGFkNTY5MDU5ZTRkMDBiZWNkMTA0ZDRiZGEwZWI4L3RleHRyZWdpb246MGEwYWQ1NjkwNTllNGQwMGJlY2QxMDRkNGJkYTBlYjhfMjA0Nw_4fcd00a7-0cd1-4b6d-b815-48b9de3a50ef">Related Party TransactionsThe Company has Pharma Services contracts with HOOKIPA Pharma, Inc., an entity with whom a director of the Company, Michael A. Kelly, was a director of until April 2023. In connection with these contracts, the Company recognized $0.2&#160;million of revenue in the Consolidated Statements of Operations for the three months ended March 31, 2023. Revenue recognized in connection with these contracts for the three months ended March 31, 2022 was immaterial.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i954166d7487547128bc5b533688dd6d9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184NS9mcmFnOjBhMGFkNTY5MDU5ZTRkMDBiZWNkMTA0ZDRiZGEwZWI4L3RleHRyZWdpb246MGEwYWQ1NjkwNTllNGQwMGJlY2QxMDRkNGJkYTBlYjhfMTgyMw_37b03f58-b588-4f31-97a2-50d1a1ef5133"
      unitRef="usd">200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTkwOQ_9bc06a6b-37b8-4df2-9702-5107487a1539">Segment Information&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under two reportable segments, (1) Clinical Services and (2) Pharma Services. The Clinical Services segment provides various clinical testing services to community-based pathology and oncology practices, hospital pathology labs, and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and self-pay patients. The Pharma Services segment supports pharmaceutical firms&#x2019; drug development programs by assisting with various clinical trials and research as well as providing informatics related services often supporting pharmaceutical commercialization efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial information reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) includes revenues, cost of revenue, and gross profit for both reportable segments.&#160;Assets are not presented at the segment level as that information&#160;is not used by the CODM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes segment information for the three months ended March 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfNTQ5NzU1ODIxOTU5_7e9cfdcc-76bf-459b-95ba-9f64df8df276"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTkxMA_70a3caa3-09af-48cd-bde3-3c996875335f">(in thousands):&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost of revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $4.3&#160;million of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 include $0.6&#160;million of amortization of acquired Inivata developed technology intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMy0yLTEtMS0xNjc1NDU_32389eac-6cba-483d-a048-fd38ad37b451"
      unitRef="usd">114869000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMy00LTEtMS0xNjc1NDU_cacc4296-29e7-4665-be5d-66d928bfcdda"
      unitRef="usd">98791000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNC0yLTEtMS0xNjc1NDU_b5937a9c-7bb7-4430-b902-7d73f65e0380"
      unitRef="usd">22351000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNC00LTEtMS0xNjc1NDU_942ff5b0-4411-4114-a865-563c700743c4"
      unitRef="usd">18378000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNS0yLTEtMS0xNjc1NDU_77f0f390-89ba-4aaf-859a-7541ba0c4b78"
      unitRef="usd">137220000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfNS00LTEtMS0xNjc1NDU_aef235e2-1ee0-4693-a955-4c0812bc290c"
      unitRef="usd">117169000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOC0yLTEtMS0xNjc1NDU_8ea9a0ad-69ac-49f3-a11d-38005e39500b"
      unitRef="usd">67292000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOC00LTEtMS0xNjc1NDU_799ade7d-e277-4822-b9e6-c87c944b1c4b"
      unitRef="usd">65267000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOS0yLTEtMS0xNjc1NDU_251814f6-8cb5-4fc5-b900-5b8c6f71503e"
      unitRef="usd">15114000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfOS00LTEtMS0xNjc1NDU_1e87aa20-0846-48ef-9c8b-8f394c0126f1"
      unitRef="usd">13670000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTAtMi0xLTEtMTY3NTQ1_dadbda83-03df-4c61-8ff7-048f8087c5e9"
      unitRef="usd">82406000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTAtNC0xLTEtMTY3NTQ1_7a996486-e019-4394-9dbe-e0cc212edd24"
      unitRef="usd">78937000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTMtMi0xLTEtMTY3NTQ1_b57edaf8-d1ee-4d7e-b55f-d18ea8b814f6"
      unitRef="usd">47577000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTMtNC0xLTEtMTY3NTQ1_b6e2f8be-e2bc-48db-a6a5-a4c5d5e80b58"
      unitRef="usd">33524000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTQtMi0xLTEtMTY3NTQ1_f480a1c2-7f7a-42e3-b21a-95397b61cf8e"
      unitRef="usd">7237000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTQtNC0xLTEtMTY3NTQ1_03b80edf-cb0c-4b8a-9eae-57962065ea9c"
      unitRef="usd">4708000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTUtMi0xLTEtMTY3NTQ1_d4743ee0-79d5-454b-af88-e76b06eac177"
      unitRef="usd">54814000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTUtNC0xLTEtMTY3NTQ1_d0416ae2-2269-4297-ba20-f87e773ccf30"
      unitRef="usd">38232000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTgtMi0xLTEtMTY3NTQ1_02005dd8-d5b7-48ea-bf16-2695c2d009aa"
      unitRef="usd">61549000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTgtNC0xLTEtMTY3NTQ1_12e2627f-6ea5-4b1d-a9dd-8916155068dd"
      unitRef="usd">66248000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTktMi0xLTEtMTY3NTQ1_b80d3ae7-9473-478a-af18-cf4225c7d994"
      unitRef="usd">7395000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMTktNC0xLTEtMTY3NTQ1_4db74006-9496-4e87-9956-f48aa16f05e3"
      unitRef="usd">7713000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjAtMi0xLTEtMTY3NTQ1_8a771858-91fc-40d4-9ac1-5db55375ca21"
      unitRef="usd">16259000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjAtNC0xLTEtMTY3NTQ1_c3ae94b7-cf1b-4002-a0db-ea566df01db4"
      unitRef="usd">16299000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:RestructuringCharges
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtMi0xLTEtMTcyMzg4_e32e2ef7-9cde-45cf-af88-8aa62e57b617"
      unitRef="usd">4684000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtNC0xLTEtMTcyMzg4_ea223d3c-eb57-4aba-812f-9089a590a9fe"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtMi0xLTEtMTY3NTQ1_3a53f132-01ab-43d8-b6e0-d903c120f479"
      unitRef="usd">89887000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjEtNC0xLTEtMTY3NTQ1_500d459e-e309-4d85-abc2-f7c164a2eb0a"
      unitRef="usd">90260000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjItMi0xLTEtMTY3NTQ1_dec30675-95f3-45a5-960f-db78ba31017c"
      unitRef="usd">-35073000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjItNC0xLTEtMTY3NTQ1_d267a51e-12bf-42a5-93cd-38903964c86b"
      unitRef="usd">-52028000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjMtMi0xLTEtMTY3NTQ1_d2877a2c-83f5-4dd4-925d-bf140170c368"
      unitRef="usd">1467000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjMtNC0xLTEtMTY3NTQ1_aabdef88-88b4-4072-9ff1-a198f46f8222"
      unitRef="usd">-1301000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjQtMi0xLTEtMTY3NTQ1_a7762951-6626-4df2-8a09-233f40e4a720"
      unitRef="usd">-114000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjQtNC0xLTEtMTY3NTQ1_0b03503b-8e1e-4fce-bc8d-d75714c21a9c"
      unitRef="usd">168000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjgtMi0xLTEtMTY3NTQ1_487aeeb3-0815-47e3-8da7-50bcc56e1b1e"
      unitRef="usd">-33720000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjgtNC0xLTEtMTY3NTQ1_6a0dbd29-2db4-4fad-bff0-e701ce8252b8"
      unitRef="usd">-53161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjktMi0xLTEtMTY3NTQ1_86bec0c6-16c2-444f-af37-73fad1060c5d"
      unitRef="usd">-2925000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMjktNC0xLTEtMTY3NTQ1_b5cbc842-170e-46e1-8484-ef94d635a6d0"
      unitRef="usd">-3753000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMzAtMi0xLTEtMTY3NTQ1_c0bdc8a9-6d9a-4411-9c60-82cfd28e356a"
      unitRef="usd">-30795000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1863049f937940c499e969956396ab07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RhYmxlOjQwODg3YWU1OGEyZjRmYjI5MDlhNmE5YmUwNDFhOThhL3RhYmxlcmFuZ2U6NDA4ODdhZTU4YTJmNGZiMjkwOWE2YTliZTA0MWE5OGFfMzAtNC0xLTEtMTY3NTQ1_1dfb214a-efdc-4e91-9c80-ebe0aeb6a1dd"
      unitRef="usd">-49408000</us-gaap:NetIncomeLoss>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="i00a79d01596040409b0f0b3e6c164729_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTEzNg_0b88e68a-f4dc-420a-b6b0-b339099f7332"
      unitRef="usd">4300000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="i78f22d3306074426850c066c83f4fad2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTEzNg_b8a94e41-6540-4211-8beb-ae7d1cb39115"
      unitRef="usd">4300000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="idbe390f745ed4eca957b49e083feac70_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTY1NQ_139100be-569a-4c89-a2ff-ce92393dc9b2"
      unitRef="usd">600000</neo:IntangibleAssetsAcquiredAmortizationExpense>
    <neo:IntangibleAssetsAcquiredAmortizationExpense
      contextRef="idd1e749ecd2c4b5ea65ba7798d85c5b1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4MDgzYjk3YWNiNTQ3YTk4MmU4NGQ3MTVlM2NmMjgzL3NlYzplODA4M2I5N2FjYjU0N2E5ODJlODRkNzE1ZTNjZjI4M184OC9mcmFnOmM3YzY1MjBmYmZkNTQzOTI4YWE0ZTk1ZjIzNTE5YTYzL3RleHRyZWdpb246YzdjNjUyMGZiZmQ1NDM5MjhhYTRlOTVmMjM1MTlhNjNfMTY1NQ_a6890b21-094b-416d-9b70-3af6aca5df04"
      unitRef="usd">600000</neo:IntangibleAssetsAcquiredAmortizationExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MB& 8,";/KE1TN\I^9XVOR=DK.'M'MDQ!80;))H#J/-JUYC22QD1:PVH"]@O
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M5.*L!R@+ W2G]XA*#_M@;)TJRF<743QU=L1Z3K(CG%15)8V%>E>:6.+ LA-
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MP4&^-8#G*P5\VMW8;Z;[;^3G_P=02P,$%     @ U(2I5F9!$2KY @  .0@
M !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RM5FM/VS 4_2M7&9I 8LVK
M32EK(Y6V""0&%87MP[0/;N(V%DX<;*<%?OVNDQ*U++RD]4-C._><>\[U*_VU
MD'<JH53#0\HS-; 2K?-CVU910E.B6B*G&;Y9")D2C5VYM%4N*8E+4,IMSW$"
M.R4LL\)^.3:585\4FK.,3B6H(DV)?#RA7*P'EFL]#URS9:+-@!WV<[*D,ZIO
M\ZG$GEVSQ"REF6(B TD7 VOH'H^Z)KX,^,GH6FVUP3B9"W%G.N?QP'*,(,II
MI T#P<>*CBCGA@AEW&\XK3JE 6ZWG]E/2^_H94X4'0G^B\4Z&5A'%L1T00JN
MK\7ZC&[\= Q?)+@J_V%=Q08]"Z)":9%NP*@@95GU) ^;.FP!W/8K &\#\#X*
M\#< OS1:*2MMC8DF85^*-4@3C6RF4=:F1*,;EIE9G&F);QGB=#BZNIQ=79R/
MAS>3,9P,+X:7HPG,SB:3FQGL3XFDF4ZH9A'A!_ -;F=CV-\[@#U@&=PDHE D
MBU7?UJC$\-G1)NM)E=5[)>L/(EO@NX?@.9[? !^]#1_3J(9[NW ;_==%\.HB
M>"6?_PK?3!--<6EJ$ LX91G)(D8X3(5BY5K[/9PK+7'%_6FR6G&WF[G-+CQ6
M.8GHP,)MIJA<42O\^L4-G.]-QO\3V4X9_+H,_EOLX53BX2#U(^"D KTO6&YJ
M<HA;+2K2@F.-8MPAF!BK8^K25(PJ0U!F,"?(*G3]HZ, )WFU;;,IS.WY3AVV
M8Z!=&VB_:6 DTA2G"S=-='<(.9&P(KR@L(^K-1:<$ZD '8)*<&$?-,FO^+M;
MNIR6X[@OU+\7M2.^4XOO?$)\*5$!*70B)'O"RAL3U6BC\HJ\LZ7)ZSC5[X7Z
MCT3N. AJ!\'G'3"EBO?5!_]H<KTNWD3MWLO:-T4&/=?O];QF]=U:???SZO'>
M4QJW \N6[UGH?MA"4V2S!7OK8#>7*IZ;2Y8IX'2!6*?511)975151XN\/.OG
M0N/-4383O-NI- 'X?B&$?NZ8ZZ/^6@C_ E!+ P04    " #4A*E6CUGP+L %
M  !O&   &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U9;4_C.!#^*U9O
M==J5%AK;>>5*)2B%K41;U!;V<T@,C3:)>[$+W+\_.VF3-G8,2'PA<3HS?F8\
MGL=C!J^T^,/6A'#PEJ4Y.^^M.=^<]?LL6I,L9*=T0W+QRQ,MLI"+8?'<9YN"
MA'&IE*5]9%EN/PN3O#<<E-_NBN& ;GF:Y.2N &R;96'QWR5)Z>MY#_;V'Q;)
M\YK+#_WA8!,^DR7A]YN[0HSZM94XR4C.$IJ#@CR=]R[@V0B7"J7$0T)>V<$[
MD*X\4OI'#B;Q><^2B$A*(BY-A.+Q0D8D3:4E@>/?G=%>/:=4/'S?6[\NG1?.
M/(:,C&CZ.XGY^KSG]T!,GL)MRA?T]1?9.>1(>Q%-6?D7O.YDK1Z(MHS3;*<L
M$&1)7CW#MUT@#A2$';T"VBF@MH+=H8!W"KATM$)6NG45\G X*.@K**2TL"9?
MRMB4VL*;))?+N.2%^#41>GPXFL^6\]O)U<5J? 66*_&8CF>K)9A?@_G=>'&Q
MF@@!< +NEU?@^[<?@*W#@C"0Y&"UIEL6YC'[";X=C0=]+H!)\_UH!^*R H$Z
M0& PI3E?,S#.8Q(?Z_>%0[57:._5)3(:G(;%*<#P)T 6PAH\HX^K(P,<7 <9
ME_;L#GLKRL,4Y&)3%N2%Y%NB"U%EPBU-R,WW,H380\@:]%\.D6O$H ?=H!8[
M0FC7"&TCPM%\N9)KOA@_C&?W8QV^RH!S,+&/;,MMP5.E/#_ GAZ=4Z-SC.AN
M%O/E$MPMYM>3E0Z:HTSJV#ZT6]!4*>PCC/30W!J:6ZKA#FCS#2E"GN3/@+R)
MTLH(.],A=$W^R5)]QC9A1,Y[HA8S4KR0WO#OOZ!K_:-+WB\R=N2O5_OKF9>"
MY,+A%(B-#L)8%*2$<1F %VU.>TK(7>C806MA-%(NLGW]PO@U4-\(="%<#XMH
M72*-Q;9+Z4;0#]?!]-6DQ8'30JD1\B#6@PQJD($1Y#),13&5" 6'_B$RCW3X
M F5JZ"*G'4:M5-!1&*#5$(3U7B!YL8WXMI!9'HGZ_TST-=Y2 -BNW]Z%&BFK
M ^(!A\$/U%>J;$4M2JC6L<#WO39,52RPD-L%%350D1'JK:QDUXOY](!>M3"1
M,O\)=BP/MW%JY!Q!6QV[!S:4!<V<-<DY$>6#@^])'M&,_-A']:<D,BUDK$*!
MMJM$5A6#V((=>!L"@V8&F_,U*?88:]#=8%6B@@IC:(1.H-L5VH;-H)G.;BEC
MX)&(,S@!/'SKR%.5KDZP.!"TSP,Z.0=#MRN@#;%!(X^(!) 1E  %UIP\)?HX
MNNKT*$#MXJD3PY[343YAPT;03$>S\0K(+:6%YBE'I1-L>4IAU\G9@6UUK7/#
M0- WG@WVX(#8Z6#YZV*A/5=!(X]]]FSP5=:.76[X#)H)[3)D221W'XAIFH8%
M Z(H5TW##ZWSE3G_,/;6J9H^6C%;OT"HH39DIK:K)-UR$G\"[\[@>WCU8EUX
M&YY#T)A0O\>3FU^R4;MX$-QQ,P:C^70ZGU6Y)7JV^Y7HX&97D]F-%KN11#^;
M:%]E[3@4#8\B,X\VB59UI/K54LD1(D?0>'NY='+8Q1ULCQH21682/4PP$TX-
M)6IQZN0,.!OR1.^T?^)#$HDSU%(L5!+I&<ELX]/Y\T76CCUN.!B9.?A#+?G.
MQG&S;?MN^^2MD0M\+^B@8-10,#)3\ >Z<J02J^L) FXCU(@YR.WHRU'#O^B=
M=O"=SARIO9WM.5[[3*@1P]A!706S86!D;@+OQ)[+0G-6?RG]?I6U8W\;^D5F
M^OU85JN-(D+8@>TUT?23/O8Z3D6X(5UL)MT/)#56>T3HJ,=SG1AVO8YJB!N:
MQ>9V\KVDWJD?;G</X79.:Z1L3SE4]@^N;C,B6FMYH\U 1+<YK^X[ZZ_UK?E%
M>5?<^GX)ST;5W7=CIKJ*GXJ./<D92,F3,&F=>B)@176[70TXW907Q(^4<YJ5
MKVL2QJ20 N+W)TKY?B GJ/_',/P?4$L#!!0    ( -2$J59!TN=C'P,  .4(
M   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK591;]HP$/XKIZR:6JEM
M0@*$=A")4KHB%:@:VCU,>S#)0:(F-K,-=/OULQV: 4W9'OJ2V,[==]]WMN_2
M7C/^+!)$"2]Y1D7'2J1<7-JVB!+,B3AG"Z3JRXSQG$@UY7-;+#B2V#CEF>TZ
M3M/.24JMH&W6[GG09DN9I13O.8AEGA/^ZPHSMNY8->MUX2&=)U(OV$%[0>88
MHGQ<W',ULTN4.,V1BI11X#CK6-W:9:^E[8W!4XIKL34&K63*V+.>#.*.Y6A"
MF&$D-0)1KQ7V,,LTD*+Q<X-IE2&UX_;X%?W&:%=:ID1@CV7?TE@F':ME08PS
MLLSD UO?XD9/0^-%+!/F">O"UE<1HZ60+-\XJWF>TN)-7C9YV')0.-4.[L;!
MW7>HO^/@;1P\([1@9F1=$TF"-F=KX-I:H>F!R8WQ5FI2JG<QE%Q]396?#'KC
M43B^&UQW)_UK""?J->R/)B&,;Z W'MX_]&_[HW#PU(>[<1C"&3R&UW!\= )'
MD%*8)&PI"(U%VY:*BT:THTW<JR*N^TY<#X:,RD1 G\88[_K;2D,IQ'T5<N4>
M!!P2?@Y>[11<Q_4J^/3^W]T]0,<K\^H9/.\=O% 2B>JT2V SZ+%<7;%$G_T5
MPH!&+$?XWIT*R=4Q_E&5O0*]7HVNK_:E6) (.Y8"%LA7: 6?/]6:SI<JZ1\$
MMI.(>IF(^B'T8-2?F+-3);+P;!I/76Y6P9GG^!>-MKW:IE]A5K^H.ZW2;(=8
MHR36.+A#X\EM_V'OD'_M#D9PK.F>7%81;GSDKGP0V([X9BF^>7A75']84E7V
ML_0WQC!7Y1Z.,R;$":C:JNKY,THRS1 $1DN>RA3%*5 TIUF2EZK<% $;6[M4
M<YK[6_G6Z,SU_%KU3OJE&/^@F F3) ,F$^00[5RU+5W_HN__#_VW1@?HMTKZ
MK8/TW];9*GZMMY? O? ]9X]AA5FCYOL7>Q3MK8Z1(Y^;1BI4]I94%C6W7"U[
M==>TJ+WU*]7#BY;[%Z;X 5 5=9Y2 1G.%*1S[JNT\:*I%A/)%J8O39E47<X,
M$_4?@EP;J.\SQN3K1 <H_VR"/U!+ P04    " #4A*E6??;+P(<'   6.
M&    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+U;:W.;1A3]*SMJIFUFHHA=
M$(_4]DPLP<33)'8MIYU.IQ\PK"S&"!1 MM-?WP7)0OO0"N+;?K%!VGO.<@]W
MV3V+3A[SXKY<4%JAIV6:E:>#156MWHU&9;2@R[!\FZ]HQKZ9Y\4RK-AI<3<J
M5P4-XR9HF8Z(8=BC99AD@[.3YK.KXNPD7U=IDM&K I7KY3(LOIW3-'\\'>#!
M\P?7R=VBJC\8G9VLPCLZH]67U57!SD8[E#A9TJQ,\@P5='XZ>(_?!2:I YH6
MOR?TL=P[1O6EW.;Y?7UR$9\.C+I'-*5154.$[-\#G= TK9%8/[YN00<[SCIP
M__@9/6@NGEW,;5C229[^D<35XG3@#E!,Y^$ZK:[SQP]T>T'C&B_*T[+YBQXW
M;1US@*)U6>7+;3#KP3+)-O_#IVTB]@+PH0"R#2!= \QM@"D$$.= @+4-L(0
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MRW53&?D<19MG1EDKC]AL#/FSJZO]$5 EN!:^K^!C:<"S''=L"D4%2>E#@@5
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M!:PP%HCM8=/SB)AC4',!%"V 0N-5;?T%K#<8CFY=J)64%_B>YQK$%"O 552
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M,2WJ!NS[>9Y7SR?U[[!V/P4\^Q=02P,$%     @ U(2I5J6?7/^1!P  )B$
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M$%Z6:EQ4!QZM/0BV61N&L,F1#JDH;#OCP(;:L9_:G:EB_.Q/%6SS-L1Q\]S
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M_?G2"T" JY#L$R$VG/?G$>)W.:@CMCQE+_SK*8X\66:++ #%B^GULAT E@"
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MM#0Z(>_9@=V91^$SZ^C%H:G@@+IAC<+80\C""(Y@$ [@6MK;HQEK2HJ(>.K
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MXJY-CS5>;MA+ ,8KY^*A(1.,KTOK?P%02P,$%     @ U(2I5FMWW2)X!0
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M1B7,:J/'G8QB+#G>E=;C[G@X:9X["F/<C0?CYOG!%W79G J7"CO@GI+2L-[
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MP<:.,.&^$WZ<KOP= P=*W%C\9X8K(AE>@/F91HHT/ZR@O71>_@U02P,$%
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M3Z^GTY?H&GXE/'>X7-3\$3@!,%J WRL'@<I?Z(#^_PA._@M02P,$%     @
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M;620C(1X,)VWX\N>8QSB&4^TL<#@L^ W/,N,(7#CZ\IFKU[23&RVU]9?6^R
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M//2%%0^<HY$ !(ABZH?(;B]YB4["J \B$L;H:LJ+9+G2"K#C.@TMKX]\'-,
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MH;7(;7/&V9A+HP#C$R'TNF,6J)]QAW\#4$L#!!0    ( -2$J59&S/NSTP0
M '4-   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*U76V_B.!3^*Q93
MC6:D;$GLW.@ $J7=W3[,J&K9W8?5/ICD0*PF,6N;TLZOWV,'4EI2%HWF 7)\
M.9_/_=C#C50/N@ PY*DJ:SWJ%<:L+OI]G150<7TN5U#CRD*JBAL<JF5?KQ3P
MW#%599_Z?MRON*A[XZ&;NU7CH5R;4M1PJXA>5Q57SY=0RLVH%_1V$W=B61@[
MT1\/5WP)]V#^6-TJ'/5;E%Q44&LA:Z)@,>I-@HO+Q.YW&_X4L-%[-+&:S*5\
ML(.;?-3SK4!00F8L L?/(TRA+"T0BO'O%K/7'FD9]^D=^J].=]1ESC5,9?F7
MR$TQZJ4]DL."KTMS)S>_PU:?R.)ELM3NGVR:O1'KD6RMC:RVS"A!)>KFRY^V
M=MAC2/UW&.B6@3JYFX.<E%?<\/%0R0U1=C>B6<*IZKA1.%%;I]P;A:L"^<SX
M-RGSC2A+PNN<W-2&UTLQ+X%,M :CR:<9QY'^/.P;/,RR]+,M\&4#3-\!9N2K
MK$VAR76=0_Z:OX]"MI+2G:27]"C@5Z[."0L\0GW*CN"Q5G/F\-B/:7XE=%9*
MO59 _I[,M5$8/_]TF:$Y)>P^Q>;4A5[Q#$8]3!H-ZA%ZXX\?@MC_<D2'L-4A
M/(8^OL<<S=<HM%R0G3Y=,AY%Z99Q5@!9R!*35M1+8FP8;#-7? =-#"YG7*EG
MN\HKN:[19BC%<F?5^3/1L,3T-80;@L[+BM9[SN17D$$U![6;I>23J!%7KC4N
MZ\\7;YD.&::HB<AX2>Y19I&A6&<DC%(O2>D>=5MP3-^7/3'S!FFX^\RD08 S
M$E'J)7&\1QWQ3]3Z)SK9/].28V0Y(QU$6Y?/CB)W^VP/ES=1G$DLG]I ;H\U
MKUSZ/]:>5%(9\9V[VCF5VI!)EJVK=<DMVC=L%U-7G= ?=U"Z;;H0*TT2\@L)
M(K1C$#(O\ -KT=0+@@2)-'0VOX)'[ 8KQ)E!5M2RE,MG$O@-(PM\C]*8L-0+
MPX30)/"29&#%>P!C!=\F:$BB<(#+#'\QF2F>8[O"5M9@>"$N,"\)4USV$AHU
M.\@W7@&AYQ&A7H22!!X+4ORG\1X$RG&#16N!P66 E-@U<O+Q0TH#^H4$S$GU
M9M@&D8^ J6^51VK@,Z388(#")!WA^U--''EQ:*?2Q NC^$03,^<7FB2(\KZ)
M68H<P7LFIA@L-/5HY'>;.!TD:. X37ZN@0<H.[5$Z./AL7\L7>,V7>.3T_5M
MCK[VUO43WHHT=.7MT2-^N-;R_=.A.1UYE%LTA0(@5=-OP?;;KH+;66-GCG6_
M5;]E/0Q5M(YHK:.1SLJU943HS$8QKBL,OWH-UCU>&K'V>RK.$FI0O.G-/,=[
MC[ =V%[@=LIK#+T!\_$_9KOXX$?0,3.P&S#W#0='PR5IPR4Y.5RNM1&5R]M3
MX^0H]OMQ NU!G2&AH*D>1K;K-IK$06>PL0,<'7W0&%:@A,PU;K1K;Z)!N/EF
MLSZ(ICNP[X <"Q9RNOUGA,8>P]J H] 6'%?3?:S'2+/0A9<K1,Q/+9T0AMTW
M2C$P 1\9"X-86*J\E+ZT:I;&GL^Z7=C?NPICX5RZ"[_M@WA!:6[%[6S[II@T
M5^F7[<V#!#5?BEJ3$A;(ZI\GV)%5<\EO!D:NW,5Z+@U6:4<6^"X"93?@^D)*
MLQO8 ]J7UO@_4$L#!!0    ( -2$J5:>3(X91P0  )H*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;+U62W/B2 S^*RIF,D6J'..W(0&J(,G,[F%F
M4DDV<]C:0V,+[(KM]G2W(?GWJVZ#0[*$RFDON!_2)ZGU26B\X>)19H@*GLJB
MDI->IE1]/AC(),.229O76-'-DHN2*=J*U4#6 EEJE,IBX#E.-"A97O6F8W-V
M(Z9CWJ@BK_!&@&S*DHGG.19\,^FYO=W!;;[*E#X83,<U6^$=JK_J&T&[08>2
MYB56,N<5"%Q.>C/W?!YI>2/PD.-&[JU!1[+@_%%O_DPG/4<[A 4F2B,P^JSQ
M$HM" Y$;O[>8O<ZD5MQ?[]"_FM@IE@63>,F+7WFJLDEOV(,4EZPIU"W?_(';
M>$*-E_!"FE_8M+(A"2>-5+S<*I,'95ZU7_:T?8<]A:'SCH*W5?",WZTAX^45
M4VPZ%GP#0DL3FEZ84(TV.9=7.BEW2M!M3GIJ>J=X\G@VI[A2N.0EY5HR\US]
M>[8H4)Z.!XK,:.%!LH6<MY#>.Y ^?.>5RB1<5RFFK_4'Y%[GH[?S<>X=!?S.
MA V^:X'G>/X1/+^+V3=X_CMXU[^;7#W#W[.%5()H\<^A&%N(X#"$+I5S6;,$
M)SVJ!8EBC;WIET]NY%P<<3#H' R.H4_OJ/32ID#@2S )@I^U2<I,<YA\/^3P
M4<C##L]VM:@-J0Q!&F.\?BD8_5 -Y5&8>\T05CU_^33TW/A"0EVP2@*U!G.K
M,H$(99M\U,D'2EV2=;F#7 +3\@7U GD./YIR0<AD_)>I'E*8K5%0,X#K)Q1)
M+A%N1)X@_&R45*Q*\VH%3,$5)FA4M\@>!);G!E;DQO 9W,@.AO!-L$HC^O[0
MBD>>/G?LR.N04^C'H>5XP]/VRG&!ZGR)N5;J^T%LQ>Y(WWF.'49O/7@36&"Y
MOF-%D3$3VG&\,Z.+Z(!\'))&H*6]D1V$<(0T84>:\,.D^<IR 0^L:,SNFI'I
MUSS:,)'N7N@0F8Z;NJ=D+[6)]<X$:A.OV6-,K+9)2!NA'^YC+-D01U"JG'HN
M7=)FRTX#!BF=0B--'F!>,&I?%#JG7D6@*>H&JC(CW_+,"$HBNO&+6'=O'-CO
M492LFOXE:*%0E-#/*WA&)N0I!+8#9Q#:(=SF\O%LJ35SBHA*2('0GO1/3L&W
M@Q,2"_2G@UKS@CIIH0M(RX2!'6FAB-AQ E=462D%#\\Y%JD1,$7E7;R4 MN6
MPE[8>X]>$_MEQ@3"Y]".HB,$BCH"11\FT"W%1X6GW6B)<ZSS'(7]8.<1+P9;
M&OV?W6<OVO\T(E,D<*5??Z^J?O!J34HZ2X>ZD6N-1H$UC%S=#CP[=KMNY+D^
M]16G;3EN" \M2M_WK<B)3;LA-GG[K6@XLH9^=-I"N=%KVV]"]"QG&%JN-VRE
MZ7N(&(.]>:%$L3)3D82$-Y5J1X?NM!N\9NV\\2+>3FUD?Y53%@I<DJICQ]0Y
M1#L)M1O%:S-]++BB6<8L,QH>46@!NE]RKG8;;: ;1Z?_ E!+ P04    " #4
MA*E6%X\C< 0$   O"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R5
M5FUOVS80_BN$6A0)H$8B+5ER:AO(RXH5:  CR;8/PS[0TEDB2HD>2<?M?OV.
ME*PXB>UU7R21NGONN3L^)*=;I;^9&L"2[XULS2RHK5U?1I$I:FBXN5!K:/'/
M2NF&6QSJ*C)K#;ST3HV,6!R/HX:+-IA/_=Q"SZ=J8Z5H8:&)V30-US^N0:KM
M+*#!;N)>5+5U$]%\NN85/(#];;W0.(H&E%(TT!JA6J)A-0NNZ.5UZNR]P>\"
MMF;OF[A,EDI]<X,OY2R('2&04%B'P/'U!#<@I0-"&G_WF,$0TCGN?^_0/_O<
M,9<E-W"CY!^BM/4LR -2PHIOI+U7VU^AS\<3+)0T_DFVG6V2!:38&*N:WAD9
M-*+MWOQ[7X<]ASP^XL!Z!^9Y=X$\RUMN^7RJU99H9XUH[L.GZKV1G&A=4QZL
MQK\"_>S\'IZ@W0"YAT)5K?"5.GOD2PGF?!I9C.#LHJ)'N^[0V!&T$;E3K:T-
M^:4MH7SI'R&S@1[;T;MF)P'ON+X@(QH2%K/1";S1D.[(XXW^(]V55@VY0:X:
MEP66W-;DQA<;-/GS:FG\_%^'"M#A)X?QG80NS9H7, M0(P;T$P3S#^_H./YT
M@GTRL$].H<\?4)+E1@)1JV?R5\: -82W)?DJ^%)(;"*80]1/@A^F_EACK91$
MZ8JV(M:MBUZ_XA\PQ.+O)RXW^(F4BATE[BF%I.!K8;E$TQ)_-HTP3LL=U\%8
M/I,F9Z)%3+4Q:&'.+PFVOZB'_I-;**!98HOZ&89-TQI:2]8U1XF^9D#.Z#EY
M3VA(&?7O?)*3KZJM/EK0S5$G=DX^O,L999\P$'E4F,(QVWWP"9N\X7.D !VO
M"67XS./X *=CCLAM/&(DH^DK8D<<'+$T2;HW.ATKV'X7WI-Q&(\S?&=AFF8G
M*O:B=Z/GLM')D;(=#9.-?5'<-J1QZ_"2Q,6@<(5IW <[TGW15>L7'BK *"E*
M;M'^FDO>%D >W$YH+GRA#H/]#Y 3DDT'R:8_+=E;87A5::BXWV9QIM^.#HGU
M).S/B[4$RX7LE%J^B:]WVZ'"LPW+TY4$@XD"F_> L** 3J^+KI/#G($*SV;[
M5K./M09X<0Z\EG&GW-=1+MV4ZW(I-![9!->)='G@\AB'.;KA>DG#F";8LP;W
MZ4*@\Y?6;+3O&:/A*$T)S4.6Y^0.2@37X*EW U$2.@[3/",T#9-QBH'EZN."
M_R T3@A+^A7[-GN4#DW"?#QQDLW#;$+?%(,Q#$Y=\%&6]T"[HP;=1UG(6.R!
MLI BT*&%%>T=XIA>Y:\J!J6S:6UWG@^SPVWHJKL$/)MW5RFL=R50_!)6Z!I?
M9+B8='<]Z096K?V5 'N.9Y[_K/%&!]H9X/^54G8W< &&.^+\7U!+ P04
M" #4A*E6K%;OLEH#  !:!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6R-5=MNVS@0_96!NB@2P(VN=NS$-A"[#;; %@F2=/NPV =:&EML*5(EJ;CN
MU^^0DE4;3;U]$,7+S)ESAAQRNE7ZBRD1+7RKA#2SH+2VO@I#DY=8,7.A:I2T
MLE:Z8I:&>A.:6B,KO%,EPB2*1F'%N SF4S]WK^=3U5C!)=YK,$U5,;U;H%#;
M61 '^XD'OBFMFPCGTYIM\!'MQ_I>TRCL40I>H31<2="XG@4W\=4B<_;>X&^.
M6W/0!Z=DI=07-WA?S(+($4*!N74(C'[/N$0A'!#1^-IA!GU(YWC8WZ/?>NVD
M9<4,+I7XQ M;SH)Q  6N62/L@]K^B9V>H</+E3"^A6UKFY%QWABKJLZ9&%1<
MMG_VK<O#@<,X^H5#TCDDGG<;R+-\RRR;3[7:@G;6A.8Z7JKW)G)<NDUYM)I6
M.?G9^0,:JYO<-IK+#9P]L95 <SX-+6$[BS#O<!8M3O(+G!0^*&E+ ^]D@<6Q
M?TB<>F+)GM@B.0GX@>D+2.,!)%&2GL!+>Z&IQTM_2RB3!3R@8!8+N'$'@UN.
M!OZY69$5G91_7\I &R![.8"KGBM3LQQG 96'0?V,P?SUJW@479^@G_7TLU/H
M)^@OE;'F);JG 9]*A+425)0.T+I][RJ3?Z=,6%K.2R8WU.?2#Y>JJIG<O7XU
M3N++:T,%E>N&".@C:BLFF,P1SKR7:@QQ->=7\(C/J/V*(W]'@!K>5;50.\16
M ]RRG MN=W"KE*T)S<)=;7G%OS-?P4LE#17;/@$M1NOZI"P3L.AB,P-J#6\Q
MQVI%)MTI2N /& XGU'H)R37U)J.(VG@PC"=PG&(2KUOQ>:,UR4P'<32$29Q"
M'(T@&\1)!N\I(US3'65=P/6>O^ZVAAF#1&X?;DC!#OM+9DJHV<[Y&R])>4FL
M^$R%W\Z>Q>?T#9+QD/[#449MFHVH30;QA.:.)5/1Y&5?-:0L&:273O$D<NUE
MXM1F@R@:P]*I(MZ"LY5C[8[_?NTO)3=O+.KJ:/5'UEHK1^WN)\*4+]$4"%+)
M-[D3Z)/0IW.?&JO^=[MSM[,7+]5.>'#?54BX[E8WY-!(VUY]_6S_<-RT]^4/
M\_;5H8QMN#0@<$VNT<7E, #=WN3MP*K:WYXK9>DN]MV2'C_4SH#6UT1^/W !
M^N=T_A]02P,$%     @ U(2I5F3<#J-C P  3 @  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&ULG59M;]LV$/XK!W4H8L"S9,ER7FH;B-,4'=!F09QM
M'X9^H*63180B59**LG^_(Z5H<><80;_(?+E[[KGC<Z07K=(/ID2T\%0):99!
M:6U]$88F*[%B9J)JE+13*%TQ2U.]"TVMD>7>J1)A'$7SL&)<!JN%7[O5JX5J
MK. 2;S68IJJ8_F>-0K7+8!H\+]SQ76G=0KA:U&R'&[1_U+>:9N& DO,*I>%*
M@L9B&5Q.+]:IL_<&?W)LS8LQN$RV2CVXR6_Y,H@<(12868? Z.<1KU (!T0T
MOO>8P1#2.;X</Z-_\KE3+EMF\$J)OWANRV5P%D".!6N$O5/M9^SS\00S)8S_
M0MO;1@%DC;&JZIV)0<5E]\N>^CJ\Q2'N'6+/NPOD67YDEJT66K6@G36AN8%/
MU7L3.2[=H6RLIEU.?G9U0^?^11D#MZAA4S*-<'+/M@+-:!%:"N#,PJP'6W=@
M\2M@"7Q5TI8&KF6.^;Y_2,0&=O$SNW5\%/ KTQ-(IF.(HS@Y@I<,V28>+WD%
M[YIIR>7N9;9_7VZ-U22.;X?R[>!FA^%<PUR8FF6X#*@C#.I'#%;OWTWGT8<C
M9&<#V=DQ]-6&&C!O!((JX/_$Q[!FAF? 9 X?N6CLCP7O$C@>XKY$*)2@SB1P
ML.[<P92J-6!I)V,B:P1SW6/@A$M:5(VA@&8,^)1A;4&2?(233TV\C"\HJU0C
MK1E=P'VI$?<D 72@63F<J/O$<'-]#U]^WVS@%SA)HO'I>3IRP]GY>!:=C?HT
M6]]>A, >4=-MT04S0/>,L43)\9_&Z3B*Y_2;C.=)]%R6G_+MHAY(CYA%D[BC
M&$UFT6@(\Q;C([)(!UFD;Y;%I;0\=^'I9H,-9HWFEE-FUT^9:%R]"ZTJN%)5
MW5A_CH>U=$@X1TD<5OZ^FFIED>@Q 0/#ONXM4FEPC^(/<G,T\]?+NL6,-0:=
M%]> 14%7/-W^C<AIBSK"\E^'F'NZ?;LH-U9E#Z#J3OS3!&;S4[A#NBIXYE@9
MO\]:IG,#Y[.83$Z=9TK5EB0SRUTOW5 -#*3C-#GKOV1R=M DGJ;]]Y!&PA<W
M?(5ZY]\Q YEKM>ZR'U:'I_*R>R'^,^_>6<IVQRDG@06Y1I-3.FG=O5W=Q*K:
MOQ=;9>GU\<.2GGO4SH#V"T64^XD+,/R!6/T+4$L#!!0    ( -2$J585.!OJ
M*P0  %P)   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;+56VV[C-A#]
ME8$V6-@ $4G4/6L;2-)V&Z#;#9*T?2CZ0$MC2X@D>DDJSO;K.Z1L;[)QTI?V
M1>)EYLP9SH6<;:6ZUS6B@<>N[?7<JXW9G/F^+FOLA#Z5&^QI9R55)PQ-U=K7
M&X6B<DI=Z_,@2/U.-+VWF+FU:[68R<&T38_7"O30=4)]O<!6;N=>Z.T7;IIU
M;>R"OYAMQ!IOT?RVN58T\P\H5=-AKQO9@\+5W#L/SRYB*^\$?F]PJY^,P7JR
ME/+>3JZJN1=80MAB:2R"H-\#7F+;6B"B\66'Z1U,6L6GXSWZ3\YW\F4I-%[*
M]H^F,O7<RSVH<"6&UMS([<^X\R>Q>*5LM?O"=I2-N ?EH(WL=LK$H&OZ\2\>
M=^?P1"$/7E'@.P7N>(^&',L?A!&+F9);4%::T.S N>JTB5S3VZ#<&D6[#>F9
MQ2VNZ8@-7/5C@.U)3>[$LD4]G?F&+%@YO]RA78QH_!6T"#[)WM0:?NPKK)[K
M^\3L0(_OZ5WP-P$_"74*4<B !SQZ R\ZN!LYO.A?W+W!C52FZ=?PY_E2&T7)
M\=<Q=T>T^#B:+9@SO1$ESCVJ"(WJ ;W%^W=A&GQX@VM\X!J_A;ZXI0*LAA9!
MKN!(F([1?1MPTO1@:CEHT5=Z>@9WM4)\%C&@\R[KPX';#X=?J34H?,!^0'T&
MEX3:E*(E2NJA*5'#"81AS/*TH%&1LZP(X;H6Q/*;".<L2D((<Q9E.=Q)0_H[
M2 BCC'$>$$C&0@*YE-I8EW?[QRQ.PBFDI%5P2!/&T^R%P0F?0I@P(D;X+,V"
MG='R.3CDG,5!"EG.BBB#CTIJ#==*KAISS&Z<L23+((I8PN,7-HD08<0L"_8N
MKAW>QN%!0F=$=**<Q#A\WJ 2+@'QD1JLMD?[$7M:;('" Z*B8F]L9MJN!6G(
MDKB -&4\SBE[-;I 6<F*7&GEQJ5'QJ(BH6\61G KJ(:=!'7;>W2V0M)/"O<K
M"@MCU%":0=F]DMQ96R=9FL?P_EW.0_YAYXA\P1;R@N5Y!D5 YQ_ +];1E9+=
M7E3V%(0H84$636&2<!;P?$KI:Y *Q0"E8BD[G.[Q&/2499.0Q6E&D6-1$,)G
M4Z-Z1=(&=A*F!.DL+Y'* L&(1QM[BD_& VLVHHP*K5D+8;=)LD<;C0EG!4](
MAF03HFB3O+50)[044!+3'@WC@O*#K-B,>YD/WV<3D8"E-#55&5ESU=6-U87'
MJLO&QE48N=@.E2VE^#2B+M^VM@T3L.ALE_I[;,MV7GX9&D5(5WWS0.U^'WQ:
M,5C6O6SE^BO!&=&O&^KA(+1&NK1=/7R?K_\Q>S@)3M/_@_RQ5NH_N?$ZI+RU
M][IU:>C->/D=5@]/A_/QQOPF/KX[R*UU0]G:XHI4@],L\4"-=_DX,7+C[D\Z
M&[J-W;"FYP\J*T#[*RG-?F(-'!Y4BW\ 4$L#!!0    ( -2$J58$>NS(<@8
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M:7[+&%@50Q+/:3[VR$WE35^L*L70/ZAT!9W28'3P)O*F!T\I!.B6"$](6*8
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ML5P0?42IQ %VBX,1&0N;#?-1Y!G#2@L*>GB(J"KLV-U6NW,6MK32T$+.!EO
M@=N,5>'$[L)Y5F09XW$BL]:6;AFW4IQTL#V5-WW!G=$V/JBLA9W"8'3P)O*F
M!T^I!.Q6"4_X8<"L^VBQZ'<R5A094 =8J0,\<O(^F+.P12GT.9J0@985*XF
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M,UX!Y.?715$^7%1/LK5/+B[_ U!+ P04    " #4A*E6%?NB;"D&   ,*
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MWQ=%_?IBWN _%^7C?HWK_P-02P,$%     @ U(2I5HJ\B6*G @  _@D  !D
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MWE3YIGD,\BZO9$-O7JY%M!1%O8'\_C[/JV]OZ@3[1V]G_P%02P,$%     @
MU(2I5HQA;MP; P  F L  !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
MM59=;]HP%/TK5E9-K;0V(>&S@TC0CZU2*U6EW1ZF/1AR :N)S6P'NOWZ73LA
M#2BP54I?P';N/3[W^,2Y_;60SVH!H,E+$G,U<!9:+\]=5TT7D%!U)I; \<E,
MR(1JG,JYJY82:&23DMCU/:_M)I1Q)^S;M7L9]D6J8\;A7A*5)@F5OT<0B_7
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M')6]0-^74IJGC570#O7)WU!+ P04    " #4A*E6GHVAH#T#  #8"@  &0
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MX8\"#V[OK^=].88MJO$I.^QCT(/;6VT83'IT'!R5N-D[&#WX:!YCRV/LYO%
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MM@OH^90^"FO#=AU-TYC\!E!+ P04    " #4A*E6<_O[3!0#   7"0  &0
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MH@AV%?.&/<$XDB08 K7HK]$X1E8GAH]_?["G)(J2Q(\ YG<011@"3R..8 [
M X9$4?4>W'D?A<U[*ES_?V_T&U!+ P04    " #4A*E6EXJ[',     3 @
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MQOOCK\O;R<%+N.(<X(?TRS=02P,$%     @ U(2I5BBT:!/# 0  B1X  !,
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M_RGKNS&KO_XYVMS32A?U,9^U?Z"GGU!+ 0(4 Q0    ( -2$J58'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ U(2I5C1!_"WO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ U(2I5IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #4
MA*E6N'*GF<X%  #"'@  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ U(2I5D/=.EX^!P  +Q\  !@
M         ("!$@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( -2$J59F01$J^0(  #D(   8              " @885  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #4A*E6CUGP+L %  !O&
M&               @(&U&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ U(2I5D'2YV,? P  Y0@  !@              ("!JQX  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -2$J59]]LO AP<
M !8X   8              " @0 B  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " #4A*E6I9]<_Y$'   F(0  &               @(&]
M*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ U(2I5@O
M0'@F P  WP8  !@              ("!A#$  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( -2$J58#98-H60@  #H6   8
M  " @> T  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #4
MA*E6!!P]G/@*  !O(@  &0              @(%O/0  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -2$J59UH&0XM 0   @,   9
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M970Q-2YX;6Q02P$"% ,4    " #4A*E69$JLK3T$   Z"0  &0
M    @(%R:   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M -2$J59K=]TB> 4  ( .   9              " @>9L  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ U(2I5IH9;7N>"0  +Q@  !D
M             ("!E7(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " #4A*E6Y4'^"L4"  "*!@  &0              @(%J?   >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -2$J5;6U[IMRP4
M ( -   9              " @69_  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ U(2I5H1O_/!Q!P  LQ,  !D              ("!
M:(4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #4A*E6
MW^ A]7D&  #2%0  &0              @($0C0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( -2$J59&S/NSTP0  '4-   9
M      " @<"3  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ U(2I5IY,CAE'!   F@H  !D              ("!RI@  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #4A*E6%X\C< 0$   O"@
M&0              @(%(G0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( -2$J5:L5N^R6@,  %H'   9              " @8.A  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ U(2I5F3<#J-C
M P  3 @  !D              ("!%*4  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " #4A*E6%3@;ZBL$  !<"0  &0
M@(&NJ   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -2$
MJ58$>NS(<@8  ,4H   9              " @1"M  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ U(2I5A7[HFPI!@  #"@  !D
M         ("!N;,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " #4A*E63+Q<5&,,   ND0  &0              @($9N@  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -2$J5:*O(EBIP(  /X)
M   9              " @;/&  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ U(2I5N4$M*^R @  - H  !D              ("!D<D
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #4A*E6NX.1
MFD,'  "&.P  &0              @(%ZS   >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( -2$J5:,86[<&P,  )@+   9
M  " @?33  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
MU(2I5C!BXPF6 @  \@8  !D              ("!1M<  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " #4A*E6&5BCU@\(   .4@  &0
M            @($3V@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( -2$J5:GI;1;:P0   \7   9              " @5GB  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ U(2I5F6F!UAL P
M^PL  !D              ("!^^8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " #4A*E6N3)-)&H#  #@"P  &0              @(&>
MZ@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( -2$J5:>
MC:&@/0,  -@*   9              " @3_N  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ U(2I5H[*&X_* @  ;@<  !D
M     ("!L_$  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -2$J59S^_M,% ,  !<)   9              "
M@9($ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ U(2I
M5D0;5EVW!   -AT  !D              ("!W0<! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " #4A*E6QPIZ(1X#  !:#0  &0
M        @('+# $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( -2$J5;R"GR(:0(  )$%   9              " @2 0 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ U(2I5B9J;H^>!0  -AD
M !D              ("!P!(! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " #4A*E6'6)Y6C8#  #L$P  #0              @ &5& $
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -2$J5:7BKL<P    !,"   +
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4!08     .P [ !00  !*)0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>249</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NatureoftheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/RevenueRecognition</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/Restructuring</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SegmentInformation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Goodwill and Intangible Assets - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Classes of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/Debt</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Revenue Recognition - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenue Recognition - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Restructuring - Schedule of Restructuring Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Restructuring - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RestructuringNarrativesDetails</Role>
      <ShortName>Restructuring - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="neo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neogenomics.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neogenomics.com/role/SegmentInformationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. neo-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="neo-20230331.htm">neo-20230331.htm</File>
    <File>a03312023neo-ex311.htm</File>
    <File>a03312023neo-ex312.htm</File>
    <File>a03312023neo-ex321.htm</File>
    <File>exhibit101-offerletterda.htm</File>
    <File>neo-20230331.xsd</File>
    <File>neo-20230331_cal.xml</File>
    <File>neo-20230331_def.xml</File>
    <File>neo-20230331_lab.xml</File>
    <File>neo-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="764">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "neo-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 764,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 221,
   "dts": {
    "calculationLink": {
     "local": [
      "neo-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "neo-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "neo-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "neo-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "neo-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "neo-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 408,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 9,
   "keyStandard": 240,
   "memberCustom": 16,
   "memberStandard": 31,
   "nsprefix": "neo",
   "nsuri": "http://neogenomics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://neogenomics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://neogenomics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://neogenomics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://neogenomics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Revenue Recognition",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://neogenomics.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://neogenomics.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://neogenomics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://neogenomics.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://neogenomics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://neogenomics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Segment Information",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://neogenomics.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://neogenomics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://neogenomics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Revenue Recognition (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://neogenomics.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Restructuring (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://neogenomics.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://neogenomics.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Segment Information (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://neogenomics.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements - Schedule of Amortized Cost (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails",
     "shortName": "Fair Value Measurements - Schedule of Amortized Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements - Fair Value by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
     "shortName": "Fair Value Measurements - Fair Value by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Fair Value Measurements - Assets Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i262590bf4922435bbe6f1bac3c1def5e_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Goodwill and Intangible Assets - Narrative (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
     "shortName": "Goodwill and Intangible Assets - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Goodwill and Intangible Assets - Classes of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Classes of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "ic7df8ca34dc349b6a74c42cd48d424c1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Goodwill and Intangible Assets - Estimated Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iba4fa73897df4f2f8b41c9cf59104254_I20210111",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Debt (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://neogenomics.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iba4fa73897df4f2f8b41c9cf59104254_I20210111",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i07ed7276d306438c829d302392f7b033_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i07ed7276d306438c829d302392f7b033_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails",
     "shortName": "Stock-Based Compensation - Fair Value of Each Stock Option Award Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i2e92033c77f541ad96bf59d87f798f51_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i2e92033c77f541ad96bf59d87f798f51_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Revenue Recognition - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Revenue Recognition - Contract Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails",
     "shortName": "Revenue Recognition - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i37155bb755b5477e8fbeac7342fd0122_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i07ed7276d306438c829d302392f7b033_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Restructuring - Schedule of Restructuring Activities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails",
     "shortName": "Restructuring - Schedule of Restructuring Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i07ed7276d306438c829d302392f7b033_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Restructuring - Narratives (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://neogenomics.com/role/RestructuringNarrativesDetails",
     "shortName": "Restructuring - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "iec351bfb82464fa9ba1cbdf2b89bd464_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "if650c426e70e4f4a8a39d610bfaab9b5_D20210111-20210111",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "if650c426e70e4f4a8a39d610bfaab9b5_D20210111-20210111",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i52bebd24ded945888e4e9c5d03543ea8_D20221220-20221220",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://neogenomics.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i52bebd24ded945888e4e9c5d03543ea8_D20221220-20221220",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i954166d7487547128bc5b533688dd6d9_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://neogenomics.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i954166d7487547128bc5b533688dd6d9_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segment Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://neogenomics.com/role/SegmentInformationDetails",
     "shortName": "Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i00a79d01596040409b0f0b3e6c164729_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "neo:IntangibleAssetsAcquiredAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i79595b9a231b4236a3065c84f3b094e4_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i79595b9a231b4236a3065c84f3b094e4_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Nature of the Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://neogenomics.com/role/NatureoftheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://neogenomics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "neo-20230331.htm",
      "contextRef": "i6446dcabcc8c4d238825994d5fcb2ed7_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neogenomics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "neo_CappedCallTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Call Transactions",
        "label": "Capped Call Transactions [Member]",
        "terseLabel": "Capped Call Transactions"
       }
      }
     },
     "localname": "CappedCallTransactionsMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ClientDirectBillingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client Direct Billing [Member]",
        "label": "Client Direct Billing [Member]",
        "terseLabel": "Client direct billing"
       }
      }
     },
     "localname": "ClientDirectBillingMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Services [Member]",
        "label": "Clinical Services [Member]",
        "terseLabel": "Clinical Services"
       }
      }
     },
     "localname": "ClinicalServicesMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_CommercialInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Insurance [Member]",
        "label": "Commercial Insurance [Member]",
        "terseLabel": "Commercial Insurance"
       }
      }
     },
     "localname": "CommercialInsuranceMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ConsultingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Costs",
        "label": "Consulting Costs [Member]",
        "terseLabel": "Consulting and Other Costs"
       }
      }
     },
     "localname": "ConsultingCostsMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails",
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ContractualObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation.",
        "label": "Contractual Obligation [Line Items]",
        "terseLabel": "Contractual Obligation [Line Items]"
       }
      }
     },
     "localname": "ContractualObligationLineItems",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_ContractualObligationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation.",
        "label": "Contractual Obligation [Table]",
        "terseLabel": "Contractual Obligation [Table]"
       }
      }
     },
     "localname": "ContractualObligationTable",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_FacilityFootprintOptimizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Footprint Optimization",
        "label": "Facility Footprint Optimization [Member]",
        "terseLabel": "Facility Footprint Optimization"
       }
      }
     },
     "localname": "FacilityFootprintOptimizationMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails",
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_FederalHealthcareProgramRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Healthcare Program Revenue",
        "label": "Federal Healthcare Program Revenue [Member]",
        "terseLabel": "Federal Healthcare Program Revenue"
       }
      }
     },
     "localname": "FederalHealthcareProgramRevenueMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_IntangibleAssetsAcquiredAmortizationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Acquired, Amortization Expense",
        "label": "Intangible Assets Acquired, Amortization Expense",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsAcquiredAmortizationExpense",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtAccretionOfDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Accretion Of Debt Discount",
        "label": "Interest Expense, Debt, Accretion Of Debt Discount",
        "terseLabel": "Interest expense, accretion of debt discount"
       }
      }
     },
     "localname": "InterestExpenseDebtAccretionOfDebtDiscount",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Amortization Of Debt Issuance Costs",
        "label": "Interest Expense, Debt, Amortization Of Debt Issuance Costs",
        "terseLabel": "Interest expense, amortization of debt issuance costs"
       }
      }
     },
     "localname": "InterestExpenseDebtAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_InterestExpenseDebtContractualCouponInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Contractual Coupon Interest",
        "label": "Interest Expense, Debt, Contractual Coupon Interest",
        "terseLabel": "Interest expense, contractual coupon interest"
       }
      }
     },
     "localname": "InterestExpenseDebtContractualCouponInterest",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_MedicareAndOtherGovernmentalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare And Other Governmental [Member]",
        "label": "Medicare And Other Governmental [Member]",
        "terseLabel": "Medicare and Medicaid"
       }
      }
     },
     "localname": "MedicareAndOtherGovernmentalMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Gain On Sale Of Property Included In Accounts Receivable, Net",
        "label": "Noncash Gain On Sale Of Property Included In Accounts Receivable, Net",
        "terseLabel": "Increase in other current assets for the sale of assets held for sale"
       }
      }
     },
     "localname": "NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_OnePointTwoFivePercentConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Two Five Percent Convertible Senior Notes",
        "label": "One Point Two Five Percent Convertible Senior Notes [Member]",
        "terseLabel": "1.25% Convertible Senior Notes",
        "verboseLabel": "2025 Convertible Notes"
       }
      }
     },
     "localname": "OnePointTwoFivePercentConvertibleSeniorNotesMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PatentInfringementComplaintMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement Complaint",
        "label": "Patent Infringement Complaint [Member]",
        "terseLabel": "Patent Infringement Complaint"
       }
      }
     },
     "localname": "PatentInfringementComplaintMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PharmaServicesContractsWithHOOKIPAPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services contracts with HOOKIPA Pharma, Inc",
        "label": "Pharma Services contracts with HOOKIPA Pharma, Inc [Member]",
        "terseLabel": "Pharma Services contracts with HOOKIPA Pharma, Inc"
       }
      }
     },
     "localname": "PharmaServicesContractsWithHOOKIPAPharmaIncMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_PharmaServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services [Member]",
        "label": "Pharma Services [Member]",
        "terseLabel": "Pharma Services"
       }
      }
     },
     "localname": "PharmaServicesMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_RepaymentsOfEquipmentAndOtherFinanceObligation": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of Equipment and Other Finance Obligation",
        "label": "Repayments of Equipment and Other Finance Obligation",
        "negatedLabel": "Repayment of equipment financing obligations"
       }
      }
     },
     "localname": "RepaymentsOfEquipmentAndOtherFinanceObligation",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "neo_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag",
        "label": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag",
        "terseLabel": "Restructuring incurred cost statement of income or comprehensive income extensible enumeration not disclosed flag"
       }
      }
     },
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "neo_ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Intangible Asset Amortization Expense",
        "label": "Schedule of Intangible Asset Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetAmortizationExpenseTableTextBlock",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "neo_SelfPayServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self Pay Services [Member]",
        "label": "Self Pay Services [Member]",
        "terseLabel": "Self-Pay"
       }
      }
     },
     "localname": "SelfPayServicesMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_SeveranceAndOtherEmployeeCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance And Other Employee Costs",
        "label": "Severance And Other Employee Costs [Member]",
        "terseLabel": "Severance and Other Employee Costs"
       }
      }
     },
     "localname": "SeveranceAndOtherEmployeeCostsMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails",
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_YankeeBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yankee Bonds",
        "label": "Yankee Bonds [Member]",
        "terseLabel": "Yankee bonds"
       }
      }
     },
     "localname": "YankeeBondsMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "neo_ZeroPointTwoFivePercentConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zero Point Two Five Percent Convertible Senior Notes",
        "label": "Zero Point Two Five Percent Convertible Senior Notes [Member]",
        "terseLabel": "0.25% Convertible Senior Notes",
        "verboseLabel": "2028 Convertible Notes"
       }
      }
     },
     "localname": "ZeroPointTwoFivePercentConvertibleSeniorNotesMember",
     "nsuri": "http://neogenomics.com/20230331",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r574",
      "r663",
      "r669",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "verboseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r401",
      "r533",
      "r564",
      "r575",
      "r576",
      "r590",
      "r601",
      "r605",
      "r659",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r401",
      "r533",
      "r564",
      "r575",
      "r576",
      "r590",
      "r601",
      "r605",
      "r659",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r261",
      "r534",
      "r591",
      "r604",
      "r654",
      "r655",
      "r661",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r261",
      "r534",
      "r591",
      "r604",
      "r654",
      "r655",
      "r661",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r393",
      "r401",
      "r428",
      "r429",
      "r430",
      "r509",
      "r533",
      "r564",
      "r575",
      "r576",
      "r590",
      "r601",
      "r605",
      "r648",
      "r659",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r393",
      "r401",
      "r428",
      "r429",
      "r430",
      "r509",
      "r533",
      "r564",
      "r575",
      "r576",
      "r590",
      "r601",
      "r605",
      "r648",
      "r659",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r628",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchaseProgramAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to adjust previously recorded stockholders' equity balances to the actual aggregate amounts paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.",
        "label": "Accelerated Share Repurchase Program, Adjustment",
        "terseLabel": "Incremental stock-based compensation for accelerated vesting"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseProgramAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r603"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r85",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "verboseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r168",
      "r560",
      "r569",
      "r572"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r121",
      "r495",
      "r565",
      "r566",
      "r615",
      "r616",
      "r617",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Amortization Period (years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r623",
      "r624",
      "r625",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense - ESPP"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r110",
      "r111",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense - options and restricted stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Stock issuance fees and expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net\u00a0cash\u00a0used in operating\u00a0activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Agency bonds"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock compensation expense (gain)"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r39",
      "r48",
      "r126",
      "r369"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of convertible debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r34",
      "r369",
      "r488",
      "r620"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issue costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r48",
      "r72",
      "r79"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangibles",
        "verboseLabel": "Total amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r598",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r48",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of facility related assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r132",
      "r144",
      "r167",
      "r192",
      "r245",
      "r251",
      "r257",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r459",
      "r461",
      "r478",
      "r603",
      "r657",
      "r658",
      "r673"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r160",
      "r172",
      "r192",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r459",
      "r461",
      "r478",
      "r603",
      "r657",
      "r658",
      "r673"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r192",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r459",
      "r461",
      "r478",
      "r657",
      "r658",
      "r673"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r68",
      "r273",
      "r558"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Over Five Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r68",
      "r272",
      "r557"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Over One Year Through Five Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r68",
      "r271",
      "r556"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "One Year or Less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "verboseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Abstract]",
        "terseLabel": "Capitalized Contract Cost [Abstract]"
       }
      }
     },
     "localname": "CapitalizedContractCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "totalLabel": "Total pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetCurrent": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalizedContractCostGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.",
        "label": "Capitalized Contract Cost, Net, Current",
        "terseLabel": "Current pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalizedContractCostGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Long-term pharma capitalized commissions"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r50",
      "r162",
      "r577"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r50",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r125"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r136",
      "r148"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r329",
      "r330",
      "r573",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments an Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r623",
      "r624",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, (250,000,000 shares authorized; 127,200,491 and 126,913,992 shares issued and outstanding, respectively)"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r177",
      "r179",
      "r183",
      "r553",
      "r561"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r376",
      "r378",
      "r389"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "totalLabel": "Total pharma contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract with Customer, Asset, Net [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r376",
      "r378",
      "r389"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Current pharma contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r376",
      "r378",
      "r389"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term pharma contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r376",
      "r377",
      "r389"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r376",
      "r377",
      "r389"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current pharma contract liabilities",
        "verboseLabel": "Pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r376",
      "r377",
      "r389"
     ],
     "calculation": {
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term pharma contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Pharma contract liability, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r99",
      "r347",
      "r348",
      "r359",
      "r360",
      "r361",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r37",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "COST OF REVENUE",
        "verboseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Amortization of intangibles included in cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r90",
      "r91",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r191",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r363",
      "r370",
      "r371",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r133",
      "r134",
      "r143",
      "r195",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r489",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r100",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Convertible notes, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days (in days)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Conversion price on applicable trading day (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days (in days)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r127",
      "r128",
      "r347",
      "r489",
      "r586",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r361",
      "r477",
      "r586",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r20",
      "r127",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate on Convertible Notes (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r195",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r489",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r270",
      "r285",
      "r286",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Current",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "verboseLabel": "Marketable securities, at fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r48",
      "r84"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r388",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r405",
      "r433",
      "r434",
      "r436",
      "r440",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r104",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r313",
      "r620",
      "r647"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of assets held for sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense, weighted-average recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r156",
      "r180",
      "r181",
      "r182",
      "r196",
      "r197",
      "r198",
      "r202",
      "r209",
      "r211",
      "r228",
      "r277",
      "r375",
      "r437",
      "r438",
      "r439",
      "r447",
      "r448",
      "r465",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r495",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r470",
      "r471",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring and Nonrecurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r361",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r471",
      "r506",
      "r507",
      "r508",
      "r586",
      "r587",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r361",
      "r394",
      "r399",
      "r471",
      "r506",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r361",
      "r394",
      "r399",
      "r471",
      "r507",
      "r586",
      "r587",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r361",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r471",
      "r508",
      "r586",
      "r587",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r361",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r506",
      "r507",
      "r508",
      "r586",
      "r587",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r474",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of equipment financing obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r274",
      "r275",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r288",
      "r289",
      "r290",
      "r372",
      "r374",
      "r463",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r583",
      "r630",
      "r631",
      "r632",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r165",
      "r310"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r307",
      "r309",
      "r310",
      "r312",
      "r535",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r78",
      "r539"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r73",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r78",
      "r535"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangibles, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsEstimatedAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Amortization of intangibles included in general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r164",
      "r295",
      "r552",
      "r584",
      "r603",
      "r636",
      "r643"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r36",
      "r192",
      "r245",
      "r250",
      "r256",
      "r259",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r478",
      "r582",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r48",
      "r83",
      "r87"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r31",
      "r131",
      "r138",
      "r152",
      "r245",
      "r250",
      "r256",
      "r259",
      "r555",
      "r582"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r30",
      "r137",
      "r139",
      "r149",
      "r184",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r218",
      "r221",
      "r222",
      "r466",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net income (loss) per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r30",
      "r149",
      "r151",
      "r184",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r218",
      "r221",
      "r222",
      "r223",
      "r466",
      "r554",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net income (loss) per share (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r314",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r444",
      "r445",
      "r446",
      "r452",
      "r454",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r194",
      "r210",
      "r211",
      "r243",
      "r443",
      "r453",
      "r455",
      "r563"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "verboseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income tax liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r619",
      "r668"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r308",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Trademark - Indefinite lived"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r75",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Total cost of intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r71",
      "r76"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "negatedLabel": "Interest (income) expense, net",
        "negatedTerseLabel": "Interest (income) expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r187",
      "r189",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r169",
      "r578",
      "r603"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r192",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r460",
      "r461",
      "r462",
      "r478",
      "r581",
      "r657",
      "r673",
      "r674"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r135",
      "r146",
      "r603",
      "r622",
      "r633",
      "r666"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r161",
      "r192",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r460",
      "r461",
      "r462",
      "r478",
      "r603",
      "r657",
      "r673",
      "r674"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r6",
      "r7",
      "r192",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r460",
      "r461",
      "r462",
      "r478",
      "r657",
      "r673",
      "r674"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r16",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/DebtDetails",
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r95",
      "r96",
      "r331",
      "r332",
      "r333",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r331",
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r95",
      "r96",
      "r331",
      "r332",
      "r333",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Marketing Assets"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r32",
      "r49",
      "r140",
      "r150",
      "r159",
      "r175",
      "r178",
      "r182",
      "r192",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r219",
      "r245",
      "r250",
      "r256",
      "r259",
      "r276",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r466",
      "r478",
      "r582",
      "r657"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "NET LOSS",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r215",
      "r216",
      "r220",
      "r223",
      "r245",
      "r250",
      "r256",
      "r259",
      "r582"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "NET LOSS"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r157",
      "r199",
      "r200",
      "r203",
      "r204",
      "r212",
      "r213",
      "r214",
      "r268",
      "r269",
      "r278",
      "r279",
      "r449",
      "r450",
      "r451",
      "r464",
      "r467",
      "r468",
      "r469",
      "r479",
      "r480",
      "r481",
      "r490",
      "r491",
      "r494",
      "r496",
      "r536",
      "r537",
      "r538",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognitionNarrativeDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r245",
      "r250",
      "r256",
      "r259",
      "r582"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NatureoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r171",
      "r603"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE GAIN (LOSS):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r176",
      "r179"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss) on marketable securities, net of tax",
        "verboseLabel": "Net unrealized gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense (income), net",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other adjustments"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r318",
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r41",
      "r65",
      "r185"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r170",
      "r291",
      "r292",
      "r579"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r65",
      "r185",
      "r186"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r86",
      "r147",
      "r559",
      "r603"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment (net of accumulated depreciation of $138,863 and $131,930, respectively)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r400",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r155",
      "r499",
      "r500",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r400",
      "r499",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r497",
      "r498",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r113",
      "r154",
      "r681"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r316",
      "r318",
      "r321",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r317",
      "r320",
      "r324",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring and Related Cost, Expected Cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r317",
      "r320",
      "r324",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring charges incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r48",
      "r322",
      "r324",
      "r649"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r317",
      "r318",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails",
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails",
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r318",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r613",
      "r650",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveNoncurrent": {
     "auth_ref": [
      "r614",
      "r650",
      "r651"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Noncurrent",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "RestructuringReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r103",
      "r145",
      "r568",
      "r572",
      "r603"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r156",
      "r196",
      "r197",
      "r198",
      "r202",
      "r209",
      "r211",
      "r277",
      "r437",
      "r438",
      "r439",
      "r447",
      "r448",
      "r465",
      "r565",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r236",
      "r237",
      "r249",
      "r254",
      "r255",
      "r261",
      "r262",
      "r264",
      "r387",
      "r388",
      "r534"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total net revenue",
        "verboseLabel": "Total Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r35",
      "r153",
      "r338",
      "r339",
      "r340",
      "r344",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r73",
      "r77",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r584",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Classes of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails",
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r88",
      "r89",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Restructuring and Related Costs"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r402",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Each Stock Option Award Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r264",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r320",
      "r326",
      "r584",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r245",
      "r248",
      "r253",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing",
        "verboseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Sales and Marketing Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Restricted Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted average fair value/share at grant date (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails",
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award",
        "verboseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "Accelerated vesting (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationFairValueofEachStockOptionAwardGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r158",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r264",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r315",
      "r320",
      "r326",
      "r584",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsNarrativeDetail",
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillDetails",
      "http://neogenomics.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://neogenomics.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r102",
      "r156",
      "r180",
      "r181",
      "r182",
      "r196",
      "r197",
      "r198",
      "r202",
      "r209",
      "r211",
      "r228",
      "r277",
      "r375",
      "r437",
      "r438",
      "r439",
      "r447",
      "r448",
      "r465",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r495",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r228",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r8",
      "r9",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock for ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r8",
      "r9",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock, net of forfeitures (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r102",
      "r103",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock for stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://neogenomics.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r8",
      "r9",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock for ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock, net of forfeitures"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r64",
      "r603",
      "r622",
      "r633",
      "r666"
     ],
     "calculation": {
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/GoodwillandIntangibleAssetsClassesofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r274",
      "r275",
      "r372",
      "r374",
      "r463",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r630",
      "r631",
      "r632",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r317",
      "r318",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/RestructuringNarrativesDetails",
      "http://neogenomics.com/role/RestructuringScheduleofRestructuringActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r580",
      "r598",
      "r600",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/FairValueMeasurementsAssetsMeasuredonRecurringBasisDetails",
      "http://neogenomics.com/role/FairValueMeasurementsFairValuebyContractualMaturityDetails",
      "http://neogenomics.com/role/FairValueMeasurementsScheduleofAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r217",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Diluted weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Basic weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/NetLossPerShareScheduleofBasicandDilutedIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r215",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neogenomics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r609": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r611": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "210-10-S99-1(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001077183-23-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001077183-23-000042-xbrl.zip
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M>&Y\7QE4E+H AHPO97&LM/ *^-YA3#DJ5 8H880*AU$G@KXHP 58E@78Z;$
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MA+:NL-99-,P49+0CEEF>(U/:\82KO S<PG&N%7.(*0%1,A,1G%D&W=+P7VY
MPFSNT=Q<R3-!(;5A7 N+"_!2I*F-K<**O)RMKLRY2-U*P&VN#2@01EN8<0Q%
M3F\L3M3F*D=9;]=/KFI1&COVLZ\P9?8?!E<N;UT4$*ZQ#BZ6L!EMLL)<O^2Z
MFR[7W@2K/LM[:>Z&W/Z_4$L#!!0    ( -2$J59=O#@2>P$    (   <
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MF2(F08*B125:O<]!R/UA&1X5.44S@&5LTAEW3ABUBC$1E8I14VJQ52)2'"O
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MN0#6Y'R8%6]&Y%0 GC2"W>\Y8\@*&Y)Q*.&O4,%I\M2D\W7HAKYIKW;]JN\
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M9Y^YH$]D3G+BG<>@%?$8%9%(2Z<U2O5$N5[\6)#2%0GT&_7!<D^I*&'-@FM
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MS<[[<_@_:GS<PXW6!FLFK?'HL+/7^OMH[WSU?+^U2AJMU;,]\O[F 4*RWVK
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M*@ SJ<N#)2P\=7NY*GZY/1'<^\[H9/MB&!_]AT,_;TW5;TU3<IOC7H1\W)Z
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MN;QCUG]%V;B;!<8$X,+ZY.HHLB4@@#@N->,D#THD:.--A4@S7IJ=Q'4*\1=
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MFV)*;>A<PN-!%/;-B8X*<"=O7-5,_.KARAE/% R",N^HMUHQ8:CR,,*5UU;
M3+16":ZN@P-NP!4.U' D'/ 864"Y]T"25'R#,*Z<25UA^,8FQDVR>!&Q7'.C
MQIKND!=1M:W#EAKF-6=&"Z'BEL4L,R@3DQ73]!(Q$8@BB9D'S!L'*%48&*0A
M$-AJIPF%/J002]DD0M9(T]<C@G]&A1T'Z??\J#$8J\^]J,GOS@UFBNE<:33C
ME')GM;%66NHPD7'A*T4="]9@[T3F+2N%9H=EWN*,3!&I"GB$((C@A8$*6H%H
M;Z4:&TA&NSJB&1'-N%E5&]58^VCP#!(S@022G,!DCQ.A*+14*:^X4HP3Q;6!
M(E.>%0.)$N617,/(9"U B(EHW%@+E,02:.&I9S3UZTH@@4035>9%?JB4QENQ
MM8@5$/ (AZFUOL=ZQ6I-CS'8;A\>I7#2W\49K%A1IA5@A=O]X:@=7O7[KLAM
MF;@3#_O=&3N=95R? =>GG YZ*JQ!C@&F@P<400ND\@$$8SD1'A/'],:FQ$T*
M>8U\[$^\RMH*,+BLT ^BT&6B1HV-5(T [W%4:.\-,$28.+\^_CI*&*9#,R&;
M4=(U4NBZ4;$EQ:$^W@B? GU[== ^/&R\.6B_W#O*W.W!N-NK07\X?#/HAQ6I
MG+D2V-Z>XJFCE*@@D0/:ZFB$8\J "L$!;!SR7DI+(-_89+0I457IQYFLU5"#
M*R=K68.7H\$E=N:,L0Y)#T2RN2AB$!B.="1K#F'E"45:;&P2V<1D#;L2U80\
M3->_]KD?Z%%*V_??SGUOZ(?/EYYG4EL.N6P:N1K!;:]\+ZZ);E'>3;NS3J\S
M' V*,@N973X<NQP+8:OGMGX2P>Y82_-^55D([F2O^KGGN%&<*0P!4@(#*I%)
M_D$$H""4QL6!&8L;%D=-1M<P>2"K]?(H9U;K!U3KR]L];YF67!@%@C/I.!?S
MR$-)I*5!R8!L$![+J-:\B>G"$6SUXZ&KP3X._- 7E1,2_7#^B^_VSU-YJ!QC
M_X"Q:F,11)3:^2& #%&50]1>F7E8CYU6! -($ =40 VT@!&B++&6*4*,X!N;
MHDD4JU&,;8ZFKSOQR#K]<#I]FW8HZP(BC (6L 0T1.YA&'<@X* )DX)Z9Y).
M"U156?RZQ<W7GG4<QA4^+FA_I@>??7*(96?'@Q&.0]_MIK#6GMN_FOV,3)4C
MTWZ9;2AK,0V$ 0I#^D$54)Z(:!\I)1CFC%"]L8FB0<2RGV.--;IRNI$U^H$T
M^C;7$,@1;QT"3#,-:#0@@+201K$9)*#A'F,UUN@IS;&SB^.A7!RCP84=70S2
MN9L]T8-/N8; P_HW?LS_]GCZ,RQ5!TOO;A ->QGG WZD4D*+,05$I0B "$)
M$N.!H,(Y[30NXC-ID\N%0WBR6Z.^JKP,M\9O5#ETOGD'OOM!/VOQO%I\^9,6
MDX\X8,:(DP!9$LF%MQ@8C!3PD74(A+4DR9%1M('#+VJDQT^P!$"_%->SE$H
M:XY7E5./ZW"KB364>4>%B/6V[.#03%B?SD^("2KRCB@H([4%5@B)C2>1DT3$
MDJHI955Y(3/7!EX5U\=35?[*R4I6_N4J?^G<A7O"A3. B& !M4X Z9$&C!!K
ME;($R=1V'38Q7WJ%CSIY26I"7Z9G,[U.R4PO#]K[T[H;W<.@6BOT^N?#<I=A
M?.#XZDX<V^O9_IE_W1]F)%N2^V2"9(YP)"T/P/$4%6*# 0H*#AC'#%'BA*!P
M8Y.P)A3E(^1_S6MRU8/!5.A4>;(84 &%R1CPV,Z7*PS@F$J"+#!1<( B:H%2
M4 *AD;*6&RZHVMADN EQ.7BU9ABP7FG9T_5T+_5/\L-1XY^=0D7^=>6)::;Z
MC$\LNN2!B<O/6'4EB3%438ROEL])GQ4"UG&9M 0A/*2< X59:L%!/#!(,6!A
MB%N.ATPKF3I'4UYVO<R.5SFL9*T]*'?0CZS2#Z+2MSD(I 0I[Q"@V/AQ=(G6
MF@-O)-<H4*Z#2"H=T7G]@DMJS3;:HQ,_N&(8UY3C_E3C21Q'+]%%DL31ZO?Z
M/YM)US%P&8CF "([A5L@3B05%"C-(* &,B"ELBF3CWCC812>*-I[U>@4.D>3
MU-"]D=5VF6I;BDXUQ&'**< A1!+AG(W\0>%H(6@D=(BR(\DDX!4X,!Z .+C.
M\+RK+],X_:^5_*'>N6X#7@M'4/*--HR/AHEOC/2W'(E3L^.L'Q[LJ\+[G=Y%
MG,F)B[O?&_Y9"&_\OJ,DP=UOHX&.DNCT].!R;^3/AG'32,,=](N\AROS-)NC
ME6TGIU/*M AA97#0 4H<!]3S (PS!!!"HT6J%>$B;B>$-,64%AYSNYCJ<2R6
M WMJP1LSEJPXEMRFICQHAIG7 "+$HD4I8;0H+0964B:]EBZD8"%&FHB7?5LU
MPY*GX/ ::U B5)%;]7SH/#4_5YW(4P2RB8W\YU@6&:RJ ZLI56(DYIJDED2!
MDFA'&PJ!$A&VC%6>"D=QD'IC$S<5+E>)>11+.ON^5HW#9)5>KDK?YA\1ERES
M2@%$1 "44PN,BE8-%I1@Y!FEF$5;IBE8!1%^.89GMF#DUNY1(P4D+ZV'VU1@
MJAW7^L?RGG]] 'EY'*OE1SG*<ADP/*4B#F+4,AYEY#@V@%J8:G7!: LR)!FC
MR!"*(@S#IIA2@*\Z,[!F7J6,=QGO'HZ 9KQ;'MZ53F2E@\X8%P%.8D"UP2"*
M3P*()0O$:XF$V]BDJDGA(H>R#X5WZW8 F@><![PJ [YZR]6.@FO0Q9!$''']
M"]/U=>Y",^LHGY+)W7BS>] X_&OKX.Y^U%4<DS[F/9Y4T;L_];!C%_%3K9OI
M,.T15]@Z>.,'AR=ZX*OUBN %3MKCB(I%-QG6Q%* V5+XO:7P?4JPC;-"0R(L
MT$9P0)UW0+MH*2#*@X92"PGMQB9\MF9'3AFBUAVB%G1D9(AZ-(BZ[<SP)D M
MC052\E3P!VF@)4+ .*P-9R@EAB2(HHM$ ];O"&TU".!.IWLQ\FZ1!,!UP]=I
MC[A^^/JX%'"R[#+"SH^P4P*/%*86,F( \JDQIL 2*!4@P-H)X@WFBLJ%26#]
M4OHS2*T[2#TN"<P@M0A(E=I\JJ =QAAP@AR@%&&@#*5 .8<#"9&_$;TP#:R^
M/D%M_.>UOL=3\(&_W]U[]=?1[DYCZ^_=@ZU7NXWM]OY^NS5VAQ\VVN^.#H^V
M6CM[K5?9-[ZVOO$UCW6^<X\>IDUPN.R:8.^+L7BW%>=$?_*MBS/C!^U0[,##
M]L5H.-*]-*6%:'(,2G7[]93JIE 23*4.P! . 95, >VH "I*UG+KN#-P8Q-A
MUH28YX(>:ZWHE9?TR(K^>(I>+L@NC%:0 !22]T K"4R@!#@-#93>D"C8I.BD
M&1=!C10]^VF?;E7#1Z4C-_T"-\$JXU1U.#6E<BE#$(< '0A"$)"J&@+IO ::
M!4@4(L1K51DAJ9^W,ZOZ(Q"2K.H/HNJW*0DE7B6Y LQUJJJ.*=!::* 0XH'K
M*-A@*J,D5?L,_QAIT_7Q;]?YLOGO^./JJ\_TX%.G5\26\J@3DR\$B6L\5S_K
MY^G%<-0)E^-?=7K.]T;/@2KP8/Q49O#'YO43_N:+;MS7^E2WI&H55U<:7MSP
M>6<4O\S^6N=QTOE#[QNC$]_0UO;/XH N4V>\7G\4OW+4+ZY<]/2%ZT0-;&SW
M>T5B@D[_>-GIZ9[MZ&[C<!1_<1:?:OCLSNF8?"?%ST1J$WC>'W;2.GD^\%T]
MZGSQ+[YVW.CD"H=N?' LW.?PQT>TB8.(B'#G1Y8^U[^'TV)J^<^S<?-G&FT!
M2UY&&]\HH:UA5$3>C[VD3B#FB0U8DH\IMWGRH9-K1_AYA$=@!EY_!CK$!WRN
MNU_UY7#CCY^78%Q_M^;]]I3=O91+$GSX62VY@/$X#+K]:K?5WM_;/FPV]EK;
M=Z^YNHQXN]TZ;+_>V]E*CNO#H_C7_F[KZ+#1?IG<UV\.=O_:;1WN_;W[<T)U
M79_FGYU>A(7^1;R'&_ZK_L.]AJ_YQ_H;B)_VL6+?^8%=12)#?-2N/A_ZYU<O
M7ESEBG1ZQ8"+#[V8[!@3P$O:>FN?*[YO?'FBR H]PU@F79[8X),OGJCYLT+-
M;VV^XVL\?I*H.R_#9^B>USB\WR=_-5@DGD$HES!82I<S6#3;;7_C/9GC".FW
M;U6EMTZQ2,:K^&%,$C73>=_1R2#RD_WXOI-A8S=R,-?8UP-[TB"H^1.Y?,"I
MO&$_SI&T6>]Y3KZ864Y,9WG@IS9Q>)Z%N&(5YN8K_O(0605/MJ#"W,]?;U]3
M+B!S3X=2ZW#B4#K[</+A["UMG;[[UL)O46LG?L_[^.^SM_'NQVS_:)\=O__0
M^?!^GUT[E,[V<.O];G(^7<8_^,/IV_A=_^D<GUIX?+K%]E^]11]>_7VR?_;A
M\VV'TO'I,3H^^O.DM?.?^.?#6?%]9__IM+X?=/9W/G_]L//WYP_O=R\_G!V$
M_0Z\+)Q)A_!;Z]3&L;W[B&&@"$H%"-0:4)+\25ZFNL20!Z=8\%174#]F7C6I
M>1)5AKNG!W>Y?LSJP1V\#7?<2V\X"\"S^(,:HR+<&0B<M9;I8)7"592/>2BX
MNR,2E\X5B;L*X95UN<=3L"/:1W_M'MSR@;[:VFLU_IFLBW\]7X9]L3;W6+EB
M.)75^5FOJ**X)T<R,/!Q*-^]:WS2G5[CG]VX/_^K$6G"F1Y\]A.GLK<7@\ZH
MXX=%\\)&/Z0:[TN-<W]B80X/T'&YZ*.VW3\['_@3WQMVODP:7KR[7@%_];MI
M0E_%=9!86KMW>"WWK4%G&"_MQ'_V/KV)#]]W<?6TPY'^ELE<562N-<5VI8X(
M#1&/MJLP@$9B#K2V#BCCJ:#,H>"*[JZ0ETW7'/14;S2HAV66<6$%<*%DY!ED
M+;(4 P&Y -0)#@QT$B C&-6,4*U(ZC9!1 6=<9YD%= U+@ZY1#Z\RBE_X_WR
MYL^C_DAW&_VBC[>]"9$WR?+"G+C"7*3%G+;UVR+K2)C3'GBUR;WI#]*XMD:C
M0<=<%-;24?^-'OC>BO1F687]KWU8YL5(6!-TD$#JHB< U\#PH(&D2$12%+C$
MI")>O&+G.D\9+NK-J#-P/#QPE(BS,SSU$\$ RZ  Q33E.T(>_XEX< A9+\3B
MQ/F!#T?6NO+&+R*5'["<U$24DQC9*=7!G^QY>?43M#Z;S/+BAZ;L+]GS4OGQ
M^M'6:+]S.Q.5(ZP##4!!: %UBL17PH*@J"!6*FHMC#N(:HHIV6GW;<]2@5K5
MO%Y?!M@,L'5B\1E@'PA@6]NW 18["RG60",;;7L7>7H4+P0H6*L0\PXCM[')
M4%,(M0X ^^N\X0I3Q!;XV%/)%K[GM#W%)&-129*QS$G&ZYMD?'C4WOY_?[5?
M[^P>'/[O_TB,Q(O&[MMW>T?'M7^JGY*-FPW_S?H$_JD42","B\[YQX^:?QQU
M_!D<Z_F\"<@$/8M<<=;LVY4XIIWKG3-/E'PF[YFE_.MK1,X\^VLY5@1GSM.N
MP6#1,R3OOEROP:IG%/.5&2N68IYD_5M<$_\J V*.V._'P*C:U020S]A,KHGM
M_ME9OQ<MB;[]/,,IQ"QB&/2_WCZO7;%)V8JC3:9+-+'>Z(X#>[W&MCY/EEV>
MHJLILO;B[*);&*3%\7#C)_=2(QT-Y\F:,ED[/G1L9Y3GYJHL2?^V6MTC/Z[F
MN\-RW[EB A\7GVQ4I "K.0=;9_V+7E48\/!O7>F$RK*,ID=I_*F[NF=],R*V
M]:E\:BJ4U"@5J:DC(E3WSD5"[FH5;S>K9LY7MQ<+*#B43@6,J>%>(^U8_$\$
M21TRZ.->6B\(_WQ&M]=Z>?ML[IX5>1^[>U=[^ZHB[][7ULZG>&^+VZ]:GS\<
M'7S^L'-RTOJ^][VULX\_['1/6F<'I_O?]^&/$[F7IQ^./I'66>MS>V>/[']_
M^S6=LNT?_=EM'\51G6[!UJOXW4?'EZ43N?>M.!Z+C_%;NG]JXW?$S[W:_;;_
MZAW;_WZ,]W?>POB<K'7ZGU11 -^.F1/"(2Z]!Y0)!:A&"F@*#7!!.Z0M9%&<
MJ2 O;RI$FDKA98?<UBG>=HD*_Y@HO^PJ*K4(2%@8YLH!"??#N'+V0>%B..EW
MX^P-=_][T1E=UB:P8$5@C-Z&,<T(E(0(P U,N;24I79&!D!'%#4,:H-\@C&1
MX2O#UQ.%+RFX2U&JV&-*E712*$VTP7&[]U!IN0A\K4+0U(I@V[?]VT%3&"JG
MH*0@;C<44"\@4%)JX 11 0G->$C]49H1R)I1OAGB,L2M$\3-$S,*"0LLQ=HS
M(ZCR**I)D!'TN+1,843OQK@[0D4SV"T9[&Z'X#O!J>,4 FBX!#3*#AC%4SJ7
MQI08;)R+3(XTI5HD0#1C7,:X.CWV7''Q!MF(:CX0!J-^&&4%MP(6%JDP6F2,
MJQG&E:+@H8VT6S (')/16@T6 15M4Q"D@@01S[!GD= QU82R;+%FE,LHMYHH
M-P^1$]X)G"Q6R"/(68E5?(F)PD&8R.^RL5H3;+O-WXCB2$71 )80C6+$@10Z
M !4DU=HS2K3>V%1*-HON("M@JJYT(OZLJKDW'%ZD0]Y4[,B.(^&&2762LC1V
M#]^\R4>]=2U)N)P#768@%Y19;!"F3'*C%8UV6##6!^C([]+;IYWLIO64UIEW
M-XL*C@]\=\_.N_U+[XLWO;D8V!,]]&^Z\7GS^6]E>'U9/O_5B'H:S0C B6"
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M.F]&C3A!-C[K*'MN5HG?_.S0WHF"W)G(\<W GW4NSC((S@."4V)KE)/$0B*
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M(RE*/A40>C/H?^DX[_Z\?#=,'O8I=88RBE:'HE/JW1-E-",< 8$1 Y1Y!93
M M!@'&2(<<SYQB:*,*HJ"#2869=6R-GTA/%A>9ZHC ^/@P\EEH4PQ8%Q"ZCF
M!$3H%T *S0%RC$.! [0PY16K)J05^)L?"1^6Z*VJ!_T2T^N0;1W^U7CYNOW^
ML/'RH+W?V&O]O7MXM-=ZU=C:/MK[>^]H;_=PJ2ZJ&>YQYXJHY.ZU&>$3KXCW
MYF)@3Z)]/4S=&\[TX+,?%5[3H;<7@UI8 >N]D5?N*WVC+XMZS4?]+?O?B\[
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MBB!9-$VC:.%:0 L=;=Z/TF2UKD$49U;KI:MUB>4P83!#4  K72KV'OF.%$(
M%["B2CH5*$Y);!22VJMU/J?.DY G(4]"#MN8'K;QPWN[OF$;*\*C'BILX^65
MR/,);?6$JK6S.Z5F:K2#O(,41#/)1D+%&)":(F"94%BK *DVR4Z*!+JF![2/
M[A3.41M+C=K(F+!D3)C2B)KJ*$<'= C)=Y(JA6 ;E[V!V'&%M((Z&5F0E;,]
MZH$).6#\\?M4UYYOGNC>)Y\*SA;,,^4)%B]2^,"7"""]T:/7FUJSJI*/23C3
MSI+^[/Z0[H$?C@8=._(N7=CJN9]_<>.=;^+C]EVY#KCM7B01['X;KZ4#/?*[
M(7B;4Y8JW*"FQ!K+5,K*20,P-RK5:(BDE6(&L _&,(-HI"!%6"'%"[/67+1V
M5>"E'D5K,]"L+M"4F+!G0@M#+.!!>T 5Y$ +&H#&BDK-A*>&1:"!347*QXBY
M\&VM.>#V7:ROV3#^4Z?7*^)&0^.\T,G'=CRN'AS/@<901$J'!7<$<DJDE5C%
MEY@H'(2)V/MQ+X$PPDLE>1E*JX/2*<V9"!68<<V H%X#BE/">90S0 JI*-N@
M ]8;FYB3)EJ!7BU9U^^KZY@R+RP5FG)+(=+&1XV7%K*HX=Y96N@ZRKJ^0KI>
MHDU!&D^"0E'7-0?4<0Q4"DB5QJ" (>2:1-I$$&_**05CZJ;K3]1']@M^Y%,?
MRX68T6^LV!F9\OCHYSF)XG;]BU0+M? 9+V;7UDT._[BG&;'PY*S+CN,M8<@$
M(S'E-&AE-++&!6RD,B[^JMAQENU"S#M.=3O.E,PE83UE5%K /$-QQU$.&&P8
M4"QXA[632,C(+@5K<EBQ2W!1/7MDAV&&V@RUE4&M#$Q;89@2R%%MJ E60DZ"
MY(1*%O#8D,]0NT)06R+W4".B(++ *NFB(8\DT$AY8"""*2#;0BPBN8>L*54Y
MV6R-H/9.N^"/HBY__-MUOFS^._ZX^L2-;[5QI?K!1*$W_VT&?VQ>3\HL'YN4
M_I_,VW@"XAB[^GSHGU^]>'$UQ$ZO4.OB0R_.].!3IW<UF>R\]/#%]XTOO_C:
M<:.3YTH]0Q@G+)C8/),O'E]%SPJ8N"7,\34NGT%![[P,GZ%[7F-$W.N3OQHL
M(L\X54L8+)'WN^OO!LMF&]!:6:O3:Y$<7IR?=WW*,=;=1ESVMML?7@S&F93)
M?@W=_M=&IS?>&2(0/7_LPB2UOL<#EPYY3':SEP U4HG&N>XLY91G86]OW69L
M=I8\[0G7A>I6'J%TM1#?Q'78\J,U(:I_?FZ]W_T:R>/W#SM;9/_T+3O&^^S#
MJ_BI5P=GK;/XV9U]V-YQGV\3U?U7;]'QT=:WUFGK\_Z.O6SM=$^/OW<_?SC=
MA_'S^!COP?WO;VD+'X3V(;PL2.HAC.^W*!+7C])*HC'!@$G- "5. X.T!9BY
M_\_>FS:UD31KPW^E@W@^S$2HF-H7>X((!O <[G<DCL?X=N OCEI!MI X6FSC
M7_]FM20VR4;L$E3$# :UNKNZNJXK,Z_*R@K*\RB(96L;?$XUDV43H OE%,IY
MD(S[0CEWHAQ\E7)(8H$H)5&4!B@G186T"!A)&@T.GC#%+%#.O15 O0_*><8I
M[R\[[(&>0'7H<Z'\=3=<6%59HJ''C886'D<7I)_))5#^_BM9-^E)8J1Q(FI>
M+-'+];LJ/^KW<X5%.QC$X2 +KA5\7N]6F<?>Y..CV GUL?SY97FKN#O%W7G,
M4I*M7C>3X=^VW=WKYBWV]M)TPYEQ>G5>:KCI/71NGFOPL?TUBZ6U5W1Q.B&U
MO\> ?L1^KWA+-_"6FOMS)FV]34IRYU#B(2!NN$1:TH "E=Z!LXN-)VO@&FE*
MZ.LE<ID*;17:>J0JFO=%6\]S%O3QN&MF%E1BI:P6#-$D<XICO6M6<@@SF0)C
M)M)<;C-7MC?+M''H(Q?3?$K(+K =*/BS8PQEQ]9.4%2=V-.,H:?(:[P5Y3]E
M#9D;9\S<C/)?:GF<+7O2AHA^Y_M)[(;V$"+Z =!]CKG"7Z-AJS<\B+5H5TC^
M_DA^3A%1FE^?Y DE[$V>0LA9+BPBB0E7(>HD0\C%<8CB2U]ML'!5X:H'F40H
M7/447#7KD":#C60>>9S (>4Y QK>)V+"L.@M4X*:S%58+E/!XT?+E[O#:?>/
MY?J"KS)JVO[7Z*:UR!]CK:YF#_48&G2:U?MN;PBW'/;J(Z.N'0'VP)'=ZG7K
M_$>;_YB4SK*=ZMT0/JAW8UC_Z?-/[LG8NLI)@2>]0;N>&^C'CAVVO\9)+N"$
M<2Z<.,DDQ.>G6 >-& U_?LJ#]S7!UQ%GW;7FBBI]X6=N;4U%46/-G%'6.\&5
M-9I&S8,B(C*?J&:?&%^;GG34/U?N#\%;Z$?[!=D$#_C*=K[9T\':'Y?ZX;C=
MG3:(TW&_+T^7S4PYU5W6VMG[>Z>UU]S=>M>H=EM;/Q]02]/BO?V==]7^7K6U
MUWJW]\_N]N;^SO9TM[+-?ZIW^_!!<Z>U_V[I'^6W,Z3_/F_DUC]^174+#FBU
M]NL^^#P:#-OI]*G>)U!?1=:KB=?3&AW#=?P]A&27'9N]_J'MMG_4$Z3GM I_
M;';#_X*7DR==\Y][Z8QGSVEV^VPN=A_:]%>G+@W_I)Y-ZW3JV?Q[M+?=!&^C
M^?WCA]WOS1__M@_VW_+FWP?B8SYOV\.]=G_ M1AX*9WX/_^>?OP03ASE\N/?
M.[SYX[]'S1]O.@>?P?OY^S]'K>W#;Q\_=[Y &W'KA__>_-R$=H?4_+%#6YN?
ML(! B3B'.,4:<2$DQ% YD HN<IITHE:,7=1V=Q3#9O8/@_<N"&<I)80SJXPS
M%-Z;PU%BS;%=JR*XBR=Y3/9'$0:$'4XFO;,Q_&LT@"$S&$S=G,GX^+GAGR3$
MY_4#\G((\UCC?+YQRN-[TC'U0)N,G^LZ9Z,5>W_';N^X[0? T%V_WJ@LM.FK
M#18ZNG_2ZX\O]UONK3R]0O'K_[5Y/K=1_T5>3S_=&OL;9Q_W^M,C%^XQ.?A[
MHQ;7VL-!-1BY03NT;;\=H059>0-85'8 S?#9&TSM&!K5$3QJWN;FI!._MX>G
ME8<>R(YBU;$N-['7/YWJ<OU0;XOSK3T\JE]QB@&NV:D.>^!==C/@ZEDB]7I0
M;4VO\L_Y57:/<UWI&IC5IA\VZJ; 7R$WHV[T $*< *=EKVGB4X78 :<'SLXI
MY-.+PD,==GLP*'P%+_5KVX]]L!,[/()!<=@>Y.71O:X__V/4/__]J#>H8Z7!
M^*[CJ?2SIX7.R@W[%CN=_.^X%'9V]<[N/NQG7^[2C8\LQ%0^CFH7NTKM_G'V
M\*X,G%L; H[G&8(+>"'T_G,2;F(%Z(-; 6CM9'X%7L7_]GM=^-6/.1[LP%9=
MCVMP-@=3?Z<-M@ &]6!)F!\WMR;,_WGS6^OX+=PG7_,_G_?VW]+F9\_A_!_
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MO;GYOU/GJ$Z#FS8\G;7U0@[F>K79Z8R_,GE6L/?0;6.-;E"WWME.;N3@PF.
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MGH4IOU&YT?#,<.78;YA%[+HW<GPS[23X8-K;C?/4UOY9AGC=GNF7@;U[W^K
MLC%1M"  'H<[T,PTZE19"A],SO&]J2S>Z74/$9#^\73!5ZVE0[C3/6S7]Y@,
M F@[]'8UM-\G%_EJ.Q.=[>*MZ[WND;.Y9[(;!,.C_E)^YO&43O[8Y6@W=R%<
M%X#2[M<#&-Y;YW2B=ASV>N%;N]-I3!H\ &J#,5";N^PA]+]F#W$,BWGOJC'S
MLG)_0W>VXS=HVMB^9;V],\XGSN,PUG 8C$U[MH/UB/O:'M3GPWL^N]'D8JDS
M=AEZW<7&<9X/&&0W ]X$W+<>K?4T19Y:F1CD\RV-IG>[)HQ[6"/\+G: X0[_
M'HLIF]VP&8[! 8+74?M7.Q,"*.HD_/TI,4J32!%AHRGBTE!DH4^1\U8;$2/5
MF#XO8YV7LXSIH&G[7V+MIT['Q,H9[O.'.3Y[F*F%JQ$/]O=X'&'8X;#?!A:O
M:1AX.AZ?='JG,:(I'?O>X(SP:Q6GOO;%B&'\"=C=,UWW:TV@<QJ1@P"P>_:,
MU\X/U<6=H=> F_O36<7,;H->MQL[9_'F=/;QW73><1!KG@3+&NKDOL'X/H.)
MX#IY;&#0L7L 3%0K<6-)KCW)#:WO_BWF3X[/&',:L Z/^A'\$^CUH\$D<(4Q
MXH^F42NKSYX3OBZF4YG5 ,@#T_-6?F.;@T$/+ T,NP_@?.U\;P_W^MOMP4D/
MQM+YAIM[_7\O6M$)9;\TIOYQB/>V=X&M_8^];6#MS4^YJKV"UX"T<1IQ%14R
M0B7$(<)22@2N<;PZ24B((2)9$01)W&%FN4].J60=92Q0<97D+_5\-O']P^LF
M,U> +^=/N%[;-_-[8^+(9C*U5_P]\)H.^_8X'VJ/LT" GZ(?G8FCH9^E'G#?
MLK[?]7G&!QRMP5BON9 !ME[-O_5$9,DNV  <[GX]B72>W3$E]S$_-B8TF7FN
M![[E<?M'OM8\6>\PYH:?' 'PQRSOXYB_)X0^)?!)/89\V3F)'UGLJM*H7W\I
MQ*%M=P;G+N?E.U[NN/,]UQL51(VVCBURG 0]6<^;Z"L]\JCZSB^R,LJ4]W3*
M>_.3EHXK!JX%L_7^98(BQWA"FCJ7(DLZ\)GD.Q.%4%9PYJ.$=V(M38Q9;+S.
M:4$N/8 32EG>%N1);.QU\V K1ZR[W6K/#WM9XL\;Z8PG/]YLOONK:D- "X[4
MYKOW .#U^BC"NG&6+YD)X2RXKG[;[YT <#46OS<N=D^F+@A6AWGM2+5Y'O:?
M??;/N>(SCE*G1P9C?6=KXG&>SY/G%DU:,YTNS^$Y!/.CDSJ\K7/U@!)'[?$<
M?2UNC#6LL18% 2^T;GA:_69]_7G_]UJH. 3V'K/Q,3!8EN3]M)D7%(NSSRZ(
M5=7D0N/T@+D"Q+S$@7_'FLMU#S[N6XDE/.CF<#(_!?<;+Y^H8_I,]M-&]*>3
M31,AY\Q/GD8,$ZGG[$D&\]IV=M,\&]Y.57M8'=D\!]<^G"00U!K"]!+KU87W
MDC,DQQ)'MI;Y]JF=5VS54TN#ZM=.^&PZXNRJD^GJAQ>QZH3@GR\[6>45)'K5
M%I LV. 56#^RV)-<OWQDV<W;_+AAL<3+V?.N]74VSK<"K3%X/G].Q#3]YERH
MN3H#FFFW5E&R,G^1,->K'9LGI6WHU0KS5,"M#=U$[Q_DRYPE1TQO<79&)OCN
ME3NN5[N7<Z#B^5T&<\]H7/IZ^VQNJ)Y L"<G</:5=OU&LFD=7A*C\W<[G?DJ
M?6TLOD$8<S37S%4][T?].B;),\UU'^?O7=J"M4[Y/^^^L=&?3(B,([7+3Y7/
MF3PZ/$(]G3^)]GZCOU\1TG_9]OI&=0MG&CC5W=M=>)B<'W-^IWINX=*[[%ZR
MI>>9(_5)>4KA:I/F-Z=N27\\GW^Y->>V^>)\P'D3QDTZ2XW+ Z*V]_#&ISEB
MV2N \_YC 2']T^JBT):C1W B;,X:JB==?)U(L="\Y-S5"/>V/D%>LS[!/.WR
M!/;@RQ/>V';_O[8SBN<+SI9FW4&K/8UZ=[Y]W&]^;WW8Q? =_A&BWM;G+[SU
M(WR&>QQ_/-XYW=M_<]S:WIR->O?_ZC3ANN.(^:@#42_=VS]D+9JO]_'X8']7
M-#\<X.9V*[6V=WXT#S\%DC"66" JO$3<R8@L<0)%XKBQ7F(FY=6@5RK%$QS&
MP5/NC#/68:R(I=Y'KV:#WMSM5=WO57,<64RBQ1NO,;C^SI=;FJ#U\& B&$:X
MYU9+"5^.G#N5DDAJV6:%YIOQNO^^UOU7K[U*=8*L'9-YG&QSG^=,_"3$^W:>
M;)>GL,]RK<9Q7";#O']#/0^>DZ:S4&7/XKD<%T*(^!TBGOJ2OT_G-B9)$4!8
M<('CW@#"PO#5=H?@>?=&@\E4R5FT=7:K\^N.;6J]_4[G4KXV-'7X+2<[3JYQ
M8G,5!+A5G1\QOOOQ^<BI:7N]'E'CL3&,_JC;_K^<+%%G"N0$C4D(F\[[[AA>
M(MSA>Q82Q]G.HW$&3,_E^9QZAJG=/1E- MT\^WKUFZ/NS'<A\KMXDZ-V[.?)
MEU,(%P>3I/-!GKUJ#XYBSDD?3*>Q\Z1-!T+1SF!L&?/%&OG7<_N?VGUH\O!;
MKYX,JL53Z+M\@?-63.?4.Q:^>K%]B^8J/MR@OF'EAG]R9U3DU5F _!18>SOJ
M#6L?HYZ\JX6!VE,8C\RQ@P8OH3M>0CC112Z,\G8<K(\KA(Q3)NK$^M.320)$
MSTVRVVO) Z+5#JHG_/YO5*?IU-BYN(SA_/YG,)\VI-W]VNM\K1WI*\U9RB35
M6XT%^NHIAT*U.\5D/2$ S-H=OZ@+PV.2;3R)728CN#&!<'[W%Y#Z<V9L5+$]
MGG2 :,(/\T#IU[FUX[]N,J "] .R7VV[4]\S-[2>%>^-^GXRPNJDZ?Z$PO*<
MQ/(N;;G5J&%/.VK>S]J(/"#B>(5-O[;A\-*'N?AW/\<($Z,WF4,Z_<4XN300
M)J9JDAQU(;>PSJ:H%=ZSV:K>M^ZE%*U)R -VU$YSLV<-[]B+&(TKF4\'TL\&
M\ 7#EN/1P?#RPHJS 3GQ)7R[[T?'.9J"4;F40^\7+_E74R071/Z+VOY9LOC$
M :[S/2[XQ;F/\C*C2<1:KT5<L5ZYG(\[\;\&=0V#O,[F?!G?=#)A>-%OJCO@
M/-'>Y0ZXI!8-IQ[F>"_'_,W)W$.>E)C<Y.KNZY<C^:D#-:A%C(N7F Y/!$,6
MY<2@B[<>*U+UK,!QKIV1,1KJY$073WMP=T(GV3>-<P$ +A0GZ:H7;Y3=./#4
M!G55AZG9N+(_P+PDQ[_&:QFK=T>Q[KO!>8[0.;; [1V,3NJ5&]-+GJW!R)4B
MP$-NA]SZ;HQATC?0<+C.&05-4E_S=>OW<L%CG9B^*5/\S$&JLT''J4MG*W'J
MUU*_IROO9X%GG31S_JN'^YRO/KW:X+'9GG7NQ_S:N_QF?CM_WY,G!'3W>W6U
MB8G!KZ6D_N2RQ[V0/?<:UZ,AP/Q'G'.KP2B[ 8.QXI9)L3].:H6N.&WG_1[@
M_E_CX/?S1E]DS7%1B_Q(]4J;F&L&UOGG1^U^0)FK3\\:5A-^G7]P88'C^_5W
MT'W]&HJG%Y_VW#^YW5M^U/2%,]5FS*U3!MWKGO'E9C>T>MTS]JC9<S^_AY<L
M[K0V/\F8HJ!*H2"519SG]?LL!*2PQU8HP8+Q5R4391PS%ANI7. Q2FU-3'!Z
MLC8:X1\BH^%1#%/JY>3YFL_SR!A<6-P\5G^SY_1CDE#:J [KO*91-\=H]<>'
M8%\&<S[OP-\32)^;LZOKJ\\<L9_PV)AWISK-/(-TZ>OUY>?D>-[S>L5'WS99
M876;;9,9'"2WW6WX5\<TE?>_$[%8)TH\R+;)I;&KU5C]\\,WV)#Z!CMY7?M5
M2F:^.Z=6]7A2_G%*.E\_@51G;EPFPTO%>1?LOB>MR7V]':N?\K?Q_/@(KA$&
MOU]ZRCN/C0F_UW7*P'VLW?$J/]*O=F9;PI&P>6;(<\K^(OM27/O@+ZCW_J[=
MF_?G[DW>3&=0>O&.O?A/[226;KQ9-Y[K8S<A])^68+]5MRR=#3A/&QF'PT^^
M&^G]#-G2PF?5PD?:!?9)D?CN"#R-\8K^N6'][9!YS3Z(Y1K/]!J/M/_VDR)F
M/'WYLY\_4ZM?^-YR"_;M2F[8M."SW6#'IJ1LX((%X7#D.%&+HU61JR!\2";%
M3[N+;2JW'=WPW=D0W)SJL6]Z_5R\X"S(S#'FSO?)S-%F+B:6]Q@=3_;\54\"
M;DYKML"I6_T8VL,<#&R-Y^=68INGV\Y>3+9YVJ2M_8-OS?W#T];V+OFX_99]
MW/YXU-QOTN;VP8_FCT/6VH?S/S?IS#9/VP>D]7GS^][V+FY^_N^7UG;XTCK>
M^=[\<?"M];GY8V_;DQ9MGC9_?$RM+7Q:;_'T#G]O?8;/M]]_"LI9*O,^HP$K
MQ+F+2'N3D#*:$"9TQ(:N;3#5P*)L25<H[J51W%52NT)YWH^.1_6*R5K..%<S
MLB0TYK9]^[V0U,U("E\E*>M,LM9;A(&E\KXO FFI'+(V.1H2"93HM8UEVH:N
M\-,+Y*??5HB@LH-5".J6!$6O$E321A O*1(V[Y5)/$..YVU^/3/,$*92WM>7
MB5F*FIFA*NQ4V.FY>$^_#A!_%A.6N._^&8M?92RIA0+.TB@(S1#71B(C;42$
M2Y6,%BYZ#(PE&PHO4]QWC0(XS;."QL9?DUWYYFV_^1*F+7XMPA[8[I<8*]?K
MAML)KXOJY/1FO3K7QJZT(0J,,A*#$CX1KGS00M+@2722*V%#42J?J\5JSRJ5
MT=+ +(W(6QP0I[GJ'.,F_R:C,F!DJ *+U6!"W=5@S6>L!W6U"R4\,B7<D[)W
M$?&I_3T&]"/V>P7L-P/[C.+G5?*>.X4<H11QGDMN>*N0=):+H"16R68SK2FA
MKPO<5PSN-Q'*GAKO12B[ ZYGA#+,&=-:*93?(.+,>S#B/I>3E8%IRZT5>FU#
MZ3OH9 7-S]]X%V%I61 ^(RQA;*W$EB!&@L["DD>6L(2B92$IJF.R.KOI5)DE
MLMLELVSSL"Y6?WM18]%$VE^1X*(3!RM.@B%I+2GXL0%<7&.=)]I@&4.R7AI>
M1(UGRI:GLZ*&"9IS 8%-I!(C3D1 3CB)J'9.<!QTR#5C90/G"L]+H\(72EA2
M2BBBQA*!?4;48,)8GY)!EKJ(N/<Z;YZA$/8.@)Z3F!*[-U&CP'VI18VGQ7L1
M->Z Z]GL'\<(-IHCR8E'G'&+;) )Y=VF3')&\IS]HV;GT5<Y^>>9HWGI_/DB
M:CP>PF=$#2J4#%& AVZT0-R2B!P7 AD35(J!2Z[CVH9H&":7R&Z73(TFP'9<
MCKLD:SPX#S++J-6>V) P5X):BK6.)$6-&9%:%EWC>1+FWIQE999@FJ@*B&$'
MK*D)!#U&>A0]TTIXSVPB:QN$-O3=TPO+A,_SYX0B;"P1VF>$#66CI$9YY$U.
MS;(J(9LH1@%C #QSWFE9LC56%>XW$3:>&N]%V+@#KF>$#:*C-"8O:S)1(JZL
M13I8CR@$N,YYHV7 :QL&TY*NL3IP7CJ/OB@;CP?Q&64C"1T-O$/D$].(1\40
M#&F.L'9!Y!W!HO;@J)/&/)27?(VGDS:V>L?'L5\7N3NQ)[%?<C8>D@FC-90;
M0BV6E MB-?=1VDA#),X+GXJV\4PI\]VLMH&Q\YB8B(3,RT^2)LAQ<(UD<$X+
MK)/$;&V#-K2>36,MD[B%$DJ)F:<']>R"$ZD58X% E"/AAQ82&:, W@1<($$2
MM1;\(%$ 70#]2-I%T2KO ^@SFH9F4C@)$8[EN52+L !TR@02RJA$L%%8^I*$
M5>!^3RY]$3<>#^LSXH;R+O 0-"(V<L2=I<A:8I&EVF"6=,1A[*D;MD1(+VD;
M==5^E!\TAKL6.2YB[Z)I;#0IQR7!X B#6;366!? ^4W<*Y$4*1+'\R3.YO[F
ML-G&WVORW#^ :[XEGP*X0ES&B"1T*>+)..1TROEOC@1-E=8L 7.2!F=WILXR
M _3\2:'D;RP3W%M;5^ >A<7P5BF2$D-0Q%P"1PG0KQQ3Q$6AD[J_H*C@?8D3
M.)X:\"6!XT[ OFK'?7#!&8!SU-@B3J1'SGB!&#6!0]Q+* U@Q\U="M,6/#]_
M^UU$CJ7!^-Y5XRU9]-%$@R+1'''E*;+4<F2\I1H+EBNNU+XZX26%8YEDCJU>
M_Z37!R-8JFX\/!-BIP$CE$J6&,2SV$C&,+7.6^\D9:64Z+.ES)U9></9)&+"
M!%FC'>+2)^2$@L@G$14C<<K693=H@RS5@KY""DM*"B6'XRE@/2-C2.H-58FC
MY UX0@)CY!B%D$>90(V36@>WME%*Z:P<I&^B8#PUIG^1QE'L^!T!?]6.RR $
MMT(B1K#/Q0;=6-[PR4A/A*8P+ 'P#6EFS7@IOK&T<%\ZM[X('(^(\AF!PPF=
MC,(6C'E=-)@%Y**(*$DK24H46("#MXX;8/&7R+2_A#R._=[0=AXB+^.Z\URO
M'V(?C1_^%8-7%'JCO+=\?N;IT6'OY%5^>X->IQW&1Y[SGF3WV37/QD!$SP1Q
MR6G*)4_6.$N\"XF"W7"Y<$_1?9ZK)=F=U7VX9Y0YSI$2@B*N!,2&*<]X1XO'
MU59] G^1BX;4]Z65WP<<GW@^K9!Q(>.E(N.BMST%G<[J;9R8R'A$$'W[G%]-
MD.61 :<&3#T6\&8SG=Y90B],6ICT)3#I363.IZ;2(G,^',]>=5NC)LQBJQ!P
M:D(<*X=T9 0)ZYW*188)\?76A^8>*O$4EBTL^ZQ9=NG$@Z(N/R*YSJC+T2N<
MD@'7E6"%>$@.&2TH\BR" \N\$+C6!&B#X>?@R=:R]!_#//[@W]#^NC%]J-;H
M&!#EQW]G'+2[(UL_Y9_PM>E#'=O^8;M;MTY>9K_/H\&PG4XGL-[XT_7_V#CK
MF?I&%RXS@22GZTK 94YZ@W:^U:M^!&^C_36^_M8.PZ,I9"^<..DT?'Z*==!%
MH^'/3[G01A\SN!Z?>6AN$R&7N^/BSZ/^M#4G]C B!W[6%V03-/:5[7RSIX.U
M/RZ_!G@'5_KPR1Y?7WEZ-??I6SM[?^^T]IJ[6^\:U6YK:_VG8V-9&KRWO_.N
MVM^KMO9:[_;^V=W>W-_9KM[LMC9;6[N;_U3O]N&#YDYK_]VR/\EOHZX%"P->
M_._S1N 5N(\-26)24N%%R%7@/+=:2F)IY-RIE$128U,)Y\2PF6V3#MH;HPDQ
M2H%I9"X:H[Q-GJE$/0\_'9/GM#&W'<HX9BPV4H')C5%J:V*2RB9KHQ%9K_VS
M)K-S?JC9$WJV8T\&\=7TE]>A/3CIV--7[6[=0?5)KR=L-B&5C*(KY%DW='QX
M C!CUA56&6.3R;W)C2?P6Z_A=\42C(\Q.$C(3P_C]=L>TU3>ZLQ?-9:(=:+$
M S26Z=+8U6JL_OGABY>]9L+[VF26&WR5DIGOS@G'QI3[1,''#!/7=GD[^GCL
M8K]BI%%!\$ ON8X+]N J1)Z_M;O5\*@W@FN$P8P(<;?AL;"#O.2#X6S6N,K3
MQHND45S[X"^H]VI!LCI7)*L\N[/0*IK2B[_HQ2SL+E9KI73C>3>^L>U^]5_;
M&<6;$/I/\\]NU2U+9P/>M+NV6Y<HKBOZ#%X]Z!*W>^G6NUR]M' E6_@2\C3?
M'8&G@8 TCRN(>+_$2<1\)DG?#IF++L,OUWA>URA+M]^OOUNO]L%G&HSZIW<M
M47<-]=UY@<?2]>WBLY+S'O'9S"Y:[(71WL6$#9<&&^N)X((Y$K'2:;R]"B6T
MI"8_UC1DZ,"=V=[V+F_1_WYI[</U/_RW?;#_'D-[OS<_OSW]^/DM/?CQA5V=
MAFS1]_"YY]!N]O'#6P+/0CY^^,\17*.]M[]SVMK^#]SKX^>]_9!:<S9,])A3
MC9E'*AJ*>* ,.4<#"HP+GC",CKQAHI -3I_ABO1"<87B2OW 52&OF<T3(D]$
M,$R K81%W&&.'+$<22-E](FE),PSKJE>V&N5V.LF2;9/35_/L1KBH]'4[':6
M-L#+,QJ1%#'B-N=\"8&1<-9X$@W&.E?]$7<IAEC8J;#3BOE6)3EU61AK=G?.
MP#TQ.B&LO,V)_P)9S2)B3NC('3?8*8@*14.I9=J:ZB4HZK_6!P]L]TN\2UW'
M4N%V01;T)'@I*=:>!TX)-S%2:A-FQ"GL>"PBVC.ERSD[<W)M-$M4(QJT0-PD
MC'0NZTB<"5Q#+R>K@2X;3-QY9\Y[+(1;*&%)*:&(3DL$]AG1B7L1DA,166H2
MXEQ2Y)2*R,>@B0F$:'M_HE.!^Q*K-$^-]Z+2W '7,RH-)\H)KQU*QC'$6=+(
MY.W[9*)1,1Y9BG9MXSY6.A<T/V/C752-94'XC*JA212<2(&"<R1O2I,WK @,
MA92W*V$N.$VSFT[E?:VW+?M5W,NVG(>QZT_+9A6/0((>TT1%<-%YKJVW2CFJ
M"&9"*FPM+Z+&,V7+]JRHH;RVB9& $A<<<4,\<IA+I"GVU&A*X:^U#4(;7"^3
M!EPX84DYH:@:2X3V&54C8<HM-A@)0PWBE%.D-:%(:2,$E4%%DIYQ*LTSA_N-
M5(TGQGM1->Z ZQE5(R0?A7(:$5YOQ"D",O#J$!=:>^VBMMCF C%EGXH5@O/2
M>?1%UG@\B,_(&IPSK*R%<4UX+BFN/#*>:42ID-Y:H5EDM:/.I%DBRUV2-9J
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M!7=NPS];O6YM*G*P5OUE.WDT5.^.8OY*/]8Q7#7LU5\]MOTOL38!%]9.KU?
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M;3"CF@ED(\9Y'85!-M& L(J,*\?AG<><!=$P>ID6V146*RRV="SV@G-E'XW
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MXP3.#VEH0@KL"^R+M+%BB)^1-D3T"9IO44H>(\Z=1T9:B1+36 F9DM4E9Z-
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M%4Y*/ "D"W1O MT9X8US"%_!%431:8^X2A8YS15B'ANIB.&2LK4-8^Y<D['
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MH^JY(04N-%,A!NY9T(2"^1.84\<5UT]1C:2X/+=DP>:L@L&C]EH+B\#CR46
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M/@?,.AZ#9C*Y-;GSY/!Z?>@*88^/4;VNU<\/XW5RRV.:LEN=^:O&$K&N"'V
MQC+-2V-7J[%FH<M>,^%[;3+'#;Y*R<QWYT1$8PY](O]_AEIKSMB./AZ[V*\8
M:53@O]-+'MZ"/;@*P=]O[6XU/.J-X!IA\/L"4^0W&!X+^[%+/AC^B5]CIR*+
MY ]<^\0OKMMHZ;;;=!LKW7:S;IM-\;EM8M.M>F3IB/U-NVN[=;'<L;#TZD%+
MS-Q+M][EZJ6%*]G"E[:$<LL.CJKX?Z/V5]L!#KTE*A=-NR[7>%[7> FINM?L
M9-?KQM/JV/:_Q&&51@^TF=U-^O.9SO$]S[FZZ(V0U!*O=,P[/SC__[/WK3UM
M)<O:?\5"9TNS)9KI2_4MLU\D)I <1F-[)W$2P1?45S QF&/#$/CU;_4R)( -
M&#!@PIH+(;ZNU5WUU%/5=9$\6Y^R8<&G."K#X(S?=E978'QE/Y8_UGZ"^2L]
MNVOM;'Q=9QN[*ZSY=8TW.Q^_-=_C-:YN'V_LKG_?X%]V-_<^<_PN>O7LKLG?
M[6SL?NDV5S]_W^AL?,=[.=[@Z[2]^F>WN?MN=_-K:V^SLXGW]3&WWM*3ZMSN
M$_W>V@VLM?IY2P<FE<N"I BE9#IS8CG$T@Z3TZ!UHC$L+#.K%C78.6H<4<-4
M#5,WCA6,WJF 0BV" 1NL1_%-7H&0+"F=Q2/#U"^7G?5D"$6O(I2B7EEE.>&R
MU(0%A"F3)"6<ENZ]TF6M]"_<QJI&J%\4H5P(&C@K70PD")N,XYP"R]Q ,LF'
M&J'F%*'X&(?REK+D$DF^-!)/*A$G=23<96="5BRP7[EY;HU0ORA"T2@EFEKO
M97803? ^69V"HU*+Z!FK7;UYABD8@RF(VFFO"1>E/D@[2<I4$^*XB8$S+;)G
M\^CJW1*R.\]VPHM--R-;_<K[OO*UG3'4DS.?U_)(ICQ$QSWU')P'IQGETEMA
M1 #%=,V-Y]+H=,?CBR TL*@T <8# 9L-,3I$ D[FY%-*6LV.&]?MF^97I:/)
M*BN7K6<&T/?UZ#'E3)GDWKG(?$TFYUFOQZ)R#G?242V)4!10KR7ZO#'30BNU
MH5I+J_+"LE"+5LE:K7]=M:8^Y"BI )%*-,L8'K*R/B>6M&49:DL]IQH]%L6R
M4@<A&2.>!K34'C3Q3"6"7,QD'8*@2M:6^C6H-#A!2VMT+Q1X)HUQ##<_I3(-
M,UE:6^IYUNNQL(^4/&N9(W$Y"@(B K',):)P=T5"*QXIG4-+_1H2M9I5$M:H
MIN]'1])GSS*N/^,%?48=F?N\]&FIT1DDAZ;DY*'S8&N2,&T:8$9+0IW(G%+(
M,9:>W";%8',.+/JI(W1U-^:Y( [M":F!@95)84:1,B2'E!@L<4PR(D+IK4J9
MY9XO+$NYB-[^'!&'6M5G/?I91Q^M!,:I \>H-UH$X7D$$TP$^PRJ7KO]]]7R
ML4">,%&F9!PQ(I>6ZPF(*:%ZRF@4,;LH73U?X36H.0W4R4"I,TZ"4=D&:B,(
M+7)D*LNI,V9K-9\#-1^+[DFM0#.:B$6GGX#DE+@ CMAH$]/@K>&A5O-7H.9>
M. ?4.H&L'5Q*7G#.#4_*)Z,MGSI@7Q/W>='UL8B?ER$KH1.:=%!HT@,G/O*B
MZRY[L$)3JN>0N+^&B-_-H8P-M_\M/600;#T2>]H$(QVMBS9P%= *6FTL&"L2
M9Y#QSSSU&4>-@O.!@I_&PQ?>1\C:&T)%R5"0R1.?LB?*J*!Y-AJ20A1<Y$K-
M4;)KK>FSUG1KA/0QLY@DQ" <&,&-UU9:_#,_1Z"R=FONJ^1CT0N*&!Z1MQ*(
M93JD8)989AC15#,;N1(ASRYIH5;S.5;SF)*-OLR$%& 9,T9$YQ+WC&O/_-3I
MA;6:SX&:CT4O K(T:ADEZ+Z@FJ<@B&,@2)99I6"=!$MK-7\%:NZU,B'H*'06
M()WTI3VR]TQS[4S2IN;M+TW7QZ(725!-9>1$!^[1KGM!;+")N)"3X)'GG/+\
M\?8Z#V-E.^V'DP<$+^H0[K2Y%]%(ZX7/R7 0*EF:!#/1)*F<-JD.7KPL$&QV
M5L:'H:8LI$I,D@BTC+UG&5&P5%#Y(!$'<Q"*+RPSOBC4@VMUZ^.:^=5USI#B
M&L\%5P!2,8]FSSO%/868HYJZW5KMU\R#FH_-[ 0&C+(8B3-*$&#2$4==)*"#
MI4'$-,O)<[6>SZ^>LR!RZ;-!%4\ .IG(K/7@&5-22OX<-KW6\_OK^55SGKFR
M8%4B47E.P%!+C$,]M\GC?S0Z!K,+8-1Z/K]Z#DJ@(^NT$X%"Z9KJ&'>)92N"
M9RK6 8R7I^QCXQ"U+,TF:2(9]Y= DI*8Y#-APD1D;CDXFN:0N]?Y%TU4W- ]
M<+TZ!>,)D##Q')'V))T49*\]B REQQ@S+$3^')Y-C80/0<*U\2B&YXB#F6M"
M=1D,B_XJL9IQXK/6RBM.A8N(A&S1L%G-A:V/;>90UZE3H"B7$2P'GZ-GSBHK
MDP\Q&WR@]FY>DIJ/13%8M%E E 29+2.0(T<UI^CGT&2MMB*I.+LH1JWG\ZOG
M6?CL8K+:,0/!(,2C6/O K,X\Z6>QZ;6>WU_/KYISH:.4,3ABC"]%)%D2QT0@
M*0HK*+.6ASH-XS7H.4,'-WAE5#0&HM?.1L^9Y$(X0W-^CI+0FKL_3-G'HAC9
M6Y0+M.(")9J -988:4N3<RJR8$ EYW/(W>M$C+I5[9-FI/'(.:<>F$Q@=$ <
MY%FQ%*W05M&:\KP@%%P?CV @N+EL5"9.*T3!D! %M>"$:Q44;CUH;^J#FU>@
MYPH$Y1&HTI A*V4<+@2W,6L9?:3UP<W+4_;Q;(P@M(\>"*M2K5"G26EO2F22
MW,<RFX>*A66^:"34JO[KJGKI<2.H\P%H *F<,5D[(;PP/D;GZTX8+TO+QW(Q
M4O((YI*HI$J,4BMBA415QR=$CI2ZXMC4)OV7UW,1+#?",58,N_0>J;O+4B<N
M&;7*NMJDOSAE'XMB2!,C<GA)LE5EZD02Q!N1"3<.G35FG8TP?R:]3L58&0[3
M(2DWFN)#FWK68=VIF_E#8#X)2\LDRI@<9=X;)B1UPMI<%]&^("QLCL<RT(E)
MUAA!=#:2 +);5+#L":6 CSCI>9X=\:F/;^97SW6V3DM3*D@B4)Z]UU9KEE6$
M))U]#CVOB<_#E'TLEJ%#IH%K@RKN&0'C,C%6:J($4.DCRYH%)#YRD;%Y&O98
MZ_JL@QG9!*YR%(PI*#U>==09/1^FG'1XY[5-?U%J/I:2@0X,17I&J D"_1LG
MB?,J$9\5^&14C"S5-OT5Z#E+DF5T;:/2"I) O]=SD:4&DWFRHDZG?GG*/A;,
ML$([Q<$2HTK+JX!4WBANB--4 [<A<&[FT*;7*1EO^X.#_L =/J2W9QW6G1()
M3=1H[9C,EE%0+'GG-/<Q:ZZ2-ZJ.8KP@$/PP'L4 W%%II2+1,4?  B/>"DI$
MCES;8+DO-27U\<TOK^= (: W*QSDC+^5A(S(./HW"2!256=DO#QE'XMBH'<C
MG(Z!4*LR 1H*X_&!2%K&4T:*/BRZ-XHM*C9/K<QK79]U]I4((OBHT8)ST#PY
M$X. K+.W)@.KHQ@O2\W'LBR#-%)Z2BC$2$IZ'3&4.F)MH(HSK[BHVV.\!CT7
M@@IEJ Y@(QBK$/^U=2ED;[+ESY)-7=OTARG[>$H&<S1YX8GC%@F\2))XZ8"8
MD$'0S(//;@YM^FO(R>CT#UWO,7(L;GN?[P]B&I#1S;\1N$6Q?U3F(I=[/G_V
ML'_PINS>L-_KQM$SMZ+AW"WQ_]PU C>3I?EE# 0K[0,T-Z8,;@G6N<PI2TI*
M_&0MI^\D4.47U</H'Q?\/T_H",)L%LXK=.B0/4,4F5C!#%'16N$-!0LE'\^P
M1:OIC&+8L]"@9S[GJO&SQL_9])-UW"@3HZ4J $O4,)]HE$I(Y[V34X__J_'S
M2?!S+""F4G9))4N .DG &4-*?0J1N(TV.Q&3RJ6WG%J44M3X6>-GC9^SG3.4
M$@/G8N9&@TS2.*-DE!G9*"0#4_?IG1(_ZR#C_:%SK.Z+2B,2LX0QI@AP[XD#
MR4DR$3=/2LKL[":=U]!90V<-G9>@,VHI,O5:RB@ '/6TC&7,)2<#!/Y14\^Y
MPL^QN"U-AE(A/4DQ! +HMA.?E"*6V2@,6,N]6%@&:A8E_Q6H9Q7P_?VPG!LL
M5[=3I+F[?^2J^_G/[['[S_)_\,?Y35SX]-VCX6$WGYSIY/)__.#WY1^W?O5]
M>VZPW=VO[D)=1L#+'_.$JLVK8/!.&J3&<?FQWV\<#O"C<AH,&_W<R-U]MU]U
M&'*5,C;Z@T:OZWRW5YVW-+K[A_WR6/_HL+S\[_1/ZC78XMDO?+$\-_I=%)UM
M'.XD_'^04F,/+VMGV$C[,<5&TPW"3D/@&Q$91,/MQ_(+7VJ\L+4<70<"4<D!
M1.%Y@X*>!N55"\LC-*ON[>\+*WBXXPX;#I>^F5S!MMC OQ?,:U2@UT"H=8U6
M?W]0#KD&*.J-/]VP.WQA"U,)62.XP>"DW,(_HUO+^,APIUJ2ZI?T?T==?"KM
M'PX7&RX$Q E<,;SSA ^C=BXV]M/AA6<.W,GH83<ZWFND[P=I?YA&J]Q'8;LD
MK8L7'@ZC$\!SL2Y/7'XE[@C"P+"+^X<?/,#-Z>^7+VLD7$6T/:G2#_PLW*E!
M&AXD1+]_4B.7G:MN;U@V<H)@K^+M['F\A+-'>2/B6J :C3YKN-,?')+#--A#
M:WB( K'T(K?Z;7\/O_FD@::]W]@;B?:P$1"&77<?86:?C$$++M?/U1O)_?Y%
MN?=%[A<;!P-<_@%>=0$?M[_=+9LR^HC%QG:_'X^[O=YHJWO]_6W2PVV)Y]^!
MWXV[NI]&'.:X>[C3.,";[,=N:*3RQ97:#BNL.N@?HH24"^SBO70'>_BWI<;%
MF_LI"@77+EY\)1G#\^MJ' W+#?R\\J/]OL?%K80:K^G@:"2">-7#QO H["R>
MO_VR%/Y TI_?=+:TY=J&5R1EW)(5V:DH$1IX([S5+G@)VEG#T:6-FLDD CJ\
M8DORA5L%[M&E2T^4KA9N2P/0-(QX1^MH#S\G7.WA!"H&YT,P 2(7QG!I+13W
MW?,4]=9J44?**"/5+Z)0T<OD\_V9)*WLEZR!,SD;8?A/(MK!;_RSUP_?GI=J
MLN9/JLE:G779[.!WG7[9;9Y^D!N==]WFWOI)^_T7I(]KT-S]P/'OA3;VTO]^
M/-G\&@\\!X54D#5WOWUOK[9V6U^;IZW5WD[SZ_H)TDW81.J*GWG26MW OW_,
M[4XXWE(4$B^UQ=;24I$$GAB3!2DU:-%++Z+4(\\ )3#%E4+72P^]1*65SFEP
MSAFMO2M]&@(S4C*Z@#H5W$$A60CH"\OGNU"I\\]]:(PVXIQ[GLG %>9U1?Q'
M.W3[!5R^8.&9RD(I!D("V&"<-,'RE(3/()/_X1@]EAQ^"CLI'O52.Y^OQ6L5
MNN;I.E[+9WS-MD3?YK2YLB5,D)2BS(5(%7HJ/A'C2K$,+K#A05H:\U61>BD6
M-/=[O?YQL1N59X)V8:]8C],S:_.#2[F]$1E"FW-N_1K^I#%,VWL5P9F2A/R&
MIO%PIW^$EQV'_WYS+>FXL$8AE70J7**S"SQS\4:^&BY5SQT,TYOS7_Z(W>%!
MSYV\Z>Y7-UR]Z8^S'3CS^^3!F*M6?=_HZ3^.N_%PYXTU2]3:$I(X2](Y^^+1
MLVRIBE9<\3M'STFUQ+6^]FFZQ.[YG %QKW?>=+',+C%E7M+%VJD^]I;TJEM3
M)Q_TT@G1QY$4/TVLS=S&<*I0VV5]G2)+ZU==B#&4NK06KR%/[RT^5*ZE\0F]
MA6YXG+Y(4\;FQJ-OKRNZ/\7]_S(A?!NM5,PA)4Y(5TUR63L=N>(^6B/9J.3J
MC*_>%,(_YZPO(F)_7T9[%K'_+#8[?WUK=7IX7>$[,M;=)L?WG'Z@K<Y.;Z.S
M(EN[VV+C-)Q>C=BW.K'7W/O VE_76>OT7;?UOGFZ\74=F2X^]O[+3G/U&V^O
MQMW6:2LW/]&3*EK_B7YOG6[0YNKZ5D@J.6F!.)HI 5_FC4;O"%<RTVP"^O1V
M81FD6=2&SS9@?[M2O(Q3S5=];OEJ3B:%%L)0#^@W.J N.>&388;B6ACF[-25
MI#6L/0*LT:NPEB0/R@5-.$<P@Y@YL10BD3;0I-$8 ?-/!FMU@XPIU?&_.PY5
MXF&$M2ZCFS;5(D%DUE&-?T)0WF0G2L\_QY1*@H6:IST;H'7'>9H$#U9#:=47
M# 'A#3'4(+1E(6-4E$F'@*;$HC7SU*2XUMH9:RT:&DL#H\ZI!#H)*[W*(47F
M:'0^AYJ&/*/6CM$0P9U(,F1B4SED8$&4/C3H71G&C*%9"B_G4&MG%!ZKOEO/
M.>>HRUGGUK>L<V)'D!^$9#Y[PT%!=M8[%CQZ--Y8'_&AFJ@]&^2?C!,UJU(V
M)>^5X>X0H%$3H[D@S@JC&,N:F[BP+#E?U$K] AFP-5K6:#E/:(G^;-1<JRBH
M*L$ZPRW^RH7E67L$R9H@/R-:CA%DF6CB@1J2/;.EW@J(=0#$A>#0L[66!?DK
MH>7E>H$?N987$]%N2II\JGRQJVF+*_OQ1PI9N?;7FD?6[H33+1]XR!+%57)K
M"%B6B5/*D^B9TS*#C()?S0547AH7T.U3,N$+F+=4HSMH@4ME0*JQ3+/G2!U;
MOYH4/4H@'AZF>):6?"&S[)JDKR?.Y[)+FNK[Y',!6]),/D**E!2/D"(%2UJ\
MF(ME2TJJ^F(?Y6(-G>YBI\R4>^94KCOU37_%R6RS6P F7^8*W)#7^#)$_:DW
M^H4NP,I>'Z_EM*JZJ"IB_UN56#5^.TEN,/SW;%?F+GE(\[UL;_O#PVEBV-/<
M\*M:N)40CO:.>@XI;B5NE^2O7M"[+V@K'=X%G<\= ?1JT\U+5+_ROJ^LM^#9
M7_DJZ@V.AOCE:=#XF'JC4NB=[L'C#F.>XC.F#N=-O;:W%+0]8WA\8ES0!.:\
M23X"I-)'VT0=C'>BU'%["]/$!5?"_QUU!RF^Z^YW#]/?I2C^:H#P:W4Y*:[@
MJKGM]'F8\E'O[VZ^W&\'[R^\B4>#0N9>9N3P/& N6[MX#;N];NG*@[^S#?ZQ
MN_&U>;JQMW':Y!_W-CKKWYM?UX_' ^;?>&LUG+2_KN,];./O7W8WW_^ULW':
MZF[BMV^^W]QI[JY]W]C],[?>7CA>W VLM?KYG_C^"\3__:NWR7O_^-W^:?GN
M=HE.?ET_:9ZNT(W=#WC/VQ37B6YV_NHVW^,GGWZ3[2^&;H6LN*$,B':&$^ A
M$!0%1H23NNQ]]#0O+.NK(>D&N;%B/K/$C#2<@9'X'_6IE-0*40JEHX-82]AK
MD3"Y%8%#"$(0$84C4%*NC4B!>.THIR8$I_C"\L^>_9/+[^LBCKJ(XW%RGB-3
M-!I#=:(@5$#9=#+0P+BW+(>I:]-NP*GW@_YP^"H.C9\*H>@5A-J2F6EFDB;(
M7Q!DC*#$VAB)TLY[Y350M K+#,0BVIP74=Q18UV-=2\0ZRY$SRX&SFKTFR'Z
M\:OH9[7U*LI,&+)K D%DX@2SQ'KO>3*EB8U;6)9FD3%=@U\-?C7X/0[XM=++
M& +W4H .K@(= AEWRANBDV $1,FS BJ)LCEK)@Q+&FF>@5D4S]0EO#/2T=72
M9[)_D&*CD\+./G[K]LFCUO$^XOJ]L$BO9D%)'6BR1@!#-A @QB"8 NT"]ZJ.
MP\TO_'VZ/0ZWN;L-&Z=_[39W5^3FZF>ZN;<NVU\_R\WW&]]+/_=V)^*]?S[=
M[!FZQ77@J7C'CMNJNZ$CEAI/)'7!*X'(RB.ZR/2.H5Y/<V8J<VVU!,[!<1D@
MI(@/&1Z3K47LM8B8W-)9!('(2KR"0, X38RC@611IO"RR"R+,P[UUE7BTY8,
M>B^"S-HC?P(>M*'6Z!!$!.4T<U/W=JCCG$^HGF-Q3J<$[J+/)%O'":@DB/?2
MD41+[VVIJ71Z85DPNLCY@XMCZJ8/KUJ=ZU#>XROX6"C/<<YUXI1D;]'#=2D1
M(R4039,1&6P05J&"FT6 !X?R:OU^U?I=1ZMFJ\MCT2K/..-42 (\&_PA@!@4
M!%1HKE&7 U#M%I:Y9HM:VSE2YM>0FMAT@V_IL%0MG@]_>-ZDQ%<2D!+)QM+V
M-WJ6(2MC2BS><I9$EMQP5T<+YA?ANK=&"\1F)^XV=]<YWNOWS=4F;7?63MJK
MWT[;7S_NMKZ6-0NBN;JS4Z4>"FHH]5F2Q$LPO[2N<UE1P@35*K* J(GP"$^7
M%S85^YB@K[\>^\A!\*"T"F6XK>:L&A!.9<!?@]9ZZOY"MP<+:HIQ%P4<SWOR
M)EMD%H1Q$0E$98FEW!.K'8T40%EK%I8E/)A>W-#.[9D.]VMM?4)MO3864.OO
M7?1WS-T'JYD0H(A-#O4W1'01J*5$2@LH%\)ZKXN+,*O!N+7^OD[]K7S]6E?O
MHJMC[KPNAYI!:")#5F5"H21.648<XSQ[0"]&YJ*KLVI*5>>73-FN=>!BVD-_
M_G&[P]=9)3_ZBGF9K,O&>IO!6O!:,O3H@PI6N<1E[<3/+ZZ=W.K$\R9OBLWW
M[W;;7W$U=K?IYMY?>^C XSUOB];>QUYK]6-OL_.QVWZ'3KSG#E0$2D!G)# B
M2&*CM22C#4LTHA-?')#ZR/\Y>(6WZ ;B+IA@$FCABXU*Z!)*S10#&>LC_SE4
MSW$77^6R:4!\$AQ=?).) :0=-@*7R=M$*90C_T5XN)=0GPB^:FVN3_P?7[_'
M0@ F&F[1V4.?WV<"5 "Z%0DUW3!0RF@60*!^+VHPM7K7ZET?^,^-*H]%"&P6
MG!4R+*F42(8-)Q:T)H"2R[TS6H;JP']1<SE'NOP:SONK($&CA:I2G_0_29!
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M1OI^D/:'J7'</=SI[J,2#P\;_8RO_2?M'Z6&VX^-[;2?!JY7_>[B'E*?X>$
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M'WBQZ>:,DDFO? T\K+.3!LGEPS2HV=ACX5[IVW,]YA68"U=Z*:Z4#:F!;^;
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M\>]%%(]>&@X;R2'@ID$1C_+*%!<;@Q13VBN_H>@-TL'1(.RX88I++PYV2^E
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MSPA:MY(=A&;4HA013VV4C.//P)#[PX0Y2+^8,:W%<^[$4VXAF8.0<B)6Q$A
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M*IRRBS]!R&) D&L/O!U-7#._)&<W'-^Z]Y&MM1O2VT?K+NOBBPFYI0)S;HR
M'YP)X64P7EM!&0DNPX3<M*VW$'M;FICO!OWNLIWFO8F+-A8<@_^YEO[Q"B)R
MN[L7!Q?0GHM_CYNM(VCGQV^'K4Z[T6JVX??CQL[AR6&,TGW_5WL^(O< VM#<
M<2?-+[MX?^?HK/G^8V?_R]X/:#?\OGL&-FZGN?/A[*#[5ZPY=CZ?'HP(PJ4B
M%F%I<\1,;I%F6B.I&;8XIYI2MK$E\KJ,]&9MCK!5P%4!U\^ BQN/I<#4:IWV
MH*5QA'N?2Z:9=)S=M/E< =>: 5>V4!M6"I^)/"#E T=,"XJ4Q I9AB7)'2..
M 7#EO)[A>^=Q7;^SMVN-0=?RT7X75,6VP>S9ZPW'@Q@[^:!FS\^R"=PVO]2S
MAD&?.0(02*2QCHF028\]$#CB57">B;SB;\\)!IMO%_D;P[E@ 0M$<QL0HSI'
M.E"%&--&Z<Q)3_C&%L%URE>5WW6-3IA6FC[1=(5UQB6UU&:2$2&4L9HZEUO&
M00:TKPC/,]/T!<)C,^5HGF<(&TG 4@/"HP.A2%B2$P)&6XYCWGI9)_*Z*//7
MD(9MG0A/PSMHXJ ('"K^:+N'<,!5^9.FA\2)(CGUDCL+EAX76H#M)SF7F0X\
MIY7'ZGGAX*=%QI,903QC 7FI+6**::2M$2C@P#E7+FAO  ?S.I?W3L>Q?AZK
M2M,GF@[,!OM<8 DZS!@FD@49M,DRK"3UMF(\STW3%QB/(TPR9Q0R(>;=8<HB
MJ3U'DNF0F5R&C&O0=%YG^0NLJO8L&<\GWPGH'WU>N74>E.0HRI3(<ZR,890'
M!2NBP<Q[08TEE#\.R:G0[?;HUE[D,8HKHKAGB,2CH(QY"?:<RQ'&SANEG%#6
M [IEJZI"5KEMUE"3?19@GL% "=(S883,! UYX((;+:SGCT-B*DV^BR8O\)00
MB+"8&Z2%)XA)&Y"6#B.C)=7&9])*MK%%UDF17X-7IDC]NABZ_A014*\VF>&=
M^_]BH#W+M% NPUSE&8/_*I.!U4)];G'.!%&5)^I9X?Z2V"DFLUP9:Q$/L7!3
M4!JIP& 9"-AR(./PB04&AUE=YJO*_[TVN5\K0*P \6Z *&0@Q%&:Y;'(!<DE
MSVR6YU;2> 32D<IA]\P <8$(4RQL9+M(! =$.,<Y4.),(.YUR!7'&>5@TBI9
M%^JZU")KAX>OP9LW=Y"S<MX]) PZXZD"LY]Q[YBW6G%AF (KD8886Y]5O/ Y
MP>#^DI@LK[QPE&LD1?"QH&>&C%09PM98+[' RHF-+4+JE-\;!BOGWAIKNL-@
M!"AO';',P"*81Z^>4-));KG!%>%Y9IJ^0'@XX#AGUB!.8O0EUQPIG&G$I""9
MP9IBK%-,%A553-93>/_F,Z\]OH6[O/! ]IH+G*Q^@%[,DG'?/*K5DK%62\:2
M\#4"("XXI0@30A'S<=O(.8HR#A]JYT&$,E@RJ*@#(UBMD;P"37L>7L4*<RO,
M?;Q$Q17FKAGF+M!T3%T.9KA$N5 &,6?SXM2H54Q:$706-(\;-:*.5[U1\X28
MNZ3TU'REF*4)1']>7RH)H)>9I$8);6->"*TD\9(Y@;FG-A!)OV+XS\;,;0\-
M M?DE^R/?$UNUAXXC^)'/QP-QG8T'D2E[KF/1>V0[9CE.J7UW6D/;:<_' _6
M):WBCT9K]\??Y/#\X(O-#RX^7^RW=GESYQMND'>=YOO#;_L[G>Y!:SMKQJ)N
MK<9%8Z>!FQ='W]W[?YG[G[\ZAZ3SW9R<GC1;#=YH?<OV6Y\O#KY\S@Z[']C^
MET/0Y@^T^?Z PYUGC8O/=/^=O-C?^< :)]_.FB??6+/U#7^UH'C,L@QAAX$*
M:>R05(PA;W))/='&23%?J<> 'H<<Y\0;SVP.C(GJG O/*)/<XX6DC%?F9E'^
M9Z5[>26A&]]WM7V,9<8;8X,3EFF"%?=YX#D/>0SQHG9IFLBU2_.]URNSM8]F
M\GW[KM&#;T5>:!WSN%\.;.UTT#\:Z&Y,UMSNPA_??<W_\'8\FE0.2!F1:\!]
MVS;FD#ZO:3OH#XLDE/W!D>Z5&?PW:ZWC]G#Z//A5UP+\YL_Z@V]%EN]8J J&
M)B5K/AVT^S%U]D5*%0[O*=\:DV*?^D%ZI.Y,VI2R4V[6KLA$S1['=-(Q[WBJ
MH.:*O.;#44R&.825/!U33\\N,DC[[FFG?^X]7#<<#>O%/ZEE_=.80_IBDF&\
M'+?_[_^1!(L_AK4C'_MT>@P(= JC%S-IU][$;TGVQSMMBY)"[_K]$72J-ZKM
M%T]+74A7X3]^*[)3QP:..Z-)E\OR;[$9<?3\P-?.XH]>OS8<QVS890=OFZV?
M;"[HQ0."YR=[[-VXXV/ZV:4P&FL\#"O<G.(F^9IEU$A#!*(!K$>F&47I3Y]3
M"[B)O37F%LEIUPYUEB6K'8Z[,:?ZA2^@ F2Y5RCK4A6;Y)2_"DYEF:[YM+2W
M*E3VTP&ZH0;GLMS4CYO>5O%-2O"O9+=E,2_NKZ5V_?EW#-\NL^L=$\;B_-<>
M6S7VH1I[XV/ENF7X7;ST6210_72%I.PG-K [(2EI];S%]L=+'9P;B-4K'IFW
M5UED(3=W%9=GT=.T%?CJ4@Q/"K7J5%5HQUNPWV"&)R3_(8*\;KKO6I?7BW:]
MWZWS+\:M'I@5G#CKL-6,AR")R)2P2F4Q1)2KKWM1##&YV9L^P^7A#S_X[M?%
M(WX/>_!=V[S_G,/S\<&%.S[\\N%L?^?HO+FS1_>_[.'#+Y_/#W<:&=B"%XWN
M'C_L?B[O^1?>Q7N'K5/HR[\GT,;.(;0WEO9KG%A^</)OY[#UU[?&Q8?L\*1Q
M?G#2Z1[^*\__;GU('O&_6[O0YR/>./IJG,F)TSGB.+.($9HCPSA#E%(I'(Y>
M\6QCB_-[.\3O)/]/'+Q6(5B%8)<YU52>"\.(]=(QFBECG"6>8FFI]$[H^R'8
M[(9?:/_P#EWX0;]"MCLCV\$\LOE,ZD U0%GN0MSNRY TAJ%<4>U8T#)D>4QA
M(6'N_JC0K4*W5XEN3LG<28QQ%@C+.:@%P3[D.J?&Y3D7%3][/!0#]#J:HAB,
M 0,4$XY+981$FGB-F#4!J3SS2'J>41T U0C;V(*/G@N"5>A3H<_EZ7@!#(J(
MW-$L9Q0,0J+@5T(5"<)DE*Z.6ZUI,-5S@:88P'H94'6QR_9;>U^SD$NC9$":
M V]E5'EDP,"',99<*,RX8S$7;9WCYV$]OH8#$0^TC]_S_:M*N%?&4417\J>1
M'J6HB_T '_>[?G\0MVP'_MCWANWOOOAP]\<H_FDZ?K<76Y<\\\W^J R;\NY=
M1Q]5VGH;;;WXN[4]8PY]2XX>:0/+&4;"FQRQ3 BDI#0HT[G(65#>8347*+40
M%'-MY%25VO0A,B4(S!V5A!GJ&+5&&66!E&>$YYG#Y<'!NYT"N3:T9E9=JX5S
MM:JXX'.5%F:1,XIR^ ^HH@W($&D1R;'/L/:&![FQ1>LX6Z>$II5^K_K$06"8
M6"JX-XI9)C4( F%:9BZ+7L9?20%P2_VN5/B.*KS@7+1.2)T3A7(O?*2^$ID<
M@PI+,%LR:O(\.##+\0NLEE<I\'2!)G'G#%9B(S23F52$.DK@$XM=#HRJ4N#U
M4.#S)7ZU(+VV3!F4$\D1XV"VRIBUC6;,6T:I,/'H"L[R-57@5Z]\#W!&NF+'
M3["T+KJ5<K!-@S 293D3B)%@D/%.(J>U$(Q@YABLK:R.[Y]+M\KW?R?UW.N>
MZO8@>G)B,%F8!%4."DVIZ>'0WRINL,HFM#Y.@7C\>'0YL6\+ET\5F+ :@,N6
MF/^:4<Y@]4(^$ GFOP](N\P!$PG*Y3YMPZXZ,&&-P@\J77XP!\!UNESI[!UU
M=L'>U\$X&\LNLF#AAS <S 5*D!+:$<(I49QL;/&5;<-7^KJ&^KIR>[]:>Q_8
MN%@P^V7N*0\X0YAAAYCT!L5$C,BX3&164K VUG[M??5ZN'+3OUHW5[1N+AKS
M-#<X$T$C[UD A0L,UDPA@/'FAA*#68I?6Z^%\P93?G(L&QKK?[[65E=>O?*Q
M VP>(>70<C![JX?'M5-]GE*-S*3GT"ZF#DB?3@1[I<W+-_DMVO?':7_8CCKV
M>_+<M+_[/V)$%:*;2]()&#WT\0$;6V_P;U>3'%2[2K<6B#=/Z>+YIQ3$=_W!
M%2=WY<I>X>I'EGAZ! XA'A%".5=@-5*2(<.91\80*:CQ*A>QN&.=R,5 C]^>
M>H>I4N95*//*?3S7*W.EKW?4UP4OCQ)6:B$-(C1PQ)C$2',7D-/<Y#P+>2 F
MDM7%?:=*6U^$MJ[<PU-IZVJT%2_QY624,>6D1C;@N$], I+116MP[JW)M<(,
M5E?*%D,XGEQ;*TU;N0^G(KF/LV@N<?'$*GX86\0 *Q$SH(<F]Q3^A(DD.?72
MQ\+'=:S6A.6^AE"-JWE_KF3VI%72G^I8YX,ZZ#7WFA ,_S#%XN$BIJWDC'/@
M4Y)AEHYUWC4DKSK6N7H\ITN<%DQGQJ@(XI@#IG,LD<P(1[GB5 :6":-DA',J
MGL>IS@K@*H!;-<!998TP\!\F)+,&*^F]S;'T@>2YS/7] *["L#MBV((CQQ!L
MG7  7Y[&XSG: )I1B80(@1-A\V!C">*L0K *P5XG@@4#@"5S*S0C3"BCM/),
M"I%EN>'ROA2M0K [6M4+SBV6!2P-=R@/1B.&A4=2:(IPEF/N1"[ JM[8$O<O
M#E?E_:G0Y]'1QUO*L0E&DF@>:F4TML8%8J0R#CZJ#,0U@2:ZS.%GA<NE%!1E
M,%6(61R0!&,?!9KEBF ")F(>#VAEV:K*'5=Y?^X=D10/,/9&M4Y;FWAJJ^U_
M[:#6;?<2;_&,F4F=*XRWDL=73;QG_=2?/?(EKL5W['VU&-]B,2YAIUJ35[@F
MLZ5KLA5@'DB#6" $,<4U4MIY%!QVW&J:"V57M";?34^J3;KKE?3O?N\(C?R@
M>^]E^;9GN*IG5.?BGM4"TNP7N3?FUY#J6-RO+A]\V?(A0LZ9#@(9KLHSZ9)J
MB9S$GFMN,FG6\ES<?4VWIV;OU3-N]XQ;DI'E==9?J6]QE4-3K565Y_&1BR$T
MWL+R]#9MBHP:+?MC?^?;^5<N7#",!\2)=H@QCY$TF4"<PG_S3'&1NP<Q<^ZE
M/O=:W?Z3ZOYN_;0^,4U@^=A'"<E]CA+6'N0 Y"UK3._/G\:,*:X[8Q?+I?>0
MC:<W4S*K:0;L28JK4;]V0RW1L@3[W$G)^;S9\'>$I79OG&YZ%H6Y_^]<HPL8
M8RPSWA@;G+!,$ZRXSP//.1#*(#VU14'OLD1W[:S=Z=3*A\0:].WA7)7NTT'_
M:*"[L;1W!.)T=M;_./46Y@@&/V4BKT75BBW0G;F[)]/5#S5]"H_Z <@[\IWS
MVO]Y^"6"WR&AX&[J4?$[OMVRD3_;9>.7:]YC>#YMMJ!?K<_P_J.O#-O,JT!0
MIFB&&+$::2$9BF%8ELJ@0. VMNCF=9OBH!0=^&NS-BN2,$M)2E)I^:&_6;A
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MO+^\.NHA_'V+9>"[CD=8;X/[E^I48?^O8O]>;Z+C&:%7(P&2/NI>$3P0YV$
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MFE*O01_KM7(:"BT_BM[47AP3F(?)S)ZGB\[BN($A!&H5)R.U)IE9G=I$-%)
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MQ;P8=Q!C7Y3+,%=YQN"_RF0A,]3G%N=,D!OC#NA/X@[>EKO.\;S+6S A^F"
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M9DFJ_6X:T,:E97H46)O/I,=IO\U3N4'I,/K"0RFU -\/@YQB[IVOI].$1(^
M,;X/TXME4IB=Q8,*/(]J"$%G">RA@\DZ^$!5N1C/1\+XK!VU +F1$".88YAT
MZU%) 1)"+8@[ZU(&3C)@>/7BLB805U0HF<J"P,1(2KAGED#[>E  %A+&$0&R
M3&QM2ED>22L,.)26:.\30S"Q2$R!<KY=K+^,IXTJ/"5M8X+P7&Y&"FC+FTEH
MLVX\7V=.R7N9W&3"C%R5"T_@IVF M<A/<N)MAV,S3ME-0F"YC!AV2Z;AKR\C
M.J7(1B_I0RNGJ=U*!^11LA9%%X_IOJ&47"E 0("'2"Q3A<=%F)T*%87ZOJ43
M_F7S(A=;UJ12OI-G""M4ME5('C3*]DK"JQ C;1FMYCX+3;-4BB;.Z!*8Y0*$
M2@8ND@E>&2[T!:-$3UM4#&,FN\B.EIPGYA,Q^B(E7BWAQ2SCQ(X%6EL*(%+5
M)@F6:DX\#TME""L4(2()XI'^58B?HK:'\L$?)2Z=X!ZRA>!Z8,P8!%%FDS,W
M@Z?YQ))1<QWQ%IG0/G:\(7,45&DR7P$X);$'EPL'%<3<4MN1-$9S:GWBY*Z%
M+4S!!"G^*/8@1FV;4?*ERA$=85JF3$U'+FM2]OX*D$=5C1Z$;#1Z#KT3/B!
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MGZUYLSB#P><!-H?&6\1W[)'Y5J!%,T]D+EU,;#[2KE2NAW8[&MDF]V5?;EP
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M;B!U?*:2(SSLJ1:#0JA^20F "/9\F]K_V+*CT9CC0&<3VY3A4I.+9 H)_*"
M'L1CZ3''%AM_]^OG+5)8$-;%1(5LH74@B?<5.T&-X^)MH;093"?P;83MP<9G
MM;(1/P336S;8K9^,<B-]SV=FVHX=SK7/GA?"H]U0NQ7;*%(6Y&WXP)\JJ=?!
MZY_81APX=M_#OUQ/"R)$LIG".0Z#9 TVS?ZI4HX'8=TD61C8&''UN1")0+6X
MU98I4&JHIU_<CHXY:P+]V&=N!H_Z82.FD#/'15[H+J?=BG9=J;L99H# @R6B
MBGBMR%,:BDUS.)SFX5R[Y":?#F&A%%T<&\D_E0[20\\\8@R]A]7VIOQ#TD_2
MY>&13?2YZ>A;@&4A+8KVAD$J641[;V%.AQ]D YM%#LD993H4@RUR2(H<DB*'
MI,@AR>>:%3DD10Y)D4/RFCZM#8V&(HQY)F',]X9>;[;V5]B<IQ!F0;VG3KV&
M7JL8.8O5%A1<4/ 6_+>JMYI[[!^4)^H]VQ22]U6C6L[1IAX^>/ITL%#>6*^6
M6^@'G7D!A0T^4EC.?N#2_2D>G+Y1.D\KR2UL",L6A>MO6870?0AW=[63=3RG
M_Y[XB;=GS$M#G[/O)3:"P7YDSB.;!^]^R7JJ;5<]O&&(-<S/])<,,)I^_^KV
MRU7_]J9W,="U7O]B?6 F+R.^Z?:[7ZYNKOKWE ?1^C30+GN#BV^#0>^VKW7[
ME_"G>_WGH#?0;C]KGWO];O^BU[W6+F[[E[U[=<W=U>#;]3U=<OOUZJZ+7PR6
MYKZ^_\G)A',>&;4V@&\HN&J4&YFXWQ;AGC1.@2J%%X^LK7[D"B"#LA:/5PY*
MM%V@ZG3Y!6>^BZ%@>!#P[D";<,=2E?(F"R8:_SNR'YB#?3Z2DG@1(.)FY,N(
MI6E29#;U1C5HGX\<$4!-5[HG Z Z?4\4^<.@V]J%YQ++QU?TO5"6XLNO&RN^
M?IS8L')VH%7*K<K/=+51[C1_UC'".A/O<^:IH3W_MC5O&O(QT!Q,UH\P9!O-
M,  >!%$<,+>QU<Q<KL[4+C'7C;#MS(IU84[@)?O!IAZ\20;,5:L,V'K<AI']
M@UO)#F('%HE;@+']=.\6>V&[MVC% X0K>^O@#1*/(;M)W'VP?<^->\CXF!H"
MC]H45^/8PM0B,V,4^9258 '5VPYF#(R9;ZD$E=1VB"9"*T^'I%\S15 N$I2N
MS1S:.S@D""OA$9UIM;+VF=F^]A_FP);<P!61S\4[\%%T3:.L7?)AF*5Q7:%E
MX'F$_7#GU&F':%?N2^2RR+*1NC*0!9]M%XC89HXV".$#05]'ME]/I17T>:A=
M8P;35UCGP00H=</)'8CR\&2+$#_NH* H3-2R+9E=%>\<R!W-P9GA8><,#K4\
M=8P02@B31 *HS*)0,!@0)$,6V*;(];)1M4P]:(8-<W")=LE.>)\.CNG )TP.
MJOV*9\/HV4YY"H=K0=.JM'9)4VA6RK5:\S6BWK7:_J/>K7*CNNN #C#86JNU
MSQ#],?B4]M<HI5.D'6P:(]Q'./'X(HHOC?CO*Q![E"M7/>$X[.I)]Z_NM>O;
MP6"G$H,B:G#N48-:16]U&OGQ,!?D6Y#O-ACY';U>R5& 9!.QHZPCUT,K^2F*
MS]^5Q=3R,^!B:F<QM878IE$G&9>7XLU3>L9IF0NK)>9OY(,4ER ,+I8>CKGP
M#R*\<QB$S,79O(8]L4T>QQ%F:QC5AEZI-G=+(\N1WGSRVU33F[4=D5G>0#\\
M"0B42QGA>"U.<]X &KMQFOT :!3;],J<9H_;M!<5<E-I43SC/%B[4"&7P\NO
MP<=?S!1RMWJ;.^I633'?_ Y;&V[A2\Z?/"K([<C(;9L>J?N7JR?M*;A<FZ-T
MB%#C*9^\55/,_<G;AM'GS\51D-N1D=L.S;#WQNC7EAO)-Y20&#[6RU1R)#_R
MQ73HL^6L&?K$=BWX[6.I$V>\KJK36/>ZCGKPYH^QK?_SSN;M2KLV[+28.6S4
M6ZS3KO)VW6H9#5XS1]5V[7\,H_$NE_G'JZIIGLP_]MS2EV[WJ\KFCCM<'"*Y
M^)D6H&^5 $U/_&B'L'/F!J5*WT0%3+R22<KZXIKFD%[6E1-I%/S'Y'R9W:V-
M?<Y"_,B'!V-)!<)O9HL.O!EVMR3 0NZ//'_*"!<3,[5'\:*()J:B8B#Y=!S9
M%E6KR,H341,@5M8$YL-L5W/5"B>W3>4*P^4,JTL>/.>!:\S"Y1.%"3 #ND>^
MMISLTXJG\!_BY>J-LEP%AOH+)K&KSI\AG\HWP@S9F*H2M"%W;/X@41)=+]0L
MV^=FZ,PU%H:^/8Q$6KBLG8&SR%/KE5H4?%/\_N1-^%0<#N&7XOO@:P4[24OI
M\[\CW!,=!O4=GVGC$! I%9Y,&RGV1&,X7Q>N&$6.ZO<ID^]I9)'OX_-A&#.&
M14FK-K6LW:R8.0V46DG&74_E<Y<F&@6B F3]7L15!4 %.-(@FLT<>B%<9;LT
M$GH^ 6!BM8OG!PA#.1*PG^)]5'3B,F<.RQ;/$-<^A!M 2&"CVA7;(%!E?3[#
MZB<Q=>J-21U3D[(B\08OD&5%ZG8J:<%/9]'0L8,)& @P+GSUC'-?U$<%_,G9
M3]E<5&*Q@ !KDQG"OJM-PT; 40C7XV)1M4V0V1AZ0(3=89]Z%193)!\3W*E8
M$((2!;%A8^-;254Z-7IU%3 JW,M-H!):H\B?>8$J*_+DV: =4*UM-YFYY='I
M@;5WF,E7DE-R5YH.;*J  [Y%?(3J2[Z5!V5MX45RDW0PT[S(L>AE!&0*)PM8
M'NQ5/!1XE6/_#9S)#N>R5[*/E4J._1WA4Q,$5.:KL_W4S*) $H)$D\5"*)L'
MY9R(O2>%W"6'"5'1=Y 1=EN*N/S57ZF)=$EFP 9=_=:[O^P>G<C&,NEJY=/"
M-.A3XQ/6?UJX@X( ^]S[PEUO:IL$V8K.B_?HO?@0UV=B>W$)2$S"73$$+#7%
M,_]1>V]_2,HPUU0=O[?AHI#]T-X/N0NO#S]HB1BEK^%["WMDPT&),;XS):>I
MBQ\^T.FBXE]@A>;WTI#AB<JTH8ZOAR?IFDV(QZ#&T?%$!K'$T^')\&!FPC$7
MH :B7A9F-O:S5:])U_3W#S#NE1C+@DO ]W"!..8!D(8-0I@)D8HS2.1-O&[)
ML@2T=IN6..:B"A"!?PGZVD7!&W-I.E:Q8XQJ2.59$[1)2[5 KYM7]JVOT#M'
M?(M:I<"W*/ M7A/?XG#5K8WF3B#<S4JY7MVL!G.[[VKMW9[Z7'5K?3-,YWP,
MMK$9O/D;UCD6-:,Y")MM"%6]+5#UV99J%D6N19'KQD6N2M5^CTKV1OCO;U8L
MN$A")QHNW'S^.8\E[KOB=04+R7-DNZ#C$Z'C?9>^[HN.3R0%=FVD=$W+UVQ<
M3OF&/NXDJHZA6"Y'!7>"4=4.3S-[;)A0U'$]SP%WZSB0(UE]XAOT E#]' FB
M8^$N%-W"B)0,2!5E==MSE*K>.>X"AE/?H)K>:M2..>7_.+C)92IP76@F6R]?
M1Z_4VP4,0+XWJ:W7.HU".WF3M>ZF\UZ\$>:@,'>,H-Q!H:;L0+FM=JVH_<_[
M)M4[AZ_\/^FHD,RK>J\24XNX4.%/?X$WJ:77&LW\^=,+.B[H>"L3N:YW6CF,
M;YYG7.BS;&6S4+<E1%<1'2JB0\I"VB)+O_#(;+V\E(E<_53X9/*]389>R3$P
M8_X@@C>_\JS<3?U-:ZD*Y]/6:UO76XUM?=N%\^FM^6A5-RH'=!&>E>IVMZI:
MLM#1=N LS7:]T-#RO4D'5Z3?VHVP#G_)J!ZB1)GVX':I^GHQI3#(Y!3N=8Q-
M@K1Z;I K2I/1LU2JE5>41J)^)B +WM<3OY6HXBQD_J94T>H4:EG.MZBJMVO;
M)D3F3RO+B3*V.B:X"+J0B^"@K H'15:SO AKS*G76-%_[J5+D^_C_KZE&\;.
M$<47K<QQ!!N+<W&>Y\+HZ!7#.*J#\300; I;I)8"@<T"M8K'2BBM==BM;ZFG
M5_>AI^]UT)V-$(&TSYLB*>DKD*I6VTJZ0N<,M(NK6X$$*J)QIA<@I-Z(\R".
MQ(4>P4*-(_C5\^?:E(4A]P5"EG@CJAT^1\!)@5?)IT%YXW%7=QHWT\8(K(FP
MD1-$;70(891IP\AV+,(W7)P#7K=B%JL7X.FY;0+J]<*C\5)8X_:[IX=W* 3"
MIS#\KA5&(RW_!9MAXH%VQP,O\LTC1-^]]S0+J$_7'KDV80\*/!?(,06RBUA\
M,]^&.=@(13D!63">:!30&7,7+^&6P/%+;M %(*E)ZP0W/\!%= 8(T]'BPY"^
MX;"<L)@!4B]0MT*U&S+WN[@(I(A/T&^;D72^%C<#72? K"2^*'*'()K"R.<)
M5*Q+,I)6DQ9W!'<*S-08QD^7Z*PQ**J _L3?3) 6M(2; ]O1(Y"_(33C(W<<
M6'@'MY\VB<: 5] /N%,/L'\*!/C1\PGZUQ1G8#U&WB:[\[9 7Z#UE"L"8&X'
MI*]&I_$JX%GUUP#/JC=?!Y;L=0;;VBO2US&8(ZN=3T],JL DR_.N;X9))C;]
M(,ADQP>N]2)8LKU@DAW?FITR(-F:#",>"C7E/2&?V^X'!>J/*-2[Y?7NL3?E
MKGAW^?,5;2RPBO7<=3W/*C7P-@8H3PR8HG'IV7>2-*IZLU,]9N2/@N".BN"J
MB!%QU,U+CX/?]Q+WU<OX_7FG_55K>JM>/?KDS!?O3.[H^Y3;?H)0KC0.2'1G
MI1A_7N'9+\IC=JA@J[4Z1Y^'62B3Q\0GF\ F6[E-*\U?+>0K5DT>JRMSPMPQ
M=9%;&X0]M-+\,GR2_!U:4&[JU6TEQ9%ASISS_KXW*GJGMG.28X'#\I+%OUC'
MQ71MR,>V:/+KC62?S,+_>^X:5+59TXWV >'Z"JH[0ZJK&4V]7<VOYGX2ZNT3
MHH!C1O.+A$"!N5=@[J'X:#7T9N7$E?F"F,^#F&N5AM[N-'-*S > ?SC,-OPA
M\]U5S<<1@CDT7J=(;,,%7"??]XXK\=Q]J3.Q4+-XZIQQ^P7(-VNL=[!IQ(YF
MXN:KD',CLJ#G4Z'G1K.S ^#FF]'S-C77QU4^?3#)*.JG#UB[?<E'\)F%!8!8
M0 R&./P8\##0'!XDGSDV&]H.)2%L5(>):%QY*<1\JIZ7O!&?19TE%K FZ<C=
MY:R+8ZD[I4G).HBD=#1=(6H);,0-:_8?@3A^,JKEE@:#=40)^G3&?%&T_E.U
M4Z[$W]BJVGW*I:*''V%-2EF[G]CXH&:Y%E\.N^)S.(?TCJ3&V/+AZ+K:<)XN
M0X8!^SR('*#-]ZJ?K\1QQ_ICSX>G)6W2=(VM;W*T6#U/OBB)%/E!>YS8,'_Q
M+K&(/QFUU.SA64 Q<*L9+S2.=-5"SSGS2QXPGA+^I,=UM@P+@'^JEIO+*Z&"
MOO1<,0A\*)&G&\>&@X6]%6<69Y4^JAJ6(*][<@P[D%WCU.C7;0J0M#W%^AJ.
M /KX7)!( 5[KC>P0UP=W69JL<H)EK>=J*(3$YH3V5,9\:$BP;=R>R1G0)S,V
M%^C\DJ) NMDNEDN;,-R H!2&40"TCUR*T922.<3ETSB]D8-@H%A_3FLHJ1*^
M$#\=6UWY-NPLR;8]8G9VN16S$L23U'ZE"^:SE/U3M;:.I0&S,]+'?;.'/LO[
M9%K'PK&*N, O^:E3KL<O7;M+<FGJP(Y1IUE6>.(:]Y^S:)FR0KZ2W,*&@>=$
MX?I;E@H=#T0!-6/!6Y#Z>^(G];%C7AH"J_M>8B,8[$?F/+)Y\.Z7+)4#B<N'
M-PRQAOF9_BHXDG>_]J]NOUSU;V]Z%P-=Z_4OUG.LO(SXIMOO?KFZN>K?$SYM
MZ]- N^P-+KX-!KW;OM;M7\*?[O6?@]Y N_VL?>[UN_V+7O=:N[CM7_;NU35W
M5X-OU_=TR>W7J[LN?C%8FOMZ,)JCX7!I"3V+@)_!SP3! 0/^SB4X1AHB):5%
MH,J5NMOW3,XMR?X%W@J*U"D+Y=UK'TMBNYZH<J<L%Y/DZO.5BRNA8X2JGY)#
M&;'83$G%IX4=W_!]VQ@B*9F)6#DVJ?VD:Z;&J[!O4%.V@R!"-!N2X-X4'JU1
M PHQ0/&TN89G)W7CDK;\[!RR.CXM(<TGJ^'&^BR^B(8!^JKL?<%]T\83+PP/
M$TCIC'36!%+K-@H=S_M^9'-[]^L?B)UE@3[9:J0,.J"?R/6Q%X%MQI!.J^&4
MB/<N$+N=6$M")06-KY:QJ-9S<O; ;(<^A#N#:#8#0SAVY<087<P!6U&MO8M2
MHZS!5)@;VJ8]0]H+)RPD6J8APQM!?[7T=2]54X-E=[@I8,. =<  1B-X(KX;
MK;'(%>!B+AX;4%&F"D)*V.2Q#><*.0:G!0;AP)$,Y<'^$6I&53**<LIC(VZ0
M\'LZ6(<AO=[UT'TUM86QJ]-#9@YS7>I!$XC^;^*UG :FS$H%Y4?'?>I%N%4^
M[IMDAS23!1@LN0KB9P(&A-6-?!3:P+-@F)$PZCEM-EYL\0?N>#,RI/D(IJNP
M_69>")_9\!P@(1C;&,'4DJYD@6Q+AG8(,985/&%#)+ZJ\3P2WR%.V[;@?"HT
M>Y5:]V-B)D9#,!,@ FXBO:\B)/+[H*<?21!$AQDAV;H9RB7ZEGH?>KV$@^8Q
MG'S2)MXC$)POC@%#&>-(XJ;K$Z$51"2*5@S@$=B/AEXI4"HY".,A"DT\R.1(
M'L[IT0]@64XS7AIB+I().?,E-D,0>*M>IP0S"5?\&,9WR4T^'<(:Q.R2!C7D
M2BWQR=!&Y:!627DGD9'64Q^4M>V4J$<>Z^? !Q_M4, @PH&=@9KP0ZT(6/*=
MK/M S@M.+YUT70N\4?B([(E<=JAP3#S'2KO5Q(()4,:(1D-< 7<6IJ&X"7TG
M9Q#P=1LFQYF%#'P!PZB?",- T67"<G5-$X\ KN-7ST%A)=CK52"H_*C82(P]
M.?,YZ.ZQ_UMN/ D4F%/L7052@C,V12V *.6;2[)R@!<%$N'3P1-KFGR&W[!D
MM4")AD?.T,Q\CZ9^M?()P?WI1^/3!R4O V!$+AL+=S%0[Y1]YQI7BTM+S4!9
MG\Z$9".&P$8CT"(D)BYJ,/AF*8811W>EQUN(5#LP'2\ VA>:/PTU%=E:ND>\
MQ2(%8$0_KUPK8I!KAN,#5X7C*"Y2B,!I\T;<1&LF5'@T/9'[JI@&K*F#8X=I
M^T+K#R=>D%HFT'6 1Z86TO<B>" R'%S/0/LKLL;)2%/+.X0+:1"<UE3Z !!<
M6*VUCYQSPB5OCL!H\E%LE+6OQ)M@D",A<8A-JV.3)H3XV 1J_67\"6[HNFY$
M,+FDB (U?@9ZTXQ*Z5]+W!UN6F3N59I.']0A#6S+08*:.K 3-.85)UA7P@"'
M"5:L.R<MT<,ED6#+D<M O\.MO$BCKWZ.=W^0[#YIHF0/.R#M0.0%L XS=;AP
MFFETZ!5+L]YH.TN?;G6]3W<+452KO-N#)UBM?'X6;5=/\!;>T)P(Z'>_]NZO
M;K1:61BW__[6[=_W[KOWO?]<D1<8/KA6OZ,3^?IV\.WN:J!U?[O]=J_==._^
M=76OW?4&_SHZ&8W&-C!>D!;$+$DNHF6M^7;P/6-^IF*^V(@:O0J:'XM.M!=@
M-E*Y-N?P1!EIHFLV=18=:O?5A.Y0_M[!U(]N(WLN6 ISE%45LA'0\<C1(50Q
M4KD.;#SV^1@G*;6FQ/226@<\H(&2B!*5T+V"0D]&\5=_)^P#!OK*#S(02,YF
M2 2?;92KC9\_X2M C@.QT" MCUPC] #0CEUO:IL+MQ)EHAI%>B%\/B.-S'MR
ML+ 8_\U@'#XMB)%9D%J]D;+&-EJ0]A,+LN*[S1:D\DH+LG*POZ=-[A&S?>V!
M.1%_>M,5-/NJ*=I!FF=D1XBLHZQ]44I[ZJ62MXAWD[D<!XY8L,A61LQQI'MJ
M[37P*KZ8U9&=(0Q4:/$R0X90[A,_/&Z[R<5NINZBL25F1WJ4JY\07R*1Z;/W
MIV>PYGZX! ^U=%$PWY_ON#.@2H\8/%!,A#+H0,44>4C<$AT-4#N._2WT21RG
M$.Y(Y<P14/Q:,.'85H1F%O</6%QI5$YCWV3*_IE%/A(*/M29'UO40%FQ(D[C
M#?]"K_(#5^IVXOO,)&&0<D_+Y#^D.<OCQ(9]DK8>A:W /N)P+'[84_L?E+)S
MFSN6<)>@P912YQ,RI"PT.F/W'KQV8L/1AB?"6^/Q"8Y'@T.!/8'YP/W"U4[;
MB)^4_@;&A";WM_*@K(TQ?.2*J<2):?)&>"T<+TUTV2!Z29SNPB1,.8&?4"A4
MHHD*+9&EO:10Z#((-05Y)BUPL=;R(M'T)C:%ESG+TN8$M%2@;.,R"P][S$95
M[HL%TP^0U.U1N'I0Z14-)G"@1.@@%7\@EDQ?I:+=P)^PY8[Q<PI298&-/<(O
M. CB^YY)2I2%AW#1^1>F4WC(6(_%!89_&+X6R!R];W+AW!4L?X%RT2(>@8'H
MR2@0F>-HA:)KDBO1(J:%'L+$@;!BI=-B;,@=29OP0-7=)37&Q,.1II%X9X@Y
MB2>A-T.2P7(FIN>G>Y7 <(<\?H<SS[!_['AB6=Q-;85\=79'@ O3485!JTEX
MD;\FZB3'B$X>='.#Y@M,%YD$3H?6 \XO7B'#N)HRD,GAY!.'I262OH)1%)+?
M:.%8D4P1RPJSH).>)MR4?IX^#.7U:5RY4+T_2\/A0AD.5\IP.$HU7+G+4VV+
M8$,NV'3HV]88^++T;/X+"-CRII_@G8X#'P^ =?S#?1"WUB=M$/T#W%_7+B9P
M0#[1.1C ]0P.*E?L%JC552'4-8X_CNJCRV3^\(*%AH3[/LEF^ UI&<[05ZSJ
M"&@\H#A\1N(,Q$#0M7_'77CBT,X.2;O$[CA^\$%R?2V*G5MTH-'ON\#PGS$7
M02V'DR2CK22=+'H%*4?RN#U1L%!MX'^ON,L3#GOYU"30>$[SKR3FE.&)(F B
MK\8P=2+N-TJP>R5:7RS;6'UR%TJ$MO::U58%</+E$*J7,1WP_N[V>D!^H*]W
MMQ=7E^CZ.62MSKJ%SS5K?"H&=ID8"V#/A+[GB,/S%3,)K4U"Z*G66ZGI-_(S
M?9(,<20\91V9Z0G/X@FC;Q_&+#1HX.=XJ=01,% F FKI3!",@*=C'B+6 U8T
MJ#&61HM-W'20Z"VQI.V:Y.TP.K4Z)7:"88)1$!T-&1]WC'ZAP044=19MX]">
M%$9A'(U"!5AJ,639"#4QT-!) 8Q-#(V&<76A^9%*#<4IR903FB0%_M,S12L>
MU.)I) I&*,,%;.C(!5Z9JB!) E-ISR5^D]A@(E]!V'# :F%99'M ^7VBE,KO
MQ9)@<!TNHD:%J'4Y5-D!<Q3FO1V0:$-?DF\)Y73)$B9'A=A76_;.XZBC"6T6
M1_D\7>B9X!OL#3P+S7H10G/GZ^]S/1EOP_P+D;L;TUB2]80[BLE_2E5%FUVF
M)Y+:FVBL&/\DVU-%%_%I/B4TT0@28_1Y[^\1'-]N*O$*# FDWSN@7\UH6"6C
MH2^0'WEP;&IAB=L2[S,ZJ)*S&$2PY@]$.M)K!.8CY88Q7V:FI$)[+R)AZ>@3
M5B'64*%?2#YX VZD#$.N !1HE,(&--%QH+)NX*#^.X+1 VN?KPBV_KNL_<8"
M8=L2R:87YH63Q,%3WIV59/-L,#6RO>-U0><,6TWP#F;);;42@BWN3OVY$]07
MB8W9$Q:(HR2VAG-/1:WO5*[!"9S]>_31"T(!+IHN?DQ,,2?A>[@0"74F21>"
M*I5W)Y67\;<X,:LSSNDNLBE7^#1T='Z@Y1!3+'KYOJ-0(L_;P@WZ=B,N;Z9I
M[K"#Z_HVYRQ!X)GYGV7.1&T_.1/-(F?BY3D3!YW4U^[=O=;K:51>5_VDW=[_
M?G4'L_M\>W=#=7(']&"\\'QO2L2=_+LPC+)V??6E>RU\%U>7O?Z7Y?K%?+L.
MWOWZF5(1T:!$OR+].T%? 67442S:'0/O(.O2 1/,446((,0VJ=XOHX*JC2*?
M@EYIP]-;\4 PA1<R$BDQT("EAB%-[3!)@+Q0B9^99,!=\_].WB=8KQ[!@>J6
M*=5+^]R]N+^].[[#]*<783 /@X=@I?)1Y*AJ1K1+.1CURJPA[_V(F:'G!S+9
M="@.V5=06+4>R#*@3%@179.)UQBST3Z+.V0"MHJ+[2T5E_PQPJT5&\QHCN.#
M^- 763]U%3%-U2D3$U@ZX0$/\;7A1)S.9PW8%^_W.MUWTS/2R/\9J9:U;_V[
MJR^]P?W5W=6E-NA>7U$-_=6_O_7N_\3M^G;7N^]=";?ZM\$5?BDE5)Y/U.HY
M?W-]/L9:8+3K!E3P#B?HZN\(DRL2AVN.Y[6:4_0]E\='\N_X5$AOQS/6J@AX
M\P?;BP**>W%7%482)V RY!LNGK)VZ5_;Z,?QEV^XZT85*1T3"GWM:QHLX?CW
MG!+A//1NDW="YCJ(VH,PZY1'?QOWW=C%GEZ(3(:;(B$5#;!=2_CM/^;:1*!:
MR#C.+)="&? $=(AEQFP6\(_JAT^J8Y3MTJ/HID_+?I(%&$":K?@ZL67+%6'/
M2F1C^6;Y=9F^6L!E%-_5JN5&M;'VZTK96/O=4X]%\+5V>Z?'/OU=NUI[C<'6
M&NN_SME@F^5VNWI,@VUN]-AG<+EST3'B6;.F\K1'_&N<!P=23#+ #=I&O !Z
M_,W<0)LL#<@+#VM]^Q&IZ%@0-V$855%2T7J51(E&N;T(Q;IRX]9"L1I/8[&F
M6G19ST"#/]OG;*--%SN8'Y)_]VL7QL+&7/M*V>E?F6VA^!;;NP6!G]JR/$?N
M:&>2<0S??8V&CFV"[@L&KX?UK);VU8%78\SFJ^^-?3;=I(7BJ2[E#6:]1U.U
MF.]A5;H)A(%,*M3^@TFL'U)+318&ECK]"8;[;SRU]-_BP/K3RWS4+8Z>A52F
MM5753\HL*\7U4,I26TMXI]27<;/%:I]ZS\W7W<^\T?[I=>G9;-Y&I=RIGS8A
M[X5)'2&'DB'6/6]NL;/%SN:HK=8!5C^.%R5Z4A)":K] 4=JTMVKNZ''[_N-%
MQ]L<:30Y:GB[H=)2+;>.O\?R:?.$W614L4MGMDMGX%81P>Y$6<@&OU_B4CD^
M>FOI[59[-[TU1W;'B_<E;R2ZM??CB'2%9KF]K:Z0/XH[;:[P(GNVV*5SV:4]
M^1;HW=5&OCDRA0Q?XD60;AZ9/K306/6DO&$=W:AMVV5^CXN4%_LD+\\H:'-?
M]M4I46=A/;^:];RVL;5\0PEEV\<:Z,&K>QN+CVS7XF[XL51+4+V>J;?-/+ZS
MP:,[Q]9=V_APR [7]TFUFFQ&&*A4\9Z+F3F(/(!)*VGX%8'_-]>J+5VBV!+H
M2)"@0[BB<5! >?28^\(<GS-K7O(>L=PF$ DS$T80'6P%4")'!,@8JTO!6V!5
MC<+Y"]F/=)M>:JLBNXY2QX&XM93L:O8U\A%(5"#3B1%DGL=E6R88A\41*"$S
M&=$)PI67Q-4]J3<2,@Q[9#Z"E"% +'PFT"*I/-^+PH!@2Q!Q<2;SKTHLSK_R
MXR1-ZF)"X'S4T CG+?H5X@NR*TS@A[246+@70]B(A' V]!Y$CRN@QF TIQ5+
MS]B#08PE\MGZE81?;7_%>B+E,)F*1T"Q@>:(KG.JL8!XOQB+'U\<HU2D-UT^
M ,$8Y9().HA)A<;-'=').L%MQ>XQCHG8.PJQP(T3X.2= H%(W7_ZA8KM_!=A
MU<K:Y=7G+K4O_?;UMJ\-KOJ]V[M4\=71%:=@0=+)TU9C92NT?-%6O:S=]/I7
MVJ#[^>K^SW1/A".DJ1#1O4!2( \]>'EG8V5?JWSM?J/\4K"'HRFF:I>;G?W7
M4K4[9:.RV6/W6T0#U/OND"636"[>*%<6^^Z\P$P]CHE?8A>T4'8#NP1M4]34
M@Y9U(;I<:;<"Q"SXI%TI%3E]Z2?,C?=L5R!VPS?+]Z&!P5U00SU_KG5]:C\H
MD"A67%Y>L0-/FZ#;\N^U.[?'-:=7?<1N@[:Y :M?6$)\S\7$YJ-TYRZY0$<G
MQFZ%L5A/D.*Y]IL'=E*6XIA8 E#YO_A\K%V6M6[DDMT)!D9#P'\2MLJ:=5%F
MA<)>28#S\.T(A(BO!^W ET_6_O((^Z'/O2\$2&V2F=<%6\01871J1\ (:51
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MS%':;6XR;%OK,VQ_&7K6'/Z9A%/GU_\?4$L#!!0    ( -2$J58&F@+W/0P
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M0HH=UE# Y!VSL%#N*4MZ4:-2Y>O$$9[\9LAO!R^>7:L7U^I[Q@3C>2G-<9E
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MF0*Q2&FXDXBA=>9^4U/XM!MR71%KFU)]$G_WQ?YOK]_N_=G4S[UX9I?^[>W
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M".,_$)]/QOD<#!H73& 6LA.JCC'6^F\-@G.???%&BQLARZ5];6\]^ FJOKN
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M9=)<?/FW(4[I)9^_O\&O.#K-=+/&68L1=!*YQE\T..X8Y)A-*4['D'HT@NY
M]L,.:JR]/GW+I<7T%WC/DV[7 +M#HV@ET+V;1\TTOLZRU51=N]KY5H(6(>;:
ME[A6:450I7:X2]J2VZQU-,X$9EJ'PPZ 6^O;3X=!K4VTU">E7H^_G,QG"PGP
M\]P5++;V#0%O4== 2VT)XWB]EKTDJ9@UNG6+W#O@'(;IU$B1JRC340M]VDY7
MH(DS:,S1MITR X_"T*Z.!"V;L+@K*MF2M/2[((AXF@391@L[6D'D&;12+^#T
MS(#SH;8FB[2,>BE )"Y%=,AY\P2A.^ \-8)LHX4>+./E!^"GC<,90Z\#AQPX
MTMJ6$SCA+:!1J% ZK]1N<A9^>%F-M-1#QO,'G,VGPS3'O!SC\D_/FWJO@;TG
M1ZL+[OWX7:TX<.MJ[1TKL(==KML8LL^()H.6H990>@\!?0)M3$'%K<3<NN'$
MX9'O'L?L(+FW@=YZX-SODS%^_SU,_\#YKR>7!2BIL"A<*("V5'O/%0B^7KZ!
MB&0'&H&FM=6]',GN[:G=:?-F)5!W5?3@FRTO.5'69++Q#,1D2C7W$D2>"F27
MH_4JF>A;WR%P(+5 >Z-'=T7TX9BM*.BWD1LON 195"U@*QH\<PBNY))C+NAY
MZTL#'FWKF$[G&@WTTT/)6-.2EG7&\J-US"J:MB!(GQTYMM'NH;>.B27I+&D>
M6UL6S:!,W08R,"PQ!!XD\M:) X?/U"U;QQP,43=1ZFY;Q^1D9&W)#KD$7QL/
MV)JK0U]%I2)*+W)H73;Q:%O';*3E]5O';**BWEO'Q&!=8<*!UO46*J4XQ)P$
MQ"",C(59QF[DJ#R)UC';J+Z[@'=X+YPJ/O)83W:0',V0$]2+UL&(Z&0(A#FV
MKC=XE*UCNBP1#52SL]8QSJD0'(%0!@F3\>"D5<"%5U&R8')HG?KQ"%O'="%+
M9[7LL'6,M&2>2>"^<% 8&(V2O@V&&<FXL=:V#@<<2+CH8,C273$[;AU3!QN3
M#% 4=Z"<+.""(PN)ODQ<^9BQM=7Z>%O'=-J3&BEIYZUCLH^T;TH.!H.FI=#7
MAFM>@_#69"="$:9]PZK'VSJFV^K32E$[:1WSVV22_QR.1F%<*]/#^&@81V>!
MW(_I,^:3$4[*^2]MWS1FJ]=T;Q?3?70W&L5PKXKCK-9<).59\$46*TQ()1GG
MA!IL]<9N2\/YT]Y<5/<:S0D9.5P8BZI7H$0(BM:JH)-,F+Q&UGI#N06BZX)W
M_L"!+$JE''FM=HDU>1@AUHT[>FF)8=IPW;I<[?S=NU_&NNGRYEJTE0Q[.%D]
M9_Z["^:?GO=XS41 XR R80F6-!!U,*"MLLRF2*MMZW9$*Z#LJHJ_K7Y;R/50
MZNH_SFG/K ]Z?C(CX<QF'T^?>YJTPC,*JVT"FY($5;L/NV0BI,#1Z>1$;NY6
MW0EH7V>M331^DT7-)-]#!.\,RYEAM@Z8G@Y KP'9SPEF0T7=I$!G*?>N^H J
MN\@]>"1DRF( 5V]Y"[29\8BTL>G6R<T[4/D]1X&[TO@FPFVHZ7IF\((^'*8P
M.G7:+J]A+R)(91TD>CN-C0D(-FM(1DFAR7;11=WC<ZQ^^N[MN@[BGC255>,C
MM?>?P_0XW,#C&!I?0H*8?0%58[*^("-XF2/ST9DBUM#=LF<_5,UUEM/*6;>C
M8,#;,)V&^? KGOJL;4, -Q_>J^-_YTANN/N88Q81@\7"%)*A'G*(,<KL H]"
MB[O<_9OOZ9Q^.)SC&WK<K1==^A*:_ETQY$808EH(2I%0BZ#('O2"^2RXL*US
M5=?!U2P4(+35S!@/A=7;2%BB>2AH"MHH??9)2O*D'DTHH+G&5T8'-A%KK]&!
M.X9\ZN8DA:EXGVE_TP)4O9,FJEB#&3ED^I;F9>O UOKH=M8)L&]B]*20AQ%I
MH#V<=G(RILB<YJ"4S!"E5J!+<))['K5K3K'#CC2T)<%&P8=-E-&[![H.F*<:
M?-A(47>ZHMM(N7?51UNT4H1"Z,IP8R1X9C7$H")9@CH)WOH,XM"##^TTOHEP
M=Q-\4")E0?Y7O68HT((FR*$.SD'43 9I6'2!W>/M'&[P82-QWQ]\V$16NP@^
MD,U*GAIC8)4FI]J3'>M-S&!Y$,4:Q7.2#S3XL*WF.LMIW\&'%Z- ?\\FY>8/
M>DE(N/=MO88G-AOKC7B%RCF*7#*S4JI44N2JQ"RE%BZ&8.5=\8I[7[R+ (9-
M!+Z6_/*D0*'CX%4@K@L3F4A6Z^8=3'81P'B6_NMD.,5\Q[O^B<.CSW/,S[[B
M-!SAWV=83D9OA@4',F6:F-8"6=../+D@(2:1:+V54;I%_DGK0_(N> \U4+(!
MLVZE!>Y*?7TT'%N-^;?I9#8;,.1!!=I4@JJ'!X(E\%*F>E>:0%.4#:GYE5#W
M8'J$%&JJAA[<G=?C,S$OQWAQB<U%S%!KR;),G(R/>FV-Y@5"(4> 6S)+E$Y>
M"=F8-IMB?(0TZE5-/933+.7Z;90I\&Q,841YGD#Q%"%RC62:LF13%-K[UG>G
MKH?L45*HN4IZ**ZY0PS/4CHY/AF%NML>3Z;SX7^'JI)!K05R4C%PSL0J"@,A
M&05%BHA6<T+>0R..#5$^0D+UK*H>:G'N0/P6YP-C,9M8E\N,LD8T+.'4&9#5
MM=22+^5V:!$1HJ=%FDU5T$.QS1)(MU=(::6)&AGDQ!FH4!QX)PQPAS9)(906
MK0^CU\'U",G27!TK*VMV<H@=3?:TS 5:[FH#61491)$"6.YD/6Y'#,T/$Q[H
M(78'TO2DD'T?8L^F\\$'&@.>9H!*Q073O%8+!%"^I+J1>@BA9%^\C\SH=:A$
M3[U"(_KNDD+77O@ #J,W4N:DJU ;NN(7(,X"].O V.2X>1T=[Z-=;@?AWU1?
M!\GUJ$AZK:;]R()4M39#%0,>50(M<[(Y,1[+6AU&]ZW %<?%[?6WB< :Z^UW
MDM3QR?'%70!!^Q@5F,1HUY$Z0#08@9>8A=212[%6+M ]FKOVTMW9;YW$/FDA
MLX;Q[@60\.T*D"@,X]KZ1=4V 4D98O(6M A2,L>URFNY<?<I[^I+'Z#RMI99
M/SU65VWNS[__'OYS,ET<4I[>*22DX-DQD,S7!K.TSWOO PAG54@H+;:_8W=]
M>(_44.I;47W<)+<:ZB70M^$8SR\G6P-N7W?);09U;VU4^U']^A1KIK?=+F%+
M84>?4]!H %WM:FV\AB!*3:!ULBCNK;0[##;NCF;W]T ]2)9MHJX>V/7B9#:?
M'./T XX6D?39Y^&7BW9H+'IF&=G;O#;/1F8)54)@S!?,3'MAFG<>6PWGH,*0
MW55YL\E/(SWTD/#QLMY5-?F"^1.FS^/):'+T_4/-3;GLR"D"0^> D9\&BE!!
MC)J^LC$4J3W+S6O$[H'TN*G24A]]W(JRN(5C.#Y:4'F)/,Z[]KI@&5=0U]-J
M+ 9P7#@PR+A+68IH6R?FK8?L<9.G!^WT8&)_FH:,QP3U'(^,M.\&47/>9"8F
M%P&$P( S3+L2113-3U!O8GC<O.@D\1[2-19XZM@N-D$E632&&%D4@BI)@+=<
M0,DE)<53"+YU%=U-#$^  =M*O(><BGLRTVX9[4IJ+HO1A*\V[_76UIX5$;R6
MJ'U Y<J.\P>?6 BG3X7UL,+< W?I_%H'<D^AG"W@[B><TRL--J-<,QWN/C]Z
M.?00"J-U%V+PM:U"[163:22"LZ)+L5+8UFWC#X9V]X1W#IYU&ZBNGRN8KIMW
M:(U7$3VM[+583Q8)$>DK88IF(3(=L/65I_LWJ'M7W'U&]2927QG)V7FSYJN9
MMJ^^?:$9B3WW;;[CC3MJX;SNF&^42R:.@>F$OA2MR' *'+,+F71KLO+ESO9.
M:[U\%R63@GNO+(=*;B*IDQ 8)C#,%%9RY-JOE0)V:"635X3Z[E9)ZB +XVA*
M)W"L3LV8,Y#>-!ANHF><6<3F19%W(CHH;W,[=MPJ>VRG@OUVC8HZ:&UIZ$X[
M!RHD"S%; \;+8EUB1C<_&7FH";<=Z-*30O:=<'MIC="6A!<]4=[4?U#55,U3
M%Z,KPD0(NOKA6M6+JV6IX^&,&</2S9X3#2S]E7 >0N!B$P+<LN?;**(7+W$I
MM#/;=!UPO84C[@"VK\!#(S6N1X\..M@Y48+%+%W6D&5MK1090A",0>$Y9VL5
M*]CZTMP]$.3>$,$^^+&)Z/O([YC,YN_*QS"ZO _1B1A,(J<SJE =6@XARGH5
MD0M:NB!]\PN4;X'8A^O?3$FWKF?J(N$>[-C?<(S3,'HVSL_R,0EV-C_M&GSF
M29Z7-!@FL.12>ZR9FAM0[W<P&41.RF?FC<FM T!K 7M,U&BOB9WTS7J)<;Y]
M@.?JO^X>K%F)Y4;@)61GD)Q$KM$J7UMJ)\TX1B]X]LZ&P=4'=9M?U;EY5UY,
M,0_GOX8T' WGWR\='HDQ2*DE2,:(+V1\@N<L08J<D5^K$)LW%+X34/?LKSB_
MO,^.'H_DQ9^,YP-37&%19=HC+=(J)R(XX2)$59RRF1G%8O.TK^58=K]FM./
M[>RN!O+N)0OP*BYRPG"*L_D'6C07*V=^3VX=_2 <D2^FF,Z*!9 N9E"83"W6
MJB4@,3*E16*J]=:R/KK'RY5F.NG!#+V.],5D_!6G\^K#?R("S#Y/1E>PDC$U
MGZ0_WD^'"3]-AT=']4(2;[Q(,8"O=\XIQQ-XC;69E<_*,!DL:UV;TQ'RX^59
MO]KK(9OP?OCUH&XX/GH9OL\&9,KX6(J#F FBPLPA,IHN+*:H!&)AMO4&OA'
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MWH?O-PS^')00MAA(I=Y:SVND'GT"+31M/EH:X>4:REWZ\(>NS^X26UD9T/;
MMR;,IOG)E#:(\SRVLS:5YQ^?-:D<DDPZG/IN\YX61[^=QW?C_%<HSEFV4:(0
MBEGO%==.%%[O'(V>N\%VKVR0_W'^\!>3V9R(3)\1^:X<TDCF,1!LB)@=$'G)
M_S-6@\BH+4\!^7K7QFZ:#G(/KB:Y+^?O.'OXU6*$PKGSG!9+)KP'56>?SR0
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M)8CF+)%O5]LJD%^GO(W@ ^VSR'T).0OI3>L[U1]6X*P?7FPB]KT$S@A"B,)
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M_80D].G/R:^T1-*ZEZX?%'W$\7 R?3N97^QU*"S7.C(0I:8ET>((D4L&2<F
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M]]?C4DN$,;\].;TIUQ>!)5DPWF M$B9CBEL.)O."3-I87.ODL,T0[F[9:<R
MVWM.;XKIQ8^YAO992E.2R;/YBS"=?J</_Q%&)S@@GRJ&E#.X4&O[M640ZO5#
MTB<> LM&8NNTG[6 /5;2-%!#^Q8+M\=^ZJ?YDJ-A(H(Q*9,G[AR08\])#$)E
M::4H9NOE<B<U)CWIMJ'8#J7ZXSI-:2]^_OUMF)],R>6_RMYJMNOBLX@,@39W
MDAA3"5P2&:Q*)0LA>9:MS=GUT>TZ0M*2"G>N',U4THO+>VV-.T5YWL-D#6B]
M!4%6PMI7)*0?C=Z]Y716QXX94WSTV9-W&.J=@\HEFC/<&! E%FM=(9>N9X.V
M?Z;<&R[9.U$VT4)CB^34L#XWIT\KS<D[)E3G[GX)QN20"RVF3('*AMQ])@DA
M%E>B9IHYN89A<N^+]A$Q::2225_R;-W2#>D98?0W#*/YYQ2F^'XZ.9J&XP_X
M%<<G> :0IZ)5';6V7A/ 9" &SZ $IEA*BHF;'8F7-W5;YV6/0^GMY;IREK=M
MIK_H=_L^3.??KYX-=NFF?_<36[33WP#SC7 9#UEIX8+4F2NO8HS)QV22$M[7
M]EZ#^Q[>M19HZ=.ON$=>).Y=JD>P$53A@18%7Z!P&Z,37IK<N@G+?9BZUS\M
M9D ]J[SR*MIDR>[1C-%^"KIV.U3:U7@R,V""8D5KAZ5YSX:58/;1*K\A%V[7
M0;40>L]]\9?/M.??K_UDX=?)0O.UIF!R7D+-DG00:RNN8$*QT4;NFQ_I; 5T
M=[WR>^1._RHZE"C,>N-;V/T.O= VD"PM([M 20M1> 5.8&91<Z5"^SO:UT6W
M_SR5WIAR:UWK16,]N-Q7\9S9ENL@ZBDV<QO-OMKI]Z._.VC20?B[H07Z($OF
M J(G4.0>2/!>BGKO?2U--R;R]F;0;NAP;Q/]?;%A$YDW9,%L.A\\*V4X&E9
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M!MIE=K=CT.WGR7"]W9>>WF ((CW_-EU,\C2&.8,8*$HQ@,@L6$FN,Y AG-I
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MR#G2>894GG@='SCV.[9%Q;;9D5ROURJE4UL!2QLWHNG&CS]ZA@(ZCH8;'?6
M<<_,] K>JJ28M3G:,KJ7"F&>0(4*EW/L==C0-S\H=L+8/!_O6FUBE7]31U+L
ME@.[4>4'&WZA:KVV"=&":9(D@&0)!U!"#AA,"# [(H:()'F6)GZU)CPM&!N1
M-;8%R;OW'PZ:(<8DMAM1,X= *2D@L<1 89&C5*04,^&7I-CK@ R3R+@:$BL4
M.FW2^695.M]Z8-YIN-RFFUZ'H/<[RNWTR2:R;T^!RK,JL&\U4I47(6M^= 0P
M6,4/W_X'KO?1$9[=:A]=&^I)H&9Q2)R@T8#>$A6]FM<RI"M]E?-:7N6U6DF6
M88C25 .1Q;:RDLX I0H"@0S3YE+FB:=2\\ .C&VR;,P/-%T._G5PW"V,>)#[
MWG8X2-HL7!7ZMV#8:/2?16M!I :+]Q.[Z6D<AY+ "6W^N(1Q>AH<;[F<ONSH
M**+S;(4IKW4S0\_O;]5]9:4M(LB1-MLYI,UV#M(\M2J2$& &H5008B5R+WV8
M0SV-;4ZJ#;4'3\7*U&C1V.HIA7(07+>)(PAD/3/\!JVUE='M,;3\95&.(1%*
M(N5@/\/*I1QS=T<ZY>@#W>CAQZ*0OTYGLT]K<0R40YBF<0(XH=0>5U- L(H!
M92Q3&1)I*J /+>ST,#8Z6!EX@C+)+HIN[_])V/3\WOO!XOW"'W0]T(N^V_Z@
M+_A!]]Z^V(<_V.V%_C1E?#JKDB0^&U.?2RM?-6$9RW.,%>!I:EYJ@BG@"6,@
M3A.(H. 8:^5SS[VWEW%><,^*^3TP//(8S39&^[W>^S%U>\5/1JKGUWS+OK-H
M8V&X%[T5@$ O^_X^!GWA6]U\^]*W?[AKE3*VK/8?UWIU?;3PO?5L:6)$7]FU
MF791NK[J7/1SO^D 2;#J42U=#5P8ZKC3NS6?')[I&L&UUCNO@CVOGY>+)9M+
MLPJ>*(*RZCHLXXD$$&H)F)8"6(FF!"FI=8Q\5JLM?8UMW7JQ51_V+/J_XS_$
M<1(]L48J_"SZ+D7Q61Q7_[_1P(C8\_*A**?_4/+?HR3-SXS%9Y F59INDN(S
MFF1GE*:KCT_KDF_VK\4&B#-;HN])"9NA/WOQ/,)M&TPWE@HT1#V3U'8QA;-5
MAO26J2%CP8[B$2P4['!/ T>"'75Y-Q#L^"-^]"35='(Y7TZ7+^=2FJ_.HJ+
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MTW%M43(XH?'!5 U.!V!;X2! :WXSVJ)<3DP/\EDL;0+XK2J_3H5:-!>1PO1
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MSLSN+\V )AAG*58PS\(DT&UU.C9".93 U>1M645NARNX[F/@1C>AD>V9=(Z
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M(6+<J8IM=Q-&QT\;,]U>HU!#X491_0+<,V.UEN]:&-KRQ3YHW:YV^ :HV77
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MVWH#%BH;UKWC8=-5O0'9R2?U;^%$'9<Z$=5FKQ9S>ZI17?LR&<=<<@9$D@D
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MZ'6+9MCN,X,)@QTT=UO]Z_"'@F;5+3Y,%V)6V+W G?JV_,'8^/>)@EDF8D9
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M@#FVPQ+XE,ZA+Y9<[_C/^M3XO9YK,UU/,L(4RPT&A&H-L$@UX @3H#*6%TI
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M4409RJ#.J74BA:N\(;FRCB7- <R$5C"WKR@LPN*+XF Z3(C1G2L8FTBKL=L
M6^H?>OX4V.VJ!5N_-6@<O'K_XE00E6J6X:.-HHG3-&9&^RDTHN6S'Q4T<#;[
M*8/W<]E/WM&->/^A7>-JK2[MY./W=27_&_-A.GNRO]VOVI"*'!:4":!8@0%&
M3%JGE&M@:*$+)14W*"CA/5#^V"BZUK/[\6@H_GF:"I1R!FB1&HN_=/V^+96G
M:4XP(5E!1&!L:(\C, RA-V/P1VU(PBM+HI8R"1TGO^] C]CW_'%H-$]JU>L\
MX;*O1 7[CMX726U1O&]&1^0B?4A"I0_Z=>D(S>M/3M?'=*X9U[0J_Z ?E]HN
M,=S"T/X\T^7I\ESM-H?]NG1IHNOGK_:E7-M_N_[GT_31+2<G*3>9S* "UIFU
M!)FK%/""6^=6:J6(_2]G*HP@8ZDV/N9L5"V=.]WH>9'PK<6)VC$YN Y=G"'U
M/-=Y@V'J^PAH9QQV;;I(-E:50[=KUT726&9_<K9=E)=LS(M:^"XJX/%JX\51
M:^CR>5'!/%!A+^[SN]&\2\R]6I25FO5</G_AZZ>EKIO$(H8SHU(&C*0:X,RN
M+X3]!4"H4 H+Q5/BU6730];8EA%.U61'UXNDTK9C(]XVE/W(-!)V/?-C=]B"
MR<X#D$C\U29I4$KR,/DUR_C<,G )L(]\NOP[GSVYI-BGARH T25O2<N$=WKY
M "<4:B3<'H:T=P-<:+?53%PU8L$5IY1F*1^D%MA)5<=&6XURB17V4*ZMGS5?
M#E8-[/30^I'=. :L9ZZ,$"_NS$U*>Y,=@R^2S6O@;!Y!I3#O87GKDF&G%?US
MU [S!CQ:$3%_B5W/(^=V";YVQ10^:+'^8@%\6B[=8A1KPADE;N_;]8)74 ,A
M[%\9T84R7*C4KUWT24EC(_L=19.5GD\7RV2^6'=*OSV.KN_Q603,>C\]V\+E
ME+2^Z4;-F$=G)Y"(=G)V3,[ !V<GS-T_-SMU0]>,?;'^-%^MEV4,RQ?['C2+
M6)BK+-,<<"@@P!A3P'): (ID[A@C+0H8EJI_6-#8V,'IF6P5=2NQAZ[+UZ/@
M^K%##,AZ)H>.:'7(Q&^'(EH*_A$Q ^?>MQN[GW1_XOHH6UQ?^=I5J;N<S?2]
M5K/G3W.S=/^DZLK%A!-6%$:"G,L<X)QPP+0T &:9E(QB0F30ZC-,_-AH9'N*
M^%@IGO!&\V3:J)X\/8:>100.2J=-LHA0#[YO5NN>;)1/-MK'+P'=#;=^MM=.
M"7_+'3=/8$YLPOD^9> R#>Y$8?V\Y=]5V>[G[CN?'\P2?G4:7?[C!VO99B$X
M,=(HDQL%4D$*@"6!ED@Y 3231:$AIY"%;^.-P;*Q<?1N20BUF,WX<I4\6M(N
MXVJ&J@X1_?4)V"H<@[XC^II$V%FLT-GQB%=UQ[:U!:BM3L5>&%)Y2>*@VMFN
M'$$AB[[&_ZW+7T2WZ\]1-*.OX8Q6:J,W!6/LE^SLRE0_KLJ0@ZG4<(), 34M
M&)!:8H"971GQG&6@R!#*&,=4Y$&?<6_)8_O,[FX@UANM<J-R\NATCO()]A^:
M+MLOD0 ?>C]F1^WF+R7LI>9][<]X8-7+ADV;W#?<P?& HWU+Q^<!'5<]\KM6
M3S-]8R[M.DNYD-CI#WVKY=.RK-EX_5/.GI16'ZV)CKB?JC3'&W/-EW.[^%I9
MUBUY>UN&'K.40)YB  MWN$0-M2N7E (FM<H@R0RA:=#R);J*8R/(QD*W6[1K
M8[(U,FFL3-S+ENS8Z6YJ+'7>9.6=!BY>XK\%GJN0-QW;OI<3\8<U^?V.N\]H
M+PT.^AN,6+Y]? 6'==)[ WC/V^Y/4I0PA#I3'\F,4F8$T-SE@#'!@:!8 )%Q
MA223 F5!@;('I8R-[5^?IY\5<1!4,.IL> :.-.BA/%0K!/V$&+Q%.:A6,T^$
M%L0I@\!7W]U_;O7^@\_<NOV;MN[LU,4UN7^XG*N7O]BY<J+MBKF@+B")Y^XH
MT4 @4FC) 1J"(#4JU6CR6*[W;]=\N?9DAW-T"IDFKS7K<<:XEG0N*\9U'RP3
MGVIU+Q*A[Z=SQ^7E&62I42#3G#F$A2$$%];M=Z?!15ZX6&0#*":("D4SP_-Z
M"*_G:I0#V.CU)L.G[6_?9. \/R5##47?GQRKV475V?%Z%_ZM[DEUB1NE5[_<
MO2/B%RH&LK&^9&?I,NP7+P9L>U_&* _MZC$_/$RKQI!6RO88W'KOAYK_L9PA
MBC+K2C." !:\ #1%%"A#TYP7VE)QH"L=(GY\/O9&>SMSDQ?JA_K;0</@ZXCW
M!6[O'OHNKNHEL/VW8.R&6S2W/DCXP/Y^%V#V%P*=GM(QNG#;&.BJBF3>M//)
MC/4.,XF!Q((!C',&."(,0"H1591F66 DX5%1H^.M2KW=IF"!X8''4?6CICA8
M]4Q#+SI^-9CUT2OI-!JQ@OF."QHV<.^DP7M!>J?OZ$80+WI@7_[@TYG;^KY;
M.)9:S&_7EH*^+V;V>:OW?#65$T)2*'D* 80R S@O[(HS=_PA=)9A*A"!00D+
M@?+'1B5?KN^2SS>WMV'\$0JZ'ZGT"&7/3&,U;UH-OG/*_Y)LU$_6BZ0R(-FU
MX"(I;8C'01W!BT1,H=('9:N.T+RFL*Z/Z1Y!M#V)V8C[N%C>VH5C=3)C_:Y+
M*9=/KI&B)0N[Q*RY=6)$C@Q5!A0<YY;;$ (\TP*@ A9:,00EDF%5H<[2)V2J
M#E,*ZF]\^5]ZS:ODSL:JBX2O$^/"*'^TAE'V,& "8L+RO'"-;@G M,@ 3SD&
M:<$PTD6>"A&49CO8< WQD?*(;.UA2'2AL((L!XH@ 7#*4\ IA\!@(EAF_TV*
M?+)VU77'-B0;G?H;DK*J\)"CX>="#(9QSPY%>:YYNT-,&U/*?EO.F(MD8TY2
MVY,T!FV6.W%#]\Y&-F(X7W==!@_Q.QNV0V%_YS^T^X9S[>U4-3$_K596R(1!
MRXTL10!2;==5!8& XD(#(3/K<Z!,I@4.W5D^(&=LGZ;:M5\Y/2^:"KS34M7N
MQ7>/8>R_;7PF<@/L#S?KH8NZ?NY%4JD9=QNX!8>(^[V'I R^L=MBZJ$=W+;+
M.[3VL;^?2CYK*K4W30 EUXH4#" L-,#*8""P44 925&F3*[]O-KC(D;'![66
MF]X! :UJ#F/8/NGC(-/W?'\-2I=&/H?1">CB<S9*0[7P"4<KK']/*Q!MS7L.
MWSA<YYY6Q5^T[6F_LG-P:KEA_8_I^OO5D_WB/^AELZW]W"Q34H%%:@H!T@PC
MU_94VT4C-H 6RA0H+30*+<?M(W9\^RM?[7?E@;L,KE+Y[D=57J@3CDB>0=>6
M@RB LXP!JNS*/:>8&$HE43H+C!".BOF0AX*/@R+OZY+&Q;-W_[3&[@^K;](H
M?)%L5.YA?1T"4;P(Y-,BAPY(]@;A0'RR_[U=PY7+SK>N\.)<35VMW]6GJL":
M>O^T_K)8_X=>NQZY$V6AMG0D 2I,[D(3M%T,N_B$0J:D((:EA0SB(T_!8^.D
MK_9!W_G*-:4QR>/![@O)=%[G-MG5,I=R\>2BAA[YL]O1"(UH]1P>3]+J ?2^
MB:MNF+VK<](HG8BG=6+53I[UNFRQ'3,:-0RJ:(&GGF('CC$- V,_G#3P_FYD
M5IUEWMK53%E8X;,;9-<AH2H]*#G7NB ,6(]5 DR0)2\B%4!$:D*-X,8$=:%L
ME38VVJJ/\C?:)HVZ'0L\MD/MQT;1 .R9@L[ +IAVO#")Q#7ML@8E&"^S7[.*
MWTW=J.3C=.XZXW[6]E._MT(P"*5V5:Q 2BFW3,(@H&EF@#0\%S 3$$$5PB1M
MPL9&))LUF>LT4V5K;QT?4QI2IEZ)V?2^'([ )5HK\'Z\$@O.GFFE5C,I]>QW
M)>:#2"12:14U**?X&/V:4KSNZ<@H._7N=1EGOA- ^C<KT'I%ZF;^S1V"NNJ.
M]H(OB_FR^:L+P%I]GL[U)\MVJXEKIRTRS8!)!76U1C 0A". >8$X08IQ&11<
M$U6[L7'6-MCF(JGL*Q=L.Q8FC8F)I;2-D>55NV:6$8ZKY'=G:5*:&N@VQ7T)
M/.GPK8:V;_Y\BU$-I]X^T(_%U5%U&Y;<^X!U[VO0BY"PSX?2T\FE=:Z4<[ ^
MSOC]A!<P8RQ/K??)&<!IF@$F30YH45"=<F6@'_7O/7ELM+U1+G':^1'M/ESM
M)'D6"#T3G*?]WI1TU-8#=++2\B_WBQ__T]Y3,8G]84L@^T\:9/(?-:"9N,<O
MZ)R)XW*;ORX7/Z9*J_?/OZU<\-FG^0^]6I?A:.OICY(-)DC@7.&,@DQAX\H^
MY(!+"$$&<0HS972F34AHK;_HH&D[0!RMRQPIRSH\UKJ[RL'31N^$;Q0/3M#Q
M'0L_OZ@?A'OF! =N68+AZPZX[YSF%N)?DHWRR>5IF+LDY 0B%B\7QU?PT&DX
M@8 <R, )?4*,\KT?[=MU^> .IB:9,9H124"120BP50+0/+,^A1*"044@A4$'
M>\<$C<V[*./1ISL%8XV]+N&EKN>4W]V!UH^'8@#6,^OL%==U6B:7[5B=64IW
M'XA>*N?NB'G#0KG[QK;7Q3UP?<<RN"YBMHJ5_?#D%BU5,?%RU7/]\#A;/&M=
M7M.<>[MVXA.B.$VI77-()9!;@EC.*'(%I$@+*',I(0ZJN=))B[$1BM._W-!=
MF$3NQ- G9K%,KF^_?@TL3=MI9/PHIW>\>^:C4K<ZNCZI+-CTDZAWA!HSJI#\
MI#$D<99$K!Q[#I"QBL-VTF'8^J_GP+17XO6LAX4G MSJF?G*GU]%::=,F8P+
M 9@P;MM=8" RJ@%14F,-,ZT$]<T#."AA;/3FE 162__X]L/ M3-4%#CZ9A^K
MGVM_<T[L_V%L_$/_S\9HH,C_#E@%1?ZWXM 2^'_XOL'B_EO5W@W[;[^P<[[C
MXU)_U_/5](>N@BCL,O3&W/&?$U8(*I$20* B=\'^&>#:"* DAX)SF>?V00';
M6"VRQK9O=77SMZ_?KO]Z_>7VT]^O.U20:8/5SRV+!%;/]/="RY<U8BX2MS]E
M_5^K\45RN5XOI^)IW=2,^<ICQY>?A"M>1N1124-G19XR^4!FY,E;SHH=G_ZW
M5DVD^M5BM79;6G6\#LT1A#JC@.:<6R>)%8!CQ%VT5,Z9$IPJ+R?)6^+8G*;7
M&2Q;_<LEXG2U"H^0.@V[)]O$!+-OSMD!;I/*XK0M&:>/W!5?<.+&?;?(>XN
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M!>!,<2 R5/"4N*XA.&PWYYBHL2V&RHAA%RA<_K"C;/*[4S<PO*,%8M\=FQC
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M L29"Q_-%> 9R@ 1.N,LDSE57AF1PZD\NH]&J6C9F[U4M4,&4;]#[/<!&=?
M]?Q)*74#[YTIR:ZYR8Z]KJ'B[G6US4EI]$52FWV1; RW/[YZ%9+?G?E);7_,
MWG"##5;,O*Q^%1X^T6N0 3B8.3:,Y(X?+7WO9'[3CVY'=7Y_R*?%*,N8?4<
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M8><Z3@%3&78]"Y'&'$IJ@F)J#PD9VYQ_Z;_+2LFPB7\02[]I?RY"@ZY^KTZ
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MRB&2UN-JXQ!W*();.$06W[4RRS^?IDNM6CI$OI+^VTJ;I]GGJ=$3C&C.!.=
M:^/:%$D$:)HQD EJ-.524AU8OZ6[,F-;(>WVU:R[RB3OGK7].H5NX9XS0IX;
MNP/AWO/7HS$C:6UUNSKP-:C,29P],0O-G(]JM'(T9Z@R<-&:\T';+VT3X9EG
M%,"9NK[*Y<%.4U4<4Y'J0@ C$ *8" $HTPP@05&6IR*'F@17P'DM96R$N%7R
M1!1Q )!^]'8V/#WSUFMD>F@<V0I!S"(X>S*&KX)SS,R#97".7MQMOO^JYY9
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M5C'9Z-C+#LTI(&(EV!T3,VQ&W EC]U+83ET?=4O2+3P^5;N>Y<\3IE/%.1=
M:L'LQU5@P*E6=B4@J,XSG1$5U!344^[XOJT'>@>[54"I\1E-A%N@/VLO^!Q
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M%4H9[/!],;/WKZ[_^31=/T]P04PA"0-:(0*P*0S@*2. $&,81)@5,"B6\I3
M(-]]L-C*G</+<B6^VM'[W_Z%9K#X]T27^G=.F#H,OQ^)Q 2U9S+Y_ K)ZW;4
MSDF5:H4B?K;487%OE3#5:GQ+SE3[?1T#M'?*)]R8C],YG\OI_+Z,WI@4)$/,
M2 VP2[S$,G=]0!4!19X1J7-9<!Y48*)-V-@V!E[7E5!:K).I=;UU(IV^@0'<
M;3#[$4DL\'HFD=>X?7"X;5J 7K5"%Q[I[8%)K*CO-E'#1H![&+T7#>YS3]=C
MF'+K]"M?KI_O["IVQ66Y-GW_O/LOES^GJTG*N4D%%H!@7@ LBA0()#00:4HS
M4R"N=%!.F+_HL;%+<UQ0*AAZ]N*-M^_Q2Q\H]GX"LP-@\KO3+FHH0R@DT<Y:
MO 4/?-P2"LC^B4OP$[HVZIS?NU()[L-S9Q]1S@129 @128$TR+HS&2> (P9!
M3J50!1.:AT72'Q(R-H[9%HUP6EXD3L]3,\4?4<_5SYDX];WB<1#=A4'4H=7F
M<0RB==8\(&+@1IK'C=SOF]ER;;=)?[.\Y_/:O[FRK+*8356UL3Y77^T;T[01
MW/@^?'9K?Z.KKBYA04]19(UH$NS:<Y&\L*C<!MBUR7GT&ZN2K5F]!%5%!3K2
M3(NCTZ!3,RJ,K^=RW(?'*T.1U:43\EP7HC Y*!2$ %-< (&E 85T#71S5! (
MSRU#D8VY#$5V?AF*[.PR%!T0ZIGTCI>AR 8J0Y$-5H8B&TL9BBR\#,7K6SHF
MXEI/X]/<A7Q5@:A*5P?H54']FWE3K377E&!FB4)K \M2-4!PH4!!&8(PRVFF
M@C8H/.6.C3FJ/;N-WA?)5O.+I@F!53XPS]9S#/Q8I@=D>V8<3U![8)] K&+E
MR'I*'387-@R*O9S7P-L[E+*KJG5\G*XDG_V'YLOKN?K@HO]8GE*:$P(H)1)@
M0RE@&8. %3ED0DA&"Z]B_VU"QL9#M9Y)I6CB-$VLJLF'MD@\?TC;F2864#W3
M2B>,PFKBG0"A6WF\8P\=KE+>";->%,T[=6W'A<OQ3B*?IW/]R2Z35A.&,<UR
MPH!(40$P4\I20$8!TC1/&30PTS1H!>,A=&Q$T-Z))_G=*9Z4F@=N;7J-@.>Z
M)S*N?2^ (D :O@X*P"C6@LA'Y+ KHP 0]I9((?=V#@!^\=PO>GW]T_71F,[O
M?UTLU!_3V6PB4YIKK2$@/,=VH:130$7! 4&YQIFBF%,30DH^0L=&2CN3AM?5
M[+I$J)X&&PD#I8 :0)H6KO1Y!JA2&DC!<6X(5B(LSB\ZV /$^@T&MA_9QX:P
M9[(_T+S.:NRBA6N=DT;IXUE/76*&O3&*%S]\6N30L<3>(!R(*_:_MV.&(I_I
M&U-&%;J6Z#=FYVC^P^*!3^>3'&*E34I!SEV[:6XXH(0A0&C&"-&"\#2HR]QI
MD6,C>J>Q._BJNZI52@8ZFAY ^S%/7/AZYIU Y,*3Z+S!B)4%=UK@L&ELW@#L
MY:'YW]DQLEC]Y]-J715]6UPJ55;SX;.O?&I=URO^.+5.0YGI)EXGPWUSX?HK
MZ^?>ZN6/J=35[MI.3:#RD&"24T@,Q!SH3%BWR. ,\-SZH(8@1!%46>#17M\*
MCX[6RO*9I3&)W,V>K1.N$I LJC3#,@Q@N6TON0IOO-G[V^#'GF,:XYZY]_+K
MIZN+PZG/VV33LE1%5<'.+)9E>+97\:WP2.V!@(\5[=VWNL-&C \$_E[4^5!R
M.S8JK#28_K>37=78<A-@$PXF#<K35%,@D*L>JM+<>KX& ZHQ34U!4H/"6A6V
MRQO;]V%'W6TAN9(A/(*].@'NQ^$18>S[;.8<!,/[&/KA$JN3X0EIP_8R]#-]
MKYNAYVUGY^_6YT<34N2B@%D*L'-4<:X4$#I7@ @$<T@)PCGIF+%[->;^)TWO
MDQC="Z^"6J"<AU#/_/"B3^%5[#8HQTV/GV![]1:M4(X;V))$^_K*CO'FZ^]Z
M6>W*->^CY-8?@"D$ A;:+D=S"01%%&!$=2JE$ 7-0KR%?1%C<Q!*#3=SNTM?
MHP,P^DWK\\#I>5I7N#0;[='G]7';8\6X[PL8-F#]J(%[T>?'KXQ04[3T!5QM
MP)5=A.C-^>HDMVL"DBD#4J6AG=^< 6Y<:P&3\5R)C" >M"/N(W1L<_]E!<S2
MIZW*8)9JGQ&1X34"?B01&]>>:2,&I.>5%#V!41_U1(^)?+MBHB= :*TD>NK>
M\'C0Z_EZNGZ^5,J^::OZ#_=<.%$R8TIH PA%.<":4< *%Q] ,,(9EIA K]V)
M5BECHYU*T:16\:+Y(2GGAG=(>CNP[>02#:Z>V:0S4D&QH2>1Z!0<>ORI@T6'
MGC1L-SST],4=-R@/5/YOEC+/$Z4X(AG) ,IS2P %*0!7FH.\T'DA"[OV4$&;
M":W2QKFO\/B=+Q]X(IN]M<[["^U(>^Y+QL*O[UW)@TU!+I*-KA&W)'T@B;4A
MV2IKV.U('[/W-B.];@HCDM5R/?FZ7"CKG]PLZZ.4LGJ#5-H(9BA +ML-:Y4"
M 1$!4F>4J3SE*/-R'HX)&)O?4.M8.M2UFD&E,(X"V4X-,>#IF0TZ(.-- Z?,
M;YOY]MZ=66__MIWQ1Q\[R"0_950SKT]>=V:R^[;_8F@!B[9'C.C-W"G-OJ-H
M+T=G/HC$3M ^).IM,K1;C#Z:HMUV3[<7^VYIO5<7BK:J$X$15+@\'<LT=OZM
M7>KR FE0&&JP$H(8%)3X]%K V+Y1I7Z)4S#,=]T#SH\%SH&CYYF_16+50SKT
M,<,C3?"]QP\ZJ8\9]WHB'[WNC/,P%\"SU-_U?#7]H:MBV+_-E[HZ8/_K8E;&
MK?/I_/-BM;J9WVKYM*SJVBZG*_M/'\HMM"K2YXM>WY@[_G,B39II)B5 2!.
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MUI[IM2.BP309#DXD'@P0/"C1A0/RFLDZ/"$\0.G*U:Q=:GZU4'K"9%K(PJ1
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MZ'Y1L)<$N]#^>SP=5R%,E[^%,QQ)XXV3%%991E0KITD0]#WD0#M<R$EK;(&
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M>9"TX5L>BA*VM$XU;$+7L$GM \&KN4*Z*&Q>XS &I'W<UJ&Z/$KBH=;!2(U
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M.1?-.W+O0&8G_L>.R'A06G18-76 Q.>SQ?)MJ;WK5U4*EX;WPVR21ZQD:41
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MQ:3"@(MZ!U;9"#Z% L:'A")%IUSK*M:CMIOYD#YA/J]MLJ]>>ZLY 3,&)<O
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MR=8=TYLRT$D'P6$STH,AHH/E\ +C\F9)GWP)XTD5Z*O9_$.8X)W3UXLRH2J
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M8Z0E]U4"]X6#0HKL ]*WP3 C&3?6VM:QZQ^]N\\^0-M?21T@[:EF,54X,<E
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M,:V["XX_I$^8SR<X*U>_M'L/D)U>TZ+[Q_[\->K[<?6.DX>$W"#JNC&#CX'
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M',"+V$_.'0%E)(M2*4=>.^W$FG9%B+54('II:>%KPW7K?EM7[^XC<ME1A8\
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MQ*&VVK8NV'N4F&$SA TP<-],M!%[!_M0E<WK*4GDO!ZP7Q3ZH#$E2@TN> I
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MM^"9=7_*:-_$!6]GM.,OUUIYO_J"B\]?PNQNE[2;?=&"*!:%T4"GR7IDNH?
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M/.M@<'S14>?NXIN@-QB5(W\$9:S^B  7?'T.+TPD7P5?YA9^\>G;X39.AX?
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MR>]V>7+/AX^;RFH/B.,EV(&C\H@1_I%DD<QCD$CN'-9W<\*1A(S5(#)JRU-
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M*2@3C\J"]?6AL3.,O/G(H4C#B]0D+]-Z5-_.Q/58 /+,F!Q&D1T@]$8V;,W
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M+65X,S$Q+FAT;5!+ 0(4 Q0    ( -2$J5:?LQ^IE@<  .LB   6
M      "  =T'  !A,#,S,3(P,C-N96\M97@S,3(N:'1M4$L! A0#%     @
MU(2I5H#"=!V'!@  ?"<  !8              ( !IP\  &$P,S,Q,C R,VYE
M;RUE>#,R,2YH=&U02P$"% ,4    " #4A*E67;PX$GL!    "   '
M        @ %B%@  97AH:6)I=#$P,2UO9F9E<FQE='1E<F1A+FAT;5!+ 0(4
M Q0    ( -2$J58P\%+_#>@! +;O%@ 0              "  1<8  !N96\M
M,C R,S S,S$N:'1M4$L! A0#%     @ U(2I5@:: O<]#   #GT  !
M         ( !4@ " &YE;RTR,#(S,#,S,2YX<V102P$"% ,4    " #4A*E6
M)L_%L3(<  #&#@$ %               @ &]# ( ;F5O+3(P,C,P,S,Q7V-A
M;"YX;6Q02P$"% ,4    " #4A*E6]6K90#!(  #%( , %
M@ $A*0( ;F5O+3(P,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    " #4A*E6^TUN
M ?JY  !+T < %               @ &#<0( ;F5O+3(P,C,P,S,Q7VQA8BYX
M;6Q02P$"% ,4    " #4A*E6_\9HLEQW  !+:P4 %               @ &O
M*P, ;F5O+3(P,C,P,S,Q7W!R92YX;6Q02P4&      H "@": @  /:,#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
